"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT00186082","Antibiotics for Postpartum Third and Fourth Degree Perineal Tear Repairs",,"Completed","No Results Available","Pregnancy Complications, Infectious","Drug: Cefotetan or Cefoxitin vs placebo","No perineal breakdown or infection","Stanford University|Santa Clara Valley Health & Hospital System","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","147","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","95339","September 2003","June 2006","June 2008","September 16, 2005",,"June 15, 2011","Santa Clara Valley Medical Center, San Jose, California, United States|Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00186082"
2,"NCT00028145","Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission",,"Completed","No Results Available","HIV Infections|Pregnancy Complications, Infectious","Behavioral: Adherence assessment","Maternal and infant response to prescribed interventions|Immune and viral parameters of participants taking prescribed interventions|Occurrences of genotypic and phenotypic resistance in HIV-infected mothers|Clinical, immunological, and virological responses in HIV-infected women|Mother-to-child transmission rates of resistance mutations|Adherence to ART among HIV-infected pregnant women during pregnancy and postpartum","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","14 Years and older   (Child, Adult, Older Adult)",,"3090","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","PACTG P1025|U01AI068632","October 2002","June 2013","June 2013","December 14, 2001",,"October 10, 2014","Univ. of Alabama Birmingham NICHD CRS (5096), Birmingham, Alabama, United States|University of South Alabama, Mobile, Alabama, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Long Beach Memorial (Pediatric), Long Beach, California, United States|Miller Children's Hospital Long Beach (5093), Long Beach, California, United States|Los Angeles County Medical Center/USC, Los Angeles, California, United States|Usc La Nichd Crs (5048), Los Angeles, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CR (3601), Los Angeles, California, United States|Univ of California, San Diego (4601), San Diego, California, United States|Univ. of California San Francisco NICHD CRS (5091), San Francisco, California, United States|Harbor-UCLA Med Ctr (5045), Torrance, California, United States|University of Colorado Denver NICHD CRS (5052), Denver, Colorado, United States|Connecticut Childrens Medical Center (Pediatric), Farmington, Connecticut, United States|University of Connecticut, Farmington, Farmington, Connecticut, United States|Yale Univ School of Med, New Haven, Connecticut, United States|Children's National Medical Center Washington DC NICHD CRS (5015), Washington, District of Columbia, United States|Washington Hospital Center NICHD CRS (5023), Washington, District of Columbia, United States|Howard Univ Hosp (5044), Washington, District of Columbia, United States|North Broward Hosp District, Fort Lauderdale, Florida, United States|South Florida CDC Ft Lauderdale NICHD CRS (5055), Ft Lauderdal, Florida, United States|University of Florida Jacksonville (5051), Jacksonville, Florida, United States|Jackson Memorial Hosp, Miami, Florida, United States|University of Miami Pediatric/Perinatal HIV/AIDS (4201), Miami, Florida, United States|University of South Florida at Tampa (5018), St Petersburg, Florida, United States|Med College of Georgia, Augusta, Georgia, United States|The Medical Center, Columbus, Georgia, United States|Womens & Childrens HIV Program, Chicago, Illinois, United States|Mt Sinai Hosp Med Ctr / Dept of Pediatrics, Chicago, Illinois, United States|Univ of Illinois, Chicago, Illinois, United States|Cook County Hospital, Chicago, Illinois, United States|Rush University Cook County Hospital NICHD CRS (5083), Chicago, Illinois, United States|Chicago Childrens Memorial Hosp (Pediatric), Chicago, Illinois, United States|Univ of Chicago Children's Hosp (4001), Chicago, Illinois, United States|Tulane University New Orleans (5095), New Orleans, Louisiana, United States|Tulane-Lakeside Hospital, New Orleans, Louisiana, United States|Tulane University Charity Hosp of New Orleans (7201), New Orleans, Louisiana, United States|University of Maryland Baltimore NICHD CRS (5094), Baltimore, Maryland, United States|Johns Hopkins University NICHD CRS (5092), Baltimore, Maryland, United States|Children's Hospital of Boston NICHD CRS (5009), Boston, Massachusetts, United States|Boston Med Ctr (Pediatric) (5011), Boston, Massachusetts, United States|Brigham and Women's Hosp, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS (7301), Worcester, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Hutzel Hospital (5089), Detroit, Michigan, United States|Wayne State University Detroit Children's Hosp of Michigan (5041), Detroit, Michigan, United States|St. Louis Children's Hosp, St. Louis, Missouri, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp (P2802), Newark, New Jersey, United States|New Jersey Medical School (2802), Newark, New Jersey, United States|Univ of Med & Dentistry of New Jersey/Univ Hosp, Newark, New Jersey, United States|Lincoln Medical & Mental Health Center, Bronx, New York, United States|Bronx-Lebanon Hospital IMPAACT (6901), Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS (5013), Bronx, New York, United States|Montefiore Medical / AECOM, Bronx, New York, United States|Children's Hospital at Downstate, Brooklyn, New York, United States|New York University NY (5012), New York, New York, United States|NYU/Bellevue Hospital, New York, New York, United States|Metropolitan Hosp Ctr (5003), New York, New York, United States|Columbia IMPAACT CRS (4101), New York, New York, United States|Univ of Rochester Med Ctr, Rochester, New York, United States|State Univ of New York at Stony Brook (5040), Stony Brook, New York, United States|SUNY Upstate Medical Univ, Syracuse, New York, United States|Duke Univ (Pediatric) (DUMC) (4701), Durham, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Hahnemann University Hospital (6706), Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Children's Hospital of Philadelphia (6701), Philadelphia, Pennsylvania, United States|The Regional Med Ctr, Memphis (6502), Memphis, Tennessee, United States|St. Jude Childrens Research Hosp, Memphis (6501), Memphis, Tennessee, United States|Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States|Texas Children's Hosp / Baylor Univ (3801), Houston, Texas, United States|Univ of Washington Children's Hospital Seattle (5017), Seattle, Washington, United States|Harborview Medical Center NICHD CRS (5027), Seattle, Washington, United States|University of Washington NICHD CRS (5029), Seattle, Washington, United States|University of Puerto Rico Pediatric HIV/AIDS (6601), San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS (5031), San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00028145"
3,"NCT05929963","Observational Study of the Interaction Between Hepatitis C Virus Infection and Pregnancy",,"Enrolling by invitation","No Results Available","Hepacivirus|Pregnancy","Other: HCV infection status","Incidence of various adverse pregnancy outcomes|Mother-to-child transmission rate of HCV|Development of children born to HCV pregnant women","Beijing Ditan Hospital","Female","20 Years to 45 Years   (Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","DTXY28","May 9, 2023","February 20, 2024","January 1, 2025","July 5, 2023",,"July 5, 2023","Beijing Ditan Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05929963"
4,"NCT01988168","Closure of Skin in ChorioAmnionitis Research Pilot Study","CSCAR","Unknown status","No Results Available","Chorioamnionitis|Pregnancy Complications, Infectious|Complications; Cesarean Section|Postoperative Complications","Procedure: Suture closure|Procedure: Staples closure","Patient recruitment rate|Follow-up rates|Wound infection|Wound disruption|Wound cosmesis|Patient satisfaction|Participation rate","University of British Columbia|BC Children's Hospital Research Institute","Female","Child, Adult, Older Adult","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","H13-03009","February 2014","December 2019","December 2019","November 20, 2013",,"May 12, 2017","Children's and Women's Health Centre of British Columbia, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT01988168"
5,"NCT04778722","Microbiome Vaginae After Use of Oral Probiotics in Pregnancy.",,"Recruiting","No Results Available","Pregnancy; Infection Genitourinary System","Dietary Supplement: Oral probiotics","CST|Lactobacilli Change","Associate Prof. Ljubomir Petricevic MD|Medical University of Vienna","Female","18 Years to 45 Years   (Adult)","Not Applicable","44","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LP2021/INF1.1","August 15, 2022","April 1, 2023","May 1, 2023","March 3, 2021",,"November 15, 2022","Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT04778722"
6,"NCT04515108","Perinatal Outcomes and Hematologic Parameters in COVID-19 Pregnancies",,"Completed","No Results Available","Pregnancy, Infections in|Covid19","Other: Clinical assessment","complete blood count parameters (including the number of lymphocytes, Leukocytes, monocytes, platelets and red blood cells).|APGAR score|maternal and newborn length|maternal and newborn weight|body temperature","Ankara City Hospital Bilkent","Female","18 Years to 42 Years   (Adult)",,"108","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","E1-20-672","March 10, 2020","August 5, 2020","August 10, 2020","August 17, 2020",,"August 17, 2020","Ankara City Hospital, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT04515108"
7,"NCT05197621","The Impact of COVID-19 on Maternal and Neonatal Outcomes",,"Recruiting","No Results Available","COVID-19|Pregnancy; Infection","Biological: mRNA COVID-19 vaccine (Pfizer or Moderna)","Evaluation of biospecimens from recently delivered pregnant women and neonates who were diagnosed with COVID-19 during their pregnancy|To evaluate the immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating people|To evaluate the efficacy of COVID-19 mRNA vaccines in pregnant and lactating people","Johns Hopkins University","Female","14 Years to 55 Years   (Child, Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00246472","April 13, 2020","May 5, 2024","May 5, 2025","January 19, 2022",,"January 12, 2024","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT05197621"
8,"NCT00194155","Cytomegalovirus (CMV) Infection in Pregnancy",,"Completed","No Results Available","Pregnancy Complications|Cytomegalovirus Infection",,,"University of Pennsylvania","Female","15 Weeks and older   (Child, Adult, Older Adult)",,"283","Other","Observational","Observational Model: Case-Only","R01 17625-03-13","May 2003","February 2008","February 2008","September 19, 2005",,"August 17, 2016","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00194155"
9,"NCT04353141","International Lung UltraSound Analysis (ILUSA) Study","ILUSA","Unknown status","No Results Available","COVID|Pregnancy Complications, Infectious|Pregnancy Related|Pregnancy, High Risk|Pregnancy Disease|Pneumonia|Pneumonia, Viral|Diagnoses Disease","Diagnostic Test: standardized Lung Ultrasound (LUS) examination","Diagnostic performance of LUS to predict poor outcome","KU Leuven","Female","Child, Adult, Older Adult",,"1850","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19: ILUSA (S63988)","April 28, 2020","May 31, 2020","December 31, 2020","April 20, 2020",,"May 7, 2020","University Hospitals Leuven, Leuven, Belgium|University of Brescia, Brescia, Italy|University of Foggia, Foggia, Italy|University of Milan, Milan, Italy|University of Parma, Parma, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Queen Charlotte's & Chelsea Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04353141"
10,"NCT03585023","Infections and Pregnancy Loss: Correlation Between Abortion and Silent Infections.",,"Completed","No Results Available","Pregnancy Loss","Diagnostic Test: Spontaneous miscarriage|Diagnostic Test: Voluntary pregnancy interruption","Individuation of DNA of intracellular agents (viral und bacterial) in chorionic tissue und blood sample.","University Hospital of Ferrara","Female","18 Years to 42 Years   (Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PRUA1GR-2013-00000220","November 15, 2014","November 15, 2016","May 14, 2017","July 12, 2018",,"July 12, 2018",,,"https://ClinicalTrials.gov/show/NCT03585023"
11,"NCT03519373","Pertussis Immunization During Pregnancy & HIV Infection",,"Completed","No Results Available","Immunization; Infection|Pertussis|HIV-1-infection|Pregnancy","Biological: TDaP","Pertussis-specific antibodies GMC after immunization|Transplacental transfer of pertussis-specific antibodies|Pertussis-specific memory B cells quantification & phenotype|Pertussis-specific antibodies glycosylation profiles","Centre Hospitalier Universitaire Saint Pierre","Female","18 Years to 60 Years   (Adult)",,"135","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Pertussis","March 1, 2017","June 1, 2019","June 1, 2019","May 9, 2018",,"September 30, 2022","CHU Saint-Pierre, Brussels, Belgium|HIS Etterbeek Ixelles, Ixelles, Belgium",,"https://ClinicalTrials.gov/show/NCT03519373"
12,"NCT00070746","Perinatal Infections in Pakistan",,"Completed","No Results Available","Bacterial Vaginosis|Fetal Membranes, Premature Rupture|Chorioamnionitis|Pregnancy",,,"NICHD Global Network for Women's and Children's Health|Global Network for Women's and Children's Health Research|Bill and Melinda Gates Foundation|Fogarty International Center of the National Institute of Health|National Center for Complementary and Integrative Health (NCCIH)|National Institute of Dental and Craniofacial Research (NIDCR)|National Cancer Institute (NCI)|RTI International|University of Alabama at Birmingham|Aga Khan University","Female","Child, Adult, Older Adult",,"1500","Other|NIH","Observational","Time Perspective: Prospective","GN 09|U01HD040607","June 2003",,"July 2005","October 10, 2003",,"July 31, 2014","Health clinic, Hyderabad, Pakistan",,"https://ClinicalTrials.gov/show/NCT00070746"
13,"NCT02845284","'HI-4-TU' Study: Health Improvement for Teen Ugandans Study",,"Completed","No Results Available","Pregnancy|Human Immunodeficiency Virus|Sexually Transmitted Diseases","Behavioral: enhanced group support|Behavioral: enhanced individual support","Composite measure of consistent condom-use and use of an effective family planning method method|Incidence of any Sexually Transmitted Infection","Johns Hopkins University|MU-JHU CARE","Female","15 Years to 19 Years   (Child, Adult)","Not Applicable","486","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00061475","March 30, 2016","December 1, 2017","December 30, 2017","July 27, 2016",,"May 17, 2019","MUJHU CARE Ltd, Kampala, Wakiso DIstrict, Uganda","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/84/NCT02845284/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02845284"
14,"NCT06160349","EnCoRe MoMS:Engaging Communities to Reduce Morbidity From Maternal Sepsis",,"Enrolling by invitation","No Results Available","Maternal Sepsis|Infections",,"Integrative Supportive Care Model","Columbia University|Northern Manhattan Perinatal Partnership|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","18 Years and older   (Adult, Older Adult)",,"200","Other|NIH","Observational","Observational Model: Ecologic or Community|Time Perspective: Retrospective","AAAU3697 - Aim 3|1UG3HD111247","July 20, 2023","August 31, 2026","September 30, 2026","December 7, 2023",,"December 7, 2023","NYC Health + Hospitals/Lincoln, Bronx, New York, United States|Columbia Unviersity Medical Center, New York, New York, United States|NYC Health+Hospitals/Harlem, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT06160349"
15,"NCT06145724","EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis",,"Enrolling by invitation","No Results Available","Maternal Sepsis|Infections","Behavioral: Maternal Sepsis Safety Bundle","Number of Participants Diagnosed with Maternal Sepsis","Columbia University|Northern Manhattan Perinatal Partnership|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","24040","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AAAU3697 - Aim 1|1UG3HD111247","January 2, 2024","August 31, 2026","September 30, 2026","November 24, 2023",,"February 6, 2024","NYC Health + Hospitals/Lincoln, Bronx, New York, United States|Columbia Unviersity Irving Medical Center, New York, New York, United States|NewYork-Presbyterian Allen Hospital, New York, New York, United States|NYC Health+Hospitals/Harlem, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT06145724"
16,"NCT06148532","EnCoRe MoMS:Engaging Communities to Reduce Morbidity From Maternal Sepsis",,"Enrolling by invitation","No Results Available","Maternal Sepsis|Infections",,"Maternal sepsis risk","Columbia University|Northern Manhattan Perinatal Partnership|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","18 Years and older   (Adult, Older Adult)",,"400000","Other|NIH","Observational","Observational Model: Ecologic or Community|Time Perspective: Retrospective","AAAU3697 - Aim 2|1UG3HD111247","April 26, 2023","August 31, 2025","September 30, 2026","November 28, 2023",,"November 28, 2023","Columbia Unviersity Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT06148532"
17,"NCT04448392","Valacyclovir in Neonatal Herpes Simplex Virus Disease",,"Recruiting","No Results Available","Neonatal Herpes Simplex Infection","Drug: Valacyclovir","Area under the curve following administration of oral valacyclovir suspension 20 mg/kg every 8 hours|Area under the curve following administration of parenteral acyclovir 20 mg/kg every 8 hours|Comparison of the Area under the curve of 20 mg/kg IV acyclovir to the area under the curve of 20 mg/kg PO valacyclovir","University of Alabama at Birmingham","All","2 Weeks to 12 Weeks   (Child)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","300005567","July 1, 2021","October 2025","November 2025","June 25, 2020",,"September 8, 2023","University of Alabama - Children's of Alabama, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04448392"
18,"NCT05958953","PeRinatal Outcomes With ACTive Versus Expectant Management of Women With Pre-labor Rupture Of Membranes","PROACT PROM","Not yet recruiting","No Results Available","Rupture of Membranes; Premature|Distress; Fetal, Complicating Delivery|Delayed Delivery After Spontaneous or Unspecified Rupture of Membranes|Maternal Sepsis","Procedure: Induction of Labor IoL","Rate of respiratory support in newborns|Stillbirth and infection rate|length of hospitalization expressed in days|use of antibiotics in both mother and newborn as quantity (mg) and quality.|neonatal infection as the yield of pathogen from blood or CFS coltures|Rate of Pathogen isolation in placenta's speciemen","University of Modena and Reggio Emilia","Female","18 Years and older   (Adult, Older Adult)","Phase 3","1400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2022-002480-30","September 2023","October 2025","November 12, 2025","July 25, 2023",,"July 25, 2023","AUO Policlinico di Modena, Modena, Italy",,"https://ClinicalTrials.gov/show/NCT05958953"
19,"NCT05023954","mSEP: Testing of Physiological and Immune-metabolic Blood Markers for Maternal Sepsis",,"Unknown status","No Results Available","Sepsis|Maternal Sepsis|Maternal Sepsis During Labor|SIRS|Pregnancy; Infection","Diagnostic Test: Blood test","Positive predictive value of genomic sepsis-test biomarker in identifying participants with confirmed sepsis","Cardiff University|Cardiff and Vale University Health Board","Female","18 Years to 50 Years   (Adult)",,"330","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","262062version2","October 12, 2020","April 1, 2022","September 1, 2022","August 27, 2021",,"August 27, 2021","Sir Geraint Evans, Cardiff University, Cardiff, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05023954"
20,"NCT05711901","Selective Lipopolysaccharide Hemosorption in Maternal Sepsis","MINERVA","Recruiting","No Results Available","Maternal sepsIs","Device: Efferon LPS","Effect of Efferon LPS hemoperfusion on SOFA (Sequential Organ Failure Assessment) scores in patients with obstetric sepsis.|The effect of Efferon-LPS hemoperfusion on hemodynamic parameters in patients with obstetric sepsis|Effect of LPS Efferon hemoperfusion on endotoxin activity|Effect of the Efferon LPS hemoperfusion on pulmonary oxygen metabolism function|Effect of the Efferon LPS hemoperfusion on the length of stay in the ICU","Efferon JSC","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","efferon-lps-2022-01","January 1, 2022","June 1, 2024","June 30, 2024","February 3, 2023",,"February 28, 2024","National Medical Research Center For Obstetrics, Gynecology and Perinatology Named After Academician V.I.Kulakov, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05711901"
21,"NCT05055388","Epidemiological Investigation of Sepsis in Obstetrics Admitted to ICU",,"Unknown status","No Results Available","Maternal Sepsis|Intensive Care Units|Drug Resistance, Multiple","Other: Multidrug-resistant bacteria","The incidence of Maternal sepsis in intensive care unit|Sepsis related maternal mortality|The incidence of multidrug resistance|The length of ICU stay|Hospital length","Peking University Third Hospital|Beijing Chao Yang Hospital|Beijing Friendship Hospital","Female","18 Years to 70 Years   (Adult, Older Adult)",,"160","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","LM2020443","December 3, 2020","December 31, 2021","May 31, 2022","September 24, 2021",,"September 24, 2021","Peking University Third Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05055388"
22,"NCT05242172","THE RELATIONSHIP OF CRP/ALBUMIN RATIO LEVEL AND PROGNOSIS IN PREGNANT COVID-19 PATIENTS",,"Unknown status","No Results Available","Corona Virus Infection|Pregnancy; Infection","Diagnostic Test: CRP/Albumin ratio","CRP/Albumin ratio","Adiyaman University Research Hospital","Female","18 Years to 65 Years   (Adult, Older Adult)",,"127","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","14/12/2021-2021/10-19","January 15, 2022","February 15, 2022","February 28, 2022","February 16, 2022",,"February 16, 2022","Adıyaman Training and Research Hospital, Adıyaman, Turkey",,"https://ClinicalTrials.gov/show/NCT05242172"
23,"NCT06286488","Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza",,"Active, not recruiting","No Results Available","Influenza|Obesity|Pregnancy; Infection|Elderly Infection|Vaccine Reaction|Vaccine Adverse Reaction|Tolerance","Drug: Vaxigrip","influenza vaccine immunogenicity, seroconversion and seroprotection|assessment of vaccination tolerance","Medical University of Warsaw","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","1500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","KB/96/2020","September 15, 2020","August 23, 2023","May 1, 2026","February 29, 2024",,"March 1, 2024","Department of Social Medicine and Public Health, Medical University of Warsaw, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT06286488"
24,"NCT05730387","Smart Discharges for Mom & Baby",,"Recruiting","No Results Available","Maternal Sepsis|Neonatal Sepsis","Other: Observational only","Post-discharge readmission or mortality|Post-natal care visits|Post-discharge health seeking","University of British Columbia","Female","12 Years and older   (Child, Adult, Older Adult)",,"6700","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H21-03709","April 14, 2022","October 31, 2023","September 30, 2024","February 15, 2023",,"June 1, 2023","BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT05730387"
25,"NCT05140941","Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy","STORC","Recruiting","No Results Available","Hepatitis C, Chronic|Pregnancy; Infection","Drug: Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet","Number of maternal participants with sustained virologic response after completion of SOF/VEL treatment (SVR12)|Number of maternal participants that deliver prior to 37 weeks' gestation|Number of maternal participants that experience an adverse event that is deemed related to Sofosbuvir/Velpatasvir|Number of infants that experience an adverse event that is deemed related to Sofosbuvir/Velpatasvir|Number of maternal participants whose pregnancy results in a stillbirth or intrauterine fetal demise|Number of maternal participants that experience intrapartum hemorrhage|Number of maternal participants that experience postpartum hemorrhage|Number of maternal participants that experience a hypertensive disorder of pregnancy|Number of maternal participants that develop gestational diabetes|Number of maternal participants that experience cholestasis of pregnancy|Number of maternal participants that experience intrauterine growth restriction|Number of maternal participants that develop severe maternal morbidity|Number of maternal participants that are admitted to the intensive care unit|Number of maternal deaths|Number of preterm neonates (<37 weeks) admitted to the neonatal intensive care unit for severe neonatal morbidity|Number of term neonates (>=37 weeks) admitted to the neonatal intensive care unit for severe neonatal morbidity|Number of neonates admitted to the neonatal intensive care unit|Number of neonatal deaths|Number of neonates with major malformations|Weight of infant participant at 8 Weeks|Weight of infant participant at 6 months|Weight of infant participant at 12 months|Length of infant participant at 8 weeks|Length of infant participant at 6 months|Length of infant participant at 12 months|Head circumference of infant participant at 8 weeks|Head circumference of infant participant at 6 months|Head circumference of infant participant at 12 months|Number of Infant Participants with Any Neurological Development Score Less than 6 at 6 months|Number of Infant Participants with Any Neurological Development Score Less than 6 at 12 months|Number of infant participants with with plasma level of HCV RNA PCR viral load that is below the lower limit of quantification at 8 weeks|Number of infant participants with with plasma level of HCV RNA PCR viral load that is below the lower limit of quantification at 6 months|Number of infant participants with with plasma level of HCV RNA PCR viral load that is below the lower limit of quantification at 12 months","Catherine Anne Chappell|Gilead Sciences|University of Pittsburgh","Female","18 Years to 45 Years   (Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY21080043","April 4, 2022","December 2024","December 2025","December 2, 2021",,"April 8, 2024","The Christ Hospital, Cincinnati, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|University of Pittsburgh, Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States|Victoria Hospital, London Health Sciences Center, London, Ontario, Canada|University Health Toronto, St Michaels Hospital, Toronto, Ontario, Canada|Toronto General Hospital, University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT05140941"
26,"NCT00046436","Rapid HIV Tests for Women Late in Pregnancy and During Labor",,"Terminated","No Results Available","HIV Infections",,,"National Institute of Allergy and Infectious Diseases (NIAID)|Centers for Disease Control and Prevention|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years and older   (Child, Adult, Older Adult)",,"7500","NIH|U.S. Fed","Observational","Time Perspective: Prospective","PACTG P1031",,,"March 2004","October 1, 2002",,"June 3, 2013","Univ. of Pennsylvania Health System, Hosp. of the Univ. of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00046436"
27,"NCT03151070","Scaling Up an Integrated Approach to Improve Delivery Care in North Guatemala With Stepped Wedge Design","QVLM","Completed","No Results Available","Maternal Sepsis During Labor|Hemorrhage, Postpartum|Eclampsia; Complicating Pregnancy|Pre-Eclampsia|Perinatal Morbidity","Other: QVLM Intervention package","Mother morbidity|Perinatal morbidity|Perinatal mortality|Counts of institutional deliveries","Hospital San Juan de Dios Guatemala|Grand Challenges Canada|PRONTO International","All","Child, Adult, Older Adult",,"32000","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","CIESARQVLM17","December 15, 2013","March 15, 2017","March 15, 2017","May 12, 2017",,"May 12, 2017",,,"https://ClinicalTrials.gov/show/NCT03151070"
28,"NCT06131749","Genital Tract Infections, the Vaginal Microbiome and Gestational Age at Birth Among Pregnant Women in South Africa",,"Active, not recruiting","No Results Available","Sexually Transmitted Infections (Not HIV or Hepatitis)|Premature Birth|Pregnancy; Infection|Microbial Colonization|Chlamydia Trachomatis Infection|Neisseria Gonorrheae Infection|Trichomonas Vaginitis|Mycoplasma Genitalium Infection|Bacterial Vaginosis|Vaginal Candida|Ureaplasma Urealyticum Infection|Genital Mycoplasma Infection|HIV Infections","Other: No intervention","Gestational age at birth|Preterm birth|Low birth weight|Miscarriage|Stillbirth","University of Bern|Foundation for Professional Development|Utrecht University|University of Pretoria|University of Cape Town|University of Southern California|University of Alabama at Birmingham|Louisiana State University Health Sciences Center in New Orleans","Female","18 Years and older   (Adult, Older Adult)",,"603","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SNSF197831","March 1, 2021","April 30, 2024","September 30, 2024","November 14, 2023",,"November 14, 2023","Empilweni Gompo Community Health Centre, East London, Eastern Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT06131749"
29,"NCT05226949","Host RNA Expression Profiles and Protein Biomarkers in Neonatal Herpes Simplex Virus Infection",,"Completed","No Results Available","Neonatal Herpes Simplex Infection|Neonatal HSV Infection|Neonatal Infection|Newborn; Infection|Herpes Simplex Virus Infection|Neonatal Sepsis|Neonatal Death|Viral Infection",,"Host RNA expression and proteomic profiles|Disease pathogenesis|Application of known host RNA profiles","Rigshospitalet, Denmark|Statens Serum Institut","All","0 Days to 28 Days   (Child)",,"159","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","H-21009288-HSV","January 1, 2022","February 28, 2022","April 30, 2022","February 7, 2022",,"December 28, 2022","Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark|Department of Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT05226949"
30,"NCT00000808","A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Nevirapine",,"National Institute of Allergy and Infectious Diseases (NIAID)","Female","13 Years to 60 Years   (Child, Adult)","Phase 1","49","NIH","Interventional","Primary Purpose: Treatment","ACTG 250|11227",,,"September 1998","August 31, 2001",,"November 4, 2021","UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States|San Francisco Gen Hosp, San Francisco, California, United States|UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States|Univ of Connecticut / Farmington, Farmington, Connecticut, United States|Connecticut Children's Med Ctr - Pediatric, Hartford, Connecticut, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Univ of Chicago Children's Hosp, Chicago, Illinois, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Boston City Hosp / Pediatrics, Boston, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Mount Sinai Med Ctr / Pediatrics, New York, New York, United States|San Juan City Hosp, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00000808"
31,"NCT03871491","Azithromycin-Prevention in Labor Use Study (A-PLUS)",,"Active, not recruiting","No Results Available","Maternal Death|Maternal Infections Affecting Fetus or Newborn|Neonatal SEPSIS|Maternal Sepsis During Labor|Neonatal Death|Postpartum Sepsis","Drug: Azithromycin|Drug: Placebo","Maternal: Incidence of maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group.|Neonatal: Incidence of intrapartum/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group|Incidence of chorioamnionitis|Incidence of endometritis|Incidence of other infections|Incidence of use of subsequent maternal antibiotic therapy|Maternal initial hospital length of stay|Incidence of maternal readmissions|Incidence of maternal admission to special care units|Incidence of maternal unscheduled visit for care|Incidence of maternal GI symptoms|Incidence of maternal death due to sepsis|Incidence of other neonatal infections (e.g. eye infection, skin infection)|Neonatal initial hospital length of stay|Incidence of neonatal readmissions|Incidence of neonatal admission to special care units|Incidence of neonatal unscheduled visit for care|Incidence of neonatal death due to sepsis|Incidence of pyloric stenosis within 42 days of delivery","NICHD Global Network for Women's and Children's Health|University of Alabama at Birmingham|University Teaching Hospital, Lusaka, Zambia|University of North Carolina, Chapel Hill|Kinshasa School of Public Health|University of Colorado, Denver|Institute of Nutrition of Central America and Panama|University of Virginia|International Centre for Diarrhoeal Disease Research, Bangladesh|Thomas Jefferson University|Columbia University|Aga Khan University|Boston University|Lata Medical Research Foundation, Nagpur|Indiana University School of Medicine|Moi Univeristy|RTI International|Bill and Melinda Gates Foundation|Jawaharlal Nehru Medical College","Female","18 Years to 45 Years   (Adult)","Phase 3","34000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","CP Azithromycin","September 1, 2020","October 7, 2022","September 30, 2024","March 12, 2019",,"May 11, 2023","ICDDRB, Dhaka, Bangladesh|Kinshasa School of Public Health, Kinshasa, Congo, The Democratic Republic of the|Institute for Nutrition of Central America and Panama (INCAP), Guatemala City, Guatemala|Jawaharlal Nehru Medical College, Belagam, India|Lata Medical Research Foundation, Nagpur, India|Moi University School of Medicine, Eldoret, Kenya|The Aga Khan University, Karachi, Pakistan|University Teaching Hospital, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT03871491"
32,"NCT04763486","Prophylactic Antibiotic After Perineal Tear","PATPET","Unknown status","No Results Available","Puerperal Infection","Drug: Cefazolin (Cefamezin)","Number of participants with a fever after delivery|Way of delivery","Meir Medical Center","Female","18 Years to 45 Years   (Adult)","Not Applicable","2500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","0189-19-MMC","March 1, 2021","March 1, 2022","March 1, 2023","February 21, 2021",,"February 23, 2021","Meir Medical Center, Kfar Saba,, Israel",,"https://ClinicalTrials.gov/show/NCT04763486"
33,"NCT04792710","Kefazolin Versus Kefazolin Plus Metronidazole to Reduce Postpartum Infection",,"Unknown status","No Results Available","Prevention of Postpartum Sepsis","Drug: Metronidazole","Efficacy of reducing surgical site infection|Efficacy of reducing urinary tact infections|Efficacy of reducing postpartum endometritis","University of Pretoria","Female","18 Years and older   (Adult, Older Adult)","Phase 4","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","PPS trial 1","March 8, 2021","March 31, 2022","June 30, 2022","March 11, 2021",,"March 11, 2021","Kalafong Provincial Tertiary Hospital, Pretoria, Gauteng Province, South Africa",,"https://ClinicalTrials.gov/show/NCT04792710"
34,"NCT00376493","Prolonged Treatment for Infected Abortion After Hospital Discharge.","APA","Terminated","No Results Available","Septic Abortion","Drug: metronidazole and doxycycline","Hospital re-admission|minimal or absent vaginal bleeding|walking normally|important decrease of pain|no fever","Hospital de Clinicas de Porto Alegre","Female","14 Years to 50 Years   (Child, Adult)","Phase 4","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APA 05-452","May 2006","December 2007","December 2007","September 15, 2006",,"March 13, 2008","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil",,"https://ClinicalTrials.gov/show/NCT00376493"
35,"NCT02309346","Clindamycin Once a Day in Septic Abortion","CLINDA-PRO","Unknown status","No Results Available","Septic Abortion","Drug: Clindamycin","Cure (Clinical improvement defined as reduce of pain, bleeding and no fever for 48h)|Complications (Return to the hospital for admission related to the evacuation procedure within 7 days)","Hospital de Clinicas de Porto Alegre","Female","13 Years to 50 Years   (Child, Adult)","Phase 4","190","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14-0328","December 31, 2014","November 2019","December 2019","December 5, 2014",,"August 28, 2018","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT02309346"
36,"NCT00353743","The Use of Antibiotics After Hospital Discharge in Septic Abortion","APA","Terminated","No Results Available","Abortion, Septic","Drug: placebo|Drug: doxycycline plus metronidazole","Clinical cure defined as no fever, no abdominal pain or bleeding.","Hospital de Clinicas de Porto Alegre","Female","18 Years to 50 Years   (Adult)","Not Applicable","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","05-452|GPPG 05-452","May 2006","November 2007","December 2007","July 19, 2006",,"December 19, 2008","Hospital de Clínias de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT00353743"
37,"NCT01507974","Examination of the Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections",,"Completed","No Results Available","Pregnancy Complications","Drug: Preventive antibiotic treatment- NITROFURANTOIN|Drug: Preventive antibiotic treatment- CEPHALEXIN|Drug: PREVENTIVE TREATMENT- AMOXICILLIN|Drug: PREVENTIVE TREATMENT- AMOXICILLIN AND CLAVULANATE POTASSIUM|Drug: PREVENTIVE TREATMENT- CEFUROXIME|Drug: PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM","Urinary tract complications","HaEmek Medical Center, Israel","Female","18 Years to 50 Years   (Adult)","Not Applicable","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0068-11-EMC","January 16, 2012","July 1, 2014","January 1, 2015","January 11, 2012",,"May 19, 2020","Dep of OG/GYN, Emek Medical Center, Afula, Israel",,"https://ClinicalTrials.gov/show/NCT01507974"
38,"NCT06231056","Probiotic Supplementation as Prophylactic for Group B β-hemolytic Streptococcus (GBS) Infection",,"Completed","No Results Available","Genitourinary; Infection, Complicating Pregnancy","Dietary Supplement: Probiotic iNatal®","Bacteriological assessment|Clinical assessments at the end of pregnancy|clinical assessments at the end of pregnancy|Rate of incidence of side effects","Liaquat University of Medical & Health Sciences|Università degli Studi dell'Insubria","Female","18 Years to 45 Years   (Adult)","Not Applicable","250","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","LUMHS/iNatal/20.01.2024","January 1, 2019","December 31, 2020","June 30, 2023","January 30, 2024",,"January 30, 2024","Department of Obstetrics and Gynecology PERUGIA HOSPITAL, Perugia, Italy",,"https://ClinicalTrials.gov/show/NCT06231056"
39,"NCT03397615","Effect of Vaginal Douching With Betadine Before CS for Prevention of Post Operative Infections",,"Unknown status","No Results Available","Puerperal Infection","Behavioral: Betadine douches","Postpartum endometritis|Postoperative wound infection|Postoperative fever","Cairo University","Female","18 Years to 40 Years   (Adult)","Not Applicable","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16","January 3, 2019","December 2019","December 2019","January 12, 2018",,"July 26, 2019","Kasr Alainy medical school, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT03397615"
40,"NCT00017797","Problems Associated With the Use of Anti-HIV Drugs in HIV-Infected Pregnant Women",,"Completed","No Results Available","HIV Infections|Pregnancy",,,"National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years and older   (Child, Adult, Older Adult)",,"160","NIH","Observational","Observational Model: Case-Control","ACTG A5084|AACTG A5084",,,,"August 31, 2001",,"August 7, 2006","Univ of Alabama at Birmingham - Pediatric, Birmingham, Alabama, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Howard Univ Hosp, Washington, District of Columbia, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|The Med Ctr Inc, Columbus, Georgia, United States|Univ of Hawaii, Honolulu, Hawaii, United States|Mt Sinai Hosp Med Ctr / Dept of Pediatrics, Chicago, Illinois, United States|Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States|The CORE Ctr, Chicago, Illinois, United States|Indiana Univ Hosp, Indianapolis, Indiana, United States|Methodist Hosp of Indiana / Life Care Clinic, Indianapolis, Indiana, United States|Wishard Hosp, Indianapolis, Indiana, United States|Univ of Marlyand (Pediatric), Baltimore, Maryland, United States|Brigham and Womens Hosp, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Hutzel Hospital, Detroit, Michigan, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Hennepin County Med Ctr, Minneapolis, Minnesota, United States|Univ of Minnesota, Minneapolis, Minnesota, United States|Washington Univ (St.Louis), St.Louis, Missouri, United States|St Peter's Med Ctr, New Brunswick, New Jersey, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Jacobi Med Ctr, Bronx, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Metropolitan Hosp Ctr, New York, New York, United States|Univ of Rochester Medical Center, Rochester, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Univ of Cincinnati, Cincinnati, Ohio, United States|Case Western Reserve Univ, Cleveland, Ohio, United States|MetroHealth Med Ctr, Cleveland, Ohio, United States|Univ of Pittsburgh, Pittsburgh, Pennsylvania, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States|Univ of Washington, Seattle, Washington, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|San Juan City Hosp, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00017797"
41,"NCT00194142","Cytomegalovirus (CMV) Infection in Amniotic Fluid",,"Completed","No Results Available","Pregnancy Complications|Cytomegalovirus Infections",,,"University of Pennsylvania","Female","15 Years to 45 Years   (Child, Adult)",,"37","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","803583|R01 17625-03-14","July 2007","May 2008","May 2008","September 19, 2005",,"August 17, 2016","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00194142"
42,"NCT00197561","Partnership on Nutrition and HIV/AIDS Research in Tanzania: Exploratory Research Study on Selenium and HIV Infection",,"Completed","No Results Available","HIV Infections|Pregnancy Complications","Dietary Supplement: Placebo|Dietary Supplement: Selenium","Change in CD4 cell counts and viral load from baseline to six weeks and six months postpartum in HIV-1 positive women|Risk of lower genital shedding of HIV-1 infected cells at 36 wks gestation|Risk of subclinical mastitis as defined by elevated sodium concentrations in breastmilk at 6 weeks postpartum|Fetal death, premature delivery, and low birth weight","Harvard School of Public Health (HSPH)|Muhimbili University of Health and Allied Sciences","Female","18 Years and older   (Adult, Older Adult)","Phase 3","915","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HD43555","September 2003","August 2006","August 2006","September 20, 2005",,"November 11, 2010","Muhimibili University College of Health Scienes, Upanga, Dar es Salaaam, Tanzania",,"https://ClinicalTrials.gov/show/NCT00197561"
43,"NCT05603624","Effect of Sterile Versus Clean Gloves Intrapartum and Postpartum Infections at Term",,"Terminated","No Results Available","Chorioamnionitis|Intrauterine Infection|Postpartum Endometritis|Puerperal Infection","Procedure: Cervical examination to assess labor","Chorioamnionitis or intraamniotic or intrauterine infection|Postpartum endometritis","Eastern Virginia Medical School","Female","18 Years to 50 Years   (Adult)","Not Applicable","163","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","21-09-FB-0206","September 2, 2021","September 1, 2022","September 1, 2022","November 2, 2022",,"August 25, 2023","Eastern Virginia Medical School, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT05603624"
44,"NCT00194311","Human Papillomavirus (HPV) Infection in Pregnancy",,"Completed","No Results Available","Papillomavirus Infections|Pregnancy Complications",,,"University of Pennsylvania|National Institutes of Health (NIH)","Female","13 Years to 45 Years   (Child, Adult)",,"620","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","801452|R01HD042100-15","April 2005","August 2007","August 2007","September 19, 2005",,"August 17, 2016","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00194311"
45,"NCT05632705","Efficacy of Using a Closing Pack to Reduce Postpartum Sepsis",,"Completed","No Results Available","Prevention of Postpartum Sepsis","Other: Closing pack","Efficacy to reduce surgical site infections within seven days|Efficacy to reduce postpartum endometritis within seven days|Feasibility of using a closure pack","University of Pretoria","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","PPS trial 2","March 8, 2021","January 31, 2022","April 30, 2022","November 30, 2022",,"November 30, 2022","Kalafong Provincial Tertiary Hospital, Pretoria, Gauteng Province, South Africa",,"https://ClinicalTrials.gov/show/NCT05632705"
46,"NCT00001106","A Study of Zidovudine in HIV-Infected Pregnant Women and Their Children",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Zidovudine",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","1 Day to 50 Years   (Child, Adult)","Phase 1","40","NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","ACTG 082|11057",,,"March 1994","August 31, 2001",,"November 1, 2021","Kaiser - Edgemont Street / UCLA Med Ctr, Los Angeles, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Boston City Hosp / Pediatrics, Boston, Massachusetts, United States|UMDNJ - New Jersy Med School, Newark, New Jersey, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Children's Hosp of Seattle, Seattle, Washington, United States|Univ of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00001106"
47,"NCT00000960","The Safety and Effectiveness of Zidovudine in HIV-Infected Pregnant Women and Their Infants",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Zidovudine",,"National Institute of Allergy and Infectious Diseases (NIAID)|Glaxo Wellcome","All","1 Day to 60 Years   (Child, Adult)","Phase 3","1496","NIH|Industry","Interventional","Primary Purpose: Treatment","ACTG 076|11050",,,"June 1994","August 31, 2001",,"October 29, 2021","Univ of Alabama at Birmingham Schl of Med / Pediatrics, Birmingham, Alabama, United States|Univ of Alabama at Birmingham, Birmingham, Alabama, United States|UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States|San Francisco Gen Hosp, San Francisco, California, United States|Children's Hosp of Denver, Denver, Colorado, United States|Univ of Connecticut / Farmington, Farmington, Connecticut, United States|Univ of Connecticut Health Ctr, Farmington, Connecticut, United States|Howard Univ Hosp, Washington, District of Columbia, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Northwestern Univ Med School, Chicago, Illinois, United States|Cook County Hosp, Chicago, Illinois, United States|Univ of Illinois College of Medicine / Pediatrics, Chicago, Illinois, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Univ of Chicago Children's Hosp, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore, Maryland, United States|Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States|Johns Hopkins Hosp, Baltimore, Maryland, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Boston City Hosp / Pediatrics, Boston, Massachusetts, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|UMDNJ - New Jersy Med School, Newark, New Jersey, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Children's Hosp of New Jersey / UMDNJ - New Jersey Med Schl, Newark, New Jersey, United States|Children's Hosp at Albany Med Ctr, Albany, New York, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Albert Einstein College of Medicine, Bronx, New York, United States|SUNY - Brooklyn, Brooklyn, New York, United States|SUNY / Health Sciences Ctr at Brooklyn / Pediatrics, Brooklyn, New York, United States|Beth Israel Med Ctr / Pediatrics, New York, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Cornell Univ Med College, New York, New York, United States|Mount Sinai Med Ctr / Pediatrics, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Univ of Rochester Medical Center, Rochester, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Westchester Hosp, Valhalla, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Carolinas Med Ctr, Charlotte, North Carolina, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Univ of Cincinnati, Cincinnati, Ohio, United States|Children's Hosp of Philadelphia, Philadelphia, Pennsylvania, United States|Hosp of the Univ of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, United States|Rhode Island Hosp / Brown Univ, Providence, Rhode Island, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Children's Med Ctr of Dallas, Dallas, Texas, United States|Lyndon Baines Johnson Gen Hosp, Houston, Texas, United States|Texas Children's Hosp / Baylor Univ, Houston, Texas, United States|Children's Hosp of Seattle, Seattle, Washington, United States|Ramon Ruiz Arnau Univ Hosp / Pediatrics, Bayamon, Puerto Rico|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico|UPR Children's Hosp / UPR School of Medicine, San Juan, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00000960"
48,"NCT00000839","A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Didanosine",,"National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb","Female","13 Years and older   (Child, Adult, Older Adult)","Phase 1","12","NIH|Industry","Interventional","Primary Purpose: Treatment","ACTG 249|11226",,,"June 2001","August 31, 2001",,"October 29, 2021","UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States|UCSD Maternal, Child, and Adolescent HIV CRS, San Diego, California, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States|Tulane Univ. Health Science Ctr., Tulane Univ. Hosp. & Clinic, New Orleans, Louisiana, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|NJ Med. School CRS, Newark, New Jersey, United States|Columbia IMPAACT CRS, New York, New York, United States|Incarnation Children's Ctr., New York, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00000839"
49,"NCT00001041","Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)",,"Completed","No Results Available","HIV Infections|Pregnancy","Biological: rgp120/HIV-1MN",,"National Institute of Allergy and Infectious Diseases (NIAID)","Female","16 Years to 40 Years   (Child, Adult)","Phase 1","24","NIH","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Prevention","ACTG 235|AVEG 104|11212",,,"July 1998","August 31, 2001",,"November 1, 2021","San Francisco Gen. Hosp., San Francisco, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States|Washington U CRS, Saint Louis, Missouri, United States|St. Louis ConnectCare, Infectious Diseases Clinic, Saint Louis, Missouri, United States|Univ. of Rochester ACTG CRS, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT00001041"
50,"NCT00136370","Prevention of Perinatal Sepsis (PoPS): Evaluation of Chlorhexidine Wipes of Birth Canal and Newborn",,"Unknown status","No Results Available","Infant, Newborn, Diseases|Sepsis|Puerperal Infection","Drug: Chlorhexidine|Procedure: Birth canal wipe|Procedure: sterile water external genital wipe","Rates of culture-confirmed or clinical neonatal sepsis, < 3 days of life|Rate of vertical transmission of colonization with group B streptococcus (GBS)|Rates of culture-confirmed or clinical neonatal sepsis (non-nosocomial), 3 to 28 days of life|Rates of serious maternal per partum infections including: endometritis, culture-confirmed post-partum sepsis, and post-partum perineal wound infection|Rates of neonatal hospitalization, < 3 days of life|Rates of neonatal hospitalization, < 28 days of life|Rates of neonatal hospitalization, suspected sepsis|Rate of vertical transmission of colonization with E. coli or Klebsiella species","Centers for Disease Control and Prevention|Bill and Melinda Gates Foundation|United States Agency for International Development (USAID)|National Vaccine Program Office","Female","15 Years and older   (Child, Adult, Older Adult)","Phase 3","8000","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CDC-NCID-3842|#U50 CCU021960, 02075|RFA CI05-059","April 2004",,"November 2007","August 29, 2005",,"September 24, 2007","Chris Hani Baragwanath Hospital, Soweto, Gauteng, South Africa",,"https://ClinicalTrials.gov/show/NCT00136370"
51,"NCT01637870","Negative Pressure Wound Therapy After Cesarean Delivery",,"Completed","Has Results","Major Puerperal Infection, Postpartum|Wound Complications|Wound Seroma|Caesarean Section Wound Separation|Wound Infection","Device: Prevena negative pressure wound system","Wound Complication Rate","Abbey Hardy-Fairbanks|Kinetic Concepts, Inc.|University of Iowa","Female","18 Years to 55 Years   (Adult)","Not Applicable","110","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","201109727","August 2012","February 2013","February 2013","July 11, 2012","April 18, 2018","April 18, 2018","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT01637870"
52,"NCT03248297","Antibiotic Prophlaxis for High-risk Laboring Women in Low Income Countries",,"Completed","Has Results","Postpartum Sepsis|Postpartum Endometritis|Postpartum Fever","Drug: Azithromycin|Drug: Azithromycin and amoxicillin|Drug: Placebo","Number of Participants Who Experienced Composite Peripartum Infection or Death|Number of Participants Who Experienced Pyelonephritis|Number of Participants Who Experienced Breast Infection|Number of Participants Who Experienced Other Infection|Number of Participants Who Experienced Fever|Number of Participants Who Experienced Hypothermia|Number of Participants Who Needed PP Antibiotic|Number of Participants Who Experienced Transfusion|Number of Participants Who Experienced Stillbirth|Length of Stay|Number of Participants Who Experienced a Clinic Visit|Number of Participants Who Experienced a Maternal Readmission","University of Alabama at Birmingham|Merck Sharp & Dohme LLC","Female","Child, Adult, Older Adult","Phase 4","756","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CHI UAB MISP # 54628","January 12, 2018","May 15, 2020","October 1, 2020","August 14, 2017","July 18, 2022","July 18, 2022","Cameroon Baptist Convention Health Services, Bamenda, Cameroon","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/97/NCT03248297/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03248297"
53,"NCT06310720","Postpartum Video Education in High Risk Populations",,"Not yet recruiting","No Results Available","Postpartum Hemorrhage|Postpartum Depression|Postpartum Sepsis|Postpartum Preeclampsia|Patient Empowerment|Patient Education|Postpartum Care","Other: Video Education","Change in baseline and post-education questionnaire score|Change in post-education and post-discharge questionnaire score|Number of participants who attended 6 week postpartum visit|Healthcare utilization: Number of clinic visits|Healthcare utilization: Number of phone calls|Healthcare utilization: Number of urgent care/emergency room visits|Mean difference in patient satisfaction rating","Weill Medical College of Cornell University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","23-10026618","March 2024","December 2024","December 2024","March 15, 2024",,"March 15, 2024","Alexandra Cohen Hospital for Women and Newborns, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT06310720"
54,"NCT05159726","Postpartum Video Education",,"Completed","No Results Available","Postpartum Hemorrhage|Postpartum Preeclampsia|Postpartum Sepsis|Postpartum Depression|Patient Empowerment|Patient Education|Postpartum Care","Other: Video Education","Change in baseline and post-education questionnaire score|Change in post-education and post-discharge questionnaire score|Compliance with Postpartum Care|Healthcare utilization|Patient satisfaction","Yale University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2000031817","July 5, 2022","August 20, 2022","December 31, 2022","December 16, 2021",,"February 1, 2023","Yale New Haven Hospital, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT05159726"
55,"NCT01039051","Diet and Lifestyle Intervention Study in Postpartum Women in China",,"Unknown status","No Results Available","Puerperal Infection|Fever|Constipation|Hemorrhoids|Anal Fissure|Breast Disease|Oral Ulcers|Anemia","Behavioral: Diet and Lifestyle Intervention in Chinese Postpartum Women","Changes in the knowledge and belief about postpartum practice among the women|Changes in the nutritional status, postpartum recovery and health status","Huazhong University of Science and Technology|Qingdao University|Southern Medical University, China|Centers for Disease Control and Prevention, China","Female","20 Years to 40 Years   (Adult)","Phase 2|Phase 3","1600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","2008BA158B07","June 2009","December 2009","June 2010","December 24, 2009",,"December 24, 2009","Southern Medical University, Guangzhou, Guangdong, China|Huazhong University of Science and Technology, Wuhan, Hubei, China|Qingdao University, Qingdao, Shandong, China",,"https://ClinicalTrials.gov/show/NCT01039051"
56,"NCT00017719","Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Lamivudine|Drug: Lamivudine/Zidovudine|Drug: Nelfinavir mesylate|Drug: Nevirapine|Drug: Zidovudine","Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery)|proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 48 weeks postpartum|Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 50 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery)|proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 50 copies/ml at 48 weeks postpartum, and to less than 500 and 50 copies/ml at 104 weeks postpartum|study treatment adherence and health status by self-report, correlated with predose nelfinavir or nevirapine level at 34 weeks gestation and 8 weeks postpartum|difference between postpartum and pregnancy 12-hour area under the concentration curve (AUC) for nevirapine|time of trough levels in relation to the morning dose of nevirapine and nelfinavir at 34 weeks gestation and 8 weeks postpartum and correlation of trough levels with viral load|incidence of HIV viral resistance by genotype among women in each treatment group at the time of virologic failure|incidence of abnormal glucose tolerance, gestational diabetes, and abnormal lactate levels during pregnancy in each treatment group|incidence of impaired glucose tolerance, diabetes, hyperinsulinemia, and elevated cholesterol and triglycerides at 8 weeks postpartum in each treatment group|incidence of anemia, hypoglycemia, and abnormal liver function studies among infants born to women in each treatment group|incidence of prematurity (less than 37 weeks), extreme prematurity (less than 32 weeks), low birth weight (less than 2.5 kg), and very low birth weight (less than 1.5 kg) among infants born to women in each treatment group|perinatal HIV transmission among infants born to women in each treatment group","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","14 Years and older   (Child, Adult, Older Adult)","Phase 3","440","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1022|10192|ACTG P1022|PACTG P1022","May 2002",,"March 2006","August 31, 2001",,"November 1, 2021","Usc La Nichd Crs, Los Angeles, California, United States|UCSD Mother-Child-Adolescent Program CRS, San Diego, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases, Torrance, California, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|Univ. of Miami Miller School of Medicine - Jackson Memorial Hosp., Miami, Florida, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Columbus Regional HealthCare System, The Med. Ctr., Columbus, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease, Chicago, Illinois, United States|Tulane Univ. Health Science Ctr., Tulane Univ. Hosp. & Clinic, New Orleans, Louisiana, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States|Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|BMC, Div. of Ped Infectious Diseases, Boston, Massachusetts, United States|Brigham and Women's Hosp., Div. of Infectious Disease, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Univ. of Mississippi Med. Ctr Children's Hosp., Jackson, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|Montefiore Med. Ctr. - AECOM, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|Strong Memorial Hospital Rochester NY NICHD CRS, Rochester, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Univ. of Cincinnati CRS, Cincinnati, Ohio, United States|Case CRS, Cleveland, Ohio, United States|MetroHealth CRS, Cleveland, Ohio, United States|Oregon Health & Science Univ. - Dept. of Peds., Div. of Infectious Disease, Portland, Oregon, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States|Vanderbilt Univ. Med. Ctr., Div. of Ped. Infectious Diseases, Nashville, Tennessee, United States|Texas Children's Hosp. CRS, Houston, Texas, United States|Univ. of Washington NICHD CRS, Seattle, Washington, United States|UW Medicine - Harborview Med. Ctr., Northwest Family Ctr., Seattle, Washington, United States|UW School of Medicine - CHRMC, Seattle, Washington, United States|Seattle Children's Hospital CRS, Seattle, Washington, United States|Princess Margaret Hosp. Bahamas NICHD CRS, Nassau, Bahamas|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hosp. dos Servidores do Estado CRS, Rio de Janeiro, Brazil|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00017719"
57,"NCT00000828","Study of Perinatal Transmission of Zidovudine-Resistant HIV Among Pregnant Women Treated With Zidovudine",,"Completed","No Results Available","HIV Infections|Pregnancy",,,"National Institute of Allergy and Infectious Diseases (NIAID)","Female","13 Years to 60 Years   (Child, Adult)",,"250","NIH","Observational",,"ACTG 255",,,,"August 31, 2001",,"June 24, 2005","Univ of Alabama at Birmingham Schl of Med / Pediatrics, Birmingham, Alabama, United States|UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|Long Beach Memorial (Pediatric), Long Beach, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States|Univ of Connecticut / Farmington, Farmington, Connecticut, United States|Connecticut Children's Med Ctr - Pediatric, Hartford, Connecticut, United States|Children's Hosp of Washington DC, Washington, District of Columbia, United States|Howard Univ Hosp, Washington, District of Columbia, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Univ of Chicago Children's Hosp, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Univ Hosp, New Orleans, Louisiana, United States|Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Brigham and Women's Hosp, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Mount Sinai Med Ctr / Pediatrics, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Incarnation Children's Ctr / Columbia Presbyterian Med Ctr, New York, New York, United States|Univ of Rochester Medical Center, Rochester, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Columbus Children's Hosp, Columbus, Ohio, United States|San Juan City Hosp, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00000828"
58,"NCT00000862","A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Zidovudine",,"National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 1","36","NIH","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Treatment","ACTG 324|11298|PACTG 324",,,"November 2003","August 31, 2001",,"October 28, 2021","UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States|Univ of California, San Francisco, San Francisco, California, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami / Jackson Memorial Hosp, Miami, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Children's Hosp of the King's Daughters, Norfolk, Virginia, United States|San Juan City Hosp, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00000862"
59,"NCT00000888","Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Ritonavir|Drug: Lamivudine|Drug: Zidovudine",,"National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years and older   (Child, Adult, Older Adult)","Phase 1","14","NIH","Interventional","Primary Purpose: Treatment","ACTG 354|10604|PACTG 354",,,"April 2001","August 31, 2001",,"October 29, 2021","Univ. of Miami Miller School of Medicine - Jackson Memorial Hosp., Miami, Florida, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Regional Med Ctr at Memphis, Memphis, Tennessee, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00000888"
60,"NCT00000878","A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Lamivudine|Drug: Stavudine|Drug: Zidovudine",,"National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years and older   (Child, Adult, Older Adult)","Phase 1","26","NIH","Interventional","Primary Purpose: Treatment","ACTG 332|11304|PACTG 332",,,"October 2001","August 31, 2001",,"October 29, 2021","Los Angeles County - USC Med Ctr, Los Angeles, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States|Howard Univ Hosp, Washington, District of Columbia, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami / Jackson Memorial Hosp, Miami, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Univ of Chicago Children's Hosp, Chicago, Illinois, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Brigham and Women's Hosp, Boston, Massachusetts, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Children's Hosp at Albany Med Ctr, Albany, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Temple Univ School of Medicine, Philadelphia, Pennsylvania, United States|Regional Med Ctr at Memphis, Memphis, Tennessee, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00000878"
61,"NCT00000887","A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Nelfinavir mesylate|Drug: Lamivudine|Drug: Zidovudine",,"National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years and older   (Child, Adult, Older Adult)","Phase 1","24","NIH","Interventional","Primary Purpose: Treatment","ACTG 353|10603|PACTG 353",,,"July 2004","August 31, 2001",,"October 29, 2021","Usc La Nichd Crs, Los Angeles, California, United States|Tulane Univ. Health Science Ctr., Tulane Univ. Hosp. & Clinic, New Orleans, Louisiana, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|UNC at Chapel Hill School of Medicine - Dept. of Peds., Div. of Immunology & Infectious Diseases, Chapel Hill, North Carolina, United States|St. Christopher's Hosp. for Children, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00000887"
62,"NCT00000944","A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Indinavir sulfate|Drug: Lamivudine|Drug: Zidovudine",,"National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years and older   (Child, Adult, Older Adult)","Phase 1","24","NIH","Interventional","Primary Purpose: Prevention","ACTG 358|PACTG 358|10606",,,"March 2003","August 31, 2001",,"October 29, 2021","UCSF Pediatric AIDS CRS, San Francisco, California, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|Jacobi Med. Ctr., Bronx, New York, United States|Montefiore Med. Ctr. - AECOM, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT00000944"
63,"NCT00000751","A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Anti-HIV Immune Serum Globulin (Human)|Drug: Globulin, Immune|Drug: Zidovudine",,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)","Female","13 Years to 60 Years   (Child, Adult)","Phase 3","1600","NIH","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Treatment","ACTG 185",,,"August 2007","August 31, 2001",,"September 30, 2008","UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States|San Francisco Gen Hosp, San Francisco, California, United States|UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States|Denver Gen Hosp, Denver, Colorado, United States|Children's Hosp of Denver, Denver, Colorado, United States|Univ of Connecticut / Farmington, Farmington, Connecticut, United States|Children's Hosp of Washington DC, Washington, District of Columbia, United States|Washington Hosp Ctr, Washington, District of Columbia, United States|Howard Univ Hosp, Washington, District of Columbia, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Univ of Illinois College of Medicine / Pediatrics, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Univ Hosp, New Orleans, Louisiana, United States|Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore, Maryland, United States|Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Brigham and Women's Hosp, Boston, Massachusetts, United States|Boston City Hosp / Pediatrics, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Children's Hosp at Albany Med Ctr, Albany, New York, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Mount Sinai Med Ctr / Pediatrics, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Univ of North Carolina at Chapel Hill / Duke Univ Med Ctr, Durham, North Carolina, United States|Case Western Reserve Univ - Pediatric, Cleveland, Ohio, United States|Children's Hosp of Philadelphia, Philadelphia, Pennsylvania, United States|Hosp of the Univ of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, United States|Saint Christopher's Hosp for Children, Philadelphia, Pennsylvania, United States|Temple Univ School of Medicine, Philadelphia, Pennsylvania, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Regional Med Ctr at Memphis, Memphis, Tennessee, United States|Methodist Hosp Central, Memphis, Tennessee, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Children's Med Ctr of Dallas, Dallas, Texas, United States|Hermann Hosp / Univ Texas Health Science Ctr, Houston, Texas, United States|Texas Children's Hosp / Baylor Univ, Houston, Texas, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|Ramon Ruiz Arnau Univ Hosp / Pediatrics, Bayamon, Puerto Rico|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00000751"
64,"NCT00000642","A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: CD4-IgG",,"National Institute of Allergy and Infectious Diseases (NIAID)|Genentech, Inc.","All","1 Day to 60 Years   (Child, Adult)","Phase 1","30","NIH|Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Prevention","ACTG 146|D0190g",,,,"August 31, 2001",,"June 24, 2005","SUNY - Brooklyn, Brooklyn, New York, United States|Texas Children's Hosp / Baylor Univ, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00000642"
65,"NCT00041964","A Study of HIV Levels During Pregnancy and After Childbirth",,"Completed","No Results Available","HIV Infections|Pregnancy",,,"National Institute of Allergy and Infectious Diseases (NIAID)","Female","13 Years and older   (Child, Adult, Older Adult)",,"129","NIH","Observational",,"ACTG A5150|ACTG A5153s|AACTG A5150|AACTG A5153s",,,,"July 22, 2002",,"July 24, 2012","Univ of Alabama at Birmingham, Birmingham, Alabama, United States|Los Angeles County Medical Center/USC, Los Angeles, California, United States|UCLA School of Medicine, Los Angeles, California, United States|UCSD Mother, Child & Adolescent HIV Program, San Diego, California, United States|San Francisco General Hosp, San Francisco, California, United States|Univ of Florida- Health Science Ctr, Jacksonville, Florida, United States|Emory Univ, Atlanta, Georgia, United States|University of Hawaii, Honolulu, Hawaii, United States|Northwestern University, Chicago, Illinois, United States|Cook County Hosp Core Ctr, Chicago, Illinois, United States|Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States|Chicago Childrens Memorial Hospital (Pediatric), Chicago, Illinois, United States|Indiana Univ Hosp, Indianapolis, Indiana, United States|Hutzel Hospital, Detroit, Michigan, United States|Childrens Hospital of Michigan, Detroit, Michigan, United States|Hennepin County Med Clinic, Minneapolis, Minnesota, United States|Univ of Med & Dentistry of NJ/Univ Hosp, Newark, New Jersey, United States|Jacobi Med Ctr, Bronx, New York, United States|NYU/Bellevue, New York,, New York, United States|Columbia University, New York, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Case Western Reserve Univ, Cleveland, Ohio, United States|MetroHealth Med Ctr, Cleveland, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Miriam Hosp / Brown Univ, Providence, Rhode Island, United States|The Regional Med Ctr, Memphis, Memphis, Tennessee, United States|Comprehensive Care Clinic, Nashville, Tennessee, United States|University of Texas, Southwestern Medical Center, Dallas, Texas, United States|Univ of Washington (Seattle), Seattle, Washington, United States|San Juan City Hosp, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00041964"
66,"NCT00001135","A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Infants",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Nevirapine",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","13 Years and older   (Child, Adult, Older Adult)","Phase 3","2009","NIH","Interventional","Masking: Double|Primary Purpose: Prevention","ACTG 316B|11292",,,"May 2001","August 31, 2001",,"November 1, 2021","Univ of Alabama at Birmingham - Pediatric, Birmingham, Alabama, United States|UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States|Children's Hosp of Washington DC, Washington, District of Columbia, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Children's Hosp of Philadelphia, Philadelphia, Pennsylvania, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Texas Children's Hosp / Baylor Univ, Houston, Texas, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00001135"
67,"NCT00000942","A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Babies",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Nevirapine",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","13 Years and older   (Child, Adult, Older Adult)","Phase 3","1244","NIH","Interventional","Masking: Double|Primary Purpose: Prevention","ACTG 316A|11291",,,"May 2001","August 31, 2001",,"October 29, 2021","Princess Margaret Hosp, Nassau, Bahamas|Hopital Hotel Dieu de Lyon, Lyon, France|CHRU de Nantes, Nantes, France|Universita Frederico II, Napoli, Italy|Hosp Doce De Octubre, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00000942"
68,"NCT00001046","Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)",,"Withdrawn","No Results Available","HIV Infections|Pregnancy|HIV Seronegativity","Biological: MF59|Biological: rgp120/HIV-1 SF-2",,"National Institute of Allergy and Infectious Diseases (NIAID)","Female","16 Years to 40 Years   (Child, Adult)","Phase 1","0","NIH","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Prevention","ACTG 233|11210",,,,"August 31, 2001",,"November 1, 2021",,,"https://ClinicalTrials.gov/show/NCT00001046"
69,"NCT00000777","Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)",,"Completed","No Results Available","HIV Infections|Pregnancy|HIV Seronegativity","Biological: gp160 Vaccine (MicroGeneSys)",,"National Institute of Allergy and Infectious Diseases (NIAID)","Female","16 Years to 40 Years   (Child, Adult)","Phase 1","24","NIH","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Treatment","ACTG 234|VEU 102|11211",,,"July 1998","August 31, 2001",,"October 28, 2021","Yale Univ Med School, New Haven, Connecticut, United States|Vanderbilt Univ Hosp, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00000777"
70,"NCT00006396","Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns",,"Completed","No Results Available","HIV Infections","Drug: Nevirapine|Drug: Zidovudine",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","1 Day and older   (Child, Adult, Older Adult)","Phase 3","1500","NIH","Interventional","Masking: Double|Primary Purpose: Prevention","HIVNET 012|11719",,,"November 2004","August 31, 2001",,"November 4, 2021","Missie Allen, Research Triangle Park, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00006396"
71,"NCT00000869","A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Nevirapine",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","13 Years and older   (Child, Adult, Older Adult)","Phase 3","2009","NIH","Interventional","Masking: Double|Primary Purpose: Treatment","ACTG 316|11290",,,"May 2001","August 31, 2001",,"October 28, 2021","Univ of Alabama at Birmingham - Pediatric, Birmingham, Alabama, United States|Univ of South Alabama, Mobile, Alabama, United States|UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|Long Beach Memorial (Pediatric), Long Beach, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States|San Francisco Gen Hosp, San Francisco, California, United States|UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States|Children's Hosp of Denver, Denver, Colorado, United States|Connecticut Children's Med Ctr, Farmington, Connecticut, United States|Univ of Connecticut / Farmington, Farmington, Connecticut, United States|Washington Hosp Ctr, Washington, District of Columbia, United States|Howard Univ Hosp, Washington, District of Columbia, United States|North Broward Hosp District, Fort Lauderdale, Florida, United States|Univ of Florida Gainesville, Gainesville, Florida, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami / Jackson Memorial Hosp, Miami, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Med College of Georgia, Augusta, Georgia, United States|The Med Ctr Inc, Columbus, Georgia, United States|Cook County Hosp, Chicago, Illinois, United States|Univ of Illinois College of Medicine / Pediatrics, Chicago, Illinois, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Univ of Chicago Children's Hosp, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Tulane Univ Hosp of New Orleans, New Orleans, Louisiana, United States|Univ Hosp, New Orleans, Louisiana, United States|Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore, Maryland, United States|Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Brigham and Women's Hosp, Boston, Massachusetts, United States|Boston City Hosp / Pediatrics, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Univ of Mississippi Med Ctr, Jackson, Mississippi, United States|Cooper Hosp - Univ Med Ctr / UMDNJ - New Jersey Med Schl, Camden, New Jersey, United States|UMDNJ - Robert Wood Johnson Med School / Pediatrics, New Brunswick, New Jersey, United States|St Peter's Med Ctr, New Brunswick, New Jersey, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Saint Joseph's Hosp and Med Ctr/UMDNJ - New Jersey Med Schl, Newark, New Jersey, United States|Children's Hosp at Albany Med Ctr, Albany, New York, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Bronx Municipal Hosp Ctr/Jacobi Med Ctr, Bronx, New York, United States|North Shore Univ Hosp, Great Neck, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Metropolitan Hosp Ctr, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Univ of Rochester Med Ctr, Rochester, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Univ of North Carolina at Chapel Hill / Duke Univ Med Ctr, Durham, North Carolina, United States|Children's Hosp of Philadelphia, Philadelphia, Pennsylvania, United States|Hosp of the Univ of Pennsylvania, Philadelphia, Pennsylvania, United States|Saint Christopher's Hosp for Children, Philadelphia, Pennsylvania, United States|Temple Univ School of Medicine, Philadelphia, Pennsylvania, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Regional Med Ctr at Memphis, Memphis, Tennessee, United States|Methodist Hosp Central, Memphis, Tennessee, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States|Children's Med Ctr of Dallas, Dallas, Texas, United States|Texas Children's Hosp / Baylor Univ, Houston, Texas, United States|Children's Hosp of the King's Daughters, Norfolk, Virginia, United States|Senetara Norfolk Gen Hosp, Norfolk, Virginia, United States|Med College of Virginia, Richmond, Virginia, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|Tacoma Gen Hosp, Tacoma, Washington, United States|Ramon Ruiz Arnau Univ Hosp / Pediatrics, Bayamon, Puerto Rico|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00000869"
72,"NCT03305991","Tuberculosis Infection in Women of Reproductive Age and Their Infants",,"Completed","No Results Available","Tuberculosis|Pregnancy Complications",,"Incidence of adverse pregnancy outcomes|Incidence of active tuberculosis in participants during pregnancy, post-partum period and periods outside pregnancy, respectively|Pattern of child growth with regard to maternal tuberculosis infection status during pregnancy|Incidence of tuberculosis infection in Ethiopian infants during the first four years of life","Lund University","Female","Child, Adult, Older Adult",,"2120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LundU-2015","December 1, 2015","March 12, 2024","March 12, 2024","October 10, 2017",,"March 13, 2024","Adama Health Center, Adama, Ethiopia|Adama Regional Hospital, Adama, Ethiopia|Gheda Health Center, Adama, Ethiopia",,"https://ClinicalTrials.gov/show/NCT03305991"
73,"NCT00006279","The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months",,"Completed","No Results Available","HIV Infections","Drug: Nevirapine",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","1 Day and older   (Child, Adult, Older Adult)","Phase 1","75","NIH","Interventional","Primary Purpose: Prevention","HIVNET 023|11720",,,"May 2005","August 31, 2001",,"November 1, 2021","Kathy George, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00006279"
74,"NCT00006075","A Study of Chlorhexidine in the Prevention of HIV-1 Transmission From Mothers to Their Babies",,"Completed","No Results Available","HIV Infections","Drug: Chlorhexidine gluconate",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","Child, Adult, Older Adult","Phase 2","150","NIH","Interventional","Primary Purpose: Prevention","HIVNET 025",,,"August 2007","August 31, 2001",,"September 30, 2008","Ann Koonce, Research Triangle Park, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00006075"
75,"NCT00001007","A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth",,"Completed","No Results Available","HIV Infections","Drug: Zidovudine",,"National Institute of Allergy and Infectious Diseases (NIAID)|Glaxo Wellcome","All","1 Day to 3 Months   (Child)","Phase 1","18","NIH|Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","ACTG 049|FDA 9D",,,,"August 31, 2001",,"July 15, 2008","Univ of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford Univ School of Medicine, Stanford, California, United States|Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States|Johns Hopkins Hosp, Baltimore, Maryland, United States|Boston Med Ctr, Boston, Massachusetts, United States|Duke Univ Med Ctr, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00001007"
76,"NCT00000864","A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women",,"Completed","No Results Available","HIV Infections","Drug: Abacavir sulfate|Drug: Zidovudine",,"National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","1 Day to 28 Days   (Child)","Phase 1","60","NIH","Interventional","Primary Purpose: Treatment","ACTG 321|11295|PACTG 321",,,"January 2001","August 31, 2001",,"October 28, 2021","UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama, United States|Usc La Nichd Crs, Los Angeles, California, United States|UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States|UCSD Maternal, Child, and Adolescent HIV CRS, San Diego, California, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Emory Univ. School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Atlanta, Georgia, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Med. Univ. of South Carolina, Div. of Ped. Infectious Diseases, Charleston, South Carolina, United States|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00000864"
77,"NCT00000879","A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers",,"Completed","No Results Available","HIV Infections|HIV Seronegativity","Biological: ALVAC(2)120(B,MN)GNP (vCP1452)|Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|Biological: ALVAC-HIV MN120TMG (vCP205)",,"National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","0 Days to 3 Days   (Child)","Phase 1","48","NIH","Interventional","Masking: Double|Primary Purpose: Prevention","ACTG 326|PACTG 326|10601",,,"April 2005","August 31, 2001",,"October 29, 2021","Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|Children's Hosp. of Orange County, Orange, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases, Torrance, California, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Chicago Children's CRS, Chicago, Illinois, United States|Tulane Univ. Health Science Ctr., Tulane Univ. Hosp. & Clinic, New Orleans, Louisiana, United States|Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|Univ. of Pennsylvania Health System, Hosp. of the Univ. of Pennsylvania, Philadelphia, Pennsylvania, United States|The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States|Seattle Children's Hospital CRS, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00000879"
78,"NCT02986802","Comparative Effectiveness of Treatment Options for Genital Herpes Infection to Reduce Adverse Pregnancy Outcomes","PCORIHSV","Completed","Has Results","HSV-2 Infection|PreTerm Birth|Pregnancy Complications",,"Number of Participants With Preterm Delivery|Number of Participants With a Low Birthweight Child","Kaiser Permanente|Patient-Centered Outcomes Research Institute","Female","18 Years and older   (Adult, Older Adult)",,"89132","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CN-16-2669","March 14, 2017","October 15, 2019","February 28, 2021","December 8, 2016","September 17, 2021","September 17, 2021","Division of Research, Oakland, California, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/02/NCT02986802/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02986802"
79,"NCT00197730","Trial of Vitamins Among Children of HIV-infected Women",,"Completed","No Results Available","HIV Infections|Pregnancy Complications","Drug: Multivitamins - vitamins B complex, C and E|Drug: Placebo","All-cause mortality and diarrheal morbidity|Child growth faltering, lower respiratory infections, HIV breastfeeding transmission, and maternal HIV disease progression in relation to breastfeeding","Harvard School of Public Health (HSPH)|Muhimbili University of Health and Allied Sciences","All","6 Weeks to 24 Months   (Child)","Phase 3","2387","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HD43688","June 2004","May 2008","May 2008","September 20, 2005",,"August 21, 2009","Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania",,"https://ClinicalTrials.gov/show/NCT00197730"
80,"NCT04463758","Covid-19 in Pregnancy: a French Population-based Cohort of Women and Newborns","Coropreg","Unknown status","No Results Available","covid19 Infection|Pregnancy Complications|Neonatal Complications","Other: An auto-questionnaire comprising three psychometric scales","Joint evaluation of morbi-mortality for mother and child up to 12 weeks postpartum|Number of women infection COVID-19|Severe forms of COVID-19 infection in the mother|Severe neonatal morbidity","Assistance Publique - Hôpitaux de Paris|INSERM, Epopé team","Female","Child, Adult, Older Adult",,"3060","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP200513","May 11, 2020","February 2022","October 2022","July 9, 2020",,"October 4, 2021","AP-HP Cochin, Paris, France",,"https://ClinicalTrials.gov/show/NCT04463758"
81,"NCT03826342","Technology-Based Intervention for Reducing Sexually Transmitted Infections and Substance Use During Pregnancy",,"Active, not recruiting","No Results Available","Sexually Transmitted Infection|Alcohol Use Complicating the Puerperium|Alcohol Use Complicating Pregnancy, Unspecified Trimester|Drug Use","Behavioral: Health Check-up for Expectant Moms|Behavioral: Time, attention, and information-matched control","Unprotected sexual occasions (USOs)|Number of days of alcohol use measured by Timeline Follow-Back (TLFB)|Number of days of illicit drug use measured by Timeline Follow-Back (TLFB)|Number of Sexually Transmitted Infections (STIs)|Number of unprotected sexual occasions (USOs)|Birth weight of baby|Baby head circumference|Baby birth length|Heavy episodic drinking days|Cost-effectiveness of Health Check-up for Expectant Moms (HCEM)","University of Michigan|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","250","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","HUM00143896|1R01HD093611-01A1","April 16, 2019","March 8, 2024","July 2024","February 1, 2019",,"April 9, 2024","West Ann Arbor Health Center, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03826342"
82,"NCT01357369","Study of Drug Concentration of Ondansetron and Cefazolin in Mothers and Neonates",,"Completed","No Results Available","Pregnancy Complications","Procedure: Phlebotomy","Pharmacokinetics (PK) results for Cefazolin and Ondansetron in maternal blood specimens|Identification of placental transfer of studied meds (Cefazolin and Ondansetron)|PK results of neonatal blood specimens","Stanford University","Female","18 Years to 45 Years   (Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SU-02252011-7482|IRB 20231","January 2011","December 2011","December 2011","May 20, 2011",,"April 21, 2016","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01357369"
83,"NCT04102644","Limiting Adverse Birth Outcomes in Resource-Limited Settings","LABOR","Completed","No Results Available","Birth Outcomes|Labor and Delivery|Respiratory Infection","Other: Observation","Number of cases of maternal death or severe morbidity|Number of cases of neonatal death or severe morbidity","University of North Carolina, Chapel Hill|Bill and Melinda Gates Foundation","All","18 Years and older   (Adult, Older Adult)",,"12020","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","19-0765|Z 31902","October 31, 2019","August 8, 2022","September 20, 2022","September 25, 2019",,"September 27, 2022","Korle Bu Teaching Hospital,, Accra, Ghana|Jawaharlal Nehru Medical College Women's and Children's Health Research Unit, KLE Academy of Higher Education and Research, Belgaum, Karnataka, India|Fakir Mohan Medical College and Hospital, Balasore, Odisha, India|Women and Newborn Hospital at University Teaching Hospital, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT04102644"
84,"NCT04416373","COVID-19 and Pregnancy Outcomes","COVID&PREG","Unknown status","No Results Available","Coronavirus Infection|Pregnancy Complications|Vertical Transmission of Infectious Disease|Breastfeeding|Neonatal Infection","Diagnostic Test: RT PCR SARS-CoV-2","SARS-CoV-2 Neonatal Infection|Perinatal mortality|ICU maternal admission|5 minute Apgar Score < 7|Preterm labour|PPROM|Miscarriage","Universidade Nova de Lisboa","Female","16 Years to 55 Years   (Child, Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID&PREG","March 22, 2020","December 2023","December 2023","June 4, 2020",,"June 4, 2020","Nova Medical School - UNL, Lisbon, Portugal",,"https://ClinicalTrials.gov/show/NCT04416373"
85,"NCT03347513","Eradication of H-pylori in Pregnancy and Its Effect on Iron Replacement Therapy?",,"Unknown status","No Results Available","Pregnancy Complications|Anemia, Iron Deficiency|H Pylori Infection","Drug: triple attack therapy|Drug: Ferrous(II)-glycine-sulphate complex 567.7 mg capsules","hemoglobin levels","Kasr El Aini Hospital","Female","up to 40 Years   (Child, Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A15112017","November 25, 2017","March 2019","May 2019","November 20, 2017",,"December 4, 2018","obstetrics and gynecology department, Kasr Alainy hospital, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT03347513"
86,"NCT05318144","Melatonin Levels on COVID-19 Positive Pregnant Women",,"Completed","No Results Available","COVID-19 Acute Respiratory Distress Syndrome|Pregnancy Related|Pregnancy Complications",,"Melatonin level","Nazan Yurtcu MD|Cumhuriyet University","Female","18 Years to 40 Years   (Adult)",,"228","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","COVID-19 and pregnancy","June 1, 2021","December 1, 2021","February 1, 2022","April 8, 2022",,"April 8, 2022","Samsun Training and Research Hospital, Samsun, Turkey",,"https://ClinicalTrials.gov/show/NCT05318144"
87,"NCT03570112","Transmission of Chronic Hepatitis C in Pregnancy",,"Completed","No Results Available","Hepatitis C|Pregnancy Complications|Vertical Disease Transmission","Drug: SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg","Evaluate the rate of vertical transmission|SVR12|Pre-Term Birth|Cholestasis of pregnancy|Low Birth Weight|Presence and severity of NAS/NOWS","The Christ Hospital|Gilead Sciences","Female","18 Years and older   (Adult, Older Adult)",,"40","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","18-08","June 8, 2018","November 22, 2022","February 27, 2023","June 26, 2018",,"February 8, 2024","Lindner Research Center at the Christ hospital, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03570112"
88,"NCT06352970","Effects of Tuberculosis Infection on Development and Function of the Placenta",,"Not yet recruiting","No Results Available","Pregnancy Related|Tuberculosis Infection|Placenta Diseases","Other: TB infection","Proportion of women with pathological placental findings according to the Amsterdam consensus criteria|Proportions of women with placental RNA and protein expression patterns linked to pregnancy- related disorders|Proportions of infants (born to participating women) with adverse outcome","Lund University|Addis Ababa University|Armauer Hansen Research Institute, Ethiopia","Female","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LundU-2024","May 1, 2024","December 31, 2025","December 31, 2027","April 8, 2024",,"April 8, 2024",,,"https://ClinicalTrials.gov/show/NCT06352970"
89,"NCT04769167","Congenital Heart Anomaly Risk in Maternal Enteroviral Infection and Diabetes","CHARMED","Active, not recruiting","No Results Available","Congenital Heart Disease|Viremia|Virus Diseases|Enterovirus|Enterovirus Infections|Heart Defects, Congenital|Heart Diseases|Prenatal Infection|Diabetes|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1|Diabetes Mellitus|Pregnancy in Diabetic|Pregnancy Complications|Prenatal","Other: Stool and Blood Specimen Collection|Other: Follow-up Medical Record Review","Prevalence of EVB Viremia|Cardiotropic Virus Detection|Maternal Immune Response","Washington University School of Medicine","Female","18 Years to 45 Years   (Adult)","Not Applicable","1500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Screening","202002043","February 1, 2021","February 20, 2024","December 2027","February 24, 2021",,"December 5, 2023","Barnes Jewish Hospital, Saint Louis, Missouri, United States|St Louis Childrens Hospital, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04769167"
90,"NCT03008421","Oral Probiotics to Reduce Vaginal Group B Streptococcal Colonization in Late Pregnancy",,"Completed","No Results Available","Vaginal Infection|Pregnancy Complications|Neonatal Sepsis|GBS","Dietary Supplement: Astarte® (HSO Health Care GmbH, Vienna, Austria)|Other: Placebo","GBS status|Neonatal sepsis|Gestational age at delivery|Neonatal birthweight|Live birth|Delivery mode","Medical University of Vienna","Female","18 Years to 55 Years   (Adult)","Not Applicable","1058","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","1001-2017","June 1, 2018","December 16, 2019","December 16, 2019","January 2, 2017",,"December 8, 2020","Medical University of Vienna, Vienna General Hospital, Department of Obstetrics and Gynecology, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT03008421"
91,"NCT05127252","Impact of the Microbiome on Time to Pregnancy and Pregnancy Outcomes in Fertile Women Attempting to Conceive","SweBioFertil","Recruiting","No Results Available","Pregnancy Complications|Contraception|Pregnancy Loss|Fertility|Microbial Colonization|Metabolome","Diagnostic Test: Vaginal and rectal microbiome and metabolome","The microbiome profile and metabolome associated with time to pregnancy, miscarriage, and live birth will be assessed.|Microbiome profiles and metabolome related to obstetric outcomes|The microbiome profile for women above age >38 and women below <38.|The influence of BMI, medications and comorbidities on the microbiome profiles.|Microbiome profile for those women who don't conceive within a year.|The metabolome of the recognized microbiome for women with normal pregnancy outcomes|The metabolome of the recognized microbiome for women who develop miscarriage or other pregnancy complications","Karolinska Institutet|Karolinska University Hospital","Female","18 Years to 40 Years   (Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Dnr 2021-03765","April 10, 2023","March 10, 2026","December 30, 2026","November 19, 2021",,"May 30, 2023","Reproductive Medicine, Karolinska University Hospital, Stockholm, Huddinge, Sweden|Reproduktionscentrum Akademiska sjukhuset, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT05127252"
92,"NCT01520597","National Study on Listeriosis and Listeria","MONALISA","Completed","No Results Available","Listeriosis|Pregnancy Complications|Infectious|Central Nervous System Infections|Septicemia|Sepsis; Listeria Monocytogenes",,"Clinical, biological and genetic risk factors for systemic listeriosis|Clinical/biological and radiological presentation of listeriosis|Current therapeutic practices","Assistance Publique - Hôpitaux de Paris|Institut Pasteur|French National sanitory","All","Child, Adult, Older Adult",,"2132","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","AOM 09068","November 1, 2009","April 5, 2013","July 20, 2023","January 30, 2012",,"January 19, 2024","Centre National de Reference et Centre Collaborateur OMS Listeria, Institut Pasteur, Paris, France",,"https://ClinicalTrials.gov/show/NCT01520597"
93,"NCT01290393","Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada",,"Terminated","No Results Available","Infections, Papillomavirus","Other: Data collection","Occurrence of spontaneous abortion during weeks 1-19 of gestation|Occurrence of other adverse pregnancy outcomes","GlaxoSmithKline|The Organization of Teratology Information Specialists","Female","15 Years to 25 Years   (Child, Adult)",,"2","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","114176","September 26, 2011","December 20, 2012","December 20, 2012","February 7, 2011",,"July 26, 2018","GSK Investigational Site, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT01290393"
94,"NCT01905462","Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK",,"Completed","No Results Available","Infections, Papillomavirus","Other: Data Collection|Biological: Cervarix","Occurrence of spontaneous abortion|Occurrence of other pregnancy outcomes|Baby's death","GlaxoSmithKline|Clinical Practice Research Datalink","Female","15 Years to 25 Years   (Child, Adult)",,"1046","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","114101","November 2012","August 2013","August 2013","July 23, 2013",,"September 30, 2013","GSK Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01905462"
95,"NCT04433364","COPE - COVID-19 in Pregnancy and Early Childhood","COPE","Active, not recruiting","No Results Available","Sars-CoV2|Covid-19|Pregnancy Complications|Pregnancy Preterm|Pregnancy in Diabetic|Neonatal Infection","Other: biological samples, questionnaires and interviews","Biobank with linkage to registers|Experiences of pregnancy during a pandemic","Sahlgrenska University Hospital, Sweden","Female","18 Years and older   (Adult, Older Adult)",,"3834","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-02848 0604","June 2, 2020","June 30, 2023","June 2, 2041","June 16, 2020",,"March 16, 2023","Falu Hospital, Falun, Dalarna, Sweden|Halmstad lasarett, Halmstad, Halland, Sweden|Varbergs sjukhus, Varberg, Halland, Sweden|Helsingborgs lasarett, Helsingborg, Skåne, Sweden|Skåne Universitetssjukhus, Lund, Skåne, Sweden|Eskiltuna hospital, Eskilstuna, Södermanland, Sweden|Boras hospital, Boras, VGR, Sweden|Sahlgrenska Univeristy Hospital, Gothenburg, VGR, Sweden|Ryhovs sjukhus, Jönköping, Sweden|Kalmar Lasarett, Kalmar, Sweden|Karlstad lasarett, Karlstad, Sweden|Kristiandstad länssjukhus, Kristianstad, Sweden|Skaraborgs sjukhus Skövde, Skövde, Sweden|BB Stockholm, Stockholm, Sweden|Danderyd, Stockholm, Sweden|Karolinska University Hospital Solna, Stockholm, Sweden|Karolinska University Hospital- Huddinge, Stockholm, Sweden|Södersjukhuset, Stockholm, Sweden|Södertälje, Stockholm, Sweden|Sundsvall, Sundsvall, Sweden|Umeå University Hospital, Umeå, Sweden|Uppsala University Hospital, Uppsala, Sweden|Västerås, Västerås, Sweden|Ystad, Ystad, Sweden|Örebro University Hospital, Örebro, Sweden|Linköping University Hospital, Linköping, Östergötland, Sweden|Vrinnevisjukhuset, Norrköping, Östergötland, Sweden",,"https://ClinicalTrials.gov/show/NCT04433364"
96,"NCT05793970","IL6 on Umbilical Cord (Evaluation of IL-6 Levels on Umbilical Cord)","INFIL-6","Recruiting","No Results Available","Intrauterine Infection|Fetus Disorder",,"IL6 Levels","Parma University Hospital","Female","18 Years to 50 Years   (Adult)",,"450","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","561/2021/OSS/AOUPR","March 25, 2022","March 23, 2023","June 1, 2023","March 31, 2023",,"March 31, 2023","University Hospital of Parma, Parma, Italy|Fondazione Universitaria Policlinico Gemelli, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT05793970"
97,"NCT01842100","To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of Pregnancy",,"Completed","No Results Available","Induced Abortion|Postaboral Pelvic Inflammatory Disease|Sexually Transmitted Infections","Drug: Universal antibiotic prophylaxis|Other: Screen-and-treat","Rate of postabortal inflammatory disease 6 weeks after induced abortion.|Rate of re-infection by sexually transmitted infections 24 weeks after induced abortion.|Proportion of women having abstinence from sexual intercourse or using condom at 6 weeks, 24 weeks and 1 year after induced abortion.","The University of Hong Kong","Female","Child, Adult, Older Adult","Not Applicable","2193","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","QMHRC99 - 15 RC/B/121","September 1999","February 2006","February 2006","April 29, 2013",,"April 29, 2013","Queen Mary Hospital, Hong Kong, Hong Kong, China",,"https://ClinicalTrials.gov/show/NCT01842100"
98,"NCT03122704","Group B Streptococcus (GBS) Infection and in Preterm Labor Women Conceived Through IVF",,"Withdrawn","No Results Available","Preterm Labor","Procedure: GBS screening","Percentage of women with GBS infection","Manh Tuong Ho|Vietnam National University","Female","18 Years to 50 Years   (Adult)","Not Applicable","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","NCKH/CGRH_09_2015","October 2015","August 2016","September 2016","April 21, 2017",,"April 21, 2017","My Duc Hospital, Ho Chi Minh City, Tan Binh District, Vietnam",,"https://ClinicalTrials.gov/show/NCT03122704"
99,"NCT00700219","Non-invasive Test to Detect Intra-amniotic Infection in Women With Preterm Labor and Intact Amniotic Membranes","IAI","Unknown status","No Results Available","Intra-amniotic Infection",,"Performance of immunoassay panel to detect intra-amniotic infection in target population.","ProteoGenix, Inc.|Obstetrix Medical Group","Female","18 Years and older   (Adult, Older Adult)",,"900","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PGX01-OBX0006","June 2008","September 2010","September 2010","June 18, 2008",,"July 21, 2010","Banner Desert Memorial Medical Center, Mesa, Arizona, United States|Banner Good Samaritan Hospital, Phoenix, Arizona, United States|Tucson Medical Center, Tucson, Arizona, United States|Long Beach Memorial Hospital, Long Beach, California, United States|Good Samaritan Hospital, San Jose, California, United States|Presbyterian St. Luke's Medical Center, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Norton Downtown, Louisville, Kentucky, United States|St. Louis University School of Medicine, St. Louis, Missouri, United States|Cooper University Hospital, Camden, New Jersey, United States|Mount Sinai School of Medicine, NYC, New York, United States|Carolinas Medical Center /Dept. OB/GYN, Charlotte, North Carolina, United States|Good Samaritan Hospital, Cincinnati, Ohio, United States|Greater Cincinnati Medical Center, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Thomas Jefferson University Medical Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|UMCG Dept of OB/GYN, Greenville, South Carolina, United States|Swedish Medical Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00700219"
100,"NCT06026969","Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure",,"Recruiting","No Results Available","Lyme Disease|Post-Treatment Lyme Disease|Chronic Lyme Disease|Tick-Borne Infections|Pregnancy Complications|Child Development","Other: Neurodevelopmental assessments and follow-up","Number of parent-infant dyads enrolled in the study through completion of their infant's 18-month follow-up visit|Warner Initial Developmental Evaluation (WIDEA)|Ages and Stages Questionnaire (ASQ)|Alberta Infant Motor Scale (AIMS)|Infant height|Infant weight|Infant head circumference|Placental tissue analysis|Analysis of parent and infant blood|Fetal neuroimaging (Magnetic resonance imaging [MRI] and ultrasound) analysis|Infant neuroimaging (Magnetic resonance imaging [MRI] and ultrasound) analysis","Children's National Research Institute|Clinical Trials Network for Lyme and Other Tick-Borne Diseases|Steven & Alexandra Cohen Foundation","All","18 Years and older   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","00000425","July 1, 2023","June 2025","June 2025","September 7, 2023",,"September 7, 2023","Children's National Hospital, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT06026969"
101,"NCT04152720","Evaluate the Efficacy and Safety of Prevention of Infection Foley Catheter as Compared to Conventional Foley Catheter",,"Unknown status","No Results Available","Urological Disease|Radical Cystectomy","Device: Foley catheter","1) Incidence of catheter-associated urinary tract infection (CAUTI) * 2 weeks after urethral catheterization|1) Period until catheter-associated urinary tract infection (CAUTI) occurs|2) Incidence of Significant Bacterial Cultures in Urethral Catheter Tip Culture|3) Catheter related complication rate|4) Catheter-associated urinary tract infection 2 weeks after urethral catheter insertion in test and control groups|5) Antibiotic administration period due to catheter-related urinary tract infection","Seoul National University Hospital|Seoul National University Bundang Hospital|Samsung Medical Center","All","19 Years to 80 Years   (Adult, Older Adult)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","APL_P_01","August 3, 2018","November 13, 2019","March 30, 2020","November 5, 2019",,"November 5, 2019","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04152720"
102,"NCT00084201","Interactions Between Cranberry Juice and Antibiotics Used to Treat Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infections","Drug: Cranberry juice|Drug: Amoxicillin","Drug Elmination|Drug absorption","National Center for Complementary and Integrative Health (NCCIH)","All","6 Years to 50 Years   (Child, Adult)","Not Applicable","18","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R21AT002077-01","July 2006",,"June 2007","June 9, 2004",,"November 30, 2006","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00084201"
103,"NCT04718220","Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19","STOPCOVID19","Active, not recruiting","No Results Available","Covid19|Pregnancy Related|Maternal Complication of Pregnancy|Coronavirus|Neonatal Infection|Prenatal Stress|Preterm Birth","Diagnostic Test: Antibody testing for SARS-CoV-2 IgG|Diagnostic Test: Testing for SARS-CoV-2 RNA|Diagnostic Test: Testing for SARS-CoV-2 IgM/IgG","Rate of preterm delivery|Rate of preeclampsia|Rate of gestational hypertension|Rate of cesarean section|Rate of stillbirth|Rate of fetal growth restriction|Rate of fetal hydrops|Rate of oligohydramnios|Perinatal death|Rate of premature preterm rupture of membranes|Rate of neonatal intensive care unit (NICU) admission|Rate of neonatal sepsis|Rate of oxygen therapy|Percentage of infants with low 5-minute Apgar|Percentage of infants with abnormal umbilical cord gas|Low birth weight|Confirmed congenital infection|Probable congenital infection|Possible congenital infection","Washington University School of Medicine|Mercy Research","Female","Child, Adult, Older Adult","Not Applicable","420","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","202012075","March 1, 2021","August 2024","August 2024","January 22, 2021",,"November 28, 2023","Washington University Medical Center, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04718220"
104,"NCT03999450","Preventing Premature Death in Patients With Serious Opioid-related Infection",,"Completed","No Results Available","Opioid Use","Behavioral: brief motivational intervention (BMI)|Behavioral: cognitive behavioral therapy","Percentage of participants who completed the week 4 follow up assessments|Percentage of participants who report intervention acceptability|Change in mean readiness|Change in mean self-regulation","University of Rochester|National Center for Advancing Translational Sciences (NCATS)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","11","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","RSRB00003696","October 8, 2019","May 31, 2020","May 31, 2020","June 26, 2019",,"July 28, 2020","University of Rochester Medical Center, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT03999450"
105,"NCT02639520","Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs",,"Completed","No Results Available","Urinary Tract Infection","Drug: Canephron® N|Drug: Fosfomycin trometamol|Drug: Canephron® N-placebo|Drug: Fosfomycin trometamol-placebo","Intake of any additional antibiotic medication for acute lower uUTIs between Visit 1 and Visit 4","Bionorica SE","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","659","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CanUTI-7","December 2015","June 2017","June 29, 2017","December 24, 2015",,"July 28, 2017","Justus-Liebig-Universität, Giessen, Hessen, Germany",,"https://ClinicalTrials.gov/show/NCT02639520"
106,"NCT01132131","Management of Urinary Tract Infections in Primary Care Facilities.",,"Completed","No Results Available","Urinary Tract Infection","Other: Delegation form","Number of patients who are clinically and bacteriologically free of symptoms of urinary tract infection.|Number of patients who are clinically and symptomatologically free of symptoms.","University of Oslo","Female","16 Years to 55 Years   (Child, Adult)","Phase 4","443","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010/486","August 2010","December 2011","December 2011","May 27, 2010",,"February 2, 2012","Legevakten i Oslo, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT01132131"
107,"NCT04992104","Microbiome and Malnutrition in Pregnancy","MMIP","Recruiting","No Results Available","Pregnancy Related|Pregnancy Loss|Pregnancy Complications|Pregnancy; Parasitic Disease|Microbial Colonization|Microbial Disease|Parasitic Disease|Metabolomics|Malnutrition|Malnutrition, Infant|Malnutrition Pregnancy|Breast Feeding",,"To assess if alterations of the microbiota in the maternal gut (dysbiosis) are associated with changes in maternal gestational weight gain.|Anthropometrics: Maternal BMI|Anthropometrics: Maternal middle upper arm circumference|Anthropometrics: Maternal triceps skinfold thickness|Anthropometrics: Maternal height|Anthropometrics: Maternal weight|Maternal blood biomarkers|Infant blood biomarkers|Infant sex|Infant morbidity|Maternal morbidity|Infant growth: weight|Infant growth: length|Infant growth: head circumference|Infant growth: mid upper arm circumference|Infant growth: triceps skinfold thickness|Infant Gestational age|Breast feeding: amount and initiation of complementary feeding|Maternal age|Reported maternal medication use|Reported Infant medication use|Maternal dietary intake|Dietary diversity|Household annual food insecurity|Self-efficacy|Perceived decision making|Perceived social support|Maternal demographics|Food insecurity|Perceived parental stress|Preterm birth|Stillbirth|Small for gestational age|Large for gestational age|Birth size: length|Birth size: head circumference|Birth size: weight|Birth defects|Delivery assessment|Infant dietary intake: NutricheQ Questionnaire|Maternal stool biomarkers: Calprotectin, Lipocalin and Claudin 15|Infant Stool biomarkers: Calprotectin, Lipocalin and Claudin 15|Maternal: incidence of pathobionts|Infant: incidence of pathobionts|Maternal: metabolomic profile of stool (metabolites involved in central metabolism as analysed by Mass Spectrometry)|Maternal gut bacteria profile as measured through 16S rDNA sequence surveys|Maternal: blood metallomics profile as measured through ICP-MS (https://www.metabolomicscentre.ca/new_service/25)|Infant: blood metallomics profile as measured through ICP-MS (https://www.metabolomicscentre.ca/new_service/25)|Infant: gut bacterial profile as measured through 16S rDNA sequence surveys|Maternal metabolic pathway expression profile as measured through whole microbiome RNASeq (metatranscriptomics)|Infant eukaryotic microbiome profile as measured through 18S and ITS rDNA sequence surveys|Maternal eukaryotic microbiome profile as measured through 18S and ITS rDNA sequence surveys|Maternal bacterial gene expression profile as measured through whole microbiome RNASeq (metatranscriptomics)|Maternal: microbiome taxonomic alpha and beta diversity|Infant: microbiome taxonomic alpha and beta diversity","The Hospital for Sick Children|Unity Health Toronto|University of Toronto|University of Calgary|Dalhousie University|Aga Khan University|University of Alberta|National Institute of Allergy and Infectious Diseases (NIAID)|Canadian Institutes of Health Research (CIHR)","Female","up to 24 Years   (Child, Adult)",,"800","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CTOREB3512|MRT-168043","February 22, 2023","December 2024","December 2024","August 5, 2021",,"April 21, 2023","St. Michael's Hospital, Toronto, Canada|The Hospital for Sick Children, Toronto, Canada","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/04/NCT04992104/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/04/NCT04992104/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04992104"
108,"NCT01884467","Gentamicin Bladder Instillation Trial",,"Unknown status","No Results Available","Urinary Tract Infections","Drug: Gentamicin|Drug: Placebo","Symptomatic UTI|Asymptomatic UTI","Gillette Children's Specialty Healthcare","All","16 Years and older   (Child, Adult, Older Adult)","Phase 4","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","1210M21603","May 2013","December 2015","December 2016","June 24, 2013",,"April 9, 2015","Gillette Lifetime Specialty Healthcare, Saint Paul, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01884467"
109,"NCT02673216","Infection and Adverse Pregnancy Outcome",,"Unknown status","No Results Available","Preterm Birth","Other: No intervention","Preterm birth <37 weeks of gestation","Statens Serum Institut|Aarhus University Hospital Skejby","Female","Child, Adult, Older Adult",,"2200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1-10-72-116-14","September 2015","December 2020","December 2023","February 3, 2016",,"May 10, 2021","Skejby University Hospital, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT02673216"
110,"NCT02695173","Complications of UTI in Patients on Dapagliflozin",,"Completed","No Results Available","Severe Complications of Urinary Tract Infections",,"Incidence of urinary tract infections (UTI) complications|Incidence of pyelonephritis","AstraZeneca","All","Child, Adult, Older Adult",,"683380","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","D1690R00008|EUPAS12113","January 1, 2017","September 1, 2020","November 30, 2020","March 1, 2016",,"December 7, 2021","Research Site, Wilmington, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02695173"
111,"NCT04400110","Short Therapy for Febrile UTI in Childhood",,"Completed","No Results Available","Urinary Tract Infections","Drug: Amoxicillin and Clavulanic Acid in Oral Dose Form","Rate of infection recurrence|Rate of complete resolution of signs and symptoms|Rate of antibiotic-resistant or of opportunistic strains in relapses","IRCCS Burlo Garofolo","All","3 Months to 5 Years   (Child)","Phase 4","154","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RC 10/18","June 8, 2020","December 31, 2022","December 31, 2022","May 22, 2020",,"March 29, 2023","Policlinico S.Orsola-Malpighi, Bologna, Emilia Romagna, Italy|Santa Maria delle Croci Hospital, Ravenna, Emilia Romagna, Italy|Ospedale San Polo, Monfalcone, Friuli Venezia Giulia, Italy|Pediatric Department, Santa Maria degli Angeli Hospital, Pordenone, Friuli Venezia Giulia, Italy|Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Friuli Venezia Giulia, Italy|ASUIUD Azienda sanitaria universitaria integrata di Udine, Udine, Friuli Venezia Giulia, Italy|Fondazione Policlinico Agostino Gemelli - IRCCS City Rome, Roma, Lazio, Italy|Fondazione IRCSS Ca Granda, Policlinico di Milano, Milano, Lombardia, Italy|Ospedali Riuniti di Ancona - Ospedale Salesi, Ancona, Marche, Italy|A.O.U.G. Martino, Messina, Sicilia, Italy|San Martino Hospital, Belluno, Veneto, Italy|Department of Woman and Child Health, University of Padua City, Padua, Veneto, Italy|UOC Pediatria Ospedale Ca' Foncello, Treviso, Veneto, Italy",,"https://ClinicalTrials.gov/show/NCT04400110"
112,"NCT01681511","A Trial for the Safety and Effectiveness of a Novel Antimicrobial-Coated Foley Catheter for Reduction of CAUTI.",,"Terminated","Has Results","Urinary Tract Infection","Device: ICET™ TIC Foley Catheter|Device: BARD® LUBRI-SIL® IC Foley Catheter","Number of Subjects Affected, During Treatment and Follow-up Time Periods, by a Catheter Associated Urinary Tract Infection (CAUTI) Event After First CAUTI Event.|The Proportion of Subjects With at Least One CAUTI|The Proportion of Subjects With Symptomatic Urinary Tract Infection (SUTI)|The Proportion of Subjects With Asymptomatic Bacteremic Urinary Tract Infection (ABUTI)","Innovative Chemical and Environmental Technologies, Inc|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","ICET-001|R44DK055891-06","May 2012","January 2013","January 2013","September 10, 2012","April 10, 2014","April 28, 2014","University of Minnesota Fairview medical center, Minneapolis,, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01681511"
113,"NCT03367910","Fecal Microbiota Transplantation (FMT) for MDRO UTI",,"Completed","Has Results","Urinary Tract Infections","Drug: Fecal microbiota transplant","Number of Patients With Adverse Events During and After FMT|Number of Patients With Recurrent UTI Post-FMT","Washington University School of Medicine|Centers for Disease Control and Prevention|University of Pennsylvania|Duke University|Rush University|Rebiotix Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","1","Other|U.S. Fed|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","201708204","February 8, 2018","December 31, 2021","December 31, 2021","December 11, 2017","February 28, 2022","March 18, 2022","Washington University, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/10/NCT03367910/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03367910"
114,"NCT01178905","Clinical Evaluation of Ultrashort-term Heat Inactivation of Cytomegalovirus (CMV) Containing Raw Breast Milk to Prevent CMV-infection of Preterm Infants",,"Completed","No Results Available","Cytomegalovirus Infection|Preterm Infants","Procedure: ultrashort heat inactivation","Number of participants with CMV viruria|Number of participants with specific neonatal outcome parameters as a measure of neonatal quality","University Hospital Tuebingen","All","23 Weeks to 40 Weeks   (Child)","Not Applicable",,"Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Prevention","BM CMV inactivation","August 2010","October 2012",,"August 10, 2010",,"April 24, 2013","Tuebingen University Hospital, Tuebingen, Germany",,"https://ClinicalTrials.gov/show/NCT01178905"
115,"NCT03176563","Observational Follow-up Study of REGATTA","REGATTA II","Completed","No Results Available","Urinary Tract Infections","Drug: Arctuvan|Drug: Placebo to Fosfomycin|Drug: Fosfomycin|Drug: Placebo to Arctuvan","number of urinary tract infections|number of pyelonephritis","University Medical Center Goettingen","Female","18 Years to 75 Years   (Adult, Older Adult)",,"398","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","01970","May 3, 2017","July 19, 2019","August 20, 2019","June 5, 2017",,"November 27, 2019","Hausarztpraxis Dr. Raby, Achim, Germany|General Practice Aden, Braunschweig, Germany|General Practice Scheffer, Braunschweig, Germany|General Practice Coutelle, Bremen, Germany|General Practice Schelp, Bremen, Germany|General Practice Dickow, Burgwedel, Germany|General Practice Kiwit-Putzer, Burgwedel, Germany|Praxis Zietz, Celle, Germany|General Practice Kutzsche, Emmerthal, Germany|Praxis Dr. Bahr, Gieboldehausen, Germany|General Practice Müller, Gillersheim, Germany|Institute of General Medicine, University Medical Center Goettingen, Goettigen, Germany|General Practice Keske, Göttingen, Germany|General Practice Koch, Göttingen, Germany|General Practice Kolb, Göttingen, Germany|General Practice Lang, Göttingen, Germany|General Practice Lückerath, Göttingen, Germany|Praxisgemeinschaft Jacob / Kling, Göttingen, Germany|Institute of General Medicine, MHH Hannover, Hannover, Germany|General Practice Barth, Hannover, Germany|Praxis Dr. Egner, Hannover, Germany|General Practice Löber, Hardegsen, Germany|Gemeinschaftspraxis Dres Schlesier / Eckhardt, Heilbad Heiligenstadt, Germany|Gemeinschaftspraxis Hartleb / Stöcking, Heilbad Heiligenstadt, Germany|Praxis Dr. Koch, Heilbad Heiligenstadt, Germany|Praxisgemeinschaft Seitz / Eckert, Herzberg Am Harz, Germany|General Practice Wilde, Hildesheim, Germany|General Practice Beverungen, Höxter, Germany|Praxisgemeinschaft Stoltz / Raddatz, Höxter, Germany|Gemeinschaftspraxis Kasperczyk / Schindewolf-Lensch, Isernhagen, Germany|General Practice Franz, Katlenburg-Lindau, Germany|Praxis Dr. Ohlendorf, Langenhagen, Germany|General Practice Ertel, Langwedel, Germany|General Practice Wehrbein, Lemforde, Germany|General Practice Lindenblatt, Neustadt, Germany|Hausarztzentrum Nörten, Nörten-Hardenberg, Germany|General Practice Preiskorn, Rehburg-Loccum, Germany|General Practice Meier-Ahrens, Rosdorf, Germany|General Practice Woitschek, Salzgitter, Germany|General Practice Beulshausen, Sattenhausen, Germany|General Practice Schulte, Scheeßel, Germany|General Practice Böttcher, Schwanewede, Germany|General Practice Albrecht, Springe, Germany|General Practice Wolf, Uslar, Germany|General Practice Schmiemann, Verden, Germany|General Practice Annweiler, Waake, Germany|General Practice Stegemann, Wunstorf, Germany",,"https://ClinicalTrials.gov/show/NCT03176563"
116,"NCT03929991","Maternal Cesarian Section Infection (MACSI) in Sierra Leone","MACSI","Unknown status","No Results Available","Infection|Cesarean Section Complications|Site Infection|Maternal Death","Other: Observational","Incidence|Prevalence of Main Features|Prevalence of Negative Outcome|Screening of Risk factors","Doctors with Africa - CUAMM|University of Bari|University of Palermo","Female","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1902","May 1, 2018","October 1, 2019","May 1, 2020","April 29, 2019",,"April 30, 2019","Princess Christian Maternity Hospital, Freetown, Sierra Leone",,"https://ClinicalTrials.gov/show/NCT03929991"
117,"NCT01803919","Efficacy Study of Antimicrobial Catheters to Avoid Urinary Infections in Spinal Cord Injured Patients","ESCALE","Terminated","No Results Available","Urinary Tract Infection","Device: Silver Alloy-Coated Urinary Catheters|Device: Conventional Urinary Catheter","Incidence of catheter associated urinary tract infection|Asymptomatic urinary tract infection|Bacteremic urinary tract infection","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Asociacion Colaboracion Cochrane Iberoamericana|European Clinical Research Infrastructure Network","All","18 Years and older   (Adult, Older Adult)","Not Applicable","489","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","IIBSP-SUR-2011-68|112210","November 2012","December 2015","January 2016","March 4, 2013",,"September 20, 2016","Mutual de la Seguridad Chilena, Santiago de Chile, Chile|Azienda Ospedaliero-Universitaria - Ospedali Riuniti di Ancona - Unità Spinale, Ancona, Italy|Azienda Ospedaliero-Universitaria Policlinico di Bari- Unità Operativa di Medicina Fisica e Riabilitazione e Unità Spinale Unipolare, Bari, Italy|Unità Operative Recupero e Riabilitazione Funzionale e Gravi Cerebrolesioni Acquisite, Ceglie Messapica, Italy|Unità Spinale Unipolare, Rome, Italy|Centro de Medicina de Reabilitação de Alcoitão, Alcoitão, Alcabideche, Portugal|Centro Clínico Académico - Braga, Associação (2CA-Braga), Braga, Portugal|Centro Hospitalar do Porto, Porto, Portugal|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital de Neurorrehabilitación Instituto Guttmann, Badalona, Barcelona, Spain|Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias, Las Palmas de Gran Canaria, Las Palmas, Spain|Hospital Universitario Cruces, Barakaldo, Vizcaya, Spain|Complexo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitario Puerta del Mar, Cadiz, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Nacional de Parapléjicos, Toledo, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Dokuz Eylul University Dept. of Physical Medicine and Rehabilitation, Alsancak, Izmir, Turkey|Ege University Dept. of Physical Medicine and Rehabilitation, Bornova, İzmir, Turkey",,"https://ClinicalTrials.gov/show/NCT01803919"
118,"NCT00678041","Nitrofurantoin and Urinary Tract Infections (UTIs)","APPIC","Terminated","Has Results","Urinary Tract Infections","Drug: Nitrofurantoin|Drug: Placebo","Frequency of Symptomatic UTI's Confirmed With a Positive Urine Culture Within 6 to 8 Weeks After CISC Teaching and Implementation|Time (Days After Surgery) to Development of Symptomatic, Culture Documented UTI|Frequency of Urine Cultures Positive for Organism Strains That Are Resistant to Nitrofurantoin and Other Commonly Used Antibiotics.|Adherence to CISC|Patient Perceptions Regarding CISC|Frequency of Adverse Events Related to CISC Such as Urethral Pain, Irritative Voiding Symptoms, Hematuria|Frequency of Adverse Events Related to Daily Nitrofurantoin Exposure Such as Nausea, Diarrhea, C. Difficile Colitis","University of Pittsburgh","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SutkinAppic","May 2008","May 2009","May 2009","May 15, 2008","August 2, 2016","September 27, 2016","Magee Womens Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00678041"
119,"NCT05591911","Urine Gene Analysis for Pathogen Detection",,"Recruiting","No Results Available","Urinary Tract Infections","Diagnostic Test: Urine PCR testing","Time in hours from patient presentation to optimal antibiotic prescription|Antibiotic costs as measured by prescription records|Number of patients with antibiotic change as measured by prescription records|Duration of antibiotic usage as measured by prescription records|Number of any HCP visits for same issue as measured by patients reports/medical records|Number of hospitalization related to UTI as measured by patients reports/medical records|Number of additional diagnostic procedures completed in relation to UTI as measured by patients reports/medical records","David Sheyn|Vikor Scientific|Thermo Fisher Scientific, Inc|University Hospitals Cleveland Medical Center","All","60 Years and older   (Adult, Older Adult)",,"100","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","STUDY20220767","June 25, 2023","August 31, 2024","August 31, 2024","October 24, 2022",,"October 24, 2023","University Hospitals, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05591911"
120,"NCT00701350","Biomarkers of Intra-amniotic Infection in Women With Preterm Premature Ruptured Amniotic Membranes","PPROM","Completed","No Results Available","Intra-amniotic Infection|Preterm Birth",,"Expression of protein biomarkers in cervial vaginal fluid","ProteoGenix, Inc.|Obstetrix Medical Group","Female","18 Years and older   (Adult, Older Adult)",,"79","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PGX03-OBX0009","June 2008","February 2010","February 2010","June 19, 2008",,"July 21, 2010","Banner Good Samaritan Hospital, Phoenix, Arizona, United States|Tucson Medical Center, Tucson, Arizona, United States|Good Samaritan Hospital, San Jose, California, United States|Presbyterian St. Luke's Medical Center, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT00701350"
121,"NCT01818180","Urell and Pregnancy",,"Terminated","No Results Available","Urinary Tract Infection (UTI)","Dietary Supplement: URELL|Other: Placebo","Recurrence of Urinary tract infections","Hopital Foch","Female","18 Years to 40 Years   (Adult)","Not Applicable","11","Other","Interventional","Allocation: Randomized|Masking: Double (Participant, Investigator)","2009/19","May 2010","September 2012",,"March 26, 2013",,"March 26, 2013","Hôpital FOCH, Suresnes, France",,"https://ClinicalTrials.gov/show/NCT01818180"
122,"NCT01231737","Efficacy of Two Prophylactic Schedules (Prulifloxacin Versus Phosphomycin)",,"Unknown status","No Results Available","Urinary Tract Infection","Drug: prulifloxacin","number of urinary tract infection episodes during prophylaxis|improving the patient's quality of life","University Of Perugia","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","002","November 2010","February 2011","February 2012","November 1, 2010",,"November 1, 2010",,,"https://ClinicalTrials.gov/show/NCT01231737"
123,"NCT03218800","Ertapenem Administered Subcutaneously Versus Intravenously",,"Terminated","No Results Available","Urinary Tract Infections","Combination Product: Ertapenem","microbiological cure|adverse events|clinical response","Instituto Nacional de Cancer, Brazil","All","18 Years and older   (Adult, Older Adult)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ertapsubcut","June 1, 2017","February 28, 2021","February 28, 2021","July 17, 2017",,"August 11, 2022","INCA Instituto Nacional do Cancer, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT03218800"
124,"NCT06017479","Effectiveness of Single Dose Fosfomycin and Single Dose Levofloxacin as Pre-urodynamic Antibiotic for UTI Prevention",,"Recruiting","No Results Available","Urological System Complication of Procedure|Urinary Tract Infections","Drug: Fosfomycin 3000 MG|Drug: Levofloxacin 500mg","Number of Participant With Urinary Tract Infection","Indonesia University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","22-11-1343","December 30, 2022","March 30, 2024","March 30, 2024","August 30, 2023",,"December 21, 2023","Cipto Mangunkusumo Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT06017479"
125,"NCT05488340","A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)","ELIMINATE","Recruiting","No Results Available","Urinary Tract Infections","Drug: LBP-EC01 0.1 x IV dose|Drug: LBP-EC01 0.01x IV Dose|Drug: LBP-EC01 IV Infusion Dose|Drug: Placebo|Drug: LBP-EC01|Drug: TMP/SMX","Part 1: Levels of LBP-EC01 in urine and blood measured by quantitative plaquing assay across the treatment period and over 48 h after the last dose|Part 2: Proportion of patients with resolution of clinical symptoms and microbiologic response of uUTI caused by drug resistant E. coli as defined at Day 10 test of cure (TOC).|Part 1: Number of patients with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part 1: Number of patients with immunogenicity|Part 2: Proportion of patients with antimicrobial drug resistant (AMR) E. coli achieving maintenance of combined clinical and microbiologic response (CCMR) at Day 21.|Part 2: Proportion of patients with CCMR of uUTI caused by E. coli at Day 10/TOC.|Part 2: Proportion of patients with CCMR of uUTI caused by multi-drug resistant (MDR) E. coli at Day 10/TOC.|Part 2: Proportion of patients with MDR E. coli achieving maintenance of CCMR at Day 21.","Locus Biosciences|Parexel","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","318","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LBx-2001","July 13, 2022","June 2025","December 2025","August 4, 2022",,"December 21, 2023","Research Site 102, Doral, Florida, United States|Research Site 107, Miami, Florida, United States|Research Site 106, Miami, Florida, United States|Research Site 103, Miami, Florida, United States|Research Site 100, Palmetto Bay, Florida, United States|Research Site 108, Forney, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05488340"
126,"NCT04959331","Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women.","SCOUT","Recruiting","No Results Available","Urinary Tract Infections","Drug: Fosfomycin Trometamol Salt|Drug: Nitrofurantoin|Drug: Pivmecillinam","Clinical effectiveness.|Bacteriological eradication.|Duration of symptoms.|Relapse rate.|Reattendance and complication rate.|Adverse event rate.|Change in quality of life.","Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina|Balearic Islands Health Service (Ibsalut)|Instituto de Investigación Sanitaria Aragón|Gerencia de Atención Primaria, Madrid","Female","18 Years and older   (Adult, Older Adult)","Phase 4","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IJG-SCOUT-2021","November 2, 2021","September 30, 2024","December 31, 2024","July 13, 2021",,"December 11, 2023","Calatayud Center, Calatayud, Aragón, Spain|Las Fuentes Center, Zaragoza, Aragón, Spain|Arrabal Health Center, Zaragoza, Aragón, Spain|Parque Goya Health Center, Zaragoza, Aragón, Spain|Santa Ponça Health Center, Calvià, Balearic Islands, Spain|Emili Darder Center, Palma De Mallorca, Balearic Islands, Spain|Camp Redó Health Center, Palma De Mallorca, Balearic Islands, Spain|Son Pisà Center, Palma De Mallorca, Balearic Islands, Spain|Son Serra-La Vileta Health Center, Palma De Mallorca, Balearic Islands, Spain|Santa Maria del Camí Center, Santa Maria del Camí, Balearic Islands, Spain|Banyoles Center, Banyoles, Catalonia, Spain|Corbera Center, Corbera De Llobregat, Catalonia, Spain|La Gavarra Health Center, Cornellà De Llobregat, Catalonia, Spain|17 de Setembre Center, El Prat De Llobregat, Catalonia, Spain|Can Vidalet Center, Esplugues De Llobregat, Catalonia, Spain|Santa Clara Center, Girona, Catalonia, Spain|Florida Center, Hospitalet de Llobregat, Catalonia, Spain|Can Serra Center, Hospitalet de Llobregat, Catalonia, Spain|Montblanc Center, Montblanc, Catalonia, Spain|Pere Garau Center, Palma De Mallorca, Catalonia, Spain|Molí Nou Center, Sant Boi De Llobregat, Catalonia, Spain|Sant Feliu de Guíxols Center, Sant Feliu De Guíxols, Catalonia, Spain|Sant Just Desvern Center, Sant Just Desvern, Catalonia, Spain|Vila Vella Center, Sant Vicenç Dels Horts, Catalonia, Spain|Jaume I Health Center, Tarragona, Catalonia, Spain|El Puerto Center, Coslada, Madrid, Spain|Valleaguado Health Center, Coslada, Madrid, Spain|San Fernando Health Center, San Fernando De Henares, Madrid, Spain|Villarejo de Salvanés Health Center, Villarejo de Salvanés, Madrid, Spain|Los Alpes Health Center, Madrid, Spain|Aquitania Health Center, Madrid, Spain|Mar Báltico Center, Madrid, Spain|Buenos Aires Center, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04959331"
127,"NCT04818762","Peripheral Fractional Tissue Oxygen Extraction and Infection in Term and Preterm Neonates","pFTOE","Recruiting","No Results Available","Neonatal Infection|Preterm Birth",,"pFTOE|cFTOE|gestational age","Medical University of Graz","All","up to 6 Hours   (Child)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","pFTOE","February 26, 2021","December 31, 2024","February 1, 2025","March 26, 2021",,"March 17, 2023","Department of Pediatrics, Division of Neonatology, Medical University of Graz, Graz, Styria, Austria",,"https://ClinicalTrials.gov/show/NCT04818762"
128,"NCT06297837","ADAPT-AST (Adaptive Antimicrobial Susceptibility Testing)","ADAPT-AST","Not yet recruiting","No Results Available","Urinary Tract Infections",,"The number of antimicrobial susceptibility results that 'should' spur action by a clinician on|The number of days until a result that 'should' spur action by a clinician|The number of antimicrobial susceptibility results that 'could' spur action by a clinician on|The number of days until a result that 'could' spur action by a clinician|The projected health economic cost per specimen, including laboratory (e.g., consumable cost) and patient (e.g., drug toxicity, clinical failure) measures.","Liverpool University Hospitals NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)",,"500000","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","LHS0205","March 2024","December 2025","March 2026","March 7, 2024",,"March 7, 2024",,"""Study Protocol and Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/37/NCT06297837/Prot_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT06297837"
129,"NCT05365906","UTI Reference Standard: Delphi Method","ORACLE","Completed","No Results Available","Urinary Tract Infections","Other: Delphi-procedure consisting of four survey rounds","Consensus","Leiden University Medical Center","All","Child, Adult, Older Adult",,"47","Other","Observational","Observational Model: Other|Time Perspective: Prospective","nWMODIV2_2022007","April 12, 2022","February 23, 2023","February 23, 2023","May 9, 2022",,"March 8, 2023","Leiden University Medical Center, Leiden, South Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT05365906"
130,"NCT05880329","DIagnoSing Care hOme UTI Study","DISCO UTI","Not yet recruiting","No Results Available","Urinary Tract Infections","Diagnostic Test: Candidate POCTs for detecting UTI","As a feasibility study, there is no primary outcome measure.|Proportion of care homes agreeing to participate when recruiting care homes as research sites.|Proportion of residents screened that are eligible and proportion of eligible that are recruited.|Proportion of baseline urine samples obtained from participants recruited (consented)|Proportion of repeated urine samples obtained of those participating in Stage 2|Quality of urine samples obtained|Adherence to urine transport protocols|Proportion of residents that experience a possible UTI during the follow-up period that are reported to the research team.|Proportion of residents with possible UTI that are not reported to the research team.|Proportion of residents with possible UTI in whom the following is obtained:|Using semi-structured interviews with qualitative analysis to describe the views of care home staff, participants and family members on:|Participant baseline demographic characteristics predictive of subsequent possible UTI/clinical outcomes|Participant clinical characteristics at point of possible UTI and association with clinical outcomes|Changes in weekly sample microbiology|Predictors of weekly sample microbiology and changes in microbiology|Association between asymptomatic bacteriuria at baseline or in weekly sampling and onset of possible UTI during follow up period|Association of each urinary biomarker with asymptomatic bacteriuria|Urinary biomarker concentrations in urine samples from asymptomatic participants without bacteriuria|Urinary biomarker concentrations in urine samples from possible UTI episodes|Failure rate of the POCT in residents with possible UTI (no result or invalid result)|Agreement between POCT result and laboratory enhanced culture result at symptom onset for each possible UTI episode, and at 28 days post symptom on set","University of Southampton|University of Oxford|University of Bristol|Public Health Wales","All","65 Years and older   (Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","79003","September 1, 2023","January 31, 2024","January 31, 2024","May 30, 2023",,"August 7, 2023",,,"https://ClinicalTrials.gov/show/NCT05880329"
131,"NCT00384462","Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants",,"Completed","No Results Available","Respiratory Syncytial Virus Infections",,"Estimate the incidence of hospitalization attributable to RSV within 150 days from enrollment in premature infants|Estimate the incidence rate of hospitalization attributable to RSV in the other relevant study populations|Estimate the incidence rate of MALRI attributable to RSV in the study populations;","MedImmune LLC","All","1 Month to 6 Months   (Child)",,"346","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MI-MA140","October 2006","November 2007","January 2008","October 6, 2006",,"February 4, 2009","University of Alabama at Birmingham, Birmingham, Alabama, United States|Central Arkansas Pediatric Clinic, P.A., Benton, Arkansas, United States|The Children's Clinic of Jonesboro, P.A., Jonesboro, Arkansas, United States|Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|Arkansas Pediatric Clinic, Little Rock, Arkansas, United States|Little Rock Children's Clinic, Little Rock, Arkansas, United States|Miller Children's Hospital, Long Beach, California, United States|Children's Hospital of Oakland, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|Children's Hospital, Denver, Colorado, United States|Pediatric Pulmonology, LLC, Stamford, Connecticut, United States|Shands Hospital at the University of Florida, Gainesville, Florida, United States|University of Miami Medical Center, Miami, Florida, United States|University of South Florida Pediatrics Ambulatory Care Center, Tampa, Florida, United States|Georgia Pediatric Pulmonology Associates, Atlanta, Georgia, United States|Kapiolani Medical Center, Honolulu, Hawaii, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Children's Memorial Hospital, Chicago, Illinois, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|University of Maryland, School of Medicine, Baltimore, Maryland, United States|Tufts-New England Medical Center, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Children's Healthcare D.B.A. Hospitals & Clinics, St. Paul, Minnesota, United States|Pediatrix Medical Group, St. John's Mercy Medical Center, St. Louis, Missouri, United States|Midwest Children's Health Research Institute, LLC, Lincoln, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Albany Medical Center, Albany, New York, United States|Bronx-Lebanon Hospital Center, Bronx, New York, United States|Jacobi Medical Center, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Winthrop University Hospital, Mineola, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University Hospital, State University of New York at Stony Brook, Stony Brook, New York, United States|Crouse Hospital NICU, Syracuse, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Raleigh Pediatric Associates, Gardner, North Carolina, United States|Raleigh Pediatric Associates, Raleigh, North Carolina, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Beehly Medical Park Women's and Children's Pavilion, Boardman, Ohio, United States|University of Cincinnati College of Medicine, Cincinnati, Ohio, United States|Metro Health Medical Center, Cleveland, Ohio, United States|Children's Medical Center, Dayton, Ohio, United States|Pediatric Associates of Dayton, Inc., Kettering, Ohio, United States|St. Vincent Medical Center, Toledo, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke's Hospital, Bethlehem, Pennsylvania, United States|Geisinger Medical Center - JW Children's Hospital, Danville, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Texas Houston Medical Center, Houston, Texas, United States|VCU Medical Center, Children's Pavillion, Richmond, Virginia, United States|University Physicians Internal Medicine, Huntington, West Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|Children's Hospital Waukesha Memorial, Waukesha, Wisconsin, United States|Children's Corporate Center, Wauwatosa, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00384462"
132,"NCT00781625","Probiotics as a Prophylactic Aid in Women With Recurrent Urinary Tract Infections (UTI's)",,"Unknown status","No Results Available","Urinary Tract Infections","Dietary Supplement: UREX-cap-5|Dietary Supplement: Placebo Y cap G-3","Reduction in number og episodes og lower UTI|Improvement of QOL|Improvement of immune function|Effects are non-dependant og nutritional status|Effects are non-dependant of known factors contributing til UTI's|Decreases inflammation in the urinary bladder epithelium|Normalizes vaginal microflora","University Hospital, Akershus|St. Olavs Hospital|Karolinska Institutet|University of Oslo|Folkehelsa","Female","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","S-08458d (REK)|08/7922(Shdir)","October 2008","December 2009","December 2010","October 29, 2008",,"October 31, 2008","Akershus Universitetssykehus HF, Lørenskog, Akershus, Norway|St.Olavs Hospital, Trondheim, Norway",,"https://ClinicalTrials.gov/show/NCT00781625"
133,"NCT00121797","Peripartum Bacteruria and Urinary Tract Infections (UTI)",,"Unknown status","No Results Available","Urinary Tract Infection","Procedure: urine culture|Drug: antibiotics according to culture","Rate of rehospitalization for postpartum fever|Incidence of UTI in the early puerperium","Hadassah Medical Organization","Female","Child, Adult, Older Adult","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","26-5.9.03-HMO-CTIL|Women's health grant 8060101","January 2004",,"June 2005","July 21, 2005",,"November 7, 2006","Clinical microbiology, Hadassah Ein-Kerem Medical centre, Jerusalem, Israel|Obs&Gyn Hadassah Ein-Kerem Medical center, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00121797"
134,"NCT04798365","Antimicrobial Stewardship in UTIs in Nursing Homes",,"Completed","No Results Available","Urinary Tract Infections","Behavioral: Intervention group","proportion of adequate prescriptions (adequate in terms of antimicrobial choice)","Medical University of Graz","All","18 Years and older   (Adult, Older Adult)","Not Applicable","326","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","33-035 ex 20/21","March 1, 2021","December 31, 2022","December 31, 2022","March 15, 2021",,"March 14, 2023","Sonnenhof, Fehring, Austria|Geriatric Health Centres of the City of Graz, Graz, Austria|Volkshilfe Steiermark, Graz, Austria|Bezirkspflege-und Seniorenheim Voitsberg, Voitsberg, Austria",,"https://ClinicalTrials.gov/show/NCT04798365"
135,"NCT05219877","Effectiveness of Preurodynamic With Posturodynamic Levofloxacin on the Incidence of UTI",,"Completed","Has Results","Urinary Tract Infections","Drug: Pre-urodynamic Levofloxacin|Drug: Post-urodynamic Levofloxacin","Number of Participant With Urinary Tract Infection","Indonesia University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","341/UN2.F1/ETIK/PPM.00.02/2021","February 4, 2022","April 3, 2022","April 13, 2022","February 2, 2022","November 13, 2023","November 13, 2023","RS Cipto Mangunkusumo, Jakarta Pusat, DKI Jakarta, Indonesia","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/77/NCT05219877/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05219877"
136,"NCT04108910","Morbidity Rate for UTI Through Use of PCR-Based Diagnosis and Management",,"Completed","No Results Available","Urinary Tract Infections","Diagnostic Test: Guidance UTI","ER Visits and or Hospital Admission Rate within 30 days of initial visit related to UTI|Examine retrospective data to determine if use of PCR, compared with conventional urine culture, leads to a reduction in UTI-related morbidity.","Pathnostics","All","18 Years to 111 Years   (Adult, Older Adult)",,"66381","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2019 R-VPA-HUS","March 2016","July 2019","April 2020","September 30, 2019",,"April 3, 2024",,,"https://ClinicalTrials.gov/show/NCT04108910"
137,"NCT04408976","Implementation Study With Decision Support Based on Data",,"Completed","No Results Available","Urinary Tract Infections",,"Non-recurrent UTI","Leiden University Medical Center|Pacmed BV|Zorgverzekeraar CZ|Zorgverzekeraar Zilveren Kruis|Zorgverzekeraar Menzis|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Netherlands Instititute for Health Services Research","All","12 Years and older   (Child, Adult, Older Adult)",,"16824","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P1746","November 13, 2017","May 16, 2018","May 16, 2018","June 1, 2020",,"June 1, 2020","Netherlands Institute for Health Services Research, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04408976"
138,"NCT02305342","Sensitivity of Antibiotics for Urinary Tract Infections Patients Attending Family Physicians",,"Completed","No Results Available","Urinary Tract Infections (UTIs)",,"Sensitivity of Uropathogens|Common UTI pathogens","Abbott","All","18 Years and older   (Adult, Older Adult)",,"350","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","ENOX5001","November 2014","February 2015","February 2015","December 2, 2014",,"March 6, 2015","Research facility ID ORG-001126, Karachi, Pakistan",,"https://ClinicalTrials.gov/show/NCT02305342"
139,"NCT00128128","Cranberry Juice for the Prevention of Recurrent Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infections","Drug: Cranberry juice cocktail","Rate of UTIs|Compliance|vaginal and rectal colonization with E. coli","National Center for Complementary and Integrative Health (NCCIH)","Female","18 Years to 45 Years   (Adult)","Phase 2","176","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","R01AT002105-01","August 2005","December 2008","June 2009","August 9, 2005",,"June 4, 2015","Yale New Haven Hospital, New Haven, Connecticut, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00128128"
140,"NCT05023395","Safety and Efficacy of MEE-HU Medicus","(SEM)","Active, not recruiting","No Results Available","Urinary Tract Infections","Drug: MEE-HU Medicus|Other: Placebo","Complete response status|Incomplete response status","Dr. Ahmed Ismail|Theodor Bilharz Research Institute|The Cairo Kidney Center|Helwan University|Zagazig University|Heliopolis University","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","00012020","October 23, 2021","March 24, 2024","May 11, 2024","August 26, 2021",,"February 8, 2024","Cairo Kidney Center, Cairo, Egypt|Theodor Bilharz Research Institute, Giza, Egypt",,"https://ClinicalTrials.gov/show/NCT05023395"
141,"NCT04024046","Uqora Supplements in Women With UTIs",,"Terminated","No Results Available","Urinary Tract Infections","Dietary Supplement: Uqora|Dietary Supplement: Group1|Dietary Supplement: Group 2","Recurrence of UTIs at six-months","Hawthorne Effect Inc.|Uqora, Inc.","Female","18 Years and older   (Adult, Older Adult)",,"360","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Pro00034128","April 18, 2019","September 16, 2020","September 16, 2020","July 18, 2019",,"September 27, 2022","Uqora, Inc., San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT04024046"
142,"NCT00100061","Effects of Cranberry-Containing Products in Women With Recurrent Urinary Tract Infections (UTIs)",,"Unknown status","No Results Available","Urinary Tract Infection","Drug: Cranberry juice|Dietary Supplement: Cranberry Juice|Dietary Supplement: Placebo cranberry juice","Minimum dose of cranberry-containing product necessary to achieve a 30% prophylaxis of UTIs in women with recurrent UTIs|Whether the degree of UTI prophylaxis is related to the dose of cranberry-containing product (dose response curve)|Whether proanthocyanidin concentration in the urine correlates with UTI prophylaxis","National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS)","Female","19 Years and older   (Adult, Older Adult)","Phase 2","350","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","R01AT002090-01","May 2007","July 2013","July 2013","December 23, 2004",,"March 12, 2013","Bladder Care Centre, University of British Columbia, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT00100061"
143,"NCT03697993","Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS)",,"Terminated","Has Results","Urinary Tract Infection","Drug: Fosfomycin tromethamine|Drug: Levofloxacin","Percentage of Participants Achieving Treatment Success at Test of Cure (TOC)|Number of Participants Reporting Solicited Adverse Events (AEs) Grade 2 and Above Among Those Who Received Fosfomycin|Number of Participants Reporting Unsolicited Adverse Events (AEs) Grade 2 and Above Among Those Who Received Fosfomycin|Number of Participants Reporting Serious Adverse Events (SAEs) Among Those Who Received at Least Two Doses of Fosfomyci|Percentage of Participants Reporting Solicited Adverse Events (AEs)|Percentage of Participants Reporting Solicited Adverse Events (AEs) by Severity|Percentage of Participants Achieving Treatment Success at End of Therapy (EOT)","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","62","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-0045|HHSN272201300018I","November 7, 2018","October 24, 2019","October 24, 2019","October 5, 2018","December 19, 2020","December 19, 2020","University of California Los Angeles - Olive View Medical Center, Sylmar, California, United States|Harbor UCLA Medical Center - Medicine - Infectious Diseases, Torrance, California, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Northwestern Medicine - Department of Obstetrics and Gynecology - Division of Female Pelvic Medicine and Reconstructive Surgery, Chicago, Illinois, United States|University of Iowa - Vaccine Research and Education Unit, Iowa City, Iowa, United States|Infectious Disease Consultants - Wichita, Wichita, Kansas, United States|Brigham and Women's Hospital - Infectious Diseases, Boston, Massachusetts, United States|Henry Ford Health System - Henry Ford Hospital, Detroit, Michigan, United States|Truman Medical Center - Hospital Hill, Kansas City, Missouri, United States|U. of New Mexico Health Sciences Center - Dept. of Emergency Medicine, Albuquerque, New Mexico, United States|University of Rochester Medical Center - Strong Memorial Hospital - Infectious Diseases, Rochester, New York, United States|The Miriam Hospital - Infectious Diseases and Immunology Center, Providence, Rhode Island, United States","""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/93/NCT03697993/SAP_000.pdf|""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/93/NCT03697993/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03697993"
144,"NCT00087828","Identification of the Cranberry Juice Compounds That Prevent Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infections","Drug: Cranberry juice cocktail",,"National Center for Complementary and Integrative Health (NCCIH)","Female","18 Years to 64 Years   (Adult)","Not Applicable","5","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","F31 AT000623-1","November 2000",,"June 2005","July 16, 2004",,"August 18, 2006","Dept Medicinal Chemistry & Pharmacognosy, COP, UIC, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00087828"
145,"NCT03680612","Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI",,"Completed","No Results Available","Urinary Tract Infections","Drug: Cefepime 1G - 2G / AAI101 0.5G - 0.75G|Drug: cefepime 1 g or cefepime 2 g","Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-Treat (mMITT) Population|Microbiological Response at the TOC Visit in the Microbiologically Evaluable (ME) Population.","Allecra|Medpace, Inc.","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AT-201","September 5, 2017","February 14, 2018","February 14, 2018","September 21, 2018",,"September 21, 2018","Kromerizska nemocnice, Kromeriz, Czechia|Jahn Ferenc Del-pesti Korhaz, Budapest, Hungary|Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie, Klinika Chorob Wewnetrznych, Nefrologii i Transplantologii, Warsaw, Poland|Fakultna nemocnica s poliklinikou J.A. Reimana Presov, Prešov, Slovakia|Chernihiv City Hospital #2 of Chernihiv City Council, department of Urology, Chernihiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT03680612"
146,"NCT06035601","EHR-integrated rUTI Texting Platform","Urotrust","Recruiting","No Results Available","Recurrent Urinary Tract Infection","Device: EHR-integrated texting platform (Urotrust)|Other: Usual care","Rate of unnecessary antibiotics|Patient self-efficacy|Patient satisfaction: Patient Global Impression of Improvement score|Healthcare-related quality of life: EQ-5D-5L score|Healthcare-related quality of life: Recurrent UTI Impact Questionnaire score|Healthcare utilization|Antibiotic prescriptions|Patient medication compliance","University of Pennsylvania|Independence Blue Cross","Female","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","853917","March 7, 2024","June 15, 2025","June 15, 2026","September 13, 2023",,"March 19, 2024","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT06035601"
147,"NCT03190421","Expanded Quantitative Urinary Culture (EQUC) vs Standard Culture (SUC) Techniques in the Clinical Care",,"Completed","No Results Available","Urinary Tract Infections","Diagnostic Test: Expanded Urinary Culture|Diagnostic Test: Standard Urine Culture (SUC)","Compare UTI symptom resolution rates in women with symptoms of UTI who are treated based on EQUC versus SUC results.|Revise the EQUC treatment algorithm.|Identify the symptom profile associated with specific organisms.","Loyola University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","225","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","209545","June 15, 2017","March 30, 2020","April 30, 2020","June 16, 2017",,"June 16, 2020","Loyola University Medical Center, Maywood, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03190421"
148,"NCT03395288","Nutraceutical Efficacy for rUTI",,"Terminated","Has Results","Urinary Tract Infections","Drug: D-Mannose","Incidence of Symptomatic, Culture Proven Urinary Tract Infections|Incidence of Symptomatic Culture Proved UTI From D-mannose Susceptible Uropathogens|Side Effects|Incidence of Symptomatic, Culture Proven UTI in All Participants Taking D-mannose","Washington University School of Medicine","Female","20 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","61","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","201711120","March 22, 2018","April 25, 2020","April 25, 2020","January 10, 2018","February 4, 2022","February 4, 2022","Washington University School of Medicine, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/88/NCT03395288/Prot_SAP_007.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/88/NCT03395288/ICF_008.pdf","https://ClinicalTrials.gov/show/NCT03395288"
149,"NCT03129295","Phase II Proof of Concept Study in Uncomplicated UTI",,"Unknown status","No Results Available","Urinary Tract Infections","Drug: MPC-SHRC|Drug: Placebo Oral Tablet","Change from baseline on assessment instrument|Change from baseline on assessment instruments|Change from baseline on Pain Scale","Mission Pharmacal","Female","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","MPC-SHRC-002","April 2017","September 2017","September 2017","April 26, 2017",,"April 26, 2017","First Urology PSC, Jeffersonville, Indiana, United States|Beyer Research, Kalamazoo, Michigan, United States|Lawrence OB/GYN Clinical Research, LLC, Lawrenceville, New Jersey, United States|Women's Health Research Center, Plainsboro, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03129295"
150,"NCT02323087","Point of Care Susceptibility Testing in Primary Care",,"Completed","No Results Available","Urinary Tract Infections","Device: FLEXICULT™ SSI-Urinary Kit|Device: ID FlexicultTM","The proportion of patients receiving correct treatment|The proportion of patients who are asymptomatic the 4'th day of treatment (clinical cure)|-The proportion of patients with no significant bacteriuria on day 14 (bacteriological cure)|Accuracy of point-of-care urine culture and susceptibility testing","University of Copenhagen","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","377","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UCCAREWP4FLEX","March 2015","May 2016","May 2016","December 23, 2014",,"May 3, 2016","21 General practices in Copenhagen area, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT02323087"
151,"NCT02789579","The Preventive Infection Role of One Week Antibiotics Before Minimally Invasive Upper Tract Lithotomy",,"Unknown status","No Results Available","Complication of Surgical Procedure","Drug: levofloxacin|Drug: Nitrofurantoin|Drug: cefuroxime","Evidence of clinically urinary tract infection confirmed by laboratory examination or urine bacterial culture.|Evidence of clinically urosepsis confirmed by laboratory examination, urine bacterial culture, and vital signs","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","All","16 Years to 75 Years   (Child, Adult, Older Adult)","Early Phase 1","150","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","XH-16-010","September 2016","December 2019","December 2019","June 3, 2016",,"October 1, 2019","Department of Pharmacy, Xinhua Hospital, Shanghai Jiaotong University School of Medicine.Kongjiang Road 1665,, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02789579"
152,"NCT02585115","Diagnostic Accuracy of Point of Care Test of First Voided Urine Compared to Midstream Voided Urine in Primary Care",,"Completed","No Results Available","Urinary Tract Infections",,"Difference in accuracy of POC urine culture on first-void urine compared to mid-stream urine wtih mid-stream urine microbiological culture as a reference|Difference in accuracy from 0 hours to 4 hours of the POCT Flexicult ID in the most precise of the above techniques.|Proportion of false-positive cultures after 0 hours at room temperature with first-void urine compared to mid-stream urine when using a urin-dipstick|Proportion of false-positive cultures after 0 hours at room temperature with first-void urine compared to mid-stream urine when using microscopy|Proportion of false-positive cultures after 1 hours at room temperature with first-void urine compared to mid-stream urine when using a urin-dipstick|Proportion of false-positive cultures after 1 hours at room temperature with first-void urine compared to mid-stream urine when using microscopy|Proportion of false-positive cultures after 4 hours at room temperature with first-void urine compared to mid-stream urine when using a urin-dipstick|Proportion of false-positive cultures after 4 hours at room temperature with first-void urine compared to mid-stream urine when using microscopy","University of Copenhagen","Female","18 Years and older   (Adult, Older Adult)",,"117","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UCCAREWP4Samples","October 2015","July 2016","July 2016","October 23, 2015",,"October 6, 2016","Vesterbro Lægehus, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT02585115"
153,"NCT00690378","Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections",,"Completed","Has Results","Complicated Urinary Tract Infection","Drug: NXL104/ceftazidime|Drug: Imipenem/Cilastatin","Number of Participants With Microbiological Outcome at the Test of Cure (TOC) Visit|Clinical Outcome in Clinically Evaluable (CE) Patients at the End of Intravenous (IV) Therapy Visit|Clinical Outcome in CE Patients at the TOC Visit|Clinical Outcome in CE Patients at the Late Follow-up (LFU) Visit|Microbiological Outcome in ME Patients at the End of IV Therapy Visit|Microbiological Outcome in ME Patients at the LFU Visit|Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the End of IV Therapy Visit|Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the End of IV Therapy Visit|Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the End of IV Therapy Visit|Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the End of IV Therapy Visit|Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the End of IV Therapy Visit|Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the TOC Visit|Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the TOC Visit|Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the TOC Visit|Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the TOC Visit|Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the TOC Visit|Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the LFU Visit|Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the LFU Visit|Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the LFU Visit|Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the LFU Visit","Pfizer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","137","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","NXL104/2001|C3591013","November 2008","June 2010","July 2010","June 4, 2008","May 25, 2018","May 25, 2018","Alabama Research Center, Birmingham, Alabama, United States|Southeast Alabama Medical Center, Dothan, Alabama, United States|Providence Hospital, Mobile, Alabama, United States|Arizona Pulmonary Specialists LTD, Phoenix, Arizona, United States|Sharp Chula Vista Medical Center, Chula Vista, California, United States|Synergy Clinical Research Center, Escondido, California, United States|Novellus Research Sites, Fountain Valley, California, United States|Novellus Research Sites, Long Beach, California, United States|Modesto Clinical Research, Modesto, California, United States|Tri City Medical Center, Oceanside, California, United States|EStudy Site, San Jose, California, United States|Olive View UCLA Medical Center, Sylmar, California, United States|Christiana Care Health Services, Newark, Delaware, United States|Century Clinical Research, Inc, Daytona Beach, Florida, United States|University of Florida, Jacksonville, Florida, United States|Southeast Regional Research Group, Columbus, Georgia, United States|St. Joseph's/Candler Health System, Savannah, Georgia, United States|Four Rivers Clinical Research Inc, Paducah, Kentucky, United States|Louisiana State University Health Services Ctr Shreveport, Shreveport, Louisiana, United States|R. Adams Cowley Shock Trauma Center, Baltimore, Maryland, United States|Henry Ford Hospital, Detroit, Michigan, United States|North Memorial Medical Center, Minneapolis, Minnesota, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|St. James Healthcare, Butte, Montana, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|University Hospital UMDNJ, Newark, New Jersey, United States|Albany Medical Center, Albany, New York, United States|Brookdale University Hospital, Brooklyn, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Staten Island University Hospital, Staten Island, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Clinical Trials of America Inc., Winston-Salem, North Carolina, United States|Summa Health System Hospitals, Akron, Ohio, United States|Remington-Davis, Columbus, Ohio, United States|Regional Infectious Disease-Infusion Center, Lima, Ohio, United States|St Vincent's Mercy Medical Center, Toledo, Ohio, United States|Thomas Jefferson Univ Hospital, Philadelphia, Pennsylvania, United States|Reading Hospital and Medical Center, West Reading, Pennsylvania, United States|Harris Methodist, Azle, Texas, United States|University of Texas MD Anderson, Houston, Texas, United States|Sentara Norfold General Hospital, Norfolk, Virginia, United States|Al-Essra hospital, Amman, Jordan|Al-Islami Hospital, Amman, Jordan|Jordan University Hospital, Amman, Jordan|King Abdullah University Hospital, Irbid, Jordan|Clinique due Levant Hospital, Beirut, Lebanon|Dr. Rizk Clinic, Beirut, Lebanon|Makassed General Hospital, Beirut, Lebanon|Rafik Hariri University Hospital, Beirut, Lebanon|Sahel General Hospital, Beirut, Lebanon|Notre Dame Des Secours Hospital, Byblos, Lebanon|Ain Wazein Hospital, Chouf, Lebanon|St. Joseph Hospital, Dora, Lebanon|Mount Lebanon Hospital, Hazmieh, Lebanon|Nabatyeh Governmental Hospital, Nabatyeh, Lebanon|Hammoud Hospital University Medical Center, Saida, Lebanon|Labib Medical Center, Saida, Lebanon|Saida Governmental Hospital, Saida, Lebanon",,"https://ClinicalTrials.gov/show/NCT00690378"
154,"NCT00446732","The Use of the UroShield Device in Patients With Indwelling Urinary Catheters","CAUTI","Unknown status","No Results Available","Urinary Tract Infection","Device: UroSshield","primary end points","Nanovibronix|Shaare Zedek Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","200","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","US-71-003","March 2007","April 2009","June 2009","March 13, 2007",,"March 25, 2009","Shaare Zedek Medical Center, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00446732"
155,"NCT02623179","Conventional and Molecular Diagnostic Method for Patients With Suspected UTI",,"Completed","No Results Available","Urinary Tract Infections-UTI","Other: culture versus Molecular diagnostics","To quantify differences in the relative abundance and presence of microbial lineages as determined by culture and sequencing technologies.|Time (as measured in hours) to preliminary and final identification of organism(s) and antibiotic sensitivity(s) results|Time from participant reported start of UTI symptoms to resolution.|Participant Quality of Life as measured by a UTI specific severity and bothersome of symptoms survey taken at baseline (at clinic visit) and at set time points post urine testing|Overall cost","Southwest Regional PCR, LLC","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PATUTI","January 15, 2016","December 31, 2016","December 31, 2016","December 7, 2015",,"October 5, 2017",,,"https://ClinicalTrials.gov/show/NCT02623179"
156,"NCT03861260","GAG Replacement vs URethral DIlAtatioN","GUARDIAN","Withdrawn","No Results Available","Recurrent Urinary Tract Infection","Procedure: Rigid cystoscopy with urethral dilatation|Procedure: Flexible cystoscopy and installation of Glycosaminoglycan layer replacement (laluril)","The number of Urinary tract infections in the 12 months following treatment|The time to first urinary tract infection after completion of treatment.|The change in the Quality of life (QoL) between the time of treatment and at 3, 6 and 12 months following initiation of treatment.|The number of adverse events recorded following treatment during the 12-month study period|The change in the Patient Satisfaction at 3, 6 and 12 months following initiation of treatment|The change in female sexual function index (FSFI) questionnaire at 3, 6 and 12 months|The change in Hospital anxiety and depression scale (HADS) questionnaire at 3, 6 and 12 months","Hampshire Hospitals NHS Foundation Trust","Female","Child, Adult, Older Adult","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-FAM-99","April 30, 2019","October 28, 2019","October 28, 2019","March 4, 2019",,"September 27, 2021","Hampshire Hospitals NHS Foundation Trust, Basingstoke, Hampshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03861260"
157,"NCT06131684","Amniotic Fluid Analysis",,"Not yet recruiting","No Results Available","Obstetric Labor Complications","Device: Intrauterine pressure catheter (IUPC) present|Device: Intrauterine pressure catheter (IUPC) absent","The number of patients who develop an intrapartum infection","Oregon Health and Science University","Female","18 Years to 50 Years   (Adult)","Early Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STUDY00024844","November 2023","June 30, 2024","June 30, 2024","November 14, 2023",,"November 14, 2023","Oregon Health & Science Univerity, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT06131684"
158,"NCT03697096","The INSPIRE-ASP UTI Trial",,"Active, not recruiting","No Results Available","Urinary Tract Infection (UTI)","Other: Routine Care|Other: INSPIRE CPOE Smart Prompt","Extended-Spectrum Days Of Antibacterial Therapy (ES-DOT) per Empiric Day|Vancomycin Days of Antibacterial Therapy per Empiric Day|Antipseudomonal Antibiotic Days Of Therapy (ES-DOT) per Empiric Day","Harvard Pilgrim Health Care|Hospital Corporation of America Healthcare (HCA)|University of California, Irvine|University of Massachusetts, Amherst|Brigham and Women's Hospital|Centers for Disease Control and Prevention","All","18 Years and older   (Adult, Older Adult)","Not Applicable","59","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","PH000619B_UTI","October 1, 2018","June 30, 2024","June 30, 2025","October 5, 2018",,"September 25, 2023","Riverside Community Hospital, Riverside, California, United States|Regional Medical Center of San Jose, San Jose, California, United States|Los Robles Regional Medical Center, Thousand Oaks, California, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Swedish Medical Center, Denver, Colorado, United States|Sky Ridge Medical Center, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Brandon Hospital, Brandon, Florida, United States|Fort Walton Medical Center, Fort Walton Beach, Florida, United States|North Florida Regional Medical Center, Gainesville, Florida, United States|Osceola Regional Medical Center, Kissimmee, Florida, United States|Poinciana Medical Center, Kissimmee, Florida, United States|Lake City Medical Center, Lake City, Florida, United States|Largo Medical Center, Largo, Florida, United States|Northwest Medical Center, Margate, Florida, United States|Kendall Regional Medical Center, Miami, Florida, United States|Twin Cities Hospital, Niceville, Florida, United States|Putnam Community Medical Center, Palatka, Florida, United States|Gulf Coast Medical Center, Panama City, Florida, United States|Westside Regional Medical Center, Plantation, Florida, United States|Fawcett Memorial Hospital, Port Charlotte, Florida, United States|St. Lucie Medical Center, Port Saint Lucie, Florida, United States|Central Florida Regional Hospital, Sanford, Florida, United States|Doctor's Hospital Sarasota, Sarasota, Florida, United States|Capital Regional Medical Center, Tallahassee, Florida, United States|Medical Center of Trinity, Trinity, Florida, United States|Cartersville Medical Center, Cartersville, Georgia, United States|Fairview Park, Dublin, Georgia, United States|Redmond Regional Medical Center, Rome, Georgia, United States|West Valley Medical Center, Caldwell, Idaho, United States|Terre Haute Regional Hospital, Terre Haute, Indiana, United States|Tulane University Hospital & Clinic, New Orleans, Louisiana, United States|Centerpoint Medical Center, Independence, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Southern Hills Hospital - Vegas, Las Vegas, Nevada, United States|TriStar Horizon Medical Center, Dickson, Tennessee, United States|Stonecrest Medical Center, Nashville, Tennessee, United States|South Austin Hospital, Austin, Texas, United States|St. David's Medical Center, Austin, Texas, United States|Valley Regional Medical Center, Brownsville, Texas, United States|Conroe Regional Medical Center, Conroe, Texas, United States|Corpus Christi Medical Center (Doctor's, Bay Area, and The Heart Hospital Campuses), Corpus Christi, Texas, United States|Medical City Denton, Denton, Texas, United States|Medical City Fort Worth, Fort Worth, Texas, United States|West Houston Medical Center, Houston, Texas, United States|Kingwood Medical Center, Kingwood, Texas, United States|Rio Grande Regional Hospital, McAllen, Texas, United States|North Hills Hospital, North Richland Hills, Texas, United States|Bayshore Medical Center, Pasadena, Texas, United States|Medical City Plano, Plano, Texas, United States|Round Rock Hospital, Round Rock, Texas, United States|Metropolitan Methodist Hospital, San Antonio, Texas, United States|Clearlake Regional Medical Center, Webster, Texas, United States|LewisGale Hospital - Montgomery, Blacksburg, Virginia, United States|John Randolph Medical Center, Hopewell, Virginia, United States|LewisGale Hospital - Pulaski, Pulaski, Virginia, United States|Reston Hospital, Reston, Virginia, United States|CJW Medical Center (Chippenham & Johnston Willis Campuses), Richmond, Virginia, United States|Henrico Doctors' Hospital (Forest, Retreat, and Parham Campuses), Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03697096"
159,"NCT05711446","Double Voiding and Post-transplant UTI",,"Recruiting","No Results Available","Urinary Tract Infections|Kidney Transplant; Complications","Other: Double Voiding|Other: Regular Voiding","Number of UTI's|Time to first bacterial culture|Number of UTI episodes|Bacterial colony count of each positive urine culture|Number of incidences of bacteremia|Number of hospital admissions","Weill Medical College of Cornell University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","438","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","22-03024620","April 7, 2023","December 2025","December 2025","February 3, 2023",,"August 30, 2023","Weill Cornell Medical College / NY Presbyterian, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT05711446"
160,"NCT01064024","Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo",,"Completed","No Results Available","Pain|Urinary Tract Infections","Drug: Phenazopyridine Hydrochloride|Drug: Placebo","proportion of subjects in each treatment group who demonstrate reduction in pain or burning when passing urine.","Amneal Pharmaceuticals, LLC|Oxford Pharmaceutical Resources, Inc.|Sristek Clinical Research|Biostudy Solutions, LLC","Female","18 Years and older   (Adult, Older Adult)","Phase 3","233","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AM-PHN-001","December 2009","December 2010","December 2010","February 8, 2010",,"January 29, 2013","Oxford Pharmaceutical Resources, Inc., Totowa, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01064024"
161,"NCT03142295","Controlled Human Urine Transfusion for UTI","SHUTUP","Unknown status","No Results Available","Recurrent Urinary Tract Infection|Safety Issues","Procedure: urine transfusion","Safety|Diversity of the urine microbiome after urine transfusion|The composition of the urine microbiome before and after urine transfusion|Frequency of UTIs after urine transfusions","Leiden University Medical Center","Female","18 Years to 45 Years   (Adult)","Not Applicable","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","NL60330.058.16","June 24, 2017","January 1, 2018","February 1, 2018","May 5, 2017",,"June 26, 2017","Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT03142295"
162,"NCT03645967","Efficacy of a Prepackaged Cleansing Cloth and Standardized Cleansing Protocol for Catheter Care at Reducing CAUTI Rates",,"Completed","No Results Available","Catheter-Associated Urinary Tract Infection","Device: ReadyCleanse Cloths","CAUTI Rates|HCP Feedback","Medline Industries","All","18 Years and older   (Adult, Older Adult)","Not Applicable","9872","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R17-019","August 1, 2018","February 26, 2021","February 26, 2021","August 24, 2018",,"October 14, 2021","NorthShore University HealthSystem - Evanston, Evanston, Illinois, United States|NorthShore University HealthSystem - Glenbrook, Glenview, Illinois, United States|NorthShore University HealthSystem - Highland Park, Highland Park, Illinois, United States|NorthShore University HealthSystem - Skokie, Skokie, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03645967"
163,"NCT04261036","Vitamin C for the Prevention of UTI in Women Who Undergo Elective Gynecological Surgeries",,"Withdrawn","No Results Available","Catheter-Associated Urinary Tract Infection, Ascorbic Acid","Drug: Ascorbic Acid 1000 mg|Other: Placebo","Proportion of participants who experienced clinically diagnosed and treated UTI.|Proportion of participants with asymptomatic bacteruria","American University of Beirut Medical Center","Female","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","OGY.TB.09/BIO-2017-0609","July 20, 2019","July 1, 2021","October 1, 2021","February 7, 2020",,"May 30, 2023","American University of Beirut Medical Center, Beirut, Lebanon",,"https://ClinicalTrials.gov/show/NCT04261036"
164,"NCT06230042","Catheter in the Prevention of Urinary Tract Infections and Crystallization Study(CPUTICS)",,"Not yet recruiting","No Results Available","Urinary Catheter","Other: Types of catheters","Catheter-Associated Urinary Tract Infection (CAUTI) Incidence|Crystal deposits on the inner wall of the catheter|Evaluation of urethral irritation response|Measuring the temperature of bladder urine","Shanghai East Hospital","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","CPUTICS-01","February 1, 2024","February 1, 2024","February 15, 2024","January 29, 2024",,"January 29, 2024","Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT06230042"
165,"NCT02292160","Does the National Health Insurance Card Allow us to Predict Antibiotic Resistance?",,"Completed","No Results Available","Urinary Tract Infection Empiric Antibiotic",,"Frequency of antibiotic resistant organisms","University Hospital, Rouen","All","15 Years and older   (Child, Adult, Older Adult)",,"1128","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2013/186/HP","September 2015","February 2017","February 2017","November 17, 2014",,"June 14, 2017","Lbmr de Normandie, Elbeuf, France|Rouen University Hospital, Rouen, France",,"https://ClinicalTrials.gov/show/NCT02292160"
166,"NCT03251898","Correlation Between Premature Rupture of Membranes and Early-onset Neonatal Infections",,"Completed","No Results Available","Premature Rupture of Membrane|Neonatal Infection",,"the incidence of early-onset neonatal infections","Bayi Children's Hospital Affiliated to PLA Army General Hospital, China|Northwest Women's and Children's Hospital, Xi'an, Shaanxi|Chengdu Women's and Children's Central Hospital|Shenzhen Maternity & Child Healthcare Hospital|Nanjing Maternity and Child Health Care Hospital|Shenzhen Bao'an Maternal and Child Health Hospital|Second Hospital of Jilin University|Seventh Medical Center of PLA General Hospital","Female","Child, Adult, Older Adult",,"15926","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BayiChildrens-01","August 15, 2017","March 31, 2018","April 30, 2018","August 16, 2017",,"April 27, 2020","Chengdu Women's and Children's Central Hospital, Chengdu, China|Second Hospital of Jilin University, Jilin, China|Nanjing Maternity and Child Health Care Hospital, Nanjing, China|Shenzhen Bao'an Maternal and Child Health Hospital, Shenzhen, China|Shenzhen Maternity & Child Healthcare Hospital, Shenzhen, China|Northwest Women's and Children's Hospital, Xi'an, China",,"https://ClinicalTrials.gov/show/NCT03251898"
167,"NCT03306719","mtDNA as Novel Biomarker for Intra-amniotic Infection","mtDNA","Unknown status","No Results Available","Preterm Premature Rupture of Membrane","Biological: Blood sampling","mtDNA in Plasma","Medical University of Vienna","Female","18 Years to 45 Years   (Adult)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1115/2017","April 5, 2017","June 30, 2018","December 31, 2018","October 11, 2017",,"October 11, 2017","Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT03306719"
168,"NCT04699578","COVID-19 Infection and Fetal-neonatal Outcomes",,"Unknown status","No Results Available","Covid19|Obstetric Complication|SARS-CoV Infection|Preterm Birth|Miscarriage|Placenta Diseases","Diagnostic Test: Covid-19 positive","Preterm birth rate|Gestational age at delivery|Preterm birth rates|Birth weight|Composite adverse neonatal outcomes|Maternal outcomes|Inflammatory markers: coagulation profile, C-reactive protein, glycaemia, ferritinemia","University of Campania ""Luigi Vanvitelli""","Female","18 Years and older   (Adult, Older Adult)",,"230","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","8453","December 28, 2020","December 31, 2021","May 1, 2022","January 7, 2021",,"January 7, 2021","University of Campania Luigi Vanvitelli, Naples, Italy",,"https://ClinicalTrials.gov/show/NCT04699578"
169,"NCT03655561","Lassa Fever Clinical Course and Prognostic Factors in Nigeria","LASCOPE","Recruiting","No Results Available","Lassa Fever|Lassa Virus Infection|Pregnancy Complications|Acute Kidney Injury|Acute Kidney Failure|Coma","Other: Non interventional research","Overall mortality|Acute kidney injury|Mother status at the end of pregnancy|Type of pregnancy termination|Pregnancy complications|Newborn status at birth|Newborn status at day 30|Newborn status at day 60","Alliance for International Medical Action|Institut National de la Santé Et de la Recherche Médicale, France|University of Oxford|Owo Federal Medical Center|Irrua Specialist Teaching Hospital|Bernhard Nocht Institute for Tropical Medicine|University Hospital, Bordeaux|University of Bordeaux|PACCI Program|African coaLition for Epidemic Research, Response and Training|Institut de Recherche pour le Developpement|ANRS, Emerging Infectious Diseases","All","Child, Adult, Older Adult",,"1200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LAS001","April 5, 2018","June 30, 2024","June 30, 2024","August 31, 2018",,"July 19, 2023","Alex Ekwueme Federal University Teaching Hospital Abakaliki, Abakaliki, Ebonyi, Nigeria|Owo Federal Medical Centre (Owo FMC), Owo, Ondo, Nigeria",,"https://ClinicalTrials.gov/show/NCT03655561"
170,"NCT05967130","Treatment Chronic UTI Post Kidney Transplant",,"Recruiting","No Results Available","Urinary Tract Infections|Transplant-Related Disorder","Biological: Phage","Urine culture","Shahid Beheshti University of Medical Sciences","All","Child, Adult, Older Adult","Phase 3","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SBMU-","July 1, 2023","January 1, 2024","July 1, 2024","August 1, 2023",,"August 1, 2023","Nooshin Dalili, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT05967130"
171,"NCT05520684","Asymptomatic Bacteriuria, Urinalysis Abnormality at the Initiation of SGLT2 Inhibitors and UTI Risk",,"Recruiting","No Results Available","Type2diabetes, SGLT2 Inhibitor, Urinary Tract Infection","Diagnostic Test: urine culture and urinalysis","Urinary tract infection","Trabzon Arakli Bayram Halil Public Hospital","Female","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","6111449","February 15, 2022","November 1, 2022","January 1, 2023","August 30, 2022",,"September 1, 2022","Trabzon Araklı Bayram Halil Public Hospital, Trabzon, Turkey",,"https://ClinicalTrials.gov/show/NCT05520684"
172,"NCT02121938","Dynamics of the Microbiome in the Premature Infant",,"Completed","No Results Available","Infection",,"antigen identification of the infant microbiome over the first year of life","Duke University","All","1 Hour to 1 Week   (Child)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00051659","April 2014","June 2016","June 2016","April 24, 2014",,"April 12, 2024","Duke University Hospital, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02121938"
173,"NCT00192985","Does a Nitrofurazone Coated Bladder Catheter Reduce the Number of Urinary Tract Infections in Trauma",,"Unknown status","No Results Available","Trauma|Urinary Tract Infections","Device: Nitrofuranzone coated bladder catheter","urinary tract infections|length of stay","Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","Phase 3","216","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Prevention","KF 01-160/02 Catheter","May 2003",,"September 2006","September 19, 2005",,"September 19, 2005","Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT00192985"
174,"NCT03346603","Prevalence of Antimicrobial-resistant Pathogens in Patients Admitted for UTIs",,"Completed","No Results Available","Urinary Tract Infections|Urosepsis","Other: urine culture and susceptibility testing","Prevalence of ESBL-producing Enterobacteriaceae|Prevalence of carbapenem-resistant Enterobacteriaceae (CRE)|Prevalence of carbapenem-resistant non fermenting gram negative bacteria","Olive View-UCLA Education & Research Institute|Centers for Disease Control and Prevention|IHMA laboratories","All","18 Years and older   (Adult, Older Adult)",,"801","Other|U.S. Fed","Observational","Observational Model: Case-Only|Time Perspective: Prospective","1057381","February 8, 2018","February 28, 2019","December 31, 2020","November 17, 2017",,"July 8, 2021","Olive View-UCLA Medical Center, Sylmar, California, United States",,"https://ClinicalTrials.gov/show/NCT03346603"
175,"NCT02641015","Study to Assess Management and Outcomes of Hospitalised Patients With Complicated UTI (RESCUING)","RESCUING","Completed","No Results Available","Urinary Tract Infections|Bacterial Resistance",,"Treatment Failure|Time to clinical response|Time to urological intervention for source control|Time to death|Duration of antibiotic therapy|Length of hospital stay|Hospital mortality|All cause mortality within 30 days of the original cUTI diagnosis|All cause of mortality for two months after hospital discharge|Cost per case of cUTI|Readmissions to the hospital within 60 days of hospital discharge|Adverse events related to antibiotic treatment including: moderate or severe allergic reactions, severe renal impairment, Clostridium difficile infection","Institut d'Investigació Biomèdica de Bellvitge|Tel Aviv University|AiCuris Anti-infective Cures AG|University of Bristol|UMC Utrecht","All","18 Years and older   (Adult, Older Adult)",,"1028","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PR 223/15","December 2015","August 2016","August 2016","December 29, 2015",,"January 18, 2017","Emergency Hospital Pirogov, Sofia, Bulgaria|University Hospital Queen Joanna, Sofia, Bulgaria|Attikon University Hospital, Athens, Greece|Hippokration Hospital, Thessaloniki, Greece|Kenezy University Hospital, Debrecen, Hungary|Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház (SZSZBMK), Nyíregyháza, Hungary|Soproni Erzsébet Oktató Kórház és Rehabilitációs Intézet, Sopron, Hungary|Rambam Health Care Campus, Haifa, Israel|Beilinson Hospital, Rabin Medical Center, Petah-Tiqva, Israel|Tel Aviv Medical Center, Tel Aviv, Israel|Azienda Ospedaliero-Universitaria Policlinico Di Modena, Modena, Italy|AORN dei Colli Monaldi, Napoli, Italy|National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy|""Spitalul Clinic de Urgenta Bucuresti. Popular unoficial name """"Floreasca """" Hospital"", Bucharest, Romania|National Institute for Infectious Diseases Prof Dr Matei Bals, Bucharest, Romania|Infectious Diseases Hospital Sfanta Parascheva Iasi, Iasi, Romania|Hospital Universitari de Bellvitge, L'Hospitalet del Llobregat, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Ankara Numune Egitim ve ArastÄ±rma Hastanesi, Ankara, Turkey|Istanbul University Cerrahpasa Medical School, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT02641015"
176,"NCT03297216","Improving Pregnancy Outcomes With Progesterone","IPOP","Completed","Has Results","Pre-term Birth|HIV-1-infection","Drug: 17P|Other: Placebo","Number of Participants Experiencing Preterm Births or Stillbirths|Number of Participants Experiencing Preterm Birth <37 Weeks|Number of Participants Experiencing Preterm Birth <34 Weeks|Number of Participants Experiencing Preterm Birth <28 Weeks|Number of Participants Experiencing Stillbirth|Number of Participants Experiencing Spontaneous Delivery <37 Weeks|Number of Participants Experiencing Spontaneous Delivery <34 Weeks|Number of Participants Experiencing Spontaneous Delivery <28 Weeks|Number of Infants With Birth Weight <10th Percentile for Gestational Age|Number of Infants With Birth Weight <3rd Percentile for Gestational Age|Number of Infants Who Experienced Maternal-to-Child HIV Transmission|Number of Neonatal Deaths|Number of Infants With 1-minute Apgar Score <7|Number of Infants With 5-minute Apgar Score <7","University of North Carolina, Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|AMAG Pharmaceuticals, Inc.|Bill and Melinda Gates Foundation","Female","18 Years and older   (Adult, Older Adult)","Phase 3","800","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","17-1173|1R01HD087119","February 7, 2018","June 25, 2020","August 6, 2020","September 29, 2017","July 9, 2021","July 22, 2021","Kamwala District Clinic, Lusaka, Zambia|University Teaching Hospital, Lusaka, Zambia","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/16/NCT03297216/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03297216"
177,"NCT03211026","Urinary Tract Infections in Kidney Transplant Recipients","URIKIT","Recruiting","No Results Available","Kidney Transplantation","Other: No intervention","Assessment of UTI due to MDR bacteria|Epidemiology of UTI in KIT recipients|Risk factors for MDR UTI|Carbapenem use to treat UTI|Coherence between antibiotic protocol and treatment received to treat UTI|UTI relapse frequency|UTI recurrence frequency with a different micororganism|Assessment of kidney function during the observation period|Graft outcome|Patients outcome","Poitiers University Hospital|Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)",,"120","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2016-A02081-50","May 4, 2017","May 4, 2022","May 4, 2024","July 7, 2017",,"April 14, 2021","CHU de Poitiers, Poitiers, France",,"https://ClinicalTrials.gov/show/NCT03211026"
178,"NCT05108675","Microbiome and Malnutrition in Pregnancy (MMiP)","MMiP","Active, not recruiting","No Results Available","Weight Gain, Pregnancy|Microbial Colonization|Pregnancy Related|Pregnancy Loss|Pregnancy Complications|Pregnancy; Parasitic Disease|Parasitic Disease|Microbial Disease|Infant Malnutrition|Malnutrition|Malnutrition in Pregnancy|Breastfeeding",,"To assess if alterations of the microbiota in the maternal gut (dysbiosis) are corelated with changes in maternal gestational weight gain|To determine the correlation between maternal microbiome dysbiosis during pregnancy and birth weight.|To determine the correlation between maternal microbiome dysbiosis during pregnancy and infant growth|Anthropometrics|Anthropometrics: Maternal middle upper arm circumference|Anthropometrics: Maternal triceps skinfold thickness|Anthropometrics: Maternal height|Anthropometrics: Maternal weight|Maternal blood biomarker-1|Maternal blood biomarker-2|Maternal blood biomarker-3|Maternal blood biomarker-4|Infant blood biomarker-1|Infant blood biomarker-2|Infant blood biomarker-3|Infant blood biomarker-4|Infant sex|Infant morbidity|Maternal morbidity|Infant growth: weight|Infant growth: length|Infant growth: head circumference|Infant growth: mid upper arm circumference|Infant growth: triceps skinfold thickness|Gestational age at birth|Maternal age|Breast feeding|Reported Maternal medicinal use|Reported Infant medication use|Maternal dietary intake Assessed through ASA 24 HR Dietary Recall system, completed 2x each time point|Dietary diversity|Household annual food insecurity|Generalized Self-efficacy|Perceived decision making|Perceived social support|Maternal demographics|Food insecurity|Perceived parental stress|Preterm Births|Small for gestational age|Large for gestational age|Delivery Assessment|Infant dietary intake|Maternal stool biomarkers-1|Maternal stool biomarkers-2|Maternal stool biomarkers-3|Maternal: incidence of pathobionts|Infant: incidence of pathobionts|Maternal: metabolomic profile of stool [Metabolites involved in central metabolism as analysed by Mass Specttrometry]|Maternal gut bacteria profile|Maternal: blood metallomics profile|Infant: blood metallomics profile|Infant: gut bacterial profile|Maternal metabolic pathway expression profile|Infant eukaryotic microbiome profile|Maternal eukaryotic microbiome profile|Maternal bacterial gene expression profile|Maternal: microbiome taxonomic alpha and beta diversity|Infant: microbiome taxonomic alpha and beta diversity","Aga Khan University|The Hospital for Sick Children|University of Toronto|University of Calgary|Dalhousie University|University of Alberta|Canadian Institutes of Health Research (CIHR)","Female","17 Years to 24 Years   (Child, Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","51950","November 24, 2021","June 30, 2024","June 30, 2024","November 5, 2021",,"July 20, 2023","Research and Training Centre Matiari, Aga Khan University, Karachi, Sindh, Pakistan","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/75/NCT05108675/Prot_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/75/NCT05108675/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT05108675"
179,"NCT01537601","CIRCumcision and Urinary Tract Infections in Boys With Posterior Urethral Valves","CIRCUP","Completed","No Results Available","Posterior Urethral Valves","Procedure: Circumcision|Other: Antibiotic prophylaxis alone","Relative risk of presenting a febrile UTI|Number of children with febrile UTIs in each group at two years|Evolution of compliance to antibioprophylaxis.|Evolution of the grade of reflux|Comparison of the number of children who will show deterioration of their DMSA scan between children who have had UTIs and those who have not.|number and type of adverse effects related to circumcision and antibiotic prophylaxis|Identification of the responsible bacteria","Centre Hospitalier Universitaire de la Réunion","Male","up to 28 Days   (Child)","Not Applicable","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012/CHR/01","August 2012","February 2019","February 18, 2019","February 23, 2012",,"June 22, 2023","Department of pediatric surgery, Bordeaux hospital, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT01537601"
180,"NCT04825093","Vitamin D Supplementarion in Pregnant Women at Risk and COVID-19","D-WOMAN","Recruiting","No Results Available","Pregnancy Complications|Covid19","Dietary Supplement: Vitamin D supplementation in pregnant women","Blood analysis of serum concentrations of 25-hydroxyvitamin D|Prevalence of preterm birth|Prevalence of preeclampsia|Prevalence of gestational diabetes mellitus|Prevalence of COVID-19 and COVID-19 inmunity|Miscarriage|Neonatal immunity|Birth Weight|Psychomotor development of offspring","Universidad de Granada","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","SVD-COVID-2020","September 29, 2021","October 30, 2023","December 30, 2024","April 1, 2021",,"March 22, 2023","Maria Jose Aguilar Cordero, Granada, Spain",,"https://ClinicalTrials.gov/show/NCT04825093"
181,"NCT04823234","Lung Ultrasound Signs and Patterns in COVID-19 Pregnant Women","PINK-CO","Completed","No Results Available","Pregnancy Complications|Covid19","Diagnostic Test: Lung ultrasound","Light Beam|Ultrasound patterns|Lung ultrasound score|Illness severity|Length of stay","Azienda Sanitaria-Universitaria Integrata di Udine","Female","18 Years to 55 Years   (Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CEUR-2021-223","March 10, 2021","June 30, 2021","September 15, 2021","March 30, 2021",,"September 28, 2021","Anesthesiology and Intensive Care Clinic - Department of Medicine - ASUIUD, Udine, Italy",,"https://ClinicalTrials.gov/show/NCT04823234"
182,"NCT05089175","The Investigation of the Prediction Model and Prevention Strategy of Serious Pregnancy Complications in Hypertensive Disorders of Pregnancy Based on the Chinese Population","HDP-RPP","Recruiting","No Results Available","Hypertensive Disorder of Pregnancy|Pregnancy Complications","Drug: Low-dose aspirin","Number diagnosed with pre-eclampsia|Number of women with adverse outcomes","Women's Hospital School Of Medicine Zhejiang University","Female","18 Years to 55 Years   (Adult)",,"4500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ChiCTR2100048266","November 30, 2021","December 30, 2023","December 30, 2024","October 22, 2021",,"December 2, 2021","Women's Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT05089175"
183,"NCT01873690","Efficacy of Antimicrobial Prophylaxis for Shock Wave Lithotripsy (SWL) on Reducing Urinary Tract Infection (UTI)",,"Terminated","No Results Available","Urolithiasis","Drug: Ciprofloxacin|Drug: Placebo","Impact of antibiotic prophylaxis on the rate of urinary tract infection|Bacteriuria post-SWL (≥105 cfu/ml)|Symptoms of cystitis (new onset burning sensation or pain with voiding, frequency, urgency)|Pyelonephritis or urosepsis (hospital admission with fever ≥38.5C)|Change in Urinary Symptom Score(reported as positive or negative integer)","Lawson Health Research Institute|The Physicians' Services Incorporated Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 3","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","103696","November 2013","December 2015","December 2015","June 10, 2013",,"February 8, 2016","St. Joseph's Hospital, St. Joseph's Health Care London, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01873690"
184,"NCT04163679","Vaginal Preparation and Azithromycin to Reduce Post Cesarean Infections",,"Terminated","No Results Available","Infection|Obstetric Labor Complications|Endometritis|Cesarean Delivery Affecting Fetus|Wounds Injuries","Procedure: Vaginal Preparation","Infection rates|Infant Birth Weight|Infant Apgar scores|Infant Length of hospital stay|Numbers of Infants admitted to NICU|Number of Infants that develop respiratory distress|Number of Infants that develop sepsis|Number of infants that die","Womack Army Medical Center","Female","18 Years to 64 Years   (Adult)","Not Applicable","84","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","RHC-A-19-033","September 18, 2019","July 30, 2021","July 30, 2021","November 15, 2019",,"October 11, 2021","Womack Army Medical Center, Fort Bragg, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04163679"
185,"NCT04519502","Maternal Morbidity and Mortality During the COVID-19 Pandemic","MFMU COVID-19","Completed","No Results Available","COVID-19|Pregnancy Complications",,"Maternal Mortality and Morbidity Composite|Cesarean Delivery|Severe maternal morbidity or mortality|Adverse maternal outcomes|Adverse neonatal outcomes|Neonatal infection|Maternal in-patient hospitalization days|Maternal ICU admission|Duration of labor and delivery|Neonatal length of stay|Neonatal ICU length of stay","The George Washington University Biostatistics Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult",,"25604","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HD36801 - MFMU COVID-19|U01HD036801","June 23, 2020","August 31, 2021","November 4, 2021","August 19, 2020",,"March 27, 2023","University of Alabama - Birmingham, Birmingham, Alabama, United States|Northwestern University, Chicago, Illinois, United States|Columbia University-St. Luke's Hospital, New York, New York, United States|University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Magee Women's Hospital, Pittsburgh, Pennsylvania, United States|Brown Univeristy, Providence, Rhode Island, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04519502"
186,"NCT01006629","Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children",,"Completed","Has Results","Respiratory Syncytial Virus Infection|Premature Birth|Bronchopulmonary Dysplasia|Congenital Heart Disease","Biological: palivizumab","Frequency of Adverse Events|Number of Hospitalizations Due to Respiratory Syncytial Virus (RSV)|Total Number of RSV Hospitalization Days|Total RSV Hospitalization Days With Increased Supplemental Oxygen Requirement|Number of Intensive Care Unit (ICU) Admissions During RSV Hospitalization|Total Days of RSV ICU Stay|Number of Subjects Who Received Mechanical Ventilation During RSV Hospitalization|Total Days of Mechanical Ventilation During RSV Hospitalization","Abbott","All","up to 2 Years   (Child)","Phase 2|Phase 3","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","W10-664","November 2009","April 2010","July 2010","November 3, 2009","July 19, 2011","July 19, 2011","Site Ref # / Investigator 22699, Ivanovo, Russian Federation|Site Ref # / Investigator 22694, Kazan, Russian Federation|Site Ref # / Investigator 24022, Moscow, Russian Federation|Site Ref # / Investigator 15744, Moscow, Russian Federation|Site Ref # / Investigator 15745, Moscow, Russian Federation|Site Ref # / Investigator 24025, Moscow, Russian Federation|Site Ref # / Investigator 15781, Moscow, Russian Federation|Site Ref # / Investigator 22686, Moscow, Russian Federation|Site Ref # / Investigator 15747, Moscow, Russian Federation|Site Ref # / Investigator 22696, Novosibirsk, Russian Federation|Site Ref # / Investigator 24023, Novosibirsk, Russian Federation|Site Ref # / Investigator 22692, Saint Petersburg, Russian Federation|Site Ref # / Investigator 22683, Saint Petersburg, Russian Federation|Site Ref # / Investigator 22693, Saint Petersburg, Russian Federation|Site Ref # / Investigator 22685, Saint Petersburg, Russian Federation|Site Ref # / Investigator 15722, Saint Petersburg, Russian Federation|Site Ref # / Investigator 15748, Saint Petersburg, Russian Federation|Site Ref # / Investigator 15782, Saint Petersburg, Russian Federation|Site Ref # / Investigator 15746, Tomsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01006629"
187,"NCT05577273","Does Antibiotic Prophylaxis at Urinary Catheter Removal Prevent Urinary Tract Infections",,"Enrolling by invitation","No Results Available","Urologic Diseases|Urinary Tract Disease","Drug: Cefuroxime axetil (trimethoprim/sulfamethoxazole if penicillin allergy)","UTI|positive culture approved UTI|Hospitalizations due to UTI|Bacteremia","Omri Schwarztuch Gildor|Clalit Health Services","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MMC-0048-18","August 14, 2018","August 31, 2023","August 31, 2023","October 13, 2022",,"October 13, 2022","Meir Medical Center, Kfar-Sava, Israel",,"https://ClinicalTrials.gov/show/NCT05577273"
188,"NCT04152278","Chlamydia Tracomatis and Other Lower Genital Tract Infections Among Women With Unexplained Early Miscarriage",,"Completed","No Results Available","Early Pregnancy","Diagnostic Test: cervicovaginal culture and qPCR for chlamydial trachomatis and wadallia chondrophila","the association of lower genital tract infection with spontaneous miscarriage","Fayoum University Hospital","Female","18 Years to 45 Years   (Adult)",,"600","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","fayoumUH","September 1, 2017","August 30, 2019","September 30, 2019","November 5, 2019",,"July 23, 2020","sahar M.Y elbaradie, Fayoum, Egypt",,"https://ClinicalTrials.gov/show/NCT04152278"
189,"NCT03700060","Communication and Compliance for Antibiotic Prescribing by General Practice to Nursing Home Residents With Suspected UTI",,"Completed","No Results Available","Urinary Tract Infections|Communication|Compliance, Medication",,"How many suspected UTIs in nursing home residents are treated in accordance with guidelines?|Is mode of communication associated compliance to the guideline?","Research Unit Of General Practice, Copenhagen","All","Child, Adult, Older Adult",,"459","Other","Observational","Observational Model: Other|Time Perspective: Prospective","UTI in nursing homes","April 3, 2018","June 30, 2018","June 30, 2018","October 9, 2018",,"October 9, 2018","Research Unit of General Practice, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03700060"
190,"NCT05438082","Antibiotic Prophylaxis to Prevent Post-procedure UTI After VCUG","APPrUV","Not yet recruiting","No Results Available","Antibiotic Prophylaxis|Voiding Cystourethrogram|Febrile Urinary Tract Infection","Drug: Antibiotic Prophylaxis|Other: Placebo","Feasibility of pilot study: randomization, compliance, enrollment targets|Resource Allocation|Febrile UTI within 7 days of VCUG Procedure","Hamilton Health Sciences Corporation|McMaster University","All","up to 3 Years   (Child)","Phase 4","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","19481","October 2023","October 2024","December 2024","June 29, 2022",,"April 12, 2023",,,"https://ClinicalTrials.gov/show/NCT05438082"
191,"NCT04832581","Developing Self-care Behaviors for Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infection During Pregnancy","Behavioral: The Self-Care Behavior Development Program","Genital Hygiene Behavior Inventory (GHBI)|Pregnant Information Form|Pregnancy Evaluation Form","Istanbul University - Cerrahpasa (IUC)","Female","22 Years to 49 Years   (Adult)","Not Applicable","67","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ECaliskan","January 20, 2020","June 3, 2020","July 8, 2020","April 6, 2021",,"April 6, 2021","Esra Çalışkan, İstanbul, Turkey|Nevin Hotun Şahin, İstanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04832581"
192,"NCT01776021","Effects of a Cranberry Beverage on Women With Recent History of Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infections|Infection|Urologic Diseases","Other: cranberry juice|Other: placebo beverage","The primary outcome variable will be UTI incidence density, defined as the semi-annualized number of UTIs in each group, adjusted for susceptible time under observation.|Time from randomization to first clinical UTI. Time from randomization to first clinical UTI w/ pyuria. Time from randomization to first clinical UTI w/ microbiological verification. The fraction of subjects w/ one or more episode(s) of clinical UTI.","Ocean Spray Cranberries, Inc.|Biofortis Clinical Research, Inc.","Female","20 Years to 70 Years   (Adult, Older Adult)","Not Applicable","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PRV-1201","January 2013","December 2014","April 2015","January 25, 2013",,"April 27, 2015","Chandler, Arizona, United States|Scottsdale, Arizona, United States|San Diego, California, United States|Santa Rosa, California, United States|Denver, Colorado, United States|Edgewater, Florida, United States|Miami, Florida, United States|Summerfield, Florida, United States|Ocean Spray Cranberries Research Sites, Addison, Illinois, United States|Evanston, Illinois, United States|Edina, Minnesota, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Anderson, South Carolina, United States|Dallas, Texas, United States|Pleasant Grove, Utah, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01776021"
193,"NCT02245815","Prevention of Necrotizing Enterocolitis of Premature Newborns Under Less Than 1500 g Using Probiotics","(PEPP)","Completed","Has Results","Infectious Diseases","Dietary Supplement: use probiotics boucardii|Dietary Supplement: use probiotics Multi-species","Number of Patients With (NEC)","Coordinación de Investigación en Salud, Mexico","All","27 Weeks to 34 Weeks   (Child)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","R-2013-1002-7","December 2013","July 2015","July 2015","September 22, 2014","January 28, 2021","January 28, 2021","University of Guanajuato School of Medicine, Leon, Guanajuato, Mexico",,"https://ClinicalTrials.gov/show/NCT02245815"
194,"NCT04076436","Efficacy of Intravenous Fosfomycin in the Treatment of Complicated Urinary in Real-life Conditions.",,"Unknown status","No Results Available","Complicated Urinary Tract Infection","Other: Drug: Intravenous fosfomycin|Other: Drug: Intravenous quinolone or beta-lactam","The difference in the proportion of subjects getting clinical-microbiological cure on the test of cure between the fosfomycin cohort and the quinolones or beta-lactams cohort|The proportion of microbiological failure on the test of cure in the fosfomycin cohort (measured as isolation of Escherichia coli in uroculture on the test of cure).|The proportion of development of resistance (or decrease in sensitivity) to fosfomycin during or after treatment: Presence of mutation in genes uhpT, uhpA, uhpB, uhpC, uhpT, crp, cyaA, ptsl and fosA and measure CMI.|To evaluate the frequency of microbiological failure and development of resistance (or decrease in sensitivity) in Escherichia coli isolates.|The difference in the proportion of solicited EAs in subjects in fosfomycin cohort and quinolones or beta-lactams cohort.","Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","FIS-FOS-2019-01","October 21, 2019","June 30, 2021","December 31, 2021","September 3, 2019",,"November 14, 2019","Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT04076436"
195,"NCT04171388","Enhancing Nutrition and Antenatal Infection Treatment for Maternal and Child Health in Ethiopia","ENAT","Withdrawn","No Results Available","Low Birthweight|Preterm Birth|Maternal; Malnutrition, Affecting Fetus|Sexually Transmitted Diseases|Urinary Tract Infections|Pregnancy and Infectious Disease","Drug: Azithromycin 500 mg|Dietary Supplement: Multiple Micronutrient or Fortified Balanced Energy Protein Supplement|Drug: Placebo oral tablet 500 mg|Other: Enhanced Infection Management Package (EIMP)","Birth weight|Birth length|Gestational age|Preterm birth|Small-for-gestational age (SGA)|Low birthweight|Length-for-age|Weight-for-age|Rate of weight gain in pregnancy|Maternal anemia|Stillbirth|Prevalence of nasopharyngeal macrolide resistance in mothers-infants","Brigham and Women's Hospital|Addis Continental Institute of Public Health|Johns Hopkins Bloomberg School of Public Health|Boston Children's Hospital|Beth Israel Deaconess Medical Center|Harvard School of Public Health (HSPH)|Amhara Public Health Institute|Jhpiego","Female","Child, Adult, Older Adult","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2018P002479","March 1, 2020","May 28, 2021","November 30, 2021","November 20, 2019",,"August 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04171388"
196,"NCT06004739","Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection","A-DONUT","Recruiting","No Results Available","Infectious Disease","Drug: Start Antibiotics / Continue Antibiotics for treatment of bacteriuria|Other: No Antibiotics for treatment of bacteriuria","Delirium at day 7 or at day of hospital discharge, whichever is earliest|Length of hospitalization|Number of participants with bacteremia (bacteria isolated in blood culture)|Number of participants who were transferred to Intensive Care Unit (ICU)|Number of participants who had a fall|Number of participants who were physically restrained|Number of participants who received antipsychotics|Days of antibiotics|Number of participants with C. difficile infection|Number of participants who died|Number of participants who were readmitted to hospital","Mount Sinai Hospital, Canada|Sault Area Hospital|Michael Garron Hospital|Unity Health Toronto|The Ottawa Hospital","All","60 Years and older   (Adult, Older Adult)","Not Applicable","550","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CTO 4466","September 2023","September 2027","September 2027","August 22, 2023",,"September 1, 2023","Sault Area Hospital, Sault Ste. Marie, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT06004739"
197,"NCT00324324","Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant",,"Terminated","No Results Available","Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor","Drug: moxifloxacin hydrochloride|Drug: Placebo","Safety and tolerability|Incidence of bacteremia|Incidence and severity of graft-versus-host disease|Infection-related mortality|Overall mortality","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 3","240","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","CDR0000472877|P30CA069533|OHSU-TPI-02027-L|OHSU 0285","May 2006","April 2007","December 2012","May 11, 2006",,"May 9, 2017","Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT00324324"
198,"NCT05624476","mNGS for Therapy of Urinary Infectious Diseases","PGS-U-UTI&UC","Not yet recruiting","No Results Available","Urinary Tract Infections|Sequelae of; Infection","Diagnostic Test: mNGS of urine cell-free DNA","Number of participants cured from urinary tract infection","Shanghai Changzheng Hospital","All","16 Years to 70 Years   (Child, Adult, Older Adult)",,"72","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CZGR2022002","January 1, 2023","September 30, 2023","December 31, 2023","November 22, 2022",,"November 22, 2022",,,"https://ClinicalTrials.gov/show/NCT05624476"
199,"NCT00064311","Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation",,"Completed","No Results Available","Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor","Drug: ravuconazole",,"National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2",,"NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Supportive Care","030205|03-C-0205|CDR0000315356","June 2003",,"September 2004","July 9, 2003",,"March 8, 2012","Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00064311"
200,"NCT01867164","A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis",,"Completed","Has Results","Vaginitis|Infectious Vaginosis","Drug: Gynoclin V|Drug: Vagitrol V","Percentage of Participants With Presence or Absence of Symptoms 3 Days After Treatment|Percentage of Participants With Presence or Absence of Symptoms 8 Days After Treatment|Percentage of Participants With the Presence of Microorganisms (Single-celled, Tiny Organisms That Include Fungi, Bacteria, Viruses) 3 Days After Treatment|Percentage of Participants With Response to Treatment Assessed by Participant|Percentage of Participants With Response to Treatment Assessed by Physician","Janssen-Cilag, S.A.","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR100569|TEROV8BAC4001","December 2007","December 2008","December 2008","June 3, 2013","December 24, 2013","December 24, 2013","DF, Mexico|Mexico D.F., Mexico",,"https://ClinicalTrials.gov/show/NCT01867164"
201,"NCT00397735","N-acetylcysteine in Intra-amniotic Infection/Inflammation",,"Completed","No Results Available","Labor, Premature|Preterm Premature Rupture of the Membranes|Infection|Inflammation|Chorioamnionitis","Procedure: amniocentesis|Drug: N-acetylcysteine or placebo","composite of mortality and severe short term neonatal morbidities (IVH, NEC, BPD, ROP, sepsis, newborn death)|neonatal sepsis|maternal and umbilical cord plasma antioxidant capacity|maternal and umbilical cord plasma N-acetylcysteine levels|umbilical cord levels of inflammatory cytokine concentrations|funisitis grades|maternal and umbilical cord blood glutathione concentration","Ohio State University","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0603001228","October 1, 2006","October 29, 2012","August 1, 2018","November 9, 2006",,"October 10, 2018","Yale New Haven Hospital, New Haven, Connecticut, United States|The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00397735"
202,"NCT04244526","Urinary Tract Infection in Pregnancy",,"Unknown status","No Results Available","Urinary Tract Infections","Other: Talking a urine sample","The percentage of virulence genes in different isolated UPEC strains|Correlation between the virulence genes and antibiotic resistance","Assiut University","Female","18 Years to 45 Years   (Adult)",,"155","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Urinary tract infection","March 1, 2020","March 1, 2021","May 1, 2021","January 28, 2020",,"January 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04244526"
203,"NCT03996057","Methenamine in a Non-antibiotic, Multimodal Approach to UTI Prevention",,"Withdrawn","No Results Available","UTI|Female Urogenital Diseases|UTI - Lower Urinary Tract Infection","Drug: Methenamine Hippurate 1000 MG|Drug: Vaginal estrogen|Dietary Supplement: D-mannose","Culture proven, symptomatic urinary tract infection (UTI)|Recruitment rate|Retention rate|Adherence|Frequency of culture proven, symptomatic urinary tract infection (UTI)|Treatment for urinary tract infection (UTI)|Side effects or adverse events","Washington University School of Medicine","Female","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","201804086","June 20, 2018","February 11, 2022","February 11, 2022","June 24, 2019",,"July 8, 2022",,,"https://ClinicalTrials.gov/show/NCT03996057"
204,"NCT02966977","Extending Urine Analysis By Direct Mass Spectrometry",,"Completed","No Results Available","Urinary Tract Infection (Diagnosis)","Other: Conventional microbiological identification by culture plate|Other: Direct mass spectrometry identification from urine sample","Time from the entry of a urine sample in the microbiological laboratory to the adequate/optimal/definitive treatment.|Time to diagnosis of a therapy relevant UTI.|Quantity of antibiotics prescribed per patient and ward.|Comparison of the length of hospital stay|Comparison of the number of possible complications connected to UTI","University Hospital, Basel, Switzerland","All","18 Years and older   (Adult, Older Adult)","Not Applicable","192","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016-01534","October 3, 2016","March 31, 2017","April 15, 2017","November 17, 2016",,"July 17, 2020","University Hospital Basel, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT02966977"
205,"NCT01488955","Immediate vs. Conditional Use of Antibiotics in Uncomplicated Urinary Tract Infection (UTI) - ICUTI",,"Completed","No Results Available","Urinary Tract Infection","Drug: Ibuprofen|Drug: Fosfomycin-Trometamol","number of additional treatments with antibiotics combined with number of symptoms|number of defined daily doses of antibiotics|number of SAEs|number of relapses|number of patients without symptoms|symptom load (AUC)|symptom load|symptoms load with regard to specific symptoms|activity impairment assessment","Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|University Medical Center Goettingen","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","494","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20110512-BG","February 2012","February 2014","July 2014","December 8, 2011",,"August 8, 2014","Univercity Medical Center Goettingen, Goettingen, Germany|MHH Hannover, Hannover, Germany",,"https://ClinicalTrials.gov/show/NCT01488955"
206,"NCT05537519","Phage Therapy for the Treatment of Urinary Tract Infection",,"Active, not recruiting","No Results Available","Recurrent Urinary Tract Infection","Biological: Phage Therapy","Safety and Tolerability|Clinical and microbial response","Unity Health Toronto|Applied Health Research Centre","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Phage Therapy 001","May 1, 2023","July 28, 2023","June 30, 2024","September 13, 2022",,"March 26, 2024","St. Joseph's Health Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT05537519"
207,"NCT00195286","Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.",,"Completed","No Results Available","Urinary Infections","Drug: piperacillin/tazobactam",,"Wyeth is now a wholly owned subsidiary of Pfizer","All","16 Years and older   (Child, Adult, Older Adult)",,"180","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","101315","June 2004","July 2007","July 2007","September 19, 2005",,"September 25, 2009","Antequera (Málaga), Spain|Avila, Spain|Barcelona, Spain|Berga (Barcelona), Spain|Caceres, Spain|Castellón, Spain|Ciudad Real, Spain|Cuenca, Spain|Cádiz, Spain|Ferrol, Spain|Granada, Spain|Jaen, Spain|Las Palmas, Spain|Lorca (Murcia), Spain|Lugo, Spain|Lérida, Spain|Madrid, Spain|Osuna (Sevilla), Spain|Palma Mallorca, Spain|Pamplona, Spain|Pontevedra, Spain|Terrasa, Spain|Torrelavega, Spain|Valencia, Spain|Valladolid, Spain|Vitoria, Spain|Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT00195286"
208,"NCT03413774","Unexplained Early Miscarriage : Role and Prevalence of Lower Genital Tract Infections",,"Completed","No Results Available","First Trimester Abortion","Procedure: vaginal swab","prevalence of lower genital tract infection","Cairo University","Female","18 Years to 40 Years   (Adult)",,"1850","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","24","October 1, 2014","December 20, 2017","January 15, 2018","January 29, 2018",,"January 29, 2018","Kasr Alainy medical school, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT03413774"
209,"NCT03399682","Incidence of Post Cystography Urinary Tract Infections in the Pediatric Population","IUCPED","Unknown status","No Results Available","Urinary Infection","Diagnostic Test: cystography","recent analysis of urinary post cystography infection rate in the pediatric population|infection rate epidemiology","University Hospital, Caen|CH Lisieux|CH Avranches","All","up to 16 Years   (Child)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2017-A02445-48","January 3, 2018","February 3, 2018","January 31, 2019","January 16, 2018",,"January 17, 2018","Caen University Hospital, Caen, France",,"https://ClinicalTrials.gov/show/NCT03399682"
210,"NCT03501901","Urinary Tract Infections Caused by ESBL-producing Enterobacteria",,"Completed","No Results Available","Urinary Tract Infections","Diagnostic Test: Antibiotic susceptibility test","Antibiotic resistance","Universidad Autonoma de Nuevo Leon|Hospital Universitario Dr. Jose E. Gonzalez","All","18 Years and older   (Adult, Older Adult)",,"353","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UR14-004","March 1, 2015","October 31, 2015","October 1, 2017","April 18, 2018",,"April 19, 2018",,,"https://ClinicalTrials.gov/show/NCT03501901"
211,"NCT05814250","Ultrasonography in Children With First Febrile Urinary Tract Infection",,"Recruiting","No Results Available","Urinary Tract Infections",,"To evaluate the diagnostic accuracy of the presence of an atypical germ combined with the possible recurrence of UTI in predicting the positivity of KUS in children aged between 2 months and 3 years with first episode of fUTI|To evaluate the diagnostic accuracy of urinary culture carried out from urinary bag vs a second sample gathered from the same patient by clean catch or bladder catheterization (gold standard)|To evaluate the concordance of the germs found in positive urinary culture carried out from urinary bag vs clean catch or bladder catheterization gathered from the same patient","IRCCS Burlo Garofolo","All","2 Months to 3 Years   (Child)",,"20","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","RC 01/22","June 13, 2022","March 31, 2025","March 31, 2028","April 14, 2023",,"March 8, 2024","AOU Meyer IRCCS, Firenze, Italy|IRCCS materno infantile Burlo Garofolo, Trieste, Italy",,"https://ClinicalTrials.gov/show/NCT05814250"
212,"NCT00642070","Host Response to Urinary Tract Infection in Women",,"Completed","No Results Available","Urinary Tract Infection",,"Determine elements of the immune response that may predispose a woman to recurrent urinary tract infection","University of Washington|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Female","18 Years to 49 Years   (Adult)",,"326","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","31467-D|NIDDK 1 P50 AR049475-06;|06-4836-D","February 2008","July 2012","July 2012","March 24, 2008",,"June 5, 2014","University of Washington/Hall Health Primary Care Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00642070"
213,"NCT01994538","Seven vs. 14 Days Treatment for Male Urinary Tract Infection",,"Completed","Has Results","Urinary Tract Infections","Other: Longer therapy duration|Other: Shorter therapy duration","Resolution of UTI Symptoms 14 Days After Completing Active Antimicrobial Therapy|Recurrent UTI Within 28 Days of Completing Active Study Medication|Adverse Drug Event in the 28 Days After Completing Study Medication|Intestinal Carriage of Antimicrobial-resistant Gram Negative Bacilli","VA Office of Research and Development","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","273","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLIN-008-13S|I01BX007080","April 24, 2014","December 31, 2019","December 31, 2019","November 25, 2013","October 28, 2020","June 2, 2021","Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/38/NCT01994538/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01994538"
214,"NCT03377426","LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)",,"Withdrawn","No Results Available","Complicated Urinary Tract Infections","Drug: LYS228|Drug: Standard of care therapy","Change from Baseline of the Clinical Response at Day 7|Plasma Pharmacokinetics (PK) of LYS228: Area Under the Plasma Concentration-time Curve from time zero to the end of dosing interval tau (AUCtau)|Plasma Pharmacokinetics (PK) of LYS228: The observed maximum plasma concentration following drug administration (Cmax)|Plasma Pharmacokinetics (PK) of LYS228: The time to reach the maximum concentration after drug administration (Tmax)|Plasma Pharmacokinetics (PK) of LYS228: The systemic (or total body) clearance from plasma following intravenous administration (CL)|Plasma Pharmacokinetics (PK) of LYS228: The volume of distribution at steady state following intravenous administration (Vss)|Plasma Pharmacokinetics (PK) of LYS228: The terminal elimination half-life (T 1/2)|Plasma Pharmacokinetics (PK) of LYS228: The amount of time in which the unbound drug concentration exceeds the minimum inhibitory concentration of the organism (%fT>MIC)|Urine Pharmacokinetics (PK) of LYS228: The amount of drug eliminated in Urine from 0 hours up to 6 hours following intravenus administration (Ae0-6h)|Urine Pharmacokinetics (PK) of LYS228: Renal Clearance (CLr)|Change from Baseline of the Microbiological Response at Day 7","Novartis Pharmaceuticals|Novartis","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","CLYS228X2201","October 19, 2018","October 28, 2019","October 28, 2019","December 19, 2017",,"October 26, 2018","Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Odense, Denmark|Novartis Investigative Site, Athens, Greece",,"https://ClinicalTrials.gov/show/NCT03377426"
215,"NCT02331862","To Study the Effect of Adjunctive Oral Methylprednisolone Therapy in Pediatric Urinary Tract Infection",,"Unknown status","No Results Available","Urinary Tract Infection","Drug: Methylprednisolone","The proportion of patients with renal scar formation|Duration of the hospitalization|Expense of the hospitalization","National Cheng-Kung University Hospital","All","1 Week to 16 Years   (Child)","Phase 3","160","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B-BR-103-050","January 2015","December 2015","December 2015","January 6, 2015",,"January 6, 2015",,,"https://ClinicalTrials.gov/show/NCT02331862"
216,"NCT05160649","Effect of Covid 19 Infection on Fetomaternal Outcome",,"Active, not recruiting","No Results Available","COVID-19|COVID-19 Pneumonia|Fetal Growth Retardation",,"First, second and third trimester fetomaternal complications.|fetal distress|fetal outcome|Time of infection and fetal complications","Fayoum University","Female","18 Years to 40 Years   (Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","S 280","October 10, 2021","June 2023","October 2023","December 16, 2021",,"April 28, 2023","Fayoum university, Fayoum, Egypt",,"https://ClinicalTrials.gov/show/NCT05160649"
217,"NCT00245791","Urinary Tract Infection Study With the Antibiotic Levofloxacin Given at a Higher Dose Over a Shorter Period of Time",,"Terminated","No Results Available","Complicated Urinary Infection","Drug: Levofloxacin","Microbiologic and clinical cure at the early post-therapy follow-up visit (12-19 days after initiating antimicrobial).|Variables will include outcomes at 2 days of therapy, failure to complete therapy, adverse drug effects, long term clinical and microbiologic outcomes, and emergence of resistant organisms.","University of Manitoba","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAPSS-383|LOF-UTI-3","October 2004",,"July 2005","October 28, 2005",,"June 3, 2015","St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada|University of Manitoba, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT00245791"
218,"NCT02289794","Vaccine Against Escherichia Coli Infection",,"Completed","No Results Available","E.Coli Infections","Biological: E.coli bioconjugate vaccine|Biological: Placebo","Number of subjects experiencing an adverse events|Comparison of E.coli vaccine-specific serotypes antibody concentrations in serum at different timepoints","GlycoVaxyn AG","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","194","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","GVXN EC-4V|2013DR1205","January 2014","July 2015","September 2015","November 13, 2014",,"February 11, 2016","Hôpitaux Universitaires de Genève, Geneve, GE, Switzerland",,"https://ClinicalTrials.gov/show/NCT02289794"
219,"NCT01138566","Clinical Significance and Optimal Treatment of Community-onset Urinary Tract Infections Caused by Extended-spectrum β-lactamase and/or AmpC β-lactamase Producing Enterobacteriaceae",,"Unknown status","No Results Available","Urinary Tract Infections",,,"Taipei Veterans General Hospital, Taiwan|Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)",,"400","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IISP37925",,,,"June 7, 2010",,"June 7, 2010","Taipei Vterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01138566"
220,"NCT02497781","Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)",,"Completed","Has Results","Complicated Urinary Tract Infections","Drug: Ceftazidime -avibactam|Drug: Cefepime","Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Percentage of Participants With Cephalosporin Class Effects and Additional Adverse Events (AEs)|Change From Baseline in Pulse Rate at End of Intravenous Treatment (EOIV) Visit|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End of Intravenous Treatment (EOIV) Visit|Change From Baseline in Respiratory Rate at End of Intravenous Treatment (EOIV) Visit|Change From Baseline in Body Temperature at End of Intravenous Treatment (EOIV) Visit|Percentage of Participants With Abnormal Physical Examination Findings at End of Intravenous Treatment (EOIV) Visit|Change From Baseline in Body Weight at End of Intravenous Treatment (EOIV) Visit|Percentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters|Percentage of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters|Percentage of Participants With Creatinine Clearance (CrCl) at Day 7|Percentage of Participants With Creatinine Clearance (CrCl) at End of Intravenous Treatment (EOIV) Visit|Percentage of Participants With Creatinine Clearance (CrCl) at Test of Cure (TOC) Visit|Plasma Concentrations of Ceftazidime and Avibactam|Percentage of Participants With Favourable Clinical Response (CR): Intent-to-treat (ITT) Analysis Population|Percentage of Participants With Favourable Clinical Response (CR): Microbiological ITT (Micro-ITT) Analysis Population|Percentage of Participants With Favourable Clinical Response (CR) at End of 72 Hours Treatment: Clinically Evaluable (CE) Analysis Set at 72 Hours|Percentage of Participants With Favourable Clinical Response (CR) at End of Intravenous Treatment (EOIV) Visit: Clinically Evaluable (CE) Analysis Set at EOIV|Percentage of Participants With Favourable Clinical Response (CR) at End of Treatment (EOT) Visit: Clinically Evaluable (CE) Analysis Set at EOT|Percentage of Participants With Favourable Clinical Response (CR) at TOC: Clinically Evaluable (CE) Analysis Set at TOC|Percentage of Participants With Favourable Clinical Response (CR): Microbiologically Evaluable (ME) Analysis Population|Percentage of Participants With Favourable Microbiological Response: Microbiological Intent-to-treat (Micro-ITT) Population|Percentage of Participants With Favourable Microbiological Response: Microbiologically Evaluable (ME) Analysis Population|Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Clinically Evaluable (CE) Analysis Set at LFU|Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Microbiologically Evaluable (ME) Analysis Set at LFU|Percentage of Participants With Emergent Infections: Microbiological Intent-to-treat (Micro-ITT) Population|Percentage of Participants With Emergent Infections: Microbiologically Evaluable (ME) Analysis Population|Percentage of Participants With Favourable Combined Response: Microbiological Intent-to-treat (Micro-ITT) Population|Percentage of Participants With Combined Response: Microbiologically Evaluable (ME) Analysis Population","Pfizer|PRA Health Sciences","All","3 Months to 17 Years   (Child)","Phase 2","97","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","D4280C00016|C3591005|2014-003244-13","September 24, 2015","September 15, 2017","September 15, 2017","July 15, 2015","April 10, 2018","July 11, 2018","Rady Children's Hospital San Diego, San Diego, California, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|ProMedica Toledo Children's Hospital, Toledo, Ohio, United States|Lekarna Oblastni nemocnice Kolin, a.s., Kolin III, Czechia|Oblastni nemocnice Kolin, a.s., nemocnice Stredoceskeho kraje - Detske oddeleni, Kolin III, Czechia|Krajska Zdravotni, A.S. - Nemocnice Most, O.Z., Detske A Dorostove Oddeleni, Most, Czechia|Lekarna Nemocnice Most., O.Z., Most, Czechia|Fakultni Nemocnice Ostrava - Klinika Detskeho Lekarstvi, Ostrava - Poruba, Czechia|Lekarna Fakultni Nemocnice Ostrava, Ostrava - Poruba, Czechia|General Children's Hospital ""Agia Sofia"", Goudi, Attica, Greece|General Children's Hospital of Athens ""P. & A. Kyriakou"", Goudi, Attica, Greece|""Hippokratio"" General Hospital of Thessaloniki, Thessaloniki, Makedonia, Greece|University General Hospital of Larissa, Larissa, Thessaly, Greece|Egyesitett Szent Istvan es Szent Laszlo Korhaz - Rendelointezet, Gyermekinfektologiai Osztaly, Budapest, Hungary|Toldy Ferenc Korhaz es Rendelointezet, Csecsemo- es Gyermekgyogyaszati Osztaly, Cegled, Hungary|Kanizsai Dorottya Korhaz, Csecsemo es Gyermekgyogyaszati Osztaly, Nagykanizsa, Hungary|Tolna Megyei Balassa Janos Korhaz, Gyermekosztaly, Szekszard, Hungary|Wojewodzki Specjalistyczny Szpital im. dr W1. Bieganskiego, Lodz, Lodzkie, Poland|Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa w Bialymstoku, Bialystok, Podlaskie, Poland|Spitalul Clinic de Boli Infectioase si Tropicale ""Dr. Victor Babes"", Sectia B2 Boli Infectioase, Bucuresti, Romania|State Autonomous Healthcare Institution of Kemerovo Region ""Kemerovo Regional Clinical Hospital"", Kemerovo, Russian Federation|Federal State Budgetary Institution, Moscow, Russian Federation|Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Ege Universitesi Tip Fakultesi, Izmir, Turkey|Celal Bayar Universitesi Hafsa Sultan Hastanesi, Manisa, Turkey","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/81/NCT02497781/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/81/NCT02497781/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02497781"
221,"NCT06109688","Effect of Lactoferrin Supplementation on Urinary Tract Infections in Infants.",,"Completed","No Results Available","Urinary Tract Infections in Children","Dietary Supplement: Bovine Lactoferrin|Dietary Supplement: placebo","Monitoring of parameters of inflammation.|Influence of lactoferrin on Interleukin-6 and Interleukin-8.|Effect of lactoferrin on white blood cells.|Effect of lactoferrin on urinary inflammatory markers.|To evaluate the efficacy of lactoferrin in the reduction of probable recurrence of Urinary Tract Infection.|The number of days of hospitalization.|Evaluation of the safety of the administration of lactoferrin by monitoring possible adverse effects.","Medical University of Lublin|Pharmabest Sp. z o.o.","All","7 Days to 12 Months   (Child)","Phase 3","55","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0254/297/2014","July 1, 2015","December 31, 2017","February 15, 2018","October 31, 2023",,"October 31, 2023",,,"https://ClinicalTrials.gov/show/NCT06109688"
222,"NCT05329883","Multicentric Study on Infections of the Urinary Tract After Stent Removal (MINUS-trial).","MINUS","Recruiting","No Results Available","Urinary Tract Infections|Stent Related Infection","Procedure: Double-J stent removal","number of participants demonstrating a post-stent removal urinary tract infection","University Hospital, Ghent|AZ Sint-Lucas Gent|Universitaire Ziekenhuizen KU Leuven|General Hospital Groeninge|University of British Columbia|Centre hospitalier de l'Université de Montréal (CHUM)","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BC-10846","November 25, 2021","December 31, 2024","December 31, 2025","April 15, 2022",,"December 15, 2023","University Hospital Ghent, Gent, Eastern-Flanders, Belgium",,"https://ClinicalTrials.gov/show/NCT05329883"
223,"NCT01219595","Cranberry Proanthocyanidins for Modification of Intestinal E. Coli Flora and Prevention of Urinary Tract Infections in UTI-Susceptible Women",,"Completed","No Results Available","Urinary Tract Infection","Other: Sweetened, dried cranberries|Other: Strawberry Fruit Pieces|Other: Observation","Pre-treatment heterogeneity or prevalence|Post-treatment heterogeneity|Patient acceptance of study regimen|Maintenance of heterogeneity in the intestinal flora|Measure Effects of sweetened, dried cranberries on E. coli clonotypes over three two-week exposures|Measure effects of sweetened, dried cranberries on E. coli clonotypes over one 4-week exposure|Measure the UTI recurrence|Comparison of sweetened dried cranberries to a placebo group","University of Wisconsin, Madison|Ocean Spray Cranberries, Inc.","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","65","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","H-2010-0107","September 2010","September 2012","September 2012","October 13, 2010",,"January 29, 2016","University of Wisconsin-Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01219595"
224,"NCT06210425","Is Re-examination of Urine Culture Necessary for Patients With Preoperative Positive Results in Predicting Infectious Complications Related to Mini-Percutaneous Nephrolithotomy?",,"Recruiting","No Results Available","Kidney Calculi|Urinary Tract Infections|Sepsis",,"Urosepsis|Fever","Junhao Zheng|The First Affiliated Hospital of Guangzhou Medical University","All","18 Years to 80 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","12440100455344205E","March 1, 2021","October 30, 2024","November 10, 2024","January 18, 2024",,"January 18, 2024","The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, GuangGong, China",,"https://ClinicalTrials.gov/show/NCT06210425"
225,"NCT00213759","Prevention Trial of Nosocomial Infections in Neutropenic Prematures With G-CSF",,"Completed","No Results Available","Neutropenia in Prematures","Drug: filgrastim|Drug: dextrose 5%","survival without infection at 4 weeks after treatment|survival free of infection at 2 weeks after treatment,mortality, increase of neutrophile, number of septic event, incidence of chronic lung disease, necrotizing enterocolitis, cerebral us abnormalities, retinopathy , duration of hospitalisation stay","University Hospital, Strasbourg, France","All","2 Days to 35 Weeks   (Child)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2712|0203222","March 2002",,"August 2006","September 21, 2005",,"November 29, 2007","Xavier Hernandorena, Bayonne, France|Alain Menget, Besancon, France|Jean-Louis Demarquez, Bordeaux, France|Bernard Guillois, Caen, France|Marie Thieuleux, Calais, France|André Labbe, Clermont-Ferrand, France|Jean-Bernard Gouyon, Dijon, France|Pierre Andrini, Grenoble, France|Jean Messer, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT00213759"
226,"NCT01092351","Efficacy and Safety of Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infections in Adults",,"Completed","No Results Available","Urinary Tract Infection","Drug: Nitrofurantoin","Evaluation of bacteriological efficacy|Evaluation of clinical efficacy|Evaluation of safety and tolerability","Mepha Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 4","37","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NIT 001-2006","January 2007","September 2008","September 2008","March 24, 2010",,"March 24, 2010","Cif Biotec, Medica Sur, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT01092351"
227,"NCT00676533","Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infection","Drug: Cipro XR (Ciprofloxacin, BAYQ3939)","Time to improvement of the signs and symptoms (eg, dysuria, frequency, urgency, gross hematuria, suprapubic pain, hesitancy, low back pain) of acute, uncomplicated, symptomatic, lower UTIs|Activity Impairment Assessment (AIA) questionnaire|Clinical and bacteriological success rates|Incidence rates of adverse events","Bayer","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","276","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100544","June 2003",,"January 2004","May 13, 2008",,"October 14, 2013","Birmingham, Alabama, United States|Huntsville, Alabama, United States|Montgomery, Alabama, United States|Tallassee, Alabama, United States|Chandler, Arizona, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Tempe, Arizona, United States|Fresno, California, United States|Mission Hills, California, United States|San Diego, California, United States|San Diego, California, United States|San Diego, California, United States|Yorba Linda, California, United States|Avon, Connecticut, United States|Chiefland, Florida, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Ocala, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Conyers, Georgia, United States|Fayetteville, Georgia, United States|Hayden, Idaho, United States|Evansville, Indiana, United States|Baltimore, Maryland, United States|Millersville, Maryland, United States|Ann Arbor, Michigan, United States|Elizabeth, New Jersey, United States|Camillus, New York, United States|Eugene, Oregon, United States|Feasterville, Pennsylvania, United States|Simpsonville, South Carolina, United States|Lake Jackson, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Seattle, Washington, United States|Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00676533"
228,"NCT01039545","Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting.",,"Terminated","No Results Available","Urinary Tract Infections","Drug: Diclofenac|Drug: Norfloxacin","The proportion of patients with resolution of symptoms on day 4|The proportion of patients ever on antibiotics between randomization at day 1 and follow-up at day 30|The proportion of patients using single dose fosfomycin on day 4|The proportion of patients with re-consultations because of UTI within 30 days|The mean composite symptom scores on days 4, 7 and 30|The proportion of patients with resolution of symptoms on day 7|The proportion of patients with complete resolution of symptoms on days 4 and 7|The time until resolution of symptoms|The proportion of patients with adverse events|Mean overall patient stratification|Health-related quality of life on day 4|Number of working days lost","Insel Gruppe AG, University Hospital Bern|University of Bern|Clinic for Infectious Diseases, University Hospital Bern, Switzerland","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","253","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","254/09","February 2012","December 2014","January 2015","December 25, 2009",,"July 9, 2015","Institute for Infectious Diseases, University of Berne, Berne, Switzerland",,"https://ClinicalTrials.gov/show/NCT01039545"
229,"NCT03597152","Nutritional Supplementation for Recurrent Urinary Tract Infections in Women",,"Unknown status","No Results Available","Recurrent Urinary Tract Infection","Dietary Supplement: WelTract|Dietary Supplement: Placebo","UTI Recurrence","AmPurity Nutraceuticals, LLC|Arkansas Urology","Female","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","250","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AMARU 001","August 1, 2020","January 14, 2022","December 31, 2022","July 24, 2018",,"January 10, 2020",,,"https://ClinicalTrials.gov/show/NCT03597152"
230,"NCT05880602","Nettle and Cranberry Capsules for Prevention of Urinary Tract Infection",,"Recruiting","No Results Available","Urinary Tract Infection","Dietary Supplement: Nettle and Cranberry complex capsules|Dietary Supplement: Placebo(starch)","UTI-free duration in 8 weeks|UTI recurrent incidence in 8 weeks|International Prostate Symptom Score (IPSS) Change from Baseline|Overactive Bladder Symptom Score (OABSS) Change from Baseline|International Consultation on Incontinence Questionnaire Overactive Bladder Score (ICIQ-OAB) Change from Baseline|Bladder diary","Chung Shan Medical University|Glory Kingdom Corporation","All","30 Years to 75 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","CS2-23025","July 5, 2023","December 31, 2023","December 31, 2023","May 30, 2023",,"October 30, 2023","Chung Shan Medical University Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT05880602"
231,"NCT01346774","Preventing Urinary Tract Infection Post-Surgery","PUPS","Completed","Has Results","Urinary Tract Infection","Drug: Cranberry powder capsules|Drug: Placebo powder capsules","Participants With Clinically-diagnosed and Treated UTI's.","Betsy Foxman|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Michigan","Female","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","R21DK085290|HUM00041108","June 2011","May 2013","October 2013","May 3, 2011","June 10, 2015","June 10, 2015","Urogynecology Clinic; University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01346774"
232,"NCT01281462","Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infections","Drug: Ceftaroline fosamil and NXL104 (q8h)|Drug: Ceftaroline fosamil and NXL104 (q12h)|Drug: Doripenem|Drug: Placebo","Microbiological response of Microbiologically Evaluable (ME) at Test of Cure (TOC)|Evaluate safety|Clinical response in CE at Test of Cure","Forest Laboratories","All","18 Years and older   (Adult, Older Adult)","Phase 2","217","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CXL-MD-02","December 2010","March 2012","July 2012","January 24, 2011",,"February 3, 2014","Investigational Site, La Mesa, California, United States|Investigational Site, San Diego, California, United States|Investigational Site, Pensacola, Florida, United States|Investigational Site, Baltimore, Maryland, United States|Investigational Site, Detroit, Michigan, United States|Investigational Site, Plovdiv, Bulgaria|Investigational Site, Ruse, Bulgaria|Investigational Site, Sofia, Bulgaria|Investigational Site, Sofia, Bulgaria|Investigational Site, Sofia, Bulgaria|Investigational Site, Varna, Bulgaria|Investigational Site, Berlin, Germany|Investigational Site, Freiburg, Germany|Investigational Site, Gießen, Germany|Investigational Site, Kassel, Germany|Investigational Site, Minden, Germany|Investigational Site, Muellheim, Germany|Investigational Site, Paderborn, Germany|Investigational Site, Planegg, Germany|Investigational Site, Beirut, Lebanon|Investigational Site, Bialystok, Poland|Investigational Site, Bielsko-Biala, Poland|Investigational Site, Częstochowa, Poland|Investigational Site, Katowice, Poland|Investigational Site, Katowice, Poland|Investigational Site, Lodz, Poland|Investigational Site, Tychy, Poland|Investigational Site, Warszawa, Poland|Investigational Site, Wolomin, Poland|Investigational Site, Wrocław, Poland|Investigational Site, Zamosc, Poland|Investigational Site, Moscow, Russian Federation|Investigational Site, Moscow, Russian Federation|Investigational Site, Moscow, Russian Federation|Investigational Site, Moscow, Russian Federation|Investigational Site, Moscow, Russian Federation|Investigational Site, Rostov-on-Don, Russian Federation|Investigational Site, Smolensk, Russian Federation|Investigational Site, St. Petersburg, Russian Federation|Investigational Site, St. Petersburg, Russian Federation|Investigational Site, St. Petersburg, Russian Federation|Investigational Site, St. Petersburg, Russian Federation|Investigational Site, St. Petersburg, Russian Federation|Investigational Site, St. Petersburg, Russian Federation|Investigational Site, St. Petersburg, Russian Federation|Investigational Site, St. Petersburg, Russian Federation|Investigational Site, Diyarbakir, Turkey|Investigational Site, Eskisehir, Turkey|Investigational Site, Izmir, Turkey|Investigational Site, Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT01281462"
233,"NCT05819229","Oral Antibiotics Alone in Children Aged 4 Weeks to 2 Months With a Urinary Tract Infection",,"Recruiting","No Results Available","Urinary Tract Infections in Children","Drug: Oral antibiotic therapy","Proportion of participants with recurrent urinary tract infection regardless of the pathogen or death of any cause|Number of days admitted related to urinary tract symptoms|Number of days with antibiotic-related non-serious adverse events.|Proportion of participants with a recurrent urinary tract infection regardless of the pathogen or death of any cause.|Proportion of participants with a recurrent infection with a bacterium resistant to the antibiotic given for the baseline infection or an opportunistic infection","Rigshospitalet, Denmark|Hvidovre University Hospital","All","4 Weeks to 2 Months   (Child)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PO AB UTI","February 27, 2023","March 31, 2024","May 31, 2024","April 19, 2023",,"April 19, 2023","Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark|Copenhagen University Hospital Herlev, Herlev, Denmark|Copenhagen University Hospital Hillerød, Hillerød, Denmark|Copenhagen University Hospital Hvidovre, Hvidovre, Denmark",,"https://ClinicalTrials.gov/show/NCT05819229"
234,"NCT03151603","Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial","REGATTA","Completed","No Results Available","Urinary Tract Infections","Drug: Arctuvan|Drug: Fosfomycin|Drug: Placebo to Arctuvan|Drug: Placebo to Fosfomycin","antibiotic courses|symptom burden|early relapses|recurrent UTI|symptom resolution|symptom sum score by patients' questionnaire|symptom burden for dysuria|symptom burden positive urine culture|symptom burden negative urine culture|activity impairment by UTI symptoms, measured as AUC|painkillers|patients taking painkillers|antibiotic use|UTI related visits|UTI related sick leave|patients with poor outcome: temperature|patients with poor outcome: worsening symptoms|patients with poor outcome: prolonged symptoms|pyelonephritis|AE and SAE|patients with at least 1 AE/ 2 AE|symptom burden for urgency|symptom burden for frequency|symptom burden for lower abdominal pain","University Medical Center Goettingen","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","398","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","01579","May 3, 2017","May 19, 2019","June 20, 2019","May 12, 2017",,"November 27, 2019","Hausarztpraxis Dr. Raby, Achim, Germany|General Practice Aden, Braunschweig, Germany|General Practice Scheffer, Braunschweig, Germany|General Practice Coutelle, Bremen, Germany|General Practice Schelp, Bremen, Germany|General Practice Dickow, Burgwedel, Germany|General Practice Kiwit-Putzer, Burgwedel, Germany|Praxis Zietz, Celle, Germany|General Practice Kutzsche, Emmerthal, Germany|Praxis Dr. Bahr, Gieboldehausen, Germany|General Practice Müller, Gillersheim, Germany|Institute of General Medicine, University Medical Center Goettingen, Göttingen, Germany|Praxisgemeinschaft Jacob / Kling, Göttingen, Germany|General Practice Keske, Göttingen, Germany|General Practice Koch, Göttingen, Germany|General Practice Kolb, Göttingen, Germany|General Practice Lang, Göttingen, Germany|General Practice Lückerath, Göttingen, Germany|Praxis Dr. Egner, Hannover, Germany|Institute of General Medicine, MHH Hannover, Hannover, Germany|General Practice Barth, Hannover, Germany|General Practice Löber, Hardegsen, Germany|Gemeinschaftspraxis Dres Schlesier / Eckhardt, Heilbad Heiligenstadt, Germany|Gemeinschaftspraxis Hartleb / Stöcking, Heilbad Heiligenstadt, Germany|Praxis Dr. Koch, Heilbad Heiligenstadt, Germany|Praxisgemeinschaft Seitz / Eckert, Herzberg, Germany|General Practice Wilde, Hildesheim, Germany|Praxisgemeinschaft Stoltz / Raddatz, Höxter, Germany|General Practice Beverungen, Höxter, Germany|Gemeinschaftspraxis Kasperczyk / Schindewolf-Lensch, Isernhagen, Germany|General Practice Franz, Katlenburg-Lindau, Germany|Praxis Dr. Ohlendorf, Langenhagen, Germany|General Practice Ertel, Langwedel, Germany|General Practice Wehrbein, Lemforde, Germany|General Practice Lindenblatt, Neustadt, Germany|Hausarztzentrum Nörten, Nörten-Hardenberg, Germany|General Practice Preiskorn, Rehburg-Loccum, Germany|General Practice Meier-Ahrens, Rosdorf, Germany|General Practice Woitschek, Salzgitter, Germany|General Practice Beulshausen, Sattenhausen, Germany|General Practice Schulte, Scheeßel, Germany|General Practice Böttcher, Schwanewede, Germany|General Practice Albrecht, Springe, Germany|General Practice Wolf, Uslar, Germany|General Practice Schmiemann, Verden, Germany|General Practice Annweiler, Waake, Germany|General Practice Stegemann, Wunstorf, Germany",,"https://ClinicalTrials.gov/show/NCT03151603"
235,"NCT00669994","Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infection","Drug: Ciprofloxacin","Bacteriologic outcome in patients with UTI caused by S. saprophyticus|Adverse Events Collection|Clinical Response|Incidence of premature terminations","Bayer","Female","18 Years to 44 Years   (Adult)","Phase 4","180","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100546","July 2003",,"October 2003","May 1, 2008",,"December 19, 2014","Birmingham, Alabama, United States|Birmingham, Alabama, United States|Pelham, Alabama, United States|Phoenix, Arizona, United States|Laguna Hills, California, United States|Long Beach, California, United States|San Diego, California, United States|San Luis Obispo, California, United States|San Mateo, California, United States|Sylmar, California, United States|Yorba Linda, California, United States|Avon, Connecticut, United States|Clearwater, Florida, United States|Pembroke Pines, Florida, United States|Evansville, Indiana, United States|Milford, Massachusetts, United States|Royal Oak, Michigan, United States|Elizabeth, New Jersey, United States|Holmdel, New Jersey, United States|Camillus, New York, United States|Beaver, Pennsylvania, United States|Feasterville, Pennsylvania, United States|Hatboro, Pennsylvania, United States|Summerville, South Carolina, United States|San Antonio, Texas, United States|Murray, Utah, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00669994"
236,"NCT06050148","Faecal Microbiota Transplantation as Means of Preventing Recurrent Urinary Tract Infections","FMT-UTI","Recruiting","No Results Available","Recurrent Urinary Tract Infection","Biological: Feacal microbial transplantation (FMT)|Other: Placebo transplantation (PT)","mean number of UTI episodes after FMT among patients with recurrent UTI|proportion of participants with UTI after FMT among patients with recurrent UTI|mean number of UTI episodes caused by sensitive E. colis after FMT among patients with recent non-ESBL/MDR UTIs|proportion of participants with UTIs caused by sensitive E. colis after FMT among patients with recent non-ESBL/MDR UTIs|mean number of UTI episodes caused by ESBL/MDR E. colis after FMT among patients with recent ESBL/MDR UTIs|proportion of participants with UTIs caused by ESBL/MDR E. colis after FMT among patients with recent ESBL/MDR UTIs|identifying groups of bacteria associated with smaller number of UTI episodes after FMT|the duration of successful prevention by FMT|proportion of participants with recurrent UTI and concurrent intestinal MDR colonisation with the same strain|proportion of participants with intestinal ESBL/MDR eradicated after FMT|confirm whether the uropathogen are identical before and after FMT|number of antibiotic courses received by FMT versus placebo recipients|proportion of participants with gastrointestinal symptoms assessed by GSRS scores before and after FMT|proportion of participants with mild to severe depression assessed by BDI scores before and after FMT|mean number of health-related quality of life (HRQoL) scores assessed by 15D before and after FMT|description of groups of bacteria in faecal and urine microbiome before and after FMT|human urine and serum metabolic profiles before and after FMT","Helsinki University Central Hospital|University of Helsinki","Female","18 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","FMT-UTI","August 1, 2023","December 31, 2028","December 31, 2029","September 22, 2023",,"September 22, 2023","Meilahti Vaccine Research Center, Helsinki University Central Hospital, Helsinki, Finland",,"https://ClinicalTrials.gov/show/NCT06050148"
237,"NCT02658903","Prevention of Catheter Associated Lower Urinary Infections Using the Oxys Indwelling Catheter",,"Unknown status","No Results Available","Urinary Infections","Device: Oxys Catheter|Device: Covidien Mona-Therm Foley catheter","Bacterial biofilm on catheter, assessed by ultrasonic culture of catheter tip removed at the end of the study.|Significant bacteriuria assessed by weekly bacterial cultures.|Clinically symptomatic catheter associated lower urinary infections.|occurence of adverse events","Oxys Medical AG","All","18 Years and older   (Adult, Older Adult)","Phase 1","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Oxys-01","January 2016","January 2017","January 2017","January 20, 2016",,"January 20, 2016","University Hospital Balgrist, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02658903"
238,"NCT06137950","Interferon Alpha Therapy for Cervical CINI and HPV Infection",,"Recruiting","No Results Available","Cervical Dysplasia|HPV Infection","Drug: gel Interferon arm|Drug: gel Interferon and interferon suppository arm","Pap smear|Colposcopic change|Histopathologic change|Immunohistochemical change","Mongolian National University of Medical Sciences|Mongolian National Cancer Center","Female","20 Years to 40 Years   (Adult)","Phase 1","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","MNUMS2021100701","November 7, 2023","March 15, 2024","September 15, 2024","November 18, 2023",,"November 18, 2023","National Cancer Center, Ulaanbaatar, Mongolia",,"https://ClinicalTrials.gov/show/NCT06137950"
239,"NCT02474706","Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli","COLIFOX","Terminated","No Results Available","Urinary Tract Infections","Drug: Cefoxitin|Drug: imipenem","Control urine culture negative|absence of fever|presence of multiresistant bacteria in a rectal swab|Composite outcome measure consisting of resolution of clinical signs observed on diagnosis","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)","Phase 4","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHRC N 2013/COLIFOX-MAY/SR","March 2016","December 2017","December 2017","June 18, 2015",,"August 11, 2017","CHRU Nancy, Nancy, France",,"https://ClinicalTrials.gov/show/NCT02474706"
240,"NCT01450800","Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)","STOPP UTI","Completed","Has Results","Urinary Tract Infection","Drug: Nitrofurantoin|Drug: Placebo","Urinary Tract Infections|Other Risk Factors for UTI","Duke University","Female","21 Years and older   (Adult, Older Adult)","Phase 4","163","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Pro00025269|3913577","August 2011","March 2013","September 2013","October 12, 2011","May 1, 2014","February 13, 2017","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01450800"
241,"NCT00092170","An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)",,"Completed","No Results Available","Infections|Pelvic Infections","Drug: MK0826, ertapenem sodium|Drug: Comparator: Ticarcillin/Clavulanate","Efficacy response at post treatment follow up assessment. Clinical and/or laboratory drug-related SAEs during study drug therapy plus 14 days post therapy","Merck Sharp & Dohme LLC","All","3 Months to 17 Years   (Child)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","0826-038|2004_062","March 2002","January 2004","January 2004","September 24, 2004",,"February 17, 2017",,,"https://ClinicalTrials.gov/show/NCT00092170"
242,"NCT03543436","Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections","TEMO-CARB","Completed","No Results Available","Urinary Tract Infections","Drug: Temocillin|Drug: meropenem or imipenem","Clinical and microbiological cure|Early microbiological eradication|Frequency of oral antibiotic switch in both arms (temocillin vs. carbapenem)|Length of hospital stay|Persistent cure rate|Clinical recurrences|Mortality|Pharmacokinetic of temocillin according to kidney function|Microbiota impact study","Assistance Publique - Hôpitaux de Paris|Fondation Hôpital Saint-Joseph|French National Network of Clinical Research in Infectious Diseases (RENARCI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P 160910J|2017-001257-14","January 4, 2019","October 29, 2020","December 14, 2020","June 1, 2018",,"April 19, 2021","CHU de Martinique, Fort-de-france, Martinique, France|CHRU La Cavale Blanche, Brest, France|CHU de Grenoble Hospital, Grenoble, France|Melun Hospital - CHU Sud, Melun, France|APHP - Cochin Hospital, Paris, France|APHP - Necker-Enfants maladies Hospital, Paris, France|Bichat hospital, Paris, France|Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France|Tenon Hospital, Paris, France|APHP - Beaujon Hospital, Paris, France|APHP - Georges Pompidou European Hospital, Paris, France|APHP - Saint-Antoine Hospital, Paris, France|Saint-Joseph Hospital, Paris, France|CHU de Pau, Pau, France|CHU de Poitiers, Poitiers, France|CHU Pontchaillou, Rennes, France",,"https://ClinicalTrials.gov/show/NCT03543436"
243,"NCT04095572","Alternative Prophylaxis in Female Recurrent Urinary Tract Infections","AlP-FrUiT","Recruiting","No Results Available","Urinary Tract Infections|Urinary Tract Infection (UTI)","Drug: intravesical instillation with HA-CS|Drug: intravesical instillation of sterile purified water","Rate of symptomatic UTIs (based on clinical diagnosis) needing treatment with antimicrobials|Symptomatic UTI (based on clinical diagnosis supported by measured bacteriuria of ≥103 cfu/ml) treated with antimicrobials|Symptoms of UTI according to the Acute Cystitis Symptom Score (ACSS) (cumulative number of each symptom)|Time to UTI recurrence (as days between randomisation and the first recurring UTI)|Asymptomatic bacteriuria of ≥105 cfu/ml|Detection of multidrug-resistant bacteria in urine culture (3Multiresistant gram negatives (MRGN), 4MRGN)|Prescribed defined daily doses (DDD) of antibiotics (cumulative sum of DDD)|Change in Pelvic Pain and Urinary/Frequency (PUF) Symptom Scale|Change in QoL Short Form (SF)-36 score","University Hospital, Basel, Switzerland|IBSA Institut Biochimique SA","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2019-01377; me19Bausch","October 27, 2020","June 2025","June 2026","September 19, 2019",,"February 7, 2024","Department of Gynecology, University Hospital Basel, Basel, Switzerland|Department of Urology, University Hospital Basel, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT04095572"
244,"NCT03154866","Lactobacillus Kefiri LKF01 (DSM32079) in Newborns Born by Caesarian Section",,"Unknown status","No Results Available","Caesarean Section;Stillbirth|Microbial Colonization","Dietary Supplement: Lactobacillus kefiri LKF01 DSM32079|Dietary Supplement: Placebo","Presence of Lactobacillus kefiri LKF01 DSM32079 (LKEF) in fecal sample|Number of participants with treatment-related adverse event","Policlinico Hospital","All","1 Hour to 4 Months   (Child)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","KEFINEO1","June 1, 2017","December 31, 2017","June 30, 2018","May 16, 2017",,"May 18, 2017","Dept Of Obstetrics and Neonatology - Section of Neonatology University of Bari Policlinico Hospital, Bari, Italy",,"https://ClinicalTrials.gov/show/NCT03154866"
245,"NCT01054690","Silver Alloyed Urinary Catheters and Incidence of Catheter Acquired Urinary Tract Infections (UTI)",,"Completed","No Results Available","Urinary Tract Infection","Device: Bactiguard Infection Protection (BIP) Cathter.|Device: Silicone Urinary Catheter","To determine whether a silver alloyed catheter with antibacterial properties will decrease the incidence of catheter associated urinary tract infection in patients undergoing elective surgery.|Patient´s evaluation of the catheterization and overall satisfaction.","Region Skane|Bactiguard AB, Sweden","All","18 Years and older   (Adult, Older Adult)","Not Applicable","511","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","H15 315/2007","October 2008","August 2009","August 2009","January 22, 2010",,"January 22, 2010","Ortopedkliniken, Hässleholms Sjukhus, Hässleholm, Sweden|Ortopedklinien, Lunds Hospital, Lund, Sweden|Ortopedkliniken Lasarettet i Trelleborg, Trelleborg, Sweden",,"https://ClinicalTrials.gov/show/NCT01054690"
246,"NCT05712434","Chlorhexidine to Prevent Catheter-related Urinary Tract Infection",,"Recruiting","No Results Available","Urinary Tract Infections","Other: Long Intervention|Other: Mid-length Intervention|Other: Short Intervention","Incidence of catheter-related urinary tract infection|Incidence of catheter-related urinary tract infection (including candiduria)|Incidence of catheter-related urinary tract infection, by different clinical relevant isolates","National Taiwan University Hospital|National Taiwan University Hospital, Yun-Lin Branch|Hualien Tzu Chi General Hospital|National Taiwan University Hospital Hsin-Chu Branch|Lotung Poh-Ai Hospital|Min-Sheng General Hospital","All","Child, Adult, Older Adult","Not Applicable","15000","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","202212030MIFA","March 1, 2023","March 31, 2024","March 31, 2024","February 3, 2023",,"May 6, 2023","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT05712434"
247,"NCT01108757","Prevention of Catheter-Associated Urinary Tract Infection in Incontinence and Reconstructive Pelvic Surgery Patients","PRECAUTION","Terminated","Has Results","Catheter-Associated Urinary Tract Infection","Drug: Bactrim|Other: Placebo","Number of Participants With Urinary Tract Infection","The Cleveland Clinic|American Urogynecologic Society","Female","21 Years and older   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","10-125","April 2010","August 2013","August 2013","April 22, 2010","October 18, 2017","October 18, 2017","Cleveland Clinic Foundation, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01108757"
248,"NCT00638170","Cranberry Juice in the Prevention of Urinary Tract Infections in Children",,"Completed","No Results Available","Urinary Tract Infections","Biological: Cranberry juice|Biological: Placebo juice","Occurrence of the first recurrence|Total number of UTI episodes and use of antimicrobials","University of Oulu|Ocean Spray, Inc.","All","1 Year to 16 Years   (Child)","Not Applicable","262","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","72/2001","May 2001","February 2009","February 2009","March 18, 2008",,"February 16, 2009","University of Oulu, Oulu, Finland",,"https://ClinicalTrials.gov/show/NCT00638170"
249,"NCT04859621","Phase II Clinical Trial of Vitamin D3 for Reducing Recurrence of Recurrent Lower Urinary Tract Infections",,"Recruiting","No Results Available","Recurrent Urinary Tract Infection","Drug: Vitamin D3 4000 IU|Drug: Vitamin D3 2000 IU|Drug: Placebo|Other: standard antibiotic therapy","UTI recurrent incidence in 48 weeks|Recurrence rate of UTI in 48 weeks|UTI-free duration in 48 weeks|Cumulative relapse-free ratio","Zensun Sci. & Tech. Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ZS-05","May 8, 2021","April 30, 2025","July 30, 2025","April 26, 2021",,"February 2, 2024","The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an, Shaanxi, China|Shanghai Oriental Hospital, Shanghai, Shanghai, China|The Fifth People's Hospital, Shanghai, Shanghai, Shanghai, China|Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine，Chongming Branch, Shanghai, Shanghai, China|Sichuan Provincial People's Hospital, Chengdu, Sichuan, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04859621"
250,"NCT00672503","Decreasing Catheter-Associated Urinary Tract Infections in the Pediatric Intensive Care Unit",,"Completed","No Results Available","Urinary Tract Infections",,"Identification of risk factors associated with indwelling urinary catheters.|Identification of nurses' knowledge of insertion, irrigation, care and maintenance of indwelling urinary catheters.","Children's Mercy Hospital Kansas City","All","1 Day to 17 Years   (Child)",,"321","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","08 04-065E","May 2008","October 2011","October 2011","May 6, 2008",,"October 12, 2011","Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00672503"
251,"NCT02832258","Urinary Tract Infection Due to Beta-lactamase-producing Enterobacteriaceae in Children","PYELOBLSE","Completed","No Results Available","Urinary Tract Infections",,"First and second lines used antibiotic therapies|Resistance patterns of ESBL types in the isolates|Clinical characteristics (fewer, clinical sepsis) of E-ESBL UTI in children|Time to apyrexia (Kaplan-Meier method)|Length of hospital stay (Kaplan-Meier method)|Molecular characterization of ESBL types in the isolates|Clinical history of patient with E-ESBL UTI in children|C reactive protein level of patient with E-ESBL UTI in children|procalcitonin level of patient with E-ESBL UTI in children|Positive blood culture|cytobacteriological examination of the urine results|urine analysis by regent strip method","Fouad Madhi|Centre Hospitalier Intercommunal Creteil","All","up to 18 Years   (Child, Adult)",,"590","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PYELOBLSE","March 2014","March 27, 2019","June 1, 2019","July 14, 2016",,"August 4, 2020","Antoine Beclère Hospital, Clamart, Ile-de France, France|Jean Verdier Hospital, Bondy, Ile-de-France, France|André Mignot Hospital, Le Chesnay, Ile-de-France, France|Hopital Ambroise Paré, Boulogne-Billancourt, France|Saint Camille Hospital, Bry-sur-Marne, France|Louis Mourier Hospital, Colombes, France|CHI Créteil, Créteil, France|Centre Hospitalier de Dourdan, Dourdan, France|CHU Le Havre, Le Havre, France|CHU Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France|Roger Salengro Hospital, Lille, France|Centre Hospitalier Général de Longjumeau, Longjumeau, France|CHU Lyon, Lyon, France|Centre Hospitalier de Meaux, Meaux, France|Centre Hospitalier Marc Jacquet, Melun, France|CHU Nantes, Nantes, France|CHU Lenval, Nice, France|Centre Hospitalier d'Orsay, Orsay, France|Hospital Trousseau, Paris, France|Hôpital Necker, Paris, France|Robert Debré, Paris, France|Centre Hospitalier Roubaix, Roubaix, France|CHU Rouen, Rouen, France|Hôpital Intercommunal de Villeneuve Saint-Georges, Villeneuve Saint-Georges, France",,"https://ClinicalTrials.gov/show/NCT02832258"
252,"NCT01173068","An Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections.",,"Unknown status","No Results Available","Urinary Tract Infections","Drug: Ertapenem","Clinical Outcome|Microbiology outcome","National University Hospital, Singapore|Merck Sharp & Dohme LLC","All","21 Years to 70 Years   (Adult, Older Adult)",,"60","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","DSRB Domain E/10/312","August 2010","September 2014","September 2014","July 30, 2010",,"April 3, 2014","National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01173068"
253,"NCT03462160","Effectiveness of Probiotics Prophylaxis of Urinary Tract Infections in Children",,"Unknown status","No Results Available","Prevention of Urinary Tract Infections in Children","Other: Placebo control group|Dietary Supplement: Probiotic experimental group","frequencies of recurrence of UTI|frequencies of hospitalization due to UTI|the number of days of antibiotic therapy due to UTI","Medical University of Warsaw|Miralex Sp. z o.o.","All","3 Years to 18 Years   (Child, Adult)","Not Applicable","106","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","UTI probiotic","April 1, 2018","April 1, 2019","September 1, 2019","March 12, 2018",,"March 12, 2018","Children's Hospital for The Medical University of Warsaw, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT03462160"
254,"NCT02034890","Intravesical Instillation of Hyaluronic Acid to Decrease Incidence of Urinary Tract Infection",,"Withdrawn","No Results Available","Urinary Tract Infection","Drug: Hyaluronic Acid","positive urinary culture|urinary tract infection","Rabin Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","RMC-7350","July 2015","March 2017",,"January 14, 2014",,"April 24, 2019","Urology department, Rabin Medical Center, Petach Tiqva, Israel",,"https://ClinicalTrials.gov/show/NCT02034890"
255,"NCT01391793","Corticosteroids for Children With Febrile Urinary Tract Infections","STARRS","Completed","Has Results","Acute Urinary Tract Infection|Urinary Tract Infection","Drug: Placebo|Drug: Dexamethasone","The Distribution of Children With Renal Scarring at the Outcome Dimercaptosuccinic Acid (DMSA) Renal Scan|The Distribution of Children With Severe Renal Scarring at the Outcome Dimercaptosuccinic Acid (DMSA) Renal Scan|The Mean Proportion of Children With Renal Scarring at the Outcome Dimercaptosuccinic Acid (DMSA) Renal Scan Taken Across the 3 Radiologists","Nader Shaikh|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pittsburgh","All","2 Months to 6 Years   (Child)","Phase 3","546","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","R01DK087870","September 2011","March 30, 2018","March 30, 2018","July 12, 2011","July 2, 2019","July 2, 2019","Children's National Medical Center, Washington, District of Columbia, United States|Nationwide Children's Hospital in Columbus, Columbus, Ohio, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Hasbro Children's Hospital, Providence, Rhode Island, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|American Family Children's Hospital, Madison, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/93/NCT01391793/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/93/NCT01391793/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT01391793"
256,"NCT03221504","7-day Compared With 10-day Antibiotic Treatment for Febrile Urinary Tract Infections in Children",,"Unknown status","No Results Available","Urinary Tract Infections in Children","Other: Longer therapy duration|Other: Shorter therapy duration","frequencies of recurrence of UTI|frequencies of reinfection of UTI|antibiotic-associated diarrhoea (AAD), compliance","Medical University of Warsaw","All","3 Months to 7 Years   (Child)","Not Applicable","221","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","WUM","January 1, 2018","July 31, 2019","January 31, 2020","July 18, 2017",,"March 20, 2018","Children's Hospital for The Medical University of Warsaw, Warsaw, Poland|The Holy Family Specialistic Hospital, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT03221504"
257,"NCT00927316","E. Coli 83972 Induced Asymptomatic Bacteriuria (ABU) in Patients With Recurrent Urinary Tract Infections (UTI)",,"Completed","No Results Available","Urinary Tract Infection","Biological: E. coli 83972","Time to UTI|Number of UTI","Region Skane|Coloplast A/S|Riksförbundet för Trafik, Olycksfall och Polioskadade (RTP), Sundbyberg, Sweden|Swedish Institute for Infectious Disease Control|Lund University Hospital","All","20 Years to 85 Years   (Adult, Older Adult)","Not Applicable","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","RTP-A2003","March 2003","December 2006","December 2006","June 24, 2009",,"November 10, 2009","Department of Urology, Lund University, Lund, Sweden",,"https://ClinicalTrials.gov/show/NCT00927316"
258,"NCT01760109","Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection","PIP-SBT","Completed","No Results Available","Respiratory Tract Infections|Urinary Tract Infections","Drug: Piperacillin Sodium and Sulbactam Sodium","The rate of bacterial clearance|Number of participants with Adverse Events","Xiangbei Welman Pharmaceutical Co., Ltd","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","2000","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2002HL0153","July 2011","June 2016","June 2016","January 3, 2013",,"July 8, 2019","Chongqing Red Cross hospital, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT01760109"
259,"NCT01897831","Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection","PIP-SBT","Unknown status","No Results Available","Respiratory Tract Infections|Urinary Tract Infections","Drug: xin te mie","overall effect|Number of participants with Adverse Events","Xiangbei Welman Pharmaceutical Co., Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 4","2000","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2002 H L 0153","August 2011","August 2015","November 2015","July 12, 2013",,"July 12, 2013",,,"https://ClinicalTrials.gov/show/NCT01897831"
260,"NCT01601093","Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection","CAZ-SBT","Suspended","No Results Available","Respiratory Tract Infections|Urinary Tract Infections","Drug: High dose|Drug: Low dose|Drug: Cefoperazone and Sulbactam Sodium (CFP/SUB)","The rate of bacterial clearance|Number of participants with Adverse Events","Xiangbei Welman Pharmaceutical Co., Ltd","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","288","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2008L03354","November 2011","August 15, 2022","December 15, 2022","May 17, 2012",,"July 5, 2019","the First Affiliated Hospital With Medical University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT01601093"
261,"NCT04753502","Laparoscopic Treatment for Appendicitis During Pregnancy",,"Completed","No Results Available","Other Specified Complications of Pregnancy","Procedure: Laparoscopy","Postoperative complication|obstetric complication","Austral University, Argentina","Female","18 Years and older   (Adult, Older Adult)",,"63","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","P20-070","September 1, 2005","July 1, 2020","November 30, 2020","February 15, 2021",,"February 15, 2021","Austral University Hospital, Buenos Aires, Argentina","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/02/NCT04753502/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04753502"
262,"NCT02444975","The Effect of Increased Water Intake on the Frequency of the Clinical Recurrent Urinary Tract Infections in Pre-menopausal Women: S-HYDRACYST","S-HYDRACYST","Completed","No Results Available","Recurrent Urinary Tract Infection","Dietary Supplement: Mineral water|Other: Coaching program|Other: No intervention","Incidence of UTI","Danone Research","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NU369","December 2013","July 2016","July 2016","May 15, 2015",,"September 7, 2016","Mc ""Comac Medical"", Sofia, Bulgaria",,"https://ClinicalTrials.gov/show/NCT02444975"
263,"NCT04876131","Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children","CHOICE UTI","Recruiting","No Results Available","Complicated Urinary Tract Infection|Infection|Pediatric Infectious Disease","Drug: Benzylpenicillin - single dose|Drug: Benzylpenicillin - three days|Drug: Gentamicin - single dose|Drug: Gentamicin - three days|Drug: Cefalexin - post single dose of IV antibiotics for the remaining two days","Risk difference between 1 dose and 3 doses IV in the proportion of participants with clinical failure at 72 hours|Risk difference between 1 dose and 3 doses IV in the proportion of participants readmitted or attending the ED within 14 days of the initial dose of IV antibiotic.|Risk difference between 1 dose and 3 doses IV in the proportion of participants readmitted or attending the ED within 1 month of the initial dose of IV antibiotics|Risk difference between 1 dose and 3 doses IV in proportion of participants transferred from HITH or ambulatory care to ward care within 72 hours of initial dose of IV antibiotics.|Risk difference between 1 dose and 3 doses IV in the proportion of participants with parental reported improvement|Mean difference between 1 dose and 3 doses IV in duration of IV antibiotics usage|Mean difference between 1 dose and 3 doses IV in duration of oral antibiotic usage.|Risk difference between 1 dose and 3 doses IV in the proportion of participants with recurrence of UTI symptoms within 14 days of initial dose of IV antibiotics|Risk difference between 1 dose and 3 doses IV in the proportion of participants with recurrence of UTI symptoms within 1 month of initial dose of IV antibiotics|Risk difference in the proportion of participants with complications within 14 days of initial dose of IV antibiotics|Mean difference in the proportion of participants who experience at least one adverse event within 14 days of the initial dose of IV antibiotics|Risk difference between the 1 dose and 3 doses IV groups in the proportion of participants who experience an allergic reaction attributable to the antibiotics administered within 14 days of the initial dose of IV antibiotics|Mean difference between 1 dose and 3 doses IV on the weighted total score of the Child Health Utility instrument administered within 24 hours after initial dose of IV antibiotics.|Mean difference between 1 dose and 3 doses IV on the weighted total score of the Child Health Utility instrument administered between day 5-7 of initial dose of IV antibiotics|Mean difference between 1 dose and 3 doses IV in the cost-effectiveness of treatment groups.|Risk difference between the 1 dose and 3 doses IV groups in the proportion of patients with bacterial growth in urine culture (day 0)|Risk difference between the 1 dose and 3 doses IV in the proportion of patients with bacterial growth in urine culture (Day 14)|Risk difference between the 1 dose and 3 doses IV group in the proportion of patients administered antiemetics|Risk difference between the 1 dose and 3 doses IV group in the proportion of patients administered antipyretic or analgesia.|Risk difference between the 1 dose and 3 doses IV group in the proportion of patients with abnormal imaging.","Murdoch Childrens Research Institute|Royal Children's Hospital","All","3 Months to 18 Years   (Child, Adult)","Phase 4","452","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","72065","May 30, 2022","May 16, 2028","May 16, 2028","May 6, 2021",,"March 22, 2024","Women and Children's Hospital, Adelaide, South Australia, Australia|Monash Health, Melbourne, Victoria, Australia|Royal Children's Hospital, Parkville, Victoria, Australia|Perth Children's Hospital, Perth, Western Australia, Australia|Starship Children's Hospital, Auckland, Auckland Province, New Zealand",,"https://ClinicalTrials.gov/show/NCT04876131"
264,"NCT03443154","VF Test for Prediction of Extremely PTB After Cerclage",,"Withdrawn","No Results Available","Preterm Birth|Infection","Diagnostic Test: VF-Test","Rate of very preterm birth (PTB)|Rate of Delivery within 7 days of cervical cerclage|Rate of Delivery at later than 34 weeks of pregnancy|Rate of a positive VF test results in association with adverse maternal and perinatal outcomes.|Comparison of AF Test and VF Test results in prediction of a positive amniotic fluid culture","Pediatrix|Hologic, Inc.","Female","18 Years and older   (Adult, Older Adult)",,"0","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","OBX0039","June 2018","June 1, 2018","June 1, 2018","February 22, 2018",,"June 27, 2018",,,"https://ClinicalTrials.gov/show/NCT03443154"
265,"NCT04287478","Bacteriophage Therapy in Patients With Urinary Tract Infections",,"Terminated","No Results Available","Urinary Tract Infection Bacterial","Biological: Bacteriophage Therapy","Identify ideal bacteriophage treatment regimens based on improvements in disease control rates|Assess the safety of bacteriophage therapy|Assess the tolerability of bacteriophage therapy","Adaptive Phage Therapeutics, Inc.|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","1","Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APT.UTI.001","December 9, 2020","February 28, 2023","February 28, 2023","February 27, 2020",,"March 3, 2023","Universal Axon Clinical Research, Doral, Florida, United States|AMPM Research Clinic, Miami Gardens, Florida, United States|AdMed Research, Miami, Florida, United States|Innovation Medical Research Center, Inc, Palmetto Bay, Florida, United States|Henry Ford Hospital, Detroit, Michigan, United States|James J. Peters VA Medical Center, Bronx, New York, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|DHR Health Institute for Research and Development, Edinburg, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04287478"
266,"NCT02198833","Efficacy of Micro-Patterned Foley Catheter to Reduce Catheter-Associated Urinary Tract Infection",,"Terminated","Has Results","Urinary Tract Infection","Biological: Urine Culture|Device: Foley Catheter Tip Culture|Device: Scanning Electron Microscopy|Procedure: Device Specific Adverse Event Assessment|Procedure: Foley Catheter Insertion","Delay Onset of Catheter Associated Symptomatic Urinary Tract Infection|Time to Occurrence of Asymptomatic Bacteruria or Funguria|Assess the Microbial Coverage and Biofilm Formation on Catheter Surface|Device Specific Adverse Event Assessments","Baylor College of Medicine|United States Department of Defense","All","21 Years and older   (Adult, Older Adult)","Not Applicable","2","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","SC120028|H-32673","September 2014","July 2015","July 2015","July 24, 2014","April 7, 2017","April 7, 2017","James A. Haley Veterans' Hospital, Tampa, Florida, United States|Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02198833"
267,"NCT05847036","Profiles of Urinary Tract Infections in General Practice","PODIUM","Not yet recruiting","No Results Available","Urinary Tract Infections",,"The primary outcome will be the number of homogeneous profiles of patients with UTI in general practice and their characteristics using clinico-bacteriological indicators.|For general practioners' practices:|For short-term evolutionary trajectories:|For the factors associated with the prescription of antibiotics:","CNGE Conseil","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CNGE-2021-05","October 1, 2023","November 15, 2023","November 30, 2024","May 6, 2023",,"September 8, 2023",,,"https://ClinicalTrials.gov/show/NCT05847036"
268,"NCT01426191","Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection","SWSB","Completed","Has Results","Respiratory Tract Infections|Urinary Tract Infections","Drug: xinzhijun","Number of Participants With Adverse Events|Clinical Effect","Xiangbei Welman Pharmaceutical Co., Ltd","All","18 Years and older   (Adult, Older Adult)",,"2032","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20090095","August 2011","April 2015","December 2016","August 31, 2011","October 4, 2019","October 4, 2019",,,"https://ClinicalTrials.gov/show/NCT01426191"
269,"NCT06192966","Effect of Probiotics on Recurrent Urinary Tract Infections","CYSCARE","Terminated","No Results Available","Urinary Tract Infections","Dietary Supplement: Food supplement|Dietary Supplement: Placebo","Recurrence of Urninary Tract Infections (UTIs)|Time without UTI|Total symptomatic UTIs number|Change in UTI symptomatology|Change in Microbiota|Incidence of Treatment-Emergent Adverse Events|Satisfaction with the product","AB Biotics, SA","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","106","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AB-CYSCARE","January 1, 2018","March 31, 2022","March 31, 2022","January 5, 2024",,"January 8, 2024","Hospital Universitario de Caceres, Caceres, Cáceres, Spain|Fundació Puigvert, Barcelona, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario Virgen de Arrixaca, Murcia, Spain",,"https://ClinicalTrials.gov/show/NCT06192966"
270,"NCT04608851","Preventing Urinary Tract Infections With E. Coli Nissle:","FinNissle","Recruiting","No Results Available","Urinary Tract Infections in Children|Secondary Prevention","Drug: E. coli Nissle|Other: Placebo control","Recurrence of urinary tract infections|Number of urinary tract infections|Hospitalization day due to bacterial culture confirmed urinary tract infection|Antimicrobial treatment days for suspected or confirmed urinary tract infection|Stomach pain|Diarrhea|Antimicrobial treatment days for any indication","University of Oulu|Turku University Hospital|Kuopio University Hospital|Tampere University Hospital|Helsinki University Central Hospital","All","up to 2 Years   (Child)","Phase 4","530","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","OYS_Tapiainen_002","January 18, 2021","December 31, 2024","December 31, 2024","October 29, 2020",,"July 6, 2022","Helsinki University Hospital, Helsinki, Finland|Kuopio University Hospital, Kuopio, Finland|Department of Pediatrics, Oulu University Hospital, Oulu, Finland|Tampere University Hospital, Tampere, Finland|Turku University Hospital, Turku, Finland",,"https://ClinicalTrials.gov/show/NCT04608851"
271,"NCT02094703","The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females",,"Unknown status","No Results Available","Urinary Tract Infection","Drug: Levofloxacin|Drug: Solifenacin succinate|Drug: Placebo (for Solifenacin succinate)","Number of participants with storage symptoms","Dr Cipto Mangunkusumo General Hospital|Astellas Pharma Indonesia Inc.|Pharos Life Corporation","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","126","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","URO-SOL-01-2012","April 2013","November 2014","December 2014","March 24, 2014",,"March 24, 2014","Cipto Mangunkusumo Hospital, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT02094703"
272,"NCT04913753","Relevance of the Urine Bacterial Culture Performed Before Double J Ablation for Post-operative Urinary Tract Infection Prevention","AblaJ","Recruiting","No Results Available","Urinary Infection","Procedure: CBEU|Procedure: No CBEU","Incidence of infection|Incidence of bacteriuria measured by CBEU|Description of the resistance type of pre-operative distribution of bacteriuria by CBEU|Description of the pre-operative distribution of bacteriuria by CBEU|Description of the resistance type of post operative distribution of bacteriuria by CBEU|Description of the post operative distribution of bacteriuria by CBEU|Composition of microbiome by bacterial urinary analysis|Health-economic outcome","University Hospital, Tours","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","2200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DR200086 - ABLAJ","June 10, 2021","September 30, 2024","October 30, 2024","June 4, 2021",,"June 15, 2023","BRUYERE, Tours, France",,"https://ClinicalTrials.gov/show/NCT04913753"
273,"NCT06268483","Effect of Hyaluronic Acid Oral Supplementation on Sexual and Urinary Symptoms of Women With Recurrent Urinary Tract Infections","JalUrol","Completed","No Results Available","Urinary Tract Infections, Recurrent","Dietary Supplement: HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg + cranberry, D-mannose, propolis extract, tumeric and Boswellia|Dietary Supplement: cranberry, D-mannose, propolis extract, tumeric and Boswellia","Improvement in sexual symptoms|Improvement in urinary symptoms","Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JalUrol|Policlinico","March 1, 2022","March 28, 2023","March 28, 2023","February 20, 2024",,"February 20, 2024","IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy",,"https://ClinicalTrials.gov/show/NCT06268483"
274,"NCT04020341","A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)",,"Completed","Has Results","Urinary Tract Infections","Drug: Gepotidacin|Drug: Placebo matching nitrofurantoin|Drug: Nitrofurantoin|Drug: Placebo matching gepotidacin","Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S (IA Set)|Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S Population|Number of Participants With Clinical Outcome at the TOC Visit - Micro-ITT NTF-S Population|Number of Participants With Clinical Response at the TOC Visit - Micro-ITT NTF-S Population|Number of Participants With Microbiological Outcome (MO) at the TOC Visit - Micro-ITT NTF-S Population|Number of Participants With Microbiological Response at the TOC Visit - Micro-ITT NTF-S Population|Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Follow up (FU) Visit-Micro-ITT NTF-S Population|Number of Participants With Clinical Outcome at the Follow up (FU) Visit - Micro-ITT NTF-S Population|Number of Participants With Clinical Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population|Number of Participants With Microbiological Outcome (MO) at the Follow up (FU) Visit - Micro-ITT NTF-S Population|Number of Participants With Microbiological Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population|Number of Participants With Clinical Outcome at the TOC Visit - Intent-to-Treat (ITT) Population|Number of Participants With Clinical Response at the TOC Visit - Intent-to-Treat (ITT) Population|Number of Participants With Clinical Outcome at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population|Number of Participants With Clinical Response at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population|Plasma Concentration of Gepotidacin|Urine Concentration of Gepotidacin|Number of Participants With Treatment-emergent Adverse Events (TEAEs)|Number of Participants With Serious Adverse Events (SAEs)|Change From Baseline in Hematology Parameters - Neutrophil Count, Lymphocyte Count, Monocyte Count, Eosinophil Count, Basophil Count and Platelet Count at On Therapy and Test of Cure Visit|Change From Baseline in Hematology Parameter-hemoglobin Level at On Therapy and Test of Cure Visit|Change From Baseline in Hematology Parameter- Hematocrit Level at On Therapy and Test of Cure Visit|Change From Baseline in Hematology Parameter- Erythrocytes Count at On Therapy and Test of Cure Visit|Change From Baseline in Hematology Parameter - Mean Corpuscular Hemoglobin (MCH) at On Therapy and Test of Cure Visit|Change From Baseline in Hematology Parameter - Mean Corpuscular Volume (MCV) at On Therapy and Test of Cure Visit|Change From Baseline in Clinical Chemistry Parameters - Serum Urea Nitrogen, Glucose, Calcium, Chloride, Sodium, Magnesium, Phosphate, and Potassium Levels at On Therapy and Test of Cure Visit|Change From Baseline in Clinical Chemistry Parameters - Total Bilirubin, Direct Bilirubin and Creatinine Levels at On Therapy and Test of Cure Visit|Change From Baseline in Clinical Chemistry Parameters - Albumin and Protein Levels at On Therapy and Test of Cure Visit|Change From Baseline in Clinical Chemistry Parameters - Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP) Levels at On Therapy and Test of Cure Visit|Number of Participants With Urinalysis Dipstick Results at Baseline, On Therapy and Test of Cure Visit|Absolute Mean Values of Urine Specific Gravity at Baseline, On Therapy and Test of Cure Visit|Absolute Mean Values of Urine Potential of Hydrogen (pH) at Baseline, On Therapy and Test of Cure Visit|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at On-Therapy and Test of Cure Visit|Change From Baseline in Pulse Rate at On Therapy and Test of Cure Visit|Change From Baseline in Body Temperature at On Therapy and Test of Cure Visit","GlaxoSmithKline","Female","12 Years and older   (Child, Adult, Older Adult)","Phase 3","1531","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","204989|2018-001801-98","October 17, 2019","November 30, 2022","November 30, 2022","July 16, 2019","June 22, 2023","June 22, 2023","GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, Chula Vista, California, United States|GSK Investigational Site, La Mesa, California, United States|GSK Investigational Site, Lomita, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Northridge, California, United States|GSK Investigational Site, Northridge, California, United States|GSK Investigational Site, Palm Springs, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, DeLand, Florida, United States|GSK Investigational Site, Hialeah, Florida, United States|GSK Investigational Site, Miami Springs, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Pompano Beach, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Columbus, Georgia, United States|GSK Investigational Site, Fayetteville, Georgia, United States|GSK Investigational Site, Wichita, Kansas, United States|GSK Investigational Site, New Orleans, Louisiana, United States|GSK Investigational Site, Shreveport, Louisiana, United States|GSK Investigational Site, Watertown, Massachusetts, United States|GSK Investigational Site, Dearborn Heights, Michigan, United States|GSK Investigational Site, Norfolk, Nebraska, United States|GSK Investigational Site, East Brunswick, New Jersey, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Endwell, New York, United States|GSK Investigational Site, Fayetteville, North Carolina, United States|GSK Investigational Site, Scottdale, Pennsylvania, United States|GSK Investigational Site, Smithfield, Pennsylvania, United States|GSK Investigational Site, Clarksville, Tennessee, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Arlington, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Corpus Christi, Texas, United States|GSK Investigational Site, Forney, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Blagoevgrad, Bulgaria|GSK Investigational Site, Dupnitsa, Bulgaria|GSK Investigational Site, Pernik, Bulgaria|GSK Investigational Site, Pleven, Bulgaria|GSK Investigational Site, Plovdiv, Bulgaria|GSK Investigational Site, Sliven, Bulgaria|GSK Investigational Site, Smolyan, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Yambol, Bulgaria|GSK Investigational Site, Bory, Czechia|GSK Investigational Site, Kromeríž, Czechia|GSK Investigational Site, Praha, Czechia|GSK Investigational Site, Giessen, Hessen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Muelheim an der Ruhr, Nordrhein-Westfalen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Heraklion, Greece|GSK Investigational Site, Larisa, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Ballószög, Hungary|GSK Investigational Site, Csongrad, Hungary|GSK Investigational Site, Nyíregyháza, Hungary|GSK Investigational Site, Orosháza-Szentetornya, Hungary|GSK Investigational Site, Ahmedabad, India|GSK Investigational Site, Surat, India|GSK Investigational Site, Varanasi, India|GSK Investigational Site, Ciudad de Mexico, Campeche, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, San Juan del Río, Querétaro, Mexico|GSK Investigational Site, Jalisco, Mexico|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Bucuresti, Romania|GSK Investigational Site, Iasi, Romania|GSK Investigational Site, Oradea, Romania|GSK Investigational Site, Timisoara, Romania|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Kosice, Slovakia|GSK Investigational Site, Nitra, Slovakia|GSK Investigational Site, Pruske, Slovakia|GSK Investigational Site, Sala, Slovakia|GSK Investigational Site, Trencin, Slovakia|GSK Investigational Site, Trencin, Slovakia|GSK Investigational Site, Alicante, Spain|GSK Investigational Site, Cordoba, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Vic, Spain|GSK Investigational Site, Crownhill, Plymouth, United Kingdom|GSK Investigational Site, Liskeard, United Kingdom|GSK Investigational Site, Peterborough, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/41/NCT04020341/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/41/NCT04020341/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04020341"
275,"NCT02897609","Clinical Evaluation of Beta-Lacta ™ Test in Urinary Infections",,"Completed","No Results Available","Urinary Infection",,"Assessment of the relevance between antibiotic susceptibility and the antibiotic chosen,with phone questionary","Fondation Hôpital Saint-Joseph","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BETA-LACTA","April 2014","January 2015","January 2015","September 13, 2016",,"August 10, 2018","Groupe Hospitalier Paris Saint Joseph, Paris, Ile-de-France, France",,"https://ClinicalTrials.gov/show/NCT02897609"
276,"NCT00809913","Febrile Urinary Tract Infection Randomized Short Treatment Trial","FUTIRST","Completed","No Results Available","Urinary Tract Infection","Drug: short treatment (ciprofloxacin)","Clinical cure rate through the 10- to 18-day posttherapy visit. Clinical cure is defined as the resolution of fever and signs and symptoms of UTI.|Microbiological cure rate 10- to 18-day posttherapy|All cause mortality|Clinical cure rate 70- to 84- day posttherapy|Relapse rate of any urinary tract infection|Adverse events|Rate of pelvic floor dysfunction as assessed by standardized questionaire|Occurence of Clostridium Difficile associated diarrhea","Leiden University Medical Center|Bronovo Hospital|Medical Center Haaglanden|Spaarne Gasthuis|Rijnland Hospital|Diaconessenhuis Leiden|Groene Hart Ziekenhuis","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NL22172.058.08","December 2008","May 2013","September 2013","December 17, 2008",,"September 16, 2016","Medical Center Haaglanden, Den Haag, Netherlands|Bronovo Hospital, Den Haag, Netherlands|Groene Hart Hospital, Gouda, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Alrijne Hospital, Leiden, Netherlands|Alrijne Hospital, Leiderdorp, Netherlands",,"https://ClinicalTrials.gov/show/NCT00809913"
277,"NCT04187144","Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)",,"Completed","Has Results","Urinary Tract Infections","Drug: Gepotidacin|Drug: Placebo matching nitrofurantoin|Drug: Nitrofurantoin|Drug: Placebo matching gepotidacin","Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S (IA Set)|Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S Population|Number of Participants With Clinical Outcome at the TOC Visit - Micro-ITT NTF-S Population|Number of Participants With Clinical Response at the TOC Visit - Micro-ITT NTF-S Population|Number of Participants With Microbiological Outcome (MO) at the TOC Visit - Micro-ITT NTF-S Population|Number of Participants With Microbiological Response at the TOC Visit - Micro-ITT NTF-S Population|Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Follow up (FU) Visit - Micro-ITT NTF-S Population|Number of Participants With Clinical Outcome at the Follow up (FU) Visit - Micro-ITT NTF-S Population|Number of Participants With Clinical Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population|Number of Participants With Microbiological Outcome (MO) at the Follow up (FU) Visit - Micro-ITT NTF-S Population|Number of Participants With Microbiological Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population|Number of Participants With Clinical Outcome at the TOC Visit - Intent-to-Treat (ITT) Population|Number of Participants With Clinical Response at the TOC Visit - Intent-to-Treat (ITT) Population|Number of Participants With Clinical Outcome at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population|Number of Participants With Clinical Response at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population|Number of Participants With Treatment-emergent Adverse Events (TEAEs)|Number of Participants With Serious Adverse Events (SAEs)|Change From Baseline in Hematology Parameters: Neutrophil Count, Lymphocyte Count, Monocyte Count, Eosinophil Count, Basophil Count and Platelet Count at On Therapy and Test of Cure Visit|Change From Baseline in Hematology Parameter: Hemoglobin Level|Change From Baseline in Hematology Parameter: Hematocrit Level|Change From Baseline in Hematology Parameter: Erythrocytes (RBC) Count|Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)|Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV)|Change From Baseline in Clinical Chemistry Parameters: Serum Blood Urea Nitrogen (BUN), Glucose Non-fasting, Calcium, Chloride, Sodium, Magnesium, Phosphate, and Potassium Levels|Change From Baseline in Clinical Chemistry Parameters: Total Bilirubin, Direct Bilirubin and Creatinine Levels|Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Levels|Change From Baseline in Clinical Chemistry Parameters: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP) Levels|Number of Participants With Urinalysis Dipstick Results|Absolute Mean Values of Urine Specific Gravity|Absolute Mean Values of Urine Potential of Hydrogen (pH)|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at On-Therapy and Test of Cure Visit|Change From Baseline in Pulse Rate at On Therapy and Test of Cure Visit|Change From Baseline in Body Temperature|Number of Participants With Maximum Change From Baseline in Electrocardiograms (ECG) Parameter: QT Interval Corrected for Heart Rate According to Bazett's Formula (QTcB) at Worst-case Post-baseline|Number of Participants With Maximum Change From Baseline in Electrocardiograms (ECG) Parameter- QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF) at Worst-case Post-baseline","GlaxoSmithKline","Female","12 Years and older   (Child, Adult, Older Adult)","Phase 3","1606","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","212390|2020-000553-27","April 23, 2020","December 1, 2022","December 1, 2022","December 5, 2019","July 18, 2023","July 18, 2023","GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Homewood, Alabama, United States|GSK Investigational Site, Huntsville, Alabama, United States|GSK Investigational Site, Gilbert, Arizona, United States|GSK Investigational Site, Peoria, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, La Mesa, California, United States|GSK Investigational Site, Modesto, California, United States|GSK Investigational Site, Northridge, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Valencia, California, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Apollo Beach, Florida, United States|GSK Investigational Site, Boynton Beach, Florida, United States|GSK Investigational Site, Clearwater, Florida, United States|GSK Investigational Site, Coconut Creek, Florida, United States|GSK Investigational Site, Gainesville, Florida, United States|GSK Investigational Site, Hialeah, Florida, United States|GSK Investigational Site, Lake Worth, Florida, United States|GSK Investigational Site, Leesburg, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Ormond Beach, Florida, United States|GSK Investigational Site, Palm Springs, Florida, United States|GSK Investigational Site, Pembroke Pines, Florida, United States|GSK Investigational Site, Plant City, Florida, United States|GSK Investigational Site, Sweetwater, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Blackfoot, Idaho, United States|GSK Investigational Site, Boise, Idaho, United States|GSK Investigational Site, Meridian, Idaho, United States|GSK Investigational Site, Hanover, Maryland, United States|GSK Investigational Site, Fall River, Massachusetts, United States|GSK Investigational Site, Butte, Montana, United States|GSK Investigational Site, Lincoln, Nebraska, United States|GSK Investigational Site, East Orange, New Jersey, United States|GSK Investigational Site, Lawrenceville, New Jersey, United States|GSK Investigational Site, Mount Laurel, New Jersey, United States|GSK Investigational Site, Bronx, New York, United States|GSK Investigational Site, Brooklyn, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Cary, North Carolina, United States|GSK Investigational Site, Wilmington, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Fargo, North Dakota, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Bala-Cynwyd, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Lancaster, South Carolina, United States|GSK Investigational Site, Union, South Carolina, United States|GSK Investigational Site, Milan, Tennessee, United States|GSK Investigational Site, New Tazewell, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Katy, Texas, United States|GSK Investigational Site, Mesquite, Texas, United States|GSK Investigational Site, Missouri City, Texas, United States|GSK Investigational Site, North Richland Hills, Texas, United States|GSK Investigational Site, Plano, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Bountiful, Utah, United States|GSK Investigational Site, Saint George, Utah, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Maroubra, New South Wales, Australia|GSK Investigational Site, Sydney, New South Wales, Australia|GSK Investigational Site, Tarragindi, Queensland, Australia|GSK Investigational Site, Gabrovo, Bulgaria|GSK Investigational Site, Haskovo, Bulgaria|GSK Investigational Site, Kyustendil, Bulgaria|GSK Investigational Site, Montana, Bulgaria|GSK Investigational Site, Pleven, Bulgaria|GSK Investigational Site, Ruse, Bulgaria|GSK Investigational Site, Shumen, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Stara Zagora, Bulgaria|GSK Investigational Site, Targovisthe, Bulgaria|GSK Investigational Site, Aurangabad, India|GSK Investigational Site, Chandrapur, India|GSK Investigational Site, Hyderabad, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Nagpur, India|GSK Investigational Site, Nagpur, India|GSK Investigational Site, Nashik, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Rajkot, India|GSK Investigational Site, Surat, India|GSK Investigational Site, Ansan-si, Korea, Republic of|GSK Investigational Site, Goyang-si, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Hwasun-gun, Jeollanam-do, Korea, Republic of|GSK Investigational Site, Incheon, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Suwon, Korea, Republic of|GSK Investigational Site, Katowice, Poland|GSK Investigational Site, Ostrowiec Swietokrzyski, Poland|GSK Investigational Site, Swidnik, Poland|GSK Investigational Site, Warszawa, Poland","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/44/NCT04187144/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/44/NCT04187144/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04187144"
278,"NCT05458700","POS-cUTI: Study on Complicated Urinary Tract Infections",,"Recruiting","No Results Available","Urinary Tract Infections","Other: Collect information","To delineate the outcomes of patients with cUTI, and the impact of managemnt-related variables; specifically the incidence of treatment failure in patients with cUTI and modifiable and non-modifiable risk factors for treatment failure|To describe the patient population with cUTI and the microbiological aetiology of cUTI in the study sites.|To determine the rate of recurrences and superinfections, and those caused by multidrugresistant organisms|To determine the mortality and its predictors in patients with cUTI.|To determine the length of hospital stay after cUTI|To describe variations in current practices in treating cUTI in the study sites.","European Clinical Research Alliance for Infectious Diseases (ECRAID)|UMC Utrecht|Hospital Universitario Virgen Macarena","All","18 Years and older   (Adult, Older Adult)",,"16000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ECRAID-Base POS-cUTI","October 10, 2022","February 2026","February 2026","July 14, 2022",,"February 21, 2024","Hospital Universitario Virgen Macarena, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT05458700"
279,"NCT00900653","Low Dose Estriol With Lactobacilli Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women",,"Unknown status","No Results Available","Urinary Tract Infections","Drug: Gynoflor E (low dose estriol with lactobacillus)","Incidence of urinary tract infection|vaginal pH|lactobacillus colonization","Yonsei University","Female","40 Years and older   (Adult, Older Adult)","Phase 4","142","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","4-2009-0022","May 2009","May 2010","July 2010","May 13, 2009",,"June 1, 2009","Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00900653"
280,"NCT02650518","Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections","CARCUTI","Unknown status","No Results Available","Catheter-Related Infections","Other: Short-course Antibiotics|Device: Catheter Change","Resolution|Short-Term Resolution|Recurrence of fever or symptoms|Haemodynamic instability|Admission to high dependency or intensive care units|Length of hospitalization|Re-admission|Secondary Infections|Recurrent Urinary Tract Infections|Urologic surgery or procedure|Antimicrobial use and duration|Colonization or infection by antibiotic-resistant organisms","National University Hospital, Singapore|Tan Tock Seng Hospital|Singapore General Hospital|National University of Singapore","All","21 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014/00589","December 2015","October 2017","October 2018","January 8, 2016",,"January 8, 2016","National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02650518"
281,"NCT05397782","Effects of Flourish on Recurrent Urinary Tract Infection",,"Completed","No Results Available","Urinary Tract Infections","Device: BioNourish, a component of Flourish HEC","Vaginal Microbiome|UTI recurrence|Associations between microbes and UTI|Vaginal pH|Vulvovaginal symptoms questionnaire (VSQ) + addendum","Vaginal Biome Science|Urology Associates, P.C., Tennessee","Female","18 Years to 52 Years   (Adult)","Not Applicable","14","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","rUTI0522","September 26, 2022","February 21, 2024","February 21, 2024","May 31, 2022",,"March 7, 2024","WISH A Place for Women, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT05397782"
282,"NCT00795470","Factorial Trial of Antimicrobial Therapy and/or Catheter Change for Catheter Urinary Tract Infections.","CAUTION","Withdrawn","No Results Available","Urinary Tract Infections","Drug: Antimicrobial|Device: Catheter change","Number of patients enrolled|Protocol Adherence Rate|ICU free days at Day 30|Microbiologic Outcome|Developement of resistance","Unity Health Toronto|Queen's University|Mount Sinai Hospital, New York|The Ottawa Hospital|Sunnybrook Health Sciences Centre","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","REB 08-287","January 2012","January 2014","January 2014","November 21, 2008",,"December 3, 2015","St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00795470"
283,"NCT03928951","General Practitioner Reassessment of Urinary Infection Antibiotherapy Prescribed by Emergency Departments","ATB-IU","Completed","No Results Available","Urinary Tract Infections","Other: General practitioner reassessment of urinary infection antibiotherapy prescribed by emergency departments","Rate of antibiotherapies modified by general practitioners|Rate of initial antibiotherapies not relevant to recommendations|Rate of initial antibiotherapies not consistent with recommendations|Rate of reassessments not relevant to recommendations|Rate of reassessments not consistent with recommendations|Frequence of use of shared medical file","Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019-CHITS-01","June 14, 2019","September 12, 2019","September 12, 2019","April 26, 2019",,"November 29, 2019","Centre Hospitalier Intercommunal Toulon - La Seyne sur Mer, Toulon, Var, France",,"https://ClinicalTrials.gov/show/NCT03928951"
284,"NCT06307067","Improving Care for Uncomplicated URinary Tract Infection-associated Symptoms in Primary Healthcare Settings in INDOnesia","URINDO","Not yet recruiting","No Results Available","Urinary Tract Infections","Diagnostic Test: Urine dipstick","appropriateness of prescriptions for uncomplicated UTI-associated symptoms in the primary health care settings in Indonesia","Erasmus Medical Center|Saiful Anwar Hospital|Brawijaya University, Malang, Indonesia|Diponegoro University/Diponegoro National Hospital, Semarang, Indonesia|Bali Mandara Hospital, Denpasar, Bali, Indonesia","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Other|Time Perspective: Prospective","URINDO","March 4, 2024","November 4, 2024","June 1, 2025","March 12, 2024",,"March 12, 2024","Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT06307067"
285,"NCT04575493","Clinical Efficacy of Crano-cure inTreatment of Urinary Tract Infection",,"Completed","No Results Available","Urinary Tract Infections","Dietary Supplement: Crano-cure|Drug: Ciprofloxacin 500 mg","Urine Culture Examination","Islamia University of Bahawalpur|Hamdard University","All","15 Years to 60 Years   (Child, Adult)","Not Applicable","205","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","EM-DP-14-001","October 5, 2020","October 30, 2020","November 30, 2020","October 5, 2020",,"June 24, 2021","Jalil Ur Rehman, Bahawalpur, Punajb, Pakistan|University College of Conventional Medicine, Bahawalpur, Pakistan",,"https://ClinicalTrials.gov/show/NCT04575493"
286,"NCT02021305","The Role of TLR-4 Polymorphisms in Children With Urinary Track Infections","TLR-4","Unknown status","No Results Available","Urinary Tract Infection",,"frequency of TLR-4 299, 399 polymorphism and expression of TLR-2 and TLR-4 by monocytes in children with urinary track infection and healthy controls.","Aristotle University Of Thessaloniki","All","6 Months to 14 Years   (Child)",,"160","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","230283","February 2013","February 2014","February 2017","December 27, 2013",,"December 27, 2013","Aristotle University of Thessaloniki, Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT02021305"
287,"NCT05141188","Extended Spectrum Beta Lactamase Producing Organisms In Urinary Tract Infections",,"Unknown status","No Results Available","Urinary Tract Infections",,"The aim of this study is to indicate the spread of extended spectrum beta lactamase producing gram negative bacteria ( that isolated from the urine of patients with urinary tract infections based on their susceptibility to antimicrobial agents )","Sohag University","All","Child, Adult, Older Adult",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Soh-Med-21-10-10","December 1, 2021","May 1, 2022","November 1, 2022","December 2, 2021",,"December 2, 2021",,,"https://ClinicalTrials.gov/show/NCT05141188"
288,"NCT04615689","The Association of Gut Microbiota With Urinary Tract Infection in Infants",,"Withdrawn","No Results Available","Urinary Tract Infections","Other: The collection of feces","The differential compositional analysis of the gut microbiota between healthy controls and infants with febrile urinary tract infection.|The differential functional analysis of the gut microbiota between healthy controls and infants with febrile urinary tract infection.","Hallym University Kangnam Sacred Heart Hospital","All","6 Months to 15 Months   (Child)",,"0","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Gut microbiota and UTI","December 1, 2021","December 1, 2022","December 1, 2023","November 4, 2020",,"March 31, 2022","Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04615689"
289,"NCT03665467","The Global Prevalence of Infections in Urology Study","GPIU","Unknown status","No Results Available","Hospital Infection|Urinary Tract Infections",,"Health care associated infection episode","European Association of Urology Research Foundation","All","Child, Adult, Older Adult",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GPIU","November 30, 2003","January 31, 2021","December 31, 2021","September 11, 2018",,"February 4, 2021","Giessen University, Medical School, Gießen, Germany|Jahn Ferenc South Pest Teaching Hospital, Budapest, Hungary|Oslo University, Oslo, Norway|University College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03665467"
290,"NCT02637986","The Efficacy of Orally Administrated Probiotic Formula in Preventing a Recurrence of a Urinary Tract Infection During Pregnancy",,"Withdrawn","No Results Available","Urinary Tract Infections (UTIs)","Dietary Supplement: Urex Plus - containing L. rhamnosus GR-1 and L. reuteri RC-14|Other: Placebo - capsule with no active ingredient","The rate of women who developed UTI after receiving probiotic formula versus placebo.|Duration of time from the beginning of study until an episode of UTI.|The number of UTIs during pregnancy.|The rate of women who suffer from bacteruria, cystitis and pyelonephritis.|The rate of women who suffer from obstetrical outcomes (preterm labor, intrauterine growth restriction).|Adverse effects of the probiotic capsules versus placebo","HaEmek Medical Center, Israel","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","0173-13-EMC","November 7, 2022","November 7, 2022","November 7, 2022","December 22, 2015",,"November 8, 2022",,,"https://ClinicalTrials.gov/show/NCT02637986"
291,"NCT03825874","Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children","MIKA","Recruiting","No Results Available","Urinary Tract Infections|Urinary Tract Infections in Children","Other: Amikacin|Other: usual antibiotic treatment","Presence of E-BLSE in stools|Type of E-BLSE strain in stools|Rate of enzymatic resistance of E-BLSE strain in stools|Fever|side effects due to antibiotic therapy|rate of relapse of urinary tract infection","Centre Hospitalier Intercommunal Creteil","All","3 Months to 3 Years   (Child)",,"200","Other","Observational","Observational Model: Other|Time Perspective: Prospective","MIKA|2017-A02372-51","January 18, 2019","January 2025","January 2025","January 31, 2019",,"January 26, 2023","Antoine Beclère Hospital, Clamart, Ile-de France, France|Jean Verdier Hospital, Bondy, Ile-de-France, France|André Mignot Hospital, Le Chesnay, Ile-de-France, France|Cabinet du Dr Benali, Charenton-le-Pont, France|Cabinet du Dr Coicadan, Chennevières-sur-Marne, France|Cabinet du Dr Corrard, Combs-la-Ville, France|Cabinet du Dr Thollot, Essey-lès-Nancy, France|CHU Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France|157 Avenue du Général Leclerc, Maisons-Alfort, France|Centre Hospitalier de Meaux, Meaux, France|Cabinet du Dr Deberdt, Nogent-sur-Marne, France|Cabinet du Dr Wollner, Nogent-sur-Marne, France|Cabinet du Dr Romain, Paris, France|Cabinet du Dr Turberg-Romain, Paris, France|Cabinet du Dr Michot, Paris, France|Hospital Robert-Debré, Paris, France|Cabinet du Dr Cohen, Saint-Maur-des-Fossés, France|Cabinet du Dr Werner, Villeneuve-lès-Avignon, France|CHI Villeneuve-Saint-Georges, Villeneuve-Saint-Georges, France|13 Villa Beauséjour, Vincennes, France",,"https://ClinicalTrials.gov/show/NCT03825874"
292,"NCT06040684","Development of Antibodies Against Transplant Kidney After Infection",,"Completed","No Results Available","Acute Infection|Kidney Failure","Diagnostic Test: Level of antibodies","Production of HLA and nonHLA antibodies - Luminex|Analysis of antibody formation according to age|Analysis of antibody formation according to time from transplantation|Creatinine value|Input Inflammatory Parameters - CRP (C-reactive protein)|Input Inflammatory Parameters - IL-6 (Interleukin-6)|Number of HLA mismatches during transplant (0-6)|Length of immunosuppression reduction|Delayed graft function after transplantation|Long-term graft function|Type of infection|Presence of antibodies|EGF value|Proteinuria","University Hospital Ostrava","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","INT-01-HLATX-Kidney|15/RVO-FNOs/2018","August 1, 2018","November 30, 2021","December 31, 2021","September 15, 2023",,"September 15, 2023","University Hospital Ostrava, Ostrava, Moravian-Silesian Region, Czechia",,"https://ClinicalTrials.gov/show/NCT06040684"
293,"NCT04301934","Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection",,"Completed","Has Results","Urinary Tract Infections","Device: Mona Lisa Touch|Drug: Conjugated estrogen|Drug: Estradiol","Prevalence of Urinary Tract Infections (UTI)","Mayo Clinic","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","18-002297","June 1, 2020","April 30, 2023","April 30, 2023","March 10, 2020","March 26, 2024","March 26, 2024","Mayo Clinic in Arizona, Phoenix, Arizona, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/34/NCT04301934/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04301934"
294,"NCT02835456","Does Micropattern on Urinary Catheter Surface Reduce Urinary Tract Infections?","SHARKLET","Completed","No Results Available","Catheter Associated Urinary Tract Infections","Device: Sharklet Catheter insertion|Device: Silicone Foley Catheter insertion","Catheter scrapings examined for colonization/biofilm burden and compared to the urine screen collected from the participant (cfu/mL)|Number of symptomatic Urinary tract infections (UTIs) determined by urine culture.|Incidence of bacteremia|Incidence of Crustation|Incidence of Discomfort|Surface analysis of the type of bacteria found on each catheter|Surface analysis of the amount of encrustation|Surface analysis of the biofilm formation","Jahn Ferenc South Pest Teaching Hospital|Cook Group Incorporated","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","RCSFC028514","August 2016","November 2016","December 2016","July 18, 2016",,"January 4, 2017","Jahn Ferenc South Pest Teaching Hospital, Budapest, Hungary",,"https://ClinicalTrials.gov/show/NCT02835456"
295,"NCT05138822","Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections",,"Suspended","No Results Available","Uncomplicated Urinary Tract Infections","Drug: GSK3882347|Drug: Nitrofurantoin|Drug: Placebo","Numbers of participants with microbiological response (responder/non-responder of GSK3882347) at the test of cure (TOC) visit|Number of participants with adverse events (AEs) and serious adverse events (SAEs)|Number of participants with clinically significant change from baseline in hematology parameters|Number of participants with clinically significant change from baseline in clinical chemistry|Number of participants with clinically significant change from baseline in urinalysis|Number of participants with clinically significant change from baseline in vital signs|Number of participants with clinically significant change from baseline in 12- lead Electrocardiogram (ECG) findings|Plasma concentration of GSK3882347 single dose|Urine concentration of GSK3882347 at 22-24-hour (h) interval collection post-dose","GlaxoSmithKline","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","212943","May 18, 2022","July 16, 2024","July 16, 2024","December 1, 2021",,"October 23, 2023","GSK Investigational Site, Anniston, Alabama, United States|GSK Investigational Site, La Mesa, California, United States|GSK Investigational Site, Lomita, California, United States|GSK Investigational Site, Modesto, California, United States|GSK Investigational Site, Doral, Florida, United States|GSK Investigational Site, Miami Lakes, Florida, United States|GSK Investigational Site, Ormond Beach, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Bronx, New York, United States|GSK Investigational Site, Arlington, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Missouri City, Texas, United States|GSK Investigational Site, Saint George, Utah, United States",,"https://ClinicalTrials.gov/show/NCT05138822"
296,"NCT03184818","Outcomes of Urinary Tract Infection Management by Pharmacists","RxOUTMAP","Completed","No Results Available","Urinary Tract Infections","Other: Advanced care","Number of patients achieving clinical cure|Antibacterials used|Pharmacist interventions|Adherence|Number of treatment failures|Reasons for treatment failures|Patient satisfaction as determined by the modified consultation satisfaction questionnaire|Access to care|Adverse events","University of Alberta|Horizon Health Network|New Brunswick Pharmacists' Association|Loblaw Companies Ltd.|Pharmasave Drugs (Atlantic) Ltd.|Alberta Pharmacists Association|The Jean Coutu Group (PJC) Inc.","All","19 Years and older   (Adult, Older Adult)",,"750","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Pro00072493","June 16, 2017","April 27, 2018","April 27, 2018","June 14, 2017",,"May 2, 2018","EPICORE Centre, University of Alberta, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT03184818"
297,"NCT00305227","Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection",,"Completed","Has Results","Urinary Tract Infection","Drug: Lactin-V|Drug: Placebo","Incidence of Urinary Tract Infection|Incidence of Vaginal Discharge","University of Washington|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Osel, Inc.","Female","18 Years to 50 Years   (Adult)","Phase 2","100","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","28552|5P01DK053369|UW/LB-001","March 2006","April 2012","April 2012","March 21, 2006","July 4, 2014","April 14, 2023","Hall Health Primary Care Center, University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00305227"
298,"NCT02808000","BIP Foley in Prevention of CAUTI at Rehab Station","CDOC","Completed","No Results Available","Complications; Catheter, Urinary Infection or Inflammation","Device: BIP Foley (latex) or BIP Foley -silicone|Device: Standard catheter","Incidence of CAUTI|Incidence and typ of advese events|To compare ease of use of catheter by the nurse. Satisfaction assessed by ticking ""easy"" or ""not easy"" after each catheter exchange.|Antibiotics type|Antibiotics dose|Antibiotics, number of treatment days|Incidence of spontaneous urinary and blood cultures and CRP blood|Incidence of bacteruria, bacteremia, urosepsis and asymptomatic bacteremia","Bactiguard AB|Rehab Station Stockholm","All","18 Years and older   (Adult, Older Adult)","Phase 4","14","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","3686-2031-CDOC","April 21, 2016","March 9, 2020","March 9, 2020","June 21, 2016",,"January 22, 2021","Rehab Station Stockholm, Stockholm, Solna, Sweden",,"https://ClinicalTrials.gov/show/NCT02808000"
299,"NCT03366207","Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)",,"Completed","Has Results","UTI - Lower Urinary Tract Infection|Antibiotic Resistant Infection","Drug: Ciprofloxacin","Number of Subjects With Combined Clinical and Microbiologic Response|Microbiologic Response","Iterum Therapeutics, International Limited","Female","18 Years and older   (Adult, Older Adult)","Phase 4","250","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IT004-401","December 15, 2017","July 31, 2018","October 26, 2018","December 8, 2017","August 21, 2019","September 6, 2019","Restore Clinical Research, Cary, North Carolina, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/07/NCT03366207/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/07/NCT03366207/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03366207"
300,"NCT01406587","Safety and Efficacy of PP4001 for the Treatment of Symptoms Associated With Uncomplicated Urinary Tract Infection",,"Completed","No Results Available","Urinary Tract Infection","Drug: PP4001|Drug: Placebo","To assess the efficacy of PP4001 for the relief of burning during urination as measured by the subject's self-reported score at the time of urination in women with uUTI in comparison to placebo.|Change from baseline in the physical exam evaluation at the End of Study visit|To assess the efficacy of PP4001 for the relief of pain as measured by the subject's self-reported score at the time of urination.|To assess the efficacy of PP4001 for reduction in urination frequency as measured by the subject's self-reported void diary.|To evaluate the duration of therapeutic response to PP4001 50 mg, 100 mg and 200 mg.|To assess global assessment of uUTI symptom severity and change over time as measured by the subject-reported global assessment diaries.|Change from baseline in vital signs at the End of Study visit|Change from baseline in ECG at the End of Study visit|Change from baseline in laboratory evaluations at the End of Study visit|Frequency, severity and relationship to study medication of treatment emergent adverse events","Pinnacle Pharmaceuticals, Inc.","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","261","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PP4001.301","July 2011","October 2011","October 2011","August 1, 2011",,"October 19, 2011","Drug Research and Analysis Corp., Montgomery, Alabama, United States|Mesa Family Medical Center/Clincal Research Advantage, Mesa, Arizona, United States|Desert Clinical Research/Clinical Research Advantage, Mesa, Arizona, United States|Central Phoenix Medical Clinic/Clinical Research Advantage, Phoenix, Arizona, United States|Northern California Research, Sacramento, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Women's Health Care Research, San Diego, California, United States|Tampa Bay Medical Research, Clearwater, Florida, United States|Health Awareness, Inc., Jupiter, Florida, United States|Urology Center of Central Florida/Triquest Clinical Research Inc., St. Cloud, Florida, United States|Soapstone Center for Clinical Research, Decatur, Georgia, United States|Hutzel Women's Health Research, Detroit, Michigan, United States|Bellevue Family Practice/Clinical Research Advantage, Bellevue, Nebraska, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|AccuMed Research Associates, Garden City, New York, United States|Wake Research Associates, Raleigh, North Carolina, United States|Hawthorne Medical Research, Inc., Winston-Salem, North Carolina, United States|Hometown Urgent Care and Research, Groveport, Ohio, United States|Hometown Urgent Care and Research, Springfield, Ohio, United States|Ellipsis Research Group, LLC, Columbia, South Carolina, United States|Palmetto Clinical Research, LLC, Greenville, South Carolina, United States|InvestiClin Research, Brentwood, Tennessee, United States|Advanced Research Associates, Corpus Christi, Texas, United States|R/D Clinical Research, Inc., Lake Jackson, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01406587"
301,"NCT03522766","Evaluation of Urine Samples and Their Relation to Urinary Tract Infection",,"Completed","No Results Available","Urinary Tract Infections","Other: urine sample","Type of bacteria present in the urine","Coloplast A/S","All","18 Years and older   (Adult, Older Adult)",,"30","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CP287","March 19, 2018","September 23, 2019","September 23, 2019","May 11, 2018",,"February 5, 2020","Coloplast A/S, Humlebæk, Denmark",,"https://ClinicalTrials.gov/show/NCT03522766"
302,"NCT03819712","Identification of Predictive Blood Biomarkers of Recurrent Urinary Tract Infections","Predict-UTI","Completed","No Results Available","Urinary Tract Infections","Procedure: Collection of blood samples|Other: Collection of fecal samples|Other: Collection of urine samples|Other: Collection of vaginal swaps","TNF-α measurement in blood cell culture media using Luminex® technology.","Centre Hospitalier Universitaire de Nice","Female","18 Years to 28 Years   (Adult)","Not Applicable","109","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","18-PP-05","June 3, 2019","December 3, 2023","December 7, 2023","January 28, 2019",,"December 12, 2023","Hôpital de l'Archet 1 - CHU de Nice - Service d'Infectiologie, Nice, France",,"https://ClinicalTrials.gov/show/NCT03819712"
303,"NCT03497598","Preventing Recurrent Urinary Tract Infections With α-D-mannose","PUTIM","Terminated","No Results Available","Urinary Tract Infections","Drug: Mannose|Drug: Lactose","Frequency of UTIs|During UTI: Dysuria|During UTI: Urgency|During UTI: Frequency|During UTI: Flank (side) pain|During UTI: Cystalgia|During UTI: Back pain","Kantonsspital Aarau","Female","18 Years and older   (Adult, Older Adult)","Phase 4","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PUTIM","May 9, 2018","May 31, 2020","May 31, 2020","April 13, 2018",,"September 2, 2020","Kantonsspital Aarau, Aarau, Switzerland",,"https://ClinicalTrials.gov/show/NCT03497598"
304,"NCT05709028","Fosfomycin Versus Standard of Care in Children With Antibiotic-resistant Urinary Tract Infections","FosUTI","Recruiting","No Results Available","Urinary Tract Infections","Drug: Fosfomycin|Drug: Standard of care antibiotics","Treatment failure within 28 days after enrolment between patients treated with standard of care versus oral fosfomycin.|Occurrence of treatment-related adverse events to Day 28|Occurrence of serious adverse events attributable to UTI to Day 28|Evidence of primary treatment failure, defined as: a) Persistent fever (>38.0C) attributable to UTI at 72h after enrolment; and/or b) Failure to return to baseline health at 28 days after enrolment|Evaluation of the cost of hospital resources in the first 28 days of enrolment in children receiving standard of care versus oral fosfomycin; including: a) Cost of prescribed drugs b) Cost of hospital services (inpatient and outpatient)|Assessment of the tolerability of oral antibiotic therapy in children, using a 5-point facial hedonic scale immediately after the first oral dose|Evaluation of quality of life at 72 hours after enrolment, measured using the parent-rated Child Health Utility instrument (CHU9D)","University of Sydney","All","1 Year to 17 Years   (Child)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FosUTI","August 2, 2023","August 2027","August 2027","February 1, 2023",,"January 11, 2024","Sydney Childrens Hospital, Sydney, New South Wales, Australia|The Children's Hospital at Westmead, Sydney, New South Wales, Australia|Queensland Children's Hospital, Brisbane, Queensland, Australia|Royal Childrens Hospital, Melbourne, Victoria, Australia|Perth Children's Hospital, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT05709028"
305,"NCT00789464","Probiotics for Girls With Recurring Urinary Tract Infections",,"Withdrawn","No Results Available","Recurrent Urinary Tract Infection","Dietary Supplement: Lactobacillus reuteri DSM 17938|Drug: trimethoprim/sulfamethoxazole","The primary outcome will be the rates of bacteriuria among the subjects and the comparison of the two arms.","Baylor College of Medicine","Female","3 Months to 17 Years   (Child)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","H-23187",,,,"November 11, 2008",,"August 18, 2020","Texas Children's Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00789464"
306,"NCT01595529","The SCOUT Study: ""Short Course Therapy for Urinary Tract Infections in Children""",,"Completed","Has Results","Urinary Tract Infection","Drug: Cefixime|Drug: Cephalexin|Other: Placebo|Drug: Trimethoprim/Sulfamethoxazole","Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics.|Comparison of Efficacy Based on Symptomatic Urinary Tract Infection (UTI) Between Short-course and Standard-course of Antibiotics. Per-protocol Population.|Comparison of Number of Subjects That Have a Recurrent Infection (Includes a Relapse UTI or a Reinfection) Following Short-course Versus Standard-course of Antibiotics.|Comparison of Number of Subjects That Have a Recurrent Infection (Includes a Relapse UTI or a Reinfection) Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population.|Comparison of the Number of Subjects That Become Colonized With Antimicrobial Resistant Escherichia Coli (E. Coli) and Klebsiella Pneumoniae (K. Pneumoniae) in the Gastrointestinal Tract Following Short-course Versus Standard Course of Antibiotics.|Comparison of the Number of Subjects That Become Colonized With Antimicrobial Resistant E. Coli and K. Pneumoniae in the Gastrointestinal Tract Following Short-course Versus Standard Course of Antibiotics. Per-protocol Population.|Comparison of the Number of Subjects With Asymptomatic Bacteriuria Following Short-course Versus Standard-course of Antibiotics.|Comparison of the Number of Subjects With Asymptomatic Bacteriuria Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population.|Comparison of the Number of Subjects With Clinical Symptoms That May be Related to a UTI Following Short-course Versus Standard-course of Antibiotics.|Comparison of the Number of Subjects With Clinical Symptoms That May be Related to a UTI Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population|Comparison of the Number of Subjects With Positive Urine Cultures Following Short-course Versus Standard-course of Antibiotics.|Comparison of the Number of Subjects With Positive Urine Cultures Following Short-course Versus Standard-course of Antibiotics. Per-protocol Population.","National Institute of Allergy and Infectious Diseases (NIAID)","All","2 Months to 10 Years   (Child)","Phase 2","717","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","09-0103","May 18, 2012","June 30, 2019","August 12, 2019","May 10, 2012","July 13, 2020","August 6, 2020","Children's Hospital of Pittsburgh of UPMC - General Academic Pediatric, Pittsburgh, Pennsylvania, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/29/NCT01595529/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/29/NCT01595529/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01595529"
307,"NCT04709601","Efficacy and Mechanism of Action of Methenamine Hippurate (Hiprex™) in Women With Recurring Urinary Tract Infections.",,"Recruiting","No Results Available","Urinary Tract Infections","Drug: Hiprex","Number of Urinary Tract Infections|Number of oral anti-biotic usage|Number of hospital re-admissions|Number of adverse events related to Hiprex|Urine acidity levels|Number of urinary tract infection episodes|Severity of UTI symptoms as measured by the UTI Symptom Assessment questionnaire|Duration of intervals between UTI episodes","University of Texas Southwestern Medical Center","Female","50 Years to 85 Years   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU-2020-0725","January 4, 2021","December 2024","December 2024","January 14, 2021",,"February 5, 2024","UT-Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04709601"
308,"NCT05761405","Potentiated Aminoglycosides in Postoperative Urinary Tract Infection Prophylaxis","UROPOT","Recruiting","No Results Available","Urinary Tract Infections|Urological System Complication of Procedure","Combination Product: mannitol-enhanced aminoglycoside|Drug: Ceftriaxon|Drug: Amikacin","Infection prophylaxis|Combined microbiological eradication|Sustained microbiological eradication|Surgical safety outcome|Pharmacokinetics outcome|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]","Centre Hospitalier Universitaire Vaudois|Ecole Polytechnique Fédérale de Lausanne|Insel Gruppe AG, University Hospital Bern","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","2022-001979","January 16, 2024","October 15, 2025","April 15, 2026","March 9, 2023",,"February 8, 2024","CHUV, Lausanne, Switzerland",,"https://ClinicalTrials.gov/show/NCT05761405"
309,"NCT04731090","Standard Antibiotic Versus Enhanced Prophylactic Measures on Rate of Urinary Tract Infection After Flexible Ureteroscopy",,"Completed","No Results Available","Urinary Tract Infections","Drug: IV fluoroquinolone 1 hour preoperatively and oral antibiotics for 24h postoperatively.|Other: Urine culture, antibiotic prophylaxis and hydrophilic-coated ureteral access sheaths","Urinary tract infection","Egyptian Biomedical Research Network","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","N2113","August 1, 2018","September 30, 2020","September 30, 2020","January 29, 2021",,"January 29, 2021","Armed forced Hospital, Mecca, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04731090"
310,"NCT05109455","Effects of a Food Supplement in the Prevention of Urinary Tract Infections in Kidney Transplant Patients.","MANOTRAS","Completed","No Results Available","Kidney Transplant Infection","Dietary Supplement: MANOSAR®|Dietary Supplement: Proanthocyanidins","Change on the incidence of urinary tract infections.|Rate of three types of urinary tract infection: asymptomatic bacteriuria, cystitis, and pyelonephritis between both treatment groups.|Rate of urinary tract infections caused by E.coli.|Rate of patients who developed bacteremia during the episode of pyelonephritis.|Rate of safety episodes between both treatment groups.|Rate of incidence of delayed renal graft function.|Change from baseline in both treatment groups of concentration of glucose in renal function.|Rate of histologically confirmed acute rejection and number of patients who lost the kidney graft.|Rate of bacterial colonization of the double J catheter in both treatment groups.|Type of bacterial colonies of the double J catheter|Change from baseline in both treatment groups of concentration of Glomerular Filtration Rate (GFR).|Change from baseline in both treatment groups of concentration of serum creatinine in renal function.|Change from baseline in both treatment groups of concentration of sodium in renal function.|Change from baseline in both treatment groups of concentration of potassium in renal function.","Arafarma Group, S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","ARA-EXP/MN-0801","April 16, 2019","March 25, 2021","February 17, 2023","November 5, 2021",,"March 24, 2023","Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT05109455"
311,"NCT01745328","Treatment of Recurrent Urinary Tract Infection (RUTI) by Traditional Chinese Medicine",,"Unknown status","No Results Available","Recurrent Urinary Tract Infection","Drug: LVX-AMX|Drug: TCM","Recovery of recurrent urinary tract infection|Urinary albumin|WBC conversion|Urination frequency|Recurrence|urgency","Beijing Institute of Disease Control and Prevention","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","WJUTI","January 2009","March 2013","July 2013","December 10, 2012",,"December 10, 2012","Wangjing Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01745328"
312,"NCT02996981","Cranberry Effect on Urinary Tract Infections",,"Completed","Has Results","Urinary Tract Infections",,"The Incidence of UTI","TriHealth Inc.","Female","18 Years and older   (Adult, Older Adult)",,"167","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","16-087","November 21, 2016","July 14, 2017","December 2017","December 19, 2016","August 31, 2023","August 31, 2023",,"""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/81/NCT02996981/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02996981"
313,"NCT03256825","Rapid Urinary Tract Infection Diagnosis and Real-time Antimicrobial Stewardship Decision Support","RUDE","Completed","No Results Available","Urinary Tract Infections","Diagnostic Test: Rapid diagnostics alone|Other: Real-time antimicrobial stewardship decision support","All-cause 30-day mortality|Adherence to guidelines for empirical therapy|Total antibiotic consumption in intervention groups and control group compared|Use of broad spectrum antibiotics - DDD/admission in intervention groups compared with control group.|Time from admission to optimal antibiotic therapy|Frequency of errors by rapid diagnostics/errors in RADS leading to non-working treatment|Treatment duration - intravenous/per oral|Intensive care unit length of stay|Hospital length of stay|Frequency of adherence to treatment suggestions given as RADS|Frequency of readmission for urinary tract infection within 30 days of discharge|Turnaround time of rapid diagnostic procedures compared to conventional diagnostics|Accuracy of rapid diagnostic procedures compared to conventional diagnostics","Helse Møre og Romsdal HF","All","18 Years and older   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RUDE/01-2016","September 1, 2017","November 1, 2019","November 1, 2019","August 22, 2017",,"May 12, 2020","Molde Hospital, Molde, Norway|Ålesund Hospital, Ålesund, Norway",,"https://ClinicalTrials.gov/show/NCT03256825"
314,"NCT01958073","Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women","VESPR","Completed","Has Results","Recurrent Urinary Tract Infection","Drug: Conjugated Estrogen Vaginal Cream|Drug: Estradiol Ring|Drug: Placebo","Occurrence of UTI During Randomization|Rates of UTI in Both Randomization Period and Within Placebo When Changed to Open Label Estrogen|Quality of Life Questionnaire: Female Sexual Function Index|Compliance During Randomization|Occurrence of UTI in Those Compliant With Treatment During Randomization|Quality of Life Questionnaire: MESA I|Quality of Life Questionnaire: MESA II|Quality of Life Questionnaire: Pelvic Floor Disability Index|Quality of Life Questionnaire: Pelvic Floor Impact Questionnaire|Quality of Life Questionnaire: Estimated Percentage of Improvement","University of California, San Diego|American Urogynecologic Society|NYU Langone Health","Female","18 Years to 100 Years   (Adult, Older Adult)","Phase 4","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","130403","October 2013","December 2017","December 2017","October 8, 2013","September 21, 2020","September 21, 2020","University of California, San Diego, La Jolla, California, United States|New York University Langone Medical Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/73/NCT01958073/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01958073"
315,"NCT03970356","Improving Antibiotic Prescribing for Urinary Tract Infections in Frail Elderly","ImpresU-WP2","Completed","No Results Available","Urinary Tract Infections","Other: antibiotic stewardship intervention","UTI prescriptions|Incorrect UTI prescriptions|UTI suspicions|Complications|Hospital referral|Hospital admission|Mortality|Mortality after UTI suspicion|UTI prescriptions in office hours","Cees Hertogh|UMC Utrecht|Medical University of Lodz|University of Oslo|Vastra Gotaland Region|Göteborg University|Amsterdam UMC, location VUmc","All","70 Years and older   (Older Adult)","Not Applicable","1146","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005035|25 (2017)|549003002|2017/25/Z/NZ7/03024|2017-05975|284253","September 1, 2019","July 21, 2021","July 21, 2021","May 31, 2019",,"May 24, 2022","University Medical Center Utrecht, Utrecht, Netherlands|University of Oslo, Oslo, Norway|Medical University of Lodz, Łódź, Poland|Research and Development Primary Health Care, Region Västra Götaland, Borås, Sweden",,"https://ClinicalTrials.gov/show/NCT03970356"
316,"NCT03099863","Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection",,"Completed","Has Results","Urinary Tract Infections","Drug: Cystoscopic Fluid containing Neosporin G. U. Irrigant|Procedure: Cystoscopy|Drug: Cystoscopic Fluid/Placebo","Urinary Tract Infection","MetroHealth Medical Center","Female","18 Years and older   (Adult, Older Adult)","Phase 4","242","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","IRB15-00769","April 2016","June 2020","June 2020","April 4, 2017","December 30, 2021","December 30, 2021","MetroHealth Medical Center, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/63/NCT03099863/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03099863"
317,"NCT04272437","TRA for Preventing Symptomatic Urinary Tract Infection Among High-risk Elderly Residing in Nursing Homes",,"Completed","No Results Available","Urinary Tract Infections","Drug: Concentrated herbal extract granules TRA|Drug: Placebo","Number of Episodes of Symptomatic UTI During Administration|Number of Episodes of Symptomatic UTI Onset From First Administration Till 180 Days|Accumulated Rate of Symptomatic UTI During Administration|Accumulated Rate of Symptomatic UTI Onset From First Administration Till 180 Days|The Change of Urinalysis From Baseline to 42 Days|Number of Deaths Onset From First Administration Till 180 Days","Changhua Christian Hospital|Ministry of Health and Welfare, Taiwan","All","65 Years and older   (Older Adult)","Phase 2","162","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","MOHW107-CMAP-M-114-122113","June 15, 2017","December 31, 2018","March 3, 2019","February 17, 2020",,"February 17, 2020","Dept. of Traditional Chinese Medicine, Changhua Christian Hospital, Changhua city, Taiwan",,"https://ClinicalTrials.gov/show/NCT04272437"
318,"NCT04361864","Cross-sectional Survey on Patients With Urinary Tract Infections in Puy-de-Dôme : Epidemiology of Recurrent Urinary Tract Infections and Risk Factors","IUR63","Completed","No Results Available","Urinary Tract Infections",,"Proportion of recurrent urinary tract infections|age in year|sexe|, medical and surgical history|life habits|number of visits at the general practitioner|number of urinalysis|number of antibiotic therapies|quality of life|bacteriological characteristics of recurrent urinary tract infections","University Hospital, Clermont-Ferrand|Caisse Primaire d'Assurance Maladie du Puy-de-Dôme","All","18 Years and older   (Adult, Older Adult)",,"561","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RNI 2019 LESENS|2019-A02703-54","January 15, 2021","February 1, 2021","February 2, 2021","April 24, 2020",,"May 7, 2021","Chu Clermont Ferrand, Clermont-Ferrand, France",,"https://ClinicalTrials.gov/show/NCT04361864"
319,"NCT01599806","Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)",,"Completed","Has Results","Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis","Drug: Ceftazidime - Avibactam ( CAZ-AVI)|Drug: Doripenem|Drug: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Drug: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)","Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test|Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test|Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test|Per-patient Microbiological Response at EOT (IV) (mMITT Analysis Set)|Per-patient Microbiological Response at LFU (mMITT Analysis Set)|Per-patient Microbiological Response at EOT (IV) (ME at EOT (IV) Analysis Set)|Per-patient Microbiological Response at TOC (ME at TOC Analysis Set)|Per-patient Microbiological Response at LFU (ME at LFU Analysis Set)|Per-patient Microbiological Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)|Per-patient Microbiological Response at TOC (Extended ME at TOC Analysis Set)|Per-patient Microbiological Response at LFU (Extended ME at LFU Analysis Set)|Investigator Determined Clinical Response at EOT (IV) (mMITT Analysis Set)|Investigator Determined Clinical Response at TOC (mMITT Analysis Set)|Investigator Determined Clinical Response at LFU (mMITT Analysis Set)|Investigator Determined Clinical Response at EOT (IV) (ME at EOT (IV) Analysis Set)|Investigator Determined Clinical Response at TOC (ME at TOC Analysis Set)|Investigator Determined Clinical Response at LFU (ME at LFU Analysis Set)|Investigator Determined Clinical Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)|Investigator Determined Clinical Response at TOC (Extended ME at TOC Analysis Set)|Investigator Determined Clinical Response at LFU (Extended ME at LFU Analysis Set)|Investigator Determined Clinical Response at EOT (IV) (CE at EOT (IV) Analysis Set)|Investigator Determined Clinical Response at TOC (CE at TOC Analysis Set)|Investigator Determined Clinical Response at LFU (CE at LFU Analysis Set)|Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)|Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)|Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)|Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)|Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)|Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)|Time to First Defervescence While on IV Study Therapy (mMITT Analysis Set)|Time to First Defervescence While on IV Study Therapy (ME at TOC Analysis Set)|Time to First Defervescence While on IV Study Therapy (Extended ME at TOC Analysis Set)|Time to First Defervescence While on IV Study Therapy (CE at TOC Analysis Set)|Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (mMITT Analysis Set)|Per-pathogen Microbiological Response at TOC for Baseline Pathogen (mMITT Analysis Set)|Per-pathogen Microbiological Response at LFU for Baseline Pathogen (mMITT Analysis Set)|Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (Extended ME at EOT (IV) Analysis Set)|Per-pathogen Microbiological Response at TOC for Baseline Pathogen (Extended ME at TOC Analysis Set)|Per-pathogen Microbiological Response at LFU for Baseline Pathogen (Extended ME at LFU Analysis Set)|Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (ME at EOT (IV) Analysis Set)|Per-pathogen Microbiological Response at TOC for Baseline Pathogen (ME at TOC Analysis Set)|Per-pathogen Microbiological Response at LFU for Baseline Pathogen (ME at LFU Analysis Set)|Per-pathogen Microbiological Response at EOT (IV) for Blood Only (mMITT Analysis Set)|Per-pathogen Microbiological Response at TOC for Blood Only (mMITT Analysis Set)|Per-pathogen Microbiological Response at LFU for Blood Only (mMITT Analysis Set)|Per-pathogen Microbiological Response at EOT (IV) for Blood Only (Extended ME at EOT (IV) Analysis Set)|Per-pathogen Microbiological Response at TOC for Blood Only (Extended ME at TOC Analysis Set)|Per-pathogen Microbiological Response at LFU for Blood Only (Extended ME at LFU Analysis Set)|Per-pathogen Microbiological Response at EOT (IV) for Blood Only (ME at EOT (IV) Analysis Set)|Per-pathogen Microbiological Response at TOC for Blood Only (ME at TOC Analysis Set)|Per-pathogen Microbiological Response at LFU for Blood Only (ME at LFU Analysis Set)|Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (mMITT Analysis Set)|Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)|Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (ME at TOC Analysis Set)|Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (mMITT Analysis Set)|Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)|Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (ME at TOC Analysis Set)|Plasma Concentrations for Ceftazidime Within 15 Minutes Before/After Dose (PK Analysis Set)|Plasma Concentrations for Ceftazidime Between 30 to 90 Minutes After Dose(PK Analysis Set)|Plasma Concentrations for Ceftazidime Between 300 to 360 Minutes After Dose(PK Analysis Set)|Plasma Concentrations for Avibactam Within 15 Minutes Before/After Dose (PK Analysis Set)|Plasma Concentrations for Avibactam Between 30 to 90 Minutes After Dose(PK Analysis Set)|Plasma Concentrations for Avibactam Between 300 to 360 Minutes After Dose(PK Analysis Set)","Pfizer|Forest Laboratories","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","641","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4280C00004|2011-005722-21","October 2012","August 2014","August 2014","May 16, 2012","March 2, 2016","September 6, 2017","Research Site, Detroit, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Indiana, Pennsylvania, United States|Research Site, Rosario, Argentina|Research Site, Pazardzhik, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Slavonski Brod, Croatia|Research Site, Zadar, Croatia|Research Site, Zagreb, Croatia|Research Site, Liberec, Czechia|Research Site, Praha, Czechia|Research Site, Hamburg, Germany|Research Site, Haifa, Israel|Research Site, Kfar-saba, Israel|Research Site, Modena, Italy|Research Site, Busan, Korea, Republic of|Research Site, Jeonnam, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Cuernavaca, MOR, Mexico|Research Site, Guadalajara, Mexico|Research Site, Zapopan, Mexico|Research Site, Arequipa, Peru|Research Site, Cercardo de Lima, Peru|Research Site, Cusco, Peru|Research Site, Lima, Peru|Research Site, Trujillo, Peru|Research Site, Białystok, Poland|Research Site, Sochaczew, Poland|Research Site, Wrocław, Poland|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Oradea, Romania|Research Site, Sibiu, Romania|Research Site, Timisoara, Romania|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.-Petersburg,, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Velikiy Novgorod, Russian Federation|Research Site, Alicante, Spain|Research Site, Alzira (Valencia), Spain|Research Site, Barcelona, Spain|Research Site, Elche, Spain|Research Site, Granada, Spain|Research Site, Terrassa, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Chernivtsi, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Simferopol, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01599806"
320,"NCT01595438","Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)",,"Completed","Has Results","Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis","Drug: Ceftazidime - Avibactam ( CAZ-AVI)|Drug: Doripenem|Drug: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Drug: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)","Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test|Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test|Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test|Per-patient Microbiological Response at EOT (IV) (mMITT Analysis Set)|Per-patient Microbiological Response at LFU (mMITT Analysis Set)|Per-patient Microbiological Response at EOT (IV) (ME at EOT (IV) Analysis Set)|Per-patient Microbiological Response at TOC (ME at TOC Analysis Set)|Per-patient Microbiological Response at LFU (ME at LFU Analysis Set)|Per-patient Microbiological Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)|Per-patient Microbiological Response at TOC (Extended ME at TOC Analysis Set)|Per-patient Microbiological Response at LFU (Extended ME at LFU Analysis Set)|Investigator Determined Clinical Response at EOT (IV) (mMITT Analysis Set)|Investigator Determined Clinical Response at TOC (mMITT Analysis Set)|Investigator Determined Clinical Response at LFU (mMITT Analysis Set)|Investigator Determined Clinical Response at EOT (IV) (ME at EOT (IV) Analysis Set)|Investigator Determined Clinical Response at TOC (ME at TOC Analysis Set)|Investigator Determined Clinical Response at LFU (ME at LFU Analysis Set)|Investigator Determined Clinical Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)|Investigator Determined Clinical Response at TOC (Extended ME at TOC Analysis Set)|Investigator Determined Clinical Response at LFU (Extended ME at LFU Analysis Set)|Investigator Determined Clinical Response at EOT (IV) (CE at EOT (IV) Analysis Set)|Investigator Determined Clinical Response at TOC (CE at TOC Analysis Set)|Investigator Determined Clinical Response at LFU (CE at LFU Analysis Set)|Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)|Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)|Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)|Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)|Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)|Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)|Time to First Defervescence While on IV Study Therapy (mMITT Analysis Set)|Time to First Defervescence While on IV Study Therapy (ME at TOC Analysis Set)|Time to First Defervescence While on IV Study Therapy (Extended ME at TOC Analysis Set)|Time to First Defervescence While on IV Study Therapy (CE at TOC Analysis Set)|Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (mMITT Analysis Set)|Per-pathogen Microbiological Response at TOC for Baseline Pathogen (mMITT Analysis Set)|Per-pathogen Microbiological Response at LFU for Baseline Pathogen (mMITT Analysis Set)|Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (Extended ME at EOT (IV) Analysis Set)|Per-pathogen Microbiological Response at TOC for Baseline Pathogen (Extended ME at TOC Analysis Set)|Per-pathogen Microbiological Response at LFU for Baseline Pathogen (Extended ME at LFU Analysis Set)|Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (ME at EOT (IV) Analysis Set)|Per-pathogen Microbiological Response at TOC for Baseline Pathogen (ME at TOC Analysis Set)|Per-pathogen Microbiological Response at LFU for Baseline Pathogen (ME at LFU Analysis Set)|Per-pathogen Microbiological Response at EOT (IV) for Blood Only (mMITT Analysis Set)|Per-pathogen Microbiological Response at TOC for Blood Only (mMITT Analysis Set)|Per-pathogen Microbiological Response at LFU for Blood Only (mMITT Analysis Set)|Per-pathogen Microbiological Response at EOT (IV) for Blood Only (Extended ME at EOT (IV) Analysis Set)|Per-pathogen Microbiological Response at TOC for Blood Only (Extended ME at TOC Analysis Set)|Per-pathogen Microbiological Response at LFU for Blood Only (Extended ME at LFU Analysis Set)|Per-pathogen Microbiological Response at EOT (IV) for Blood Only (ME at EOT (IV) Analysis Set)|Per-pathogen Microbiological Response at TOC for Blood Only (ME at TOC Analysis Set)|Per-pathogen Microbiological Response at LFU for Blood Only (ME at LFU Analysis Set)|Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (mMITT Analysis Set)|Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)|Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (ME at TOC Analysis Set)|Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (mMITT Analysis Set)|Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)|Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (ME at TOC Analysis Set)|Plasma Concentrations for Ceftazidime Within 15 Minutes Before/After Dose (PK Analysis Set)|Plasma Concentrations for Ceftazidime Between 30 to 90 Minutes After Dose(PK Analysis Set)|Plasma Concentrations for Ceftazidime Between 300 to 360 Minutes After Dose(PK Analysis Set)|Plasma Concentrations for Avibactam Within 15 Minutes Before/After Dose (PK Analysis Set)|Plasma Concentrations for Avibactam Between 30 to 90 Minutes After Dose(PK Analysis Set)|Plasma Concentrations for Avibactam Between 300 to 360 Minutes After Dose(PK Analysis Set)","Pfizer|Forest Laboratories","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","598","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4280C00002|2011-005721-43","October 2012","August 2014","August 2014","May 10, 2012","March 9, 2016","September 6, 2017","Research Site, Sylmar, California, United States|Research Site, Royal Oak, Michigan, United States|Research Site, Lima, Ohio, United States|Research Site, Cordoba, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Mendoza, Argentina|Research Site, Santa Fe, Argentina|Research Site, Belo Horizonte, Brazil|Research Site, Campinas/SP, Brazil|Research Site, Salvador, Brazil|Research Site, São José do Rio Preto - SP, Brazil|Research Site, São Paulo, Brazil|Research Site, Vila Clementino, Brazil|Research Site, Pleven, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Zagreb, Croatia|Research Site, Kyjov, Czechia|Research Site, Opava, Czechia|Research Site, Jena, Germany|Research Site, Wuppertal, Germany|Research Site, Athens, Greece|Research Site, Budapest, Hungary|Research Site, Nagykanizsa, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Jerusalem, Israel|Research Site, Petach-Tikva, Israel|Research Site, Safed, Israel|Research Site, Fukuoka-shi, Japan|Research Site, Koshigaya-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nara-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Sunto-gun, Japan|Research Site, Tokushima-shi, Japan|Research Site, Ueda-shi, Japan|Research Site, Utsunomiya-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Wonju, Korea, Republic of|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Inowrocław, Poland|Research Site, Krakow, Poland|Research Site, Warszawa, Poland|Research Site, Lisboa, Portugal|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Vsevolozhsk, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Poprad, Slovakia|Research Site, Presov, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Chiayi, Taiwan|Research Site, Taipei, Taiwan|Research Site, Diyarbakir, Turkey|Research Site, Cherkasy, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Mykolaiv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Odessa, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01595438"
321,"NCT05545514","Individualized Homeopathy to Reduce the Use of Antibiotics in Women With Recurrent Uncomplicated Urinary Tract Infections","iHOM","Recruiting","No Results Available","Urinary Tract Infection Chronic","Drug: One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000,","ICIQ-FLUTS:|ICIQ-FLUTS and ACSS|ICIQ-FLUTS and ACCS|SF 12","Technical University of Munich|School of Medicine, Technical University Munich, Münchner Studienzentrum|Klinikum rechts der Isar, TUM Institute for AI and Informatics in Medicine (AIIM)","Female","18 Years to 64 Years   (Adult)","Phase 4","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IHO-0000-REN-0220-S","March 15, 2023","July 31, 2024","January 31, 2025","September 19, 2022",,"November 24, 2023","Klinikum rechts der Isar, Department of Nephrology, München, Bayern, Germany",,"https://ClinicalTrials.gov/show/NCT05545514"
322,"NCT02572895","Cranberry Extract and Urinary Infection Prevention: a Clinical Trial","PACCANN","Unknown status","No Results Available","Urinary Tract Infections","Dietary Supplement: Cranberry extract","Mean number of urinary tract infections","Laval University|Ministry of Agriculture, Fisheries and Food, Quebec|Nutra Canada","Female","18 Years and older   (Adult, Older Adult)","Phase 1","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PACCANN_2015","August 2015","June 2017","December 2017","October 9, 2015",,"September 9, 2016","Laval University, Québec, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02572895"
323,"NCT03715062","Reducing Antibiotic Prescriptions for Urinary Tract Infection in Long-Term Care Facilities",,"Completed","No Results Available","Urinary Tract Infections","Other: Dialogue tool","Prescription of antibiotics for urinary tract infection|Hospitalization|Death|Appropriate prescription of antibiotics for urinary tract infections","Research Unit Of General Practice, Copenhagen|Ministry of the Interior and Health, Denmark|Velux Fonden|Herlev Hospital","All","65 Years and older   (Older Adult)","Not Applicable","1491","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","111","December 1, 2018","March 31, 2019","March 31, 2019","October 22, 2018",,"June 4, 2019","Research Unit of General Practice, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03715062"
324,"NCT00156546","Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a Previous Urinary Tract Infection",,"Unknown status","No Results Available","Urinary Tract Infections","Drug: antibiotic to reduce the recurrence of infection","The primary end-point is UTI Recurrence Rate during the 12-month observation period and the Development of renal damage (parenchymal scar) after 12 months.|The secondary objectives are the comparison, in terms of efficacy and effectiveness, between two antimicrobial agents that are currently approved for prophylactic use: co-trimoxazole 15 mg/kg daily versus amoxicillin + clavulanic acid 15 mg/kg daily.","University of Padova|Regione Veneto|IL Sogno di Stefano","All","2 Months to 6 Years   (Child)","Phase 4","660","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRIS 2","May 2000",,"July 2006","September 12, 2005",,"December 1, 2005","Pediatric Unit, Ospedale di Bentivoglio, Bentivoglio, Bologna, Italy|Pediatric Unit, Ospedale di Este - Monselice, Monselice, Padova, Italy|Pediatric Unit, Ospedale di Piove di Sacco e Chioggia, Piove di Sacco, Padova, Italy|Pediatric Unit, Ospedale di Castelfranco, Castelfranco Veneto, Treviso, Italy|Pediatric Unit, Ospedale di Motta di Livenza, Motta di Livenza Oderzo, Treviso, Italy|Pediatric Unit, Ospedale di Dolo, Dolo, Venezia, Italy|Pediatric Unit, Ospedale di Soave, Soave, Verona, Italy|Pediatric Unit, Ospedale di Schio/Thiene, Thiene, Vicenza, Italy|Pediatric Unit, Ospedale di Belluno, Belluno, Italy|Pediatric Department, Ospedale Maggiore, Bologna, Italy|- Pediatric Department, Ospedale di Bolzano, Bolzano, Italy|Pediatric Unit, Ospedale di Cuneo, Cuneo, Italy|Pediatric Unit, Ospedale di Mestre, Mestre Venezia, Italy|Nephrology, Dialysis and transplant Unit Pediatric Depatment,, Padova, Italy|Pediatric Unit, Ospedale di Ravenna, Ravenna, Italy|Pediatric Unit, Ospedale di Verona, Verona, Italy",,"https://ClinicalTrials.gov/show/NCT00156546"
325,"NCT01881165","Cranberry on Urinary Tract Infections",,"Withdrawn","No Results Available","Urinary Tract Infection","Drug: Cranberry|Drug: Placebo","Number of urinary tract infections|Side effects","University of British Columbia","Female","Child, Adult, Older Adult","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","H13-01491","September 2014","December 2015","March 2016","June 19, 2013",,"December 16, 2014","The University of British Columbia, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT01881165"
326,"NCT03019172","Clinical Trial of L. Reuteri in Urinary Tract Infections in Non Pregnant Women","UTIReuteri","Completed","No Results Available","Urinary Tract Infections","Combination Product: Lactobacillus reuteri|Dietary Supplement: Sachet with cranberry + placebo","clinical and bacteriological cure|clinical or bacteriological relapse|Adverse events","Innovacion y Desarrollo de Estrategias en Salud","Female","18 Years to 45 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UTIReuteri2016","March 5, 2017","July 30, 2017","September 30, 2017","January 12, 2017",,"November 29, 2017","Hospital General Dr. Manuel Gea Gonzalez, Mexico city, Tlalpan, Mexico",,"https://ClinicalTrials.gov/show/NCT03019172"
327,"NCT02368847","Urinary Tract Infections in Older Persons Admitted to a Psychogeriatric Ward","UTI_UCP","Unknown status","No Results Available","Urinary Tract Infections","Device: Diagnostic tests","Serious infection|Reliability of the uricult dipslide in a population of institutionalized older patients","KU Leuven","All","65 Years and older   (Older Adult)","Not Applicable","120","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UTI_UCP","March 2015","August 2015","December 2015","February 23, 2015",,"February 23, 2015",,,"https://ClinicalTrials.gov/show/NCT02368847"
328,"NCT03160807","Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections","Levolet-KZ16","Unknown status","No Results Available","Urinary Tract Infection","Drug: Levofloxacin","Percentage of patients with clinical cure rates at test of cure visit (TOC) defined as follows- Cure: a complete resolution of clinically significant signs & symptoms|Percentage of patients with microbiological eradication at test of cure visit (TOC)|No. of adverse events in entire study duration|Percentage of patient compliant to therapy in each study arm.|Percentage of patient samples sensitive to levofloxacin in each study arm.","Dr. Reddy's Laboratories Limited","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 4","214","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EM_KZ_LEVOLET","April 15, 2017","March 2018","March 2018","May 19, 2017",,"May 19, 2017","Scientific Centre of Urology named after B.U Dzharbusynov 2, Basenov street,, Almaty, Kazakhstan",,"https://ClinicalTrials.gov/show/NCT03160807"
329,"NCT03687255","Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infections","Drug: cefepime/AAI101 combination|Drug: Piperacillin/tazobactam","Proportion of patients in the Microbiological Modified Intent to Treat (m-MITT) Population who achieve overall treatment success at Test Of Cure (TOC)|Proportion of patients in the m-MITT Population with overall treatment success at End of Treatment (EOT)","Allecra|Medpace, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","1043","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AT-301","September 24, 2018","January 30, 2020","February 15, 2020","September 27, 2018",,"March 10, 2020","St. Josephs Clinical Research, Anaheim, California, United States|Southbay Pharma Research, Buena Park, California, United States|Florida Urology Partners, Tampa, Florida, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercury Street Medical, Butte, Montana, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|HIGA Dr Ramon Carrillo, Buenos Aires, Argentina|Brest Regional Hospital, Brest, Belarus|MHAT Rahila Angelova AD, Pernik, Pernik, Bulgaria|University Hospital for Infectious Diseases ""Dr. Fran Mihaljevic"" Department for general infectious diseases, Zagreb, Croatia|Tartu University Hospital, Tartu, Estonia|Unimed Adjara - Kutaisi oncological centre, Kutaisi, Georgia|Bugat Pal Korhaz, Gyöngyös, Hungary|Uroklinika, LLC, Riga, Latvia|Republican Siauliai caunty hospital, Šiauliai, Lithuania|Centro Especializado en Investigación Clínica S.C., Boca Del Río, Mexico|Clinica Internacional - Sede San Borja, Lima, Peru|Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie, Klinika Chorob Wewnetrznych, Nefrologii i Transplantologii, Warsaw, Poland|Scientific Research Center Eco-Safety, Saint Petersburg, Russian Federation|Clinical Hospital Center Zvezdara, Belgrade, Serbia|Interne oddelenie, Nemocnica Malacky, Nemocnicna a.s., Malacky, Slovakia|Clinical Projects Research, Worcester, South Africa|Hospital del Mar, Department of Infectious Disease, Barcelona, Spain|Chernihiv City Hospital #2 of Chernihiv City Council, department of Urology, Chernihiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT03687255"
330,"NCT03042273","High Strength Cranberry Supplementation for Prevention of Recurrent Urinary Tract Infection",,"Completed","No Results Available","Urinary Tract Infection","Dietary Supplement: High Strength Cranberry|Dietary Supplement: Placebo","Incidence of UTI","Swisse Wellness Pty Ltd|Commonwealth Scientific and Industrial Research Organisation, Australia","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","150","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","PAC-001","May 15, 2017","December 31, 2019","December 31, 2019","February 3, 2017",,"March 18, 2020","Holdsworth House Medical Centre, Sydney, New South Wales, Australia|Holdsworth House Medical Centre, Brisbane, Queensland, Australia|Griffith University Clinical Trial Unit (Griffith Health), Gold Coast, Queensland, Australia|CSIRO Nutrition and Health Research Clinic, Adelaide, South Australia, Australia|Monash Alfred Psychiatry Research Centre (MAPrc), Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03042273"
331,"NCT02698332","Effect of a Diagnostic Algorithm for Urinary Tract Infection in General Practice",,"Completed","No Results Available","Urinary Tract Infection","Device: Algorithm for UTI","Difference in appropriate primary choice of treatment in the two groups.|Difference in price of point-of-care diagnostics used in the two groups|Difference in appropriate final choice of treatment in the two groups.|Difference in appropriate choice of treatment on the day of consultation (day 1) in the two groups|Difference in appropriate choice of treatment on the day after consultation (day ) in the two groups|Difference in correct decision to treat on the day of consultation (day 1) in the two groups|Difference in correct decision to treat on the day after consultation (day 2) in the two groups|Number of diagnostics used in the two groups|Practice satisfaction with participation in the project in the two groups|Practice acceptance of the algorithm in the intervention group","University of Copenhagen","All","Child, Adult, Older Adult","Not Applicable","1550","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","UCCAREALG","March 2016","June 2016","June 2016","March 3, 2016",,"July 26, 2016","General Practice Copenhagen Region, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT02698332"
332,"NCT02454309","Cranberry for the Prevention of Urinary Tract Infections",,"Unknown status","No Results Available","Urinary Tract Infection","Dietary Supplement: Cranberry concentrate|Dietary Supplement: Placebo","Number of urinary tract infections","University of British Columbia","Female","18 Years and older   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","H15-00892","July 2015","December 2016","March 2017","May 27, 2015",,"June 1, 2016","The University of British Columbia, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT02454309"
333,"NCT01808755","D Mannose in Recurrent Urinary Tract Infections",,"Completed","Has Results","Recurrent Urinary Tract Infection","Dietary Supplement: D Mannose|Drug: trimethoprim/sulfamethoxazole","Days","IRCCS Policlinico S. Matteo","Female","22 Years to 75 Years   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DMannose UTIs","January 2012","October 2012","October 2012","March 11, 2013","May 21, 2014","May 21, 2014","Urology Department Fondazione IRCCS Policlinico San Matteo, Pavia, Italy",,"https://ClinicalTrials.gov/show/NCT01808755"
334,"NCT03019874","Observational Study With Mode of Action-Analysis of Cystorenal Cranberry Extract in Patients With Recurrent Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infections","Dietary Supplement: Cranberry Extract","Number of urinary tract infections|Quality of life (SF-36)","Charite University, Berlin, Germany","Female","18 Years to 70 Years   (Adult, Older Adult)",,"23","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Cranberry","January 2017","December 2018","February 2019","January 13, 2017",,"February 16, 2021","Charité Hochschulambulanz für Naturheilkunde am Immanuel Krankenhaus, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03019874"
335,"NCT02681263","Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae","TEMO-ESBL","Unknown status","No Results Available","Urinary Tract Infections","Drug: Temocillin","Microbiological efficacy at Test of Cure in patients microbiologically evaluable|Clinical efficacy in clinical evaluable group|Microbiological efficacy|Development of resistance to temocillin during treatment","University Hospital, Grenoble|French National Network of Clinical Research in Infectious Diseases (RENARCI)","All","18 Years and older   (Adult, Older Adult)","Phase 4","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","38RC15.213|2015-004178-14","April 2016","April 2018","September 2018","February 12, 2016",,"June 6, 2018","CH Ajaccio, Ajaccio, France|CH Annecy Genevois, Annecy, France|APHP - Avicenne Hospital, Bobigny, France|APHP - Beaujon Hospital, Clichy, France|CHU de Martinique, Fort De France, France|CHU de Grenoble, Grenoble, France|APHP - Bicêtre Hospital, Kremlin-Bicêtre, France|CHU de Lille, Lille, France|CHU de Nantes, Nantes, France|CHU de Nice, Nice, France|APHP - Bichat Hospital, Paris, France|APHP - Cochin Hospital, Paris, France|APHP - St Louis, Paris, France|CH de Perpignan, Perpignan, France|CHU de Pointe à Pitre, Pointe À Pitre, France|CHU de Poitiers, Poitiers, France|CHU de Rouen, Rouen, France|CHU de Saint Etienne, Saint Etienne, France|CHU de Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT02681263"
336,"NCT05469984","Comparing Two Prophylactic Antibiotic Protocols in Women With Term Prolonged Pre-labor Rupture of Membrane and Preterm Labor",,"Not yet recruiting","No Results Available","Preterm Labor With Preterm Delivery|Premature Rupture of Membranes Prolonged","Drug: Ampicillin Only Product|Drug: ampicillin plus gentamicin","endometritis rate|chorioamnionitis rate|cord blood pH|maternal intrapartum fever|NICU (neonatal intensive care unit) hospitalization length,|rate of neonatal early onset sepsis|neonatal APGAR score|Rate of participants treated with antibiotics during the postpartum period|maternal postpartum hospitalization length|Number of neonate with ventilation support|Number of neonate treated with antibiotics","Western Galilee Hospital-Nahariya","Female","18 Years to 48 Years   (Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","0103-22-NHR","September 2022","September 2024","September 2025","July 22, 2022",,"July 22, 2022",,,"https://ClinicalTrials.gov/show/NCT05469984"
337,"NCT03174795","A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection",,"Completed","No Results Available","Urinary Tract Infections","Drug: RO7079901|Drug: Meropenem","Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval (AUC0-tau) of RO7079901|Total Clearance (CL) of RO7079901|Renal Clearance (CLr) of RO7079901|Maximum Observed Plasma Concentration (Cmax) of RO7079901|Cumulative Amount Excreted in Urine Over the Dosing Interval (Ae) of RO7079901|Fraction Excreted into the Urine (Fe) of RO7079901|Time of Maximum Observed Plasma Concentration (Tmax) of RO7079901|Steady State Volume of Distribution (Vss) of RO7079901|AUC0-tau of Meropenem|CL of Meropenem|CLr of Meropenem|Cmax of Meropenem|Ae of Meropenem|Fe of Meropenem|Tmax of Meropenem|Vss of Meropenem","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NP39596|2016-004478-16","July 11, 2017","December 4, 2017","December 16, 2017","June 5, 2017",,"May 15, 2018","eStudySite, La Mesa, California, United States|Jacksonville Center For Clinical Research, Jacksonville, Florida, United States|Semmelweis University, First Dept of Medicine, Budapest, Hungary|Szent Imre Egyetemi Oktatokorhaz, Budapest, Hungary|Kenezy Gyula Korhaz-Rend. Eges. Szol.; Klinikai Farm. Infek. es Allerg. Intezet, Debrecen, Hungary|Liepaja Regional hospital, Liepaja, Latvia|P.Stradina Kliniska Uni Tes Slimnica; Latvian Center of Nephrology, Riga, Latvia|Riga East clinical university hospital, Riga, Latvia|Klinika Urologii Ogólnej: Collegium Medicum Uniwersytetu Mikołaja Kopernika w Toruniu; Urology, Bydgoszcz, Poland|Szpital Kliniczny Dzieciątka Jezus; Oddział Urologii, Warszawa, Poland|Uniwersytecki Szpital Kliniczny im WAM CSW; Klinika Nefrologii i Transplantologii Nerek, Łódź, Poland|Clinical Center of Serbia; Clinic of Urology, Belgrade, Serbia|Clinical Center Zemun, Belgrade, Serbia|Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia",,"https://ClinicalTrials.gov/show/NCT03174795"
338,"NCT04191785","Evaluation of the Plasmatic NGAL as a Predictive Marker of Renal Injury in Children With Urinary Infection. (Perf-NGAL-IU)","Perf-NGAL-IU","Completed","No Results Available","Urinary Tract Infections","Diagnostic Test: plasmatic NGAl and MRI","Compare plasmatic Neutrophil Gelatinase-Associated Lipocalin (NGAL) with gold standard Reno vesical Magnetic Resonance Imaging (MRI)|Define performance of plasmatic NGAL for the diagnostic of renal abnormality due to a pyelonephritis|Performance and area under the curve (AUC) of C-reactive Protein (CRP) for the diagnostic of pyelonephritis|Performance and area under the curve (AUC) of Procalcitonin (PCT) for the diagnostic of pyelonephritis|Compare the AUC of plasmatic NGAL and CRP|Compare the AUC of plasmatic NGAL and PCT.|Performance of urinary NGAL|Performance of doppler echography","Fondation Lenval","All","4 Years to 18 Years   (Child, Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18-HPNCL-08","March 11, 2020","April 20, 2023","October 26, 2023","December 10, 2019",,"October 30, 2023","Fondation Lenval Hopitaux Pediatriques de Nice Chu Lenval, Nice, France",,"https://ClinicalTrials.gov/show/NCT04191785"
339,"NCT03287089","Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery","NAUTICA","Completed","Has Results","Catheter-Associated Urinary Tract Infection","Drug: Nitrofurantoin 100 MG|Drug: Placebo Oral Tablet","UTI|Adverse Events|Medication Compliance","Wake Forest University Health Sciences","Female","18 Years and older   (Adult, Older Adult)","Phase 4","164","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Pro00022622","September 29, 2017","May 30, 2019","June 1, 2019","September 19, 2017","June 9, 2020","August 9, 2022","Atrium Health, Charlotte, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/89/NCT03287089/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/89/NCT03287089/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03287089"
340,"NCT03568942","Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis)",,"Completed","Has Results","Infections, Bacterial","Drug: Gepotidacin","Area Under the Plasma Concentration-time Curve (AUC) From Zero (Pre-dose) Over the Dosing Interval (AUC[0-tau]) of Gepotidacin|Maximum Plasma Concentration (Cmax) of Gepotidacin|Time of Occurrence of Cmax (Tmax) of Gepotidacin|Apparent Steady State Clearance (CLss/F) of Gepotidacin|Accumulation Ratio (Ro) of Gepotidacin|Plasma Pre-dose Concentration (Ctau) of Gepotidacin|Amount of Drug Excreted Over 12 Hours (Ae12hours) of Gepotidacin|Amount of Drug Excreted in Urine in a Time Interval (Ae[t1-t2]) of Gepotidacin|Percentage of the Given Dose of Drug Excreted in Urine (fe%) of Gepotidacin|Renal Clearance (CLr) of Gepotidacin|Urine Pre-dose Concentration (Ctau) of Gepotidacin|Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious AEs (SAEs)|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Pulse Rate|Change From Baseline in Body Temperature|Change From Baseline in Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB) and Corrected QT Interval Using Fridericia's Formula (QTcF)|Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet Counts|Change From Baseline in Hematology Parameter: Hemoglobin|Change From Baseline in Hematology Parameter: Hematocrit|Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Hemoglobin|Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume|Change From Baseline in Hematology Parameter: Red Blood Cell Count|Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein|Change From Baseline in Clinical Chemistry Parameters: Creatinine and Bilirubin|Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Alkaline Phosphatase (ALP)|Change From Baseline in Clinical Chemistry Parameters: Glucose, Calcium, Chloride, Potassium, Sodium and Urea|Number of Participants With Urinalysis Dipstick Results: Glucose and Nitrites|Number of Participants With Urinalysis Dipstick Results: Ketones|Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase|Number of Participants With Urinalysis Dipstick Results: Occult Blood|Number of Participants With Urinalysis Dipstick Results: Protein|Number of Participants With Abnormal Physical Examination Findings","GlaxoSmithKline|Biomedical Advanced Research and Development Authority","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","22","Industry|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","206899","July 23, 2018","January 7, 2019","January 7, 2019","June 26, 2018","January 7, 2020","June 29, 2020","GSK Investigational Site, La Mesa, California, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/42/NCT03568942/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/42/NCT03568942/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03568942"
341,"NCT02959957","Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infections","Drug: Temocillin|Drug: Cefotaxime","Number of patients with emergence of any of the two following events: Colonisation or infection with C. difficile and/or with Enterobacteriaceae resistant to 3rd generation cephalosporins. Measured in cultures from faecal samples.|Number of patients with clinical cure in each treatment group.|Number of patients with early clinical response.|Bacteriological cure per patient and per pathogen measured as negative urine Culture <1000 CFU/ml.|Early bacteriological response measured as negative urine Culture <1000 CFU/ml.|Rate of patients with diarrhea (≥ 3 loose stools per day)","Håkan Hanberger|Public Health Agency of Sweden","All","18 Years and older   (Adult, Older Adult)","Phase 4","157","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FoHM/UVI 2015|2015-003898-15","May 20, 2016","August 2019","August 2019","November 9, 2016",,"September 16, 2019","Karolinska University Hospital, Solna, Stockholm, Sweden|Helsingborg Hospital, Helsingborg, Sweden|Centralsjukhuset Kristianstad, Kristianstad, Sweden|Linköping University Hospital, Linköping, Sweden|Skåne University Hospital, Lund, Sweden|Vrinnevisjukhuset i Norrköping, Norrköping, Sweden|Capio S:t Görans hospital, Stockholm, Sweden|Sundsvall Hospital, Sundsvall, Sweden|University Hospital of Umeå, Umeå, Sweden|Västmanlands sjukhus i Västerås, Västerås, Sweden|Örebro University Hospital, Örebro, Sweden|Östersund Hospital, Östersund, Sweden",,"https://ClinicalTrials.gov/show/NCT02959957"
342,"NCT05630833","A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)","EAGLE-J","Recruiting","No Results Available","Urinary Tract Infections","Drug: Gepotidacin|Drug: Nitrofurantoin|Drug: Placebo","Number of participants with therapeutic response (combined per participant clinical and microbiological response) at the TOC Visit|Number of participants with therapeutic response to gepotidacin compared to nitrofurantoin at the TOC Visit|Number of participants with clinical outcome and response at the TOC visit|Number of participants with per participant microbiological outcome and response at the TOC visit|Number of participants with therapeutic response in female participants with acute uncomplicated cystitis who have qualifying uropathogen(s) resistant to two or more specific classes of antimicrobials|Number of participants with clinical outcome and response in female participants with acute uncomplicated cystitis who have qualifying uropathogen(s) resistant to two or more specific classes of antimicrobials|Number of participants with microbiological outcome and response in female participants with acute uncomplicated cystitis who have qualifying uropathogen(s) resistant to two or more specific classes of antimicrobials|Number of participants with Investigator assessment of clinical response at the TOC Visit|Number of participants with Treatment-Emergent Adverse Events (TEAEs)|Number of participants with Serious Adverse Events (SAEs)|Number of participants with Adverse Events of Special Interest (AESIs)|Change from baseline in hematology parameters: neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count and platelet count (Giga cells per liter)|Change from baseline in hematology parameter: Red Blood Cell (RBC) count (Trillion cells per liter)|Change from baseline in hematology parameter: Hemoglobin (Hb) (Grams per liter)|Change from baseline in hematology parameter: Hematocrit (Proportion of red blood cells in blood)|Change from baseline in hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters)|Change from baseline in hematology parameter: Mean Corpuscular Hemoglobin (MCH) (Picograms)|Change from baseline in clinical chemistry parameters: Blood urea nitrogen [BUN], glucose [non-fasting], calcium, chloride, sodium, magnesium, phosphate, and potassium levels (Millimoles per liter)|Change from baseline in clinical chemistry parameters: Total bilirubin, direct bilirubin and creatinine levels (Micromoles per liter)|Change from baseline in clinical chemistry parameters: albumin and total protein levels (Gram per liter)|Change from baseline in clinical chemistry parameters: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase levels (International units per liter)|Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury [mmHg])|Change from baseline in pulse rate (Beats per minute)|Change from baseline in body temperature (Degrees Celsius)|Change from baseline in heart rate (Beats per minute)|Change from baseline in electrocardiogram parameters: PR Interval, QRS Duration, QT Interval, QT interval corrected for heart rate according Fridericia's formula (QTcF) and Bazett's formula (QTcB) (Milliseconds [msec])|Plasma concentration of gepotidacin|Urine concentration of gepotidacin","GlaxoSmithKline","Female","12 Years and older   (Child, Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","214144","January 11, 2023","September 11, 2023","October 9, 2023","November 30, 2022",,"February 10, 2023","GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Saitama, Japan",,"https://ClinicalTrials.gov/show/NCT05630833"
343,"NCT02249273","Diagnostic Tools in Patients With a Suspected Urinary Tract Infection in Primary Care",,"Completed","No Results Available","Urinary Tract Infections","Other: Diagnostic approaches","Percentage of patients with appropriate antibiotic treatment decisions for each diagnostic approach during the consultation.|Number of days until clinical cure.|Number of days until microbiological cure.|Prevalence of resistant strains","University of Copenhagen","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UC-CARE-001","December 2014","December 2015","December 2015","September 25, 2014",,"October 9, 2017","Lægerne Simonsen og Grubbe, Copenhague, Denmark",,"https://ClinicalTrials.gov/show/NCT02249273"
344,"NCT05545137","Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection",,"Recruiting","No Results Available","Uncomplicated Urinary Tract Infection","Drug: Pivmecillinam hydrochloride tablets|Drug: Fosfomycin Tromethamine Granules","Change in urinary tract infection symptom score|Urine white blood cell count|Urine culture pathogen count at visit|Safety variables","Benova (Tianjin) Innovative medicine Research Co., Ltd.|Greenpine Pharma Group Co., ltd.","Female","18 Years and older   (Adult, Older Adult)","Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CS1046","September 29, 2022","December 31, 2024","December 31, 2024","September 19, 2022",,"January 2, 2024","Beijing hospital, Beijing, Beijing, China|Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China|Guangxi Zhuang Autonomous Region People's Hospital, Nanning, Guangxi, China|The second hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Wuhan Central Hospital, Wuhan, Hubei, China|Xiangya Humanity Rehabilitation hospital, Changsha, Hunan, China|Loudi Central Hospital, Loudi, Hunan, China|Yueyang people's Hospital, Yueyang, Hunan, China|Jiangsu Provincial Hospital of Integrated Chinese and Western Medicine, Nanjing, Jiangsu, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Yantai Yuhuangding hospital, Yantai, Shandong, China",,"https://ClinicalTrials.gov/show/NCT05545137"
345,"NCT01381549","GSK2251052 in Complicated Urinary Tract Infection",,"Terminated","Has Results","Infections, Urinary Tract","Drug: GSK2251052|Drug: imipenem-cilastatin|Other: Placebo","Change From Baseline in Clinical Laboratory Parameters- Albumin and Total Protein|Change From Baseline in Clinical Laboratory Parameters- Creatinine Clearance, Estimated (CCE)|Change From Baseline in Clinical Laboratory Parameters- Creatinine, Direct Bilirubin and Total Bilirubin|Change From Baseline in Clinical Laboratory Parameters- Calcium, Carbon-dioxide (C02) Content/Bicarbonate, Chloride, Glucose, Potassium, Sodium and Urea/Blood Urea Nitrogen (BUN)|Change From Baseline in Clinical Laboratory Parameters- Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase and Gamma Glutamyl Transferase (GGT)|Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)|Number of Participants With Abnormal Electrocardiogram (ECG) Findings|Summary of Vital Signs: Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Summary of Vital Signs- Mean Heart Rate|Summary of Vital Signs- Mean Respiration Rate|Summary of Vital Signs- Mean Temperature|Therapeutic Response at the Test of Cure Visit|Change From Baseline in Hematology Parameters- Hematocrit|Change From Baseline in Hematology Parameters- Mean Corpuscle Hemoglobin (MCH)|Change From Baseline in Hematology Parameters- Mean Corpuscle Volume (MCV)|Change From Baseline in Hematology Parameters- Red Blood Cell (RBC) Count and Reticulocytes|Change From Baseline in Hematology Parameters- Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC)|Change From Baseline in Hematology Parameters- Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Total Neutrophils and White Blood Cell Count (WBC)|Microbiological Response at the End of IV Therapy Visit, Test of Cure Visit and Late Follow-Up Visit|Clinical Response at the End of IV Therapy Visit, Test of Cure Visit and Late Follow-Up Visit|Therapeutic Response (Combined Clinical and Microbiological Response) at the End of IV Visit and Late Follow-Up Visit|Maximum Plasma Concentration (Cmax) of GSK2251052|Area Under the Concentration Time Curve (AUC) of GSK2251052|Time to Cmax (Tmax) of GSK2251052|Cmax of GSK2251052 Using Non-intensive PK Sampling|AUC of GSK2251052 Using Non-intensive PK Sampling|Tmax of GSK2251052 Using Non-intensive PK Sampling|Cmax of GSK2251052 Using Intensive PK Sampling|AUC of GSK2251052 Using Intensive PK Sampling|Tmax of GSK2251052 Using Intensive PK Sampling","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","114688","June 28, 2011","March 6, 2012","March 6, 2012","June 27, 2011","September 8, 2017","September 8, 2017","GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Council Bluffs, Iowa, United States|GSK Investigational Site, Topeka, Kansas, United States|GSK Investigational Site, Corsicana, Texas, United States|GSK Investigational Site, Chicoutimi, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Suresnes, France|GSK Investigational Site, Toulouse cedex 9, France|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Chaidari, Greece|GSK Investigational Site, Goudi, Athens, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Irkutsk, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Rostov-on-Don, Russian Federation|GSK Investigational Site, Smolensk, Russian Federation|GSK Investigational Site, St'Petersburg, Russian Federation|GSK Investigational Site, Alicante, Spain|GSK Investigational Site, Elche (Alicante), Spain|GSK Investigational Site, Getafe/Madrid, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Murcia, Spain|GSK Investigational Site, Pama de Mallorca, Spain",,"https://ClinicalTrials.gov/show/NCT01381549"
346,"NCT04228081","MicroUDxTM: a Rapid Diagnostic Tool That Will Prevent Death and Disability From Common Infections","MicroUDxTM","Not yet recruiting","No Results Available","Bacterial Urinary Tract Infection",,"Assay ID Validation|Susceptibility - anti-microbial susceptibility of new assay versus standard laboratory methods|Turn-around-time to bacterial detection and susceptibility","University of Calgary|Alberta Health services","All","Child, Adult, Older Adult",,"10000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","REB19-00442","August 1, 2022","August 1, 2023","October 15, 2023","January 14, 2020",,"June 2, 2022","University of Calgary, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04228081"
347,"NCT04880343","Clinical Study to Evaluate the Efficacy of the Dietary Supplement UROMANNOSA® in Women With Recurrent Lower Urinary Tract Infections",,"Suspended","No Results Available","Lower Urinary Tract Infection","Dietary Supplement: Group (A)|Dietary Supplement: Group (B)","UTI Recurrence|Number of symptomatic UTIs","Carmen Gonzalez Enguita|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","Female","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","FJD-URO-19-001","January 26, 2021","January 26, 2024","January 26, 2024","May 10, 2021",,"September 29, 2023","Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04880343"
348,"NCT05573334","Vaginal Care System for Menopausal Women With Urinary Tract Infections",,"Recruiting","No Results Available","Urinary Tract Infections|Vaginal Flora Imbalance","Device: BioNourish","Change in vaginal microbiome composition|Change in vaginal pH|Frequency of UTI|Frequency of UTI with estrogen-use covariate","Vaginal Biome Science|ChristianaCare","Female","up to 89 Years   (Child, Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MUTI0822","July 10, 2023","February 2025","September 2025","October 10, 2022",,"July 19, 2023","Center for Urogynecology & Pelvic Reconstructive Surgery, Newark, Delaware, United States",,"https://ClinicalTrials.gov/show/NCT05573334"
349,"NCT03868969","Clinical Efficacy of Fosfomycin Trometamol Per os in the Treatment of Documented Male Urinary Tract Infections With ESBL-producing Enterobacteriaceae With ESBL Producing Enterobacteriaceae and Resistance Associated With Fluoroquinolones and Cotrimoxazole (FOSF'HOM)","FOSF'HOM","Unknown status","No Results Available","Urinary Tract Infections","Drug: Fosfomycin Oral Suspension","Number of patients with no signs of urinary tract infection|Number of patients with persistence of clinical signs of urinary tract infection|Number of patients with reoccurrence of clinical signs of urinary tract infection and positive urinary analysis|Number of patients with digestive, cutaneous disturbance","Centre Hospitalier Universitaire de Besancon","Male","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","API/2017/90","April 2019","April 2021","September 2021","March 11, 2019",,"March 11, 2019","BOUILLER, Besançon, France",,"https://ClinicalTrials.gov/show/NCT03868969"
350,"NCT05913180","Vitamin C Effectiveness in Preventing Urinary Tract Infections After Gynecological Surgeries",,"Not yet recruiting","No Results Available","Catheter-Associated Urinary Tract Infection","Drug: Ascorbic Acid 1000 MG|Drug: Placebo","Incidence of UTI|Asymptomatic UTI","American University of Beirut Medical Center|Moscow State University of Medicine and Dentistry","Female","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","62/137-H/77-2023-25-2295","June 15, 2023","August 15, 2025","August 15, 2025","June 22, 2023",,"June 22, 2023",,,"https://ClinicalTrials.gov/show/NCT05913180"
351,"NCT01834391","Diagnosis of Subclinical Urinary Tract Infections Using Advanced Microbiome Survey Techniques in High Risk Trauma Patients",,"Completed","No Results Available","Urinary Tract Infection",,"Identify of bacteria, genes and proteins that are highly predictive of UTI development|Biomarker candidates for UTIs recalcitrant to antibiotic treatment.|Morbidity|Mortality","Mayo Clinic|J. Craig Venter Institute","All","65 Years and older   (Older Adult)",,"129","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","12-010185","March 2013","September 2013","September 2015","April 17, 2013",,"April 28, 2016","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01834391"
352,"NCT00161330","Oral vs Initial Intravenous Antibiotic Treatment of Urinary Tract Infections in Children: a RCT",,"Terminated","No Results Available","Urinary Tract Infections","Drug: oral amoxicilline/clavulanic acid|Drug: iv ceftriaxone","1. Duration of fever (>38°),|2. Sterilization of the urine,|3. Reduction of the blood inflammatory indices,|4. Incidence of renal scarring documented at 12 month.","University of Padova|Regione Veneto|IL Sogno di Stefano","All","2 Months to 6 Years   (Child)","Phase 3","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRIS 1","June 2000",,"July 2005","September 12, 2005",,"December 14, 2020",,,"https://ClinicalTrials.gov/show/NCT00161330"
353,"NCT02302092","An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections","FLORUS","Terminated","Has Results","Urinary Tract Infection","Drug: Flomoxef|Drug: Cefepime","Percentage of Participants Who Achieved Resolution of All Clinical Symptoms of a Complicated Urinary Tract Infection (cUTI) at the End of Treatment (EOT) Visit|Percentage of Participants With Microbiological Success at the EOT and Test-of-Cure (TOC) Visits|Percentage of Participants Who Achieved Clinical Resolution of Symptoms of a cUTI at Visit 3, TOC and Late Follow-up (LFU) Visits|Percentage of Participants With Microbiologic Eradication of the Unique Pathogen at the EOT and TOC Visits|Percentage of Participants With Microbiologic Persistence of the Unique Pathogen at the EOT and TOC Visits|Percentage of Participants With a New Infection at the EOT and TOC Visits|Percentage of Participants With a Superinfection at the EOT and TOC Visits|Number of Participants With Serious Adverse Events (SAEs) and Treatment-Emergent-Adverse Events (TEAEs)|Number of Participants With Clinically Significant Abnormal Laboratory Values|Number of Participants With Clinically Significant Change in Vital Signs|Number of Participants With Clinically Significant Change in Physical Examination Findings","Takeda","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","13","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FLOMOXEF_301|U1111-1154-2448","December 1, 2015","February 2, 2016","December 15, 2016","November 26, 2014","October 27, 2017","October 27, 2017","Moscow, Russian Federation|Rostov-on-Don, Russian Federation|Saint Petersburg, Russian Federation|Volgograd, Russian Federation|Yaroslavl, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02302092"
354,"NCT04315129","Smart Catheter: A Novel Biosensor for Early Detection of Catheter Associated Urinary Tract Infection",,"Completed","No Results Available","Catheter-Associated Urinary Tract Infection","Diagnostic Test: Smart Catheter Biosensor","Time difference of diagnosis|Sensitivity|Specificity|False Positive Rate|False Negative Rate","Imperial College London","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","17SM4299","April 1, 2018","July 31, 2021","July 31, 2021","March 19, 2020",,"September 2, 2021","St Mary's Hospital, London, Greater LOndon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04315129"
355,"NCT03658291","Clinical Study of Sanjin Tablets for the Treatment of Acute Simple Lower Urinary Tract Infection",,"Unknown status","No Results Available","Urinary Tract Infection Lower Acute","Drug: Sanjin tablets|Drug: Sanjin tablets simulants|Drug: Levofloxacin","The lower urinary tract infection symptoms of 252 participants will be assessed|The urine leukocyte of 252 participants will be assessed|The bacteriological examination of 252 participants|The recurrence rate of subjects who is cured in 252 participants will be assessed by lower urinary tract infection symptoms|The recurrence rate of subjects who is cured in 252 participants will be assessed by urine leukocyte|The recurrence rate of subjects who is cured in 252 participants will be assessed by bacteriological examination","China Academy of Chinese Medical Sciences|Xiyuan Hospital of China Academy of Chinese Medical Sciences|Shanghai University of Traditional Chinese Medicine|Guangdong Provincial Hospital of Traditional Chinese Medicine|Hubei Hospital of Traditional Chinese Medicine|Chengdu University of Traditional Chinese Medicine|Yunnan Provinical Hospital of Traditional Chinese Medicine","All","18 Years to 50 Years   (Adult)","Phase 4","252","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Sanjin tablets","January 1, 2019","June 30, 2019","December 31, 2019","September 5, 2018",,"November 26, 2018",,,"https://ClinicalTrials.gov/show/NCT03658291"
356,"NCT01531023","Treatment of Extended Spectrum Betalactamase Producing Bacteria Causing Urinary Tract Infections in General Practice",,"Completed","No Results Available","Urinary Tract Infections",,"Number of days until symptomatic resolution|Number of patients with ESBL producing bacteria detected in a urine sample taken two weeks after finishing initial treatment|Number of patients who received a second treatment regime in the follow-up period","University of Oslo|University Hospital of North Norway|St. Olavs Hospital|Helse Stavanger HF|The Hospital of Vestfold|Vestre Viken Hospital Trust|University Hospital, Akershus|Unilabs","All","16 Years and older   (Child, Adult, Older Adult)",,"168","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2011/2214-3","April 2013","September 2016","September 2016","February 10, 2012",,"October 31, 2016","Vestre Viken Hospital Trust, Bærum, Norway|University Hospital Akershus, Lørenskog, Norway|Unilabs, Skien, Norway|Helse Stavanger HF, Stavanger, Norway|University Hospital of North Norway, Tromsø, Norway|St Olavs Hospital, Trondheim, Norway|Vestfold Hospital Trust, Tønsberg, Norway",,"https://ClinicalTrials.gov/show/NCT01531023"
357,"NCT01478620","Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)",,"Completed","Has Results","Urinary Tract Infection","Drug: Canephron® N","Incidence of Adverse Drug Reactions During 7-day Treatment of uUTI Symptoms With Canephron® N|Incidence of Adverse Drug Reactions During the 7-day Treatment of uUTI Symptoms With Canephron® N in the Subgroup of Patients Who Take Canephron® N for at Least 7 Days|Proportion of Patients With no Symptoms Worse Than Mild on Day 7 (i.e. Responders)|Severity of uUTI Symptoms on Day 7|Severity of uUTI Symptoms on Day 37|Duration of uUTI Symptoms|Proportion of Patients Who Require Antibiotic Treatment Until Day 7|Proportion of Patients With Early Recurrence [Days] After Clearance of uUTI Symptoms|Time to First Early Recurrence [Days] After Clearance of uUTI Symptoms","Bionorica SE","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","125","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CanUTI2|2011-000838-11","October 2011","May 2012","August 2012","November 23, 2011","October 13, 2014","February 27, 2019","Kiev Regional City Hospital, Kiev, Ukraine",,"https://ClinicalTrials.gov/show/NCT01478620"
358,"NCT05670964","Evaluation of the Impact of the UPLUG Device Onto the Infection Rate of Indwelling Central Venous Catheters in Patients Undergoing Chronic Hemodialysis","UPLUG-EVIDENCE","Recruiting","No Results Available","Renal Disease, Chronic|Hemodialysis Catheter Infection","Device: Connecting valve system|Device: Central haemodialysis Venous Catheter","Number of bacterial infection within the 16 weeks of treatment period|Number of clinical suspicion of bacterial infection during the 16 weeks of the treatment period, evaluated at Day 29, Day 57, Day 85 and Day 113|Number of positive blood culture during the 16 weeks of the treatment period evaluated at Day 29, Day 57, Day 85 and Day 113|Number of dysfunction estimated by blood flow rate (Qb) evaluated at Day 29, Day 57, Day 85 and Day 113|Number of adverse events during the 16 weeks of treatment period evaluated at D29, D57, D85 and D113|Number of infections other than bacterial during the 16 weeks of treatment period evaluated at Day 29, Day 57, Day 85 and Day 113|The patient satisfaction|Number of patients with at least one bacterial infection during the 16 weeks of treatment period evaluated at Day 29, Day 57, Day 85 and Day 113|Rate of infections other than bacterial evaluated at Day 29, Day 57, Day 85 and Day 113|Rate of unplanned hospitalisation at Day 113 and at the end of the study|Time spent by session by the nurse to connect the patient at Day 1, Day 29, Day 57, Day 85 and Day 113|The nurse satisfaction for the patients in UPLUG arm","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","464","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP211510","October 16, 2023","April 2025","September 2025","January 4, 2023",,"October 25, 2023","Hôpital Tenon, service de Néphrologie, Paris, France",,"https://ClinicalTrials.gov/show/NCT05670964"
359,"NCT01543347","Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL)/AmpC Enterobacteriaceae","TEA","Withdrawn","No Results Available","Urinary Tract Infection","Drug: Temocillin","Microbiological cure|Clinical cure|Development of resistance during treatment|Infection relapses monitored over 4-6 weeks|Monitoring of AE|ESBL & AmpC fecal carriage (optional)|Incidence of C. difficile infection","Belpharma s.a.","All","21 Years and older   (Adult, Older Adult)","Phase 4","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMO-07001|2008-005912-41","February 2012","November 2012","November 2012","March 5, 2012",,"January 29, 2013","Birmingham Heartlands Hospital, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01543347"
360,"NCT04671290","Temocillin Versus Carbapenems for Urinary Tract Infection Due to ESBL-producing Enterobacteriaceae","TEMO-BLSE","Completed","No Results Available","Urinary Tract Infection Bacterial","Other: Any intervention","Rate of clinical cure|Kinetic of fever defervescence|Inflammatory biomarkers|Length of hospital stay|Relapse of UTI|Loss to follow-up, re-hospitalization, and mortality (safety endpoints)","Centre Hospitalier Annecy Genevois|APHP|Sorbonne University|Hopitaux Civils de Colmar|Hopital Foch|CH Annecy Genevois","All","18 Years and older   (Adult, Older Adult)",,"144","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","19-10","January 1, 2015","October 31, 2019","October 31, 2019","December 17, 2020",,"December 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04671290"
361,"NCT03354598","Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women",,"Completed","Has Results","Uncomplicated Urinary Tract Infections","Drug: Sulopenem-Etzadroxil/Probenecid|Drug: Ciprofloxacin","Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Overall Success|Percentage of Microbiologic Modified Intent to Treat Susceptible (Micro-MITTS) Participants With Overall Success|Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Patients With Microbiologic Success","Iterum Therapeutics, International Limited","Female","18 Years and older   (Adult, Older Adult)","Phase 3","1671","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IT001-301","August 1, 2018","January 16, 2020","January 20, 2020","November 28, 2017","December 17, 2020","January 12, 2021","Medical Facility, Birmingham, Alabama, United States|Medical Facility, Phoenix, Arizona, United States|Medical Facility, Tolleson, Arizona, United States|Medical Facility, Cerritos, California, United States|Medical Facility, Chula Vista, California, United States|Medical Facility, Fullerton, California, United States|Medical Facility, La Mesa, California, United States|Medical Facility, Los Angeles, California, United States|Medical Facility, San Diego, California, United States|Medical Facility, Sylmar, California, United States|Medical Facility, Washington, District of Columbia, United States|Medical Facility, Bradenton, Florida, United States|Medical Facility, Clearwater, Florida, United States|Medical Facility, Doral, Florida, United States|Medical Facility, Edgewater, Florida, United States|Medical Facility, Hialeah, Florida, United States|Medical Facility, Lauderdale Lakes, Florida, United States|Medical Facility, Miami Springs, Florida, United States|Medical Facility, Miami, Florida, United States|Medical Facility, Miami, Florida, United States|Medical Facility, Miami, Florida, United States|Medical Facility, Miami, Florida, United States|Medical Facility, Miami, Florida, United States|Medical Facility, Miami, Florida, United States|Medical Facility, Miami, Florida, United States|Medical Facility, Miami, Florida, United States|Medical Facility, New Port Richey, Florida, United States|Medical Facility, Ormond Beach, Florida, United States|Medical Facility, Palmetto Bay, Florida, United States|Medical Facility, Saint Petersburg, Florida, United States|Medical Facility, Winter Haven, Florida, United States|Medical Facility, Atlanta, Georgia, United States|Medical Facility, Norcross, Georgia, United States|Medical Facility, Perry, Georgia, United States|Medical Facility, Lake Charles, Louisiana, United States|Medical Facility, Metairie, Louisiana, United States|Medical Facility, New Orleans, Louisiana, United States|Medical Facility, Las Vegas, Nevada, United States|Medical Facility, Las Vegas, Nevada, United States|Medical Facility, Brooklyn, New York, United States|Medical Facility, Raleigh, North Carolina, United States|Medical Facility, Hugo, Oklahoma, United States|Medical Facility, Easley, South Carolina, United States|Medical Facility, Lancaster, South Carolina, United States|Medical Facility, Myrtle Beach, South Carolina, United States|Medical Facility, Austin, Texas, United States|Medical Facility, Austin, Texas, United States|Medical Facility, Carrollton, Texas, United States|Medical Facility, Corpus Christi, Texas, United States|Medical Facility, Dallas, Texas, United States|Medical Facility, Houston, Texas, United States|Medical Facility, Houston, Texas, United States|Medical Facility, Pearland, Texas, United States|Medical Facility, Plano, Texas, United States|Medical Facility, Sugar Land, Texas, United States|Medical Facility, Bountiful, Utah, United States|Medical Facility, Saint George, Utah, United States|Medical Facility, Salt Lake City, Utah, United States|Medical Facility, Salt Lake City, Utah, United States|Medical Facility, South Jordan, Utah, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/98/NCT03354598/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/98/NCT03354598/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03354598"
362,"NCT05066854","INterest of the Negative Predictive Value of Integrons in Choosing a Narrow-spectrum Empirical anTibiotic Treatment vs Usual Empirical Antibiotic Treatment for Urinary Tract infectionS in the PEDiatric Emergency Department","INVICTUS PED","Recruiting","No Results Available","Urinary Tract Infections in Children","Procedure: integron research|Procedure: usual practice","Recovery|patients treated|Duration treatment|Antibiotic treatment changes|Adaptation of antibiotherapy with the AST result|Resistance of enterobacteria|Predictive values of the integrons|Apyrexia|Early repetition of urinary tract infection|Treatment interruption for adverse effects|Time spent in the pediatric emergency department","University Hospital, Limoges","All","3 Months to 18 Years   (Child, Adult)","Not Applicable","232","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","87RI20_0029 (INVICTUS PED)","October 18, 2022","November 18, 2025","November 18, 2025","October 4, 2021",,"September 14, 2023","Bordeaux university Hospital, Bordeaux, France|Limoges university Hospital, Limoges, France|Montpellier university Hospital, Montpellier, France|Toulouse university Hospital, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT05066854"
363,"NCT00093054","Cranberry Juice for Treatment of Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infections","Drug: Cranberry juice|Dietary Supplement: Placebo cranberry juice","Culture","National Center for Complementary and Integrative Health (NCCIH)","Female","18 Years to 40 Years   (Adult)","Phase 2|Phase 3","319","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01AT002086","November 2004","March 2008","December 2009","October 1, 2004",,"May 5, 2015","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00093054"
364,"NCT03032510","Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections","IGNITE3","Completed","Has Results","Complicated Urinary Tract Infections","Drug: Eravacycline|Drug: Ertapenem|Drug: Placebo|Drug: Levofloxacin","Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the EOI Visit|Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the Test-Of-Cure (TOC) Visit|Proportion of Participants in the ITT Population With Favorable Clinical Outcomes at TOC Visit","Tetraphase Pharmaceuticals, Inc.|La Jolla Pharmaceutical Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","1205","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TP-434-021","January 2017","December 2017","January 2018","January 26, 2017","October 2, 2019","January 6, 2022","Fullerton, California, United States|Los Angeles, California, United States|Torrance, California, United States|Coral Gables, Florida, United States|Doral, Florida, United States|Miami, Florida, United States|Columbus, Georgia, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Baytown, Texas, United States|Graz, Austria|Linz, Austria|Salzburg, Austria|Pleven, Bulgaria|Plovdiv, Bulgaria|Razgrad, Bulgaria|Ruse, Bulgaria|Smyadovo, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Veliko Tarnovo, Bulgaria|Tallinn, Estonia|Tartu, Estonia|Voru, Estonia|K'ut'aisi, Georgia|T'bilisi, Georgia|Baja, Hungary|Budapest, Hungary|Miskolc, Hungary|Nagykanizsa, Hungary|Nyiregyhaza, Hungary|Sopron, Hungary|Szentes, Hungary|Tatabanya, Hungary|Jelgava, Latvia|Riga, Latvia|Valmiera, Latvia|Chisinau, Moldova, Republic of|Braşov, Romania|Bucharest, Romania|Craiova, Romania|Oradea, Romania|Arkhangel'sk, Russian Federation|Moscow, Russian Federation|Pyatigorsk, Russian Federation|Rostov-on-the-Don, Russian Federation|Saint Petersburg, Russian Federation|Smolensk, Russian Federation|Vsevolozhsk, Russian Federation|Yaroslavl', Russian Federation|Nitra, Slovakia|Poprad, Slovakia|Presov, Slovakia|Svidnik, Slovakia|Zilina, Slovakia|Chernihiv, Ukraine|Chernivtsi, Ukraine|Dnipro, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|L'viv, Ukraine|Lviv, Ukraine|Mykolaiv, Ukraine|Odesa, Ukraine|Poltava, Ukraine|Uzhgorod, Ukraine|Uzhorod, Ukraine|Vinnytsya, Ukraine|Zaporizhia, Ukraine|Zhytomyr, Ukraine","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/10/NCT03032510/Prot_001.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/10/NCT03032510/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03032510"
365,"NCT01014013","Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)",,"Completed","Has Results","Urinary Tract Infection","Drug: ertapenem sodium (MK0826)|Drug: Comparator: ceftriaxone sodium","Microbiological Response Assessment Profile|The Number of Patients Who Experience Any Drug-related Adverse Experiences Leading to Discontinuation of Parenteral Study Drug and the Number of Patients With Any Drug-related Serious Adverse Experiences (AEs) During Parenteral Treatment|Clinical Response Assessment Profile","Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","271","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0826-055|MK0826-055|2009_690","April 2008","February 2009","February 2009","November 16, 2009","March 1, 2010","March 22, 2017",,,"https://ClinicalTrials.gov/show/NCT01014013"
366,"NCT01913860","Supporting the Improvement and Management of Prescribing for Urinary Tract Infections (SIMPle)","SIMPle","Completed","No Results Available","Uncomplicated Urinary Tract Infection","Behavioral: Improving GP antibiotics prescribing behaviour","Relative number of prescriptions of first line antimicrobials|Relative number of antimicrobial prescriptions for UTI|Number of delayed prescriptions for UTI","National University of Ireland, Galway, Ireland|Health Research Board, Ireland","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2577","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","ICE/2011/10","September 2013","March 2014","September 2014","August 1, 2013",,"December 5, 2014","NUI Galway, Galway, Ireland",,"https://ClinicalTrials.gov/show/NCT01913860"
367,"NCT04200807","Non-invasive Measurement of Neonatal Central and Peripheral Hemodynamics","NInHeDyNeo","Completed","No Results Available","Pre-Term|Neonatal Infection","Device: Ultrasound Cardiac Output Monitor (USCOM 1A)","Weight measurement|Height measurement|Chest and head circumference|Blood pressure measurement|Pulse rate measurement|Near- Infrared Spectroscopy for regional blood flow|Echocardioscopy for left ventricular outflow tract diameter|Echocardioscopy to measure velocity time integral|USCOM examination","Vilnius University","All","26 Weeks to 44 Weeks   (Child)",,"163","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NCPKV-2017","September 12, 2017","September 30, 2020","September 30, 2020","December 16, 2019",,"April 21, 2021","Vilnius University, Neonatology Centre, Vilnius, Lithuania",,"https://ClinicalTrials.gov/show/NCT04200807"
368,"NCT03801213","Evaluation of Urine Samples Obtained by Bladder Stimulation for the Diagnosis of Urinary Tract Infection in Infants","EEStiVeN","Completed","No Results Available","Urinary Tract Infection Bacterial","Device: urinary catheterization|Procedure: manual bladder stimulation technique","Bacterial contamination rates of urine samples per bladder stimulation and urinary catheterization|Pain of bladder stimulation|Pain of bladder catheterization|Diagnostic performance of the dipstick urine test|Risk factors associated with the failure of the bladder stimulation technique","Fondation Lenval","All","up to 6 Months   (Child)","Not Applicable","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18-HPNCL-03","December 12, 2019","December 12, 2023","December 12, 2023","January 11, 2019",,"February 26, 2024","CH Antibes Juans les Pins, Antibes, France|CH Grasse, Grasse, France|CHRU Lille, Lille, France|Hôpitaux Pédiatriques de Nice CHU-Lenval, Nice, France",,"https://ClinicalTrials.gov/show/NCT03801213"
369,"NCT00177112","Impact of Sterilization Technique on Incidence of Urinary Tract Infection After Cystoscopy",,"Completed","No Results Available","Urinary Tract Infections","Procedure: clean patient preparation for cystoscopy|Procedure: sterile patient preparation for cystoscopy","To verify that the incidence rate of urinary tract infections after a routine outpatient cystoscopy is the same for non-sterile (clean) and sterile procedural techniques","University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 3","275","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0412M65852|3519A","June 2005",,"October 2007","September 15, 2005",,"February 4, 2008","VAMC Minneapolis, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00177112"
370,"NCT00668122","Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections","EMERON","Completed","No Results Available","Urinary Tract Infection","Drug: Cipro XR (Ciprofloxacin, BAYQ3939)|Drug: Cipro IR (Ciprofloxacin, BAYQ3939)","Bacteriological response 5 to 9 days after the last dose of study medication (TOC visit).|Bacteriological outcome during treatment|Bacteriological outcome at follow-up|Clinical outcome during treatment|Clinical outcome at the test-of-cure visit|Clinical outcome at follow-up|Adverse event collection","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","212","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11454","March 2004",,"January 2006","April 28, 2008",,"June 30, 2009","Monza, Milano, Italy|Camposampiero, Padova, Italy|Orbassano, Torino, Italy|Busto Arsizio, Varese, Italy|Bassano del Grappa, Vicenza, Italy|Alessandria, Italy|Bari, Italy|Benevento, Italy|Bergamo, Italy|Bologna, Italy|Caserta, Italy|Catania, Italy|Chieti, Italy|Firenze, Italy|Frosinone, Italy|Genova, Italy|Genova, Italy|L'Aquila, Italy|Mantova, Italy|Massa Carrara, Italy|Messina, Italy|Milano, Italy|Napoli, Italy|Palermo, Italy|Perugia, Italy|Potenza, Italy|Reggio Calabria, Italy|Reggio Emilia, Italy|Rimini, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Sassari, Italy|Siracusa, Italy|Torino, Italy|Trieste, Italy|Varese, Italy|Verona, Italy",,"https://ClinicalTrials.gov/show/NCT00668122"
371,"NCT02321800","A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections","APEKS-cUTI","Completed","Has Results","Urinary Tract Infections","Drug: Cefiderocol|Drug: Imipenem/cilastatin","Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure|Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Early Assessment|Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at End of Treatment|Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Follow-up|Percentage of Participants With Microbiological Eradication at Test of Cure|Percentage of Participants With Microbiological Eradication at Early Assessment|Percentage of Participants With Microbiological Eradication at End of Treatment|Percentage of Participants With Microbiological Eradication at Follow-up|Percentage of Participants With Microbiological Eradication at Test of Cure Per Uropathogen|Percentage of Participants With Microbiological Eradication at Early Assessment Per Uropathogen|Percentage of Participants With Microbiological Eradication at End of Treatment Per Uropathogen|Percentage of Participants With Microbiological Eradication at Follow-up Per Uropathogen|Percentage of Participants With Clinical Response at Test of Cure|Percentage of Participants With Clinical Response at Early Assessment|Percentage of Participants With Clinical Response at End of Treatment|Percentage of Participants With Clinical Response at Follow-up|Percentage of Participants With Clinical Response at Test of Cure Per Uropathogen|Percentage of Participants With Clinical Response at Early Assessment Per Uropathogen|Percentage of Participants With Clinical Response at End of Treatment Per Uropathogen|Percentage of Participants With Clinical Response at Follow-up Per Uropathogen|Plasma Concentration of Cefiderocol|Urine Concentration of Cefiderocol|Number of Participants With Adverse Events","Shionogi|Shionogi Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","452","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1409R2121","February 5, 2015","July 26, 2016","August 16, 2016","December 22, 2014","December 12, 2019","December 12, 2019",,,"https://ClinicalTrials.gov/show/NCT02321800"
372,"NCT00771316","Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)",,"Terminated","Has Results","Urinary Tract Infections","Drug: MK0826 (ertapenem)|Drug: Comparator: meropenem","Number of Participants With Serious Urinary Tract Infection With an Overall Microbiological Response to MK0826 Compared to Meropenem at the 5 to 9 Day Post Therapy Early Follow-up Visit|Number of Participants With Serious Urinary Tract Infection With a Clinical Response to MK0826 Compared to Meropenem at Discontinuation of Intravenous Therapy (DCIV)|Number of Participants With Serious Urinary Tract Infection With an Overall Microbiological Response to MK0826 Compared to Meropenem at Discontinuation of Intravenous Therapy (DCIV)","Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","6","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0826-054|MK0826-054|2008_562","December 2008","June 2009","June 2009","October 13, 2008","July 9, 2010","March 21, 2017",,,"https://ClinicalTrials.gov/show/NCT00771316"
373,"NCT00216853","A Study of Vaginal MicroFlora and Immune Profiles of Patients With Recurrent Urinary Tract Infection",,"Completed","No Results Available","Urinary Tract Infections",,,"Lawson Health Research Institute|Natural Sciences and Engineering Research Council, Canada","Female","20 Years to 80 Years   (Adult, Older Adult)",,"44","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","R-03-202|9875E","September 2003","June 2006","March 2007","September 22, 2005",,"April 16, 2009","St. Joseph's Health Centre, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00216853"
374,"NCT02424461","Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection","PROSTASHORT","Unknown status","No Results Available","Acute Male Urinary Tract Infection","Drug: Ceftriaxone|Drug: Ofloxacine|Drug: Placebo of ofloxacine","Success defined by resolution of fever|Intestinal carriage of antimicrobial-resistant Gram-negative bacilli|Incidence and severity of adverse drug events|Recurrent UTI","Assistance Publique - Hôpitaux de Paris","Male","18 Years and older   (Adult, Older Adult)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P120116|AOM12268","February 2015","February 2020","December 2020","April 23, 2015",,"February 11, 2020","Saint Louis hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT02424461"
375,"NCT00318591","Comparative Study of Intermittent Catheters and Occurrence of Urinary Tract Infections",,"Completed","Has Results","Urinary Tract Infections","Device: SpeediCath|Device: Conveen Uncoated","Occurrence of Symptomatic Urinary Tract Infections (UTIs)|UTIs With Bacteriuria >=100 Colony Forming Units (CFU)/ml|Nurse Evaluation of Catheters - Overall Satisfaction|Patient or Caregiver's Evaluation of Catheters - Overall Satisfaction|Nurse Time Spent on Catheterization Procedure|Device-related or Possibly Device-related AEs|Number of Participants With One or More Urinary Tract Infection","Coloplast A/S","All","18 Years and older   (Adult, Older Adult)","Not Applicable","219","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","DK046CC","April 2006","October 2009","October 2009","April 27, 2006","May 25, 2011","February 10, 2021","Rancho Los Amigos National Rehabilitation Center, Downey, California, United States|Santa Clara Valley Medical Center, San Jose, California, United States|Craig Hospital, Englewood, Colorado, United States|University of Miami, Miami, Florida, United States|Shepherd Center, Atlanta, Georgia, United States|Boston Medical School, Boston, Massachusetts, United States|University of Michigan Helaths Systems, Ann Arbor, Michigan, United States|Mayo Clinic, Saint Mary Hospital MB3CF Rehabilitation, Rochester, Minnesota, United States|Kessler Institute for Rehabilitation, West Orange, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|The Institute for Rehabilitation and Research (TIRR), Houston, Texas, United States|University of Alberta, Edmonton, Alberta, Canada|G.F.Strong Rehabilitation Centre, Vancouver, British Columbia, Canada|Parkwood Rehabilitation Centre, London, Ontario, Canada|Toronto Rehabilitation Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00318591"
376,"NCT02568800","Prolonged Infusion Cefepime and Nosocomial Infections","PICNIC","Unknown status","No Results Available","Urinary Tract Infection|Respiratory Tract Infection","Drug: Prolonged Cefepime Infusion|Drug: Usual Cefepime Infusion","Death|Duration of hospital stay|Intensive care unit (ICU) admission|Duration of intensive care unit (ICU) stay|Treatment change|Treatment success|Time to clinical stability","Hospital de Clinicas de Porto Alegre","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-0392","October 2015","March 2016","September 2016","October 6, 2015",,"October 16, 2015","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT02568800"
377,"NCT05153694","Infectious Complications After Cystectomy: A Prospective Observational Study",,"Recruiting","No Results Available","Bladder Cancer|Infections|Infection, Bacterial|Infection, Hospital|Infection Wound|Urinary Tract Infections|Urinary Bladder Diseases|Urinary Tract Disease","Procedure: Cystectomy","Infectious Complications","Ludwig-Maximilians - University of Munich","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RCXINFLMU","December 1, 2021","November 30, 2023","November 30, 2024","December 10, 2021",,"December 10, 2021","Urology Department - LMU Klinikum, Munich, Outside U.S./Canada, Germany",,"https://ClinicalTrials.gov/show/NCT05153694"
378,"NCT00379951","A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)",,"Completed","No Results Available","Urinary Tract Infection","Drug: ertapenem sodium","Safety and tolerability|Compare signs and symptoms of urinary tract infections at 14 days after treatment compared with signs and symptoms before treatment","Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","107","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0826-048|2006_036","June 2005","May 2006","May 2006","September 25, 2006",,"February 17, 2017",,,"https://ClinicalTrials.gov/show/NCT00379951"
379,"NCT04831840","Recurrent Urinary Tract Infections and the Microbiome",,"Recruiting","No Results Available","Recurrent Urinary Tract Infection",,"Proportion of uropathogens|Proportion of patients negative for repeat testing","University of Miami","Female","18 Years to 90 Years   (Adult, Older Adult)",,"180","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20201198","May 26, 2021","June 1, 2024","June 1, 2024","April 5, 2021",,"April 12, 2023","Holy Cross Hospital, Fort Lauderdale, Florida, United States|University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04831840"
380,"NCT05509413","DEFLAGYN® Vaginal Gel and Spontaneous Remission and Regression of Unclear Cervical Smears and HPV High-risk Infections","HPV-VG1","Recruiting","No Results Available","Cervix Dysplasia|HPV Infection","Device: DEFLAGYN vaginal gel","Rate of hr-HPV-positive cervical smears|Rate of progression|Rate of newly diagnosed dysplasia|Complications","Ruhr University of Bochum","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","168","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HPV-VG1","November 8, 2022","May 2024","November 2024","August 22, 2022",,"January 26, 2023","Marien Hospital Herne, Herne, North Rhine-Westphalia, Germany",,"https://ClinicalTrials.gov/show/NCT05509413"
381,"NCT05309317","Preventing Catheter-Associated Urinary Tract Infections With a Virtual Simulation Game","CAUTI-VSG","Completed","No Results Available","Catheter-Associated Urinary Tract Infection|Nurse's Role","Other: Virtual Simulation Game for the Prevention of Catheter-Associated Urinary Tract Infections|Other: Ongoing education","Knowledge Level|Skill level|Opinions of the experimental group about the virtual simulation game","Gazi University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","57440","May 21, 2022","May 28, 2022","October 25, 2022","April 4, 2022",,"March 1, 2024","Gazi University, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT05309317"
382,"NCT01067768","Reduction of Catheter-associated Urinary Tract Infection With a Daily Nursing Review of the Indication",,"Completed","Has Results","Urinary Tract Infections|Urinary Tract; Accessory","Other: Daily review","Rate of Catheter-associated Urinary Tract Infection|Catheter Days","Hospital Pablo Tobón Uribe","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1209","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","5100-66592","November 2009","September 2010","September 2010","February 12, 2010","August 4, 2011","March 5, 2019","Hospital Pablo Tobon Uribe, Medellin, Antioquia, Colombia",,"https://ClinicalTrials.gov/show/NCT01067768"
383,"NCT05826067","Study of E. Coli Isolates From Recurrent Urinary Tract Infections","Per-UTI","Not yet recruiting","No Results Available","Urinary Tract Infections|Patients With Suprabubic Catheter|Patients With Nephrostomy Catheter","Other: collection of bacterial strains","collection of longitudinal E. coli to be used for fundamental research","Université Catholique de Louvain","All","18 Years and older   (Adult, Older Adult)",,"45","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Per-UTI","April 20, 2023","December 31, 2024","December 31, 2024","April 24, 2023",,"April 26, 2023",,,"https://ClinicalTrials.gov/show/NCT05826067"
384,"NCT00261248","Vaccine for Recurrent Urinary Tract Infections in Women",,"Completed","No Results Available","Recurrent Urinary Tract Infections in Women","Biological: Immunization with inactivated bacteria","Rate of re-infection over the study|Infection-free status at completion of study","University of Wisconsin, Madison|National Institutes of Health (NIH)","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","75","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","1996-295|DK-30808","November 1996",,"December 2003","December 2, 2005",,"October 5, 2015","University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00261248"
385,"NCT00801021","Treatment and/or Prevention of Urinary Tract Infections","UTI","Completed","No Results Available","Cystitis|Urinary Tract Infections","Drug: Frio Mouth Rinse","The primary efficacy endpoint is the reduction of the baseline pathogen at the Days 7 to 10 ""Test of Cure"" visit.|The secondary efficacy endpoint of microbiological evaluation classified into four categories (i.e., Eradication, Persistence, Superinfection, and New Infection)","Biomedical Development Corporation|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Baylor College of Medicine","Female","18 Years and older   (Adult, Older Adult)","Phase 1","3","Industry|NIH|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","H-23281|1R41DK082089-01","December 2008","June 2009","June 2009","December 3, 2008",,"March 8, 2010","Ben Taub General Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00801021"
386,"NCT01505634","Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)",,"Completed","Has Results","Urinary Tract Infections|Pyelonephritis","Drug: Relebactam 250 mg|Drug: Relebactam 125 mg|Drug: imipenem/cilastatin 500 mg|Drug: Placebo to relebactam|Drug: Ciprofloxacin","Percentage of Participants With a Favorable Microbiological Response at Completion of IV Study Therapy|Percentage of Participants With an Elevated Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) Laboratory Value That Was Greater Than or Equal to 5 Times the Upper Limit of Normal (ULN)|Percentage of Participants With Elevated AST or ALT Laboratory Values ≥ 3 Times the ULN, as Well as Elevated Total Bilirubin ≥ 2 Times the ULN, and Alkaline Phosphatase Values That Were < 2 Times the ULN|Percentage of Participants With at Least 1 Adverse Event (AE)|Percentage of Participants With Any Serious Adverse Event (SAE)|Percentage of Participants With Any Drug-related AE|Percentage of Participants With a Drug-related SAE|Percentage of Participants Who Discontinued IV Study Therapy Due to an AE|Percentage of Participants Who Discontinued IV Study Therapy Due to a Drug-related AE|Percentage of Participants With Specific AEs With Incidence of >= 4 Participants in One Treatment Group|Percentage of Participants With a Favorable Microbiological Response at Completion of IV Study Therapy Who Had Imipenem-resistant, Gram-negative cUTI Infections.|Percentage of Participants With a Favorable Microbiological Response at Early Follow-up|Percentage of Participants With a Favorable Clinical Response at Completion of IV Study Therapy|Percentage of Participants With a Favorable Clinical Response at Early Follow-up|Percentage of Participants With a Favorable Clinical Response at Late Follow-up|Percentage of Participants With a Favorable Microbiological Response at Late Follow-up","Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","302","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","7655-003|2011-005707-32|MK-7655-003","May 16, 2012","July 28, 2015","July 28, 2015","January 6, 2012","May 24, 2019","May 24, 2019",,,"https://ClinicalTrials.gov/show/NCT01505634"
387,"NCT05553652","The Effect of ASTARTE™ on Recurrent Urinary Tract Infection","rUTI","Recruiting","No Results Available","Recurrent Urinary Tract Infection","Dietary Supplement: ASTARTE™ oral capsules|Dietary Supplement: Placebo oral capsules","Reduction of UTI cases|Number of UTI after intervention|UTI symptoms|Change of vaginal microbiome|Change of gut microbiome","Hvidovre University Hospital","Female","18 Years to 40 Years   (Adult)","Not Applicable","720","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","H-22014666","September 19, 2022","August 1, 2024","December 1, 2027","September 23, 2022",,"September 23, 2022","Gastrounit, Copenhagen University Hospital Hvidovre, Hvidovre, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT05553652"
388,"NCT00678028","Association Between Deficiency of MBL (Mannose-Binding Lectin) and Polymorphisms in MBL2 Gene to Urinary Tract Infection",,"Completed","No Results Available","Recurrent Urinary Tract Infections",,,"HaEmek Medical Center, Israel","Female","18 Years to 50 Years   (Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","0080-07-EMC","February 2008",,,"May 15, 2008",,"April 23, 2009","Ha'Emek Medical Center, Afula, Israel",,"https://ClinicalTrials.gov/show/NCT00678028"
389,"NCT03140085","Bacteriophages for Treating Urinary Tract Infections in Patients Undergoing Transurethral Resection of the Prostate",,"Completed","No Results Available","Intravesical Bacteriophage Treatment for Urinary Tract Infections","Biological: PYO Phage|Drug: Antibiotics|Other: Sterile bacteriology media","Normalisation of urine culture|Urine culture|Bladder diary|Pain diary|IPSS questionnaire","Balgrist University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","97","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","02/283","June 2, 2017","December 14, 2018","December 14, 2018","May 4, 2017",,"March 21, 2019","National Center of Urology, Tbilisi, Georgia",,"https://ClinicalTrials.gov/show/NCT03140085"
390,"NCT05723601","Preference of Women With Recurrent Urinary Tract Infection for Vaginal Estradiol Tablet vs Cream",,"Recruiting","No Results Available","Recurrent Urinary Tract Infection","Drug: Estradiol vaginal cream|Drug: Estradiol Vaginal Tablet","Patient preference rate for vaginal estradiol cream versus tablet|Change in vaginal and urinary microbiome Lactobacillus amount with the use of vaginal estradiol tablet versus cream|Change in overall satisfaction, convenience, side effects, and effectiveness of vaginal estradiol cream vs tablet using Treatment Satisfaction Questionnaire for Medication (TSQM)|Changes in adherence scores","Wake Forest University Health Sciences","Female","20 Years to 80 Years   (Adult, Older Adult)","Phase 4","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","IRB00092892","January 12, 2024","January 2025","January 2025","February 10, 2023",,"January 19, 2024","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT05723601"
391,"NCT03612297","Selective Reporting of Antibiotic Susceptibility Test Results in Urinary Tract Infections in the Outpatient Setting",,"Unknown status","No Results Available","Urinary Tract Infections","Diagnostic Test: Selective reporting of Antibiotic Susceptibility Tests","Impact of selective reporting of AST for E. coli positive urine cultures in outpatient setting on the prescription of broad-spectrum antibiotics frequently used on UTIs (amoxicillin-clavulanate, third generation cephalosporins and fluoroquinolones)|Laboratory expenditures (in euros) for the implementation of the intervention|Satisfaction of GPs and laboratory staffs about selective reporting of AST, assessed by a visual analog scale","Central Hospital, Nancy, France|University of Lorraine","All","18 Years and older   (Adult, Older Adult)",,"64000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PREPS-17-0026","September 1, 2018","December 31, 2019","April 30, 2020","August 2, 2018",,"August 2, 2018",,,"https://ClinicalTrials.gov/show/NCT03612297"
392,"NCT04846803","Bacterial Interference for Preventing Recurrent Urinary Tract Infection - New Ways of Treatment","BIrUTI","Recruiting","No Results Available","Recurrent Urinary Tract Infections","Biological: ABU bladder lavage|Biological: Saline bladder lavage","The number of UTI events in the follow-up period|Time to first UTI after the intervention|Quality of life by standard Questionnaires_ICIQ-OABqol 08/04|O´Leary-Sant Voiding and Pain symptom score|EQ-5D-5L|CRF|Hospitalization|Complications (bleeding, pain)|Microbiological diagnostics: Etiology, resistance|Creatinin|Leukocytes and neutrofilocytes|Natrium and kalium|CRP","Odense University Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","BIrUTI","January 9, 2024","August 1, 2025","December 1, 2026","April 15, 2021",,"January 23, 2024","Aarhus University Hospital, Aarhus N, Denmark|Odense University Hospital, Odense C, Denmark",,"https://ClinicalTrials.gov/show/NCT04846803"
393,"NCT05652374","Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard Study","GT RACING","Recruiting","No Results Available","Recurrent Urinary Tract Infection","Device: Ialuril 50ml Prefill|Drug: Nitrofurantoin","Number of urinary tract infections|Time to first urinary tract infection|Global Assessment of Improvement|Antibiotics resistance|Cost-effectiveness: medical consumption questionnaire|Cost-effectiveness: productivity cost questionnaire|Therapy specific patient reported outcomes (symptoms & bother)|General quality of life questionnaire (mobility, self-care, daily activities, pain/discomfort, anxiety/depression)","Radboud University Medical Center|IBSA Institut Biochimique SA|Goodlife Pharma B.V.","Female","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","111802|NL76892.091.21","October 20, 2022","October 2025","October 2025","December 15, 2022",,"December 15, 2022","Radboudumc, Nijmegen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT05652374"
394,"NCT05895578","Effect of a Probiotic on the Urinary Tract Microbiota of Participants With Recurrent Urinary Tract Infection.","PROBUTI","Recruiting","No Results Available","Recurrent Urinary Tract Infection","Dietary Supplement: Probiotic|Dietary Supplement: Probiotic + placebo|Dietary Supplement: Placebo","Evaluate the number of participants with a positive urine culture|Evaluate the total bacterial count in urine samples.|Number of UTI episodes|Infection free participants (%)|Elapsed time until the 1st episode of UTI.|Elapsed time between the 1st and 2nd episode of UTI.|Elapsed time between the 2nd and 3rd episode of UTI.|Duration of UTI episodes.|The number of participants which associate sexual activity with the UTI episodes|Number of present symptoms during new UTI episodes.|Number of participants with dysuria.|Duration of dysuria.|Number of participants with pollakiuria|Duration of pollakiuria|Number of participants with urinary urgency.|Duration of urinary urgency.|Number of participants with tenesmus.|Duration of tenesmus.|Number of participants with hematuria.|Duration of hematuria|Number of participants with dyspareunia|Duration of dyspareunia|Number of participants with pelvic pain|Duration of pelvic pain|Number of participants with fever (Tª ≥ 38ºC).|Duration of fever (Tª ≥ 38ºC).|Number of participants with cloudy and smelly urine|Duration of cloudy and smelly urine|Number of antibiotics administered for the UTI episode.|Duration of antibiotic treatment for the UTI episode.|Number of antibiotic treatments administered during new UTI episodes.|Duration of antibiotic treatments administered during new UTI episodes.|Microbiome composition of stool samples determined by 16S sequencing.|Microbiota composition of urine samples determined by culture techniques.|Metabolomic profile of urine samples.","ProbiSearch SL","Female","18 Years to 55 Years   (Adult)","Not Applicable","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UTI/23.01","June 21, 2023","September 2024","November 2024","June 8, 2023",,"January 17, 2024","Hospital La Moraleja, Madrid, Spain|Hospital La Zarzuela, Madrid, Spain|Hospital San Francisco de Asís, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT05895578"
395,"NCT03293485","Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)",,"Completed","Has Results","Complicated Intra-abdominal Infection|Complicated Urinary Tract Infection","Drug: Imipenem+Cilastatin/Relebactam","Percentage of Participants Experiencing ≥1 Adverse Events (AE)|Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (AE)|Percentage of Complicated Intra-Abdominal Infection (cIAI) Participants With Favorable Clinical Response at End of Therapy Visit|Percentage of Complicated Urinary Tract Infection (cUTI) Participants With Favorable Overall Microbiological Response at End of Therapy Visit|Percentage of Complicated Intra-Abdominal Infection (cIAI) Participants With Favorable Clinical Response at Test of Cure Visit|Percentage of Complicated Urinary Tract Infection (cUTI) Participants With Favorable Overall Microbiological Response at Test of Cure Visit","Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","83","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7655A-017|173738","October 4, 2017","September 14, 2018","September 14, 2018","September 26, 2017","September 17, 2019","February 12, 2021","Nagoya Ekisaikai Hospital ( Site 1724), Nagoya, Aichi, Japan|Toyota Memorial Hospital ( Site 1708), Toyota, Aichi, Japan|Medical Corporation Chiyukai Fukuoka Shin Mizumaki Hospital ( Site 1710), Onga-gun, Fukuoka, Japan|Shin Yukuhashi Hospital ( Site 1722), Yukuhashi, Fukuoka, Japan|National Hospital Organization Fukuyama Medical Center ( Site 1706), Fukuyama, Hiroshima, Japan|Fukuyama City Hospital ( Site 1721), Fukuyama, Hiroshima, Japan|KKR Sapporo Medical Center ( Site 1728), Sapporo, Hokkaido, Japan|Sano Hospital ( Site 1701), Kobe, Hyogo, Japan|National Hospital Organization Mito Medical Center ( Site 1729), Higashiibaraki-gun, Ibaraki, Japan|Medical Corporation Tokushukai Koga General Hospital ( Site 1712), Koga, Ibaraki, Japan|Ishikawa Prefectural Central Hospital ( Site 1707), Kanazawa, Ishikawa, Japan|National Hospital Organization Kanazawa Medical Center ( Site 1716), Kanazawa, Ishikawa, Japan|Kawahara Clinic ( Site 1719), Aira, Kagoshima, Japan|National Hospital Organization Yokohama Medical Center ( Site 1702), Yokohama, Kanagawa, Japan|National Hospital Organization Mie Chuo Medical Center ( Site 1727), Tsu, Mie, Japan|Japan Labour Health And Safety Organization Tohoku Rosai Hospital ( Site 1714), Sendai, Miyagi, Japan|National Hospital Organization Sendai Medical Center ( Site 1723), Sendai, Miyagi, Japan|Suwa Red Cross Hospital ( Site 1705), Suwa, Nagano, Japan|National Hospital Organization Nagasaki Medical Center ( Site 1718), Omura, Nagasaki, Japan|National Hospital Organization Osaka Minami Medical Center ( Site 1715), Kawachinagano, Osaka, Japan|National Hospital Organization Utsunomiya National Hospital ( Site 1711), Utsunomiya, Tochigi, Japan|National Hospital Organization Minami Wakayama Medical Center ( Site 1725), Tanabe, Wakayama, Japan|Yamanashi Prefectural Central Hospital ( Site 1703), Kofu, Yamanashi, Japan|Fukuiken Saiseikai Hospital ( Site 1704), Fukui, Japan|Medical Corporation Chiyukai Fukuoka Wajiro Hospital ( Site 1709), Fukuoka, Japan|Medical Corporation Shingenkai Kawahara Urological Clinic ( Site 1726), Kagoshima, Japan|Medical Corporation Seifukai Yagi Clinic ( Site 1720), Kagoshima, Japan|National Hospital Organization Kumamoto Medical Center ( Site 1713), Kumamoto, Japan|National Hospital Organization Oita Medical Center ( Site 1717), Oita, Japan","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/85/NCT03293485/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03293485"
396,"NCT02439632","A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control",,"Completed","No Results Available","Acute Lower Urinary Tract Infection","Drug: prulifloxacin|Drug: Levofloxacin|Drug: Prulifloxacin Placebo|Drug: Levofloxacin Placebo","The efficacy of prulifloxacin film-coated tablet was meaured by the number of patient have been cured|The safety of prulifloxacin film-coated tablet was measured by the number fo AE and SAE","Lee's Pharmaceutical Limited","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Prulifloxacin aulut ZK-004","February 2014","March 2015","July 2015","May 12, 2015",,"July 16, 2015","Peking Medical Union Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02439632"
397,"NCT05472779","Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections","TAPER","Recruiting","No Results Available","Recurrent Urinary Tract Infection","Drug: Periurethral application of estradiol cream|Drug: Intravaginal application of estradiol cream","Percentage of participants who are UTI-free at 6 months|Change from baseline in urinary symptoms at 6 months|Change from baseline in vaginal symptoms at 6 months|Change from baseline in sexual function at 6 months|Amount of estrogen cream used|Participant experience with use of estrogen cream|Change from baseline in vaginal pH at 6 months|Change from baseline in vaginal maturation index at 6 months|Change from baseline in Vaginal and urinary Lactobacillus levels at 6 months|Change from baseline in Vaginal and urinary E. coli levels at 6 months","Stephanie Wang Zuo|University of Pittsburgh","Female","18 Years and older   (Adult, Older Adult)","Phase 2","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","STUDY22010147","January 3, 2023","July 31, 2024","January 1, 2025","July 25, 2022",,"January 9, 2024","UPMC Lemieux Sports Complex, Cranberry Township, Pennsylvania, United States|UPMC Hamot, Erie, Pennsylvania, United States|University of Pittsburgh Medical Center-Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|UPMC Passavant-McCandless, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05472779"
398,"NCT00921024","Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections",,"Completed","Has Results","Complicated Urinary Tract Infection","Drug: CXA-101|Drug: Ceftazidime","Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-Treat (mMITT) Population|Microbiological Response at the TOC Visit in the Microbiologically Evaluable (ME) Population.","Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","129","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","7625-001|CXA 101-03","June 30, 2009","February 25, 2010","March 11, 2010","June 16, 2009","January 15, 2015","October 18, 2018","Healthcare Partners Medical Group, Los Angeles, California, United States|Compass Research, LLC, Orlando, Florida, United States|Atlanta Institute for Medical Research, Inc., Decatur, Georgia, United States|Infectious Disease of Indiana, PSC, Indianapolis, Indiana, United States|Mississippi Medical Research, LLC, Picayune, Mississippi, United States|Great Falls Clinic, LLP, Butte, Montana, United States|Remington-Davis, Inc. Clinical Research, Columbus, Ohio, United States|Kreiskrankenhaus Backnang, Backnang, Germany|URO Forschungs GmbH, Berlin, Germany|Uniklinikum Giessen, Giessen, Germany|Evangelisches Krankenhaus Giessen Urologie, Giessen, Germany|Universitätsklinikum Schleswig Holstein Campus Lübeck, Lübeck, Germany|Brüderkrankenhaus St. Josef Paderborn, Paderborn, Germany|Urologische Klinik Dr. Castringius München-Planegg, Planegg, Germany|Samodzielny Publiczny Szpital Kliniczny nr 4 Katedra i Klinika Nefrologii, Lublin, Poland|Wojewódźki Szpital Specjalistyczny nr 1 Oddział Chorób Wewnętrznych, Tychy, Poland|Szpital Bielański im.Ks. Jerzego Popiełuszki Samodzielny Publiczny Zakład Opieki Zdrowotnej IV Kliniczny Oddzial Chorób Wewnętrznych, Warszawa, Poland|Szpital Kliniczny Dzieciątka Jezus-Centrum Leczenia Obrażeń Klinika Urologii Ogólnej, Onkologicznej Czynnościowej, Warszawa, Poland|Szpital Praski p.w. Przemienienia Pańskiego Samodzielny Publiczny Zakład Opieki Zdrowotnej ll Oddział Wewnętrznych, Warszawa, Poland|Wojewódźki Szpital Specjalistyczny Oddział Nefrologiczny, Wrocław, Poland|Samodzielny Publiczny Szpital Wojewódźki im. Papieża Jana Pawła ll Oddział Wewnętrznych Nefrologiczno-Endokrynologiczny ze Stacją Dializ, Zamość, Poland",,"https://ClinicalTrials.gov/show/NCT00921024"
399,"NCT06295627","The Analysis of Factors Causing Indwelling Urinary Catheter-related Infections in ICU Patients and Their Nursing Strategies",,"Completed","No Results Available","Catheter-associated Urinary Tract Infection","Other: There were no interventions in retrospective analysis","How many patients in the infected group and how many patients in the non-infected group had bladder irrigation|How many patients in the infected group and how many patients in the non-infected group were given enema|How many times the indwelling catheter was changed in patients in the infected group and patients in the non-infected group respectively|How many patients in the infected group and the non-infected group had co-diabetes","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","All","15 Years and older   (Child, Adult, Older Adult)",,"291","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","SYSKY-2024-115-01","January 30, 2023","September 30, 2023","January 15, 2024","March 6, 2024",,"March 6, 2024","Sun Yat-Sen Memorial Hospital, Canton, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT06295627"
400,"NCT01650051","Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)",,"Completed","No Results Available","Uncomplicated Urinary Tract Infections","Drug: Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|Drug: Phenazopyridine Hydrochloride Tables, USP 200 mg","Self-assessments","Amneal Pharmaceuticals, LLC|Symbio, LLC","Female","18 Years and older   (Adult, Older Adult)","Phase 3","424","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AM-PHN-004","February 2012","February 2013","February 2014","July 26, 2012",,"June 26, 2014","Symbio, LLC, Port Jefferson, New York, United States",,"https://ClinicalTrials.gov/show/NCT01650051"
401,"NCT01644643","Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens",,"Completed","Has Results","Complicated Urinary Tract Infection|Complicated Intra-abdominal Infection","Drug: Ceftazidime - Avibactam ( CAZ-AVI)|Drug: Best Available Therapy|Drug: Metronidazole","Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set|Clinical Response at End of Treatment (EOT) in mMITT Analysis Set.|Clinical Response at Follow-up 1 (FU1) in mMITT Analysis Set|Clinical Response at Follow-up 2 (FU2) in mMITT Analysis Set|Clinical Response at EOT in Extended Microbiologically Evaluable (EME) at EOT Analysis Set.|Clinical Response at TOC in EME at TOC Analysis Set.|Clinical Response at FU1 in EME at FU1 Analysis Set.|Clinical Response at FU2 in EME at FU2 Analysis Set|Clinical Cure at TOC by Baseline Gram-negative Pathogen in mMITT Analysis Set|Clinical Cure at TOC by Baseline Gram-negative Pathogen in EME at TOC Analysis Set|Clinical Cure at TOC by Previously Failed Treatment Class in mMITT Analysis Set|Clinical Cure at EOT by Previously Failed Treatment Class in EME at EOT Analysis Set|Clinical Cure at TOC by Previously Failed Treatment Class in EME at TOC Analysis Set|Clinical Cure at FU1 by Previously Failed Treatment Class in EME at FU1 Analysis Set|Clinical Cure at FU2 by Previously Failed Treatment Class in EME at FU2 Analysis Set|Per-patient Microbiological Response at EOT in mMITT Analysis Set|Per-patient Microbiological Response at TOC in mMITT Analysis Set|Per-patient Microbiological Response at FU1 in mMITT Analysis Set|Per-patient Microbiological Response at FU2 in mMITT Analysis Set|Per-patient Microbiological Response at EOT in EME at EOT Analysis Set|Per-patient Microbiological Response at TOC in EME at TOC Analysis Set|Per-patient Microbiological Response at FU1 in EME at FU1 Analysis Set|Per-patient Microbiological Response at FU2 in EME at FU2 Analysis Set|Per-pathogen Microbiological Response of Gram-negative Pathogen at EOT in mMITT Analysis Set|Per-pathogen Microbiological Response of Gram-negative Pathogen at TOC in mMITT Analysis Set|Per-pathogen Microbiological Response of Gram-negative Pathogen at FU1 in mMITT Analysis Set|Per-pathogen Microbiological Response of Gram-negative Pathogen at FU2 in mMITT Analysis Set|Per-pathogen Microbiological Response of Gram-negative Pathogen at EOT in EME at EOT Analysis Set|Per-pathogen Microbiological Response of Gram-negative Pathogen at TOC in EME at TOC Analysis Set|Per-pathogen Microbiological Response of Gram-negative Pathogen at FU1 in EME at FU1 Analysis Set|Per-pathogen Microbiological Response of Gram-negative Pathogen at FU2 in EME at FU2 Analysis Set|Per-pathogen Microbiological Response of Gram-negative Pathogen at TOC by CAZ-AVI MIC in mMITT Analysis Set|Per-pathogen Microbiological Response of Gram-negative Pathogen at TOC by CAZ-AVI MIC in EME at TOC Analysis Set|The Reason for Treatment Change/Discontinuation in mMITT Analysis Set|The 28 Days All Cause Mortality Rate in mMITT Analysis Set|The 28 Days All Cause Mortality Rate in EME at TOC Analysis Set|Plasma Concentrations for Ceftazidime and Avibactam - cIAI in PK Analysis Set|Plasma Concentrations for Ceftazidime and Avibactam - cUTI in PK Analysis Set","Pfizer|Forest Laboratories","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","345","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D4280C00006|2012-000726-21","January 2013","September 2014","September 2014","July 19, 2012","December 14, 2015","September 29, 2017","Research Site, Shreveport, Louisiana, United States|Research Site, Lima, Ohio, United States|Research Site, El Talar, Argentina|Research Site, La Plata, Argentina|Research Site, Pazardzhik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Turnovo, Bulgaria|Research Site, Slavonski Brod, Croatia|Research Site, Zagreb, Croatia|Research Site, Praha 5, Czechia|Research Site, Tours, France|Research Site, Nazareth, Israel|Research Site, Petach Tikva, Israel|Research Site, Ramat-Gan, Israel|Research Site, Tel Aviv, Israel|Research Site, Seoul, Korea, Republic of|Research Site, Guadalajara, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Cusco, Peru|Research Site, Surco, Peru|Research Site, Manila, Philippines|Research Site, Szczecin, Poland|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Irkutsk, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.-Petersburg,, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Johannesburg, South Africa|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Diyarbakir, Turkey|Research Site, Istanbul, Turkey|Research Site, Dnipropetrovsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01644643"
402,"NCT04285320","Antibiotic Bladder Instillations vs. Oral Suppression for the Treatment of Recurrent Urinary Tract Infections",,"Unknown status","No Results Available","Recurrent Urinary Tract Infection","Drug: Intravesical antibiotic instillation|Drug: Antibiotic oral suppressive therapy","The percentage of participants with urinary tract infections following treatment course|The rate of antibiotic resistance of pathogens in participants developing urinary tract infections after completing the treatment course.|the percentage of patients developing side effects of the 2 treatments","Atlantic Health System","Female","Child, Adult, Older Adult","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1565199","March 2021","April 2023","April 2023","February 26, 2020",,"January 14, 2021",,,"https://ClinicalTrials.gov/show/NCT04285320"
403,"NCT02246270","Recurrent Urinary Tract Infections and Heparin (RUTIH Trial)",,"Recruiting","No Results Available","Recurrent Urinary Tract Infections","Drug: Intravesical Heparin|Other: Placebo","Change from Baseline in UTI rate at 6 months|Change from Baseline in median time to UTI recurrence at 6 months","University of Oklahoma","Female","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","8481","November 28, 2017","December 2024","December 2024","September 22, 2014",,"December 13, 2023","University of Oklahoma-Tulsa OB/GYN Dept and OU-Physicians, Tulsa, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT02246270"
404,"NCT01388413","Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder","PACHIU","Completed","No Results Available","Neurogenic Bladder|Urinary Tract Infection","Drug: Weekly Oral Cyclic Antibiotic programme","Number of symptomatic UTIs|The number of feverish UTIs|The number of hospitalizations|The duration of UTI-related hospitalizations|The tolerance level to the Weekly Oral Cyclic Antibiotic Programme, measured by any adverse effects to antibiotics|The global antibiotic consumption.|The number of urine culture negative|The emergence of multi-resistant bacteria in urine (cultures), digestive bacteria (anal swabs), oro-pharynx bacteria (nasal swabs), and semi-quantitative research of multi-resistant bacteria in the stool.|the quality of life","University Hospital, Tours","All","18 Years and older   (Adult, Older Adult)","Phase 4","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PHRI06-LB/PACHIU|2010-021241-44|A101183-72|2010-R31","August 2011","January 2016","February 2017","July 6, 2011",,"February 24, 2017","University Hospital, Raymond Poincaré / APHP, Garches, France|University Hospital, St Jacques / NANTES, Nantes, France|University Hospital, Pontchaillou / RENNES, Rennes, France|University Hospital, Bretonneau / TOURS, Tours, France",,"https://ClinicalTrials.gov/show/NCT01388413"
405,"NCT03788967","Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","ADAPT-PO","Completed","Has Results","Complicated Urinary Tract Infection|Acute Pyelonephritis","Drug: TBPM-PI-HBr|Drug: Ertapenem|Drug: Dummy Infusion|Drug: Dummy tablets","Overall Response (Combined Clinical Cure and Microbiological Eradication) at Test-of-Cure (TOC) in Micro Intent-to-Treat Population|Number of Participants With Treatment Emergent Adverse Events (TEAEs) in The Safety Population|Overall Response (Combined Clinical Cure Plus Microbiological Eradication) At Test-Of-Cure (TOC) In The Microbiologically Evaluable (ME) - TOC Population|Clinical Cure at End-of-Treatment (EOT), TOC, and Sustained Clinical Cure at Late Follow-Up (LFU) Days in the Micro-ITT Populations|Clinical Cure at EOT Days the Clinically Evaluable (CE-EOT) Populations|Clinical Cure at TOC in the CE-TOC Populations|Sustained Clinical Cure at LFU in the CE-LFU Populations|Clinical Cure at EOT in the ME-EOT Populations|Clinical Cure at TOC Days in the ME-TOC Populations|Sustained Clinical Cure at LFU in the ME-LFU Population|By-Patient Microbiological Eradication at EOT, TOC, and Sustained Microbiological Eradication at LFU Days in the Micro-ITT Population|By-Pathogen Microbiological Eradication Rate at EOT in the Micro-ITT Population|By-Pathogen Microbiological Eradication Rate at TOC in the Micro-ITT Population|By-Pathogen Sustained Microbiological Eradication Rate at LFU in the Micro-ITT Population (m-ITT)|By-Patient Microbiological Eradication at EOT in the ME-EOT Populations|By-Patient Microbiological Eradication at TOC in the ME-TOC Population|By-Patient Sustained Microbiological Eradication at LFU Days in the ME-LFU Populations|By-pathogen Microbiological Eradication Rate in Participants at EOT in the ME-EOT Populations|By-pathogen Microbiological Eradication Rate in Participants at TOC in the ME-TOC Populations|By-pathogen Sustained Microbiological Eradication Rate in Participants at LFU in the ME-LFU Populations|Overall Response Rate (Combined Clinical Cure Plus Microbiological Eradication) In Subgroup Including: Stratified Infection Category|Overall Response Rate (Combined Clinical Cure Plus Microbiological Eradication) at TOC In Subgroup Stratified Age Category|Overall Response Rate (Combined Clinical Cure Plus Microbiological Eradication) at TOC In Subgroup Including Region|Time (Days) to Resolution or Improvement of Signs and Symptoms of cUTI and AP Present a Baseline in the Micro-ITT Populations|Time (Days) to Defervescence in Micro-ITT Population With a Documented Fever at Screening or Day 1|Rate of Clinical Relapse at the LFU Days in the Micro-ITT Population|Rates Of Superinfection And New Infection In The Micro-ITT Population|Apparent Volume of Distribution (Vss) at Steady State in TBPM-PI-HBr Recipients in the Pharmacokinetic (PK) Population|Cmax in TBPM-PI-HBr Recipients in the PK Population|Area Under Curve (AUC 0-24) in TBPM-PI-HBr Recipients in the PK Population|Minimum Concentration (Cmin) in TBPM-PI-HBr Recipients in the PK Population|Systemic Clearance (CL) in TBPM-PI-HBr Recipients in the PK Population","Spero Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","1372","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPR994-301|2018-003671-35","June 3, 2019","May 20, 2020","May 27, 2020","December 28, 2018","July 25, 2022","July 25, 2022","Medical Facility, La Mesa, California, United States|Medical Facility, Miami, Florida, United States|Medical Facility, Blagoevgrad, Bulgaria|Medical Facility, Dobrich, Bulgaria|Medical Facility, Ruse, Bulgaria|Medical Facility, Shumen, Bulgaria|Medical Facility, Sofia, Bulgaria|Medical Facility, Sofia, Bulgaria|Medical Facility, Veliko Tarnovo, Bulgaria|Medical Facility, Karlovy Vary, Czechia|Medical Facility, Liberec, Czechia|Medical Facility, Prague, Czechia|Medical Facility, Zlin, Czechia|Medical Facility, Ústí Nad Labem, Czechia|Medical Facility, Kohtla-Jarve, Estonia|Medical Facility, Tallinn, Estonia|Medical Facility, Voru, Estonia|Medical Facility, Tbilisi, Georgia|Medical Facility, Tbilisi, Georgia|Medical Facility, Tbilisi, Georgia|Medical Facility, Tbilisi, Georgia|Medical Facility, Zestap'oni, Georgia|Medical Facility, Budapest, Hungary|Medical Facility, Budapest, Hungary|Medical Facility, Nagykanizsa, Hungary|Medical Facility, Nyíregyháza, Hungary|Medical Facility, Tatabánya, Hungary|Medical Facility, Riga, Latvia|Medical Facility, Riga, Latvia|Medical Facility, Valmiera, Latvia|Medical Facility, Chisinau, Moldova, Republic of|Medical Facility, Chisinau, Moldova, Republic of|Medical Facility, Katowice, Poland|Medical Facility, Kraków, Poland|Medical Facility, Oswiecim, Poland|Medical Facility, Wrocław, Poland|Medical Facility, Łódź, Poland|Medical Facility, Bucharest, Romania|Medical Facility, Bucharest, Romania|Medical Facility, Bucharest, Romania|Medical Facility, Craiova, Romania|Medical Facility, Iaşi, Romania|Medical Facility, Oradea, Romania|Medical Facility, Arkhangelsk, Russian Federation|Medical Facility, Lomonosov, Russian Federation|Medical Facility, Penza, Russian Federation|Medical Facility, Pyatigorsk, Russian Federation|Medical Facility, Saint Petersburg, Russian Federation|Medical Facility, Saint Petersburg, Russian Federation|Medical Facility, Saint Petersburg, Russian Federation|Medical Facility, Saint Petersburg, Russian Federation|Medical Facility, Saint Petersburg, Russian Federation|Medical Facility, Saint Petersburg, Russian Federation|Medical Facility, Saint Petersburg, Russian Federation|Medical Facility, Saint Petersburg, Russian Federation|Medical Facility, Saint Petersburg, Russian Federation|Medical Facility, Saint Petersburg, Russian Federation|Medical Facility, Saint Petersburg, Russian Federation|Medical facility, Saint Petersburg, Russian Federation|Medical Facility, Smolensk, Russian Federation|Medical Facility, Smolensk, Russian Federation|Medical Facility, Vsevolozhsk, Russian Federation|Medical Facility, Yaroslavl, Russian Federation|Medical Facility, Belgrade, Serbia|Medical Facility, Belgrade, Serbia|Medical Facility, Kragujevac, Serbia|Medical Facility, Novi Sad, Serbia|Medical Facility, Vršac, Serbia|Medical Facility, Bratislava, Slovakia|Medical Facility, Galanta, Slovakia|Medical Facility, Lučenec, Slovakia|Medical Facility, Martin, Slovakia|Medical Facility, Poprad, Slovakia|Medical Facility, Svidník, Slovakia|Medical Facility, Benoni, South Africa|Medical Facility, Chatsworth, South Africa|Medical Facility, Durban, South Africa|Medical Facility, Johannesburg, South Africa|Medical Facility, Middelburg, South Africa|Medical Facility, Pretoria, South Africa|Medical Facility, Cherkasy, Ukraine|Medical Facility, Chernihiv, Ukraine|Medical Facility, Dnipro, Ukraine|Medical Facility, Ivano-Frankivs'k, Ukraine|Medical Facility, Ivano-Frankivs'k, Ukraine|Medical Facility, Kharkiv, Ukraine|Medical Facility, Kharkiv, Ukraine|Medical Facility, Lviv, Ukraine|Medical Facility, Lviv, Ukraine|Medical Facility, Mykolaiv, Ukraine|Medical Facility, Odesa, Ukraine|Medical Facility, Odesa, Ukraine|Medical Facility, Uzhhorod, Ukraine|Medical Facility, Vinnytsia, Ukraine|Medical Facility, Zaporizhia, Ukraine|Medical Facility, Zhytomyr, Ukraine","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/67/NCT03788967/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/67/NCT03788967/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03788967"
406,"NCT05730998","Cranberry for the Prevention of Urinary Tract Infections",,"Completed","No Results Available","Diabetes|Urinary Infection","Dietary Supplement: ANTHOCRAN FITOSOMA|Dietary Supplement: PLACEBO","urinalysis|urine culture","Azienda di Servizi alla Persona di Pavia","Female","70 Years and older   (Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","2207/01072022","September 1, 2022","December 31, 2022","January 31, 2023","February 16, 2023",,"February 16, 2023","l'Istituto di Riabilitazione e cura ""Santa Margherita"" di Pavia, Azienda di Servizi alla Persona (ASP)., Pavia, Italy",,"https://ClinicalTrials.gov/show/NCT05730998"
407,"NCT04306731","Effect of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.",,"Completed","No Results Available","Recurrent Urinary Tract Infection","Dietary Supplement: Nanotechnology Structured water Magnalife|Drug: Trimethoprim|Dietary Supplement: Ordinary bottled drinking water","Recurrent Urinary Tract Infection|Time to first recurrent UTI","University of Sulaimani","Female","24 Years to 80 Years   (Adult, Older Adult)","Not Applicable","437","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","College of Medicine","September 20, 2014","April 21, 2017","April 21, 2017","March 13, 2020",,"March 17, 2020","College of Medicine, University of Sulaimani, Sulaymaniyah, Kurdistan Region, Iraq",,"https://ClinicalTrials.gov/show/NCT04306731"
408,"NCT03910907","Comparison of Standard of Care Guidelines for Mycoplasma Genitalium Infections Among Men With Non-gonococcal Urethritis",,"Terminated","No Results Available","Mycoplasma Genitalium Infection","Drug: Comparison of two standard of care regimens","Participants with Molecular Clearance|Positive Participants with Macrolide-Resistant Mycoplasma","University of Alabama at Birmingham","Male","18 Years to 99 Years   (Adult, Older Adult)",,"10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB-300003178","November 19, 2019","March 20, 2020","March 20, 2020","April 10, 2019",,"June 2, 2023","UAB, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03910907"
409,"NCT00316043","Prevention of Renal Failure in Children With Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infections","Behavioral: Written information for parents|Behavioral: Distance learning package for General Practitioners|Behavioral: Distance learning package for practice assistants","Number of antibiotic prescriptions|Number of referrals|Number of follow-up appointments","Radboud University Medical Center|Dutch Kidney Foundation","All","up to 12 Years   (Child)","Not Applicable","124","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)","WOK_PNKU_01|OV02 (Dutch Kidney Foundation)","May 2006",,"June 2006","April 19, 2006",,"July 31, 2007","UMC St Radboud, Nijmegen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT00316043"
410,"NCT00481689","Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens",,"Completed","No Results Available","Urinary Tract Infections","Drug: Cipro XR (Ciprofloxacin, BAYQ3939)","To evaluate safety and efficacy of ciprofloxacin XR for treatment of subjects with complicated urinary tract infections caused by P. aeruginosa and other urinary pathogens.|Clinical response|Clinical response post- treatment|Adverse Event collection","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11490","May 2004",,"September 2005","June 4, 2007",,"June 26, 2009","Birmingham, Alabama, United States|Birmingham, Alabama, United States|Huntsville, Alabama, United States|Scottsdale, Arizona, United States|Cudahy, California, United States|Fresno, California, United States|La Mesa, California, United States|Laguna Hills, California, United States|Long Beach, California, United States|Los Angeles, California, United States|San Diego, California, United States|Torrance, California, United States|Waterbury, Connecticut, United States|Ocala, Florida, United States|Pembroke Pines, Florida, United States|Indianapolis, Indiana, United States|Des Moines, Iowa, United States|Iowa City, Iowa, United States|Watertown, Massachusetts, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|Reno, Nevada, United States|East Orange, New Jersey, United States|Albuquerque, New Mexico, United States|Albuquerque, New Mexico, United States|Manhasset, New York, United States|North Massapequa, New York, United States|Troy, New York, United States|Eugene, Oregon, United States|Philadelphia, Pennsylvania, United States|Memphis, Tennessee, United States|San Antonio, Texas, United States|Richmond, Virginia, United States|Tacoma, Washington, United States|Cheyenne, Wyoming, United States",,"https://ClinicalTrials.gov/show/NCT00481689"
411,"NCT00603603","Controlled Clinical Trial of Supplemental Oxygen for the Prevention of Post-Cesarean Infectious Morbidity","Peri-Op","Completed","No Results Available","Infection; Cesarean Section|Surgical Wound Infection|Endometritis","Other: 80% inhaled oxygen via non-rebreather mask|Other: 30% inhaled oxygen via nasal cannula","Composite of Wound Infection and Endometritis|Maternal temperature greater than 38 degrees after the first 24 hours post-op|Antibiotic usage greater than 24 hours post-op|Wound opening greater than one centimeter for any cause|Maternal hospital readmission","Washington University School of Medicine|Barnes-Jewish Hospital","Female","12 Years to 50 Years   (Child, Adult)","Not Applicable","606","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","07-0598","February 2008","March 2010","May 2010","January 29, 2008",,"June 22, 2016","Barnes Jewish Hospital/Washington University School. of Medicine, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00603603"
412,"NCT02705495","Acupuncture for Prevention of Recurrent Urinary Tract Infections.","SARUTI","Completed","No Results Available","Recurrent Urinary Tract Infection","Other: acupuncture|Drug: Cranberry products","Urinary tract infection (UTI)|Urinary symptoms|Study diary|Health related quality of life","Medical University of Graz","Female","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","SARUTI V1.6","May 2015","December 2021","June 2022","March 10, 2016",,"August 5, 2022","Department of Gynecology/ Medical University of Graz, Graz, Austria",,"https://ClinicalTrials.gov/show/NCT02705495"
413,"NCT00210990","Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis",,"Completed","No Results Available","Urinary Tract Infections|Pyelonephritis","Drug: doripenem","Microbiological response measured at test of cure visit at early follow-up.|Clinical response (cure) assessed at early follow-up visit. Proportion of patients with sustained microbiological and clinical response measured at late follow-up visit. Safety evaluations conducted throughout the study.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Peninsula Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","403","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR005398","March 2004",,"April 2006","September 21, 2005",,"June 10, 2011",,,"https://ClinicalTrials.gov/show/NCT00210990"
414,"NCT00229021","Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis",,"Completed","No Results Available","Urinary Tract Infections|Pyelonephritis","Drug: doripenum","Microbiological response measured at test of cure visit at early follow-up.|Clinical response (cure) assessed at early follow-up visit. Proportion of patients with sustained microbiological and clinical response measured at late follow-up visit. Safety evaluations will be conducted throughout the study.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Peninsula Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","741","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR005404","December 2003",,"March 2006","September 29, 2005",,"June 10, 2011",,,"https://ClinicalTrials.gov/show/NCT00229021"
415,"NCT01060956","The Clinical Impact of Isolation of Two Different Bacteria in Urinary Cultures",,"Completed","No Results Available","Urinary Tract Infection","Other: reporting of two different bacteria in urine culture|Other: reporting ""mixed growth"" on urine culture","Change of antibiotic treatment|Days to clinical resolution|Increase/decrease in the spectrum of antibiotic|Length of stay in hospital","Shaare Zedek Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","UTI1","February 2010","February 2011","February 2011","February 2, 2010",,"July 27, 2011",,,"https://ClinicalTrials.gov/show/NCT01060956"
416,"NCT02016118","Retrospective Analysis of Ialuril vs. Standard of Care in Recurrent Urinary Tract Infections","RAISC-RUTI","Unknown status","No Results Available","Recurrent Urinary Tract Infections","Device: Ialuril","Occurrence of Urinary tract infection recurrence|Occurrence of symptomatic urinary tract infection recurrence","Study Group for Urogenital Diseases, Italy","Female","18 Years to 75 Years   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","RAISC-RUTI","January 2014","March 2014","December 2014","December 19, 2013",,"February 12, 2014","Ospedale S. Maria della Misericordia, Perugia, Italy",,"https://ClinicalTrials.gov/show/NCT02016118"
417,"NCT06251336","Uroial Plus in the Management of Infections and Urinary Symptoms Associated With Ureteral Stents","USSIAL","Not yet recruiting","No Results Available","Ureteral Stent-Related Symptom|Urinary Tract Infections","Other: UroialTM Plus|Other: Placebo","Improvement rate|Recruitment feasibility|Complications|Impact on employment","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","All","18 Years and older   (Adult, Older Adult)","Not Applicable","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","6184","March 1, 2024","September 1, 2024","January 1, 2025","February 9, 2024",,"February 12, 2024",,,"https://ClinicalTrials.gov/show/NCT06251336"
418,"NCT03837015","Estrogen, Probiotics and Vaginal Health to Prevent HIV Infection in ACB Women",,"Completed","No Results Available","HIV-1-infection|Bacterial Vaginoses","Drug: Estring Vaginal Ring|Other: RepHresh Pro-B","Refusal rate|Participant retention rate|Incidence of treatment emergent adverse events|Rate of adherence|Changes in proportion of Lactobacillus species in the vaginal microbiota|Change in innate inflammatory cytokine/chemokine levels|Changes in number of HIV target cells in the genital tract","McMaster University|CIHR Canadian HIV Trials Network","Female","18 Years to 49 Years   (Adult)","Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CTN308","November 4, 2019","December 14, 2021","December 14, 2021","February 11, 2019",,"December 17, 2021","Women's Health in Women's Hands, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03837015"
419,"NCT00731315","Computer-Assisted Treatment of Urinary Tract Infection in Emergency Departments and Community Health Centers","UTI-Kiosk","Terminated","No Results Available","Urinary Tract Infections","Other: Computer-assisted treatment group|Other: Usual care group","The proportion of subjects with treatment failure or relapse|Patient acceptability of treatment by computer","University of California, San Francisco","Female","18 Years to 64 Years   (Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","H12132-32499-02","August 2008","July 2011","July 2011","August 11, 2008",,"March 6, 2015","CMC Fresno Emergency Department, Fresno, California, United States|La Clinica, Oakland, California, United States|Highland Hospital Emergency Department, Oakland, California, United States|San Francisco General Hospital - Emergency Department, San Francisco, California, United States|UCSF Emergency Deparmtent, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00731315"
420,"NCT03644966","Probiotics and Multi-Drug Resistant Urinary Tract Infection",,"Completed","No Results Available","Urinary Tract Infections|Recurrent UTI|Antibiotic Resistant Infection","Dietary Supplement: Bifidobacterium infantis|Other: Placebo|Drug: Antibiotics","Change in Resistance Pattern|Bacterial isolate genomic characteristics|UTI reduction|Antibiotics Quantity|Healthcare visit|Length of time for change in resistance|Sensitivity pattern post-probiotic therapy","Ochsner Health System|Procter and Gamble","Female","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","25","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2017564","July 5, 2018","December 15, 2022","December 15, 2022","August 23, 2018",,"April 12, 2023","Ochsner Health System, Jefferson, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT03644966"
421,"NCT00068120","ORWH:SCOR - Sex/Gender Factors Affecting Women's Health",,"Completed","No Results Available","Urinary Tract Infection",,,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Female","18 Years to 49 Years   (Adult)",,"200","NIH","Observational","Time Perspective: Prospective","ORWHSCOR-dk64540 (compltd)",,,,"September 9, 2003",,"January 14, 2010","University of Washington, Hall Health Primary Care Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00068120"
422,"NCT01110408","A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections",,"Terminated","Has Results","Complicated Urinary Tract Infections or Pyelonephritis","Drug: Doripenem|Drug: Doripenem placebo|Drug: Cefepime|Drug: Cefepime placebo|Drug: Amoxicillin/clavulanate potassium","The Number of Participants With Clinical Cure Rate at Test Of Cure (TOC) Visit|The Number of Participants With Clinical Improvement Rate at End of IV (EIV) Visit|The Number of Participants With Clinical Cure Rate at Late Follow-Up (LFU) Visit|The Number of Participants With Favorable Per-participant Microbiological Response|Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at End of IV (EIV) Visit|Number of Participants With Favorable Per-pathogen Microbiological Outcome Rate at Test Of Cure (TOC) Visit|Number of Participants With Sustained Favorable Per-pathogen Microbiological Outcome Rate at Late Follow-Up (LFU) Visit","Janssen Research & Development, LLC","All","3 Months to 18 Years   (Child, Adult)","Phase 3","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR016792|DORIPED3002|2009-015953-18","December 2010","June 2013","June 2013","April 26, 2010","July 2, 2014","July 15, 2014","Little Rock, Arkansas, United States|Oakland, California, United States|Orange, California, United States|San Diego, California, United States|Washington, District of Columbia, United States|New Brunswick, New Jersey, United States|Albany, New York, United States|Bronx, New York, United States|Cleveland, Ohio, United States|Toledo, Ohio, United States|Pittsburgh, Pennsylvania, United States|Buenos Aires, Argentina|Córdoba, Argentina|Loma Hermosa N/A, Argentina|Santa Fe, Argentina|Belo Horizonte, Brazil|Caxias Do Sul, Brazil|Passo Fundo, Brazil|São Paulo, Brazil|Santiago, Chile|Valdivia X Región, Chile|Bogota, Colombia|Cali, Colombia|Floridablanca, Colombia|Medellin, Colombia|Hradec Kralove, Czech Republic|Praha, Czech Republic|Riga, Latvia|Kaunas, Lithuania|Vilnius, Lithuania|Guadajalara, Mexico|Monterrey, Mexico|Zapopan, Mexico|Zona, Panama|Lublin, Poland|Szczecin, Poland|Kharkiv, Ukraine|Poltava, Ukraine",,"https://ClinicalTrials.gov/show/NCT01110408"
423,"NCT03270540","Abdominal Ultrasonography in Urinary Tract Infection - When and Why?",,"Completed","No Results Available","Urinary Tract Infections|UTI",,"USG abnormality persistence","Medical University of Warsaw","All","up to 3 Years   (Child)",,"65","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","WarsawMU2W9","March 13, 2017","November 18, 2018","November 18, 2018","September 1, 2017",,"November 26, 2018","Medical University of Warsaw Children's Hospital, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT03270540"
424,"NCT05244967","Epidemiology of Sexually Transmitted Infections and Its iMpAcT on fEmale Infertility","ESTIMATE","Recruiting","No Results Available","Sexually Transmitted Infection","Other: vaginal swab","number of young women with STIs|monitoring of STIs and their impact on infertility","University of Luebeck","Female","18 Years to 22 Years   (Adult)",,"533","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-022","November 11, 2020","December 31, 2028","June 30, 2029","February 17, 2022",,"November 29, 2023","Klinik für Infektiologie und Mikrobiologie, Lübeck, Germany",,"https://ClinicalTrials.gov/show/NCT05244967"
425,"NCT05301023","Individualized Antibiotic Therapy in Children With Acute Uncomplicated Febrile Urinary Tract Infection",,"Recruiting","No Results Available","Febrile Urinary Tract Infection","Other: Individualized antibiotic therapy|Other: Standard antibiotic therapy","Proportion of participants with recurrent urinary tract infection regardless of the pathogen or death of any cause|Number of days with antibiotic therapy|Number of days with absence from school or daycare due to illness","Rigshospitalet, Denmark|Hvidovre University Hospital","All","3 Months to 12 Years   (Child)","Phase 4","408","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-21057310 (UVI RCT)","April 1, 2022","May 2024","July 2024","March 29, 2022",,"March 15, 2023","Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark|Copenhagen University Hospital Herlev, Herlev, Denmark|Copenhagen University Hospital Hillerød, Hillerød, Denmark|Copenhagen University Hospital Holbæk, Holbæk, Denmark|Copenhagen University Hospital Hvidovre, Hvidovre, Denmark|Copenhagen University Hospital Nykøbing Falster, Nykøbing Falster, Denmark|Copenhagen University Hospital Roskilde, Roskilde, Denmark|Copenhagen University Hospital Slagelse, Slagelse, Denmark",,"https://ClinicalTrials.gov/show/NCT05301023"
426,"NCT04629001","Effect of Covid-19 on Outcomes of Pregnancy",,"Unknown status","No Results Available","Pregnancy Without Complications Except Getting Covid-19 Infection","Diagnostic Test: Covid-19 PCR , IGM","Fetal morbidity","Assiut University","Female","18 Years to 40 Years   (Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","12789","September 1, 2020","September 1, 2021","December 1, 2021","November 16, 2020",,"November 16, 2020","Medicine, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT04629001"
427,"NCT04305808","Characterization of Vaginal, Urinary and Fecal Microbiomes in Women With Recurrent Urinary Tract Infections",,"Recruiting","No Results Available","Urinary Tract Infections|Menopause",,"Characterization of the microbiome using molecular methods.","Hadassah Medical Organization","Female","Child, Adult, Older Adult",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0014-20-HMO","August 1, 2021","December 30, 2024","December 30, 2024","March 12, 2020",,"March 12, 2024","Hadassah Medical Center, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT04305808"
428,"NCT01601041","Role of Residual Urine and Asymptomatic Prostatitis in the Development of Urinary Tract Infections in Spinal Cord Injury",,"Completed","No Results Available","Urinary Tract Infection","Other: sonographic assessment of residual urine, urine culture","amount of residual urine|bacterial prostate infection|bacteriuria|number of leucocytes in urine|number of erythrocytes in urine|patient characteristics|type of neurogenic bladder dysfunction|type of catheter used for intermittent catheterization|annual rate of symptomatic urinary tract infections","Swiss Paraplegic Research, Nottwil","Male","18 Years to 70 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2011-16","December 2011","February 2013","February 2013","May 17, 2012",,"November 22, 2016","Swiss Paraplegic Centre, Nottwil, LU, Switzerland",,"https://ClinicalTrials.gov/show/NCT01601041"
429,"NCT03101371","Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion",,"Completed","Has Results","Urinary Tract Infections|Catheter Infection|Catheter-Related Infections","Drug: Catheter insertion with Povidone Iodine|Procedure: Standard of care catheter insertion","Number of Participants With a Catheter Associated Urinary Tract Infection (CAUTI)|Number of Participants Who Received the ""Fill and Pull"" Versus the ""Pull and Void"" Method of Catheter Discontinuation|Average Patient Satisfaction|Number of Participants With Extended Hospital Stay Due to a Urinary Tract Infection (UTI)|Number of Participants With Closed Drainage System Disrupted During Placement of Catheter|Number of Participants That Were Readmitted, Had Additional Clinic Visits or Went to the Emergency Department (ED) for Any Reason|Number of Patients That Used Antibiotics at the Time of Surgery and Post-surgery","University of Colorado, Denver","Female","18 Years to 89 Years   (Adult, Older Adult)","Phase 2","99","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16-1096","October 10, 2017","February 15, 2019","February 15, 2019","April 5, 2017","February 18, 2020","March 10, 2020","University of Colorado Denver, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/71/NCT03101371/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/71/NCT03101371/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03101371"
430,"NCT05585970","Comparison of Procalcitonin Level in Normal Population and in Chronic Kidney Disease Patients Who Don't Have Infection",,"Not yet recruiting","No Results Available","Chronic Kidney Disease Patients Who Don't Have Infection","Diagnostic Test: procalcitonin","procalcitonin Level","Sohag University","Female","40 Years to 80 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Soh-Med-22-10-06","November 1, 2022","May 1, 2023","May 1, 2023","October 19, 2022",,"October 19, 2022","Sohag University Hospital, Sohag, Egypt",,"https://ClinicalTrials.gov/show/NCT05585970"
431,"NCT00157625","Automatic Stop Orders for Urinary Catheters",,"Completed","No Results Available","Urinary Tract Infections","Behavioral: Automatic stop order","Urinary tract infections|days of indwelling urinary catheterization,|symptomatic urinary tract infection,|isolation of antimicrobial-resistant bacteria from catheterized urine,|antimicrobial use,|bacteremia (blood-stream) infection secondary to urinary tract infection,|cost","McMaster University|The Physicians' Services Incorporated Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","630","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","03-24","April 2003",,"July 2006","September 12, 2005",,"October 26, 2018","McMaster University Medical Centre, Hamilton, Ontario, Canada|Henderson Hospital, Hamilton, Ontario, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00157625"
432,"NCT03366077","Double-blinded, Randomized, Placebo-controlled Study Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection",,"Completed","No Results Available","Recurrent Urinary Tract Infection in Adult Women","Dietary Supplement: Probiotic","Mean number of confirmed UTIs during six months from start of intervention, as compared to placebo","BioGaia AB","Female","18 Years to 50 Years   (Adult)","Not Applicable","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","CSUB0144","December 13, 2017","July 12, 2019","July 12, 2019","December 8, 2017",,"January 5, 2021","Clinical Trial Consultants AB, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT03366077"
433,"NCT04505683","A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)",,"Completed","No Results Available","Complicated Urinary Tract Infection Including Acute Pyelonephritis","Drug: Benapenem|Drug: Ertapenem","Percentage of patients with clinical cure at test-of-cure (TOC) visit","Sihuan Pharmaceutical Holdings Group Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","112","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","5081-II-2001","December 13, 2018","May 8, 2020","May 8, 2020","August 10, 2020",,"August 10, 2020","Peking University First Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04505683"
434,"NCT06144060","A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis",,"Not yet recruiting","No Results Available","Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)","Drug: HRS -8427|Drug: Imipenem and Cilastatin Sodium","Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure (TOC)|Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Early Assessment（EA）、End of Treatment（EOT）and Late Follow-Up (LFU)|Percentage of Participants With Microbiological Eradication at EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment）|Percentage of Participants With Microbiological Eradication at EA （Day 4）、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment） Per Uropathogen|Percentage of Participants With Clinical Response at EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment）|Percentage of Participants With Clinical Response at EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU （14 days after end of treatment）Per Uropathogen","Jiangsu HengRui Medicine Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","126","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HRS-8427-202","December 2023","June 2024","July 2024","November 22, 2023",,"November 22, 2023",,,"https://ClinicalTrials.gov/show/NCT06144060"
435,"NCT04667546","Assessment of the Efficacy on the 5th Day of Antibiotic Therapy for Febrile Urinary Tract Infections Among Children From 3 Months to 18 Years Old","PEDIU5","Unknown status","No Results Available","Urinary Tract Infections|Pediatric Disorder","Other: Survey","Effectiveness of treatment|Leukocyte count|Mode of sampling|Rate of failure|Procalcitonin levels|CRP levels|Polynuclear cell count","Centre Hospitalier Universitaire de Besancon","All","3 Months to 18 Years   (Child, Adult)","Not Applicable","54","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2020/530","December 2020","January 2022","January 2022","December 14, 2020",,"December 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04667546"
436,"NCT05341284","Impact of HPV Vaccination on HPV Infection and Cervical Related Disease Burden in Real-World Settings (HPV-RWS)","HPV-RWS","Not yet recruiting","No Results Available","HPV Infection|Cervical Disease","Other: Questionnaire Survey and Cervical Cancer Screening","Number of Participants with Cervical infection with HPV-16 and/or HPV-18 (by PCR)|The occurrence of high-risk HPV infection 12 other hr-HPV positive besides of type 16/18|Number of Participants with Any cervical lesions or diseases","Peking University|Center for Disease Control and Prevention of Yinzhou District, Ningbo City, China|GlaxoSmithKline","Female","9 Years to 45 Years   (Child, Adult)",,"12118","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HPV-RWS","August 1, 2022","August 1, 2027","August 1, 2027","April 22, 2022",,"April 29, 2022",,,"https://ClinicalTrials.gov/show/NCT05341284"
437,"NCT02402907","STRIPES Study: Study To Reduce Infection Post cEsarean Section",,"Completed","Has Results","Chlorhexidine Gluconate Cloths|Infection; Cesarean Section|Infectious Morbidity|Surgical Site Infections|Endometritis","Device: 2% chlorhexidine gluconate (CHG) cloth|Device: Placebo cloth","Number of Participants With Incisional SSI|Number of Adherent Participants With Incisional SSI|Number of Participants With Endometritis|Number of Participants With Maternal Complications|Incidence of Neonatal ICU Admissions|Maternal Length of Stay|Number of Participants With Maternal Readmissions","Icahn School of Medicine at Mount Sinai","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","1356","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","GCO 14-1410","April 2015","October 11, 2019","October 11, 2019","March 30, 2015","November 9, 2020","November 9, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/07/NCT02402907/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02402907"
438,"NCT05674942","Urinary Tract Infection in Patients With Chronic Kidney Disease",,"Recruiting","No Results Available","Urinary Tract Infections|Chronic Kidney Diseases","Other: Patients with urinary tract infection and chronic kidney disease","prevalence of UTI in CKD patients|isolated microorganisms causing UTI in CKD patients|sensitivity pattern of urine cultures in CKD","Alexandria University","All","18 Years and older   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","Urinary Tract Infection","June 1, 2023","April 15, 2024","May 15, 2024","January 9, 2023",,"March 18, 2024","Faculty of Medicine, Alexandria University, Alexandria, Egypt",,"https://ClinicalTrials.gov/show/NCT05674942"
439,"NCT01333254","A Trial of Different Methods for Bladder Drainage in Hip Surgery Patients",,"Completed","No Results Available","Urinary Tract Infections","Procedure: Intermittent urinary catheterisation","Nosocomial urinary tract infection|Time to normal bladder function|Costs for material and labour related to urinary catheterisation and nosocomial UTI during the first year after hip surgery|Health effects during the first year after hip surgery","Region Örebro County","All","50 Years and older   (Adult, Older Adult)","Not Applicable","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2009-075","September 2009","June 2011","June 2012","April 11, 2011",,"October 5, 2016","Dept of Orthopaedic Surgery at Örebro University Hospital, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT01333254"
440,"NCT01653392","BioThrax® (Anthrax) Vaccine in Pregnancy Registry",,"Completed","No Results Available","Pregnancy Complications|Pregnancy Outcome|Congenital Abnormalities","Biological: Observational Intervention","Pregnancy Outcomes|Maternal Outcomes|Infant Outcomes","Emergent BioSolutions|Naval Health Research Center","Female","Child, Adult, Older Adult",,"98","Industry|U.S. Fed","Observational","Observational Model: Case-Control|Time Perspective: Prospective","EBS.AVA.010 / NHRC.2012.0003","July 2012","February 2020","February 2020","July 31, 2012",,"March 15, 2024","Naval Health Research Center, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT01653392"
441,"NCT04100980","A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Chronic Urinary Tract Infections (UTI)",,"Unknown status","No Results Available","Chronic UTI|Chronic Urinary Tract Infection","Other: No Intervention","Correlation of Microbiome to chronic Urinary Tract Infection (UTI) via Relative Abundance Found in Microbiome Sequencing|Validation of Sequencing Methods","ProgenaBiome","All","18 Years and older   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PRG-014","March 2, 2020","March 2023","July 2023","September 24, 2019",,"September 5, 2021","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04100980"
442,"NCT03840148","Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections","CERTAIN-1","Completed","No Results Available","Urinary Tract Infections|Acute Pyelonephritis","Drug: Cefepime/VNRX-5133 (taniborbactam)|Drug: Meropenem","Composite of microbiological eradication and symptomatic clinical success in the microbiological intent-to-treat (microITT) population at test of cure (TOC)|Microbiological and symptomatic success at test of cure (TOC)|Clinical and microbiological success at end of treatment (EOT) and last follow-up (LFU)|Per-patient microbiological success at EOT, TOC and LFU|Patients with symptomatic clinical success at EOT, TOC and LFU|Investigator opinion of clinical success at TOC|Per-pathogen microbiological success at EOT, TOC and LFU|Microbiological and clinical success in cefepime-resistant pathogens at EOT, TOC and LFU|Per-patient microbiological success among those with cefepime-resistant pathogens at EOT, TOC and LFU|Per-pathogen microbiological success among those with cefepime-resistant pathogens at EOT, TOC and LFU|Symptomatic clinical success among those with cefepime-resistant pathogens at EOT, TOC and LFU cefepime-resistant pathogens","Venatorx Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","661","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VNRX-5133-201|2018-001451-13","August 7, 2019","December 14, 2021","December 14, 2021","February 15, 2019",,"February 15, 2024","Site 184003, Buena Park, California, United States|Site 184002, Chula Vista, California, United States|Site 184001, La Mesa, California, United States|184012, Northridge, California, United States|Site 103203, Córdoba, Argentina|Site 107601, Belo Horizonte, Brazil|Site 107608, San Paolo, Brazil|Site 110009, Gabrovo, Bulgaria|Site 110002, Pleven, Bulgaria|Site 110007, Plovdiv, Bulgaria|Site 110003, Ruse, Bulgaria|Site 110010, Sofia, Bulgaria|Site 110004, Sofia, Bulgaria|Site 110005, Sofia, Bulgaria|Site 110008, Sofia, Bulgaria|Site 110001, Veliko Tarnovo, Bulgaria|Site 156022, Baotou, China|Site 156002, Beijing, China|Site 156006, Beijing, China|Site 156015, Chendu, China|Site 156011, Chongqing, China|Site 156012, Chongqing, China|Site 156004, Dalian, China|Site 156030, Fujian, China|Site 156014, Guangdong, China|Site 156027, Guangdong, China|Site 156025, Guangzhou, China|Site 156018, Guiyang, China|Site 156003, Nanchang, China|Site 156005, Nanjing, China|Site 156008, Nanjing, China|Site 156007, Nanjing, China|Site 156013, Ningbo, China|Site 156028, Shandong, China|Site 156017, Shanghai, China|Site 156016, Shijiazhuang, China|Site 156020, Tianjin, China|Site 156010, Xiamen, China|Site 156029, Ürümqi, China|Site 119103, Split, Croatia|Site 119101, Zagreb, Croatia|Site 119106, Zagreb, Croatia|Site 134801, Budapest, Hungary|Site 134803, Nyiregyhaza, Hungary|Site 134804, Szeged, Hungary|Site 142803, Daugavpils, Latvia|Site 142804, Riga, Latvia|Site 142801, Riga, Latvia|Site 148402, Colima, Mexico|Site 148401, Guadalajara, Mexico|Site 160403, Cuzco, Peru|Site 160410, Lima, Peru|Site 160406, Lima, Peru|Site 160404, Trujillo, Peru|Site 164204, Bucharest, Romania|Site 164206, Bucuresti, Romania|Site 164205, Bucuresti, Romania|Site 164201, Craiova, Romania|Site 164307, Moscow, Russian Federation|Site 164301, Penza, Russian Federation|Site 164308, Pyatigorsk, Russian Federation|Site 164311, Rostov-on-Don, Russian Federation|Site 164303, Sankt Peterburg, Russian Federation|Site 164302, Saratov, Russian Federation|Site 189001, Belgrade, Serbia|Site 189002, Belgrade, Serbia|Site 179207, Adapazarı, Turkey|Site 179203, Bornova, Turkey|Site 179202, Bostanci, Turkey|Site 179204, Diyarbakır, Turkey|Site 179205, Çankaya, Turkey|Site 180404, Dnipro, Ukraine|Site 180408, Ivano-Frankivs'k, Ukraine|Site 180402, Kharkiv, Ukraine|Site 180406, Kyiv, Ukraine|Site 180401, Luts'k, Ukraine|Site 180403, Vinnytsia, Ukraine|Site 180407, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT03840148"
443,"NCT02186145","Efficacy and Safety Study of Metronidazole, Nystatin and Dexamethasone Combination Therapy in Bacterial and Fungal Vaginal Infections",,"Unknown status","No Results Available","Bacterial Vaginosis|Fungal Vaginal Infections","Drug: Association of metronidazole; nystatin and dexamethasone|Drug: Flagyl","Therapeutic cure|Evaluation on vulvovaginal inflammation","Marjan Industria e Comercio ltda","Female","18 Years to 50 Years   (Adult)","Phase 3","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MJ 3002-13","January 2016","January 2017","January 2017","July 10, 2014",,"April 9, 2015","Faculty of Medicine of ABC (FMABC), Santo André, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT02186145"
444,"NCT01862822","Position of Children During Urine Collection: Evaluation Study","PUCES","Completed","No Results Available","Urinary Infection","Other: upright position","Proportion of polybacterial urine analysis in each group|The failure rate in upright position in private practice","University Hospital, Limoges","All","2 Months to 36 Months   (Child)","Not Applicable","803","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","I11 016","June 2013","April 2017","December 2017","May 27, 2013",,"January 15, 2019","University Hospital, Limoges, Limoges, France",,"https://ClinicalTrials.gov/show/NCT01862822"
445,"NCT03235947","Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients","PERIFOS","Completed","No Results Available","Urinary Tract Infection|Asymptomatic Bacteriuria","Drug: Fosfomycin disodium|Drug: Trimethoprim / Sulfamethoxazole|Drug: Intravenous placebo","To compare the efficacy of Fosfomycin-disodium/Trimethoprim-sulfamethoxazole with Placebo/Trimetoprim-sulfamexazol in the prophylaxis of urinary tract infection or significant asymptomatic bacteriuria among kidney transplantation recipients.|The elapsed time period until the first urinary tract infection or asymptomatic bacteriuria developed","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Laboratorios Senosiain, S.A. de C.V.","All","18 Years and older   (Adult, Older Adult)","Phase 4","82","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1649","September 7, 2016","November 6, 2017","November 6, 2017","August 1, 2017",,"November 13, 2017","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT03235947"
446,"NCT03036839","Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease","ESRD","Completed","Has Results","Hepatitis C Virus Infection","Drug: LDV/SOF","Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)|Percentage of Participants Who Permanently Discontinued Study Drug Due to an Adverse Event|Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)|Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)|Percentage of Participants With HCV RNA < LLOQ on Treatment|HCV RNA|Change From Baseline in HCV RNA|Percentage of Participants With Virologic Failure|Percentage of Participants Who Developed Resistance to LDV and SOF|Pharmacokinetics (PK) Parameter: AUCtau of LDV|PK Parameter: AUCtau of SOF|PK Parameter: AUCtau of GS-331007 (Metabolite of SOF)|PK Parameter: Cmax of LDV|PK Parameter: Cmax of SOF|PK Parameter: Cmax of GS-331007 (Metabolite of SOF)","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","95","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-337-4063|2016-003489-25","June 27, 2017","November 22, 2018","February 14, 2019","January 30, 2017","December 9, 2019","March 2, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|James J. Peters VA Hospital, Bronx, New York, United States|The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States|Texas Liver Institute/American Research Corporation, San Antonio, Texas, United States|University of Washington/Harborview Medical Center, Seattle, Washington, United States|CUB Hopital Erasme, Brussels, Belgium|Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium|Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, Germany|Universitatsklinikum Hamburg-Eppendorf (UKE), Zentrum fur Innere Medizin - Studienambulanz Hepatol., Hamburg, Germany|Ifi Studien und Projekt GmbH an der Asklepios Klinik St. Georg, Hamburg, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|IRCCS Ospedale Casa Sollievo Della Sofferrenza, San Giovanni Rotondo, Foggia, Italy|Ospedale Santa Maria Annunziata, Antella, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Chang Gung Medical Foundation, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/39/NCT03036839/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/39/NCT03036839/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03036839"
447,"NCT06124820","RCT Comparing Intravaginal Laser Therapy to Sham in Post-menopausal Women With Recurrent Urinary Tract Infections","UTIEXTERMINATE","Recruiting","No Results Available","Recurrent Urinary Tract Infection|Genitourinary Syndrome of Menopause","Device: Deka SmartXide Touch C60 (MonaLisa Touch)|Device: Sham","To determine and compare the incidence of symptomatic antibiotic-treated UTI during the 6-month follow-up period after completion of allocated treatment|UTI history diary|Vaginal Health Index Score (VHIS)|King's Health Questionnaire (KHQ)|International Consultation on Incontinence Questionnaire - Female Lower Urinary Tract Symptoms (ICIQ-FLUTS)|International Consultation on Incontinence Questionnaire - Vaginal Symptoms (ICIQ-VS)|10 cm Visual Analogue Scale for Symptoms (VAS)|Urinary Tract Infection Symptom Assessment Questionnaire (UTISA)|Female Sexual Function Index Scoring (FSFI)|Health Service Utilisation Questionnaire (HSU-Q)|Treatment satisfaction questionnaire for laser (TSQ-L)|Vulvoscopic Genital Tissue Appearance Scale (VGTA)|Adverse event recording|Dipstick urine analysis|Standard urine culture|Expanded Quantitative Urine Culture (EQUC)|16S rRNA rapid Next-generation Gene Sequencing|Shotgun metagenomic sequencing","King's College Hospital NHS Trust","Female","Child, Adult, Older Adult","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","302037","October 1, 2023","October 1, 2025","October 1, 2026","November 9, 2023",,"November 9, 2023","King's College Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT06124820"
448,"NCT01966653","Study Comparing Nitrofurantoin to Fosfomycin for Acute Urinary Tract Infection in Women","AIDA-WP2","Unknown status","No Results Available","Urinary Tract Infections|Cystitis","Drug: nitrofurantoin|Drug: fosfomycin","Number of participants with clinical cure, clinical failure, or indeterminate clinical response (see description below)|Number of participants with bacteriologic cure and with bacteriologic recurrence","University Hospital, Geneva|European Commission","Female","18 Years and older   (Adult, Older Adult)","Phase 4","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-014","October 2013","May 2017","August 2017","October 21, 2013",,"May 2, 2017","Tel Aviv University, Tel Aviv, Israel|Lodz University Hospital, Lodz, Poland|University Hospitals of Geneva, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT01966653"
449,"NCT02083276","Mecillinam for Treatment of Genital Chlamydia Infection","MecillinamCT","Terminated","No Results Available","Chlamydia Trachomatis Infection|Chlamydial Urethritis","Drug: Pivmecillinamhydrochlorid","Negative control test for Chlamydia in urine (NAAT; Nucleic Acid AmplificationTest)","Oslo University Hospital|Møre og Romsdal Hospital Trust","Male","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013/1917|2013-002379-17","March 2014","April 2015","May 2015","March 11, 2014",,"June 19, 2015","Olafia Clinic,Oslo University Hosptial, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT02083276"
450,"NCT04049994","Immunomodulation Therapy for Urinary Tract Infections","UROVAXOM-P","Completed","No Results Available","Spinal Cord Injuries|Urinary Tract Infections","Drug: Uro-Vaxom|Drug: Placebo oral tablet","randomization rate|positive screening rate|retention rate|drop-out rate|urine culture result|change in urinary immunoglobulin A levels|count of urinary tract infection","Swiss Paraplegic Research, Nottwil|Swiss Spinal Cord Injury Cohort Study (SwiSCI)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","2018-22","June 1, 2020","September 4, 2023","October 31, 2023","August 8, 2019",,"November 7, 2023","Swiss Paraplegic Centre, Nottwil, LU, Switzerland",,"https://ClinicalTrials.gov/show/NCT04049994"
451,"NCT03477422","CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria","PLEA","Completed","No Results Available","Urinary Tract Infection Complicated|Acute Pyelonephritis","Drug: CSE-1034 (Ceftriaxone + Sulbactam + EDTA)|Drug: Meropenem","Proportion of patients with symptomatic resolution (or return to premorbid state) of all UTI-specific symptoms (frequency/urgency/ flank pain / suprapubic pain) at the TOC visit in the Microbiological Modified Intent-To-Treat (mMITT) analysis set|Proportion of patients with both a per-patient microbiological eradication and symptomatic resolution (or return to premorbid state) of all UTI-specific symptoms (frequency/urgency/ flank pain / suprapubic pain) at the TOC visit in the mMITT analysis set|Proportion of patients with a favorable per-patient microbiological response at the TOC visit in the mMITT analysis set|Proportion of patients with a favorable per-patient microbiological response in the mMITT analysis set|Proportion of patients with a favorable per-patient microbiological response in the Microbiological Evaluable (ME) analysis set|Proportion of patients with a favorable per-patient microbiological response in the extended ME analysis set|Proportion of patients with symptomatic resolution (or return to premorbid state) of all UTI-specific symptoms (frequency/urgency/ flank pain / suprapubic pain) in the mMITT analysis set|Proportion of patients with symptomatic resolution (or return to premorbid state) of all UTI-specific symptoms (frequency/urgency/ flank pain / suprapubic pain) in the CE analysis set|Proportion of patients with symptomatic resolution (or return to premorbid state) of all UTI-specific symptoms (frequency/urgency/ flank pain / suprapubic pain) in the extended ME analysis set|Proportion of favorable per-pathogen microbiological response in the mMITT analysis set|Proportion of favorable per-pathogen microbiological response in the ME analysis set|Proportion of favorable per-pathogen microbiological response in the extended ME analysis set|Proportion of patients with symptomatic resolution (as defined in the co-primary variables) for patients infected with a Meropenem -resistant pathogen in the extended ME analysis set|Proportion of patients with favorable per-patient microbiological response for patients infected with a Meropenem-resistant pathogen in the extended ME analysis sets|Time to first defervescence while on IV study therapy in patients in the mMITT analysis set who had fever at study entry|Time to first defervescence while on IV study therapy in patients in the ME analysis set who had fever at study entry|Time to first defervescence while on IV study therapy in patients in the extended ME analysis set who had fever at study entry|Time to first defervescence while on IV study therapy in patients in the CE analysis set who had fever at study entry|Number of deaths due to cUTI with more than 5 days of treatment till TOC visit|Total duration of treatment in the ME analysis sets|Total duration of treatment in the CE analysis sets|To measure the difference change in Patient Quality of life using Medical Outcome Study (MOS)-Short Form Survey (SF-36) scale|Analysis of pharmacoeconomic data of CSE-1034 versus the comparator for mMITT population|Analysis of pharmacoeconomic data of CSE-1034 versus the comparator for CE population","Venus Remedies Limited","All","18 Years and older   (Adult, Older Adult)","Phase 3","230","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VRL/CSE-1034/05/2012|CTRI/2013/11/004133","January 11, 2014","May 8, 2017","May 8, 2017","March 26, 2018",,"August 29, 2019","Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu & Kashmir, India|Sapthagiri Institute of Medical Sciences and Research Center, Bangalore, Karnataka, India|KLES, Dr Prabhakar Kore Hospital and Medical Centre , , India, Belgaum, Karnataka, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India|Christian Medical College & Hospital, Ludhiana, Punjab, India|S.P. Medical College, Bikaner, Rajasthan, India|J. N. Medical College, Aligarh Muslim University, Alīgarh, Uttar Pradesh, India|King George's Medical University (KGMU), -, India, Lucknow, Uttar Pradesh, India|M.V. Hospital and Research Centre, Lucknow, Uttar Pradesh, India|Ajanta Hospital & Research Centre, 765, ABC Complex, Kanpur Road, Alambagh, -, , India., Lucknow, Uttar Pradesh, India|Trimurti Hospital, Varanasi, Uttar Pradesh, India|Sudbhawana Hospital, Varanasi, Uttar Pradesh, India|Om Surgical Centre and Maternity Home, Varanasi, Uttar Pradesh, India|P. G. I. M. E. R., Sector 12, - India, Chandigarh, India|PGIMER Dr. RML Hospital, New Delhi, India|All India Institute of Medical Science, New Delhi, India|Sir Ganga Ram Hospital, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT03477422"
452,"NCT00560924","Preventive Effect of Treatment With Estradiol Vaginal Tablets on Recurrent Urinary Tract Infections in Post-menopausal Women",,"Terminated","No Results Available","Menopause|Urinary Infections","Drug: estradiol, 25 mcg","Time to first symptom of urinary tract infection (UTI)|Number of urinary tract infection (UTI)","Novo Nordisk A/S","Female","Child, Adult, Older Adult","Phase 3","6","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VAG-1458","March 21, 2003","March 17, 2004","March 17, 2004","November 20, 2007",,"February 28, 2017","Novo Nordisk Investigational Site, Malmö, Sweden",,"https://ClinicalTrials.gov/show/NCT00560924"
453,"NCT06128213","NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis",,"Not yet recruiting","No Results Available","Urinary Tract Infections|Pyelonephritis","Drug: NRX101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone))","Microbiologic Response","NeuroRx, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","13","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NRX101-010","March 31, 2024","June 30, 2024","September 30, 2024","November 13, 2023",,"November 13, 2023",,,"https://ClinicalTrials.gov/show/NCT06128213"
454,"NCT02922868","Assessment of Infection Control, Practice Efficiency, and Health Economics of Sheathed Versus Standard Cystoscopy",,"Completed","Has Results","Bacteriuria","Device: EndoSheath CST-5000 Scope|Device: Olympus Visera Elite OTV-S190 Scope","Number of Participants Who Had Post-Procedure Bacteriuria|Number of Cystoscopes With Positive Bioburden Post-procedure.|Total Time to Reprocess a Cystoscope|Subject Assessment of Procedure.|Staff Assessment of Cystoscope Reprocessing.|Total Cost of Cystoscopy Reprocessing|Number of Procedures Per Day Per Scope.","Wake Forest University Health Sciences|Cogenix Medical Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","IRB00036203","March 2016","December 2016","December 2016","October 4, 2016","February 22, 2018","September 12, 2018","Wake Forest Baptist Health - Department of Urology, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02922868"
455,"NCT01456962","Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract",,"Completed","Has Results","Women's Health|HIV Infection|Genital Diseases, Female",,"CD4+ to CD8+ T Cell Ratio in Cervical Biopsies","University of Colorado, Denver","Female","18 Years to 80 Years   (Adult, Older Adult)",,"36","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","11-1265|39423","October 2011","August 2013","August 2013","October 21, 2011","June 12, 2015","June 9, 2017","University of Colorado, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01456962"
456,"NCT04182230","UROGEN WELL D-ONE : Evaluation of a Novel Diagnostic for Sexually Transmitted Bacterial Infections",,"Completed","No Results Available","Sexually Transmitted Diseases, Bacterial|Bacterial Urinary Tract Infection|Antimicrobial Resistance","Other: No intervention. This study was an evalution with no intervention.","UROGEN WELL D-ONE PRIMARY OUTCOME|UROGEN WELL D-ONE SECONDARY OUTCOME","Cwm Taf University Health Board (NHS)|Cardiff University","All","16 Years to 100 Years   (Child, Adult, Older Adult)",,"500","Other","Observational","Observational Model: Other|Time Perspective: Prospective","CT 251053 3/07/18","September 5, 2018","September 5, 2019","September 5, 2019","December 2, 2019",,"December 2, 2019","Department of Sexual Health, Cwm Taf University Health board, Llantrisant, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04182230"
457,"NCT05399797","Management of Acute Uncomplicated UTIs in Adults by Community Pharmacists","[UTI]","Recruiting","No Results Available","Urinary Tract Infections|Urinary Tract Infection Lower Acute","Other: Educational training","Questioning skill score|Correct diagnosis of Acute Uncomplicated Urinary Tract Infection|Appropriate management of urinary tract infection","University of Ibadan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","taofiqclinical","March 21, 2022","September 2022","November 2022","June 1, 2022",,"June 1, 2022","University of Ibadan, Ibadan, Oyo, Nigeria",,"https://ClinicalTrials.gov/show/NCT05399797"
458,"NCT06353269","Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections",,"Recruiting","No Results Available","Recurrent Urinary Tract Infection|Hypoestrogenism","Drug: Estring Vaginal Product|Drug: Vagifem|Drug: Estrace 0.01% Vaginal Cream","Adherence to vaginal estrogen treatment|UTI rates|validated patient questionnaire - Urinary Distress Inventory Short Form (UDI-6)|validated patient questionnaires - UTI Symptoms Assessment Questionnaire (UTISA)|validated patient questionnaires - Treatment Satisfaction with Medications Questionnaire (SATMED-Q)|validated patient questionnaires - Patient Global Impression of Improvement Questionnaire (PGI-I)|validated patient questionnaires - Medication Adherence Report Scale (MARS-5)|optical coherence tomography measurements for nested OCT cohort - vaginal epithelial thickness|optical coherence tomography measurements for nested OCT cohort - blood vessel density|Vaginal health index for nested microbiome cohort|Vaginal maturation index for nested microbiome cohort|Urologic microbiome results for nested microbiome cohort|Vaginal microbiome results for nested microbiome cohort","University of California, Irvine","Female","18 Years and older   (Adult, Older Adult)","Phase 4","111","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","4255","April 2024","January 2027","October 2027","April 9, 2024",,"April 9, 2024","University of California Irvine Medical Center, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT06353269"
459,"NCT03638830","Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa",,"Unknown status","No Results Available","Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa|Pseudomonas Aeruginosa|Pseudomonas Infections|Urinary Tract Infections","Drug: Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim|Drug: Ftortiazinon (tablets 300 mg) full dose + Maxipim|Other: placebo+Maxipim","clinical cure and microbiological eradication|proportion of patients with clinical cure response|proportion of patients with response in the form of microbiological eradication|microbiological eradication|number of patients with treatment response as clinical cure|Number of Participants With Adverse Events|Number of Participants With Serious Adverse Events|Number of Participants with Solicited Local and Systemic Adverse Events","Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|Acellena Contract Drug Research and Development","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","777","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","04-FT-2018","October 17, 2018","December 31, 2021","January 31, 2022","August 20, 2018",,"January 14, 2021","Road Clinical Hospital of Open Joint Stock Company ""Russian Railways, Saint Petersburg, Russian Federation|St. Petersburg state budgetary institution of health care "" City hospital № 26"", Saint Petersburg, Russian Federation|Baltic Medicine, Saint-Petersburg, Russian Federation|Scientific and Research Center ""Eco-Safety"", Saint-Petersburg, Russian Federation|Vsevolozhsk Clinical Interdistrict Hospital, Vsevolozhsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03638830"
460,"NCT05584657","Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women","REASSURE","Active, not recruiting","No Results Available","Urinary Tract Infections|Cystitis","Drug: Sulopenem etzadroxil/probenecid|Drug: Amoxicillin/clavulanate","Percentage of Microbiologic Modified Intent to Treat (Micro-MITT) Participants with Overall Success|Percentage of Microbiologic Modified Intent to Treat Susceptible (Micro-MITTS) Participants With Overall Success|Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Overall Success|Percentage of Modified Intent to Treat (MITT) Participants With Clinical Success|Percentage of Microbiologic Modified Intent to Treat (Micro-MITT) Participants With Clinical Success|Percentage of Microbiologic Modified Intent to Treat Susceptible (Micro-MITTS) Participants With Clinical Success|Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Clinical Success|Percentage of Microbiologic Modified Intent to Treat (Micro-MITT) Participants With Asymptomatic Bacteriuria|Percentage of Microbiologic Modified Intent to Treat Susceptible (Micro-MITTS) Participants With Asymptomatic Bacteriuria|Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Asymptomatic Bacteriuria|Percentage of Microbiologic Modified Intent to Treat (Micro-MITT) Participants With Microbiologic Success|Percentage of Microbiologic Modified Intent to Treat Susceptible (Micro-MITTS) Participants With Microbiologic Success|Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Microbiologic Success","Iterum Therapeutics, International Limited","Female","18 Years and older   (Adult, Older Adult)","Phase 3","2229","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IT001-310","October 18, 2022","November 2023","November 2023","October 18, 2022",,"October 27, 2023","Medical Facility, Cullman, Alabama, United States|Medical Facility, Saraland, Alabama, United States|Medical Facility, Sheffield, Alabama, United States|Medical Facility, Peoria, Arizona, United States|Medical Facility3, Phoenix, Arizona, United States|Medical Facility, Phoenix, Arizona, United States|Medical Facility2, Phoenix, Arizona, United States|Medical Facility, Tucson, Arizona, United States|Medical Facility2, Hot Springs, Arkansas, United States|Medical Facility, Hot Springs, Arkansas, United States|Medical Facility, Bakersfield, California, United States|Medical Facility, Chula Vista, California, United States|Medical Facility, Fullerton, California, United States|Medical Facility, Garden Grove, California, United States|Medical Facility, Huntington Beach, California, United States|Medical Facility 2, Huntington Park, California, United States|Medical Facility, Huntington Park, California, United States|Medical Facility, Irvine, California, United States|Medical Facility, La Mesa, California, United States|Medical Facility, Lancaster, California, United States|Medical Facility, Lomita, California, United States|Medical Facility2, Los Angeles, California, United States|Medical Facility, Los Angeles, California, United States|Medical Facility, Pomona, California, United States|Medical Facility, Sacramento, California, United States|Medical Facility, San Diego, California, United States|Medical Facility, Upland, California, United States|Medical Facility, Victorville, California, United States|Medical Facility, Grand Junction, Colorado, United States|Medical Facility, Lakewood, Colorado, United States|Medical Facility, Aventura, Florida, United States|Medical Facility, Boynton Beach, Florida, United States|Medical Facility, Cape Coral, Florida, United States|Medical Facility, Doral, Florida, United States|Medical Facility, Edgewater, Florida, United States|Medical Facility, Hialeah, Florida, United States|Medical Facility, Hollywood, Florida, United States|Medical Facility, Homestead, Florida, United States|Medical Facility, Lake Worth, Florida, United States|Medical Facility2, Lake Worth, Florida, United States|Medical Facility, Leesburg, Florida, United States|Medical Facility, Miami Beach, Florida, United States|Medical Facility, Miami Gardens, Florida, United States|Medical Facility2, Miami Lakes, Florida, United States|Medical Facility, Miami Lakes, Florida, United States|Medical Facility3, Miami, Florida, United States|Medical Facility2, Miami, Florida, United States|Medical Facility, Miami, Florida, United States|Medical Facility9, Miami, Florida, United States|Medical Facility5, Miami, Florida, United States|Medical Facility8, Miami, Florida, United States|Medical Facility6, Miami, Florida, United States|Medical Facility7, Miami, Florida, United States|Medical Facility4, Miami, Florida, United States|Medical Facility, Orlando, Florida, United States|Medical Facility2, Orlando, Florida, United States|Medical Facility, Ormond Beach, Florida, United States|Medical Facility, Pompano Beach, Florida, United States|Medical Facility, Sweetwater, Florida, United States|Medical Facility, Tamarac, Florida, United States|Medical Facility, Tampa, Florida, United States|Medical Facility3, Tampa, Florida, United States|Medical Facility4, Tampa, Florida, United States|Medical Facility2, Tampa, Florida, United States|Medical Facility5, Tampa, Florida, United States|Medical Facility, Winter Haven, Florida, United States|Medical Facility3, Atlanta, Georgia, United States|Medical Facility2, Atlanta, Georgia, United States|Medical Facility, Atlanta, Georgia, United States|Medical Facility, Decatur, Georgia, United States|Medical Facility, Lawrenceville, Georgia, United States|Medical Facility, Union City, Georgia, United States|Medical Facility, Woodstock, Georgia, United States|Medical Facility, Blackfoot, Idaho, United States|Medical Facility2, Idaho Falls, Idaho, United States|Medical Facility, Idaho Falls, Idaho, United States|Medical Facility, Chicago, Illinois, United States|Medical Facility, Eunice, Louisiana, United States|Medical Facility, Mandeville, Louisiana, United States|Medical Facility, Marrero, Louisiana, United States|Medical Facility, Metairie, Louisiana, United States|Medical Facility, New Orleans, Louisiana, United States|Medical Facility2, New Orleans, Louisiana, United States|Medical Facility, Prairieville, Louisiana, United States|Medical Facility, Shreveport, Louisiana, United States|Medical Facility, Columbia, Maryland, United States|Medical Facility, Oxon Hill, Maryland, United States|Medical Facility, Towson, Maryland, United States|Medical Facility, Fayette, Mississippi, United States|Medical Facility, Gulfport, Mississippi, United States|Medical Facility, Jackson, Mississippi, United States|Medical Facility, Ridgeland, Mississippi, United States|Medical Facility, Great Falls, Montana, United States|Medical Facility, Kalispell, Montana, United States|Medical Facility, Missoula, Montana, United States|Medical Facility2, Las Vegas, Nevada, United States|Medical Facility, Las Vegas, Nevada, United States|Medical Facility2, Albuquerque, New Mexico, United States|Medical Facility, Albuquerque, New Mexico, United States|Medical Facility, Bronx, New York, United States|Medical Facility, Brooklyn, New York, United States|Medical Facility2, Brooklyn, New York, United States|Medical Facility, Garden City, New York, United States|Medical Facility, Schenectady, New York, United States|Medical Facility, Charlotte, North Carolina, United States|Medical Facility, Greensboro, North Carolina, United States|Medical Facility, New Bern, North Carolina, United States|Medical Facility, Winston-Salem, North Carolina, United States|Medical Facility, Cincinnati, Ohio, United States|Medical Facility2, Columbus, Ohio, United States|Medical Facility, Columbus, Ohio, United States|Medical Facility, Dayton, Ohio, United States|Medical Facility2, Dayton, Ohio, United States|Medical Facility, Lima, Ohio, United States|Medical Facility, Middleburg Heights, Ohio, United States|Medical Facility, Tulsa, Oklahoma, United States|Medical Facility, Eugene, Oregon, United States|Medical Facility, Portland, Oregon, United States|Medical Facility, Beaver, Pennsylvania, United States|Medical Facility, Scottdale, Pennsylvania, United States|Medical Facility, Smithfield, Pennsylvania, United States|Medical Facility, Upper Saint Clair, Pennsylvania, United States|Medical Facility, Charleston, South Carolina, United States|Medical Facility, Easley, South Carolina, United States|Medical Facility, Greenville, South Carolina, United States|Medical Facility, Lancaster, South Carolina, United States|Medical Facility, Myrtle Beach, South Carolina, United States|Medical Facility, Powdersville, South Carolina, United States|Medical Facility, Seneca, South Carolina, United States|Medical Facility, Summerville, South Carolina, United States|Medical Facility2, Chattanooga, Tennessee, United States|Medical Facility, Chattanooga, Tennessee, United States|Medical Facility, Hendersonville, Tennessee, United States|Medical Facility, Memphis, Tennessee, United States|Medical Facility, Nashville, Tennessee, United States|Medical Facility, Austin, Texas, United States|Medical Facility, Carrollton, Texas, United States|Medical Facility2, Carrollton, Texas, United States|Medical Facility, Corpus Christi, Texas, United States|Medical Facility, Dallas, Texas, United States|Medical Facility, Frisco, Texas, United States|Medical Facility, Georgetown, Texas, United States|Medical Facility2, Houston, Texas, United States|Medical Facility, Houston, Texas, United States|Medical Facility, Kingwood, Texas, United States|Medical Facility, League City, Texas, United States|Medical Facility2, McKinney, Texas, United States|Medical Facility, McKinney, Texas, United States|Medical Facility2, Mesquite, Texas, United States|Medical Facility, Mesquite, Texas, United States|Medical Facility, Missouri City, Texas, United States|Medical Facility, Pearland, Texas, United States|Medical Facility2, Plano, Texas, United States|Medical Facility, Plano, Texas, United States|Medical Facility, San Antonio, Texas, United States|Medical Facility 2, Sugar Land, Texas, United States|Medical Facility3, Sugar Land, Texas, United States|Medical Facility, Sugar Land, Texas, United States|Medical Facility 2, Draper, Utah, United States|Medical Facility, Draper, Utah, United States|Medical Facility, Pleasant Grove, Utah, United States|Medical Facility, Salt Lake City, Utah, United States|Medical Facility, Falls Church, Virginia, United States|Medical Facility, Manassas, Virginia, United States|Medical Facility, Norfolk, Virginia, United States|Medical Facility, Kingwood, West Virginia, United States|Medical Facility, Morgantown, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT05584657"
461,"NCT00210886","A Comparison of the Effectiveness and Safety of Levofloxacin to That of Ciprofloxacin in Treating Complicated Urinary Tract Infection and Acute Pyelonephritis.",,"Completed","No Results Available","Urinary Tract Infections|Pyelonephritis","Drug: levofloxacin","Combination of clinical success and microbiologic eradication (known as therapeutic response) at post-therapy visit.|By patient and pathogen microbiologic and clinical responses at the post-therapy and post-study visits.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PriCara, Unit of Ortho-McNeil, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","1109","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR004705","October 2004",,"April 2006","September 21, 2005",,"June 10, 2011",,,"https://ClinicalTrials.gov/show/NCT00210886"
462,"NCT05335213","Urinary Tract Infections in Cirrhosis",,"Unknown status","No Results Available","Liver Cirrhosis|Urinary Tract Infections","Diagnostic Test: 16S rRNA gene sequencing","Number of Participants with variceal bleeding|Number of Participants with hepatic coma|Number of Participants with hepatorenal syndrome","Gomel State Medical University","All","18 Years to 80 Years   (Adult, Older Adult)",,"35","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2.15","January 5, 2022","April 10, 2022","April 5, 2024","April 19, 2022",,"April 19, 2022","Gomel State Clinical Hospital №3, Gomel, Ilicha Str. 286, Belarus",,"https://ClinicalTrials.gov/show/NCT05335213"
463,"NCT02946346","Kinetics and Ecology of Human Papillomavirus Genital Infections in Young Women","PAPCLEAR","Terminated","No Results Available","HPV Genital Infection (Primary Condition Studied)|Bacterial Vaginosis|Chlamydiae Infection","Other: vaginal sampling","Times series of HPV virus load in cervical smears measured by qPCR|Times series of local innate and adaptive immune cell densities in cervical smears counted using Flow Cytometryor clearance)|Times series of vaginal cytokine densities measured using MesoScale Discovery technique|Times series of anti-HPV circulating antibody titers|Times series of the vaginal microbiota determined using 16S RNA and shotgun sequencing","University Hospital, Montpellier|Université Montpellier","Female","18 Years to 25 Years   (Adult)","Not Applicable","190","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","UF 9554","November 11, 2016","September 29, 2020","September 29, 2020","October 27, 2016",,"October 19, 2020","Pr Reynes, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT02946346"
464,"NCT04197739","Fixed-dose Amikacin for Elderly UTI",,"Unknown status","No Results Available","Urinary Tract Infections|Elderly Infection","Drug: Amikacin","Composite clinical failure|Rate of time-interval changes between amikacin doses|Rates of antimicrobial drug change|Clinical failure at day 5|Safety: acute kidney injury|Vestibular toxicity","Rabin Medical Center","All","65 Years and older   (Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RMC-0619-19","December 2019","December 2021","December 2021","December 13, 2019",,"December 13, 2019",,,"https://ClinicalTrials.gov/show/NCT04197739"
465,"NCT01114347","Prevention of Nosocomial E. Coli Infections After Placement of an Indwelling Catheter During Pelvic Surgery: an Evaluation of Cranberry Gel Capsules","NosoPink","Completed","No Results Available","Cross Infection|Bacteriuria","Dietary Supplement: cranberry type A pro anthocyandines|Dietary Supplement: Placebo","Presence/absence of Asymptomatic bacteriuria","Centre Hospitalier Universitaire de Nīmes","All","18 Years and older   (Adult, Older Adult)","Phase 2","270","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","AOI/2009/VL-01|2008-AO1604-51","August 2010","February 2014","March 2014","May 3, 2010",,"March 26, 2015","CHU de Nîmes - Hôpital Universitaire Carémeau, Nîmes, France",,"https://ClinicalTrials.gov/show/NCT01114347"
466,"NCT06059846","A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","PIVOT-PO","Recruiting","No Results Available","Urinary Tract Infection|Acute Pyelonephritis","Drug: TBP-PI-HBr|Drug: Imipenem-cilastatin|Drug: Dummy Infusion|Drug: Dummy Tablets","Number of Participants With Overall Response at the Test-of-Cure (TOC) Visit|Number of Participants in the Microbiologically Evaluable Population With Overall Response at the TOC Visit|Number of Participants With Overall Response at the End-of-Treatment (EOT) and Late Follow-Up (LFU) Visits|Number of Participants With Clinical Response at the EOT, TOC and LFU Visits|Number of Participants With Microbiological Response at the EOT, TOC and LFU Visits|Number of Participants With Overall Response at the EOT, TOC, and LFU Visits in Participants With Drug-resistant Enterobacterales|Number of Participants With Clinical Response at the EOT, TOC, and LFU Visits in Participants With Drug-resistant Enterobacterales|Number of Participants With Microbiological Response at the EOT, TOC, and LFU Visits in Participants With Drug-resistant Enterobacterales|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Plasma Concentration of Tebipenem","Spero Therapeutics|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","2648","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPR994-305|2023-503785-22-00","December 21, 2023","November 2025","December 2025","September 29, 2023",,"April 9, 2024","Medical facility, Miami, Florida, United States|Medical facility, Lom, Bulgaria|Medical facility, Ruse, Bulgaria|Medical facility, Shumen, Bulgaria|Medical facility, Sofia, Bulgaria|Medical facility, Tbilisi, Georgia|Medical Facility, Chisinau, Moldova, Republic of|Medical facility, Bucharest, Romania|Medical facility, Craiova, Romania|Medical facility, Belgrade, Serbia|Medical facility, Kragujevac, Serbia|Medical facility, Nis, Serbia|Medical facility, Novi Sad, Serbia|Medical facility, Benoni, South Africa|Medical facility, Durban, South Africa",,"https://ClinicalTrials.gov/show/NCT06059846"
467,"NCT02651428","Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection",,"Completed","Has Results","Kidney Failure, Chronic|Catheter-Related Infections","Drug: Neutrolin|Drug: Heparin","Presence of a CAC-Adjudicated Catheter-Related Bloodstream Infection (CRBSI) in Subjects Receiving Hemodialysis for the Treatment of End Stage Renal Disease (ESRD): Final Analysis|Participants With a Study Catheter Removal for Any Reason","CorMedix|PPD|JMI Laboratories|Spectra Clinical Research|Davita Clinical Research|Frenova Renal Research","All","18 Years and older   (Adult, Older Adult)","Phase 3","806","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","LOCK-IT-100","December 2015","October 2018","October 2018","January 11, 2016","August 31, 2021","August 31, 2021","Riverside Nephrology Physicians/Van Buren Dialysis center, Riverside, California, United States|North America Research Institute, San Dimas, California, United States|North Beach Dialysis Center Inc., Miami Gardens, Florida, United States|Lower Manhattan Dialysis Center, New York, New York, United States|Diagnostic Clinic of Houston, Houston, Texas, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/28/NCT02651428/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/28/NCT02651428/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02651428"
468,"NCT03147807","BetaLACTA® Test for Early De-escalation of Empirical Carbapenems in Pulmonary, Urinary and Bloodstream Infections in ICU","BLUE-CarbA","Completed","No Results Available","Pneumonia|Urinary Tract Infections|Bloodstream Infection","Device: betaLACTA® rapid diagnostic test","mortality at D90 and infection recurrence during the ICU stay|Exposure to carbapenems|Total use of ICU and hospital resources and cost-effectiveness of early de-escalation compared to standard de-escalation.|Occurrence of other infections.|Colonization of the digestive tractus of patients with 3rd generation cephalosporins (3rdGC) resistant Gram-negative bacteria|Composition of intestinal microbiota at Day 0|Composition of intestinal microbiota at day 3|Composition of intestinal microbiota after antibiotic exposur","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P 150940|N° IDRCB 2016-A00941-50","October 20, 2017","September 21, 2019","October 20, 2019","May 10, 2017",,"December 19, 2022","Anesthesiology and Critical Care Medicine Department, Paris, France",,"https://ClinicalTrials.gov/show/NCT03147807"
469,"NCT02486627","A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)","EPIC","Completed","Has Results","Complicated Urinary Tract Infection|Acute Pyelonephritis","Drug: plazomicin|Drug: meropenem|Drug: levofloxacin (oral)","Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the Microbiological Modified ITT (mMITT) Population at Day 5|Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the mMITT Population at Test of Cure (TOC)|Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the ME Population at Day 5|Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the ME Population at TOC|Percentage of Patients With Treatment-Emergent Adverse Events (TEAEs)|Plasma Pharmacokinetics (PK): Area Under the Curve From 0 to 24 Hours (AUC 0-24h)|Plasma PK: Maximum Observed Plasma Drug Concentration (Cmax)|Plasma PK: Minimum Observed Plasma Drug Concentration (Cmin)","Achaogen, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","609","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACHN-490-009|2015-001588-37|U1111-1171-1554","January 11, 2016","September 22, 2016","September 22, 2016","July 1, 2015","August 23, 2018","August 23, 2018",,,"https://ClinicalTrials.gov/show/NCT02486627"
470,"NCT00000920","Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Ritonavir|Drug: Saquinavir|Drug: Lamivudine|Drug: Zidovudine",,"National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years and older   (Child, Adult, Older Adult)","Phase 1","24","NIH","Interventional","Primary Purpose: Treatment","ACTG 386|11345|PACTG 386",,,"April 2003","August 31, 2001",,"October 29, 2021","Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States|Howard Univ Hosp, Washington, District of Columbia, United States|Univ of Miami / Jackson Memorial Hosp, Miami, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Univ of Illinois College of Medicine / Pediatrics, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Univ Hosp, New Orleans, Louisiana, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00000920"
471,"NCT05060419","Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections",,"Unknown status","No Results Available","Complicated Urinary Tract Infection|Acute Pyelonephritis","Drug: Meropenem- FL058|Drug: Piperacillin -tazobactam|Drug: Saline","Proportion of patients in the Microbiological Modified Intent to Treat (m-MITT) Population who achieve overall treatment success at Test Of Cure (TOC).","Qilu Pharmaceutical Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","FL058-II-01","October 8, 2021","April 29, 2022","August 31, 2022","September 29, 2021",,"September 29, 2021",,,"https://ClinicalTrials.gov/show/NCT05060419"
472,"NCT06022835","Chlorhexidine Gluconate-gel Dressing for Exit Site Infection in Peritoneal Dialysis",,"Completed","No Results Available","Peritoneal Dialysis Catheter Exit Site Infection|End Stage Renal Disease on Dialysis|Dialysis; Complications","Other: Chlorhexidine Gluconate-gel (CHG) Dressing","The incidence rate of exit site infection|time to first ESI and PD-associated peritonitis|PD-associated peritonitis|PD-related hospitalisation rate","National Healthcare Group, Singapore","All","21 Years to 99 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2019/00493","September 27, 2019","July 31, 2023","July 31, 2023","September 5, 2023",,"September 5, 2023","Allen Liu, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT06022835"
473,"NCT00670020","Supplemental Perioperative Oxygen to Reduce the Incidence of Post-Cesarean Endometritis and Wound Infection",,"Completed","No Results Available","Wound Infection or Endometritis Post Cesarean Section","Procedure: supplemental perioperative oxygen","surgical site infection","University of Washington","Female","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","143","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","18821","January 2001","December 2006","December 2006","May 1, 2008",,"May 1, 2008",,,"https://ClinicalTrials.gov/show/NCT00670020"
474,"NCT05091931","Diagnosis, Antibiotic Prescribing Practices and Outcomes of cUTI in an Outpatient Setting",,"Active, not recruiting","No Results Available","Urinary Tract Infections",,"The percentage of outpatients seen for suspected UTI started on empiric treatment|Rate of Adverse Events through 30 days|Resolution of the Initial UTI Symptoms by Day 14|Resolution of Symptoms|Antibiotics Concordance with Sensitivity Results|Biomarkers","Pathnostics","All","18 Years and older   (Adult, Older Adult)",,"10071","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2021-UTI-PMAS","March 28, 2022","June 23, 2024","June 23, 2024","October 25, 2021",,"February 21, 2024","Comprehensive Urology, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT05091931"
475,"NCT05435430","COVID-19 Infection and Reproductive Health in Infertile Women","COVINF","Recruiting","No Results Available","Infertility, Female","Other: PERSPECTIVE, MULTICENTRIC and observational","Main outcome|secondary outcomes","University of Palermo","Female","25 Years to 45 Years   (Adult)",,"150","Other","Observational","Observational Model: Other|Time Perspective: Prospective","AOOR VILLA SOFIA CERVELLO","September 1, 2022","September 30, 2023","March 1, 2024","June 28, 2022",,"June 28, 2022","Aoor Villa Sofia Cervello, Palermo, Italy",,"https://ClinicalTrials.gov/show/NCT05435430"
476,"NCT03508921","Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection",,"Terminated","Has Results","Overactive Bladder|Urinary Tract Infections","Drug: Periprocedural Antibiotics|Drug: Extended Antibiotics|Procedure: Injection of OnabotulinumtoxinA (BTX-A)","Post Procedural- Urinary Tract Infection|Urinary Retention|Recurrent Urinary Tract Infection","Vanderbilt University Medical Center|The Allergan Foundation|Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction","All","18 Years and older   (Adult, Older Adult)","Phase 4","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","00011112222","July 1, 2018","June 1, 2022","June 1, 2022","April 26, 2018","November 2, 2023","November 2, 2023","Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/21/NCT03508921/Prot_SAP_003.pdf","https://ClinicalTrials.gov/show/NCT03508921"
477,"NCT04682834","Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection",,"Available","No Results Available","Complicated Urinary Tract Infection|Acute Pyelonephritis","Drug: Sulopenem Etzadroxil/Probenecid",,"Iterum Therapeutics, International Limited","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"IT001-307",,,,"December 24, 2020",,"October 13, 2023",,,"https://ClinicalTrials.gov/show/NCT04682834"
478,"NCT00787085","The Significance of Funguria in Hospitalized Patients","FACES","Completed","No Results Available","Urinary Tract Infections",,"Funguria","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|National Institute of Allergy and Infectious Diseases (NIAID)|Cedars-Sinai Medical Center","All","Child, Adult, Older Adult",,"919","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","10024-05|NIH-AI01831","September 2001","February 2006","February 2006","November 7, 2008",,"November 7, 2008","Cedars-Sinai Medical Center, Los Angeles, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States",,"https://ClinicalTrials.gov/show/NCT00787085"
479,"NCT03146403","Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection",,"Terminated","Has Results","Genital Herpes|HSV-2 Infection","Biological: GEN-003|Biological: Matrix-M2|Other: 0.9% normal saline","Percentage of Days With Genital Herpes Lesions|Number of Genital Herpes Recurrences|Number of Subjects Without Genital Herpes Recurrence|Days Until First Genital Herpes Recurrence|Duration of Genital Herpes Recurrences","Genocea Biosciences, Inc.","All","Child, Adult, Older Adult","Phase 2","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GEN-003-005","May 24, 2017","December 22, 2017","June 11, 2018","May 9, 2017","February 19, 2019","February 19, 2019","University of Alabama Birmingham, Birmingham, Alabama, United States|Medical Center for Clinical Research, San Diego, California, United States|Optimus Medical Group, San Francisco, California, United States|UNC Health, Chapel Hill, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|NW Dermatology and Research Clinic, Portland, Oregon, United States|Tekton Research, Austin, Texas, United States|University of Washington, Seattle, Washington, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/03/NCT03146403/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/03/NCT03146403/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03146403"
480,"NCT04979806","Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)",,"Recruiting","No Results Available","Complicated Urinary Tract Infection|Acute Pyelonephritis","Drug: Cefepime-zidebactam (FEP-ZID)|Drug: Meropenem","Percentage of subjects with overall success at Test-of-Cure|Percentage of subjects with Treatment-Emergent Adverse Events (TEAE)|Percentage of subjects with overall success at End-of-Treatment|Percentage of subjects with clinical cure at End-of-Treatment|Percent of subjects with microbiological eradication at End-of-Treatment|Percentage of subjects with clinical cure at Test-of-Cure|Percent of subjects with microbiological eradication at Test-of-Cure|Percentage of subjects with clinical cure at Late Follow-up|Plasma Concentration of FEP-ZID","Wockhardt|Medpace, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","528","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","W-5222-301","August 28, 2022","April 2024","May 2024","July 28, 2021",,"December 14, 2023","Chula Vista, Chula Vista, California, United States|St. Louis, Saint Louis, Missouri, United States|Dobrich, Dobrich, Bulgaria|Pleven, Pleven, Bulgaria|Plovdiv, Plovdiv, Bulgaria|Ruse, Ruse, Bulgaria|Silistra, Silistra, Bulgaria|Sofia, Sofia, Bulgaria|Varna, Varna, Bulgaria|Changsha, Changsha, China|Changsha, Changsha, China|Changsha, Changsha, China|Chengdu, Chengdu, China|Chongqing, Chongqing, China|Liaoyang, Liaoyang, China|Shanghai, Shanghai, China|Kohtla-Jarve, Kohtla-Järve, Estonia|Tallinn, Tallinn, Estonia|Tallinn, Tallin, Estonia|Tartu, Tartu, Estonia|Voru, Võru, Estonia|Ahmedabad, Ahmedabad, Gujarat, India|Sūrat, Sūrat, Gujarat, India|Hisar, Hisar, Haryana, India|Bengaluru, Bengaluru, Karnataka, India|Nagpur, Nagpur, Maharashtra, India|Chandigarh, Chandigarh, Punjab, India|Kolkata, Kolkata, West Bengal, India|Kaunas, Kaunas, Lithuania|Klaipeda, Klaipeda, Lithuania|Vilnius, Vilnius, Lithuania|Vilnius, Vilnius, Lithuania|Vilnius, Vilnius, Lithuania|Chihuahua, Chihuahua, Mexico|Cuernavaca, Cuernavaca, Mexico|Guadalajara, Guadalajara, Mexico|Mérida, Mérida, Mexico|San Luis Potosí, San Luis Potosí, Mexico|Cusco, Cusco, Peru|Iquitos, Iquitos, Peru|Lima, Lima, Peru|Lima, Lima, Peru|Boleslawiec, Bolesławiec, Poland|Krakow, Krakow, Poland|Lodz, Lodz, Poland|Ostroleka, Ostroleka, Poland",,"https://ClinicalTrials.gov/show/NCT04979806"
481,"NCT01096849","A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)",,"Completed","Has Results","Complicated Urinary Tract Infection|Acute Pyelonephritis","Drug: levofloxacin|Drug: plazomicin|Drug: placebo","Percentage of Patients Who Attained Microbiological Eradication (MBE) at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population|Percentage of Patients Who Attained MBE at the TOC Visit in the Microbiologically Evaluable (ME) Population|Percentage of Patients With Treatment-Emergent Adverse Events (TEAE)|Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at TOC Visit in the Intent-to-treat (ITT) Population|Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at the TOC Visit in the CE Population|Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at the End of Treatment (EOT) Visit in the CE Population|Percentage of Patients Who Attained MBE at the EOT Visit in the ME Population|Percentage of Patients Who Attained MBE at the EOT Visit in the MITT Population|Percentage of Patients Who Attained MBE at the TOC Visit in the ME Population by Baseline Pathogen|Percentage of Patients Who Attained MBE at the TOC Visit in the ME Population Stratified by Infection Category|Percentage of Patients Who Attained MBE at the TOC Visit in the ME Population by Country/Region|Time (Days) to Resolution of Signs and Symptoms of cUTI and AP in the MITT Population|Time (Days) to Clinical Cure Based on Investigator's and Sponsor's Assessments in the MITT Population|Time (Days) to Defervescense in the MITT Population|Percentage of Patients Experiencing a Clinical Relapse or Microbiological Recurrence in the ME Population|Percentage of Patients With a Superinfection or New Infection in the ME Population","Achaogen, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","145","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACHN-490-002","July 13, 2010","April 3, 2012","April 3, 2012","March 31, 2010","August 22, 2018","August 22, 2018",,,"https://ClinicalTrials.gov/show/NCT01096849"
482,"NCT02886143","Effect of Active vs. Passive Voiding Trials on Time to Discharge, Urinary Tract Infection, and Urinary Retention",,"Completed","No Results Available","Urinary Retention|Urinary Tract Infections","Procedure: Active Voiding Trial|Procedure: Passive Voiding Trial","time from removal of Foley catheter until hospital discharge|urinary tract infection|Urinary retention","University of Virginia","All","18 Years and older   (Adult, Older Adult)","Phase 3","274","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","18345","October 2015","July 2016","July 2016","September 1, 2016",,"September 1, 2016",,,"https://ClinicalTrials.gov/show/NCT02886143"
483,"NCT03362697","Lactobacillus Reuteri for Treatment of Uncomplicated UTI in Pregnant Women","UTIPregnant","Completed","No Results Available","Urinary Tract Infection in Pregnancy","Dietary Supplement: Probiotics|Drug: Antibiotics","Clinical and/or Bacteriological cure|Recurrence rate|Time to relapse|Frequency of pyelonephritis|Frequency of preterm babies|Antibiotic rescue|Adverse events","Innovacion y Desarrollo de Estrategias en Salud|BioGaia AB","Female","18 Years to 40 Years   (Adult)","Not Applicable","150","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CSUB 0139","December 15, 2017","December 30, 2018","June 18, 2019","December 5, 2017",,"June 20, 2019","Hospital General Dr. Manuel Gea Gonzalez, Mexico city, Tlalpan, Mexico",,"https://ClinicalTrials.gov/show/NCT03362697"
484,"NCT05887908","Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis","Integral-1","Recruiting","No Results Available","Complicated Urinary Tract Infection|Acute Pyelonephritis","Drug: co-administration of cefepime and nacubactam|Drug: co-administration of aztreonam and nacubactam|Drug: imipenem/cilastatin","The primary efficacy endpoint is the proportion of patients who achieve composite clinical and microbiological success at TOC in the Microbiological Modified Intent-to-Treat (m-MITT) Population.","Meiji Seika Pharma Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OP0595-5","May 23, 2023","August 2024","August 2024","June 5, 2023",,"June 5, 2023","Meiji Research Site, Meegomäe, Voru, Estonia",,"https://ClinicalTrials.gov/show/NCT05887908"
485,"NCT05385939","Gastric Bacterial Colonization of Preterm Neonates",,"Completed","No Results Available","Microbial Colonization|Preterm Birth","Other: Observational","Microorganisms identified in stool samples|Microorganisms identified in environmental samples","Christiana Care Health Services|University of Delaware","All","1 Week to 6 Months   (Child)",,"122","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Christiana Care Health System","April 1, 2019","October 31, 2021","May 1, 2022","May 23, 2022",,"May 23, 2022","Christiana Care Health Services, Inc., Newark, Delaware, United States",,"https://ClinicalTrials.gov/show/NCT05385939"
486,"NCT00722735","Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI)","FLUT","Completed","No Results Available","Urinary Tract Infections","Drug: Finafloxacin|Drug: Ciprofloxacin","Bacteriological eradication of the initial pathogen.|Clinical cure: Absence of signs or symptoms of uUTI.","MerLion Pharmaceuticals GmbH","Female","18 Years to 55 Years   (Adult)","Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FINA-003","October 2008","April 2009","April 2009","July 28, 2008",,"June 11, 2009","Medical practice, Dr. J. Hein (Principal Study Investigator), Marburg, Germany|National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT00722735"
487,"NCT01477502","Clinical Value of Homeopathic Prophylaxis of Recurrent Urinary Tract Infections in Persons With Spinal Cord Injury",,"Completed","No Results Available","Symptomatic Urinary Tract Infection|Spinal Cord Injury","Other: individual homeopathic treatment|Other: standard treatment without homeopathy","number of symptomatic urinary tract infections|number of symptomatic urinary tract infections compared to the previous year","Swiss Paraplegic Research, Nottwil","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2011-24|11050","November 2011","August 2016","October 2016","November 22, 2011",,"February 13, 2024","Swiss Paraplegic center, Nottwil, Lucerne, Switzerland",,"https://ClinicalTrials.gov/show/NCT01477502"
488,"NCT00591240","A Biochip for Rapid Diagnosis of Complicated Urinary Tract Infection",,"Completed","Has Results","Urinary Tract Infections|Bladder, Neurogenic",,"Clinical Validation of Biosensor Assays Used for Pathogen Identification and Antimicrobial Susceptibility Testing in Patients at Risk of Urinary Tract Infections.","VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)",,"338","U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","B4872-R","July 2007","June 2011","June 2011","January 11, 2008","June 27, 2016","June 27, 2016","VA Palo Alto Health Care System, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT00591240"
489,"NCT02753946","Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections","ZEUS","Completed","Has Results","Urinary Tract Infection Symptomatic|Acute Pyelonephritis|Urinary Tract Infection Complicated","Drug: ZTI-01|Drug: Piperacillin-tazobactam","Number of Patients With an Overall Success|Number of Patients With a Response of Clinical Cure in Various Protocol Populations|Number of Patients With a Response of Microbiologic Eradication","Nabriva Therapeutics AG|Medpace, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","465","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ZTI-01-200|2015-003372-73","April 2016","January 12, 2017","May 30, 2017","April 28, 2016","December 11, 2018","March 7, 2019","Pensacola, Florida, United States|Augusta, Georgia, United States|Columbus, Georgia, United States|Boylston, Massachusetts, United States|Saint Louis, Missouri, United States|Butte, Montana, United States|Brest, Belarus|Gomel, Belarus|Grodno, Belarus|Minsk, Belarus|Vitebsk, Belarus|Plovdiv, Bulgaria|Sofia, Bulgaria|Slavonski Brod, Croatia|Split, Croatia|Zagreb, Croatia|Brno, Czechia|Hradec Kralove, Czechia|Liberec, Czechia|Kohtla Jarve, Estonia|Tallinn, Estonia|Batumi, Georgia|Kutaisi, Georgia|Tbilisi, Georgia|Ambelokipoi, Greece|Athens, Greece|Thessaloníki, Greece|Budapest, Hungary|Miskolc, Hungary|Nagykanizsa, Hungary|Pecs, Hungary|Szekszard, Hungary|Szentes, Hungary|Riga, Latvia|Valmiera, Latvia|Kaunas, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Bielsko-Biala, Poland|Krakow, Poland|Lodz, Poland|Piaseczno, Poland|Tychy, Poland|Wrocław, Poland|Zamosc, Poland|Bucharest, Romania|Craiova, Romania|Oradea, Romania|Krasnoyarsk, Russian Federation|Moscow, Zelenograd, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Penza, Russian Federation|Rostov-On-Don, Russian Federation|Saratov, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|St. Petersburg, Russian Federation|Vsevolozhsk, Russian Federation|Martin, Slovakia|Poprad, Slovakia|Zilina, Slovakia|Chernihiv, Ukraine|Dnipropetrovsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Odesa, Ukraine|Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT02753946"
490,"NCT03630081","Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)",,"Not yet recruiting","No Results Available","Complicated Urinary Tract Infection|Acute Pyelonephritis","Drug: WCK 4282 (FEP-TAZ) 4 g|Drug: Meropenem|Drug: ciprofloxacin 500 mg Optional Oral Switch|Other: Infusion of normal saline","Percentage of subjects with overall success at Day 5|Percentage of subjects with overall success at Test-of-Cure|Percentage of subjects with Treatment-Emergent Adverse Events (TEAE)","Wockhardt","All","18 Years and older   (Adult, Older Adult)","Phase 3","1004","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","W-4282-301","January 2024","January 2026","February 2026","August 14, 2018",,"July 17, 2023",,,"https://ClinicalTrials.gov/show/NCT03630081"
491,"NCT00594594","Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury",,"Terminated","No Results Available","Spinal Cord Injury|Urinary Tract Infections","Other: Probiotic Lactobacillus GR-1 and RC-14","Increase time to next UTI|Numbers of infections of any type occurring during probiotic treatment","Lawson Health Research Institute|Ontario Neurotrauma Foundation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","2","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","R-06-213|HSREB 12845","September 2007","May 2009","May 2009","January 15, 2008",,"July 7, 2009","St. Joseph's Health Care, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00594594"
492,"NCT04130165","Matching Donor Human Milk On Maternal Secretor Status (MMOMSS) Study","MMOMSS","Recruiting","No Results Available","Microbial Colonization|Preterm Birth","Other: Matched donor human milk","Fecal microbiome composition","University of Manitoba|University of Calgary","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","REB19-0542","May 29, 2023","July 31, 2024","July 31, 2025","October 17, 2019",,"June 2, 2023","University of Calgary, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04130165"
493,"NCT04669886","Serum Endotoxin Assay to Predict the Development of Postoperative Infectious Complications and Systemic Inflammatory Response Following Percutaneous Nephrolithotomy.",,"Recruiting","No Results Available","Nephrolithiasis|Urosepsis",,"Number of participants at each endotoxin activity level after surgery.|Corelation of endotoxin activity level with post-operative infectious complication","University of Miami","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20200234","November 1, 2023","April 30, 2025","September 1, 2025","December 17, 2020",,"November 30, 2023","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04669886"
494,"NCT00713999","Urogenital Schistosomiasis and Sexually Transmitted Infections in Madagascar","FGS/MGS/STI","Completed","No Results Available","Sexually Transmitted Infections|Schistosoma Haematobium","Drug: Treatment with anti-STI and anti-schistosoma regimens","Measurement of urogenital schistosomiasis and STI prevalence|Urogenital and STI associated morbidity","University of Aarhus|Statens Serum Institut","All","15 Years to 49 Years   (Child, Adult)","Not Applicable","680","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","IPM/DBL 01|RFU 1008600437","August 2001","April 2002","September 2003","July 14, 2008",,"July 14, 2008","Institut Pasteur, Antananarivo, Madagascar",,"https://ClinicalTrials.gov/show/NCT00713999"
495,"NCT03230838","MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)",,"Completed","Has Results","Complicated Urinary Tract Infection|Pyelonephritis","Drug: Ceftolozane/Tazobactam|Drug: Meropenem","Number of Participants With ≥1 Adverse Events (AEs)|Number of Participants Discontinuing Study Therapy Due to AE|Percentage of Participants With a Clinical Response of Cure at the Test of Cure Visit|Percentage of Participants With a Clinical Response of Cure at the End of Treatment Visit|Percentage of Participants With Microbiological Eradication of All Baseline Pathogens at the Test of Cure Visit|Percentage of Participants With Microbiological Eradication of All Baseline Pathogens at the End of Treatment Visit","Merck Sharp & Dohme LLC","All","7 Days to 17 Years   (Child)","Phase 2","134","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","7625A-034|2016-004153-32","April 26, 2018","December 3, 2020","December 3, 2020","July 26, 2017","December 1, 2021","May 6, 2023","Children's Hospital - Los Angeles ( Site 2509), Los Angeles, California, United States|Children's Hospital of Orange County ( Site 2502), Orange, California, United States|Rady Children's Hospital-San Diego ( Site 2505), San Diego, California, United States|Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 2519), Chicago, Illinois, United States|Our Lady of the Lake Hospital ( Site 2512), Baton Rouge, Louisiana, United States|St. Louis Children's Hospital ( Site 2508), Saint Louis, Missouri, United States|SUNY Upstate Medical University Hospital ( Site 2510), Syracuse, New York, United States|Wake Forest Baptist Health ( Site 2520), Winston-Salem, North Carolina, United States|Baylor College Of Medicine ( Site 2515), Houston, Texas, United States|Pan and Aglaia Kyriakou Children s Hospital ( Site 0780), Athens, Attiki, Greece|University of Athens - Aghia Sophia Childrens Hospital ( Site 0730), Athens, Attiki, Greece|Athens University Hospital ATTIKON ( Site 0790), Athens, Attiki, Greece|General University Hospital of Larissa ( Site 0740), Larissa, Thessalia, Greece|Hippokration General Hospital of Thessaloniki ( Site 0700), Thessaloniki, Thessaloníki, Greece|PTE AOK Klinikai Kozpont ( Site 0809), Pecs, Baranya, Hungary|SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 0804), Szeged, Csongrad, Hungary|SzSzBMK es Egyetemi Oktatokorhaz Josa Andras Oktatokorhaz ( Site 0808), Nyiregyhaza, Szabolcs-Szatmar-Bereg, Hungary|Semmelweis Egyetem ( Site 0810), Budapest, Hungary|Heim Pal Orszagos Gyermekgyogyaszati Intezet ( Site 0801), Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont ( Site 0803), Debrecen, Hungary|Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 1202), Guadalajara, Jalisco, Mexico|Instituto Tecnologico y de Estudios Superiores de Monterrey ( Site 1204), Monterrey, Nuevo Leon, Mexico|Instituto Nacional de Pediatria ( Site 1201), Mexico City, Mexico|Hospital Infantil de Mexico Federico Gomez ( Site 1203), Mexico City, Mexico|Wojewodzki Szpital Obserwacyjno Zakazny ( Site 1606), Bydgoszcz, Kujawsko-pomorskie, Poland|Szpital Uniwersytecki nr 1 im. Dr. Antoniego Jurasza w Bydgoszczy ( Site 1600), Bydgoszcz, Kujawsko-pomorskie, Poland|Wojewodzki Szpital Zespolony im. Rydgiera ( Site 1607), Torun, Kujawsko-pomorskie, Poland|Instytut Centrum Zdrowia Matki Polki ( Site 1602), Lodz, Lodzkie, Poland|Uniw. Szpital Dzieciecy w Krakowie ( Site 1609), Krakow, Malopolskie, Poland|SPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym ( Site 1608), Lomianki, Mazowieckie, Poland|Spitalul Clinic de Urgenta pentru Copii Maria Sklodowska Curie ( Site 1707), Bucharest, Bucuresti, Romania|Spit. Cl. de Urg. Copii Cluj Napoca ( Site 1708), Cluj-Napoca, Cluj, Romania|Spitalul Clinic de Urgenta pentru Copii Brasov ( Site 1703), Brasov, Romania|Institutul National de Boli Infectioase Prof. Dr. Matei Bals ( Site 1706), Bucuresti, Romania|Russian Pediatric Clinical Hospital ( Site 1808), Moscow, Moskva, Russian Federation|St.Petersburg State Pediatric Medical University ( Site 1811), Saint Petersburg, Sankt-Peterburg, Russian Federation|Smolensk Regional Clinical Hospital ( Site 1800), Smolensk, Smolenskaya Oblast, Russian Federation|Regional Childrens Clinical Hospital ( Site 1805), Stavropol, Stavropol Skiy Kray, Russian Federation|Molotlegi Street ( Site 1903), Pretoria, Gauteng, South Africa|Inkosi Albert Luthuli Central Hospital ( Site 1902), Durban, Kwazulu-Natal, South Africa|Red Cross War Memorial Children's Hospital ( Site 1900), Cape Town, Western Cape, South Africa|Cukurova Universitesi Tıp Fakultesi Balcalı Hastanesi ( Site 2200), Adana, Turkey|Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 2201), Ankara, Turkey|Eskisehir Osmangazi Unv. Tip Fakultesi ( Site 2202), Eskisehir, Turkey|SBU Sariyer Hamidiye Etfal Egitim ve Arastirma Hastanesi ( Site 2203), Istanbul, Turkey|SI Dnipropetrovsk Regional Children Clinical Hospital DOR ( Site 2402), Dnipro, Dnipropetrovska Oblast, Ukraine|PI Kryvorizka city clinical hospital 8 ( Site 2408), Kryvyy Rig, Dnipropetrovska Oblast, Ukraine|Ivano-Frankivsk Regional Children Clinical Hospital ( Site 2411), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|Reg. Clinical Center of Urology and Nephrology n.a. V. I. Shapoval ( Site 2410), Kharkiv, Kharkivska Oblast, Ukraine|Kharkiv City Children Hospital 16 ( Site 2414), Kharkiv, Kharkivska Oblast, Ukraine|National Children Specialised Hospital OHMADYT MOH Ukraine ( Site 2409), Kyiv, Kyivska Oblast, Ukraine|Municipal Institution City Children s Clinical Hospital of Poltava City Council ( Site 2404), Poltava, Poltavska Oblast, Ukraine","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/38/NCT03230838/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03230838"
496,"NCT03445195","Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections",,"Completed","Has Results","Complicated Urinary Tract Infection|Acute Pyelonephritis","Drug: Sulbactam-ETX2514|Drug: Placebo|Drug: Imipenem-cilastatin","Number of Participants With Overall Success|Clinical Cure|Microbiologic Eradication","Entasis Therapeutics","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CS2514-2017-0003","January 17, 2018","May 17, 2018","May 17, 2018","February 26, 2018","June 5, 2019","January 22, 2020","Universeity Multiprofile Hospital for Active Teatment, Sofia, Bulgaria|University Multiprofile Hospital for Active Teatment-Clinic of Nephrology, Sofia, Bulgaria|Multiprofile Hospital for Active Teatment (MHAT) and Emergency Medicine - Pirogov, Sofia, Bulgaria|Multiprofile Hospital for Active Teatment (MHAT) and Emergency Medicine - Doverie, Sofia, Bulgaria","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/95/NCT03445195/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/95/NCT03445195/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03445195"
497,"NCT00869427","Vitamin C for Prevention of Urinary Tract Infections in the Spinal Cord Injured",,"Terminated","No Results Available","Urinary Tract Infection|Spinal Cord Injury","Drug: vitamin C","Clinical episodes of UVI treated by antibiotics|Silent bacteriuria","Sunnaas Rehabilitation Hospital|Dentsply Sirona Implants and Consumables","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","545-07286a 1.2007.2483 (REK)|2007-005657-29 (EudraCT)","March 2009","June 2011","June 2011","March 26, 2009",,"July 5, 2010",,,"https://ClinicalTrials.gov/show/NCT00869427"
498,"NCT06164600","Bovine Colostrum for Prophylaxis Against Recurrent Urinary Tract Infection in Children",,"Recruiting","No Results Available","Urinary Tract Infections|Recurrent|Child|Prevention & Control|Infections|Urologic Diseases|Communicable Diseases","Dietary Supplement: Bovine colostrum|Drug: Placebo","Number of symptomatic UTIs|Number of UTIs with urinary bacterial colony count through urinary catheter > 10,000 CFU/ml having fever and pyuria|Number of patients with asymptomatic bacteruria|Number of asymptomatic patients with bacterial colony count > 10.000 CFU/ml and< 50,000 for specimen collected by urinary catheter.|Number of symptomatic infections elsewhere GIT/respiratory|Adverse effects to the prescribed bovine colostrum: GIT problems or allergy","Ain Shams University","All","up to 18 Years   (Child, Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","FMAUS MS 2444/2023","June 1, 2023","February 2024","March 2024","December 11, 2023",,"December 11, 2023","Ain Shams University Pediatric Hospital, Cairo, Abbasseiya, Egypt",,"https://ClinicalTrials.gov/show/NCT06164600"
499,"NCT03719755","Urinary Tract Infections Rates Using 50% Dextrose Plus Washout Versus Normal Saline as Cystoscopy Fluid",,"Active, not recruiting","No Results Available","Hysterectomy","Procedure: 50% dextrose|Procedure: Normal Saline","rates of urinary tract infections at 6-9 days post-operative","Mayo Clinic","Female","Child, Adult, Older Adult","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","17-000176","February 1, 2018","December 30, 2024","December 30, 2024","October 25, 2018",,"March 26, 2024","Mayo Clinic, Scottsdale, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03719755"
500,"NCT03127280","Can Investigators Reduce Urinary Catheter Use and Lower Urinary Tract Infection Among Women Undergoing Benign Gynecologic Surgery?","CAUTI","Completed","No Results Available","Urinary Tract Infections|Urinary Retention|Satisfaction","Other: Fast Track foley removal","Foley Duration|Incidence of urinary tract infection|Patient satisfaction|Voiding dysfunction","The Christ Hospital","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","14-38","November 4, 2014","January 1, 2018","January 14, 2018","April 25, 2017",,"January 30, 2018","The Christ Hospital, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03127280"
501,"NCT06257576","Function of Tamsulosin in Older Males Undergoing Surgery With Indwelling Catheter","FOLI","Recruiting","No Results Available","Postoperative Urinary Tract Infection","Drug: Tamsulosin|Other: Control Group","Number of participants who develop postoperative urinary retention (POUR) postoperatively (efficacy).|Number of participants with catheter-associated urinary tract infections (CAUTI),","Emory University|ABRAHAM J & PHYLLIS KATZ FOUNDATION","Male","50 Years and older   (Adult, Older Adult)","Phase 3","212","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STUDY00006810","February 26, 2024","February 2026","August 2026","February 14, 2024",,"March 6, 2024","Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital (EUH), Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT06257576"
502,"NCT04165252","Vaginal, Placental and Neonatal Buccal Mycobiota and Microbiome in Preterm Birth",,"Unknown status","No Results Available","Preterm Birth|Microbial Colonization","Diagnostic Test: Collection of vaginal, neonatal buccal and placental samples","Characterization of Maternal-Fetal microbiome and mycobiome|The effect of progesterone on maternal microbiome (vaginal and placenta) with progesterone|Variety of microbial and mycobial fingerprintings","Koç University|The Scientific and Technological Research Council of Turkey","Female","18 Years to 45 Years   (Adult)",,"92","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","119S463","April 1, 2020","December 1, 2021","December 1, 2022","November 15, 2019",,"June 2, 2021","Koc University Hospital, Istanbul, Turkey","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/52/NCT04165252/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04165252"
503,"NCT05726318","Randomized Trial of Culture Directed Versus Empiric Antibiotics for Urinary Tract Infections in Older Women","REDUCTION","Recruiting","No Results Available","UTI","Drug: Antibiotics","Proportion of eligible participants that were enrolled in the study|Number of persons that were screened for participation|Proportion of persons screened who met inclusion/exclusion criteria|Proportion of persons screened who declined participation or were ineligible|Proportion of participants enrolled who completed the study|Monthly enrollment rate|Proportion of enrolled participants that completed all study procedures|Proportion of enrolled participants that took alternative agents for management of symptoms|Proportion of participants in the culture-directed arm that acquired off-protocol antibiotics for their symptoms|Proportion of enrolled participants that completed electronic surveys","Megan Bradley|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pittsburgh","Female","65 Years and older   (Older Adult)","Phase 4","70","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY22060176|DK131273","February 17, 2023","June 2024","July 2024","February 13, 2023",,"February 7, 2024","Magee Women's Hospital of UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05726318"
504,"NCT04694495","HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study",,"Unknown status","No Results Available","Papillomavirus Infections|Uterine Cervical Neoplasms|Sexual Transmitted Disease","Diagnostic Test: 16S rRNA gene sequencing of cervical secretions","alteration of genital microecology from baseline at month 6","Zhujiang Hospital|Peking University Hospital|The Affiliated Hospital Of Guizhou Medical University|Hainan People's Hospital|LanZhou University|Lianyungang Hospital Affiliated Bengbu Medical College|General Hospital of Ningxia Medical University|Jinan Central Hospital|First Affiliated Hospital Xi'an Jiaotong University|Tibet Autonomous Region People's Hospital|The Affiliated Hospital Of Southwest Medical University|Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region|Yan'an Hospital of Kunming City|The First Affiliated Hospital of University of Science and Technology of China|Zunyi First People's Hospital|Peking University Shenzhen Hospital|Dongguan People's Hospital|Guangdong Provincial Hospital of Integrated Traditional Chinese and Western Medicine|The Third Affiliated Hospital of Southern Medical University|Taihe Branch of Nanfang Hospital|First Affiliated Hospital, Sun Yat-Sen University|Shenzhen Luohu Hospital Group Luohu People's Hospital|Zhuhai Center for Maternal and Child Health Care|Obstetrics & Gynecology Hospital of Fudan University|First Affiliated Hospital of Guangxi Medical University|The Second Hospital of Hebei Medical University|Jilin Central General Hospital|The First Hospital fo Qiqihar|Qinghai Red Cross Hospital|Changzhi People's Hospital|Shanghai East Hospital Tongji University|Sir Run Run Shaw Hospital|The Third Affiliated Hospital of Guangzhou University of Chinese Medicine|Fifth Affiliated Hospital of Guangzhou Medical University|Shenzhen Hospital of Guangzhou University of Chinese Medicine|Huizhou Municipal Central Hospital|First Affiliated Hospital of Jinan University|Nanfang Hospital, Southern Medical University|Shenzhen Third People's Hospital|Yuebei People's Hospital|The Seventh Affiliated Hospital of Sun Yat-sen University|Xiaolan People's Hospital of Zhongshan|Chaozhou Central Hospital|The Third Affiliated Hospital of CQMU|Changsha Central Hospital","Female","18 Years to 50 Years   (Adult)",,"10000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CALM2004","November 12, 2020","December 11, 2021","December 12, 2022","January 5, 2021",,"August 3, 2021","The First Affiliated Hospital of USTC, Hefei, Anhui, China|The First Hospital of Lanzhou University, Lanzhou, Gansu, China|Chaozhou Central Hospital, Chaozhou, Guangdong, China|Dongguan People's Hospital, Dongguan, Guangdong, China|Guangdong Provincial Hospital of Intergrated Traditional Chinese and Western Medicine, Foshan, Guangdong, China|Zhujiang Hospital, Guangzhou, Guangdong, China|Nanfang Hospital, Guangzhou, Guangdong, China|Taihe Branch of Nanfang Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China|The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China|The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China|Huizhou Municipal Central Hospital, Huizhou, Guangdong, China|Peking University Shenzhen Hospital, Shenzhen, Guangdong, China|Shenzhen Hospital of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China|Shenzhen Luohu Hospital Group Luohu People's Hospital, Shenzhen, Guangdong, China|The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China|The Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China|Xiaolan People's Hospital of Zhongshan, Zhongshan, Guangdong, China|The First Affiliated Hospital, Sun Yat-Sen Univeristy, Guangzhou, Guangzhou, China|Zhuhai Women and Children's Hospital, Zhuhai, Guangzhou, China|The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China|The First People's Hospital of Zunyi, Zunyi, Guizhou, China|Yue Bei People's Hospital, Shaoguan, Gunagdong, China|Hainan General Hospital, Haikou, Hainan, China|The Second Hospital of Hebei Medical University, Shijia Zhuang, Hebei, China|The First Hospital fo Qiqihar, Qiqihar, Hei Longjiang, China|The Second People's Hospital of Lianyungang, Lianyungang, Jiangsu, China|Jilin Central General Hospital, Jilin, Jilin, China|General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|Qinghai Red Cross Hospital, Xining, Qinghai, China|Jinan Central Hospital, Jinan, Shandong, China|Obstetrics&Gynecology Hospital of Fudan University, Shanghai, Shanghai, China|Changzhi People's Hospital, Changzhi, Shanxi, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China|The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China|Tibet Autonomous Region People's Hospital, Lasa, Tibet, China|Yan'an Hospital of Kunming City, Kunming, Yunnan, China|Sir Run Run Shaw Hospital, Hanzhou, Zhejiang, China|Changsha Central Hospital, Changsha, China|The Third Affiliated Hospital of CQMU, Chongqing, China|The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|Shanghai East Hospital Tongji University, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04694495"
505,"NCT03506256","Noroxin Efficacy and Safety Trial","NEST","Unknown status","No Results Available","Urinary Tract Infections","Drug: Norfloxacin 400 MG","Number of Patients treated with Noroxin (Efficacy)|Number of Adverse Effects with Noroxin (Safety)","OBS Pakistan","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","1000","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OBS-NEST-003","May 10, 2018","June 10, 2018","July 30, 2018","April 24, 2018",,"April 24, 2018",,,"https://ClinicalTrials.gov/show/NCT03506256"
506,"NCT00554996","Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study",,"Completed","Has Results","Urinary Tract Infection","Device: E. coli 83972 coated urinary catheter","Rate of UTI While Colonized With E. Coli 83972.","US Department of Veterans Affairs|VA Office of Research and Development","All","50 Years and older   (Adult, Older Adult)","Phase 1","10","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","B4623-R","August 2012","June 2014","June 2014","November 7, 2007","September 16, 2015","October 16, 2015","Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00554996"
507,"NCT01345929","Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis",,"Completed","Has Results","Complicated Urinary Tract Infection|Pyelonephritis","Drug: CXA-201|Drug: Levofloxacin","The Percentage of Subjects Who Have Both a Per-subject Microbiological Outcome of Eradication and a Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Modified ITT (mMITT) Population|The Percentage of Subjects Who Have Both a Per-subject Microbiological Outcome of Eradication and a Clinical Outcome of Cure at the TOC Visit in the Microbiologically Evaluable (ME) Population.","Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","All","18 Years and older   (Adult, Older Adult)","Phase 3","558","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","7625A-005|CXA-cUTI-10-04|CXA-cUTI-10-05","June 20, 2011","August 11, 2013","September 4, 2013","May 2, 2011","January 15, 2015","October 25, 2018","San Diego, California, United States|Wheat Ridge, Colorado, United States|Hialeah, Florida, United States|Teaneck, New Jersey, United States|Charleston, South Carolina, United States|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande De Sul, Brazil|Joinville, Santa Catarina, Brazil|Campinas, Sao Paulo, Brazil|Sao Jose De Rio Preto, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Cali, Valle Del Cauca, Colombia|Armenia, Colombia|Barranquilla, Colombia|Bogota, Colombia|Kohtla-Jarve, Estonia|Tallinn, Estonia|Tartu, Estonia|Tbilsi, Georgia|Giessen, Hessen, Germany|Lubeck, Schleswig-Holstein, Germany|Miskolc, Borsod-Abauj-Zemplen, Hungary|Gyor, Budapest, Hungary|Szentes, Csongrad, Hungary|Sopron, Gyor-moson-sopron, Hungary|Salgotarjan, Nograd, Hungary|Nyiregyhaza, Szabolcs-Szatmar-Bereg, Hungary|Zalaegerszeg, Zala, Hungary|Budapest, Hungary|Tatabánya, Hungary|Kfar Saba, Sharon, Israel|Petach Tikva, Teah Tiqwa, Israel|Tel Hashomer, Tel Aviv, Israel|Haifa, Israel|Jerusalem, Israel|Safed, Israel|Daugavpils, Latvia|Liepaja, Latvia|Riga, Latvia|Valmiera, Latvia|Ventspills, Latvia|Guadalajara, Jalisco, Mexico|Chihuahua, Mexico|San Luis Potosi, Mexico|Veracruz, Mexico|Chisinau, Moldova, Republic of|Oradea, Bihor, Romania|Bucharest, Bucuresti, Romania|Timisoara, Timis, Romania|Brasov, Romania|Bucuresti, Romania|Iasi, Romania|Sibiu, Romania|Kemerovo, Russian Federation|Moscow, Russian Federation|Nizhniy Novgorod, Russian Federation|Novosibirsk, Russian Federation|Penza, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|Belgrade, Serbia|Banska Bystrica, Slovakia|Levice, Slovakia|Martin, Slovakia|Presov, Slovakia|Skalica, Slovakia|Bloemfontein, Free State, South Africa|Pretoria, Gauteng, South Africa|Soweto, Gauteng, South Africa|Middleburg, Mpumalanga, South Africa|Bellville, Western Cape, South Africa|Nakorn Ratchasima, Nakhon Ratchasima, Thailand|Chiang Mai, Thailand|Lop Buri, Thailand|Prachuap Khiri Khan, Thailand",,"https://ClinicalTrials.gov/show/NCT01345929"
508,"NCT03299387","INtravesical Antimicrobial Agents v STANDard Oral Antibiotics for the Treatment of Acute UTI in Women With rUTI","INSTANT","Withdrawn","No Results Available","Urinary Tract Infections","Drug: Nitrofurantoin|Drug: Gentamicin","Change in microbiologic effect of a chronic acute Urinary Tract Infection|Change in symptomatic relief of a chronic acute Urinary Tract Infection|To establish the clinical FTE needs for providing urgent intravesical treatments","Mayo Clinic","Female","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-002887","June 28, 2017","July 5, 2018","July 5, 2018","October 3, 2017",,"June 6, 2019",,,"https://ClinicalTrials.gov/show/NCT03299387"
509,"NCT04910802","Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden",,"Recruiting","No Results Available","HPV Infection|CIN 2/3|Cervical Cancer","Biological: Gardasil9","Prevalence of HPV|Number of women with histopathologically confirmed cervical intraepithelial neoplasia grade 2, 3, or cervical cancer (CIN2+)|Consumption of resources|Number of women with obstetrical complications|Number of women with cervical specimens found to be benign","Miriam Elfström|Karolinska University Hospital|Region Stockholm","Female","22 Years to 27 Years   (Adult)","Phase 4","150000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Catch-up vaccination","May 3, 2021","December 31, 2025","December 31, 2027","June 2, 2021",,"September 16, 2021","Cancer prevention, screening, and counseling unit, Regional Cancer Center of Stockholm-Gotland, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT04910802"
510,"NCT04735042","SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.","UTI-flog","Unknown status","No Results Available","Type 2 Diabetes|Urinary Tract Infections","Drug: Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill|Drug: Empagliflozin or Dapagliflozin Pill","Change from Baseline in metagenomic analysis based on rRNA 16S gene|Change from Baseline of total bacterial load|Fasting glucose|Glycated Haemoglobin|Renal function|Albumin excretion|Total cholesterol|HDL cholesterol|Triglycerides","University of Pisa","All","18 Years to 70 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AS0005","October 7, 2020","October 7, 2021","April 7, 2022","February 2, 2021",,"February 2, 2021","University of Pisa, Pisa, Italy",,"https://ClinicalTrials.gov/show/NCT04735042"
511,"NCT00875069","Efficacy and Safety of Ethanol Lock Solution in Prevention of Catheter Related Bloodstream Infection for Patients Suffering Acute Renal Failure, and Hospitalized in Intensive Care Unit. A Multi-Center, Randomized, Versus Placebo, Double Blinded Clinical Trial","ELVIS","Completed","No Results Available","Acute Renal Failure|Infection","Other: Ethanol","The number of major catheter-related infections (CRI) defined as either catheter-related clinical sepsis without bloodstream infection or catheter-related bloodstream infection (CRBSI), during the ICU stay|frequencies of catheter colonization, severe mechanical complications, and adverse events","University Hospital, Clermont-Ferrand","All","18 Years and older   (Adult, Older Adult)","Phase 3","1460","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","CHU-0050","April 2009","June 2011","February 2013","April 3, 2009",,"June 16, 2014","CHU Clermont-Ferrand, Clermont-Ferrand, France",,"https://ClinicalTrials.gov/show/NCT00875069"
512,"NCT04488770","Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.",,"Completed","Has Results","Urinary Tract Infections","Drug: GSK3882347|Drug: Placebo","Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part 2: Number of Participants With Non-serious AEs and SAEs|Part 1: Number of Participants With Treatment Related AEs|Part 2: Number of Participants With Treatment Related AEs|Part 1: Number of Participants With Worst-case Hematology Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline|Part 2: Number of Participants With Worst-case Hematology Results Relative to PCI Criteria Post-Baseline Relative to Baseline|Part 1: Number of Participants With Worst-case Clinical Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline|Part 2: Number of Participants With Worst-case Clinical Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline|Part 1: Number of Participants With Worst Case Urinalysis Results Post Baseline Relative to Baseline|Part 2: Number of Participants With Worst Case Urinalysis Results Post Baseline Relative to Baseline|Part 1: Number of Participants With Worst Case Vital Signs Results Relative to PCI Criteria Post Baseline Relative to Baseline|Part 2: Number of Participants With Worst Case Vital Signs Results Relative to PCI Criteria Post Baseline Relative to Baseline|Part 1: Number of Participants With Worst Case Abnormal Electrocardiogram (ECG) Results Post Baseline Relative to Baseline|Part 2: Number of Participants With Worst Case Abnormal ECG Results Post Baseline Relative to Baseline|Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose Administration of GSK3882347|Part 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC[0-t]) After Single Dose Administration of GSK3882347|Part 1: Area Under the Concentration-time Curve Extrapolated From Time Zero to Infinity (AUC[0-infinity]) After Single Dose Administration of GSK3882347|Part 1: Maximum Plasma Concentration (Cmax) After Single Dose Administration of GSK3882347|Part 1: Plasma Concentrations at 24 Hours (C24h) After Single Dose Administration of GSK3882347|Part 1: Time to Cmax (Tmax) After Single Dose Administration of GSK3882347|Part 1: Lag Time for Absorption (Tlag) After Single Dose Administration of GSK3882347|Part 1: Terminal Elimination Half-life (T1/2) After Single Dose Administration of GSK3882347|Part 2: Area Under the Concentration-time Curve Over the Dosing Interval Tau (AUC[0-tau]) After Repeat Dose Administration of GSK3882347|Part 2: Cmax After Repeat Dose Administration of GSK3882347|Part 2: Tmax After Repeat Dose Administration of GSK3882347|Part 2: Plasma Concentrations Over the Dosing Interval (Ctau) After Repeat Dose Administration of GSK3882347|Part 1: Urine Concentration Between 22-24 Hours (C22-24) After Single Dose Administration of GSK3882347|Part 2: Urine Concentration Between 22-24 Hours (C22-24) After Repeat Dose Administration of GSK3882347|Part 1: Amount of Drug Excreted in Urine of Unchanged Drug (Ae Total) After Single Dose Administration of GSK3882347|Part 2: Amount of Drug Excreted in Urine of Unchanged Drug (Ae Total) After Repeat Dose Administration of GSK3882347|Part 1: Percentage of the Given Dose of Drug Excreted in Urine (%fe Total) After Single Dose Administration of GSK3882347|Part 2: Percentage of the Given Dose of Drug Excreted in Urine (%fe Total) After Single Dose Administration of GSK3882347|Part 1: Renal Clearance of Drug (CLr) After Single Dose Administration of GSK3882347|Part 2: Renal Clearance of Drug (CLr) After Repeat Dose Administration of GSK3882347|Part 1: Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) After Single Dose Administration of GSK3882347|Part 1: Plasma Concentrations at 12 Hours (C12) After Single Dose Administration of GSK3882347|Part 1: Apparent Oral Clearance (CL/F) After Single Dose Administration of GSK3882347|Part 1: Apparent Volume of Distribution After Oral Administration (Vz/F) After Single Dose Administration of GSK3882347|Part 1: Mean Residence Time (MRT) After Single Dose Administration of GSK3882347|Part 2: Area Under the Concentration-time Curve From Time Zero to 12 Hours (AUC[0-12]) After Repeat Dose Administration of GSK3882347|Part 2: Plasma Concentrations at 12 Hours (C12) After Repeat Dose Administration of GSK3882347|Part 1: Dose Proportionality of GSK3882347 for Dose Levels 15 mg to 900 mg Using AUC(0-infinity) After Single Dose Administration of GSK3882347 Under Fasted Condition|Part 1: Dose Proportionality of GSK3882347 for Dose Levels 15 mg to 900 mg Using Cmax After Single Dose Administration of GSK3882347 Under Fasted Condition|Part 2: Dose Proportionality of GSK3882347 for Dose Levels 50 mg to 900 mg Using AUC(0-tau) After Repeat Dose Administration of GSK3882347|Part 2: Dose Proportionality of GSK3882347 for Dose Levels 50 mg to 900 mg Using Cmax After Repeat Dose Administration of GSK3882347|Part 2: Observed Accumulation Ratio (Ro) Using AUC(0-tau) After Repeat Dose Administration of GSK3882347|Part 2: Time Invariance of GSK3882347|Part 2: Pre-dose Plasma Concentrations After Repeat Dose Administration of GSK3882347 From Days 3 to 7|Part 1: Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect|Part 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC [0-t]) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect|Part 1: Area Under the Concentration-time Curve Extrapolated From Time Zero to Infinity (AUC [0-infinity]) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect|Part 1: Maximum Plasma Concentration (Cmax) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect|Part 1: Plasma Concentrations at 24 Hours (C24h) After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect|Part 1: Tmax After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect|Part 1: Tlag After Single Dose Administration of GSK3882347 250 mg Under Fasted and Fed Conditions for Assessment of Food Effect","GlaxoSmithKline|Department of Health and Human Services|Wellcome Trust","All","18 Years to 50 Years   (Adult)","Phase 1","61","Industry|U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","212148|2020-000680-23","August 24, 2020","May 14, 2021","May 14, 2021","July 28, 2020","February 17, 2023","February 17, 2023","GSK Investigational Site, Cambridge, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/70/NCT04488770/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/70/NCT04488770/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04488770"
513,"NCT01861561","Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children","Low/highIVCY","Terminated","No Results Available","Renal Insufficiency|Infection","Drug: Low-dose intravenous cyclophosphamide|Drug: High-dose intravenous cyclophosphamide","renal response|infection","Mahidol University","All","up to 15 Years   (Child)","Phase 4","43","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","125/2556(EC2)","May 2013","May 2019","May 2019","May 23, 2013",,"September 4, 2020","Nephrology division, Department of Pediatrics, Siriraj Hospital, Bangkoknoi, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT01861561"
514,"NCT00243360","Optimizing Antibiotic Use in Long Term Care",,"Completed","No Results Available","Urinary Tract Infection, Antibiotic Use","Behavioral: diagnostic and treatment clinical algorithms","Antimicrobial prescriptions|Urinary cultures,|hospitalizations, deaths","Agency for Healthcare Research and Quality (AHRQ)","All","0 Years and older   (Child, Adult, Older Adult)","Not Applicable",,"U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training","U18HS011113-01","January 2001",,"July 2003","October 24, 2005",,"October 24, 2005","McMaster University, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00243360"
515,"NCT05219110","Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection","HIKO-STEC","Recruiting","No Results Available","Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection|Hemolytic-Uremic Syndrome","Other: Infusion of 200% maintenance fluids as balanced crystalloid IV solution|Other: Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution","Major Adverse Kidney Events by 30 days (MAKE30)|Number of Participants with Significant Extrarenal Complications (life-threatening):|Number of Participants who Develop HUS among those without it at randomization","University of Calgary|National Institute of Allergy and Infectious Diseases (NIAID)|Children's Hospital Medical Center, Cincinnati|Washington University School of Medicine|University of Utah|Seattle Children's Hospital|University of Colorado, Denver|Emory University|University of California, Davis|Baylor College of Medicine|Indiana University School of Medicine|University of Alabama at Birmingham|Arkansas Children's Hospital Research Institute|Children's National Research Institute|Children's Hospitals and Clinics of Minnesota|Medical University of South Carolina|University of Louisville|University of Oklahoma|Oregon Health and Science University|University of California, San Diego|McMaster University|The Hospital for Sick Children|University of Alberta|University of Kentucky|Case Western Reserve University|Nationwide Children's Hospital|Vanderbilt University Medical Center","All","9 Months to 21 Years   (Child, Adult)","Phase 3","1040","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DMID 21-0042|R01AI165327","September 29, 2022","August 31, 2026","August 31, 2027","February 1, 2022",,"July 25, 2023","University of Alabama at Birmingham, Birmingham, Alabama, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|University of California, San Diego, La Jolla, California, United States|University of California, Davis, Sacramento, California, United States|University of Colorado Denver, Denver, Colorado, United States|Children's Research Institute, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Indiana University Children's Hospital, Indianapolis, Indiana, United States|University of Kentucky, Lexington, Kentucky, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Children's Minnesota Hospital, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Children's Hospital Medical Center, Cincinnati, Ohio, United States|University Hospitals Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|Alberta Children's Hospital, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|McMaster University, Hamilton, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT05219110"
516,"NCT01952964","The Effects of Anti-microbial Spray Dressing in Preventing Tenckhoff Catheter Exit Site Infection for End Stage Renal Failure Patients","JUCspray","Unknown status","No Results Available","Signs and Symptoms of Exit Site Infection|Physical Damage of the Tenckhoff Catheter|Skin Allery","Other: JUC spray dressing","The effectiveness of spray dressing in preventing exit site infection|Prevention of infection|Prevention of skin allergy","The Queen Elizabeth Hospital|The Hong Kong Polytechnic University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","78","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","KC/KE-10-0196/ER-3","March 2011","September 2013","October 2013","September 30, 2013",,"September 30, 2013","Renal Unit of Queen Elizabeth Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT01952964"
517,"NCT01978938","Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections",,"Completed","Has Results","cUTI","Drug: Eravacycline|Drug: Levofloxacin","Participants In The Microbiological Intent-To-Treat (Micro-ITT) Population With A Responder Outcome At The Post-Treatment (PT) Visit|Participants In The Microbiological Modified ITT (Micro-MITT) Population With A Microbiological Response|Participants In The Microbiologically Evaluable (ME) Population With A Microbiological Response","Tetraphase Pharmaceuticals, Inc.|La Jolla Pharmaceutical Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","908","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TP-434-010","October 6, 2014","June 3, 2015","August 21, 2015","November 8, 2013","December 11, 2018","January 11, 2022","San Diego Clinical Trials, San Diego, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|Tampa General Hospital, Tampa, Florida, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sunrise Hospital and Medical Centre, Las Vegas, Nevada, United States|Columbus Regional Research Institute, Columbus, Ohio, United States|Multiprofile Hospital for Active Treatment ""Dr. Tota Venkova"", Gabrovo, Department of Nephrology, Gabrovo, Bulgaria|Multiprofile Hospital for Active Treatment ""Dr. Stamen Iliev"", Montana, Department of Nephrology and Dialysis, Montana, Bulgaria|University Multiprofile Hospital for Active Treatment ""Dr. Georgi Stranski"", Pleven, Urology Clinic, Pleven, Bulgaria|Multiprofile Hospital for Active Treatment, Ruse, Department of Urology, Rousse, Bulgaria|Multiprofile Hospital for Active Treatment, Sofia at Military Medical Academy, General Urology Clinic, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment ""Aleksandrovska"", Sofia, Department of Laparoscopic Urology, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment and Emergency Medicine ""N.I. Pirogov"", Sofia, Urology Clinic, Sofia, Bulgaria|Multiprofile Regional Hospital for Active Treatment ""Dr. Stefan Cherkezov"", Veliko Tarnovo, Department of Urology, Veliko Tarnovo, Bulgaria|Fundacion Cardiomet, Armenia, Colombia|De la Costa Clinic. Ltd. Research Centre, Barranquilla, Colombia|University Hospital Brno, Clinic of Urology, Brno, Czechia|University Hospital Hradec Kralove, Clinic of Urology, Hradec Kralove, Czechia|Hospital Novy Jicin, Department of Urology, Novy Jicin, Czechia|University Hospital Olomouc, Olomouc, Czechia|Thomayer Hospital, Department of Urology, Prague, Czechia|East Viru Central Hospital, Surgery Clinic, Kohtla-Jarve, Estonia|East Tallinn Central Hospital, Department of Internal Medicine, Tallinn, Estonia|West Tallinn Central Hospital, Department of Urology, Tallinn, Estonia|Tartu University Hospital, Surgery Clinic, Department of Urology and Renal Transplantation, Tartu, Estonia|Western Georgia National Medical Center, Kutaisi, Georgia|Aversi Clinic, Tbilisi, Georgia|Modern Medical Technologies - Guram Karazanashvili's clinic, Tbilisi, Georgia|Research Institute of Clinical Medicine, Tbilisi, Georgia|Tsulukidze National Center of Urology, Tbilisi, Georgia|Evaggelismos Hospital, Kolonaki, Greece|Papageorgiou General Hospital, Thessaloníki, Greece|Principal SMO Kft., Baja, Hungary|Jahn Ferenc South Pest Hospital, Department of Urology, Budapest, Hungary|Petz Aladar County Teaching Hospital, Department of Urology, Gyor, Hungary|Elisabeth Teaching Hospital and Rehabilitation Institute of Sopron, Department of Urology, Sopron, Hungary|Csongrad County Dr. Bugyi Istvan Hospital, Department of Urology, Szentes, Hungary|St. Borbala Hospital, Department of Urology, Tatabanya, Hungary|Zion Medical Center, Haifa, Israel|Hospital Mater Domini, Castellanza, Italy|Liepajas Regional Hospital, Liepaja, Latvia|P. Stradins Clinical University Hospital, Riga, Latvia|Riga East University Hospital, LLC, Riga, Latvia|SIA 'URO' Clinic, Riga, Latvia|Vidzemes Hospital, Valmiera, Latvia|Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico|Hospital Civil Guadalajara Dr. Juan I. Mendoza, Guadalajara, Mexico|National Scientific Practical Center for Emergency Medicine, Department of Urology, Chisinau, Moldova, Republic of|Republican Clinical Hospital, Department of Urology, Chisinau, Moldova, Republic of|Boni Fratres Catoviensis Sp. z o.o., Department of Internal Diseases with Cardiologic Diagnostics Unit, Katowice, Poland|Military Medical Academy University Teaching Hospital - Central Veterans' Hospital, Clinical and Didactic Center of the Medical University of Lodz, Teaching Department of Nephrology, Hypertension and Renal Transplantation, Lodz, Poland|Medicome Sp. z o.o., Oswiecim, Poland|HEUREKA Hanna Szalecka, Piaseczno, Poland|Pope John Paul 2nd Independent Public Provincial Hospital, Zamość, Poland|Emergency Clinical County Hospital Brasov, Brasov, Romania|""Prof. Dr. Th. Burghele"" Clinical Hospital, Bucharest, Romania|Delta Hospital, Bucharest, Romania|Craiova Emergency Clinical County Hospital, Craiova, Romania|Clinical Hospital ""Dr. C. I. Parhon"", Iași, Romania|Oradea Clinical Municipal Hospital ""Dr. Gavril Curteanu"", Oradea, Romania|Sibiu County Emergency Clinical Hospital, Sibiu, Romania|Central Clinical Hospital of Civil Aviation, Moscow, Russian Federation|City Clinical Hospital #57 under Moscow Healthcare Department, Moscow, Russian Federation|Federal Clinical Center for High Medical Technologies, Moscow, Russian Federation|City Clinical Hospital of Emergency Care #2, Novosibirsk, Russian Federation|Penza Regional Clinical Hospital n.a. N.N. Burdenko, Penza, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|North-Western State Medical University n.a. I.I. Mechnikov, Saint Petersburg, Russian Federation|Saint-Petersburg Scientific Research Institute for Phthisiopulmonology, Saint Petersburg, Russian Federation|St. Petersburg Clinical Hospital under the Russian Academy of Sciences, Saint Petersburg, Russian Federation|St. Petersburg State Healthcare Institution: City Hospital #15, Saint Petersburg, Russian Federation|St. Petersburg State Healthcare Institution: St. George the Martyr City Hospital, Saint Petersburg, Russian Federation|St. Petersburg State-Funded Healthcare Institution: City Hospital #26, Saint Petersburg, Russian Federation|Saratov State Medical University n.a. V.I. Razumovsky, Saratov, Russian Federation|Smolensk Regional Clinical Hospital, Smolensk, Russian Federation|Novgorod Regional Clinical Hospital, Veliky Novgorod, Russian Federation|Vsevolozhsk Clinical Central District Hospital, Vsevolozhsk, Russian Federation|Lakeview Hospital, Benoni, South Africa|Clinresco Centres, Kempton Park, South Africa|Mzansi Ethical Research Centre, Middleburg, South Africa|St. Georges Hospital, Port Elizabeth, South Africa|Regional Municipal Institution ""Chernivtsi Regional Hospital"", Chernivtsi, Ukraine|Dnipropetrovsk City Multispecialty Clinical Hospital #4, Dnipropetrovsk, Ukraine|Dnipropetrovsk I.I. Mechnikov Regional Clinical Hospital, Dnipropetrovsk, Ukraine|Ivano-Frankivsk City Clinical Hospital #1, Ivano-Frankivs'k, Ukraine|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivs'k, Ukraine|O.I. Meschaninov Clinical Hospital of Emergency and Urgent Medical Care, Kharkiv, Ukraine|Shapoval Regional Clinical Center of Urology and Nephrology, Kharkiv, Ukraine|Khmelnytskyi Regional Hospital, Khmel'nyts'kyy, Ukraine|Institute of Urology, Kyiv, Ukraine|Lviv Regional Clinical Hospital, L'viv, Ukraine|Volyn Regional Clinical Hospital, Luts'k, Ukraine|Mykolaiv Regional Hospital, Center for Nephrology and Dialysis, Mykolaiv, Ukraine|City Clinical Hospital #10, Urology Department #1, Odesa, Ukraine|Odesa Regional Clinical Hospital, Odessa, Ukraine|Poltava M.V. Sklifosovskyi Regional Clinical Hospital, Poltava, Ukraine|State Institution: Uzhhorod Railway Station Clinical Hospital under State Territorial Industry-Specific Association:Lviv Railway, Uzhhorod, Ukraine|Vinnytsia M.I. Pyrohov Regional Clinical Hospital, Vinnytsya, Ukraine|Municipal Institution ""Zaporizhzhia Reqional Clinical Hospital"" of Zaporizhzhia Regional Councill, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01978938"
518,"NCT00564135","Postoperative Urinary Retention and Urinary Track Infection (UTI) After Laparoscopic Assisted Vaginal Hysterectomy (LAVH) for Benign Disease",,"Completed","No Results Available","Hysterectomy|Urinary Retention|Urinary Tract Infection","Procedure: on Foley time","all cause mortality","Chang Gung Memorial Hospital","Female","34 Years to 68 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","96-0424C","March 2007","January 2008","July 2008","November 27, 2007",,"June 3, 2015",,,"https://ClinicalTrials.gov/show/NCT00564135"
519,"NCT00847392","Study to Determine Pediatric Bladder Volume Prior to Catheterization","PV-BUS","Withdrawn","No Results Available","Urinary Tract Infection","Procedure: Ultrasound prior to bladder catheterization","The proportion of patients in each arm from whom at least 2 ml of urine is obtained on first attempt at catheterization.","Hamilton Health Sciences Corporation|McMaster University","All","up to 36 Months   (Child)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PV-BUS","March 2009","June 2009","June 2009","February 19, 2009",,"September 19, 2016","Hamilton Health Sciences, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00847392"
520,"NCT06069102","Optimal Blood Pressure Treatment Thresholds Postpartum",,"Recruiting","No Results Available","Hypertensive Disorder of Pregnancy|Pre-Eclampsia|Hypertension|Eclampsia|Gestational Hypertension|Cardiovascular Diseases|Toxemia|Pregnancy Complications|Vascular Diseases|Hypertension, Pregnancy Induced|Hypertension;Pre-Eclamptic","Drug: Usual care|Drug: Tight blood pressure control","Percent of participants eligible, enrolled and retained (feasibility)|Anti-hypertensive medication use (efficacy)|Anti-hypertensive medication use|Mean arterial pressure (efficacy)|Mean arterial pressure|Systolic blood pressure|Diastolic blood pressure|Change in MAP|Change in systolic BP|Change in diastolic BP|Proportion of participants with readmissions|Proportion of participants with ER visits","Alisse Hauspurg|University of Pittsburgh","Female","18 Years to 55 Years   (Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STUDY23060147","November 15, 2023","January 1, 2025","December 1, 2025","October 5, 2023",,"March 1, 2024","University of Pittsburgh Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT06069102"
521,"NCT03981458","Hyaluronate for the Treatment and Prevention of Recurrent Urinary Tract Infection in Women Suffering Atrophic Vaginitis","HATPIN","Unknown status","No Results Available","Atrophic Vaginitis|Urinary Tract Infections","Device: Hyalofemme|Device: Ialuril","Reduced incidence of medically confirmed urinary tract infection|Number of microbiologically-proven UTIs|Effect on vaginal atrophy|Uropathogen identification|Innate immune response in urine and vaginal douche samples measured by ELISA for cytokines and antimicrobial peptides (e.g. interleukin-8, beta-defensin 2).|Analysis of polymorphisms in receptor proteins known to be involved in UTI|Participant quality of life - does either treatment increase overall quality of life by decreasing symptoms from UTI and/or atrophy?|Reduction in antibiotic use for UTI as a result of hyaluronate treatment by either route of administration","Newcastle-upon-Tyne Hospitals NHS Trust|The Urology Foundation, UK","Female","30 Years to 90 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HATPIN|8904","July 1, 2019","July 2020","July 2020","June 10, 2019",,"July 8, 2019","Freeman Hospital, Newcastle upon Tyne, Tyne And Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03981458"
522,"NCT01079169","Effect of Cranberry Capsules on Urinary Infection Rates in Spinal Cord Injured Patients During Post Acute Rehabilitation",,"Terminated","No Results Available","Spinal Cord Injury|Urinary Tract Infection|Rehabilitation","Dietary Supplement: Cranberry capsules","Number of symptomatic urinary tract infections per patient per month during in-patient post acute rehabilitation|Percentage of in-patient rehabilitation days on which patients were unable to participate in active rehabilitation due to urinary tract infection.|Patient's experience of urinary symptoms in the absence of symptomatic urinary tract infection.","Uppsala University","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","2009/280","March 2010","March 2012","March 2012","March 3, 2010",,"May 16, 2016","Dept of Rehabilitation Medicine, University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT01079169"
523,"NCT06052033","Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection",,"Recruiting","No Results Available","HPV-Related Cervical Carcinoma|Low-Grade Squamous Intraepithelial Lesions|HPV Infection|Photodynamic Therapy","Procedure: CO2","Regression of Cervical Lesions.|Adverse Events.","First Affiliated Hospital of Wenzhou Medical University","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","KY2023-188","September 11, 2023","August 10, 2024","September 1, 2024","September 25, 2023",,"September 26, 2023","first affiliated hospital of Wenzhou medical university, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT06052033"
524,"NCT00732238","Multifaceted Treatment of Catheter-related Urinary Tract Infection",,"Completed","Has Results","Spinal Cord Injury|Neurogenic Bladder|Urinary Tract Infection","Other: Shortened course of antibiotic therapy|Other: Standard Therapy","The Primary Efficacy Outcome of the Study is Response to Treatment Which Will be Assessed at the End of Therapy. Successful Response to Treatment is Defined as Resolution of Clinical Manifestations of Infection Plus Lack of Growth of the Original Infect|The Secondary Efficacy Outcome is Recurrence of UTI up to 180 Days After the End of Therapy","US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Phase 2","61","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B4747-P|H-18309","July 2007","December 2012","December 2012","August 11, 2008","November 2, 2014","February 16, 2015","Michael E. DeBakey VA Medical Center (152), Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00732238"
525,"NCT05384197","Enhanced Versus Extended Preoperative Antibiotic Prophylaxis Regimens for Retrograde Intrarenal Surgery in High Infectious Risk Patients",,"Recruiting","No Results Available","Renal Stone","Drug: Enhanced regimen|Drug: Extended regimen","Rate of postoperative sepsis|Rate of postoperative fever|Rate of postoperative UTI","Mansoura University","All","18 Years and older   (Adult, Older Adult)","Phase 3","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AS-5-2022","May 1, 2022","May 1, 2023","July 1, 2023","May 20, 2022",,"November 14, 2022","Mansoura Urology and Nephrology Center, Mansoura, Outside U.S./Canada, Egypt",,"https://ClinicalTrials.gov/show/NCT05384197"
526,"NCT02044965","Can Probiotics be Used in the Prevention of Recurrent UTI in Paediatric Neurogenic Bladder",,"Unknown status","No Results Available","Urinary Tract Infection","Other: Antibiotic|Drug: Probiotic","Side effects|Mean number of recurrent urinary tract infection episodes|Time to first urinary tract infection|Changes in pro-inflammatory cytokines|Changes in metabolomic profiles of urine|Bladder storage function","London Health Sciences Centre|Canadian Urological Association","All","12 Years to 17 Years   (Child)","Phase 1|Phase 2","36","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","LHSC - AP 1","January 2015","December 2022","December 2023","January 24, 2014",,"September 9, 2021","London Health Sciences Centre, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02044965"
527,"NCT00458471","E. Coli for Prevention of Catheter UTI in SCI Patients",,"Completed","No Results Available","Urinary Tract Infection(UTI)","Device: Insertion of a urinary catheter coated with benign E. coli","bladder colonization and rate of urinary tract infection","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","18 Years to 64 Years   (Adult)","Phase 1","12","NIH","Interventional","Allocation: Non-Randomized|Primary Purpose: Prevention","H-11717","November 2003",,"July 2005","April 10, 2007",,"April 10, 2007","Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00458471"
528,"NCT04936815","Echocardiographic Screening of Pregnant Women During Antenatal Care",,"Recruiting","No Results Available","Valvular Heart Disease|Rheumatic Heart Disease|Pregnancy Complications","Diagnostic Test: Transthoracic echocardiography","Composite endpoint|Incidence of maternal adverse events|Incidence of fetal/neonatal adverse events","Thomas Pilgrim|B.P. Koirala Institute of Health Sciences|Insel Gruppe AG, University Hospital Bern","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","9000","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","IRC/2121/021","December 1, 2021","November 30, 2024","December 31, 2024","June 23, 2021",,"December 23, 2022","B.P. Koirala Institute of Health Sciences, Dharān Bāzār, Nepal|Department of Cardiology, Bern University Hospital, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT04936815"
529,"NCT00451386","Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)",,"Completed","No Results Available","Urinary Tract Infections|Bacterial Pneumonia|Soft Tissue Infections","Drug: MK0826, ertapenem sodium /Duration of Treatment: 14 Days|Drug: Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days","To evaluate the incidence of any clinical and/or laboratory drug-related serious adverse experience during the parenteral therapy period in pediatric patients treated with ertapenem.|To compare the safety of ertapenem versus ceftriaxone during the parenteral therapy period with respect to the proportion of patients with any drug-related adverse experiences in pediatric patients with UTI, SSTI, or CAP.","Merck Sharp & Dohme LLC","All","3 Months to 17 Years   (Child)","Phase 2","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0826-036|2007_525","January 2002","December 2003","December 2003","March 23, 2007",,"February 17, 2017",,,"https://ClinicalTrials.gov/show/NCT00451386"
530,"NCT01102738","Defining the Intestinal Microbiota in Premature Neonates",,"Completed","Has Results","Premature Intestinal Microbiota|Necrotizing Enterocolitis|Late Onset Bloodstream Infection",,"The Composition of Bacteria Present, Established by Ultra-deep RNA Gene Sequencing, in Pre-morbid Faecal Samples From Neonates With Necrotizing Enterocolitis and Late-onset Bacterial Sepsis.","Imperial College London|The Winnicott Foundation|National Heart and Lung Institute|Chelsea and Westminster NHS Foundation Trust","All","up to 32 Weeks   (Child)",,"369","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","CR01542","January 2011","January 2013","June 2014","April 13, 2010","May 1, 2020","May 1, 2020","Imperial College London, London, United Kingdom|Queen Charlotte's and Chelsea Hospital - NICU, London, United Kingdom|St. Mary's Hospital - Winnicott Baby Unit, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01102738"
531,"NCT00116974","Periodontal Infection and Prematurity Study",,"Terminated","No Results Available","Periodontal Diseases|Premature Birth","Procedure: Scaling and root planing","Whether screening and treating periodontal disease using scaling and root planing early in pregnancy can reduce the incidence of spontaneous preterm birth <35 weeks","University of Pennsylvania","Female","Child, Adult, Older Adult","Phase 3","2100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","801404","October 2004","February 2009","February 2009","July 1, 2005",,"August 15, 2016","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00116974"
532,"NCT02304770","Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia",,"Completed","No Results Available","Cervical Persistent High Risk HPV Infection|Cervical Intraepithelial Neoplasia","Drug: Aminolaevulinic acid photodynamic therapy","Response Rate|clearance of high risk HPV","Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","Female","25 Years to 50 Years   (Adult)","Phase 2","73","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FDZJALA-201409","January 2015","January 2017","January 2017","December 2, 2014",,"June 12, 2019","The First Affliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|The Obstetrics & Gynecology Hospital of Fudan University, Shanghai, Shanghai, China|Women's Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT02304770"
533,"NCT00114712","The Ribavirin Pregnancy Registry","RPR","Terminated","No Results Available","Birth Defects|Pregnancy Complications|Hepatitis C",,"To evaluate association between ribavirin and birth defects|Estimate risk of birth defects in exposed pregnancies","Syneos Health|Aurobindo Pharma Ltd|Sandoz|Merck Sharp & Dohme LLC|Teva Pharmaceuticals USA|Zydus Pharmaceuticals USA, Inc.","Female","18 Years to 65 Years   (Adult, Older Adult)",,"477","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","RPR-1","January 2004","November 2, 2020","November 2, 2020","June 17, 2005",,"December 14, 2020","INC Research, LLC, Wilmington, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00114712"
534,"NCT01958281","Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency",,"Completed","Has Results","HCV Infection","Drug: SOF|Drug: RBV|Drug: LDV/SOF","Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)|Percentage of Participants Experiencing Treatment-Emergent Adverse Events|Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities|Percentage of Participants Experiencing Clinically Significant 12-lead Electrocardiogram (ECG) Abnormalities|Percentage of Participants Experiencing Treatment-Emergent Adverse Events Associated With Vital Sign Abnormalities|Pharmacokinetic (PK) Parameter: AUCtau of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)|PK Parameter: AUCtau of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)|PK Parameter: AUCtau of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)|PK Parameter: Cmax of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)|PK Parameter: Cmax of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)|PK Parameter: Cmax of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)|PK Parameter: Ctau of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)|PK Parameter: Ctau of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)|PK Parameter: Ctau of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)|Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)|Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)|Percentage of Participants With Overall Virologic Failure|PK Parameter: AUClast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)|PK Parameter: AUClast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)|PK Parameter: AUClast of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)|PK Parameter: Clast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)|PK Parameter: Clast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)|PK Parameter: Clast of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)|PK Parameter: Tmax of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)|PK Parameter: Tmax of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)|PK Parameter: Tmax of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)|PK Parameter: Tlast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)|PK Parameter: Tlast of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)|PK Parameter: Tlast of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)|PK Parameter: λz of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)|PK Parameter: λz of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)|PK Parameter: λz of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)|PK Parameter: t1/2 of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 2 (Cohorts 1 and 2)|PK Parameter: t1/2 of SOF, Its Metabolites (GS-566500 and GS-331007), and RBV at Week 12 (Cohorts 1 and 2)|PK Parameter: t1/2 of SOF, Its Metabolites (GS-566500 and GS-331007), and LDV at Week 2 or 4 (Cohort 3)","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","38","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-334-0154|2013-002897-30","October 7, 2013","July 18, 2017","October 19, 2017","October 9, 2013","August 8, 2018","August 8, 2018","San Francisco, California, United States|Miami, Florida, United States|Chicago, Illinois, United States|Detroit, Michigan, United States|Rochester, New York, United States|San Antonio, Texas, United States|Seattle, Washington, United States|Grafton, Auckland, New Zealand|Christchurch, New Zealand|San Juan, Puerto Rico","""Study Protocol: Original"", https://classic.clinicaltrials.gov/ProvidedDocs/81/NCT01958281/Prot_000.pdf|""Study Protocol: Amendment 1"", https://classic.clinicaltrials.gov/ProvidedDocs/81/NCT01958281/Prot_001.pdf|""Study Protocol: Amendment 2"", https://classic.clinicaltrials.gov/ProvidedDocs/81/NCT01958281/Prot_002.pdf|""Study Protocol: Amendment 3"", https://classic.clinicaltrials.gov/ProvidedDocs/81/NCT01958281/Prot_003.pdf|""Study Protocol: Amendment 4"", https://classic.clinicaltrials.gov/ProvidedDocs/81/NCT01958281/Prot_004.pdf|""Statistical Analysis Plan: Statistical Analysis Plan for Cohorts 1 and 2"", https://classic.clinicaltrials.gov/ProvidedDocs/81/NCT01958281/SAP_005.pdf|""Statistical Analysis Plan: Statistical Analysis Plan for Cohort 3"", https://classic.clinicaltrials.gov/ProvidedDocs/81/NCT01958281/SAP_006.pdf","https://ClinicalTrials.gov/show/NCT01958281"
535,"NCT01659190","The Painful Real-life Experience of the Child of Less Than Three Years During the Removal of the Collecting Bags in the Pediatric Urgency: What Strategy of Coverage?","LINIPOCHE","Completed","No Results Available","Urinary Infection","Other: Oiled-limestone liniment","The level of pain measured by the FLACC scale|Comparison at the girls and the boys of the score of the FLACC scale","University Hospital, Limoges","All","up to 36 Months   (Child)","Not Applicable","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","I10028","August 2012","July 2013","December 2013","August 7, 2012",,"January 13, 2014","Limoges university hospital center, Limoges, France",,"https://ClinicalTrials.gov/show/NCT01659190"
536,"NCT06296901","To Wipe or Not To Wipe?: That Is The Question",,"Not yet recruiting","No Results Available","Urinary Tract Infections","Other: Perineal Wipe","Rate of Contamination","Joanna A. Orzel|University of Iowa","Female","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","202310353","April 2024","April 2025","October 2025","March 6, 2024",,"March 6, 2024",,,"https://ClinicalTrials.gov/show/NCT06296901"
537,"NCT06265142","Clean Catch Urine Feasibility and Contamination Rate Compared to Bladder Catheterization Urine in Pre-Continent Children",,"Not yet recruiting","No Results Available","Urinary Tract Infections","Procedure: Bladder catheterization|Procedure: clean catch urine via bladder massage technique","Urine culture contamination rate|Parental satisfaction questionnaire|duration of the procedure|Pain score","Oman Medical Speciality Board","All","1 Day to 6 Months   (Child)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","MoH/CSR/23/26368","February 15, 2024","September 1, 2024","December 1, 2024","February 20, 2024",,"February 20, 2024",,"""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/42/NCT06265142/Prot_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/42/NCT06265142/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT06265142"
538,"NCT06091670","Genital Hygiene Behaviors and Predicting Factors",,"Completed","No Results Available","Urinary Tract Infections","Other: No intervention","Genital Hygiene Behavior Inventory (GHBI)|Data collection form:","Istanbul University - Cerrahpasa (IUC)","Female","18 Years and older   (Adult, Older Adult)",,"881","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","ECaliskan1","July 7, 2022","November 12, 2022","February 15, 2023","October 19, 2023",,"October 19, 2023",,,"https://ClinicalTrials.gov/show/NCT06091670"
539,"NCT06067386","Selective Reporting for Antibiotic Susceptibility Testing and GPs' Prescribing of Broad-spectrum Antibiotics in Women With E. Coli UTIs","ABC-MG","Not yet recruiting","No Results Available","Urinary Tract Infections","Other: Dissemination of a selective reporting for antibiotic susceptibility testing|Other: Standard antibiotic susceptibility testing report","Rate of broad-spectrum antibiotic dispensing|Rate of directed broad-spectrum antibiotic dispensing (=within 5 days after report of the antibiotic susceptibility testing)|""Antibiotic de-escalation"" rate: modification of an empirical broad-spectrum antibiotic therapy to a directed narrow-spectrum antibiotic therapy|Rate of broad-spectrum antibiotic dispensing as a function of the number of selective antibiotic susceptibility testings received per practice, as a continuous variable (""dose-effect"") and ordinal variable (""threshold-effect"")|GP characteristics: demographics (age, gender), practice patterns (type of practice commune based on INSEE urban area zoning), number of encounters/year, and number of patients declared|Patient characteristics (age, diabetes, pregnancy, nursing home)|E.coli antimicrobial susceptibility profiles","Nantes University Hospital","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","3000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","RC22_0003","October 15, 2023","October 15, 2024","October 15, 2024","October 4, 2023",,"October 4, 2023","University Hospital, Nantes, France",,"https://ClinicalTrials.gov/show/NCT06067386"
540,"NCT01763008","A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections",,"Completed","No Results Available","Pneumonia, Bacterial|Nosocomial Infection|Intraabdominal Infections|Urinary Tract Infection","Drug: No intervention","Number of patients with incidence of adverse events|Number of patients with incidence of discontinuation of study medication due to adverse events|Number of patients with nosocomial pneumonia (including ventilator-associated pneumonia patients) who achieved clinical cure at test-of-cure visit|Number of patients with complicated urinary tract infection who achieved clinical cure at test-of-cure visit|Number of patients with complicated intra-abdominal infections who achieved clinical cure at test-of-cure visit","Janssen Pharmaceutica","All","18 Years and older   (Adult, Older Adult)",,"170","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CR016972|DORIBAC4001|DOR-PHL-MA1|Dor-C-08-PH-001-A","November 2009","November 2012","November 2012","January 8, 2013",,"August 9, 2013","Cebu, Philippines|Davao City, Philippines|Manila, Philippines|Quezon City, Philippines",,"https://ClinicalTrials.gov/show/NCT01763008"
541,"NCT03513146","Oropharyngeal Administration of Mother's Milk in Preterm Infants and Neonatal Infection","OPAMM","Completed","No Results Available","Preterm Infant|Neonatal SEPSIS|Neonatal Feeding Disorder","Procedure: Oropharyngeal Administration of Mother's Milk (OPAMM)","Hospital Acquired late onset neonatal sepsis|Colonization of the oro-pharyngeal pouch with pathogenic micro-organism|Colonization of the GIT with pathogenic micro-organism|Necrotizing enterocolitis|Ventilator associated pneumonia","Mansoura University Children Hospital","All","1 Day to 90 Days   (Child)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","MS-15.09.03","May 1, 2016","December 1, 2018","December 1, 2018","May 1, 2018",,"June 16, 2020","Mansoura University Children Hospital, Mansourah, El Dakahlya, Egypt",,"https://ClinicalTrials.gov/show/NCT03513146"
542,"NCT05760261","Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years",,"Suspended","No Results Available","Urinary Tract Infections","Drug: Midazolam|Drug: GSK3882347","Period 1: Area under the curve from time zero to 24 hours (AUC [0-24]) for plasma concentration of MDZ|Period 1: AUC (0-24) for plasma concentration of 1-hydroxy-MDZ|Period 2: AUC (0-24) for plasma concentration of MDZ|Period 2: AUC (0-24) for plasma concentration of 1-hydroxy-MDZ|Period 1: AUC from time zero to last time of quantifiable concentration (AUC [0-tau]) for plasma concentration of MDZ|Period 1: AUC (0-tau) for plasma concentration of 1-hydroxy-MDZ|Period 2: AUC (0-tau) for plasma concentration of MDZ|Period 2: AUC (0-tau) for plasma concentration of 1-hydroxy-MDZ|Period 1: AUC from time zero extrapolated to infinite time (AUC [0-inf]) for plasma concentration of MDZ|Period 1: AUC (0-inf) for plasma concentration of 1-hydroxy-MDZ|Period 2: AUC (0-inf) for plasma concentration of MDZ|Period 2: AUC (0-inf) for plasma concentration of 1-hydroxy-MDZ|Period 1: Maximum plasma concentration (Cmax) of MDZ|Period 1: Cmax of 1-hydroxy-MDZ|Period 2: Cmax of MDZ|Period 2: Cmax of 1-hydroxy-MDZ|Period 1: Time to Cmax (Tmax) of MDZ|Period 1: Tmax of 1-hydroxy-MDZ|Period 2: Tmax of MDZ|Period 2: Tmax of 1-hydroxy-MDZ|Period 1: Time lag before observation of measurable concentrations (Tlag) of MDZ|Period 1: Tlag of 1-hydroxy-MDZ|Period 2: Tlag of MDZ|Period 2: Tlag of 1-hydroxy-MDZ|Period 1: Time to half-life (T1/2) of MDZ|Period 1: T1/2 of 1-hydroxy-MDZ|Period 2: T1/2 of MDZ|Period 2: T1/2 of 1-hydroxy-MDZ|Number of participants with adverse events (AEs) and serious adverse events (SAEs)|Number of participants with clinically significant changes in hematology laboratory values|Number of participants with clinically significant changes in chemistry laboratory values|Number of participants with clinically significant changes in urinalysis laboratory values|Number of participants with clinically significant changes in vital sign values|Number of participants with clinically significant changes in 12-lead electrocardiogram (ECG) readings|AUC (0-24) for plasma concentration of GSK3882347|Plasma concentrations over the dosing interval tau (Ctau) of GSK3882347|Oral clearance (CL/F) of GSK3882347|Volume of distribution/ Bioavailability (Vd/F) of GSK3882347|Mean residence time (MRT) of GSK3882347|AUC(0-inf) for single dose of GSK3882347|Cmax for single dose of GSK3882347|AUC(0-tau) for repeat dose of GSK3882347|Cmax for repeat dose of GSK3882347|Accumulation ratio (Ro) using AUC (0-tau) for repeat dose of GSK3882347|Time invariance using AUC(0-tau) (repeat dose) of GSK3882347|Time invariance using AUC(0-inf) (single dose) of GSK3882347|Achievement of steady state of GSK3882347","GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","213252","March 6, 2023","August 1, 2023","August 1, 2023","March 8, 2023",,"July 11, 2023","GSK Clinical Unit Cambridge, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05760261"
543,"NCT05719753","The Effectiveness of a Bacteriophobic Coating on Urinary Catheters","PRO033CSP","Completed","No Results Available","Urinary Tract Infections","Device: Camstent Coated Catheter|Device: Standard Care","An analytic characterisation of catheters after routine patient use, will yield estimates of the difference in biofilm density between coated and non-coated catheters.|catheter blockage|catheter associated infection|Ease of insertion and removal of the catheter since it creates a very smooth and slippery surface using the NHS staff standard clinical feedback form.","Camstent Ltd.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","18057","September 15, 2020","September 20, 2021","December 20, 2021","February 9, 2023",,"February 9, 2023","University of Nottingham, Nottingham, Nottinghamshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05719753"
544,"NCT05513677","Characterisation of Biofilm Growth on Coated vs. Uncoated Urinary Catheter Surfaces in Normal Clinical Use","PRO30CSP","Completed","No Results Available","Urinary Tract Infections","Device: M4D|Device: Standard of Care","The primary outcome is the percentage of catheter surface colonised by biofilm, calculated as (light / (light + dark) x 100% in measurement of stained samples using fluorescence microscopy.|Secondary outcomes will be logging of events, including catheter blockage or presumed CAUTI.","Camstent Ltd.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","PRO30CSP","August 14, 2018","May 20, 2020","December 30, 2021","August 24, 2022",,"August 31, 2022","The James Cook University Hospital,, Middlesbrough, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05513677"
545,"NCT04837963","Does Hirschsprung Disease Increase the Risk of Febrile Urinary Tract Infection in Children",,"Completed","No Results Available","Hirschsprung Disease|Febrile Urinary Tract Infection (Disorder)",,"Compare the risk of febril urinary tract infection|Compare the age at the time of febrile urinary tract infection|Febrile urinary tract infection risk factor","University Hospital, Montpellier","All","up to 18 Years   (Child, Adult)",,"630","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","RECHMPL21_0225","May 16, 2021","June 30, 2021","July 30, 2021","April 8, 2021",,"October 19, 2021","University hospital of Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04837963"
546,"NCT06281665","Treatment With Aspirin After Preeclampsia: TAP Trial","TAP","Not yet recruiting","No Results Available","Hypertensive Disorder of Pregnancy|Pre-Eclampsia|Hypertension|Eclampsia|Gestational Hypertension|Cardiovascular Diseases|Toxemia|Pregnancy Complications|Vascular Diseases|Hypertension, Pregnancy Induced|Hypertension;Pre-Eclamptic","Drug: Low-dose aspirin|Drug: Placebo","Percent of participants eligible, enrolled and retained (feasibility)|Study visit systolic BP|Study visit diastolic BP|Study visit mean arterial pressure|Anti-hypertensive medication use|Therapeutic intensity score|Mean home systolic blood pressure|Mean home diastolic blood pressure|Mean home mean arterial pressure|Mean daytime systolic blood pressure|Mean nocturnal systolic blood pressure|Mean daytime diastolic blood pressure|Mean nocturnal diastolic blood pressure|Mean nocturnal mean arterial pressure|Mean daytime mean arterial pressure|Mean overall mean arterial pressure|Mean overall systolic blood pressure|Mean overall diastolic blood pressure|Classification of hypertension|Endothelial function EC50%|Endothelial function Emax|Endothelial function change in Emax|Endothelial function change in EC50%|Change in systolic blood pressure|Change in diastolic blood pressure|Change in mean arterial pressure","Alisse Hauspurg|National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh","Female","18 Years to 55 Years   (Adult)","Phase 4","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","STUDY23080099|K23HL168356","May 1, 2024","April 1, 2025","April 1, 2026","February 28, 2024",,"April 4, 2024","University of Pittsburgh Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT06281665"
547,"NCT05206500","NextGen - Clinical Implication of Next Generation Sequencing",,"Recruiting","No Results Available","Urinary Tract Infections","Drug: Antibiotic|Device: Next Gen","Next Generation Sequencing (NGS) Results (numbers of colony count (CC)) of Urinary Tract Infection (UTI)|Patient Improvement (King's Questionnaire Outcome measure) in UTI symptoms with CC <10,000","Wake Forest University Health Sciences","Female","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00073565","May 17, 2022","December 2025","June 2026","January 25, 2022",,"April 10, 2024","Wake Forest Health Sciences, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT05206500"
548,"NCT04950582","In Vitro Analysis of Human Urine With the CloudCath Device",,"Suspended","No Results Available","Urinary Tract Infections","Diagnostic Test: Spectral characteristics assessment","Spectral characteristics of urine specimens","CloudCath","All","18 Years and older   (Adult, Older Adult)",,"500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CC-L-008","June 4, 2021","June 15, 2024","June 15, 2024","July 6, 2021",,"September 21, 2023","CloudCath Investigational Site, Guadalajara, Jalisco, Mexico",,"https://ClinicalTrials.gov/show/NCT04950582"
549,"NCT02691559","The Possible Effect Of Amniotic Fluid pH On Neonatal Morbidities In Maternal Inflammation/Infection Associated Pregnancies",,"Completed","No Results Available","Respiratory Distress Syndrome|Transient Tachypnea of Newborn|Intrauterine Growth Retardation","Device: Amniotic fluid analysis by blood gas device","A total of 200 amniotic fluid (1ml per one) would be collected and analyzed for the study.","Kanuni Sultan Suleyman Training and Research Hospital","All","up to 5 Minutes   (Child)","Not Applicable","184","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1","August 2015","April 2016","April 2016","February 25, 2016",,"November 27, 2019","Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT02691559"
550,"NCT02358993","Short-course Methenamine Hippurate for Prevention of Post-operative UTI","NO-UTI","Completed","Has Results","Urinary Tract Infections|Catheter-Related Infections","Drug: methenamine hippurate|Drug: Ciprofloxacin","Treatment of Clinically Suspected UTI - Using Intent to Treat Analysis|Treatment of Clinically Suspected UTI - Per Protocol|Number of Participants With Culture-positive Symptomatic UTI|Antibiotic Resistance of Culture-positive Symptomatic UTI|Cost-effectiveness of Prophylaxis With Methenamine Hippurate for Prevention of Post-operative UTI Compared to Prophylaxis With Fluoroquinolones|Prevalence of Side Effects","University of Pennsylvania","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","201","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","820117","December 2014","September 30, 2020","September 30, 2020","February 9, 2015","February 25, 2022","February 25, 2022","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Chestnut Hill Hospital, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/93/NCT02358993/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/93/NCT02358993/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02358993"
551,"NCT04817865","Comparison of Pre-procedural PCR and Culture-based UTI Assessment Prior to Intravesical Botox Injection",,"Withdrawn","No Results Available","Urinary Tract Infections","Diagnostic Test: Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST)|Diagnostic Test: Urine Culture","Post procedural UTI|Recurrent UTI|Resistant UTI|Antibiotic Usage|Visit Reschedule/Cancellation Rate|UTI-related ED Visit Rate|UTI-hospital Admission Rate","Pathnostics","All","18 Years and older   (Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020-btxuti","August 15, 2020","February 10, 2021","July 31, 2023","March 26, 2021",,"November 18, 2023","Comprehensive Urologic Care, Barrington, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04817865"
552,"NCT04815369","Evaluating UTI Diagnosis in Nursing Homes",,"Suspended","No Results Available","Urinary Tract Infections",,"Examine prospective data to determine if the use of Guidance® UTI Clinical Pathway, compared to traditional clinical pathways, will reduce the proportion of patients with UTI-related adverse events.|Examine prospective data to determine if the use of Guidance® UTI Clinical Pathway, compared to traditional clinical pathways, will reduce overall inappropriate antibiotic use.|Examine prospective data to determine if the use of Guidance® UTI Clinical Pathway is more effective than standard urine testing approaches in the clinical evaluation of UTI diagnosis and management .|Examine prospective data to determine if the use of Guidance® UTI Clinical Pathway, compared to traditional clinical pathways, will reduce UTI antibiotic collateral effects.","Pathnostics","All","65 Years and older   (Older Adult)",,"40000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2021-PUTINH","June 7, 2021","May 2024","May 2024","March 25, 2021",,"August 28, 2023","Pathnostics, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT04815369"
553,"NCT04680325","Impact of Cranberry Juice Consumption on Gut and Vaginal Microbiota in Post-menopausal Women",,"Completed","No Results Available","Urinary Tract Infections","Dietary Supplement: Juice daily consumption","Changes in the vaginal microbiota profile assessed by sequencing of swab samples|Changes in the gut microbiota profile assessed by sequencing of stool samples","University of Arkansas, Fayetteville|Ocean Spray, Inc.","Female","Child, Adult, Older Adult","Not Applicable","23","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Ocean Spray","July 1, 2017","November 15, 2017","August 31, 2018","December 22, 2020",,"December 22, 2020","University of Arkansas, Fayetteville, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT04680325"
554,"NCT04587999","Quick-Wee Versus Bladder Stimulation System to Collect Midstream Urine From Pre-continent Infants","ES-Stimquick U","Completed","No Results Available","Urinary Tract Infections","Other: bladder stimulation|Other: Quick wee","volume of urine collection to measure the effectiveness of two techniques|time needed to obtain urines|patient comfort|Bacterial contamination rates of urine samples|collection of patient data to define risk factors associated with the failure of the bladder stimulation techniques","Fondation Lenval","All","up to 1 Year   (Child)","Not Applicable","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20-HPNCL-04","January 29, 2021","June 6, 2022","November 17, 2022","October 14, 2020",,"September 29, 2023","Centre Hospitalier Universitaire de Sainte-Justine, Montréal, Canada|Centre Hospitalier Antibes Juan les Pins, Antibes, France|Hôpitaux Pédiatriques de Nice CHU-Lenval, Nice, France",,"https://ClinicalTrials.gov/show/NCT04587999"
555,"NCT04371159","A Comparative, Controlled Study to Evaluate the Clinical Accuracy of the Velieve U.S. UTI Urine Analysis Test System",,"Completed","No Results Available","Urinary Tract Infections","Device: Velieve U.S.","Evaluation of the % agreement of the Velieve U.S., tested by the lay user, as compared to a comparator device, tested by a professional user.|Evaluation of the Velieve U.S. usability success rate, by potential lay users under actual use conditions.","Healthy.io Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","125","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CTP-Velieve-MC-02","February 5, 2020","May 30, 2020","May 30, 2020","May 1, 2020",,"June 23, 2020","Comprehensive Clinical Trials, LLC, West Palm Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04371159"
556,"NCT04191148","Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli",,"Completed","Has Results","Urinary Tract Infections","Drug: LBP-EC01|Drug: Placebo","Number of Participants With Treatment-related Adverse Events as Assessed by DAIDS v2.1|Pharmacokinetics of LBP-EC01: Cmax|Pharmacokinetics of LBP-EC01: Tmax|Pharmacokinetics of LBP-EC01: AUC|Reduction in Urinary E.Coli Burden at Any of the Following Time Points: Day 2, Day 3, Day 5, Day 7 (EOT), Day 14 and Day 28|Time to 1 Logarithmic Reduction in Urinary E.Coli Count From Baseline|Recurrence of E.Coli Colonization or Incidence of Infection Based on Clinical Signs and Symptoms|Changes in Immunoglobulin (Ig)A|Changes in IgE|Changes in IgG|Changes in IgM","Locus Biosciences","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","LBx-1001","December 30, 2019","November 19, 2020","November 19, 2020","December 9, 2019","March 16, 2022","March 16, 2022","Pinnacle Research Group, Anniston, Alabama, United States|Tilda Research, Irvine, California, United States|Universal Axon Clinical Research, Doral, Florida, United States|Universal Axon - Homestead, LL, Homestead, Florida, United States|AMPM Research Clinic, Miami Gardens, Florida, United States|Innovation Medical Research Center, Palmetto Bay, Florida, United States|Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT04191148/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT04191148/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04191148"
557,"NCT04077749","Probiotic Bladder Instillation for Prevention of Catheter Associated UTIs in Chronically Catheterized Patients",,"Withdrawn","No Results Available","Urinary Tract Infections","Biological: Femdophilus probiotic|Other: Normal Saline","Bladder colonization with Lactobacillus","Lahey Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","2017-041","April 1, 2021","June 30, 2021","September 15, 2021","September 4, 2019",,"July 8, 2021",,,"https://ClinicalTrials.gov/show/NCT04077749"
558,"NCT00386477","Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial",,"Terminated","Has Results","Cesarean Section|Endometritis|Surgical Wound Infection","Procedure: Vaginal cleansing before cesarean delivery","Number of Participants Who Experienced Composite Endometritis Plus Wound Complications.","Indiana University School of Medicine|Indiana University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","0509-55 (Study #)|0509-55","September 2006","May 2009","May 2009","October 11, 2006","February 8, 2010","February 8, 2010","Methodist Hospital, Indianapolis, Indiana, United States|University Hospital, Indianapolis, Indiana, United States|Wishard Memorial Hospital, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00386477"
559,"NCT03716804","Establish the Relationship Between Shift in Prescribing Pattern and Associated Shift in Sensitivity Pattern of Causative Microbes in UTI Patients in a Closed Community","UTI","Completed","No Results Available","Uncomplicated Urinary Tract Infection|Antibiotic Resistant Infection","Drug: Tablet Nitrofurantoin|Drug: Tablet Ciprofloxacin/ Tablet Cefixime/ Tablet Cefuroxime","Shift in sensitivity pattern of microorganisms in urinary pathogens|Non-inferiority of the drug","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","62","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","BSMMU/2018/4643","June 6, 2018","December 31, 2018","January 31, 2019","October 23, 2018",,"August 5, 2020","Combined Military Hosptal, Dhaka, Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT03716804"
560,"NCT03526484","The Utility of Urinalysis Prior to In-Office Procedures",,"Completed","No Results Available","Urinary Tract Infections","Behavioral: Standard of Care|Behavioral: Experimental","Proportion of Patients who Developed a Urinary Tract Infection Post Procedure","University of Wisconsin, Madison","All","18 Years and older   (Adult, Older Adult)","Not Applicable","664","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","2017-1124|Protocol Version 5/28/2020|A539998|SMPH\VOLUNTEER STAFF\UROLOGY","September 28, 2018","November 15, 2021","November 15, 2021","May 16, 2018",,"December 2, 2021","William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/84/NCT03526484/Prot_SAP_001.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/84/NCT03526484/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03526484"
561,"NCT03488355","Modified Reporting From Indwelling Catheters",,"Completed","Has Results","Urinary Tract Infections","Other: Modified laboratory report","Number of Participants With Appropriate Treatment|Death|Adverse Events","Memorial University of Newfoundland","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","MUN-3","November 5, 2018","July 31, 2019","July 31, 2019","April 5, 2018","January 25, 2023","January 25, 2023","Health Sciences Center, Saint John's, Newfoundland and Labrador, Canada","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/55/NCT03488355/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03488355"
562,"NCT01063452","Impact of Atkinson Product Design Urinary Slide Valve Versus Standard Catheter Drainage System on Social Functioning",,"Withdrawn","No Results Available","Urinary Catheterization|Urinary Tract Infections","Device: Truvalve|Other: Control (catheter drainage bag)","The primary objective of this study is to evaluate the impact of the Atkinson Product Design urinary slide valve on patient morbidity and freedom as measured by impact on activities of daily living (ADL) and quality of life (QOL).|Secondary objectives include assessing the impact of the device on bacteruria and evaluating the impact of the primary treatment on ADL and QOL.","The Cleveland Clinic","Male","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","Truvalve","February 2010","February 2010","February 2010","February 5, 2010",,"January 5, 2017","Urology Associates, Edina, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01063452"
563,"NCT03174834","Bladder Stimulation Technique for Clean Catch Urine Collection in Infants",,"Unknown status","No Results Available","Urinary Tract Infections","Other: Bladder Stimulation technique","Proportion of patients for whom urine collection is successful using the bladder stimulation technique|Proportion of bacterial contamination among samples collected using the bladder stimulation technique|Time required for successful urine collection using the bladder stimulation technique|Time required for successful urine collection from the start of feeding|Patient distress ( parental perception ) during bladder stimulation technique|Parent and provider satisfaction with bladder stimulation technique|Economic impact of the bladder stimulation technique","Children's Hospital of Michigan|Sarnaik Endowment Fund|CHMF Annual Fund|Blue Cross Blue Shield of Michigan Foundation","All","up to 6 Months   (Child)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1702000315","September 1, 2017","May 31, 2018","December 31, 2018","June 5, 2017",,"July 17, 2018","Children's Hospital of Michigan, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03174834"
564,"NCT03163394","HD5 Levels in Catheter Versus Bag Urine Specimens in Young Children for the Diagnosis of UTI",,"Terminated","No Results Available","Urinary Tract Infections",,"Sensitivity and specificity of HD5 as marker for UTI","Le Bonheur Children's Hospital","All","1 Month to 24 Months   (Child)",,"5","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","HD52017","April 23, 2017","June 10, 2019","June 10, 2019","May 23, 2017",,"February 27, 2020","LeBonheur Children's Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03163394"
565,"NCT03152851","The Effect of Sonographic Bladder Compressive Technique for Bag Urine Collection in Pediatrics",,"Unknown status","No Results Available","Urinary Tract Infections","Procedure: Pressure stimulus group","The urine collection time|The antibiotic administration time|Emergency department(ED) length of stay time|Comparison between the patients who were diagnosed as actual urinary tract infections and those who were not.|Complications","Seoul National University Bundang Hospital|Seoul National University Hospital","All","3 Months to 35 Months   (Child)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Diagnostic","B-1609-362-001","November 1, 2016","December 31, 2018","March 31, 2019","May 15, 2017",,"April 18, 2018","The Seoul National Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of|Seoum national university, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03152851"
566,"NCT02569944","Feasibility of Bladder Stimulation in Infants",,"Completed","No Results Available","Urinary Tract Infection","Procedure: Bladder stimulation|Procedure: Perineal bag","Urine sample collection","Hospital del Río Hortega","All","up to 12 Months   (Child)","Not Applicable","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PEDHURH-001","June 2013","December 2014","December 2014","October 7, 2015",,"October 7, 2015",,,"https://ClinicalTrials.gov/show/NCT02569944"
567,"NCT02446496","A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Dose Administration to Healthy Subjects",,"Completed","Has Results","Infections, Urinary Tract","Drug: Cefadroxil tablets manufactured by GSK|Drug: Cefadroxil tablets manufactured by NP","Maximal Measured Plasma Concentration (Cmax) After a Single Dose|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) and Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-infinity)|Time of the Maximum Plasma Concentration (T-max) and Terminal Half- Life (T-half)|Apparent First-order Elimination or Terminal Rate Constant (Ke)","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 4","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","201529","March 31, 2014","April 8, 2014","April 8, 2014","May 18, 2015","April 25, 2017","September 21, 2017","GSK Investigational Site, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02446496"
568,"NCT02509403","An Open-label Trial to Evaluate the Safety of an Essential Oil Infused Perineal Towel","WIPEAWAY","Withdrawn","No Results Available","Urinary Tract Infections","Drug: Essential oils infused Perineal Hygiene wipe","Number of participants without any adverse events as a measure of safety|Ease of use of the perineal hygiene wipe by the participants on a daily basis|Self-reported comfort score on a scale of 1 to 10","University of Alberta|Taiga BioActives Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAI-WA-0707","January 2020","January 2020","January 2020","July 28, 2015",,"April 1, 2020","Division of Geriatric Medicine, Clinical Sciences Building, University of Alberta Hosp, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT02509403"
569,"NCT01349738","Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants","ASB","Unknown status","No Results Available","Bacteriuria|Urinary Tract Infections|Asymptomatic Infections|Transplantation Infection","Drug: Antibiotic","Prevalence of Asymptomatic Bacteriuria and Risk of Developing Symptomatic Urinary Tract Infections or Renal Allograft Injury in Renal Transplant Patients|Host Characteristics of Renal Transplant Patients with Asymptomatic Bacteriuria at Risk to Develop Symptomatic Urinary Tract Infection|Determine the characteristics of uropathogenic bacteria that cause acute allograft injury in renal transplant patients.","Rice, James C., M.D.|University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","ASB in Transplants","May 2011",,"May 2013","May 9, 2011",,"September 1, 2011","Scripps Green Hospital, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT01349738"
570,"NCT02276508","Open Label Trial of Nissle 1917",,"Completed","No Results Available","Urinary Tract Infections","Drug: E. coli Nissle 1917","Number of adverse events associated with ingestion of E. coli Nissle 1917","Elizabeth Lucas|Nationwide Children's Hospital","All","21 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","IRB14-00586","October 2014","December 2014","February 2015","October 28, 2014",,"February 18, 2015","Nationwide Children's Hospital, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02276508"
571,"NCT02087735","Measurement of Urinary Catabolites of PACs as Biomarkers of Consumption of Cranberry Extracts","CUPACS","Completed","No Results Available","Urinary Tract Infections","Dietary Supplement: Cranberry extract","Urinary catabolites of PACs","Laval University","Female","18 Years to 40 Years   (Adult)","Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","PACS-2013-SD","January 2014","March 2014","March 2014","March 14, 2014",,"October 10, 2016","Laval University, Department of Medecine, Institut sur la nutrition et les aliments fonctionnels (INAF)., Québec, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02087735"
572,"NCT03050515","Fecal Microbiota Transplantation for the Treatment of Recurrent Urinary Tract Infections",,"Completed","No Results Available","Recurrent Urinary Tract Infection","Biological: Fecal Microbiota Transplantation","Change in frequency of culture proven urinary tract infections following fecal transplant|Efficacy of fecal transplant in transforming recurrent urinary tract infection bacteria profile to that of pan-sensitive organisms on urine culture specimens|Change in the gut microbiome following fecal transplantation measured via 16s sequencing of stool samples","University of California, Irvine","Female","18 Years to 100 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-3541","February 5, 2018","June 30, 2019","February 23, 2020","February 13, 2017",,"June 18, 2020","UCI Women's Healthcare Center, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT03050515"
573,"NCT00258102","A Study of the Safety and Effectiveness of Levofloxacin Compared With Lomefloxacin in the Treatment of Complicated Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infections|Bacterial Infections|Bacteriuria|Urologic Diseases","Drug: Levofloxacin","Clinical response, the resolution of signs and symptoms at post-therapy compared with those at start of study; Microbiological response, the eradication at post-therapy of infectious organism identified at start of study.|Overall clinical response, described as cured, improved, or failed; incidence of adverse events throughout the study; change in clinical laboratory tests and physical examinations from start of study to post-therapy.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PriCara, Unit of Ortho-McNeil, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","603","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR005488","January 1993",,"January 1995","November 24, 2005",,"June 10, 2011",,,"https://ClinicalTrials.gov/show/NCT00258102"
574,"NCT05623033","The Predictive Value of Dynamic Changes of CD4+T Lymphocytes in Primary Nephrotic Syndrome With Infection",,"Recruiting","No Results Available","Nephrotic Syndrome|Infections|Lymphocyte","Other: The study is an observational study without intervention","Dynamic changes of CD4+T cells","Fifth Affiliated Hospital, Sun Yat-Sen University|Nanfang Hospital, Southern Medical University|Guangdong traditional Chinese medicine hospital, Zhuhai","All","14 Years to 75 Years   (Child, Adult, Older Adult)",,"156","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","WPZhu","November 16, 2022","August 31, 2025","December 31, 2025","November 21, 2022",,"November 22, 2022","the fifth affiliated hospital of SUN YAT-SEN university, Zhuhai, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05623033"
575,"NCT03577769","Nosocomial Bacteriuria in Geriatric Internal Medicine Services and Follow-up Care and Geriatric Rehabilitation of the Strasbourg University Hospitals",,"Unknown status","No Results Available","Urinary Tract Infection",,"Bacterial sensitivity (antibiotic resistance testing)","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","7024","June 1, 2018","June 2019","June 2019","July 5, 2018",,"July 5, 2018","Service Geriatrie - Soins de Suite Et Readaptation, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT03577769"
576,"NCT05485051","Daily Chlorexidine Bath for Health Care Associated Infection Prevention","CLEAN-IT","Active, not recruiting","No Results Available","Health Care Associated Infection|Ventilator Associated Pneumonia|Central Line-associated Bloodstream Infection (CLABSI)|Catheter-Associated Urinary Tract Infection","Other: 2% chlorhexidine digluconate solution with surface-active agents|Other: Usual Baths","Composite of healthcare-associated infections (HAI)|Rates of multi-drug-resistant pathogens|Ventilator associated pneumonia (VAP)|Central line-associated blood stream infections (CLABSI)|Catheter-associated urinary tract infection (CAUTI)|Hospital length of stay|Intensive Care Unit length of stay|Antibiotic use|In hospital mortality|Intensive Care Unit mortality","Hospital do Coracao|Hospital Sírio-Libanês|Hospital Israelita Albert Einstein|Hospital Moinhos de Vento|Hospital Alemão Oswaldo Cruz|A Beneficência Portuguesa de São Paulo","All","18 Years and older   (Adult, Older Adult)","Phase 3","12600","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","ip_hcor_cleanit","August 3, 2022","March 31, 2024","March 31, 2024","August 2, 2022",,"February 20, 2024","Hospital da Bahia, Salvador, BA, Brazil|Hospital da Cidade, Salvador, BA, Brazil|Hospital Universitário de Brasília, Brasília, DF, Brazil|Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil|Hospital Regional do Baixo Amazonas Dr. Waldemar Penna, Santarém, PA, Brazil|Hospital das Clínicas da Universidade Federal de Pernambuco, Recife, PE, Brazil|Hospital Municipal de Maringá, Maringá, PR, Brazil|Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil|Hospital Santa Cruz, Santa Cruz do Sul, RS, Brazil|Hospital Nereu Ramos, Florianópolis, Sc, Brazil|Instituto Baía Sul de Ensino e Pesquisa Irineu May Brodbeck, Florianópolis, SC, Brazil|Hospital São Lucas, Aracaju, SE, Brazil|Hospital Aviccena, São Paulo, SP, Brazil|Hospital Naval Marcílio Dias, Rio De Janeiro, Brazil|AC Camargo Câncer Center, São Paulo, Brazil|BP-A Beneficiência Portuguesa de São Paulo, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT05485051"
577,"NCT01803191","Efficacy Study of Prophylaxis With Fosfomycin Versus Ciprofloxacin Prior Prostate Biopsy","BIPROST","Completed","No Results Available","Urinary Tract Infections","Drug: Fosfomycin 3 g|Drug: Ciprofloxacin 500 mg","Bacteriuria|Urinary Tract Infection|Sepsis|Pathogens present in urine and antimicrobial resistance|Bacteremia|Hematuria|Hemospermia|Rectal bleeding|Urinary retention|Difficulty for miction|Genitourinary infections associated to fever (>38ºC)|Number of participants with adverse events","Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Hospital General Universitario Santa Lucía|Hospital General Universitario Los Arcos del Mar Menor","Male","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","461","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","BIPROST|2012-001031-31","August 2012","January 25, 2016","January 25, 2016","March 4, 2013",,"December 13, 2017","Hospital General Universitario Santa Lucía, Cartagena, Murcia, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain|Hospital General Universitario Los Arcos del Mar Menor, San Javier, Murcia, Spain",,"https://ClinicalTrials.gov/show/NCT01803191"
578,"NCT01690767","A Study to Assess the Ability of 2% Lidocaine Gel to Reduce the Discomfort of Urethral Catheterization",,"Completed","No Results Available","Urinary Tract Infection","Drug: 2% lidocaine gel|Drug: Health Care Lubricating Jelly","Brow Bulging Score|Facial grimacing score","Lawson Health Research Institute","All","up to 24 Months   (Child)","Phase 2","133","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","17770","December 2011","December 2014","December 2014","September 24, 2012",,"March 27, 2015","Children's Hospital, London Health Sciences Center, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01690767"
579,"NCT01687114","Urinary Proanthocyanidin-A2 as a Biomarker of Compliance to Intake of Cranberry Products",,"Completed","Has Results","Urinary Tract Infection","Other: cranberry juice","Proanthocyanidin A2","Tufts University","Female","20 Years to 40 Years   (Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HNRC2785","September 2012","March 2013","April 2014","September 18, 2012","December 15, 2014","December 15, 2014","Jean Mayer USDA Human Nutrition Research Center on Aging, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01687114"
580,"NCT02669342","Sharklet Catheter Study",,"Unknown status","No Results Available","Urinary Catheter|Urinary Tract Infections","Device: Radiance™ Clear Sharklet® Silicone Foley Catheter|Device: Silicone Foley Catheter","Catheter scrapings examined for colonization/biofilm burden and compared to the urine screen collected from the participant (cfu/mL)|Number of symptomatic Urinary tract infections (UTIs) determined by urine culture|Delay to symptomatic CA-SUTI|Incidence of bacteria|Incidence of Crustation|Incidence of Discomfort|Surface analysis of the type of bacteria found on each catheter|Surface analysis of the amount of encrustation|Surface analysis of the biofilm formation","University of British Columbia","All","19 Years and older   (Adult, Older Adult)","Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","H15-03435","August 2016","February 2019","February 2019","February 1, 2016",,"April 6, 2017","The Stone Centre, VGH/UBC, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT02669342"
581,"NCT05826990","A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI",,"Recruiting","No Results Available","Complicated Urinary Tract Infection","Drug: cefepime and enmetazobactam combination","Pharmacokinetics Cmax|Pharmacokinetics Tmax|Pharmacokinetics AUC0-tau|Pharmacokinetics AUC0-inf|Pharmacokinetics t1/2|Pharmacokinetics CL & Vd|Pharmacokinetics Cmin|Safety and Tolerability|Efficacy assessment","Allecra|Linical Co., Ltd.","All","up to 18 Years   (Child, Adult)","Phase 2","40","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AT-202","September 11, 2023","September 30, 2025","March 30, 2026","April 24, 2023",,"January 12, 2024","Fakultní nemocnice Hradec Králové -Ústav klinické biochemie a diagnostiky, Hradec Králové, Czechia|Hopital des Enfants, Toulouse, France|Debreceni Egyetem Klinikai Központ Gyermekgyógyászati Klinika, Debrecen, Hungary|SZPZOZ im. Dzieci Warszawy w Dziekanowie Leśnym, Łomianki, Poland|Národný ústav detských chorôb (NÚDCH), Bratislava, Slovakia|Hospital Universitario La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT05826990"
582,"NCT01611519","Early or Late Foley Removal After Thoracotomy",,"Completed","No Results Available","Urinary Tract Infections",,"Need for insertion of catheter after Foley removed.|Development of urinary tract infection","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)",,"375","Other","Observational","Time Perspective: Prospective","11-006618","December 2011","October 2014","October 2014","June 5, 2012",,"September 13, 2016","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01611519"
583,"NCT01487148","POCARED Diagnostics, LTD, Field Study Protocol",,"Unknown status","No Results Available","Urinary Tract Infections",,"Agreement|Sensitivity|Specificity","Pocared Diagnostics","All","Child, Adult, Older Adult",,"40000","Industry","Observational","Time Perspective: Prospective","POCARED001","December 2011","June 2012","June 2012","December 7, 2011",,"December 7, 2011","Southern California Permanente Medical Group (SCPMG) Regional Reference Laboratories, North Hollywood, California, United States|Mayo Clinic, Rochester, Minnesota, United States|Cleveland Clinic, Cleveland, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Chaim Sheba Medical Center, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT01487148"
584,"NCT05015400","Female Urogenital Nutrition- Health Study","FUN-Health","Completed","No Results Available","Bacterial Urinary Tract Infection","Other: Plain Water","Uropathogenic Bacterial Activity|Hydration Status","Arizona State University","Female","18 Years to 34 Years   (Adult)","Not Applicable","13","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","STUDY00014289","September 5, 2021","December 15, 2021","January 1, 2022","August 20, 2021",,"May 6, 2022","Arizona State University, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT05015400"
585,"NCT05402319","Comparison of Three Different Antibiotic Treatments Against Recurrent Urinary Tract Infections in Catheterized Patients",,"Not yet recruiting","No Results Available","Recurrent Urinary Tract Infections|Chronic Urinary-catheter-carrier|Biofilm Infection|Antibiotic Treatment|Replacement of Urinary Catheter","Combination Product: Antibiotic combination therapy","Infection control|UTI recurrence expectation","University of Southern Denmark|Hospital of South West Jutland","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Projekt-ID: S-20190083G CSF","June 20, 2023","March 31, 2025","September 1, 2025","June 2, 2022",,"May 10, 2023",,,"https://ClinicalTrials.gov/show/NCT05402319"
586,"NCT05283239","Research About Impact of HPV Integration on the Prognosis of Women With Persistent HR-HPV Infection",,"Recruiting","No Results Available","HPV Infection|LSIL, Low-Grade Squamous Intraepithelial Lesions|HSIL, High-Grade Squamous Intraepithelial Lesions|Virus Integration","Other: Follow up","Cervical histopathology testing at baseline|Cervical histopathology testing at 6-month follow-up|Cervical histopathology testing at 12-month follow-up|Cervical histopathology testing at 18-month follow-up|Cervical histopathology testing at 24-month follow-up|Human Papillomavirus (HPV) virus integration test at baseline|Human Papillomavirus (HPV) virus integration test at 6-month follow-up|Human Papillomavirus (HPV) virus integration test at 12-month follow-up|Human Papillomavirus (HPV) virus integration test at 18-month follow-up|Human Papillomavirus (HPV) virus integration test at 24-month follow-up|Cervical cytology testing at baseline|Cervical cytology testing at 6-month follow-up|Cervical cytology testing at 12-month follow-up|Cervical cytology testing at 18-month follow-up|Cervical cytology testing at 24-month follow-up|Human Papillomavirus (HPV) genotyping tests at baseline|Human Papillomavirus (HPV) genotyping tests at 6-month follow-up|Human Papillomavirus (HPV) genotyping tests at 12-month follow-up|Human Papillomavirus (HPV) genotyping tests at 18-month follow-up|Human Papillomavirus (HPV) genotyping tests at 24-month follow-up|16SrRNA sequencing of the vaginal secretions at baseline|16SrRNA sequencing of the vaginal secretions at 6-month follow-up|16SrRNA sequencing of the vaginal secretions at 12-month follow-up|16SrRNA sequencing of the vaginal secretions at 18-month follow-up|16SrRNA sequencing of the vaginal secretions at 24-month follow-up","Fujian Maternity and Child Health Hospital","Female","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HIHP2201","January 1, 2022","November 30, 2024","December 31, 2024","March 16, 2022",,"November 18, 2023","Fujian Maternity and Child Health Hospital, Fuzhou, Fujian, China|Mindong Hospital of Ningde City, Ningde, Fujian, China|Ningde Municipal Hospital of Ningde Normal University, Ningde, Fujian, China|The First Hospital of Putian City, Putian, Fujian, China|Quanzhou First Hospital Afflicated to Fujian Medical University, Quanzhou, Fujian, China|Xiamen Maternity and Child Health Hospital Affiliated to Xiamen University, Xiamen, Fujian, China|Zhangzhou affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian, China|Longyan First Hospital, Longyan, China|Nanping Second Hospital, Nanjing, China|Sanming Second Hospital, Sanming, China|Shenzhen Maternity and child Healthcare Hospital, Shenzhen, China",,"https://ClinicalTrials.gov/show/NCT05283239"
587,"NCT00200616","Usefulness of Antimicrobial Prophylaxis in Children With Isolated Vesico-Ureteral Reflux.",,"Completed","No Results Available","Urinary Tract Infection","Procedure: Antimicrobial prophylaxis","End point : recurrence of urinary tract infection during the study period (0 è 18 months)|1) Type of urinary tract infection (pyelonephritis or cystitis)|2) Evaluation of the quality of life with a validated questionnaire done at 9 months","Nantes University Hospital","All","1 Day to 3 Years   (Child)","Not Applicable","232","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BRD/00/10-O","April 2001","July 2006","July 2006","September 20, 2005",,"July 1, 2008","Nantes University Hospital, Nantes, France",,"https://ClinicalTrials.gov/show/NCT00200616"
588,"NCT02728089","Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)",,"Completed","Has Results","Urinary Tract Infection (UTI)|Complicated Urinary Tract Infection|Pyelonephritis|Uncomplicated Pyelonephritis","Drug: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)","Percentage of Participants With Microbiological Response of Eradication at Test of Cure (TOC)|Percentage of Participants Who Report 1 or More Adverse Event (AE)|Percentage of Participants Discontinuing Study Drug Due to an AE|Percentage of Participants With Microbiological Response of Eradication at End Of Therapy (EOT)|Percentage of Participants With Microbiological Response of Eradication at Late Follow-up (LFU)|Percentage of Participants With Clinical Response of Clinical Cure at TOC|Percentage of Participants With Clinical Response of Clinical Cure at EOT|Percentage of Participants With Clinical Response of Clinical Cure at LFU|Percentage of Participants With a Composite Response of Both Eradication and Clinical Cure at TOC|Percentage of Participants With Microbiological Response of Eradication, by Pathogen at EOT|Percentage of Participants With Microbiological Response of Eradication by Pathogen at TOC|Percentage of Participants With Microbiological Response of Eradication by Pathogen at LFU","Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","115","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7625A-014|MK-7625A-014|163276","April 14, 2016","September 5, 2017","September 5, 2017","April 5, 2016","September 19, 2018","February 5, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/89/NCT02728089/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02728089"
589,"NCT00262106","Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection",,"Completed","No Results Available","HIV Infections|Gonorrhea|Chlamydial Infections|Genital Herpes","Drug: PRO 2000/5|Drug: Placebo","Acquisition of HIV infection before or at the 12 month time point, confirmed in a central laboratory, in participants confirmed to be HIV negative at enrollment|Grade 3 (severe) or 4 (life-threatening) clinical or laboratory adverse event confirmed on examination or repeat testing, respectively|Acquisition of HIV infection before or at the 6, 9, or beyond 12 month time points, confirmed in a central laboratory, in participants confirmed to be HIV negative at enrollment|HSV-2 incidence rates by the 9 month time point in participants uninfected at enrollment. Although prevalence rates are high, 75% - 85% in some sites, data from feasibility studies indicate that incidence rates are also likely to be high|HSV-2 incidence rates by the 12 month time point in participants uninfected at enrolment. Although prevalence rates are high, 75% - 85% in some sites, data from feasibility studies indicate that incidence rates are also likely to be high|Cross-sectional prevalence of Neisseria gonorrhoeae at 24 weeks, determined by a positive nucleic acid amplification assay|Cross-sectional prevalence of Chlamydia trachomatis at 24 weeks, determined by a positive nucleic acid amplification assay","Endo Pharmaceuticals|Medical Research Council|Department for International Development, United Kingdom","Female","16 Years and older   (Child, Adult, Older Adult)","Phase 3","9404","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","MDP301|ISRCTN64716212","October 2005","August 2008","September 2009","December 6, 2005",,"September 10, 2012","Reproductive Health and HIV Research Unit, Chris Hani Baragwanath Hospital, Bertsham, South Africa|Africa Centre for Health and Population Studies, Mtubatuba, South Africa|HIV Prevention Research Unit, Medical Research Council, Westville, South Africa|AMREF Lake Zone Programme, Mwanza, Tanzania|MRC Programme on AIDS in Uganda, Uganda Virus Research Institute, Entebbe, Uganda|MDP Zambia, Nakambala Sugar Estate, Mazabuka, Zambia",,"https://ClinicalTrials.gov/show/NCT00262106"
590,"NCT04763967","A Study of the PedSCath Pediatric Sampling Catheter Versus Current Standard of Care.",,"Terminated","No Results Available","Urinary Tract Infections in Children","Device: PedSCath Pediatric Urinary Catheter|Device: Standard of Care","The primary effectiveness endpoint is the proportion of PedSCath subjects with positive UTI diagnosis versus that of Control subjects.","Big Blue Biotech, Inc.","All","up to 3 Years   (Child)",,"2","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","BBBInc: 0619","August 27, 2021","February 2, 2023","February 2, 2023","February 21, 2021",,"June 22, 2023","NewYork-Presbyterian Queens, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04763967"
591,"NCT02515656","Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis","PRISM","Completed","Has Results","Vaginitis","Drug: POLYGYNAX®|Drug: GYNODAKTARIN®|Drug: Placebo","Clinical Treatment Efficacy Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Treatment Visit|Change in Vaginal Discharge and in Each Associated Vaginal Clinical Symptoms Reported by the Patient in the Diary|Number of Patients With Change in Vaginal Discharge Assessed by the Investigator|Clinical Treatment Efficacy (Success/Failure) Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Study Visit|Investigator's Global Satisfaction|Patient's Global Satisfaction","Laboratoire Innotech International|International Clinical Trials Association|Venn Life Sciences","Female","18 Years to 64 Years   (Adult)","Phase 3","661","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PGX 401-11|2014-001759-22","September 2015","August 2016","August 2016","August 5, 2015","January 22, 2019","January 22, 2019","TURKOVA, Praha, Czechia|PERCEVAL, Lyon, France|MARICIC, Belgrade, Serbia|GATOVA, Martin, Slovakia",,"https://ClinicalTrials.gov/show/NCT02515656"
592,"NCT00702286","Evaluation of Surface Acoustics Ultrasound Device for the Treatment of Patients With Percutaneous Nephrostomy Catheters","NV-US-04-001","Unknown status","No Results Available","Urinary Tract Infection",,"Reduction in pain and discomfort in patients with PCN catheters, improvement of catheter's patency.|Renal function improvement","Assaf-Harofeh Medical Center|Nanovibronix","All","18 Years and older   (Adult, Older Adult)",,"24","Other|Industry","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","75/08","August 2008",,,"June 20, 2008",,"June 20, 2008","Assaf Harofeh MC, Zerifin, Isarel, Israel",,"https://ClinicalTrials.gov/show/NCT00702286"
593,"NCT00596635","Cranberry for UTI Prevention in Residents of Long Term Care Facilities","PACS","Completed","Has Results","Urinary Tract Infection","Dietary Supplement: Once Daily Cranberry Capsule|Dietary Supplement: Twice Daily Cranberry Capsules","Number of Urine Cultures Collected Out of the Total Number Expected to be Collected.|Number of Participants With E.Coli Isolated From Urine Culture|Number of Participants With >100,000 Colony Forming Units Per Milliliter of Any Organism Isolated From Urine Culture","Yale University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","56","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","0606001581|DF06-005","January 2007","August 2008","August 2008","January 17, 2008","September 23, 2010","March 29, 2013","Yale University School of Medicine, Internal Medicine, Section of Infectious Diseases, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00596635"
594,"NCT00663806","A Phase IV Study of Cipro XR in Uncomplicated UTI","EXPRESS","Completed","No Results Available","Urinary Tract Infections","Behavioral: Cipro XR (Ciprofloxacin, BAYQ3939)","To compare the effect on knowledge of uncomplicated urinary tract infection (uUTI) in patients who were given a disease-directed educational brochure to read versus patients who were not given the brochure.|To examine the difference between physician and patient perceptions of the symptoms of uUTI.|To collect data on the clinical efficacy and safety of Cipro XR, 500 mg, PO once daily, for 3 days, in the treatment of uUTI in a naturalistic setting.","Bayer","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","7614","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","100534","February 2003",,"July 2003","April 22, 2008",,"December 2, 2014",,,"https://ClinicalTrials.gov/show/NCT00663806"
595,"NCT01275261","Pilot Study of Avoidance of Bladder Catheters in Stroke Patients to Avoid Urinary Tract Infections",,"Terminated","No Results Available","Stroke|Catheter Associated Urinary Tract Infection","Behavioral: Nursing protocol to avoid Foley catheter placement","Patient comfort.|Amount of time spent by nurses on patient urinary care|Incidence of Urinary Tract infection|Stroke Functional Outcome","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","10-00820","January 2011","September 2011","September 2011","January 12, 2011",,"November 14, 2012","University of California San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01275261"
596,"NCT00309114","Prevention of Urinary Tract Infection (UTI) in Persons With Spinal Cord Injury (SCI)",,"Completed","No Results Available","Urinary Tract Infections","Procedure: bacterial interference","Putting E. coli 83972 into the bladder of SCI patients reduces the rate of symptomatic UTI.|Study the affect of bladder colonization with E. coli 83972 on the rate of symptom causing UTI in a large group of SCI and Spina Bifida patients.","Baylor College of Medicine","All","15 Years to 64 Years   (Child, Adult)","Not Applicable","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","5R01HD043943-03|H-8393","February 2004","November 2009","November 2009","March 31, 2006",,"February 23, 2017","Shepherd Center, Atlanta, Georgia, United States|Rehab Institute Chicago, Chicago, Illinois, United States|UT Southwestern, Dallas, Texas, United States|Michael E Debakey VA Medical Center, Houston, Texas, United States|The Institute for Rehabilitation and Research (TIRR), Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00309114"
597,"NCT03357614","Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults",,"Completed","Has Results","Complicated Urinary Tract Infections","Drug: Sulopenem|Drug: Sulopenem-Etzadroxil/Probenecid|Drug: Ertapenem|Drug: Ciprofloxacin|Drug: Amoxicillin-clavulanate","Percentage of Participants With Overall Success|Percentage of Participants With Microbiologic Success","Iterum Therapeutics, International Limited","All","18 Years and older   (Adult, Older Adult)","Phase 3","1395","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IT001-302","September 18, 2018","December 14, 2019","December 14, 2019","November 30, 2017","December 29, 2020","December 29, 2020","Medical Facility, Bellflower, California, United States|Medical Facility, Chula Vista, California, United States|Medical Facility, La Mesa, California, United States|Medical Facility, La Palma, California, United States|Medical Facility, Torrance, California, United States|Medical Facility, Miami Lakes, Florida, United States|Medical Facility, Columbus, Georgia, United States|Medical Facility, Idaho Falls, Idaho, United States|Medical Facility, Boston, Massachusetts, United States|Medical Facility, Royal Oak, Michigan, United States|Medical Facility, Butte, Montana, United States|Medical Facility, Columbus, Ohio, United States|Medical Facility, Columbus, Ohio, United States|Medical Facility, Dallas, Texas, United States|Medical Facility, Houston, Texas, United States|Medical Facility, Kohtla-Järve, Estonia|Medical Facility, Tallinn, Estonia|Medical Facility, Võru, Estonia|Medical Facility, Tbilisi, Georgia|Medical Facility, Tbilisi, Georgia|Medical Facility, Tbilisi, Georgia|Medical Facility, Baja, Hungary|Medical Facility, Budapest, Hungary|Medical Facility, Nagykanizsa, Hungary|Medical Facility, Nyiregyhaza, Hungary|Medical Facility, Szentes, Hungary|Medical Facility, Tatabánya, Hungary|Medical Facility, Daugavpils, Latvia|Medical Facility, Liepāja, Latvia|Medical Facility, Riga, Latvia|Medical Facility, Riga, Latvia|Medical Facility, Valmiera, Latvia","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/14/NCT03357614/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/14/NCT03357614/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03357614"
598,"NCT05821946","Web-Based Multi-Resource Training on the Prevention of Urinary Tract Infections in Adult Kidney Transplant Recipients",,"Recruiting","No Results Available","Kidney Transplantation|Adult|Urinary Tract Infections|Prevention|Medical Informatics","Other: Web-Based Multi-Source Training on the Prevention of Urinary Tract İnfections","Infection status|Number of applications to the emergency department|Hospital readmission status|Adult kidney transplant recipients who are ready for discharge versus those who are not ready for release are significantly different in clinical outcomes.|Views of adult kidney transplant recipients on web-based multi-source urinary tract infection prevention education","Akdeniz University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","KAEK-896-2021","January 1, 2023","January 30, 2024","March 30, 2024","April 20, 2023",,"October 6, 2023","Akdeniz University, Antalya, Turkey",,"https://ClinicalTrials.gov/show/NCT05821946"
599,"NCT04066621","PHase IV Clinical Trial of Ceftriaxone Sodium and Sulbactam Sodium for Injection (CRO-SBT)","CRO-SBT","Completed","No Results Available","Respiratory Tract Infections|Urinary Tract Infections in Children","Drug: Ceftriaxone Sodium and Sulbactam Sodium for Injection","The cure rate of patients|bacterial clearance rate","Xiangbei Welman Pharmaceutical Co., Ltd","All","6 Years to 14 Years   (Child)","Phase 4","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LENVOCRO (2012)CSSSI-0.4","April 28, 2015","June 11, 2016","May 27, 2017","August 26, 2019",,"August 28, 2019",,,"https://ClinicalTrials.gov/show/NCT04066621"
600,"NCT00368888","Clinical Study of New Urine Collection Bag for Infants.",,"Completed","No Results Available","Urinary Tract Infection","Device: Urine collection bag for infants",,"Bergaliden Barnavårdscentral","All","0 Years to 3 Years   (Child)","Not Applicable",,"Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","LIVI4099","March 2004",,"September 2006","August 29, 2006",,"September 12, 2006","Bergaliden Barnavårdscentral (Child Care Center), Helsingborg, Sweden",,"https://ClinicalTrials.gov/show/NCT00368888"
601,"NCT03991793","Granzyme A in Patients With E. Coli Bacteremic Urinary Tract Infections","GABEC","Unknown status","No Results Available","Bloodstream Infection|Sepsis|Pathogenesis|Escherichia Coli Bacteremia",,"Granzyme A serum levels|gzmA polymorphisms|Granzyme A serum kinetics","Instituto de Investigación Sanitaria Aragón","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","PI19/070","June 20, 2019","May 30, 2020","December 31, 2020","June 19, 2019",,"June 19, 2019",,"""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/93/NCT03991793/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03991793"
602,"NCT00203515","Study Comparing the DOVER Silver Foley Catheter to a Standard of Care Catheter and a Marketed Silver Coated Foley Catheter",,"Completed","No Results Available","Urinary Tract Infections","Device: Standard Latex Foley Catheter|Device: Silver Coated Latex Foley Catheter","Catheter associated urinary tract infection (UTI)|Catheter tolerance|Cost of care","Tyco Healthcare Group","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention","302.18","January 2005","March 2007",,"September 20, 2005",,"January 14, 2008","University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00203515"
603,"NCT05511779","Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation",,"Recruiting","No Results Available","BK Virus Infection|Nephropathy|Kidney Transplantation","Drug: Brincidofovir","Incidence of treatment-emergent adverse events (TEAEs)|Antiviral Effects","SymBio Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCV-BN01","October 14, 2022","December 16, 2024","February 16, 2025","August 23, 2022",,"February 28, 2023","Royal Adelaide Hospital, Adelaide, Australia|Austin Health, Melbourne, Australia|The Royal Melbourne Hospital, Melbourne, Australia|Tokyo Medical University Hachioji Medical Center, Hachiōji, Japan|Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan|Osaka General Medical Center, Osaka, Japan|Osaka Metropolitan University Hospital, Osaka, Japan|Hokkaido University Hospital, Sapporo, Japan|Sapporo City General Hospital, Sapporo, Japan|Jichi Medical University Hospital, Shimotsuke, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Japan|Osaka University Hospital, Suita, Japan|Fujita Health University Hospital, Toyoake, Japan|Yokohama City University Medical Center, Yokohama, Japan",,"https://ClinicalTrials.gov/show/NCT05511779"
604,"NCT03520010","Facilitated Implementation of Antibiotic Stewardship in Wisconsin Nursing Homes","IMUNIFI","Completed","No Results Available","UTI - Urinary Tract Infection","Behavioral: Externally-facilitated implementation|Behavioral: Internally-driven implementation","Urine culture orders per 1,000 resident-days|Antibiotic starts for treatment of suspected UTI per 1,000 resident-days|Days of therapy for treatment of suspected UTI per 1,000 resident-days|Fluoroquinolone antibiotic starts and days of therapy per 1000 resident-days|Percentage of antibiotic starts for UTI meeting appropriateness criteria|Percentage of urine cultures meeting appropriateness criteria|Percentage of urine cultures positive for resistant bacteria|Number of positive clostridium difficile tests|Number of transfers to hospitals or emergency departments per 1000 resident-days|Number of resident deaths per 1000 resident-days","University of Wisconsin, Madison","All","18 Years and older   (Adult, Older Adult)","Not Applicable","338","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2018-0125|A534265|SMPH/MEDICINE/MEDICINE*I|Protocol Version 6/16/2020","June 1, 2018","November 24, 2021","November 24, 2021","May 9, 2018",,"December 23, 2021","University of Wisconsin-Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03520010"
605,"NCT04502095","Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy",,"Recruiting","No Results Available","Bladder Carcinoma|Refractory Bladder Carcinoma|Urinary Tract Infection","Drug: Clindamycin|Other: Diary|Drug: Ertapenem|Drug: Levofloxacin|Drug: Nitrofurantoin|Drug: Trimethoprim-Sulfamethoxazole","90-day urinary tract infection (UTI) status|Identify pre-operative factors associated with the development of UTI|Development of Clostridium difficile (C Diff)|Infections occurring during antibiotic use|Identify post operative factors associated with the development of UTI","Roswell Park Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 573720|NCI-2020-04928","September 2, 2020","September 2, 2024","September 2, 2025","August 6, 2020",,"January 31, 2024","Roswell Park Cancer Institute, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT04502095"
606,"NCT03151967","Lactobacillus Probiotic for Prevention of UTI",,"Completed","Has Results","Urinary Tract Infections (UTI's)","Drug: Lactobacillus crispatus CTV-05|Drug: Placebo","UTI Incidence as Described Below, Over the 16 Week Study Period Following Randomization, in the LACTIN-V Treatment Group (Group A) as Compared to the Placebo Group (Group B).|Parameter of Vaginal Colonization","University of Washington|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Female","18 Years to 45 Years   (Adult)","Phase 2|Phase 3","27","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","STUDY00000160|1R01DK088830-01A1","September 2015","April 5, 2017","April 5, 2017","May 12, 2017","March 1, 2023","March 1, 2023","Hall Health Primary Care Center, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/67/NCT03151967/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/67/NCT03151967/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03151967"
607,"NCT05763693","Vitality in Infants Via Azithromycin for Neonates Trial","VIVANT","Not yet recruiting","No Results Available","Neonatal Death|Infectious Disease|Nutritional Deficiency","Drug: Azithromycin at Baseline|Drug: Azithromycin at Day 21|Other: Placebo at Baseline|Other: Placebo at Day 21","weight gain at 6 month of age|IHPS|Mortality at 6 months","University of California, San Francisco|Centre de Recherche en Sante de Nouna, Burkina Faso","All","1 Day to 27 Days   (Child)","Phase 4","5000","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","21-34232","July 31, 2024","July 31, 2027","July 31, 2027","March 10, 2023",,"December 4, 2023","Centre de Recherche en santé de Nouna, Nouna, Burkina Faso",,"https://ClinicalTrials.gov/show/NCT05763693"
608,"NCT01726166","Suprapubic Aspiration Versus Urinary Catheterization In Neonates.","SPA","Terminated","No Results Available","Neonatal Urinary Tract Infection","Procedure: Suprapubic Aspiration|Procedure: Urinary Catheterization","Number of contaminated urine samples per SPA and UC|Success rates of obtaining urine by SPA versus UC|Time to perform the respective procedures|Complication rates of SPA versus UC|Contamination rates of SPA versus UC (excluding clean catch urine)|Number of attempts per procedure","Children's Hospital of Eastern Ontario|The Physicians' Services Incorporated Foundation","All","72 Hours to 12 Months   (Child)","Not Applicable","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2011813-01H","April 2013","May 2016","May 2016","November 14, 2012",,"January 22, 2020","Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Ottawa Hospital - General campus, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01726166"
609,"NCT01054677","Swedish Antibiotic Nursing Home Trial","SANT","Completed","No Results Available","Infections|Urinary Tract Infections","Behavioral: Educational intervention on antibiotic prescribing",,"Karolinska Institutet|The national corporation of Swedish pharmacies, Apoteket AB",,"Child, Adult, Older Adult","Not Applicable",,"Other","Interventional","Primary Purpose: Health Services Research","dnr 03-070",,,,"January 22, 2010",,"January 22, 2010",,,"https://ClinicalTrials.gov/show/NCT01054677"
610,"NCT05762016","Outcomes of a Novel Technique of Mini- Incision and Self-Express (MISE) for Breast Abscess",,"Active, not recruiting","No Results Available","Breast Infection","Procedure: Bedside Mini-Incision and Self-Express (MISE)","recovery time","KK Women's and Children's Hospital","Female","18 Years to 70 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CIRB Ref:2021/2634","January 1, 2018","October 31, 2024","October 31, 2024","March 9, 2023",,"March 9, 2023","KK Women's and Children's Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT05762016"
611,"NCT04476407","Pharmacokinetics of Benapenem in Subjects With Renal Impairment",,"Completed","No Results Available","Complicated Urinary Tract Infection; Cuti","Drug: benapenem","Area under the plasma concentration-time curve|Maximum observed plasma concentration(Cmax)|Observed terminal elimination half-life (T1/2)|Total body clearance (CLt)|Apparent volume of distribution (Vz)|Cumulative urine exeretion|Renal clearance (CLr)|Metabolite-to-parent ratio of AUC0-inf","Sihuan Pharmaceutical Holdings Group Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5081-I-1004","June 15, 2019","October 21, 2019","October 21, 2019","July 20, 2020",,"July 20, 2020","Shanghai Tongji Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04476407"
612,"NCT00037921","UTI Prophylaxis Using Bacterial Interference Following SCI",,"Completed","No Results Available","Urinary Tract Infections","Procedure: Bacterial colonization",,"US Department of Veterans Affairs|VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment","B2410R","January 2001","December 2003","December 2003","May 27, 2002",,"May 7, 2010","Michael E. DeBakey VA Medical Center (152), Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00037921"
613,"NCT02256579","Utility of Urinary beta2 Microglobulin as an Early Marker of Renal Dysfunction in Vietnamese HIV-Infected Patients",,"Unknown status","No Results Available","HIV Infection|Renal Function Disorder|Renal Tubular Disorder",,"Evaluation of urinary beta2microglobulin, urinary protein and serum creatinine among Vietnamese HIV-infected patients|Evaluation of risk factors for renal dysfunction and tubular dysfunction","National Center for Global Health and Medicine, Japan","All","20 Years and older   (Adult, Older Adult)",,"1800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NCGM-G-001074-01","October 2014","November 2016","March 2017","October 3, 2014",,"October 3, 2014",,,"https://ClinicalTrials.gov/show/NCT02256579"
614,"NCT01861353","Cranberry-lingonberry Juice Started During Acute Infection in Prevention of Urinary Tract Infections in Children",,"Completed","No Results Available","Urinary Tract Infection|Pyelonephritis|Cystitis","Other: Cranberry-lingonberry juice|Other: Placebo juice","Change of the intestinal and urinary microbiome|The occurrence of urinary tract infections (infection episodes/person years at risk)|Time to the first recurrence","University of Oulu","All","1 Year to 16 Years   (Child)","Not Applicable","113","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","EETTMK74/2012","May 2013","February 28, 2019","February 28, 2019","May 23, 2013",,"May 9, 2022","Department of Pediatrics, University of Oulu, Oulu, Finland",,"https://ClinicalTrials.gov/show/NCT01861353"
615,"NCT02751073","Evaluation of the Relationship Between Vaginal and Lower Urinary Tract Microbiomes and Infection After Hysterectomy",,"Completed","No Results Available","Pelvic Organ Prolapse|Hysterectomy|Urinary Tract Infection",,"Identification of baseline vaginal microbiome through DNA extraction and 16S rRNA gene sequencing|Identification of baseline urinary tract microbiome through DNA extraction and 16S rRNA gene sequencing|Identification of pre-operative vaginal microbiome through DNA extraction and 16S rRNA gene sequencing|Identification of pre-operative urinary tract microbiome through DNA extraction and 16S rRNA gene sequencing|Identification of the immediate postoperative vaginal microbiome through DNA extraction and 16S rRNA gene sequencing|Identification of the immediate postoperative urinary tract microbiome through DNA extraction and 16S rRNA gene sequencing|Identification of the postoperative vaginal microbiome through DNA extraction and 16S rRNA gene sequencing|Identification of the postoperative urinary tract microbiome through DNA extraction and 16S rRNA gene sequencing|Identification of vaginal microbiome in the setting of postoperative urinary tract infection through DNA extraction and 16S rRNA gene sequencing|Identification of urinary tract microbiome in the setting of postoperative urinary tract infection through DNA extraction and 16S rRNA gene sequencing|Identification of key biomarkers associated with risk of postoperative urinary tract infection through proteomic mass spectrometry analysis of vaginal swab collected in the setting of postoperative urinary tract infection|Identification of the vaginal microbiome at least 6 weeks following surgery through DNA extraction and 16S rRNA gene sequencing|Identification of the postoperative urinary tract microbiome at least 6 weeks following surgery through DNA extraction and 16S rRNA gene sequencing","Mayo Clinic","Female","40 Years and older   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","15-006300","February 2016","May 31, 2017","July 30, 2018","April 26, 2016",,"August 16, 2018","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02751073"
616,"NCT02357758","Effects of Antibiotic Prophylaxis on Recurrent UTI in Children",,"Completed","Has Results","Urinary Tract Infection|Recurrent Urinary Tract Infection","Drug: Antibiotic Prophylaxis","Changes to the Urinary Microbiota|Changes to Metabolic Profiles of Urine|Changes to Antibiotic Susceptibility|Changes in Pro-inflammatory Cytokines","Lawson Health Research Institute|University of Western Ontario, Canada","All","3 Years to 15 Years   (Child)","Phase 4","59","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","R-12-387","September 2012","January 2016","March 2016","February 6, 2015","October 14, 2019","September 21, 2021","Children's Hospital - London Health Sciences Centre, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02357758"
617,"NCT00404625","Infections Caused by ESbL-Producing Enterobacteriaceae in Italy",,"Unknown status","No Results Available","Enterobacteriaceae Infections|Bacteremia|Pneumonia|Skin Diseases|Urinary Tract Infections","Behavioral: Risk factors for infections due to ESBL+ Enterobacteriaceae|Behavioral: Risk factors for inadequate initial antimicrobial therapy|Behavioral: Overall and 30-day mortality in bad first antibiotic therapy",,"University of Siena|Merck Sharp & Dohme LLC","All","16 Years and older   (Child, Adult, Older Adult)",,"813","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Other","P1908","October 2006",,"November 2006","November 29, 2006",,"November 29, 2006","Università Politecnica delle Marche, Ancona, Italy|A.O. ""Ospedali Riuniti di Bergamo"", Bergamo, Italy|Univeristà di Firenze, Ospedale Careggi, Firenze, Italy|Ospedale Niguarda Ca' Granda, Milano, Italy|Università Cattolica S. Cuore, Policlinico Gemelli, Roma, Italy|Università di Varese, Varese, Italy",,"https://ClinicalTrials.gov/show/NCT00404625"
618,"NCT00528476","Risk Factors for Recurrent Urinary Tract Infection in Children",,"Completed","No Results Available","Urinary Tract Infection|Pyelonephritis|Cystitis",,,"Kaunas University of Medicine","All","5 Years to 18 Years   (Child, Adult)",,"161","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","BE-2-68","November 2004",,"January 2007","September 12, 2007",,"September 12, 2007","Kaunas University of Medicine, Kaunas, Lithuania",,"https://ClinicalTrials.gov/show/NCT00528476"
619,"NCT04077580","The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing in Elderly Women With Recurrent UTI","ImpresUWP3","Enrolling by invitation","No Results Available","Recurrent Urinary Tract Infection","Drug: Methenamine Hippurate 1000 MG","The primary objective of this study is to investigate if taking methenamine hippurate reduces the need for antibiotic usage due to recurrent UTI (measured as number of antibiotic courses).|Use of methenamine will give prolonged effect on antibiotic usage .|Use of methenamine will reduced incidence of UTI.|Use of methenamine reduce severity of UTI symptoms.|Use of methenamine hippurate reduce duration of UTI episodes.|Use of methenamine will reduce complications such as pyelonephritis and hospital admission for UTI","University of Oslo|Amsterdam UMC, location VUmc|UMC Utrecht|Göteborg University|Medical University of Lodz","Female","70 Years to 99 Years   (Older Adult)","Phase 4","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Eudract 2018-002235-15","November 1, 2019","November 30, 2023","November 30, 2023","September 4, 2019",,"June 29, 2023","Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|University of Oslo, Oslo, Norway|Medical University of Lodz,, Łódź, Poland|Research and Development Primary Health Care, Region Västra Götaland,, Borås, Sweden","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/80/NCT04077580/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/80/NCT04077580/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04077580"
620,"NCT05510830","Diagnostic Cervical Conization for Persistent Infection or Integration of HPV",,"Not yet recruiting","No Results Available","Human Papilloma Virus Infection|Human Papilloma Virus Integration|Cervical Intraepithelial Neoplasia|Cervical Cancer|Cervical Conization","Procedure: diagnostic cervical conization","The incidence of discovering concealed cervical cancer or percancerous lesions|The incidence of HPV clearance after the cervical conization","Tongji Hospital|National Natural Science Foundation of China","Female","25 Years to 70 Years   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TJ-IRB20220769","October 2022","January 2028","January 2030","August 22, 2022",,"September 8, 2022","Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT05510830"
621,"NCT06149455","Preoperative Prophylactic Antibiotic Duration in Moderate to High Risk Ureteroscopy",,"Not yet recruiting","No Results Available","Infections, Urinary Tract|Nephrolithiasis","Other: Duration of antibiotics","infectious complication rate|Non-infectious complications including readmission|Adverse reaction to antibiotic regimen|Identification of secondary markers of post-operative sepsis","University of California, San Francisco","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","22-37824","January 1, 2024","January 1, 2026","January 1, 2026","November 29, 2023",,"December 15, 2023","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT06149455"
622,"NCT05007405","Spectrum of Bacterial Infections in Rheumatology","SIBERIE","Completed","No Results Available","Articular Disease","Other: Groups/Cohortes","Identification of the spectrum of osteoarticular infections in adult, in a rheumatology department|Prevalence of urinary origin in osteoarticular infections in adults, compared with other origins","Hôpital NOVO","All","18 Years and older   (Adult, Older Adult)",,"81","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CHRD 1820","February 12, 2021","December 31, 2021","December 31, 2021","August 16, 2021",,"January 26, 2022","Department of Rheumatology, Hospital René Dubos, Pontoise, Pontoise, France",,"https://ClinicalTrials.gov/show/NCT05007405"
623,"NCT01142752","Vaginal, Oral and Systemic Inflammation in Preterm Birth",,"Completed","No Results Available","Local or Systemic Signs for Infection, Preterm Birth",,"Difference in systemic and local parameters of infection between patients at risk and controls","Insel Gruppe AG, University Hospital Bern","Female","18 Years and older   (Adult, Older Adult)",,"71","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","KEK091/10","November 2011","April 2015","May 2015","June 11, 2010",,"August 3, 2016","University Women's Hospital, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT01142752"
624,"NCT04495699","Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections",,"Recruiting","No Results Available","Urinary Tract Infections|Kidney Stone","Other: None - observational","Recurrent urinary tract infections|Time to first UTI|Pyelonephritis/urosepsis|Incidence of complications from intervention within 30 days|Incidence of further intervention for stones|Stone analysis correlation with rUTI|Stone free vs not stone free correlation with rUTI|Correlation of selected demographic factors with rUTI|Number free from recurrent UTIs|Number free from any UTI|Crossover from observation to intervention","Vanderbilt University Medical Center|University of British Columbia|University of California, San Diego|Mayo Clinic|Massachusetts General Hospital|Columbia University","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0000000","September 9, 2020","May 2025","June 2025","August 3, 2020",,"July 24, 2023","Mayo Clinic Arizona, Phoenix, Arizona, United States|University of California San Diego, San Diego, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Columbia University, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Vancouver General Hospital/University of British Columbia, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT04495699"
625,"NCT01104662","Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment","RENSE","Terminated","Has Results","Complicated Skin and Skin Structure Infections|S. Aureus Bacteremia|Renal Impairment","Drug: Vancomycin|Drug: Daptomycin|Drug: Semi-Synthetic Penicillin","Number of Participants With Treatment-emergent Creatine Phosphokinase (CPK) Elevations Through End of Therapy/Early Termination (EOT/ET)|Overall Therapeutic Outcome at Test of Cure (TOC)/Safety Visit","Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","All","18 Years and older   (Adult, Older Adult)","Phase 4","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","3009-022|DAP-RENSE-08-05","April 19, 2010","June 12, 2012","June 12, 2012","April 15, 2010","May 13, 2015","September 5, 2018","Azusa, California, United States|Los Angeles, California, United States|Torrance, California, United States|Washington, District of Columbia, United States|Decatur, Georgia, United States|Somers Point, New Jersey, United States|Winston-Salem, North Carolina, United States|Columbus, Ohio, United States|West Reading, Pennsylvania, United States|Mission, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01104662"
626,"NCT02216253","L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract to Prevent Postoperative Urinary Tract Infection.",,"Completed","No Results Available","Urinary Tract Infection|Pelvic Organ Prolapse|Urinary Incontinence","Drug: L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|Other: Placebo","Treatment for urinary tract infection after surgery.","IRCCS San Raffaele","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UTI 2014","October 2014","August 2015",,"August 13, 2014",,"August 26, 2015","IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Lombardy, Italy",,"https://ClinicalTrials.gov/show/NCT02216253"
627,"NCT01275170","A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)",,"Completed","Has Results","Infectious Disease","Drug: MK-7655|Drug: Imipenem + Cilastatin|Drug: Caffeine|Drug: Midazolam|Drug: Omeprazole","Part 1: Area Under the Plasma Concentration-time Curve From Dosing to Infinity (AUC0-inf) of MK-7655 in Combination With PRIMAXIN®|Dialysis Clearance (CLD) of MK-7655 in Participants With End-stage Renal Diseases Requiring Hemodialysis (ESRD/HD)|Extraction Coefficient of MK-7655 in Participants With End-stage Renal Diseases Requiring Hemodialysis (ESRD/HD)|Part 1: Concentration at End of Infusion (Ceoi) of MK-7655 in Combination With PRIMAXIN®|Part 1: Predicted Clearance (CLpred) of MK-7655 in Combination With PRIMAXIN®|Part 1: Predicted Volume of Distribution During the Terminal Phase (VZpred) of MK-7655 in Combination With PRIMAXIN®|Part 1: Time of Maximum Plasma Concentration (Tmax) of MK-7655 in Combination With PRIMAXIN®|Part 1: Apparent Plasma Half-life (t½) of MK-7655 in Combination With PRIMAXIN®|Part 1: AUC0-inf of Imipenem in Combination With MK-7655|Part 1: Ceoi of Imipenem in Combination With MK-7655|Part 1: CLpred of Imipenem in Combination With MK-7655|Part 1: VZpred of Imipenem in Combination With MK-7655|Part 1: Tmax of Imipenem in Combination With MK-7655|Part 1: Apparent t½ of Imipenem in Combination With MK-7655|Part 1: AUC0-inf of Cilastin in Combination With MK-7655|Part 1: Ceoi of Cilastin in Combination With MK-7655|Part 1: CLpred of Cilastin in Combination With MK-7655|Part 1: VZpred of Cilastin in Combination With MK-7655|Part 1: Tmax of Cilastin in Combination With MK-7655|Part 1: Apparent t½ of Cilastin in Combination With MK-7655|Part 1: Renal Clearance (CLR) of MK-7655 in Urine|Part 1: CLR of Imipenem in Urine|Part 1: CLR of Cilastin in Urine|Part 2: Plasma AUC0-∞ of Caffeine as a Probe Substrate of Cytochrome P450 Enzyme (CYP)1A2|Part 2: Plasma AUC0-∞ of Midazolam as a Probe Substrate of Cytochrome P450 Enzyme (CYP)3A4|Part 2: Plasma AUC0-∞ of Omeprazole as a Probe Substrate of Cytochrome P450 Enzyme (CYP)2C19|Parts 1 and 2: Percentage of Participants With ≥1 Adverse Events (AEs)","Merck Sharp & Dohme LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7655-005","January 28, 2011","March 5, 2012","March 5, 2012","January 12, 2011","July 19, 2019","June 11, 2020",,,"https://ClinicalTrials.gov/show/NCT01275170"
628,"NCT05667207","Dipsticks and Microscopy to Reduce Antibiotic Use in Women's Urinary Tract Infections: a Pilot Trial (MicUTI)","MicUTI","Recruiting","No Results Available","Cystitis Acute|Antibiotic Resistant Infection|Medication Adherence|Urinary Tract Infection Bacterial|Urinary Tract Infection Lower Acute","Diagnostic Test: Point-of-care microscopy and dipstick guided management","Recruitment efficacy|Retention|Total antibiotic use|Antibiotic doses|Inappropriate antibiotic use|Immediate and delayed antibiotics|Early relapses|Recurrent urinary tract infections (UTIs)|Upper UTIs|Re-consultations|Symptom resolution|Symptom Burden|Diagnostic accuracy","Wuerzburg University Hospital|University Hospital Erlangen|LMU Klinikum|University of Bristol|University of Santiago de Compostela|Università degli Studi di Trento|University of Wuerzburg|University of Georgia","Female","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","109/22-sc","June 15, 2023","February 1, 2024","February 1, 2024","December 28, 2022",,"November 15, 2023","Stefanie Stark, Erlangen, Germany|University Hospital Würzburg, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT05667207"
629,"NCT03229603","A Pilot Study on HPV and Cervical Cancer Screening in Mumbai","HPV","Unknown status","No Results Available","HPV Infection","Other: Cluster of 3000 women","The feasibility of HPV testing as a single visit approach will be summarized using the appropriate descriptive statistics.|Overall agreement between clinician-collected versus self-collected samples will be compared using pairwise t tests|The focus group data will be analyzed using constant comparative data analysis to identify thematic components and sub-themes.|The HPV GeneXpert by health care provider and HPV HC2 samples by health care provider will be compared to study the agreement rates.|Documentation of six different genotypes/ genotype families of HPV from cervical tissue samples, which will inform the development of HPV vaccinations specific to the strains of HPV in India.|Probe for perceptions about self-collection of vaginal samples to describe acceptability of this process.|Fit a predictive model of HPV infection(s).","Tata Memorial Hospital|University of Arizona","Female","30 Years to 55 Years   (Adult)","Not Applicable","227","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TMHPO1763","April 2018","April 2018","May 2018","July 25, 2017",,"December 22, 2017","Tata Memorial Hospital, Mumbai, Mharashtra, India",,"https://ClinicalTrials.gov/show/NCT03229603"
630,"NCT05793814","Assess the Effects of a Limosilactobacillus Supplement on Recurrence of UTI in Healthy Women During a 6-month Period",,"Recruiting","No Results Available","Uncomplicated Symptomatic Urinary Tract Infections","Dietary Supplement: Limosilactobacillus reuteri 3613|Dietary Supplement: Placebo","Incidence rate of symptomatic UTI|Proportion of subjects experiencing ≥1 symptomatic UTI|UTI symptom severity|Proportion of subjects experiencing different numbers of UTI|Total UTI count|Time for the first UTI|Vaginal pH change|Quality of Life change","Church & Dwight Company, Inc.","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AFCRO-138","May 7, 2021","June 2023","June 2023","March 31, 2023",,"March 31, 2023","Church &Dwight., Inc, Princeton, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT05793814"
631,"NCT03800667","Vitamin C for the Prevention of UTI in Women Who Undergo Elective GYN Surgeries",,"Withdrawn","No Results Available","Catheter-Associated Urinary Tract Infection, Ascorbic Acid","Drug: Ascorbic Acid 1000 MG","Proportion of participants who experienced clinically diagnosed and treated UTI.","American University of Beirut Medical Center","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","OGY.TB.09","August 8, 2018","July 12, 2019","July 12, 2019","January 11, 2019",,"July 15, 2019","American University of Beirut Medical Center, Beirut, Lebanon",,"https://ClinicalTrials.gov/show/NCT03800667"
632,"NCT03548129","the Use of Fosfomycin as a Single Dose Oral Treatment of Asymptomatic Bacteriuria",,"Unknown status","No Results Available","Urinary Tract Infection","Drug: phosphomycin|Drug: Culture specific antibiotic therapy|Diagnostic Test: Pre-treatment Urine Culture|Diagnostic Test: Antimicrobial sensitivity testing|Diagnostic Test: Post-treatment urine culture","Resolution of asymptomatic bacteriuria|Need for further treatment|Need for further investigations|Incidence of adverse drug reactions .","Ain Shams University","Female","18 Years to 40 Years   (Adult)","Phase 2","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","phosphomycin","July 2016","July 2018","August 2018","June 7, 2018",,"June 7, 2018",,,"https://ClinicalTrials.gov/show/NCT03548129"
633,"NCT01396798","Validation of Vital Signs and Symptoms for the Diagnosis of Serious Infections in Children in the Paediatric A&E.","ERNIE3","Completed","No Results Available","Community-Acquired Infections|Respiratory Tract Infections|Sepsis|Urinary Tract Infections|Meningitis|Gastroenteritis",,"serious infections: meningitis, sepsis, pneumonia, pyelonephritis, osteomyelitis and cellulitis, gastroenteritis with sever dehydration, complicated urinary tract infection and complicated viral airway infection with hypoxia.","KU Leuven","All","1 Month to 16 Years   (Child)",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","S52996","February 2011","March 2012","March 2012","July 19, 2011",,"September 14, 2012","Dienst Algemene Kindergeneeskunde, Universitaire Ziekenhuizen Leuven, Leuven, Vlaams-Brabant, Belgium",,"https://ClinicalTrials.gov/show/NCT01396798"
634,"NCT03176394","Efficacy of BLASTX in Catheter Associated Bacteriuria Versus Standard of Care (SOC)",,"Terminated","No Results Available","Urinary Tract Infections","Device: BLASTX Gel|Device: McKesson Jelly","Urine microorganisms DNA analysis|Catheter microorganisms DNA analysis|Incidence of Urinary Tract Infections (UTIs)","Next Science TM","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CSP-005","May 24, 2017","October 18, 2019","October 18, 2019","June 5, 2017",,"November 7, 2023","American Medical Research Institute, Celebration, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03176394"
635,"NCT05204368","Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)",,"Not yet recruiting","No Results Available","Complicated Urinary Tract Infection Including Acute Pyelonephritis","Drug: Combination of Imipenem/Cilastatin and XNW4107|Drug: Meropenem","overall success|symptomatic clinical success|microbiological success|By-pathogen microbiological success|The proportion of overall success; symptomatic clinical, and microbiologic success|clinical success","Evopoint Biosciences Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","780","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XNW4107-301","March 30, 2023","June 2025","December 2025","January 24, 2022",,"February 16, 2023","University of Maryland Medical Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT05204368"
636,"NCT04246996","Gentamicin Intravesical Efficacy for Infection of Urinary Tract","GIVEIT","Completed","Has Results","Postoperative Urinary Tract Infection|Pelvic Organ Prolapse|Stress Urinary Incontinence","Drug: gentamicin sulfate|Other: Catheter clamping only","Post-operative Urinary Tract Infection|Adverse Events|Number of Participants With Isolated Uropathogen on Post-operative Urine Culture","Kaiser Permanente|University of California, San Diego","Female","18 Years and older   (Adult, Older Adult)","Phase 2","370","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","GIVEIT|12297|191835","January 29, 2020","December 5, 2021","December 5, 2021","January 29, 2020","November 8, 2022","November 8, 2022","UC San Diego Health, La Jolla, California, United States|Kaiser Permanente San Diego, San Diego, California, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/96/NCT04246996/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04246996"
637,"NCT03522961","Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery",,"Active, not recruiting","No Results Available","Urinary Tract Infections|Pelvic Organ Prolapse|Urinary Incontinence","Drug: Nitrofurantoin Prophylaxis/Placebo|Drug: Cranberry capsules","The primary outcome will be treatment for clinically suspected or culture-proven UTI in the cranberry capsule group versus the nitrofurantoin group within 4 weeks (28 days) after surgery.|Prevalence of bacterial resistance to nitrofurantoin on postoperative urine cultures for those participants who have culture-proven UTIs|Adherence to assigned treatment:cranberry capsule vs. nitrofurantoin|Reasons for non-adherence to assigned treatment|Risk factors for postoperative UTI|Time to first postoperative UTI|Number of postoperative UTIs","Brigham and Women's Hospital|Theralogix LLC","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","142","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","2017P002904|016086","August 15, 2018","September 30, 2023","January 31, 2024","May 14, 2018",,"August 28, 2023","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03522961"
638,"NCT04173013","Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)",,"No longer available","No Results Available","Urinary Tract Infections|Chronic Urinary Tract Infection|Recurrent Urinary Tract Infection|Urinary Tract Infection Bacterial|Bladder Infection","Biological: Uromune",,"Impatients N.V. trading as myTomorrows|Inmunotek S.L.","All","Child, Adult, Older Adult",,,"Industry","Expanded Access",,"2019-UROMUNEINM-EU",,,,"November 21, 2019",,"September 29, 2023","Belgium, Brussels, Belgium|Czech Republic, Praha, Czechia|Denmark, Copenhagen, Denmark|Finland, Helsinki, Finland|France, Paris, France|Germany, Berlin, Germany|Luxembourg, Luxembourg, Luxembourg|The Netherlands, Amsterdam, Netherlands|Norway, Oslo, Norway|Romania, Bukarest, Romania|Serbia, Belgrade, Serbia|Slovakia, Bratislava, Slovakia|Slovenia, Ljubljana, Slovenia|Sweden, Stockholm, Sweden|Turkey, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04173013"
639,"NCT01780324","Lidocaine Analgesia for Urethral Catheterization in Children",,"Completed","Has Results","Pediatric Presentation of Urinary Tract Infection","Drug: Lidocaine","Pain Score on the Face, Legs, Arms, Cry, Consolability (FLACC) Scale","Seattle Children's Hospital","All","up to 3 Years   (Child)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","24080004","January 2013","May 2014","May 2015","January 31, 2013","April 11, 2016","April 11, 2016","Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01780324"
640,"NCT02265445","Deescalating Carbapenems in Hospital Setting","CARBEPARGNE","Terminated","No Results Available","Urinary Infection|Digestive Infection|Biliary Infection|Expanded-spectrum Beta-lactamase Producing ESBL","Drug: Deescalation therapy|Drug: Maintaining carbapenem therapy","Clinical response|Vital status of patients|absence of relapse of the infection due to the same ESBL-PE strain","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 4","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P130949|AOM 13063","June 2015","June 2016","June 2016","October 16, 2014",,"February 23, 2017",,,"https://ClinicalTrials.gov/show/NCT02265445"
641,"NCT02543827","Evaluation of the Efficacy and Safety of MV140","MV140","Completed","No Results Available","Urinary Tract Infection Bacterial","Biological: MV140|Biological: Placebo","Decrease in the number of RUTI exacerbations.|Severity of RUTI exacerbations|First RUTI exacerbation|Medication consumption|Health resource consumption|Number of visits to the emergency service|Number of hospitalizations due to RUTI exacerbations|Changes from baseline in RUTI Assessment Test|Percentage of difference in immunological parameters from baseline to end of the trial|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Inmunotek S.L.","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","MV140-SLG-003|2013-001838-17","November 2015","November 4, 2020","December 2020","September 7, 2015",,"February 18, 2021","Centro de Salud Universidad Centro, Salamanca, Castilla Y LEÓN, Spain|Centro de Salud Capuchinos, Salamanca, Castilla Y LEÓN, Spain|Hospital Universitario de Salamanca, Salamanca, Castilla Y LEÓN, Spain|CENTRO DE SALUD de PEÑARANDA, Peñaranda de Bracamonte, Salamanca, Castilla Y LEÓN, Spain|Royal Berkshire Hospital Nhs Foundation Trust, Reading, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02543827"
642,"NCT00280592","Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients","CANNEBERGE","Completed","No Results Available","Multiple Sclerosis|Urinary Tract Infections|Bladder Dysfunction","Drug: Cranberry|Drug: Placebo","Time to onset of a first UTI within one year of treatment.|Rate of patients with at least one UTI during the one-year treatment|Number of UTI|Score on Qualiveen® scale|Symptomatology of urinary disorders|EDSS score|Number of multiple sclerosis attacks|Antibiotics consumption|Safety of cranberry|Patients' observance to treatment","Rennes University Hospital|Pierre Fabre Laboratories|Ministry of Health, France","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","171","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AFSSAPS 051016|PHRC/04-03|CIC0203/039","January 2006","March 2008","October 2008","January 23, 2006",,"May 21, 2012","Unité de Médecine Physique et Réadaptation - CHU Jean Minjoz, Besançon, France|Service de Médecine Physique et Réadaptation - Hôpital Pellegrin, Bordeaux, France|Service de Médecine Physique et Réadaptation - Hôpital Raymond Poincaré, Garches, France|Consultations maladies infectieuses et tropicales, Hôpital Raymond Poincaré, Garches, France|Médecine Physique et Réadaptation - Groupe Hospitalier de l'institut Catholique de Lille - Hôpital Saint Philibert, Lomme, France|Rééducation Neurologique et Explorations Périnéales - Hôpital Rothschild, Paris, France|Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de KERPAPE, Ploemeur, France|Service de Médecine Physique et Réadaptation - Hôpital Pontchaillou, Rennes, France|Centre de Médecine Physique et Réadaptation Notre Dame de Lourdes, Rennes, France|Service de médecine physique et réadapation Hopital de Rangueil, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT00280592"
643,"NCT00620984","Staphylococcus Aureus Carrier Status in Breastfeeding Mothers and Infants and the Risk of Lactation Mastitis",,"Completed","No Results Available","Mastitis|Staphylococcus Aureus|Staphylococcal Infections",,"Our primary objective is to determine the association of nasal carriage of S. aureus in breastfeeding mothers and infants with the rate development of mastitis in the mothers.|Secondary objective will be to document the S. aureus carriage rate, including methicillin-resistant Staphylococcus aureus (MRSA), in early post-partum period and to assess the relationship between S. aureus carrier status of the mother and the infant.","State University of New York - Upstate Medical University","Female","18 Years and older   (Adult, Older Adult)",,"557","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","5395","August 2006","August 2009","December 2009","February 22, 2008",,"June 2, 2015","SUNY Upstate Medical University, Syracuse, New York, United States",,"https://ClinicalTrials.gov/show/NCT00620984"
644,"NCT00577525","Latent Viral Infection of Lymphoid Cells in Idiopathic Nephrotic Syndrome","Nephrovir","Completed","No Results Available","NEPHROSIS, LIPOID",,"Hybridization of viral genome will be studied at the first manifestation of idiopathic nephrotic syndrome|Steroid sensitivity will be checked by 1 month of prednisone therapy according to the recommendation of the "" SOCIETE DE NEPROLOGIE PEDIATRIQUE"" and steroid dependency will be checked at 4.5 months of prednisone therapy.","Assistance Publique - Hôpitaux de Paris","All","1 Year to 16 Years   (Child)",,"401","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","P070126","December 2007","July 2010","February 2012","December 20, 2007",,"February 27, 2014","Hospital Robert Debre, Paris, France",,"https://ClinicalTrials.gov/show/NCT00577525"
645,"NCT05274672","Role of Prophylactic Postoperative Antibiotics in HoLEP",,"Unknown status","No Results Available","Benign Prostatic Hyperplasia|Urinary Tract Infections","Drug: Nitrofurantoin|Drug: Cephalexin|Drug: Sulfamethoxazole Trimethoprim Combination|Drug: Ciprofloxacin|Procedure: Holmium Laser Enucleation of prostate","the rates of urinary tract infection within the 30-day post-operative period after HoLEP|The incidence of irritative voiding symptoms after HoLEP and all the other urinary functional outcomes.","Baylor Research Institute|Albert Einstein Healthcare Network","Male","40 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","022-046","March 1, 2022","March 1, 2023","June 1, 2023","March 10, 2022",,"March 11, 2022","Einstein Healthcare network, Philadelphia, Pennsylvania, United States|Baylor Scott and White, Temple, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05274672"
646,"NCT00398099","To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)",,"Completed","No Results Available","Infection|Pneumonia|Urinary Tract Infection","Drug: MK0826, ertapenem sodium / Duration of Treatment: 14 Days","Signs and symptoms of infection on days 3, 4, 7 and 14 during treatment|Safety and Tolerability","Merck Sharp & Dohme LLC","All","20 Years and older   (Adult, Older Adult)","Phase 3","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0826-052|2006_046","July 2005","January 2006","January 2006","November 10, 2006",,"February 17, 2017",,,"https://ClinicalTrials.gov/show/NCT00398099"
647,"NCT01779193","Probiotics Capsule as Supplemental Therapy for Group B Streptococci Infection and Vaginitis During Pregnancy",,"Unknown status","No Results Available","Pregnancy","Dietary Supplement: lactic acid bacteria|Dietary Supplement: cranberry|Dietary Supplement: placebo","all cases vaginal group B streptococcus colonies","Meng-Hsing Wu|National Cheng-Kung University Hospital","Female","20 Years to 50 Years   (Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A-BR-101-065","June 2012","July 2015","July 2015","January 30, 2013",,"April 28, 2015","Department of Obstetrics and Gynecology, College of Medicine, National Cheng Kung University, Tainan, Taiwan",,"https://ClinicalTrials.gov/show/NCT01779193"
648,"NCT00937547","Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in Venezuela","HPI","Completed","Has Results","Cervical Cancer",,"HPV Identification|HPV Type 16|HPV Type 18|HPV Type 31|HPV Type 33|HPV Type 45|HPV Type 58|HPV Type 51","Instituto Oncologico Luis Razetti|Merck Sharp & Dohme LLC","Female","Child, Adult, Older Adult",,"329","Other|Industry","Observational","Time Perspective: Prospective","CERVICAL CANCER AND HPV","November 2009","July 2011","July 2011","July 13, 2009","November 8, 2012","December 4, 2012","Instituto Oncologico Luis razetti, Caracas, DF, Venezuela|Jorge Sanchez Lander, Caracas, Miranda, Venezuela",,"https://ClinicalTrials.gov/show/NCT00937547"
649,"NCT03854396","Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women",,"Withdrawn","No Results Available","Recurrent Urinary Tract Infection|Postmenopause|Postmenopausal Syndrome|Postmenopausal Symptoms|Menopause","Drug: Prasterone|Drug: Placebo","Incidence of urinary tract infections (UTIs)|Mean days of antibiotic use","Olivia Cardenas-Trowers, M.D.|AMAG Pharmaceuticals, Inc.|University of Louisville","Female","18 Years and older   (Adult, Older Adult)","Phase 3","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","19.0075","May 2020","February 2021","February 2021","February 26, 2019",,"June 30, 2021","University of Louisville Urogynecology at Springs Medical Center, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT03854396"
650,"NCT03744741","HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study",,"Completed","No Results Available","Respiratory Tract Infections|Urinary Tract Infections|Skin and Soft Tissue Infections|Intraabdominal Infections|Sepsis","Diagnostic Test: HostDx Sepsis","Concordance of HostDx Sepsis diagnostic test read-out: likelihood of bacterial infection|Concordance of HostDx Sepsis diagnostic test read-out: likelihood of viral infection|Concordance of HostDx Sepsis prognostic read-out (severity) with patient outcome","Inflammatix","All","18 Years and older   (Adult, Older Adult)",,"585","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","OSCCCx-INF-02","July 23, 2018","November 25, 2019","January 20, 2020","November 16, 2018",,"December 3, 2021","Emory University, Atlanta, Georgia, United States|University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Texas Tech University Health Sciences Center El Paso, El Paso, Texas, United States|Attikon University Hospital, Chaïdári, Greece",,"https://ClinicalTrials.gov/show/NCT03744741"
651,"NCT02840825","Biochip for HCMV Detection in Breast Milk","VIRUMILK","Terminated","No Results Available","Cytomegalovirus Infections|Breast Feeding|Premature Birth of Newborn",,"optical detection of HCMV specifically captured on the biochip with respect to the reference (PCR) technique.","Centre Hospitalier Universitaire de Besancon","Female","18 Years and older   (Adult, Older Adult)",,"2","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","API/2015/63","March 8, 2016","September 29, 2021","September 29, 2021","July 21, 2016",,"July 28, 2022","CHRU de Besançon, Besançon, France",,"https://ClinicalTrials.gov/show/NCT02840825"
652,"NCT01281319","Evaluation of a Serology Diagnostic Kit for the Detection of Genital Mycoplasma in Pregnancy",,"Unknown status","No Results Available","Genital Mycoplasma Infection|High Risk Pregnancy|Preterm Labor",,"Efficacy of the novel serology kit|Antibody titer according to gestational age|Correlation between culture and serology|Correlation between antibody titer and pregnancy outcome","Promyco Diagnostics|Soroka University Medical Center","Female","18 Years to 45 Years   (Adult)",,"300","Industry|Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","SOR510010CTIL","January 2011","December 2011","December 2012","January 21, 2011",,"January 21, 2011","Soroka University Medical Center, Beer Sheba, Israel",,"https://ClinicalTrials.gov/show/NCT01281319"
653,"NCT00965848","A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections",,"Completed","Has Results","Infection|Cross Infection|Bacterial Infections|Pneumonia, Ventilator-Associated|Intra-abdominal Infections|Urinary Tract Infections","Drug: Doripenem","Number of Participants With Adverse Events (AEs) and Number of Participants Discontinued Because of AEs|Percentage of Participants With Clinical Response at End-of-Treatment (EOT)|Percentage of Participants With Clinical Response at Test-of-Cure (TOC)|Number of Participants With 90-day Mortality","Janssen-Cilag Ltd.,Thailand","All","18 Years and older   (Adult, Older Adult)","Phase 4","270","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR015766|DORIBAC4003","June 2009","July 2010","July 2010","August 26, 2009","August 28, 2013","October 30, 2013","Bangkok, Thailand|Chiang Mai, Thailand|Chiang Rai, Thailand|Chonburi, Thailand|Khon Kaen, Thailand|Khon Khen, Thailand|Nakhonratsima, Thailand|Nakornnayok, Thailand|Pathumthani, Thailand",,"https://ClinicalTrials.gov/show/NCT00965848"
654,"NCT06317688","Effectiveness of Highly Purified Anhydrous (HPA) Lanolin Versus Extra-Virgin Coconut Oil in Preventing Subacute Lactation Mastitis",,"Enrolling by invitation","No Results Available","Lactation Mastitis|Breast Feeding|Staphylococcus Aureus Infection","Dietary Supplement: Extra-Virgin Coconut Oil","Measurement of change in pain level (Numeric Pain Rating Scale McCaffery, 1989)|Measurement of Development of Nipple Crack (Nipple Tenderness Scale Storr 1988)","Texas Woman's University|Harris Health System (Houston, Texas)","Female","18 Years to 45 Years   (Adult)","Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TWU IRB-FY2023-157","November 6, 2023","August 14, 2024","August 14, 2024","March 19, 2024",,"March 27, 2024","Harris Health System, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT06317688"
655,"NCT01871753","The Bacteriuria in Renal Transplantation (BiRT) Study: A Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria","BiRT","Completed","No Results Available","Asymptomatic Bacteriuria|Bacteriuria|Urinary Tract Infections|Kidney Transplantation","Other: Anti-Infective Agents","cumulative incidence of a first episode of symptomatic urinary tract infection|incidence of a first episode of pyelonephritis|clearance of asymptomatic bacteriuria|occurrence of new episodes of asymptomatic bacteriuria|graft function/graft survival|incidence of graft rejection|patient survival|utility of a control urine culture for diagnosis of asymptomatic bacteriuria in kidney transplant recipients|level of antimicrobial resistance in bacteria responsible for symptomatic urinary tract infections|total number of days of antimicrobial therapy|cost of antimicrobial treatment for asymptomatic bacteriuria and symptomatic urinary tract infection|number of hospitalizations for asymptomatic bacteriuria and symptomatic urinary tract infection treatment|total number of symptomatic urinary tract infections in both groups","Erasme University Hospital|University Hospital, Lille|Universitair Ziekenhuis Brussel|Hôpital Necker Enfants-Malades, Université de Paris Descartes, APHP, France|Centre Hospitalier Universitaire Brugmann|Centre Hospitalier Universitaire de Charleroi|University Ghent|Centre Hospitalier Epicura, Belgium|University of Liege|Nantes University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","198","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BiRT study|2012-003857-26","April 2014","July 2019","July 2019","June 7, 2013",,"July 18, 2019","Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium|Centre Hospitalier Epicura, Baudour, Belgium|Centre Hospitalier Universitaire Brugmann, Brussels, Belgium|Hôpital Universitaire Erasme, Brussels, Belgium|Universitair Ziekenhuis Brussel - Vrije Universiteit Brussel, Brussels, Belgium|Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Groupe Henri Mondor-Albert Chenevier, Assistance Publique-Hôpitaux de Paris, Créteil, France|Centre Hospitalier Régional Universitaire de Lille, Lille, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Department of Kidney Transplantation, Hôpital Necker Enfants-Malades, Université de Paris Descartes, APHP, Paris, France|Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France|Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France|Centre Hospitalier Universitaire Rangueil, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT01871753"
656,"NCT01963013","Non-returning Catheter Valve for Reducing CAUTI",,"Completed","No Results Available","Catheter Associated Urinary Tract Infection|Critically Ill Patients","Device: Non-returning catheter valve|Device: Conventional urine bag","Incidence density of the catheter associated urinary tract infection (CAUTI)","Khon Kaen University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CAUTI-001","June 2012","February 2013","April 2013","October 16, 2013",,"October 21, 2013","Srinagarind hospital, Muang, Khon Kaen, Thailand",,"https://ClinicalTrials.gov/show/NCT01963013"
657,"NCT04598971","Urine pH and Urinary Tract Infection","PHURINE","Unknown status","No Results Available","Urinary Tract Infections|Urinary Stone",,"Urine pH","Centre Hospitalier Universitaire Vaudois","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2020-00779","August 1, 2020","December 31, 2020","December 13, 2021","October 22, 2020",,"October 22, 2020","UniSanté, Lausanne, VD, Switzerland",,"https://ClinicalTrials.gov/show/NCT04598971"
658,"NCT04229511","Development of Risk Score Model and Decision Tree Algorithm for Predicting Infections With CRKp in Colonized Patients","DETERMINE","Unknown status","No Results Available","Bloodstream Infection|Pneumonia, Bacterial|Intra-abdominal Infection|Urinary Tract Infections|Osteomyelitis|Central Nervous System Infections|Acute Bacterial Skin and Skin Structure Infection","Diagnostic Test: Detection of CRKp colonization","The factors that are associated with the development of subsequent BSI or other types of invasive infection with CRKp in CRKp carriers.|Calculation of sensitivity and specificity rates, positive and negative predictive values of risk score model.|Calculation of sensitivity and specificity rates, positive and negative predictive values of decision tree algorithm.","SCARE (Study group for carbapenem resistance)","All","18 Years and older   (Adult, Older Adult)",,"520","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DETERMINE301219","April 2020","April 2021","November 2021","January 18, 2020",,"January 18, 2020","Abdullah Tarık Aslan, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT04229511"
659,"NCT06070454","Prospective Evaluation of Infectious Vulvovaginitis on Wound Complication Rates After Vulvar Excision for Premalignant Lesions",,"Not yet recruiting","No Results Available","Vaginitis|Vulvar Diseases","Diagnostic Test: vaginitis panel","the rate of perioperative vulvovaginitis|rate of vulvovaginitis with rate of wound cellulitis and incisional breakdown","University of Virginia","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","91","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","HSR230407","November 14, 2023","November 14, 2025","November 14, 2025","October 6, 2023",,"October 6, 2023","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT06070454"
660,"NCT00021671","Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission",,"Completed","No Results Available","HIV Infections","Drug: Erythromycin|Drug: Nevirapine|Drug: Ampicillin sodium|Drug: Metronidazole",,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Mental Health (NIMH)|National Institute on Drug Abuse (NIDA)","Female","Child, Adult, Older Adult","Phase 3","3720","NIH","Interventional","Masking: Double|Primary Purpose: Prevention","HIVNET 024|11622",,,"November 2004","August 31, 2001",,"November 1, 2021","Megan Valentine, Research Triangle Park, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00021671"
661,"NCT01970371","A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)","CARE","Completed","Has Results","Bloodstream Infections (BSI) Due to CRE|Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE|Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE|Complicated Urinary Tract Infection (cUTI) Due to CRE|Acute Pyelonephritis (AP) Due to CRE","Drug: plazomicin|Drug: colistin|Drug: meropenem|Drug: tigecycline|Drug: antibiotic of Investigator's choice","Percentage of Patients With All Cause Mortality (ACM) at Day 28 or Significant Disease-Related Complication (SDRC) in the Microbiological Modified Intent to Treat (mMITT) Population in Cohort 1|Percentage of Patients With ACM at Day 28 in the mMITT Population in Cohort 1|Percentage of Patients With Adjudicated Clinical Cure at the Test of Cure (TOC) Visit in the mMITT Population in Cohort 1|Time to Death Through Day 28 in the mMITT Population in Cohort 1|Percentage of Patients With ACM at Day 14 in the mMITT Population in Cohort 1|Percentage of Patients With Dose Adjustment Due to Therapeutic Drug Management (TDM)|Percentage of Patients With Treatment-Emergent Adverse Events (TEAEs)|Plasma Pharmacokinetics (PK): Area Under the Curve From 0 to 24 Hours (AUC 0-24h)|Plasma Pharmacokinetics (PK): Maximum Observed Plasma Drug Concentration (Cmax)|Plasma Pharmacokinetics (PK): Minimum Observed Plasma Drug Concentration (Cmin)","Achaogen, Inc.|Department of Health and Human Services","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","69","Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACHN-490-007|2013-001997-18|U1111-1151-2686","September 16, 2014","August 18, 2016","September 15, 2016","October 28, 2013","October 16, 2018","October 16, 2018",,,"https://ClinicalTrials.gov/show/NCT01970371"
662,"NCT04332861","Evaluation of Infection in Obstructing Urolithiasis","eIOU","Completed","No Results Available","Kidney Stone|Kidney Calculi|Urinary Tract Obstruction|Infection|Sepsis","Other: Initial clinical and laboratory evaluation","Urinary tract infection (positive urine culture)|Intensive care unit admission and/or death due to sepsis during inpatient encounter|Bacteremia (at least one positive blood culture)|Pyonephrosis (drainage of pus from the involved kidney) during inpatient encounter","University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Older Adult)",,"477","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STU-2018-0028","September 3, 2019","July 28, 2020","July 28, 2020","April 3, 2020",,"December 13, 2023","Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern Medical Center Clements University Hospital, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04332861"
663,"NCT03785262","Low Energy Surface Waves for Neurogenic Bladder Patients With Indwelling Catheters",,"Terminated","No Results Available","Neurogenic Bladder|Urinary Tract Infections","Device: Uroshield|Device: Sham Uroshield","Bacteriuria|Neurogenic bladder symptom score (NBSS)|Patient subjective rating of amount of sediment/debris at the end of the 30 days|Total bacterial cell counts|Microbiome comparison of biofilms|Scanning electron microscopy of biofilms","Lawson Health Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","113221","January 30, 2019","December 30, 2023","December 30, 2023","December 24, 2018",,"January 12, 2024","St Josephs Hospital, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03785262"
664,"NCT04094818","HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis","SEPSIS-SHIELD","Recruiting","No Results Available","Respiratory Tract Infections|Urinary Tract Infections|Intra-Abdominal Infections|Skin and Soft Tissue Infection|Suspected Meningitis/Encephalitis or Any Other Infection|Sepsis","Diagnostic Test: HostDx Sepsis","Evaluation of the diagnostic performance of HostDx Sepsis|Evaluation of the prognostic performance of HostDx Sepsis|Evaluation of the prognostic performance of HostDx Sepsis for 28-Day Hospital Mortality","Inflammatix","All","18 Years and older   (Adult, Older Adult)",,"1500","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","INF-04","February 28, 2020","May 5, 2024","May 15, 2024","September 19, 2019",,"December 22, 2023","University of South Alabama, Mobile, Alabama, United States|University of Southern California, Los Angeles, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Medstar Health Research Institute, Washington, District of Columbia, United States|University of Florida (UF) - Jacksonville, Jacksonville, Florida, United States|Emory University, Atlanta, Georgia, United States|University of Iowa, Iowa City, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Essentia Institute of Rural Health, Duluth, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Hackensack Meridian Health, Montclair, New Jersey, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oklahoma University Health, Oklahoma City, Oklahoma, United States|Geisinger Health, Danville, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Tech University Health Sciences Center - El Paso, El Paso, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|ATTIKON University Hospital, Athens, Greece",,"https://ClinicalTrials.gov/show/NCT04094818"
665,"NCT02023788","Long-term Safety and Efficacy Follow-up Study of PNEUMOSTEM® in Patients Who Completed PNEUMOSTEM® Phase-I Study",,"Completed","No Results Available","Bronchopulmonary Dysplasia|Respiratory Tract Infections|Premature Birth of Newborn","Biological: PNEUMOSTEM","Number of subjects with adverse drug reactions|Respiratory outcomes|Survival|Z-score|Potential neurological development test outcomes","Medipost Co Ltd.","All","45 Months to 63 Months   (Child)",,"8","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MP-CR-006-F/U-5y","April 2014","October 2016","October 2016","December 30, 2013",,"September 4, 2018","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02023788"
666,"NCT00130221","Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections",,"Completed","No Results Available","Nosocomial Infection|Bacteremia|Sepsis|Pneumonia|Urinary Tract Infection|Clostridium Infection","Drug: 2% chlorhexidine gluconate impregnated cloth|Other: Daily bathing with Bar soap","Clinical: Primary blood stream infections and culture negative sepsis|Microbiologic: Skin colonization from environment and endotracheal secretions|Clinical: Laboratory confirmed blood stream infections|Nosocomial infections","Cook County Health|Sage Products, Inc.|Centers for Disease Control and Prevention","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1","208","Other|Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","05-006","June 2005","June 2006","July 26, 2006","August 15, 2005",,"June 18, 2023","John H. Stroger Hospital of Cook County, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00130221"
667,"NCT01297647","Incidence of Urinary Tract Infection After Urodynamic Investigation",,"Completed","No Results Available","Neurogenic Bladder","Procedure: urodynamic examination","Incidence of urinary tract infection following urodynamic investigation|Name and number of identified bacterial species|Number of hospitalized and number of ambulatory patients with infection of the lower urinary tract|Incidence of urinary tract infection before urodynamic investigation","Balgrist University Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","317","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","EK 2010-0191/0","May 2010","May 2012","May 2012","February 17, 2011",,"December 16, 2016","Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT01297647"
668,"NCT04496726","Cranberry and Quillaja on Symptoms of Uncomplicated UTI",,"Terminated","No Results Available","Urinary Tract Infections|UTI|UTI - Lower Urinary Tract Infection","Other: Pacran and Sapnov P quillaja","Urinary Tract Infection Symptoms Assessment Questionnaire (UTISA)|Time to UTI antibiotic initiation|Microbiome changes prior to and post antibiotic initiation","Lawson Health Research Institute|Urobiome Therapeutics|St. Joseph's Health Care London","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00043294","January 1, 2021","June 1, 2023","June 1, 2023","August 3, 2020",,"January 12, 2024","St. Joseph's Health Care London, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04496726"
669,"NCT03954990","Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity",,"Terminated","No Results Available","Bacterial Vaginoses","Drug: Metronidazole Oral|Drug: Placebo Oral Tablet","Rate of Composite outcome of maternal infections|Rate of Chorioamnionitis|Rate of Postpartum Endometritis|Rate of Surgical Site Infection|Rate of Pelvic Septic Thrombosis|Rate of Pelvic abscess|Rate of Puerperal fever|Rate of Maternal Death|Rate of additional postpartum procedures|Rate of Postpartum Antibiotics use|Rate of ER and unscheduled postpartum clinic visit|Number of days of hospital stay postpartum|Rate of Adverse events|Rate of Confirmed neonatal sepsis|Rate of Suspected neonatal sepsis|Rate of Neonatal morbidities","The University of Texas Medical Branch, Galveston","Female","18 Years to 50 Years   (Adult)","Phase 1","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","18-0103","October 11, 2019","September 26, 2022","September 26, 2022","May 17, 2019",,"December 12, 2023","University of Texas Medical Branch, Galveston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03954990"
670,"NCT04730830","Occurrence of Emerging Infections After Placement of a Peritoneal Dialysis CatHeter","SINEPHILE","Recruiting","No Results Available","End Stage Renal Disease on Dialysis|Peritoneal Dialysis","Other: Questionnaire","Risk of infections on emergence site","Centre Hospitalier Universitaire de Besancon","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2020/504","February 1, 2021","February 2023","August 2025","January 29, 2021",,"August 2, 2022","Service de néphrologie, CHU de Besançon, Besançon, France|Besancon University Hospital, Besançon, France",,"https://ClinicalTrials.gov/show/NCT04730830"
671,"NCT05966649","Synbiotics in Patients at RIsk fOr Preterm Birth","PRIORI","Active, not recruiting","No Results Available","Preterm Spontaneous Labor With Preterm Delivery|Preterm Birth|Microbial Colonization","Other: Synbiotics|Other: Placebo","Gestational age at delivery|Incidence of PTB, defined as GA at delivery < 37 weeks|Proportion of PTB in different categories|PPROM|Composition of the vaginal microbiome|Incidence of neonatal admissions|Duration of neonatal admissions|Incidence of maternal admissions|Duration of maternal admissions|Quality Of Life during pregnancy and during neonatal admission at a neonatal intensive care unit|Neonatal outcome: infectious parameters|Neonatal outcome: bronchopulmonary dysplasia (BPD)|Neonatal outcome: intraventricular haemorrhage|Neonatal outcome: periventricular leukomalacia|Neonatal outcome: respiratory support|Neonatal outcome: retinopathy|Neonatal outcome: neonatal morbidity|Neonatal outcome: birth weight","Ziekenhuis Oost-Limburg","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","402","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Z-2022080","March 16, 2023","December 2027","June 2028","July 28, 2023",,"December 14, 2023","Ziekenhuis Oost-Limburg, Genk, Limburg, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Limburg, Belgium|UZ Gent, Gent, Oost-Vlaanderen, Belgium|AZ Sint-Jan, Brugge, West-Vlaanderen, Belgium|AZ Sint-Lucas, Brugge, West-Vlaanderen, Belgium|CHR Citadelle, Liège, Belgium",,"https://ClinicalTrials.gov/show/NCT05966649"
672,"NCT05905055","P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales","Integral-2","Recruiting","No Results Available","Complicated Urinary Tract Infection|Acute Pyelonephritis|Hospital-acquired Bacterial Pneumonia|Ventilator-associated Bacterial Pneumonia|Complicated Intra-abdominal Infection","Drug: co-administration of cefepime and nacubactam|Drug: co-administration of aztreonam and nacubactam|Drug: BAT","The primary efficacy endpoint is the proportion of patients with overall treatment success at TOC across all infection types (ie, cUTI, AP, HABP, VABP, and cIAI), which is a composite endpoint derived from the efficacy outcomes of each infection type.","Meiji Seika Pharma Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","OP0595-6","September 22, 2023","February 2025","February 2025","June 15, 2023",,"October 26, 2023","Meiji Research Site, Nankoku, Kochi, Japan",,"https://ClinicalTrials.gov/show/NCT05905055"
673,"NCT05880069","Clinical Outcomes in Patients With Infection by Resistant Microorganism",,"Enrolling by invitation","No Results Available","Pneumonia|Bloodstream Infection|Urinary Tract Infections|Skin Infection|Surgical Site Infection|Staphylococcus Aureus|Klebsiella Pneumonia|Escherichia Coli|Enterococcus Faecium Infection|Acinetobacter Infections|Pseudomonas Aeruginosa","Other: Pathogen resistant phenotype","Mortality|Number of participants with ICU admission|Number of participants with clinical cure|Number of participants with microbiological cure|Number of participants with recurrence of infection|Number of participants with superinfection|Number of participants with cognitive impairment / disability","Hospital Universitario Virgen Macarena|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Other|Time Perspective: Other","PRIMAVERA","October 1, 2022","June 2023","October 2023","May 30, 2023",,"May 30, 2023","Hospital Universitario Virgen Macarena, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT05880069"
674,"NCT01123603","Lower Urinary Tract Infection (UTI) Evaluation in Women With Uterine Leiomyomata","LOTUS","Completed","No Results Available","Urinary Tract Infection|Leiomyoma",,"To measure prevalence of lower urinary tract symptoms including urinary incontinence symptoms in patients who present for care for symptomatic leiomyomata.","The Cleveland Clinic","Female","18 Years and older   (Adult, Older Adult)",,"860","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","09-923","May 2010","June 2014","June 2014","May 14, 2010",,"January 14, 2015","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01123603"
675,"NCT01820897","Efficacy of Fosfomycin-Trometamol in Urinary Tract Infection Prophylaxis After Kidney Transplantation",,"Completed","No Results Available","Urinary Tract Infection|Asymptomatic Bacteriuria|Allograft Rejection|Microbiologic Resistance|Hospitalization","Drug: Fosfomycin-Trometamol|Drug: Sulfamethoxazole trimethoprim","Urinary tract infection incidence in the first six months after kidney transplantation|Complications related to the intervention, including rate of microbiological resistance.","JOSE MANUEL ARREOLA GUERRA|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","UTIPROPH-625","April 2013","March 2015","March 2015","March 29, 2013",,"March 26, 2015","National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico city, Distrito Federal, Mexico|National Institute of Medical Science and Nutrition Salvador Zubiran, México, Mexico DF, Mexico",,"https://ClinicalTrials.gov/show/NCT01820897"
676,"NCT05651217","Clinical Study on Disposable Sterile Urinary Catheter",,"Terminated","No Results Available","Urinary Catheters|Urinary Tract Infection","Device: disposable urinary catheter|Device: super smooth antibacterial urinary catheter","Urinary tract infection rate|Success rate of catheterization|level of urethral irritation|Incidence of device related adverse events|time of catheter duration|rating of operation convenience|rate of packaging integrity|rate of device defect rate","Shandong Branden Med.Device Co.,Ltd","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","136","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B201703","December 11, 2019","September 12, 2021","February 10, 2023","December 14, 2022",,"February 21, 2023","Liaoning Cancer Hospital & institute, Dalian, Liaoning, China",,"https://ClinicalTrials.gov/show/NCT05651217"
677,"NCT03898310","UTI Prophylaxis With Cranberry Extract After Female Incontinence Surgery",,"Completed","No Results Available","Urinary Tract Infections|Incontinence","Dietary Supplement: Cranberry extract capsules|Dietary Supplement: Placebo capsule","Urine culture based on type of symptoms|Duration of symptoms","University of Oklahoma","Female","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","141","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","9977","February 5, 2019","January 22, 2023","January 22, 2023","April 1, 2019",,"June 13, 2023","University of Oklahoma, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT03898310"
678,"NCT04899336","A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years",,"Recruiting","No Results Available","Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention","Biological: ExPEC9V|Other: Placebo","Number of Participants with First Invasive Extraintestinal Pathogenic E.coli Disease(IED) Event with Microbiological Confirmation in Blood, Other Sterile Sites, or Urine, Caused by 9-valent Extraintestinal Pathogenic E. coli Vaccine (ExPEC9V) O-serotypes|Number of Participants with First IED Event with Microbiological Confirmation in Blood or Other Sterile Sites Caused by ExPEC9V O-serotypes|Number of Participants with All IEDs (Including Multiple IEDs per Participant) Caused by ExPEC9V O-serotypes|Number of Participants with First Hospitalized IED Event Caused by ExPEC9V O-serotypes|Number of Participants with First IED Event Meeting Criteria for Sepsis Caused by ExPEC9V O-serotypes|Number of Participants with First Bacteremic IED Event Caused by ExPEC9V O-serotypes|Number of Participants with First Pyelonephritis Event Caused by ExPEC9V O-serotypes|Number of Participants with First Urinary Tract Infection (UTI) Event Caused by ExPEC9V O-serotypes|Number of Participants with All UTIs (Including Multiple UTIs per Participant) Caused by ExPEC9V O-serotypes|Number of Participants with First IED Event Caused by Escherichia coli (E.coli)|Number of Participants with First Pyelonephritis Event caused By E.coli|Number of Participants with First UTI Event caused by E.coli|Antibody Titers to Vaccine O-serotype Antigens as Determined by Multiplex Electrochemiluminescent (ECL)-based Immunoassay|Antibody Titers to Genetically Detoxified Form of Exotoxin A Derived from Pseudomonas Aeruginosa (EPA) as Determined by Multiplex ECL-based Immunoassay|Antibody Titers to Vaccine O-serotype Antigens as Determined by Multiplex Opsonophagocytic Assay (MOPA)|Number of Participants with Solicited Local Adverse Events (AEs)|Number of Participants with Solicited Systemic AEs|Number of Participants with Unsolicited AEs|Number of Participants with Serious Adverse Events (SAEs)|Short Form-36 (SF-36) Total Scores|European Quality of Life (EuroQol) 5-Dimension 5-Level Questionnaire (EQ-5D-5L) Scores|Change from Baseline in Frailty Index|Medical Resource Utilization (MRU) for IED Events|MRU for UTI Events|MRU for Acute Bacterial Prostatitis (ABP)|Number of Participants with the Hospitalization for IED or, UTI, or ABP Events|Length of Stay in Hospital for IED, UTI, or ABP Events|Number of Participants with the Intensive Care Unit (ICU) Hospitalization for IED or UTI or ABP Events|Length of ICU Stay in Hospital for IED, UTI, or ABP Events|Number of Participants with IED-related and All-cause Mortality","Janssen Research & Development, LLC","All","60 Years and older   (Adult, Older Adult)","Phase 3","18556","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","CR109000|2020-005273-27|VAC52416BAC3001|2023-506589-30|2023-506589-30-00","June 30, 2021","May 19, 2025","November 22, 2027","May 24, 2021",,"March 27, 2024","Lakeview Clinical Research, Guntersville, Alabama, United States|Hope Research Institute, Phoenix, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Interspond-Clinical Research Institute of AZ, Sun City West, Arizona, United States|Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States|Sun Urology - Buena Park Office, Buena Park, California, United States|Hope clinical Research LLC, Canoga Park, California, United States|Velocity Clinical Research, Inc., Chula Vista, California, United States|Marvel Clinical Research, Huntington Beach, California, United States|California Adult Circumcision - Alvarado La Mesa Urology Center, La Mesa, California, United States|Om Research LLC, Lancaster, California, United States|Atlantic Urology Medical Group, Long Beach, California, United States|Long Beach Clinical Trials, LLC, Long Beach, California, United States|American Institute of Research, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|Comprehensive Urology, Los Angeles, California, United States|Veterans Affairs Greater Los Angeles HCS, Los Angeles, California, United States|VA Sacramento Medical Center, Mather, California, United States|Hoag Medical Group, Newport Beach, California, United States|Empire Clinical Research, LLC, Pomona, California, United States|Inland Urology Medical Group, Pomona, California, United States|UC Davis Health System, Sacramento, California, United States|Northern California Research, Sacramento, California, United States|San Diego Sports Medicine & Family Health Center, San Diego, California, United States|Medical Associates Research Group, Inc., San Diego, California, United States|California Kidney Specialists, San Dimas, California, United States|Prestige Medical Group, Santa Ana, California, United States|Millennium Clinical Trials, LLC, Simi Valley, California, United States|San Antonio Regional Hospital, Upland, California, United States|Yale University, New Haven, Connecticut, United States|Ideal Clinical Research, Adventura, Florida, United States|Bay Pines VA Healthcare System, Bay Pines, Florida, United States|Nova Clinical Research, LLC, Bradenton, Florida, United States|Clinical Research of Brandon, Brandon, Florida, United States|Moore Clinical Reseach - Brandon Clinic, Brandon, Florida, United States|Florida Medical Center of Clearwater, Clearwater, Florida, United States|Innovative Research of West Florida, Incorporated, Clearwater, Florida, United States|Advanced Clinical Research Network, Coral Gables, Florida, United States|Prestige Clinical Research Center, Inc., Coral Gables, Florida, United States|Accel Research Sites, DeLand, Florida, United States|Doral Medical Research, Doral, Florida, United States|Universal Axon Clinical Research, Doral, Florida, United States|Florida Medical Research Institute, Gainesville, Florida, United States|Indago Research & Health Center Inc, Hialeah, Florida, United States|Prestige Clinical Research, Homestead, Florida, United States|Multi-Specialty Research Associates, Inc., Lake City, Florida, United States|ClinCloud Clinical Research, Maitland, Florida, United States|Nova Clinical Research Center, Miami, Florida, United States|Finlay Medical Research, Miami, Florida, United States|Royal Care Medical Research Corporation, Miami, Florida, United States|Retreat Medical Research LLC, Miami, Florida, United States|Suncoast Research Group, Miami, Florida, United States|Continental Research, Miami, Florida, United States|Dynamic Medical Research, LLC, Miami, Florida, United States|Florida International Medical Research, Miami, Florida, United States|Health- Life Research Inst, Miami, Florida, United States|Office of Dr. Marisela Gonzalez, Miami, Florida, United States|Felicidad Medical Research, Miami, Florida, United States|A&R Research Group, Miami, Florida, United States|Alpha Science Research, Miami, Florida, United States|Clinical NeuroScience Solutions Inc, Orlando, Florida, United States|Omega Research Consultants, Orlando, Florida, United States|Pines Care Research Center Inc, Pembroke Pines, Florida, United States|Clinical Research of Central Florida, Plant City, Florida, United States|Care Access Research, Spring Hill, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Theia Clincial Research, LLC, Tampa, Florida, United States|Precision Research Institute, Tampa, Florida, United States|St. Joseph's Comprehensive Research Institute, Tampa, Florida, United States|Santos Research Center, Tampa, Florida, United States|Care Access Research, Tampa, Florida, United States|Agile Clinical Research Trials, LLC, Atlanta, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Clinical Research Prime, Idaho Falls, Idaho, United States|Snake River Research, PLLC, Idaho Falls, Idaho, United States|Jesse Brown VAMC Department of Surgery, Chicago, Illinois, United States|University Of Illinois, Chicago, Illinois, United States|Medisphere Medical Research Center, Llc, Evansville, Indiana, United States|Asha Clinical Research-Munster Llc, Hammond, Indiana, United States|Mishawaka Osteopathic Clinic/MOC Research, Mishawaka, Indiana, United States|Cypress Medical Research Center, Wichita, Kansas, United States|Tandem Clinical Research, Marrero, Louisiana, United States|KAMP Medical Research, Inc, Natchitoches, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Kaiser Permanente, Rockville, Maryland, United States|Floating Hospital For Children at Tufts Medical Center, Boston, Massachusetts, United States|West Roxbury Veterans Affairs Medical Center, West Roxbury, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|MediSync Clinical Research, Petal, Mississippi, United States|Meridian Clinical Research, LLC, Grand Island, Nebraska, United States|Meridian Clinical Research, LLC, Norfolk, Nebraska, United States|Hope Research Institute, Las Vegas, Nevada, United States|Sierra Clinical Research, Las Vegas, Nevada, United States|Excel Clinical Research, Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|I.D. Care, Inc., Hillsborough, New Jersey, United States|Meridian Clinical Research, LLC, Binghamton, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Meridian Clinical Research, LLC, Endwell, New York, United States|Manhattan Medical Research, New York, New York, United States|Durham VAMC, Durham, North Carolina, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Plains Clinical Research, Fargo, North Dakota, United States|Kroger Health, Centerville, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Remington Davis Inc, Columbus, Ohio, United States|Kroger Health, Englewood, Ohio, United States|The Little Clinic, Englewood, Ohio, United States|Comprehensive Internal Medicine, Wooster, Ohio, United States|Tekton Research Inc., Yukon, Oklahoma, United States|Capital Area Research, Camp Hill, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Hugh D. Durrence, MD, PC, Charleston, South Carolina, United States|Waterway Familiy Medicine, Little River, South Carolina, United States|Novel Research LLC, Bellaire, Texas, United States|Global Medical Research - Dallas, Dallas, Texas, United States|Medical City Dallas, Dallas, Texas, United States|North Texas Infectious Diseases Consultants, Dallas, Texas, United States|Digestive Health Associates, Houston, Texas, United States|EPIC Clinical Research, Lewisville, Texas, United States|SMS Clinical Research LLC, Mesquite, Texas, United States|Be Well Clinical Studies, Round Rock, Texas, United States|Audie L Murphy Memorial Va Ho, San Antonio, Texas, United States|Sherman Clinical Research, Sherman, Texas, United States|Lone Peak Family Medicine, Draper, Utah, United States|Clinical Alliance for Research and Education, Annandale, Virginia, United States|Charlottesville Medical Research Center, LLC, Charlottesville, Virginia, United States|Infectious Disease Associates of Central Virginia, Lynchburg, Virginia, United States|IACT - Suffolk Multispecialty Research, Suffolk, Virginia, United States|Selma Medical Associates, Winchester, Virginia, United States|Multicare Institute For Research & Innovation - Rockwood Clinic - Cheney, Cheney, Washington, United States|Exemplar Research, Inc, Morgantown, West Virginia, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Saint Andrew's War Memorial Hospital, Brisbane, Australia|GP Surgery - Campbelltown, Campbelltown, Australia|Barwon Health - University Hospital Geelong, Geelong, Australia|CMAX Clinical Research, Melbourne, Australia|John Hunter Hospital, New Lambton, Australia|Fiona Stanley Hospital, Palmyra DC, Australia|McIntyre Medical Center, Para Hills West, Australia|North West Medical Center, Salisbury, Australia|Mater Medical Centre South Brisbane, South Brisbane, Australia|Bene Aged Care - Italian Village, St Agnes, Australia|Westmead Hospital, Sydney, Australia|AusTrials Pty Ltd, Taringa, Australia|AusTrials Pty Ltd, Tarragindi, Australia|Adelaide Medical Solutions, Woodville, Australia|University of Alberta, Edmonton, Alberta, Canada|CARe Clinical Ltd, Red Deer, Alberta, Canada|Vancouver ID Research and Care Centre Society, Vancouver, British Columbia, Canada|Dawson Road Family Health Team, Guelph, Ontario, Canada|Bluewater Clinical Research Group Inc., Sarnia, Ontario, Canada|Health Sciences North, Sudbury, Ontario, Canada|Winchester District Memorial Hospital, Winchester, Ontario, Canada|Alpha Recherche Clinique, Quebec, Canada|Alpha Recherche Clinique, Quebec, Canada|West China School of Medicine/West China Hospital, Sichuan University, Chengdu, China|Funan Center for Disease Control and Prevention, Fuyang, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|1st Affiliated Hospital of Zhejiang University Medical College, Hangzhou, China|Anhui Provincial Center for Disease Control and Prevention, Hefei, China|Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China|Nanjing Medical University, Nanjing, China|Huashan Hospital affiliated to Fudan University, Shanghai, China|Suzhou Municipal Hospital, Suzhou, China|Taizhou Peoples Hospital, Taizhou, China|Yixing People's Hospital, Wuxi, China|Clinica de la Costa, Barranquilla, Colombia|IPS Centro Cientifico Asisitencial Jose Luis Accini S.A.S., Barranquilla, Colombia|Centro de Investigaciones y Proyectos en Neurociencias CIPNA, Barranquilla, Colombia|Centro de Atencion e Investigacion Medica S.A. - CAIMED, Casanare, Colombia|Centro de Atencion e Investigacion Medica S.A. - CAIMED, Girardot, Colombia|Centro de Atencion e Investigacion Medica S.A. - CAIMED, Helechos, Colombia|Asociacion IPS Medicos Internistas de Caldas, Manizales, Colombia|CAIMED Acacias, Meta, Colombia|Fundacion Centro de Investigaciones Clinicas IPS Cardiomet, Pereira, Colombia|Uromeda, Brno, Czechia|Ordinace Hradebni s.r.o., Ceske Budejovice, Czechia|Aesculap Ambulance sro - Zdravotni Stredisko Centrum Zdravi, Dolni Brezany, Czechia|Centrum Ockovani a Cestovi Mediciny, Hradec Kralove, Czechia|Res Medica, Novy Knin, Czechia|PreventaMed, s.r.o., Olomouc, Czechia|GYNURO s.r.o, Ostrava-Proskovice, Czechia|MUDr. Mita Rosenberg, Plzen 1, Czechia|Ambulance name: Gynekologická ordinace MUDr, Plzeň, Czechia|Gona s.R.o- Orfinace Harov, Praha 3, Czechia|Zdravi-fit, s.r.o., Protivin, Czechia|Nemocnice Slany, Slany, Czechia|Progerint s.r.o., Vysoke Myto, Czechia|Aalborg Universitetshospital Nord, Hellerup, Denmark|Gentofte Hospital, Herlev, Denmark|Nordsjaellands Hospital - Hillerod, Hilleroed, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense Universitetshospital, Odense M, Denmark|Sjællands University hospital, Roskilde, Denmark|CHU Dijon Bourgogne- Hopital Francois Mitterrand, Dijon, France|CHU de Limoges, Limousis, France|Hopital de La Croix Rousse, Lyon, France|CHU Nimes Hopital Caremeau, Nîmes, France|Centre hospitalier Lyon-Sud, Pierre Benite cedex, France|CHU Saint-Etienne - Hopital Nord, Saint-Priest en Jarez, France|Universitatsklinikum Jena, Jena, Germany|Familienmedizinisches Zentrum Radowsky, Leipzig, Germany|SIBAmed GmbH & Co. KG, Leipzig, Germany|Red-Institut für medizinische Forschung und Fortbildung, Oldenburg in Holstein, Germany|Praxis Dr. Weimer, Reinfeld, Germany|Universitaetsmedizin Rostock, Rostock, Germany|Samson Assuta Ashdod University Hospital, Ashdod, Israel|Hadassah Medical Center, Jerusalem, Israel|The Chaim Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel|ASL2 Lanciano - Vasto - Chieti - Ospedale 'SS Annunziata' di Chieti, Chieti, Italy|Istituto Nazionale Tumori Regina Elena, Roma, Italy|Azienda Ospedaliera Sant Andrea, Rome, Italy|Fukuoka Wajiro Hospital, Fukuoka-Shi, Japan|Fukuoka Shinmizumaki Hospital, Fukuoka, Japan|Matsunami General Hospital, Hashima-gun, Japan|Teine Keijinkai Hospital, Hokkaido, Japan|Aso Co.,Ltd Iizuka Hospital, Iizuka, Japan|Inoue Hospital, Itoshima-City, Japan|Medical Corporation Toyoshikai Kano Hospital, Kasuya-gun, Japan|Japan Community Health care Organization Kyushu Hospital, Kitakyushu, Japan|Shinkomonji hospital, Kitakyusyu, Japan|JRC Nagasaki Genbaku Hospital, Nagasaki-Shi, Japan|Medical Corporation Kyoujinkai Clinic Komatsu, Neyagawa, Japan|Abe Diabetes Clinic, Oita, Japan|Almeida Memorial Hospital, Oita, Japan|National Hospital Organization Nagasaki Medical Center, Omura, Japan|Omuta City Hospital, Omuta-Shi, Japan|Japan Community Health Care Organization Osaka Hospital, Osaka City, Japan|Kyobashi Sugimoto Clinic, Osaka-shi, Japan|Sanuki Munincipal Hospital, Sanuki, Japan|Teine Maeda Urology Clinic, Sapporo-Shi, Japan|Teine Urological Clinic, Sapporo-Shi, Japan|Nanbu Tokushukai Hospital, Shimajiri-Gun, Japan|Shimonoseki City Hospital, Shimonoseki-shi, Japan|Tokyo Shinagawa Hospital, Shinagawa City, Japan|Suita Tokushukai Hospital, Suita-Shi, Japan|Suwa Red Cross Hospital, Suwa-Shi, Japan|Japan Community Health Care Organization Kyusyu Hospital, Yahatanishi-ku, Japan|Shimonoseki City Hospital, Yamaguchi, Japan|National Hospital Organization Yokohama Medical Center, Yokohama, Japan|Dong-A University Hospital, Busan, Korea, Republic of|Hallym University Chuncehon Medical Center, ChunCheon, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Chunnam National University Hospital, Gwangju, Korea, Republic of|Korea University Ansan Hospital, Gyeonggi-do, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Korea University Guro Hospital, Seoul Teugbyeolsi, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hallym University Sacred Heart Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|The Catholic university of Korea, St. Vincent's Hospital, Suwon-si, Korea, Republic of|WonJu Severance Christian Hospital, Wonju, Korea, Republic of|Leiden University Medical Center, Leiden, Netherlands|Ziekenhuis, Uden, Netherlands|The Julius Center - Utrecht Science Park - Stratenum, Utrecht, Netherlands|Southern Clinical Trials Totara Clinical Research, Auckland, New Zealand|Southern Clinical Trials Ltd, Auckland, New Zealand|Optimal Clinical Trials, Auckland, New Zealand|Tauranga Urology Research Limited, Bay Of Plenty, New Zealand|Southern Clinical Trials Ltd, Christchurch Central, New Zealand|Canterbury Urology Research Trust, Christchurch, New Zealand|P3 Research Ltd, Dunedin, New Zealand|Lakeland Clinical Trials, Hamilton, New Zealand|P3 Research Ltd, Hastings, New Zealand|P3 Research - Lower Hutt, Lower Hutt, New Zealand|Southern Clinical Trials Ltd, Nelson, New Zealand|P3 Research Ltd, Palmerston North, New Zealand|Culloden Research Ltd, Papamoa, New Zealand|Middlemore Clinical Trials, Papatoetoe, New Zealand|Optimal Clinical Trials, Rosedale, New Zealand|Lakeland Clinical Trials, Rotorua, New Zealand|P3 Research Ltd, Tauranga, New Zealand|Lakeland Clinical Trials, Upper Hutt, New Zealand|P3 Research Limited Kapiti, Wellington, New Zealand|Capatial & Coast District Health Board, Wellington, New Zealand|Hosp. Clinic de Barcelona, Barcelona, Spain|Hosp. Univ. de Bellvitge, Barcelona, Spain|Hosp. Del Mar, Barcelona, Spain|Consorci D'Atenció Primària de Salut Barcelona Esquerra, Barcelona, Spain|Hosp. Reina Sofia, Córdoba, Spain|Hosp. Univ. Dr. Josep Trueta, Girona, Spain|CAP Dr. Vicenç Papaceit ABS LA ROCA, La Roca del Valles, Spain|Hosp. Univ. La Paz, Madrid, Spain|Hospital Sanitas La Moraleja, Madrid, Spain|Hosp. Univ. Hm Monteprincipe, Madrid, Spain|Hosp. Quirónsalud Málaga, Málaga, Spain|Complexo Hosp. Univ. de Ourense, Ourense, Spain|Hosp. Univ. Son Espases, Palma de Mallorca, Spain|Corporacio Sanitari Parc Tauli, Sabadell, Spain|Hosp. Virgen Macarena, Sevilla, Spain|BTH Research & Development Clinic, Karlskrona, Sweden|CTC Ebbepark, Linkoaping, Sweden|Skanes universitetssjukhus, Malmoe, Sweden|ClinSmart Sweden AB, Solna, Sweden|ClinSmart Sweden AB, Uppsala, Sweden|Universitetssjukhuset Orebro, Örebro, Sweden|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Thai Red Cross Aids Research Centre, Bangkok, Thailand|Ramathibodi Hospital, Bangkok, Thailand|Tropical Medicine Hospital, Mahidol University, Bangkok, Thailand|Siriraj Hospital, Bangkok, Thailand|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Atherstone Surgery, Atherstone, United Kingdom|Banbury Cross Health Center, Banbury, United Kingdom|FutureMeds Bridle Clinic, Birkenhead, United Kingdom|FutureMeds-Soho UK, Birmingham, United Kingdom|Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom|Royal Bournemouth Hospital, Bournemouth, United Kingdom|North Bristol NHS Trust, Bristol, United Kingdom|University Hospitals Bristol NHS Trust, Bristol, United Kingdom|Royal Devon & Exeter NHS Foundation Trust, Exeter, United Kingdom|Eynsham Medical Centre, Eynsham, United Kingdom|The Garth Surgery, Guisborough, United Kingdom|University Hospitals Of Leicester Nhs Trust, Leicester, United Kingdom|King's College Hospital NHS Foundation Trust, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|The NIHR Manchester Clinical Research Facility, Manchester, United Kingdom|South Tees Hospitals NHS Foundation Trust, Middlesbrough, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Plymouth University Hospitals Trust, Plymouth, United Kingdom|Ashgrove Surgery, Pontypridd, United Kingdom|The Adam Practice, Poole, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom|Midlands Partnership NHS Foundation Trust, Stafford, United Kingdom|Mid Yorkshire Hospital NHS Trust- Pinderfields Hospital, Wakefield, United Kingdom|Church Street Practice, Wantage, United Kingdom|Windrush Medical Practice, Witney, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04899336"
679,"NCT05227937","Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study",,"Recruiting","No Results Available","Urinary Tract Infections","Drug: Amikacin","Resolution of Urinary Tract Infection Symptoms","Antonios Likourezos|Maimonides Medical Center","Female","14 Years to 110 Years   (Child, Adult, Older Adult)",,"75","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2021-07-07","September 21, 2022","December 31, 2024","December 31, 2024","February 8, 2022",,"September 21, 2023","Maimonides Medical Center, Brooklyn, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/37/NCT05227937/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05227937"
680,"NCT06268509","Nutrition Optimalization Among Pregnant Women to Improve Maternal and Neonatal Outcome in DKI Jakarta","MONAS","Recruiting","No Results Available","Pregnancy Complications|Maternal Death|Preeclampsia|Intrauterine Infection|Pregnancy Hemorrhage|Preterm Birth|Neonatal Death|Low; Birthweight, Extremely (999 Grams or Less)|Asphyxia Neonatorum|IUGR","Diagnostic Test: Nutritional panel laboratory examination|Dietary Supplement: Pregnancy supplements (other than provided by Ministry of Health)|Diagnostic Test: Fetomaternal ultrasound","Composite of poor maternal outcomes|Composite of poor neonatal outcomes","Dr Cipto Mangunkusumo General Hospital|Dinas Kesehatan DKI Jakarta|Fakultas Kedokteran Universitas Indonesia","Female","Child, Adult, Older Adult","Not Applicable","245","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MONAS","April 1, 2023","June 2024","August 2024","February 20, 2024",,"February 20, 2024","Jakarta Primary Care Health Facility (Puskesmas) under Jakarta Health Office, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT06268509"
681,"NCT02166476","Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP",,"Completed","Has Results","Urinary Tract Infection Complicated|Acute Pyelonephritis","Drug: Meropenem-Vaborbactam|Drug: Piperacillin-Tazobactam|Drug: Levofloxacin|Drug: Saline","Proportion Of Participants In The Microbiological Modified Intent-To-Treat (m-MITT) Population Who Achieved Overall Success At The End Of Intravenous Treatment Visit|Proportion Of Participants In The m-MITT Population Who Achieved A Microbiologic Outcome Of Eradication At The Test Of Cure Visit|Proportion Of Participants In The Microbiological Evaluable (ME) Population Who Achieved A Microbiologic Outcome Of Eradication At The TOC Visit|Proportion Of Participants In The m-MITT Population With Overall Success|Proportion Of Participants In The ME Population With Overall Success|Proportion Of Participants In The m-MITT Population Who Achieved A Microbiologic Outcome Of Eradication|Proportion Of Participants In The ME Population Who Achieved A Microbiologic Outcome Of Eradication|Proportion Of Participants With A Clinical Outcome Of Cure In The m-MITT Population|Proportion Of Participants With A Clinical Outcome Of Cure In The Clinical Evaluable (CE) Population|Proportion Of Participants With A Clinical Outcome Of Cure In The ME Population|Per-Pathogen Microbiological Outcome (FDA) In The m-MITT Population|Per-Pathogen Microbiological Outcome (FDA) In The ME Population|Per-Pathogen Microbiological Outcome (EMA) In The m-MITT Population|Per-Pathogen Microbiological Outcome (EMA) In The ME Population|Pharmacokinetic (PK) Characterization Of Plasma Exposure Of Meropenem/Vaborbactam","Melinta Therapeutics, Inc.|Department of Health and Human Services","All","18 Years and older   (Adult, Older Adult)","Phase 3","550","Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rempex 505","November 20, 2014","April 28, 2016","April 28, 2016","June 18, 2014","October 26, 2017","June 11, 2018","Mobile, Alabama, United States|San Diego, California, United States|Denver, Colorado, United States|Tampa, Florida, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|New Brunswick, New Jersey, United States|Buffalo, New York, United States|Brest, Belarus|Gomel, Belarus|Grodno, Belarus|Minsk, Belarus|Minsk, Belarus|Vitebsk, Belarus|Sao Jose do Rio Preto, São Paulo, Brazil|Belo Horizonte, Brazil|Belo Horizonte, Brazil|Campinas, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Lovech, Bulgaria|Montana, Bulgaria|Silistra, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Hradec Kralove, Czechia|Karlovy Vary, Czechia|Opava, Czechia|Usti nad Labem, Czechia|Zlin, Czechia|Athens, Greece|Athens, Greece|Athens, Greece|Athens, Greece|Thessaloniki, Greece|Baja, Hungary|Budapest, Hungary|Debrecen, Hungary|Sopron, Hungary|Bologna, Italy|Catania, Italy|Firenze, Italy|Perugia, Italy|Torino, Italy|Gyeonggi-do, Korea, Republic of|Arequipa, Peru|Cusco, Peru|Ica, Peru|Lima, Peru|San Martin de Porres, Peru|Czestochowa, Poland|Gdansk, Poland|Kutno, Poland|Piaseczno, Poland|Warszawa, Poland|Bucharest, Romania|Bucharest, Romania|Craiova, Romania|Poprad, Slovakia|Ruzomberok, Slovakia|Trnava, Slovakia|Zilina, Slovakia|Golnik, Slovenia|Ljubljana, Slovenia|Barcelona, Spain|Madrid, Spain|Kaohsiung, Taiwan|Taichung, Taiwan|Chernivtsi, Ukraine|Dnipropetrovsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Odesa, Ukraine|Poltava, Ukraine|Vinnitsa, Ukraine|Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT02166476"
682,"NCT01309529","Day Zero Urinary Catheter Removal in Gen Thoracic Surgery Patients",,"Unknown status","No Results Available","Postoperative Retention of Urine|Postoperative Urinary Tract Infection",,"Evaluate rates of recatheterization due to urinary retention and occurrence of urinary tract infections in a general thoracic surgery population receiving thoracic epidural analgesia.","Memorial Health System","All","18 Years and older   (Adult, Older Adult)",,"45","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB11.03.01","March 2011","August 2011","October 2011","March 7, 2011",,"March 7, 2011","Memorial Hospital, Chattanooga, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01309529"
683,"NCT04287504","Point-of-care Tests for Bacterial Vaginosis and Candidosis",,"Unknown status","No Results Available","Infection, Bacterial|Infection, Fungal|Preterm Birth","Diagnostic Test: SavvyCheck Vaginal Yeast Test|Diagnostic Test: OSOM BVBLUE Test","Test result of OSOM BVBLUE Test or SavvyCheck Vaginal Yeast Test|Gestational age of delivery","Medical University of Vienna","Female","18 Years to 45 Years   (Adult)",,"400","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2115-2019","February 14, 2020","March 18, 2021","July 31, 2021","February 27, 2020",,"March 19, 2021","Medical University of Vienna, Dept. of Obstetrics and Gynecology, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT04287504"
684,"NCT03080389","Sensitivity of Extended Cultures in Diagnosing Urinary Tract Infections",,"Terminated","No Results Available","Overactive Bladder|Overactive Detrusor|Urgency-Frequency Syndrome|UTI","Procedure: Extended Urine Culture","Sensitivity of extended urine cultures compared to standard urine cultures.|Treatment of uropathogens found on extended cultures result in negative repeat extended urine culture.|Treatment of uropathogens found on extended cultures improves urinary tract symptoms measured by the Bother and UDI-6 questionnaires","The Cleveland Clinic","Female","18 Years to 70 Years   (Adult, Older Adult)",,"16","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FLA 16-108","July 1, 2017","August 1, 2018","August 1, 2018","March 15, 2017",,"September 4, 2018","Cleveland Clinic Florida, Weston, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03080389"
685,"NCT03790254","D Mannose for Prevention and Treatment of RUTIs","mannoseRUTIs","Completed","No Results Available","Recurrent Urinary Tract Infections|Antibiotic Prophylaxis|Antibiotic Resistance","Other: systematic review","research literature data on d mannose for prevention and treatment of recurrent urinary tract infections.","IRCCS Policlinico S. Matteo","All","18 Years to 90 Years   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","ReviewUTIs","January 1, 2010","December 20, 2018","December 25, 2018","December 31, 2018",,"December 31, 2018","Urology Department Fondazione IRCCS Policlinico San Matteo, Pavia, Italy",,"https://ClinicalTrials.gov/show/NCT03790254"
686,"NCT02714595","Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens","CREDIBLE - CR","Completed","Has Results","Healthcare-associated Pneumonia (HCAP)|Bloodstream Infections (BSI)|Hospital Acquired Pneumonia (HAP)|Complicated Urinary Tract Infection (cUTI)|Sepsis|Ventilator Associated Pneumonia (VAP)","Drug: Cefiderocol|Drug: Best Available Therapy","Percentage of Participants With Clinical Cure at Test of Cure (TOC) in Participants With HAP/VAP/HCAP or BSI/Sepsis|Percentage of Participants With Microbiologic Eradication at TOC in Participants With cUTI|Percentage of Participants With Clinical Cure at End of Treatment (EOT) in Participants With HAP/VAP/HCAP or BSI/Sepsis|Percentage of Participants With Sustained Clinical Cure at Follow-up (FU) in Participants With HAP/VAP/HCAP or BSI/Sepsis|Percentage of Participants With Clinical Cure at Test of Cure in Participants With cUTI|Percentage of Participants With Clinical Cure at End of Treatment (EOT) in Participants With cUTI|Percentage of Participants With Sustained Clinical Cure at Follow-up in Participants With cUTI|Percentage of Participants With Clinical Cure at End of Treatment in Participants With HAP/VAP/HCAP + BSI/Sepsis, and Overall|Percentage of Participants With Clinical Cure at Test of Cure in Participants With HAP/VAP/HCAP + BSI/Sepsis, and Overall|Percentage of Participants With Sustained Clinical Cure at Follow-up in Participants With HAP/VAP/HCAP + BSI/Sepsis, and Overall|Percentage of Participants With Clinical Cure at End of Treatment By Baseline Pathogen|Percentage of Participants With Clinical Cure at Test of Cure By Baseline Pathogen|Percentage of Participants With Sustained Clinical Cure at Follow-up By Baseline Pathogen|Percentage of Participants With Clinical Cure at EOT By Baseline Carbapenem-resistant Pathogen|Percentage of Participants With Clinical Cure at TOC By Baseline Carbapenem-resistant Pathogen|Percentage of Participants With Sustained Clinical Cure at Follow-up By Baseline Carbapenem-resistant Pathogen|Percentage of Participants With Microbiologic Eradication at EOT in Participants With HAP/VAP/HCAP or BSI/Sepsis|Percentage of Participants With Microbiologic Eradication at TOC in Participants With HAP/VAP/HCAP or BSI/Sepsis|Percentage of Participants With Sustained Microbiologic Eradication at Follow-up in Participants With HAP/VAP/HCAP or BSI/Sepsis|Percentage of Participants With Microbiologic Eradication at EOT in Participants With cUTI|Percentage of Participants With Sustained Microbiologic Eradication at Follow-up in Participants With cUTI|Percentage of Participants With Microbiologic Eradication at EOT in Participants With HAP/VAP/HCAP + BSI/Sepsis, and Overall|Percentage of Participants With Microbiologic Eradication at TOC in Participants With HAP/VAP/HCAP + BSI/Sepsis, and Overall|Percentage of Participants With Sustained Microbiologic Eradication at Follow-up in Participants With HAP/VAP/HCAP + BSI/Sepsis, and Overall|Percentage of Participants With Microbiologic Eradication at EOT By Baseline Pathogen|Percentage of Participants With Microbiologic Eradication at TOC By Baseline Pathogen|Percentage of Participants With Sustained Microbiologic Eradication at Follow-up By Baseline Pathogen|Percentage of Participants With Microbiologic Eradication at EOT By Baseline Carbapenem-resistant Pathogen|Percentage of Participants With Microbiologic Eradication at TOC By Baseline Carbapenem-resistant Pathogen|Percentage of Participants With Sustained Microbiologic Eradication at Follow-up By Baseline Carbapenem-resistant Pathogen|Percentage of Participants With Microbiologic Eradication at EOT in Participants With Documented Carbapenem-resistant Gram-negative Bacteremia|Percentage of Participants With Microbiologic Eradication at TOC in Participants With Documented Carbapenem-resistant Gram-negative Bacteremia|Percentage of Participants With Sustained Microbiologic Eradication at Follow-up in Participants With Documented Carbapenem-resistant Gram-negative Bacteremia|Percentage of Participants With a Composite Clinical and Microbiological Response at EOT|Percentage of Participants With a Composite Clinical and Microbiological Response at TOC|Percentage of Participants With a Composite Clinical and Microbiological Response at Follow-up|All-cause Mortality at Day 14 and Day 28|Percentage of Participants Alive and With No Change in Antibiotic Treatment Due to Either Lack of Therapeutic Benefit or Drug-related Toxicity at TOC|Survival Time|Change From Baseline in Clinical Pulmonary Infection Score (CPIS) in Participants With Pneumonia (HAP/VAP/HCAP)|Change From Baseline in Sequential Organ Failure Assessment (SOFA)|Number of Participants With Adverse Events","Shionogi|Shionogi Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","152","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1424R2131|2015-004703-23","September 7, 2016","April 1, 2019","April 22, 2019","March 21, 2016","December 17, 2020","January 12, 2021","Shionogi Research Site, Hartford, Connecticut, United States|Shionogi Research Site, Newark, Delaware, United States|Shionogi Research Site, Chicago, Illinois, United States|Shionogi Research Site, New Orleans, Louisiana, United States|Shionogi Research Site, Detroit, Michigan, United States|Shionogi Research Site, Pittsburgh, Pennsylvania, United States|Shionogi Research Site, Salvador, Bahia, Brazil|Shionogi Research Site, Curitiba, Parana, Brazil|Shionogi Research Site, Passo Fundo, RIO Grande DO SUL, Brazil|Shionogi Research Site, Porto Alegre, RIO Grande DO SUL, Brazil|Shionogi Research Site, Porto Alegre, RIO Grande DO SUL, Brazil|Shionogi Research Site, Santa Maria, RIO Grande DO SUL, Brazil|Shionogi Research Site, São José do Rio Preto, SAO Paulo, Brazil|Shionogi Research Site, São Paulo, SAO Paulo, Brazil|Shionogi Research Site, Rijeka, Primorje-Gorski Kotar, Croatia|Shionogi Research Site, Split, Croatia|Shionogi Research Site, Zagreb, Croatia|Shionogi Research Site, Paris, Ile-de-france, France|Shionogi Research Site, La Tronche, Rhone-alpes, France|Shionogi Research Site, Heidelberg, Baden-wuerttemberg, Germany|Shionogi Research Site, Bonn, Nordrhein-westfalen, Germany|Shionogi Research Site, Berlin, Germany|Shionogi Research Site, Athens, Attica, Greece|Shionogi Research Site, Athens, Attica, Greece|Shionogi Research Site, Patra, Peloponnese, Greece|Shionogi Research Site, Larisa, Thessaly, Greece|Shionogi Research Site, Larisa, Thessaly, Greece|Shionogi Research Site, Ciudad de Guatemala, Guatemala|Shionogi Research Site, Beer-Sheva, Beersheba, Israel|Shionogi Research Site, Be'er Ya'akov, Rehoboth, Israel|Shionogi Research Site, Tel Hashomer, Tel Aviv, Israel|Shionogi Research Site, Tel-Aviv, Tel Aviv, Israel|Shionogi Research Site, Safed, Zefat, Israel|Shionogi Research Site, Hadera, Israel|Shionogi Research Site, Haifa, Israel|Shionogi Research Site, Haifa, Israel|Shionogi Research Site, Holon, Israel|Shionogi Research Site, Jerusalem, Israel|Shionogi Research Site, Cisanello, Pisa, Italy|Shionogi Research Site, Milano, Italy|Shionogi Research Site, Milano, Italy|Shionogi Research Site, Milano, Italy|Shionogi Research Site, Modena, Italy|Shionogi Research Site, Udine, Italy|Shionogi Research Site, Nagakute, Aichi, Japan|Shionogi Research Site, Shinagawa-ku, Tokyo, Japan|Shionogi Research Site, Nagasaki, Japan|Shionogi Research Site, Wonju-si, Gangwon-Do, Korea, Republic of|Shionogi Research Site, Seoul, Gwangjin-gu, Korea, Republic of|Shionogi Research Site, Daegu, Korea, Republic of|Shionogi Research Site, Daegu, Korea, Republic of|Shionogi Research Site, Seoul, Korea, Republic of|Shionogi Research Site, Seoul, Korea, Republic of|Shionogi Research Site, Seoul, Korea, Republic of|Shionogi Research Site, Seoul, Korea, Republic of|Shionogi Research Site, Terrassa, Barcelona, Spain|Shionogi Research Site, Córdoba, Cordoba, Spain|Shionogi Research Site, Lérida, Lleida, Spain|Shionogi Research Site, Barcelona, Spain|Shionogi Research Site, Barcelona, Spain|Shionogi Research Site, Barcelona, Spain|Shionogi Research Site, Ciudad Real, Spain|Shionogi Research Site, Gerona, Spain|Shionogi Research Site, Madrid, Spain|Shionogi Research Site, Malaga, Spain|Shionogi Research Site, Sevilla, Spain|Shionogi Research Site, Valencia, Spain|Shionogi Research Site, Zaragoza, Spain|Shionogi Research Site, Taichung, ROC, Taiwan|Shionogi Research Site, Taipei City, Taipei, Taiwan|Shionogi Research Site, Hualien, Taiwan|Shionogi Research Site, Kaohsiung, Taiwan|Shionogi Research Site, Taichung, Taiwan|Shionogi Research Site, Bangkok, Thailand|Shionogi Research Site, Muang Nonthaburi, Thailand|Shionogi Research Site, Muang, Thailand|Shionogi Research Site, Bornova, Izmir, Turkey|Shionogi Research Site, Ankara, Turkey|Shionogi Research Site, Istanbul, Turkey|Shionogi Research Site, Istanbul, Turkey|Shionogi Research Site, Trabzon, Turkey|Shionogi Research Site, London, England, United Kingdom|Shionogi Research Site, London, England, United Kingdom|Shionogi Research Site, London, England, United Kingdom|Shionogi Research Site, London, England, United Kingdom","""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/95/NCT02714595/SAP_000.pdf|""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/95/NCT02714595/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02714595"
687,"NCT02117102","Effect of Use of a New Technique for Pediatric Urine Collection in ER","BLST","Unknown status","No Results Available","Urinary Tract Infection|Unspecified Fever","Other: Bladder and lumbar stimulation technic","Success rate of bladder and lumbar stimulation techninc|Urine collection time","Jeju National University Hospital","All","6 Months to 36 Months   (Child)","Not Applicable","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BLSTJEJUNUH","May 2014","September 2014","December 2014","April 17, 2014",,"April 17, 2014","Jeju national university hospital, Jeju City, Jeju special governing province, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02117102"
688,"NCT03090373","The Effect of Surface Acoustic Waves on the Prevention of Colonization in Longterm Indwelling Urinary Caatheters",,"Unknown status","No Results Available","Baacterial Colonization|Urinary Tract Infections","Device: UroShield","Bacterial Colonization","Rosenblum, Jonathan I., DPM|Nanovibronix","All","18 Years and older   (Adult, Older Adult)","Not Applicable","63","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","US-2","January 1, 2017","December 31, 2017","March 1, 2018","March 24, 2017",,"March 24, 2017","NanoVibronix, Elmsford, New York, United States",,"https://ClinicalTrials.gov/show/NCT03090373"
689,"NCT01895465","Improvement in Urine Collection Methods in Children","0244-12-RMC","Unknown status","No Results Available","Urinary Tract Infection|Unspecified Fever","Device: Slitted diaper","Recording of time elapsed between physician's request for an urine test to be taken until obtained|Percentage of contamination in urine cultures obtained","Rabin Medical Center","All","1 Month to 14 Years   (Child)","Not Applicable","150","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","SCHNEIDER/7329","August 2013","August 2014","July 2015","July 10, 2013",,"July 23, 2013","Schneider Children's Medical Center of Israel, Petach Tikva, Israel",,"https://ClinicalTrials.gov/show/NCT01895465"
690,"NCT04823026","Host RNA Profiles to Detect Infections in Young Infants","CHILD_YIC","Completed","No Results Available","Bacterial Infections|Urinary Tract Infections|Sepsis|Fever|Viral Infection|Infant, Newborn, Disease|Bacteremia|Meningitis",,"Host RNA expression profiles|Application of known host RNA profiles|Time study","Rigshospitalet, Denmark","All","up to 3 Months   (Child)",,"152","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","H-18065635-YIC","May 15, 2020","December 31, 2021","December 31, 2021","March 30, 2021",,"December 28, 2022","Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark|Department of Paediatrics and Adolescent Medicine, Herlev Hospital, Herlev, Denmark|Department of Paediatrics and Adolescent Medicine, Nordsjællands Hospital - Hillerød, Hillerød, Denmark|Department of Paediatrics, Hvidovre Hospital, Hvidovre, Denmark",,"https://ClinicalTrials.gov/show/NCT04823026"
691,"NCT01685086","Surveillance and Follow-up for Latent Tuberculosis Infection and Observation of the Effect of Prophylactic Latent Tuberculosis Treatment in Patients With Severe Chronic Kidney Disease or Receiving Long-term Dialysis",,"Unknown status","No Results Available","To Determine the Prevalence of Latent Tuberculosis in Each Group|To Monitor the Occurrence of Active Tuberculosis",,"occurrence of active tuberculosis|Latent tuberculosis infection","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201110013RC","March 2012",,,"September 13, 2012",,"September 13, 2012","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01685086"
692,"NCT02697162","Antiseptic-coated Intermittent Urinary Catheter","GuardianCath","Withdrawn","No Results Available","Neurogenic Bladder|Catheter-Related Infections","Device: Antiseptic-coated catheter|Device: Hydrophilic catheter|Drug: Octenidine chloride","Number of urinary tract infections|Safety during catheterisation|Adverse reactions|Expenses of infection-associated treatment|Improvement in health-related quality of life measured by PedsQL 4.0 Generic Core questionnaire","Children's Hospital Zagreb|GuardianMed j.d.o.o. Research and development in medicine","All","1 Month to 18 Years   (Child, Adult)","Phase 2|Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","GCath-CHZ-01","June 2016","December 2016","June 2018","March 3, 2016",,"February 9, 2021","Children's Hospital Zagreb, Zagreb, Croatia",,"https://ClinicalTrials.gov/show/NCT02697162"
693,"NCT00164099","The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study",,"Terminated","No Results Available","Surgical Wound Infection|Cystitis|Bacteremia|Pneumonia|Enterocolitis, Pseudomembranous","Drug: Synbiotic 2000","Infection|Tolerance","Beth Israel Medical Center","All","Child, Adult, Older Adult","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","224-04","November 2005",,"June 2007","September 14, 2005",,"November 1, 2007","Beth Israel Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00164099"
694,"NCT03503513","Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury",,"Active, not recruiting","No Results Available","Urinary Tract Infections|Spinal Cord Injuries|Spinal Cord Diseases|Neurogenic Bladder","Drug: Gentamicin Sulfate","Number of urinary tract infections (UTI)|Change in score of Neurogenic Bladder Symptom Severity scale|Change in score of Neurogenic Bowel Dysfunction","University of Michigan|Department of Health and Human Services","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","13","Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HUM00137086|90IFRE0002","August 24, 2018","August 15, 2023","August 15, 2023","April 19, 2018",,"March 6, 2023","University of Michigan Health System, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03503513"
695,"NCT00126698","Prophylactic Antibiotics on Urethral Catheter Withdrawal",,"Completed","No Results Available","Urinary Tract Infection|Bacteriuria","Drug: trimethoprim-sulfamethoxazole|Drug: ciprofloxacin","Symptomatic bacteriuria|Asymptomatic bacteriuria|Antibiotic resistance patterns","St. Antonius Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","2005-01|CAD-Trial","January 2005",,"April 2007","August 4, 2005",,"April 19, 2007","Sint Antonius Hospital, Nieuwegein, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT00126698"
696,"NCT04882085","Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults",,"Completed","No Results Available","Urinary Tract Infection|Acute Pyelonephritis|Hospital Acquired Pneumonia|Ventilator-associated Pneumonia|Bacteremia|Intra-abdominal Infection","Drug: Zavicefta, Ceftazidime-Avibactam|Drug: Best Available Treatment","The percentage of participants in Microbiologically Modified Intent to Treat (mMITT) analysis set having clinical cure|The percentage of participants in mMITT analysis set having clinical cure|The percentage of participants in Microbiologically Evaluable (ME) analysis set having clinical cure|The percentage of participants in ME analysis set having clinical cure|The percentage of participants in mMITT analysis set having favorable microbiological response|The percentage of participants in ME analysis set having favorable microbiological response|The percentage of participants who have died due to any cause|The number of treatment-emergent adverse events|The percentage of participants experiencing the AEs","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C3591033","August 26, 2021","August 31, 2023","August 31, 2023","May 11, 2021",,"December 15, 2023","The First Affiliated Hospital of Bengbu Medical, Bengbu, Anhui, China|The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China|Chizhou People's Hospital, Chizhou, Anhui, China|Fuyang People's Hospital, Fuyang, Anhui, China|Peking University Third Hospital, Beijing, Beijing, China|Zhongshan Hospital Xiamen University, Xiamen, Fujian, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|Qingyuan People's Hospital, Qingyuan, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|The Second People's Hospital of Shenzhen, Shenzhen, Guangdong, China|Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China|Affiliated Hospital of Guilin Medical College, Guilin, Guangxi, China|Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China|Affiliated Hospital of Hebei University, Baoding, Hebei, China|Luoyang Central Hospital, Luoyang, Henan, China|NanYang central hospital, Nanyang, Henan, China|Henan provincial people's hospital, Zhengzhou, Henan, China|Henan provincial people's hospital, Zhengzhou, Henan, China|Baotou Central Hospital, Baotou, Inner Mongolia Autonomous Region, China|Jiangyin People's Hospital, Jiangyin, Jiangsu, China|Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China|Subei People's Hospital of Jiangsu province, Yangzhou, Jiangsu, China|Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China|Huashan Hospital, Fudan University, Shanghai, Shanghai, China|Chengdu Xinhua Hospital, Chengdu, Sichuan, China|Tianjin Chest Hospital, Tianjin, Tianjin, China|The First People's Hospital of Kunming (South Hospital), Kunming, Yunnan, China|The First people's Hospital of Kunming, Kunming, Yunnan, China|The First People's Hospital of Kunming Ganmei Hospital (North Hospital), Kunming, Yunnan, China|Zhejiang Hospital, Hangzhou, Zhejiang, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China|Lishui People's Hospital, Lishui, Zhejiang, China|Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, China|The 2nd Affiliated Hospital of WMU, Wenzhou, Zhejiang, China|Wenzhou Central Hospital, Wenzhou, Zhejiang, China|Jiangyin People's Hospital, Jiangyin, China|Shanghai Fifth People's Hospital, Fudan University, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04882085"
697,"NCT00093938","Cranberry Juice for Preventing Bacteria in Urine During Pregnancy",,"Completed","No Results Available","Urinary Tract Infection|Bacteriuria","Drug: Cranberry juice","Number of cases of asymptomatic bacteriuria|Number of cases of symptomatic urinary tract infection|Compliance with recommended therapy|Number of preterm deliveries","National Center for Complementary and Integrative Health (NCCIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Female","18 Years and older   (Adult, Older Adult)","Phase 1","360","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","DK068527-01 (completed)","December 2004",,,"October 8, 2004",,"January 14, 2010","Women's Pavilion at Miller Children's Hospital (Long Beach Memorial Medical Center), Long Beach, California, United States|University of California, Irvine Medical Center, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT00093938"
698,"NCT06319352","Evaluation of Quality-of-Life Improvements Using UroShield Device",,"Not yet recruiting","No Results Available","Quality of Life|Catheter-Associated Urinary Tract Infection","Device: Active UroShield|Device: Sham UroShield","Recruitment rate|Device use adherence|Device accountability|Efficiency of data collection","University of Michigan|Nanovibronix","All","18 Years and older   (Adult, Older Adult)","Not Applicable","16","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Device Feasibility","HUM00243293","March 29, 2024","October 2024","October 2024","March 20, 2024",,"March 25, 2024",,,"https://ClinicalTrials.gov/show/NCT06319352"
699,"NCT02285075","Temocillin Pharmacokinetic in Hemodialysis",,"Completed","No Results Available","Gram-Negative Bacterial Infections|Renal Failure Chronic Requiring Hemodialysis","Drug: temocillin PK/PD in haemodialysis","% of the dosing interval time above an MIC of 8 and 16 mg/L (% T>MIC 8 or 16 mg/L)|Determine basic pharmacokinetic parameters of temocillin in intermittent haemodialysis","AZ Sint-Jan AV|Paul Tulkens, Louvain drug research institute, belgium|Francoise Van Bambeke, Louvain drug research institute, belgium|Ana Miranda Bastos, Louvain drug research institute, belgium","All","18 Years and older   (Adult, Older Adult)","Phase 4","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SVDC Temocillin 1","June 2011","December 2014","December 2014","November 6, 2014",,"January 5, 2016","AZ Sint-Jan Brugge Oostende AV, Brugge, Belgium|Louvain Drug Research Institute (LDRI), Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT02285075"
700,"NCT02486653","Prevention of Post-operative Urinary Retention","POUR","Completed","Has Results","Urinary Retention|Urinary Tract Infections","Drug: Tamsulosin|Drug: Placebo","Need for Any Intermittent Catheterization Postoperatively as a Binary Outcome|Need for Replacement of Indwelling Urinary Catheter as a Binary Outcome|Time Until First Spontaneous Void|Total Number of Intermittent Catheterizations Required Per Subject|First Post-void Residual Urine Volume|Discharge From Hospital With Indwelling Urinary Catheter|Urinary Tract Infection (UTI)|Hospital Length of Stay in Days|Number of Participants Who Experienced Adverse Events","University of Wisconsin, Madison","All","18 Years and older   (Adult, Older Adult)","Phase 3","158","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2014-1494","August 2015","April 1, 2018","May 2, 2018","July 1, 2015","April 23, 2019","September 25, 2019","University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/53/NCT02486653/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02486653"
701,"NCT02420366","Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae",,"Completed","No Results Available","Urinary Tract Infection, Complicated|Acute Pyelonephritis|Hospital Acquired Bacterial Pneumonia|Ventilator-associated Bacterial Pneumonia|Bacteremia",,"Prevalence of positive CRE infections (specifically cUTI, AP, HABP, VABP, Bacteremia) in a target patient population","Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)|Melinta Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)",,"257","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","Rempex 506 NH","May 2014","January 2015","January 2015","April 17, 2015",,"May 2, 2018","Chicago, Illinois, United States|Evanston, Illinois, United States|Detroit, Michigan, United States|New Brunswick, New Jersey, United States|Somers Point, New Jersey, United States|New York, New York, United States|New York, New York, United States|Rochester, New York, United States|Durham, North Carolina, United States|Cleveland, Ohio, United States|Pittsburgh, Pennsylvania, United States|Charlottesville, Virginia, United States|Athens, Greece|Bologna, Italy|Firenze, Italy|Genova, Italy|Pisa, Italy|Roma, Italy|Rome, Italy|Udine, Italy|Manchester, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02420366"
702,"NCT03789513","Evaluation of Triage Options After HPV Testing for Cervical Cancer Screening Among HIV-infected Women","AIMA-CC","Unknown status","No Results Available","HIV Infections|HPV - Anogenital Human Papilloma Virus Infection","Diagnostic Test: HPV test with partial genotyping and VIA triage","Sensitivity of the triage options|Specificity of the triage options|Positive and negative predictive value (PPV and NPV) of the triage options|Positive and negative diagnostic likelihood ratio (DLR) of the triage options|Acceptability and feasibility|Prevalence of CIN2+ lesions|Prevalence of CIN3+ lesions|Prevalence of cervical cancer|Adverse events|Proportion of the women eligible to HPV screening who were actually screened and treated (if required)|Evaluation of the micro-costing|Evaluation of post-treatment HPV clearance|Evaluation of post-treatment cervical lesion","ANRS, Emerging Infectious Diseases|Institut de Recherche pour le Developpement|International Agency for Research on Cancer|Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire|University Hospital, Geneva|University of Bordeaux","Female","30 Years to 49 Years   (Adult)","Not Applicable","3000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","ANRS12375 AIMA-CC","March 1, 2019","September 1, 2022","September 2022","December 28, 2018",,"February 16, 2022","HIV day care center, Bobo-Dioulasso, Burkina Faso|Calmette Hospital, Phnom Penh, Cambodia|CEPREF, Abidjan, Côte D'Ivoire",,"https://ClinicalTrials.gov/show/NCT03789513"
703,"NCT01792973","HPV Infection and Cervical Lesions in HIV Infected Women in Thailand: A Prospective Study","PapilloV","Completed","No Results Available","Cervical Cancer",,"High risk HPV infection|High grade cervical lesions","Institut de Recherche pour le Developpement|National Cancer Institute, France|Fondation de France","Female","18 Years and older   (Adult, Older Adult)",,"829","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PapilloV","February 2012","December 2016","December 2016","February 15, 2013",,"October 22, 2021","Prapokklao Hospital, Chanthaburi, Chantaburi, Thailand|Lamphun Hospital, Lamphun, Chiang Mai, Thailand|Nakornping Hospital, Mae Rim, Chiang Mai, Thailand|Sanpatong Hospital, San Pa Tong, Chiang Mai, Thailand|Mae Chan Hospital, Mae Chan, Chiang Rai, Thailand|Mae Sai Hospital, Mae Sai, Chiang Rai, Thailand|Phan Hospital, Phan, Chiang Rai, Thailand|Chiangrai Prachanukroh Hospital, Chiang Rai, Chiangrai, Thailand|Chonburi Hospital, Chon Buri, Chonburi, Thailand|Mahasarakam Hospital, Maha Sarakham, Mahasarakam, Thailand|Nakhonpathom Hospital, Nakhon Pathom, Nakhonpathom, Thailand|Chiang Kham Hospital, Chiang Kham, Phayao, Thailand|Buddhachinaraj Hospital, Phitsanulok, Pitsanulok, Thailand|Samutprakarn Hospital, Samut Prakan, Samutprakarn, Thailand|Samutsakorn Hospital, Samut Sakhon, Samutsakorn, Thailand|Hat Yai Hospital, Hat Yai, Songkla, Thailand|Bhumibol Adulyadej Hospital, Bangkok, Thailand|Bhuddasothorn Hospital, Chachoengsao, Thailand|Lampang Hospital, Lampang, Thailand|Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand|Nong Khai Hospital, Nong Khai, Thailand|Phayao Hospital, Phayao, Thailand|Ratchaburi Hospital, Ratchaburi, Thailand|Rayong Hospital, Rayong, Thailand",,"https://ClinicalTrials.gov/show/NCT01792973"
704,"NCT00714402","Procalcitonin Level and Kinetics in Children With Bacterial Infections",,"Completed","No Results Available","Bacterial Infections|Bacteremia|Meningitis|Urinary Tract Infection|Mastoiditis|Lobar Pneumonia|Septic Arthritis|Cellulitis|Osteomyelitis",,"time to defervescence|length of hospitalization","Shaare Zedek Medical Center","All","3 Days to 16 Years   (Child)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","pct.ctil","August 2008",,,"July 14, 2008",,"May 18, 2011","Shaare Zedek Medical Center, Jerusalem, Pob 3235, Israel",,"https://ClinicalTrials.gov/show/NCT00714402"
705,"NCT04831086","To Optimize Antenatal Management of Women With Pre Term Labor Using Amniocentesis","OPTIM-PTL","Recruiting","No Results Available","Preterm Birth|Preterm Labor|Intra-amniotic Infection|Amniocentesis Affecting Fetus or Newborn","Drug: Steroid Drug|Drug: Tocolytic Agents","Antenatal steroid doses|maternal stay length|Clinical chorioamnionitis","Fundacion Clinic per a la Recerca Biomédica|Hospital Vall d'Hebron|Hospital Universitario La Fe|Hospital Universitario La Paz|Hospital Universitario 12 de Octubre|Consorci Sanitari de Terrassa|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Hospital Universitario Puerta del Mar|Hospital Sant Joan de Deu|Germans Trias i Pujol Hospital|University Hospital Virgen de las Nieves|Hospital Clínico Universitario Lozano Blesa|Parc Taulí Hospital Universitari","Female","18 Years and older   (Adult, Older Adult)","Phase 3","340","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OPTIM-PTL","May 5, 2021","September 30, 2023","December 30, 2023","April 5, 2021",,"May 18, 2022","Fundació Recerca Biomèdica Clínica, Barcelona, Spain","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/86/NCT04831086/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04831086"
706,"NCT05477953","An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health",,"Active, not recruiting","No Results Available","Chagas Disease","Drug: Nifurtimox (BAYA2502)","Major Congenital Malformations (birth defects)|Events of Interest in Neonates and Infants through 12 Months of Age: Hospitalizations for serious illness|Events of Interest in Neonates and Infants through 12 Months of Age: Medications|Events of Interest in Neonates and Infants through 12 Months of Age: Growth and development milestones|Events of Interest in Neonates and Infants through 12 Months of Age: Neonatal or infant mortality|Maternal Complications: Premature rupture of membranes (PROM)|Maternal Complications: Preeclampsia|Maternal Complications: Severe pregnancy-induced hypertension (PIH)|Maternal Complications: Proteinuria|Maternal Complications: Gestational diabetes|Maternal Complications: Measures of fetal growth deficiency (small for gestational age)|Spontaneous abortion|Elective/Induced abortion|Fetal death/Still birth|Preterm delivery|Live Birth|Ectopic or Molar Pregnancy","Bayer","Female","Child, Adult, Older Adult",,"50","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","21944","August 17, 2022","March 31, 2032","March 31, 2032","July 28, 2022",,"April 12, 2024","Many Locations, Multiple Locations, West Virginia, United States|Many Locations, Multiple Locations, Argentina|Many Locations, Multiple Locations, Bolivia|Many Locations, Multiple Locations, Chile|Many Locations, Multiple Locations, Uruguay",,"https://ClinicalTrials.gov/show/NCT05477953"
707,"NCT00258089","A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections",,"Completed","No Results Available","Urinary Tract Infections|Bacteriuria|Urologic Diseases|Pyelonephritis|Neurogenic Bladder","Drug: Levofloxacin","Clinical response, the resolution of signs and symptoms at post-therapy compared with those at the start of study; Microbiological response, the eradication at post-therapy of infectious organism identified at start of study.|Overall clinical response (described as cured, improved or failed) at long-term follow up; incidence of adverse events throughout the study; change in clinical laboratory tests and physical examinations from start of study to post-therapy.","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PriCara, Unit of Ortho-McNeil, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","578","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR005482","June 1993",,"January 1995","November 24, 2005",,"May 23, 2011",,,"https://ClinicalTrials.gov/show/NCT00258089"
708,"NCT02168946","Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults",,"Completed","Has Results","Urinary Tract Infection Complicated|Acute Pyelonephritis|Hospital Acquired Bacterial Pneumonia|Ventilator-associated Bacterial Pneumonia|Bacteremia|Abdominal Infection","Drug: Vabomere|Drug: Best Available Therapy","Proportion of Subjects in the Microbiological Carbapenem-resistant Enterobacteriaceae Modified Intent-to-Treat (mCRE-MITT) Population With a Response of Overall Success [Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Subjects]|All-cause Mortality Rate in the mCRE-MITT Population [Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP) and Bacteremia Subjects)|Proportion of Subjects in the mCRE-MITT Population With a Clinical Outcome of Cure [Complicated Intra-abdominal Infection (cIAI) Subjects Only]|The All-cause Mortality Rate in the mCRE-MITT Population (All Indications)|The All-cause Mortality Rate in the m-MITT Population (All Indications)|The All-cause Mortality Rate in the mCRE-MITT Population (cUTI/AP)|Proportion of Subjects in the mCRE-MITT Population With a Clinical Outcome of Cure (All Indications)|Proportion of Subjects in the mCRE-MITT Population With a Clinical Outcome of Cure (cUTI/AP Subjects Only)|Proportion of Subjects in the mCRE-MITT Population With a Clinical Outcome of Cure (HABP/VABP and Bacteremia)|Proportion of Subjects in the Microbiological Modified Intent-to-Treat (m-MITT) Population With a Clinical Outcome of Cure (All Indications)|Proportion of Subjects in the m-MITT Population With a Clinical Outcome of Cure (cUTI/AP)|Proportion of Subjects in the m-MITT Population With a Clinical Outcome of Cure (HABP/VABP and Bacteremia)|Proportion of Subjects in the mCRE-MITT Population With a Microbiological Outcome of Eradication (All Indications)|Proportion of Subjects in the m-MITT Population With a Microbiological Outcome of Eradication (All Indications)|Proportion of Subjects in the m-MITT Populations With a With a Response of Overall Success (cUTI/AP)|Proportion of Subjects in the m-MITT Populations With a With a Response of Overall Success (Bacteremia Only)","Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)|Department of Health and Human Services|Melinta Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","77","Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Rempex 506","July 2014","July 21, 2017","July 21, 2017","June 20, 2014","December 11, 2018","March 4, 2019","Hartford, Connecticut, United States|Tampa, Florida, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Evanston, Illinois, United States|Indianapolis, Indiana, United States|Detroit, Michigan, United States|Royal Oak, Michigan, United States|New Brunswick, New Jersey, United States|Bronx, New York, United States|Buffalo, New York, United States|Flushing, New York, United States|New York, New York, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Cleveland, Ohio, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Charlottesville, Virginia, United States|Ciudad Autónoma de Buenos Aires, Argentina|Córdoba, Argentina|La Plata, Argentina|Mendoza, Argentina|Sao Jose do Rio Preto, São Paulo, Brazil|Belo Horizonte, Brazil|Curitiba, Brazil|Porto Alegre, Brazil|Sao Paulo, Brazil|São Paulo, Brazil|São Paulo, Brazil|Barranquilla, Colombia|Bogota, Colombia|Medellin, Colombia|Athens, Greece|Athens, Greece|Athens, Greece|Thessaloniki, Greece|Haifa, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Bologna, Italy|Firenze, Italy|Genova, Italy|Pisa, Italy|Rome, Italy|Udine, Italy|Manchester, United Kingdom|Manchester, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/46/NCT02168946/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/46/NCT02168946/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02168946"
709,"NCT01615341","Study of Subclinical Viral Infection",,"Unknown status","No Results Available","Kidney Transplantation|Kidney Failure, Chronic",,"Change in measured GFR from baseline|Change in interstitial fibrosis and tubular atrophy of renal allograft from baseline|Change in innate immune activation of renal allograft from baseline","Seattle Children's Hospital|University of Washington","All","1 Year to 25 Years   (Child, Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","R01DK088914-01A1","October 2011","October 2016","October 2016","June 8, 2012",,"June 8, 2012","Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01615341"
710,"NCT02145338","Antibiotic Prophylaxis for Clean Intermittent Catheterisation","AnTIC","Completed","No Results Available","Urinary Tract Infections, Recurrent","Drug: Nitrofurantoin or Trimethoprim or Cefalexin|Other: No prophylaxis","Relative incidence of symptomatic antibiotic-treated UTI","Newcastle-upon-Tyne Hospitals NHS Trust|NHS Health Technology Assessment Programme|Newcastle University|Glasgow Caledonian University|University of Aberdeen|Cambridge University Hospitals NHS Foundation Trust|North Bristol NHS Trust|University of Southampton","All","18 Years and older   (Adult, Older Adult)","Phase 4","404","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","AnTIC:6672|2013-002556-32|11-72-01","September 2013","February 22, 2017","February 22, 2017","May 22, 2014",,"March 30, 2018","Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02145338"
711,"NCT00734968","Does Treatment With Macrobid Reduce Urinary Tract Infections in Patients Receiving a Sub-Urethral Sling for Incontinence",,"Completed","Has Results","Stress Incontinence","Drug: Nitrofurantoin|Other: Placebo","Incidence of Post-operative UTI Following the Placement of Sub-urethral Sling for the Treatment of Stress Urinary Incontinence|Incidence of Post-operative UTI in Placebo Group|Incidence of Post-operative UTI in Treatment Group","University of Missouri-Columbia|Texas A&M University","Female","18 Years and older   (Adult, Older Adult)","Phase 4","161","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1108717","May 2008","May 2010","May 2010","August 14, 2008","October 11, 2016","October 11, 2016","Scott and White Hosptial, Texas A&M University, Temple, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00734968"
712,"NCT05040334","Role of Prophylactic Antibiotics in Preventing Pelvic Infection After Surgical Evacuation",,"Unknown status","No Results Available","Antibiotics Causing Adverse Effects in Therapeutic Use","Drug: Group 1: Antibiotic receiving group","Change of pelvic infection after surg ical evacuation of miscarriage with use of antibiotic prophylaxis.|Change in the risk of severe puerperal sepsis following the surgical procedure","Cairo University","Female","18 Years to 35 Years   (Adult)","Phase 4","138","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Cairo University Obygyn","January 1, 2021","April 1, 2022","May 1, 2022","September 10, 2021",,"March 28, 2022","Department of Obstetrics and Gynecology, Kasr Al-Ainy University Hospital, Cairo University., Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05040334"
713,"NCT01800799","Urinary NGF as A Biomarker for Acute Bacterial Cystitis",,"Completed","No Results Available","Urinary Tract Infection","Drug: Baktar 800mg h.s.|Drug: Celecoxib 200mg QD","Change from Baseline in urinary nerve growth factor (NGF) at different time points|Change from Baseline in one-day voiding diary at different time points|Change from Baseline in Overactive Bladder Symptom Score (OABSS) at different time points|Change from Baseline in visual analog scale of pain (VAS) at different time points","Buddhist Tzu Chi General Hospital","Female","20 Years to 90 Years   (Adult, Older Adult)","Not Applicable","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCGHUROL007","February 2013","December 2014","December 2014","February 28, 2013",,"February 17, 2017","Buddhist Tzu Chi General Hospital, Hualien, Taiwan",,"https://ClinicalTrials.gov/show/NCT01800799"
714,"NCT05959928","Continuous Temperature Telemonitoring of Patients With COVID-19 and Other Infectious Diseases in Hospital at Home Using Viture","Viture","Completed","No Results Available","COVID-19|Infectious Disease|Tract Infection, Urinary|Bacteremia|Respiratory Infection|Cellulitis","Device: Continuous wearable thermometer placed on patient's armpit to monitor body temperature remotely","Verify that, under normal conditions of use, the performance of Viture for body temperature measurement is equivalent to the devices used in the standard practice.|Evaluate the safety, usability and comfort of Viture Device","Vitio Medical S.L.|Hospital Universitario de Navarra|NAVARRABIOMED","All","18 Years and older   (Adult, Older Adult)",,"209","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","859/20/EC","February 9, 2021","June 2, 2021","June 2, 2021","July 25, 2023",,"July 27, 2023","Hospital Universitario de Navarra, Pamplona, Navarra, Spain",,"https://ClinicalTrials.gov/show/NCT05959928"
715,"NCT00400595","Use of Ointments in Prevention of Catheter Related Infections in PD",,"Completed","No Results Available","End Stage Renal Disease","Drug: Mupirocin ointment|Drug: Polysporin Triple","The primary endpoint is the time to first catheter related infection.|Removal of the catheter to prevent or halt progression of a catheter related infection|Hospitalizations related to catheter related infection|Death due to catheter-related infection|All-cause mortality|Technique failure (i.e. transfer to hemodialysis)|Mupirocin or Polysporin Triple resistance","University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","05-0850-AE","February 2006","June 2009","June 2010","November 17, 2006",,"March 18, 2015","Scarborough General Hospital, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00400595"
716,"NCT00190281","Contrast-Enhanced US of Spleen, Liver and Kidney",,"Unknown status","No Results Available","Malaria|Pyelonephritis|Bacterial Infections",,,"Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"53","Other","Observational","Observational Model: Defined Population|Time Perspective: Prospective","04 025","August 2005",,,"September 19, 2005",,"December 13, 2005","Department of Adult Radiology, Necker University Hospital, Paris, Ile de france, France",,"https://ClinicalTrials.gov/show/NCT00190281"
717,"NCT02215902","Safety Study of the Aethlon Hemopurifier","AEMD-IDE-20","Terminated","No Results Available","End Stage Renal Disease|Hepatitis C Infection","Device: Affinity plasmapheresis","Rate of adverse events|Viral load reduction","Aethlon Medical Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","8","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AEMD - IDE - 2013","December 2014","March 10, 2017","March 10, 2017","August 13, 2014",,"March 14, 2017","DaVita Med Center Dialysis, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02215902"
718,"NCT06149676","A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections",,"Recruiting","No Results Available","Recurrent Uti","Drug: Saccharomyces Boulardii 250 MG [Florastor]","Reduction in UTI episodes","Ann & Robert H Lurie Children's Hospital of Chicago","All","2 Years to 17 Years   (Child)","Early Phase 1","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB 2022-4941","February 2, 2022","December 31, 2024","December 31, 2025","November 29, 2023",,"November 29, 2023","Lurie Children's Hospital, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT06149676"
719,"NCT02381834","Evaluation of a Novel Midstream Urine Collection Technique for Infants in the Emergency Department",,"Completed","No Results Available","Urinary Tract Infection","Procedure: Bladder stimulation technique","Proportion of patients for whom the technique is successful for urine collection within 5 minutes (success being defined as the collection of an adequate sample volume [≥ 1 mL] for urinalysis and urine culture testing)|Proportion of contaminated samples (contamination being defined as growth of ≥ 2 microorganisms or growth of a single type of non-uropathogenic organism)|Length of bladder stimulation time (minutes) required for successful urine collection.|Length of time (minutes) required to complete the full study protocol (from initiation of feeding/IV fluid administration to completed urine collection)|Patient distress as perceived by parent/guardian, measured using a 10 cm Visual Analog Scale (VAS).|Components of satisfaction relating to the procedure for the parent/guardian and the Registered Nurse (RN) or Medical Doctor (MD) performing the procedure.","Children's Hospital of Eastern Ontario","All","up to 90 Days   (Child)","Not Applicable","150","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14/190X","March 2015","January 2016","January 2016","March 6, 2015",,"January 12, 2016","Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02381834"
720,"NCT03655548","Optimization Management Study of Community Urinary Tract Infections Spectrum","OPTICUR-EBLSE","Completed","No Results Available","Urinary Tract Infections|Resistant Infection|Community-Acquired Infections|Beta Lactam Resistant Bacterial Infection",,"percentage of adequation to ANSM 2015 guidelines of antibotics prescription for community acquired urinary tract infection before and after CBEU report","University Hospital, Brest","All","18 Years and older   (Adult, Older Adult)",,"108","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","OPTICUR-EBLSE","October 1, 2016","February 28, 2017","February 28, 2017","August 31, 2018",,"August 31, 2018",,,"https://ClinicalTrials.gov/show/NCT03655548"
721,"NCT01235546","Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection","C/SOAP","Completed","Has Results","Endometritis|Wound Infection|Abscess|Surgical Site Infection","Drug: Azithromycin and standard of care|Drug: Placebo and standard of care","Participants With Endometritis and/or Wound Infection and/or Other Post-cesarean Infections (Occurring Within 6 Weeks of Delivery)","Alan Tita|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Texas|University of North Carolina|Mission Hospital|Ochsner Health System|The University of Texas Health Science Center, Houston|Columbia University|University of Utah|University of Mississippi Medical Center|University of Alabama at Birmingham","Female","14 Years and older   (Child, Adult, Older Adult)","Not Applicable","2013","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","F090323006|NIH 1R01HD064729-01A1","May 2011","December 2015","December 2015","November 5, 2010","July 28, 2017","July 28, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Columbia University, New York, New York, United States|Mission Hospital, Asheville, North Carolina, United States|University of North Carolina, Chapel Hill, North Carolina, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01235546"
722,"NCT04700787","Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents",,"Withdrawn","No Results Available","Urinary Tract Infections|Pyelonephritis Acute|Intraabdominal Infections","Drug: Sulopenem","Maximum plasma concentration|Time to maximum plasma concentration|Time above minimum inhibitory concentration|Area under the plasma concentration-time curve from time zero to time of last quantifiable plasma concentration|Area under the plasma concentration-time curve from time zero extrapolated to infinity|Percentage of area under the concentration-time curve extrapolated|Terminal elimination half-life|Total body clearance for intravenous administration|Apparent total body clearance for oral administration|Volume of distribution for intravenous administration|Apparent volume of distribution for oral administration","Iterum Therapeutics, International Limited","All","12 Years to 18 Years   (Child, Adult)","Phase 1","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IT001-106","April 30, 2021","March 25, 2022","April 4, 2022","January 8, 2021",,"June 13, 2022","Medical Facility, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04700787"
723,"NCT05554081","Effect of Standardization of Urine Collection Using PEEZY Device as Compared to Clean Peezy for DAB","Peezy-DAB","Recruiting","No Results Available","Asymptomatic Bacteriuria|Urinary Tract Infections","Device: Peezy urine collection device","Urine contamination rates|Maternal comorbidities and contamination","Loyola University","Female","18 Years and older   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","216104","August 1, 2022","August 31, 2023","December 31, 2023","September 26, 2022",,"September 26, 2022","Loyola University medical Center, Maywood, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT05554081"
724,"NCT03310463","Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects",,"Completed","No Results Available","Acinetobacter Baumannii Infection","Drug: ETX2514SUL","Mean maximum observed drug concentration (Cmax) in blood: Cohorts 1 and 2|Mean Cmax in blood: Cohorts 3 and 4|Mean Cmax in blood: Cohort 5|Mean time to reach the maximum concentration (tmax) in blood: Cohorts 1 and 2|Mean tmax in blood: Cohorts 3 and 4|Mean tmax in blood: Cohort 5|Mean AUC0-24 in blood: Cohorts 1 and 2|Mean AUC0-48 in blood: Cohorts 1 and 2|Mean AUC0-last in blood: Cohorts 1 and 2|Mean AUC0-∞ in blood: Cohorts 1 and 2|Mean AUC0-24 in blood: Cohorts 3 and 4|Mean AUC0-48 in blood: Cohorts 3 and 4|Mean AUC0-60 in blood: Cohorts 3 and 4|Mean AUC0-last in blood: Cohorts 3 and 4|Mean AUC0-∞ in blood: Cohorts 3 and 4|Mean AUC0-24 in blood: Cohort 5|Mean AUC0-48 in blood: Cohort 5|Mean AUC0-60 in blood: Cohort 5|Mean AUC0-last in blood: Cohort 5|Mean AUC0-∞ in blood: Cohort 5|Mean terminal elimination rate constant (λz) in blood: Cohorts 1 and 2|Mean λz in blood: Cohorts 3 and 4|Mean λz in blood: Cohort 5|Mean terminal half life (t1/2) in blood: Cohorts 1 and 2|Mean t1/2 in blood: Cohorts 3 and 4|Mean t1/2 in blood: Cohort 5|Mean total clearance (CL) from blood: Cohorts 1 and 2|Mean CL from blood: Cohorts 3 and 4|Mean CL in blood: Cohort 5|Mean volume of distribution in the terminal elimination phase (Vz) in blood: Cohorts 1 and 2|Mean Vz in blood: Cohorts 3 and 4|Mean Vz in blood: Cohort 5|Mean cumulative amount of drug excreted in urine (Aeu): Cohorts 1 and 2|Mean Aeu: Cohorts 3 and 4|Mean renal clearance (CLR): Cohorts 1 and 2|Mean CLR: Cohorts 3 and 4|Mean fraction of the dose renally eliminated (Feu): Cohorts 1 and 2|Mean Feu: Cohorts 3 and 4|Mean amount dialyzed (AHD): Cohort 5|Mean fraction of the dose removed by hemodialysis (FHD): Cohort 5|Estimated hemodialysis (HD) recovery clearance (CLD Recovery): Cohort 5|Number of participants with any non-serious adverse event (AE)|Number of participants with any serious adverse event (SAE)|Number of participants with an adverse event of the indicated causality and severity|Number of participants with abnormal, clinically significant physical examination findings at the indicated time points|Number of participants with abnormal, clinically significant vital sign values at the indicated time points|Change from Baseline in electrocardiogram (ECG) parameters at the indicated time points|Number of participants with abnormal, clinically significant hematology and clinical chemistry laboratory values at the indicated time points","Entasis Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","34","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CS2514-2017-0002","October 3, 2017","May 25, 2018","May 29, 2018","October 16, 2017",,"June 14, 2018","DaVita Clinical Research, Lakewood, Colorado, United States|University of Miami, Division of Clinical Pharmacology, Miami, Florida, United States|Davita Clinical Research, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03310463"
725,"NCT00009009","Kidney Transplant for HIV-Infected Patients in Renal Failure",,"Completed","No Results Available","Chronic Kidney Failure|HIV Infection","Drug: immunosuppressive regimen designed to complement HAART",,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","10","NIH","Interventional","Primary Purpose: Treatment","010061|01-DK-0061","January 2001",,"December 2002","January 22, 2001",,"March 4, 2008","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00009009"
726,"NCT03554603","Modified Reporting of Positive Urine Cultures Collected From Long Term Care",,"Completed","Has Results","Urinary Tract Infections|Asymptomatic Bacteriuria","Behavioral: Modified Report","Proportion of Asymptomatic Bacteriuria Treated With Antibiotics and Urinary Tract Infection Treated With Antibiotics","Memorial University of Newfoundland","All","Child, Adult, Older Adult","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","MUN-04","November 5, 2018","July 31, 2019","July 31, 2019","June 13, 2018","March 1, 2024","March 1, 2024","Health Sciences Center, Saint John's, Newfoundland and Labrador, Canada","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/03/NCT03554603/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03554603"
727,"NCT05039203","Bacteriuria and Indwelling Urinary Catheter.",,"Enrolling by invitation","No Results Available","Bacteriuria Asymptomatic|Urinary Tract Infections","Device: Indwelling urinary catheter","Symptomatic bacteriuria (urinary tract infection)|Asymptomatic bacteriuria (ABU)|Persistence of ABU","Region Stockholm","All","65 Years and older   (Older Adult)",,"800","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2021-02410","May 24, 2022","September 2024","September 2024","September 9, 2021",,"September 6, 2023","Geriatric Department, Södertälje Hospital, Södertälje, Sweden",,"https://ClinicalTrials.gov/show/NCT05039203"
728,"NCT01263392","Comparing Urinary Tract Infections in Children With Spina Bifida Using Two Types of Catheters for Catheterization",,"Completed","No Results Available","Neurogenic Bladder|Spina Bifida","Device: Intermittent catheterization","Symptomatic urinary tract infection (UTI)|Subject satisfaction","University of Alberta","All","3 Months to 18 Years   (Child, Adult)","Not Applicable","46","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Speedi 10","April 2007","January 2013","January 2013","December 20, 2010",,"June 20, 2013","Alberta Children's Hospital, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|BC Children's Hospital, Vancouver, British Columbia, Canada|Winnipeg Children's Hospital, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT01263392"
729,"NCT04616352","Cefuroxime Resistance in Pyelonephritis",,"Completed","No Results Available","Urinary Tract Infections","Other: Resistance to cefuroxime","Time to hospital discharge|Readmission|Time to readmission","Universidad Nacional de Colombia","All","18 Years and older   (Adult, Older Adult)",,"973","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ivucef001","December 26, 2020","June 30, 2021","July 30, 2021","November 4, 2020",,"August 3, 2021","Clínica Reina Sofía, Bogota, DC, Colombia",,"https://ClinicalTrials.gov/show/NCT04616352"
730,"NCT04096820","Uromune in Treating Recurrent Urinary Tract Infections in Women",,"Active, not recruiting","No Results Available","Recurrent Uti","Biological: Uromune","Complete Responder|Responder Rate","Queen's University","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","62","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","6026618","September 6, 2019","October 31, 2022","January 1, 2023","September 20, 2019",,"July 29, 2022","Centre for Advanced Urological Research, Kingston, Ontario, Canada","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/20/NCT04096820/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/20/NCT04096820/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04096820"
731,"NCT04955717","Antenatal Chlamydia Trachomatis and Neisseria Gonorrhoeae Testing to Prevent Adverse Neonatal Consequences",,"Completed","No Results Available","Chlamydia Trachomatis Infection|Neonatal Infection|Preterm Birth|Gonorrhea","Other: Chlamydia trachomatis and Neisseria gonorrhoeae screening using the GeneXpert","Neonatal Chlamydia trachomatis or Neisseria gonorrhoeae infection|Preterm birth","University of Southern California|Botswana Harvard AIDS Institute Partnership|University of California, San Diego","Female","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","HS-21-00245","February 24, 2021","January 31, 2023","January 31, 2023","July 9, 2021",,"May 10, 2023","University of Southern California, Los Angeles, California, United States|DHMT Clinics, Gaborone, Botswana",,"https://ClinicalTrials.gov/show/NCT04955717"
732,"NCT01597804","Bathing Bundle Regimen in Reducing Gynecological Surgical Site Infection in Patients Undergoing Surgery",,"Completed","No Results Available","Malignant Female Reproductive System Neoplasm","Procedure: Infection Prophylaxis and Management","Presence of a site infection, compared with historical SSI rates among RPCI GYN surgery patients treated with the standard of care before July 1, 2010","Roswell Park Cancer Institute","Female","19 Years and older   (Adult, Older Adult)","Not Applicable","435","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","I 189910|NCI-2012-00273","April 2011","February 2014","April 2016","May 14, 2012",,"July 23, 2020","Roswell Park Cancer Institute, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT01597804"
733,"NCT05551949","Preventing Recurrent UTI With Vaginal Estrogen","PRUVE","Enrolling by invitation","No Results Available","Recurrent Urinary Tract Infection|Urinary Tract Infections|Cystitis Recurrent","Drug: Vaginal estradiol tablets","Change in Vaginal microbiota|Change in Vaginal Interleukin-6 level|Change in Urinary microbiota|Change in Urinary Interleukin-6 level|Urinary tract infection recurrence","Johns Hopkins University|University of Maryland|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Female","55 Years to 100 Years   (Adult, Older Adult)","Phase 4","50","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00314740|R01DK130856","January 31, 2023","August 31, 2025","August 31, 2025","September 23, 2022",,"October 19, 2023","Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT05551949"
734,"NCT02277171","Evaluation of Safety and Tolerability of Nitric Oxide Impregnated Urinary Catheters",,"Completed","No Results Available","Urinary Tract Infection|Bacteriuria","Device: Nitric Oxide impregnated catheter","Number of participants with adverse events associated with Nitric Oxide impregnated catheters|Proportion of patients (%) who prematurely discontinued the study due to adverse events or severe adverse events associated with Nitric oxide impregnated catheters|Measuring biofilm forming bacteria on the surface of Nitric Oxide impregnated and non impregnated Foley catheters after indwelling for 7 to 14 days|Measuring bacteriuria (by urine culture) for Nitric Oxide impregnated and non impregnated Foley catheters prior to insertion, 1 day after insertion, every day during hospitalization, on catheter removal day, and 30 days after catheterization|Measuring number of urinary tract infection (UTI) events following catheterization with Nitric Oxide impregnated and non impregnated Foley catheters|Proportion of patients (%) who prematurely discontinued the study for any reason","Enox Israel Ltd|Rabin Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","15","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ENOX PHASE I_1.1","December 2014","June 2015","September 2015","October 28, 2014",,"December 24, 2015",,,"https://ClinicalTrials.gov/show/NCT02277171"
735,"NCT03445312","Safety and Effectiveness of a Laboratory Intervention to Effectively NOT Treat Asymptomatic Bacteriuria","Salient","Completed","No Results Available","Asymptomatic Bacteriuria|Urinary Tract Infections","Behavioral: not processing urine cultures","serious adverse events (SAE) associated with not processing urine culture|Differences in SAE|SAE due to antibiotics|Non-response","Mount Sinai Hospital, Canada","All","Child, Adult, Older Adult",,"1394","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MSH 16-0302E","August 31, 2017","May 15, 2019","November 15, 2019","February 26, 2018",,"June 1, 2020","Mount Sinai Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03445312"
736,"NCT02797613","Restricted Reporting for Positive Urine Cultures",,"Completed","Has Results","Bacteriuria|Urinary Tract Infection","Behavioral: Restricted Reporting","The Number of Patients Receiving Appropriate Treatment","Memorial University of Newfoundland","All","18 Years and older   (Adult, Older Adult)","Not Applicable","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","MUN-01","January 1, 2017","May 1, 2017","May 1, 2017","June 13, 2016","February 27, 2020","February 27, 2020","Health Sciences Center, Saint John's, Newfoundland and Labrador, Canada","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/13/NCT02797613/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02797613"
737,"NCT01989130","Evaluation of Immediate v. Delayed CT/NG Test for Treatment in the ED",,"Completed","Has Results","Reproductive Tract Infections","Device: Roche AMPLICOR CT/NG|Device: Cepheid Xpert CT/NG Test","Percentage of Participants Prescribed Antibiotic Treatment|Health Utilization|Healthcare Cost|Resolution of Symptoms","George Washington University|Cepheid","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","071346","October 2013","March 2015","March 2015","November 20, 2013","April 21, 2017","August 13, 2019","The George Washington University Hospital, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT01989130"
738,"NCT02034851","Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection","DEXCAR-0212","Completed","No Results Available","Acute Pyelonephritis",,"renal scarring","Institut Investigacio Sanitaria Pere Virgili|Hospital Universitari Sant Joan de Reus|Hospital Universitari Joan XXIII de Tarragona.|Pius Hospital de Valls|Hospital Arnau de Vilanova|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Maternal-Infantil Vall d´Hebron Hospital|Hospital General Universitario Santa Lucía|University Rovira i Virgili","All","2 Months to 14 Years   (Child)",,"183","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IISPV_Pediatria_Dexcar|2011-005805-66","April 2013","May 2016","June 2019","January 14, 2014",,"September 16, 2020","Hospital General Universitario Santa Lucía de Cartagena, Cartagena, Murica, Spain|Iispv- Hospital Sant Joan de Reus, Reus, Tarragona, Spain|Pius Hospital de Valls, Valls, Tarragona, Spain|Hospital Maternoinfantil Vall D'Hebron, Barcelona, Spain|Hospital de La Santa Creu I Sant Pau de Barcelona, Barcelona, Spain|Hospital Arnau de Vilanova de Lleida, Lleida, Spain|Iispv-Hospital Joan Xxii de Tarragona, Tarragona, Spain",,"https://ClinicalTrials.gov/show/NCT02034851"
739,"NCT05086900","Developing a PROM for Recurrent Urinary Tract Infection",,"Unknown status","No Results Available","Urologic Diseases|Patient Satisfaction|Pain, Chronic|Sexual Dysfunction","Other: Non-interventional Cross-sectional Patient Reported Outcome Measure Development","Recurrent Urinary Tract Infection Symptom Scale|Recurrent Urinary Tract Infection Impact Questionnaire|Urinary Tract Infection Symptom Assessment|Numerical Pain Rating Scale|Depression|Anxiety|Loneliness|Work Productivity and Impairment Questionnaire|Sexual Distress|Satisfaction with Treatment","University of Reading|Live UTI Free|University of Buckingham","All","18 Years and older   (Adult, Older Adult)",,"145","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","RUTI01-KF-2021","May 1, 2021","December 1, 2021","December 1, 2021","October 21, 2021",,"October 21, 2021","University of Reading, Reading, Berkshire, United Kingdom","""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/00/NCT05086900/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT05086900"
740,"NCT00827970","Randomized Population-Based Study on Chlamydia Trachomatis Screening",,"Completed","No Results Available","Chlamydia Trachomatis|Infertility|Ectopic Pregnancy","Behavioral: Screening for urogenital Chlamydia trachomatis","Long term infertility complications","University of Aarhus|Aarhus County, Denmark|Novo foundation|The Danish Medical Research Council","All","21 Years to 24 Years   (Adult)","Not Applicable","30000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Cesoirs01","October 1997","February 1998","August 2007","January 23, 2009",,"January 23, 2009","Department of Infectious Diseases, Aarhus University Hospital Skejby, Aarhus N, Denmark",,"https://ClinicalTrials.gov/show/NCT00827970"
741,"NCT01030731","Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease",,"Completed","No Results Available","Staphylococcal Skin Infections|Streptococcal Infections","Drug: Ceftobiprole","To characterize the pharmacokinetics of ceftobiprole and its open-ring metabolite in patients undergoing dialysis.|To assess the safety and tolerability of ceftobiprole in patients with ESRD undergoing dialysis and in a control group of healthy volunteers with normal renal function|To compare the pharmacokinetics of ceftobiprole and its open-ring metabolite in patients with ESRD undergoing hemodialysis with a control group of healthy volunteers with normal renal function|To determine the extent of the ceftobiprole dose removed by hemodialysis","Basilea Pharmaceutica|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CR012448","May 2007","August 2007","August 2007","December 11, 2009",,"August 28, 2012",,,"https://ClinicalTrials.gov/show/NCT01030731"
742,"NCT00714792","Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?",,"Completed","Has Results","Overactive Bladder",,"Number of Subjects With Evidence of Bacteria in Urine Sample by Microbiologic Evaluation","University of Rochester","Female","21 Years and older   (Adult, Older Adult)",,"18","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","23123","June 2008","March 2009","March 2009","July 14, 2008","April 28, 2017","April 28, 2017","Urogynecology and Reconstructive Pelvic Surgery Center, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT00714792"
743,"NCT04067557","Diagnosis of Bacterial Vaginosis Comparing Modified Hay/Ison With Molecular Diagnosis",,"Completed","No Results Available","Infection, Bacterial","Diagnostic Test: molecuar test of BV","Diagnosis of bacterial vaginosis comparing modified Hay/Ison with molecular diagnosis","Skaraborg Hospital",,"Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Other|Time Perspective: Prospective","BV","January 1, 2013","May 1, 2013","June 1, 2013","August 26, 2019",,"August 28, 2019","Department of Ob/Gyn, Skaraborgshospital Skövde, Skövde, Sweden",,"https://ClinicalTrials.gov/show/NCT04067557"
744,"NCT00767988","Probiotics in Girls With Spina Bifida",,"Withdrawn","No Results Available","Urinary Tract Infection","Dietary Supplement: Urex-cap-5 (2x10^9 cfu each of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1)|Other: Placebo","The primary outcome will be the rates of bacteriuria among patients in the placebo versus probiotics arms.|The secondary outcomes include rates of fungal vaginitis, mean number of urinary tract infections, mean Bristol STool Scale scores, and number of episodes of stool incontinence.","Baylor College of Medicine|Shriners Hospitals for Children","Female","3 Months to 17 Years   (Child)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","H-23245",,,,"October 7, 2008",,"September 15, 2015","Texas Children's Hospital, Houston, Texas, United States|Shriner's Childrens Hospital Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00767988"
745,"NCT04807894","Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo","PIVoT","Recruiting","No Results Available","Recurrent Urinary Tract Infection|Vaginal Atrophy|Postmenopausal Disorder","Drug: Vaginal Cream with Applicator","To assess whether topical vaginal testosterone cream is more effective than placebo in reducing the incidence of urinary tract infections in postmenopausal women with recurrent urinary tract infections.|To determine whether topically applied vaginal testosterone cream is more effective than placebo cream in changing vaginal flora and pH in postmenopausal women with recurrent urinary tract infections.","Maimonides Medical Center|American Urological Association","Female","60 Years to 90 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","702576","November 1, 2020","August 31, 2024","December 31, 2024","March 19, 2021",,"October 23, 2023","Maimonides Medical Center, Brooklyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT04807894"
746,"NCT05376670","Patient Satisfaction and Long-term Safety of Intravesical Aminoglycoside Instillations in UTI Prevention","INSTILMENT","Completed","No Results Available","Urinary Tract Infections|Recurrent Urinary Tract Infection","Drug: Intravesical aminoglycoside instillations","Treatment satisfaction regarding intravesical aminoglycoside instillations (IAI)|Time to first UTI recurrence after initiation of IAI|Number of UTI recurrences|Number of UTI recurrences that are treated with IAI alone (no systemic antimicrobial therapy)|Number of patients that wish to (dis)continue IAI|Proportion of patients that have a UTI episode caused by the same MDRO uropathogen as before start of IAI","Leiden University Medical Center","All","18 Years and older   (Adult, Older Adult)",,"44","Other","Observational","Observational Model: Other|Time Perspective: Other","nWMODIV2_2022013","April 20, 2022","March 7, 2023","March 7, 2023","May 17, 2022",,"March 8, 2023","Leiden University Medical Center, Leiden, South Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT05376670"
747,"NCT05385536","Evaluating UTI Outcomes in at Risk Populations","At Risk","Recruiting","No Results Available","Urinary Tract Infections|Complicated Urinary Tract Infection",,"UTI-related ED visit and/or hospitalization within 30 days of index visit|Composite of adverse events associated with index UTI event|Recurrent UTI (rUTI) - The proportion of subjects reporting recurrence of symptomatic UTI and receive antimicrobial treatment (re-prescription) within 30 days.|Rate of empirical antibiotic starts for UTI indication|Rate of antimicrobial changes for UTI indication|Recurrent UTI within 1 year of index visit suspected UTI as measured by total antibiotics prescribed.|UTI-related ED visit and/or hospitalization within 1 year of index visit","Pathnostics","All","65 Years and older   (Older Adult)",,"34000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2022-PARS","July 18, 2022","March 29, 2024","March 29, 2024","May 23, 2022",,"February 21, 2024","Dispatch Health, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT05385536"
748,"NCT00076232","A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes",,"Completed","No Results Available","HIV Infections|HIV Seronegativity|Herpes Genitalis","Drug: Acyclovir|Drug: Acyclovir placebo","Serologically confirmed HIV infection|Occurrence and frequency of genital ulcers|Proportion of doses missed by study participants assigned to twice-daily acyclovir and twice-daily placebo","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)","All","Child, Adult, Older Adult","Phase 3","3682","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","HPTN 039|1R01AI052054|5U01AI047981-05|DAIDS-ES ID 10066","April 2005","June 2007","November 2007","January 16, 2004",,"December 30, 2010","San Francisco Department of Public Health, AIDS Office, Research Section, San Francisco, California, United States|New York Blood Center, New York City, New York, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00076232"
749,"NCT02729038","Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function",,"Completed","Has Results","Infections, Bacterial","Drug: Gepotidacin","Area Under the Plasma Concentration Time Curve (AUC) From Hour 0 to Infinity (AUC[0-inf]) of Gepotidacin for Part 1|AUC (0-inf) of Gepotidacin for Part 2|Maximum Observed Plasma Concentration (Cmax) of Gepotidacin for Part 1|Cmax of Gepotidacin for Part 2|Total Amount Excreted in Urine (Ae Total), Part 1|Ae Total of Gepotidacin for Part 2|Percentage of the Given Dose Excreted in Urine (fe%) of Gepotidacin for Part 1|fe% of Gepotidacin for Part 2|Renal Clearance (CLr) of Gepotidacin for Part 1|CLr of Gepotidacin for Part 2|AUC (t0-t1) of Gepotidacin for Part 2|Dialysis Clearance (CLD) of Gepotidacin for Part 2|Fraction (%) of the Dose Removed by Hemodialysis From 0 to 4 Hours After the Start of Hemodialysis (Frem%[0-4]) of Gepotidacin for Part 2|Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Readings for Part 1|Number of Participants With Abnormal 12-lead ECG Readings for Part 2|Change From Baseline in Vitals- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure, Part 1|Change From Baseline in Vitals- SBP and DBP, Part 2|Change From Baseline in Vitals- Pulse Rate, Part 1|Change From Baseline in Vitals- Pulse Rate, Part 2|Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs) for Part 1|Number of Participants With Any AEs and Any SAEs for Part 2|Number of Participants With Clinical Laboratory Test Results for Grade 3 or Higher for Part 1|Number of Participants With Clinical Laboratory Test Results for Grade 3 or Higher for Part 2|Number of Participants With Abnormal Physical Examination Results for Part 1|Number of Participants With Abnormal Physical Examination Results for Part 2|AUC (0-t) of Gepotidacin for Part 1|AUC (0-t) of Gepotidacin for Part 2|Systemic Clearance (CL) of Gepotidacin for Part 1|CL of Gepotidacin for Part 2|Terminal Elimination Rate Constant (lambda_z) of Gepotidacin for Part 1|Lambda_z of Gepotidacin for Part 2|Terminal Phase Half-life (t1/2) of Gepotidacin for Part 1|t1/2 of Gepotidacin for Part 2|Time to Maximum Plasma Concentration (Tmax) of Gepotidacin for Part1|Tmax of Gepotidacin for Part 2|Volume of Distribution at Steady State of Parent Drug (Vss) of Gepotidacin for Part 1|Vss of Gepotidacin for Part 2|Volume of Distribution of the Terminal Phase (Vz) of Gepotidacin for Part 1|Vz of Gepotidacin for Part 2|Cumulative Amount of Drug Excreted in Urine From Time t1 to t2 (Ae[t1-t2]) of Gepotidacin for Part 1, for Normal|Cumulative Amount of Drug Excreted in Urine From Time t1 to t2 (Ae[t1-t2]) of Gepotidacin for Part 1, for Moderate and Severe|Ae(t1-t2) of Gepotidacin for Part 2|Total Amount of Unchanged Amount of Drug Removed by Hemodialysis (Arem) From Time 0 to 1 Hour After the Start of Hemodialysis (Arem[0-1]), Arem (1-2), Arem (2-3), Arem (3-4) for Part 2","GlaxoSmithKline","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","116849","June 29, 2016","June 20, 2017","June 20, 2017","April 6, 2016","November 20, 2018","July 21, 2020","GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Minneapolis, Minnesota, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/38/NCT02729038/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/38/NCT02729038/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02729038"
750,"NCT03931408","Gentamicin Bladder Instillation in Individuals With Spinal Cord Injury Having Chronic Urinary Tract Infections",,"Unknown status","No Results Available","Neurogenic Bladder|Spinal Cord Injuries","Drug: Gentamicin Sulfate|Other: Placebo instillation (saline alone)|Other: No instillation","Incidence of urinary tract infections measured with Urinalysis and Culture|Presence of abnormal ranges of complete cell counts measured by an 8ml blood draw.|Evaluate bladder storage using Urodynamics|Evaluate bladder emptying via measurements of voiding efficiency (%) via Urodynamics assessment or uroflow (if appropriate).|Presence of bladder and kidney anatomical and morphological changes measured with Ultrasound.|Prevalence of different bladder management techniques, such as medication usage, measured by SCI data set Questionnaires.|Rate of urinary tract infections measured by SCI data set Questionnaires.|Presence of abnormal ranges of metabolic markers measured by an 8ml blood draw for a comprehensive metabolic panel.","University of Louisville","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","18.0586","February 19, 2019","January 15, 2023","January 15, 2023","April 30, 2019",,"March 3, 2022","Frazier Rehab, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT03931408"
751,"NCT04209192","Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB)",,"Completed","No Results Available","Urinary Tract Infections|Bladder Cancer|Urologic Surgical Procedures","Drug: Fosfomycin Tromethamine 3G Sachet|Drug: Amikacin","Incidence of urinary tract infection after transurethral resection of bladder|Incidence of asymptomatic bacteriuria after transurethral resection of bladder|Relative risk of asymptomatic bacteriuria after transurethral resection of bladder|Relative Risk of urinary tract infection after transurethral resection of bladder|Relative risk of patients presenting a single bladder tumor|% of patients presenting a single bladder tumor|Relative risk of patients presenting 2 to 7 bladder tumors|% of patients presenting 2 to 7 bladder tumors|Relative risk of patients presenting more than 7 bladder tumors|% of patients presenting more than 7 bladder tumors|Relative risk of bleeding during surgery|Relative risk of patients with I on ASA classification|% of patients with I on ASA classification|Relative risk of patients with II on ASA classification|% of patients with II on ASA classification|Relative risk of patients with III on ASA classification|% of patients with III on ASA classification|Relative risk of patients with IV on ASA classification|% of patients with IV on ASA classification|Relative risk of patients with a urethral catheter removed 24 hours after procedure|% of patients with a urethral catheter removed 24 hours after procedure|Relative risk of muscle invasive bladder cancer|% of patients with muscle invasive bladder cancer|Relative risk of non-muscle invasive bladder cancer|% of patients with non-muscle invasive bladder cancer|Relative risk of chronic cystitis|% of patients with chronic cystitis|Relative risk of number of days of urethral catheter after procedure","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Laboratorios Senosiain, S.A. de C.V.","All","18 Years and older   (Adult, Older Adult)","Phase 2","75","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Prevention","URO-2995-19-20-1","January 1, 2020","April 1, 2023","April 1, 2023","December 24, 2019",,"April 4, 2023","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT04209192"
752,"NCT02729116","Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients",,"Active, not recruiting","No Results Available","Anti-Infective Agents, Urinary|Escherichia Coli Infections|Klebsiella Infections|Kidney Transplantation|Urinary Tract Infections","Drug: Sitafloxacin|Drug: Ertapenem","Number of patients with clinical cure of acute urinary tract infection|Number of patients with micrological cure of acute urinary tract infection","Khon Kaen University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HE581520","July 2016","December 2023","January 2024","April 6, 2016",,"March 8, 2023","Khon Kaen University, Ban Khanaen, Khonkaen, Thailand|Khon Kaen University, Ban Khanaen, Khonkaen, Thailand",,"https://ClinicalTrials.gov/show/NCT02729116"
753,"NCT04235322","Study of 2LHERP® in Genital Herpes Infections","HEARTH-GEN","Terminated","No Results Available","Herpes Simplex, Genital","Drug: 2LHERP®|Drug: Placebo","Evaluation of the efficacy of 2LHERP® on the reduction of the number of recurrent genital herpes infections at 12 months compare to placebo.|Comparison of the efficacy of 2LHERP® versus placebo according to the number of episodes at 6 months.|Comparison of the efficacy of 2LHERP® versus placebo according to - remaining herpes infection recurrence free 6 and 12 months after the treatment initiation|Comparison of the efficacy of 2LHERP® versus placebo according to the time to first episode during the treatment|Comparison of the efficacy of 2LHERP® versus placebo according to the duration of episodes|Comparison of the efficacy of 2LHERP® versus placebo according to the symptomatology during the entire relapse time|Comparison of the efficacy of 2LHERP® versus placebo according to the use of Rescue Medication|Comparison of the efficacy of 2LHERP® versus placebo according to the evaluation of impact on the quality of life|Comparison of the efficacy of 2LHERP® versus placebo according to safety issues","Labo'Life","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","6","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LLB-2019-01","January 25, 2021","April 18, 2023","April 18, 2023","January 21, 2020",,"October 10, 2023","Private practice, Lodelinsart, Charleroi, Belgium|Polyclinique D'Andenne, Andenne, Belgium|Dr MANOUACH Fatiha, Bruxelles, Belgium|Dr VERHEVEN Cécile, Bruxelles, Belgium|Private Practice, Bruxelles, Belgium|CHU Charleroi - Hopital Marie Curie, Charleroi, Belgium|Cabinet privé, Gozée, Belgium|Centre Hospitalier Regional de Huy, Huy, Belgium|Private Practice, Libramont, Belgium|Vivalia - Centre Hospitalier de L'Ardenne - Libramont Chevigny, Libramont, Belgium|Dr PETTEAU Myriam, Nivelles, Belgium|Dr ROULEFF Denis, Noirefontaine, Belgium|Private Practice, Oisquercq, Belgium",,"https://ClinicalTrials.gov/show/NCT04235322"
754,"NCT03672214","Caesarean Delivery With or Without an Indwelling Bladder Catheter",,"Unknown status","No Results Available","Urinary Tract Infections|Cesarean Section; Infection","Procedure: Without placement of indwelling catheter|Procedure: With placement of indwelling catheter","The incidence of urinary tract infection (UTI).|The incidence of UTI later than second day postpartum|Any need for catheterization due to postoperative urinary retention|Postpartum blood loss >1000 mL.|Time to ambulation|Length of hospital stay|Intraoperative laceration of the bladder|The incidence of preoperative bacteria in urineculture","University of Aarhus|Randers Regional Hospital","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1-10-72-113-17_2","June 1, 2019","June 1, 2023","November 1, 2023","September 14, 2018",,"April 25, 2019","The Regional Hospital of Randers, Randers, Denmark",,"https://ClinicalTrials.gov/show/NCT03672214"
755,"NCT06093035","Analysis of Urinary, Vaginal and Intestinal Microbiota in Patients With Neurogenic Bladder",,"Not yet recruiting","No Results Available","Microbial Colonization",,"Characterization of the urinary vaginal and intestinal microbiome","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","Female","18 Years to 50 Years   (Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","5931","November 10, 2023","May 31, 2024","December 31, 2024","October 23, 2023",,"October 23, 2023",,,"https://ClinicalTrials.gov/show/NCT06093035"
756,"NCT01832480","Trichomonas Vaginalis Repeat Infections Among HIV Negative Women",,"Completed","Has Results","Vaginitis Trichomonal or Due to Trichomonas","Drug: MTZ 500 mg twice daily x 7 days|Drug: MTZ 2 g","Number of Subjects That Were Trichomonas Vaginalis (TV) Positive After Treatment With Metronidazole (MTZ)","Tulane University Health Sciences Center|Tulane University","Female","18 Years and older   (Adult, Older Adult)","Phase 3","623","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4042013","October 6, 2014","June 5, 2017","June 5, 2017","April 16, 2013","February 12, 2019","February 12, 2019","Jefferson County Dept of Health/STD Specialty Clinic, Birmingham, Alabama, United States|CrescentCare Health and Wellness Center, New Orleans, Louisiana, United States|Crossroads Clinic, Jackson, Mississippi, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/80/NCT01832480/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01832480"
757,"NCT04385238","Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic",,"Completed","Has Results","COVID-19|Pregnancy Complications|Mental Health Wellness 1|Anxiety|Depression|Ptsd|Coronavirus","Other: This is an online survey with no intervention.","Number of Participants With Symptoms of Post-traumatic Stress Disorder|Number of Participants With Symptoms of Anxiety and Depression","Pregistry|Harvard School of Public Health (HSPH)","Female","18 Years and older   (Adult, Older Adult)",,"6894","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","0002","May 15, 2020","June 20, 2020","June 20, 2020","May 12, 2020","January 7, 2021","January 7, 2021","Pregistry, Los Angeles, California, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/38/NCT04385238/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/38/NCT04385238/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04385238"
758,"NCT05429346","Treating Genital Herpes Infection to Reduce Racial Disparities in the Risk of Severe Maternal Morbidity","PCORISMM","Recruiting","No Results Available","Genital Herpes Simplex|Maternal Morbidity|Racial Disparities",,"Women with SMM","Kaiser Permanente|Patient-Centered Outcomes Research Institute","Female","18 Years to 55 Years   (Adult)",,"339000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1873689","January 8, 2023","January 31, 2025","April 30, 2026","June 23, 2022",,"March 15, 2023","Division of Research, Kaiser Permanente Northern California, Oakland, California, United States",,"https://ClinicalTrials.gov/show/NCT05429346"
759,"NCT02871024","Efficacy of Polymyxin B Hemoperfusion on Severe Sepsis Secondary to Pneumonia or Urinary Tract Infection",,"Terminated","No Results Available","Sepsis","Device: Toraymyxin","Reversal of sepsis-associated circulatory failure|Lactate clearance of survived subjects|Change of endotoxin levels (Endotoxin Activity Assay)|Change of Sequential Organ Failure Assessment (SOFA) score|Vasopressor-free days|28-day all-cause mortality|Catheter-related complications|Thrombocytopenia (<25,000/μL)|Cases with major bleeding needed transfusion with packed red blood cells > 2 units/day","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)","Not Applicable","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201411023RIPB","August 2016","March 26, 2019","March 26, 2019","August 18, 2016",,"March 28, 2019","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02871024"
760,"NCT06243731","A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation",,"Not yet recruiting","No Results Available","Cytomegalovirus (CMV)|Kidney Disease|Kidney Failure","Other: No Intervention","Number of Participants With Adverse Events (AEs)|Number of Participants With Adverse Events of Special Interest (AESIs)","Takeda","All","18 Years and older   (Adult, Older Adult)",,"10","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","TAK-620-4007","May 30, 2025","January 31, 2027","January 31, 2027","February 6, 2024",,"March 8, 2024",,,"https://ClinicalTrials.gov/show/NCT06243731"
761,"NCT02829060","Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2","PNLABXPART2","Recruiting","No Results Available","Nephrolithiasis|Urinary Tract Infection (UTI)|Sepsis","Drug: Nitrofurantoin 100 MG, 7d|Drug: Gentamicin, 5mg/kg|Drug: Ampicillin 2g|Drug: Nitrofurantoin 100 mg, 48 hrs|Drug: Gentamicin, 80 mg, 7d|Drug: Gentamicin, 80 mg, 48hr","postoperative sepsis|rate of nonseptic bacteruria|stone-free rate|Length of hospital stay","University of California, San Diego","All","Child, Adult, Older Adult","Not Applicable","330","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","160158","January 2016","January 2025","January 2025","July 12, 2016",,"March 24, 2020","University of California San Diego, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT02829060"
762,"NCT03914144","Postnatal Prevalence of Bacteriuria in Women With Catheter Versus no Catheter in Labour: a Prospective Cohort Study",,"Unknown status","No Results Available","Urinary Tract Infection in Pregnancy|Urinary Tract Infection Following Delivery|Catheter Infection","Other: Catheter insertion","Postpartum Urinary Tract Infection|Postpartum asymptomatic bacteriuria","Gloucestershire Hospitals NHS Foundation Trust","Female","Child, Adult, Older Adult",,"638","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","18/105/GHT","May 1, 2019","August 1, 2019","August 1, 2019","April 16, 2019",,"April 16, 2019",,,"https://ClinicalTrials.gov/show/NCT03914144"
763,"NCT00160966","Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy",,"Completed","No Results Available","Polyomavirus Infections","Drug: Ciclosporin and Mycophenolate-mofetil|Drug: Tacrolimus and Mycophenolate-mofetil|Drug: Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus","incidence of polyomavirus associated transplant nephropathy (PVN)|incidence of polyoma viremia|urine polyomavirus concentration within the first two years post-transplant|patients' and grafts' survival|incidence of acute rejections|transplant function 1 and 2 years post-transplant|comparison of urine cytology and polymerase chain reaction (PCR) quantitative data regarding diagnosis of PVN|predictive value of immune parameters prognostically relevant for acute or chronic rejection|side effects of immunosuppressive drugs","University of Giessen|Heidelberg University|Hoffmann-La Roche|Astellas Pharma Inc|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 4","108","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NTx-PV-002","September 2004","March 2010","March 2010","September 12, 2005",,"March 28, 2017","Department of Internal Medicine, University of Giessen, Giessen, Germany",,"https://ClinicalTrials.gov/show/NCT00160966"
764,"NCT06261840","Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole",,"Not yet recruiting","No Results Available","Trichomonas Vaginitis","Drug: Metronidazole 500 mg|Drug: Secnidazole 2000 MG","Treatment, as Measured by the Number of Participants that are Cured of Trichomonas Vaginalis","Tulane University|University of Alabama at Birmingham|Louisiana State University Health Sciences Center in New Orleans","All","18 Years and older   (Adult, Older Adult)","Phase 4","1200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2024-101","July 1, 2024","May 1, 2029","July 31, 2029","February 15, 2024",,"February 15, 2024",,,"https://ClinicalTrials.gov/show/NCT06261840"
765,"NCT01249443","Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection",,"Terminated","No Results Available","HIV Infection|Recurrent Anal Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Anal Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Unspecified Adult Solid Tumor, Protocol Specific","Drug: vorinostat|Other: diagnostic laboratory biomarker analysis|Other: pharmacological study|Drug: carboplatin|Drug: paclitaxel","Incidence of adverse events during paclitaxel and carboplatin treatment according to dose-limiting toxicities (DLTs), graded using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)|Response rates in patients with lung, head and neck, and esophageal cancers assessed by Response Evaluation Criteria for Solid Tumors (RECIST) 1.1|Effects of therapy on HIV viral load and CD4 cell count","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC|University of Arkansas","All","18 Years and older   (Adult, Older Adult)","Phase 1","17","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMC-078|NCI-2011-02511|CDR0000689900|U01CA121947","November 2013","May 2016","December 2017","November 29, 2010",,"July 29, 2020","UC San Diego Moores Cancer Center, La Jolla, California, United States|UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Boston Medical Center, Boston, Massachusetts, United States|Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States|Montefiore Medical Center, Bronx, New York, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01249443"
766,"NCT01928433","Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis",,"Completed","Has Results","Urinary Tract Infections|Acute Pyelonephritis","Drug: Finafloxacin 800 mg i.v. once daily|Drug: Finafloxacin placebo i.v. once daily|Drug: Finafloxacin 800 mg tablets once daily|Drug: Finafloxacin placebo tablets once daily|Drug: Ciprofloxacin 400 mg i.v. twice daily|Drug: Ciprofloxacin placebo i.v. twice daily|Drug: Ciprofloxacin 500 mg oral twice daily|Drug: Ciprofloxacin placebo oral twice daily","Number of Participants With Clinical and Microbiological Response|Number of Participants With Clinical and Microbiological Response at the On Therapy (OT) Visit (Day 3).|Number of Participants With Clinical and Microbiological Response at the End of Therapy (EoT) Visit (Day 10).|Number of Participants With Clinical and Microbiological Response at the End of Study (EoS) Visit (Day 24).|The Safety and Tolerability of Multiple Doses of Finafloxacin: Number of Treatment-emergent Adverse Events|The Safety and Tolerability of Multiple Doses of Finafloxacin: Number of Participants Who Discontinued Due to TEAE","MerLion Pharmaceuticals GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","225","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FINA-007|2011-006041-14","December 2012","June 2014","October 2015","August 26, 2013","June 20, 2017","June 20, 2017","Universitätsklinikum Giessen, Klinik für Urologie, Kinderurologie und Andrologie, Giessen, Germany",,"https://ClinicalTrials.gov/show/NCT01928433"
767,"NCT02364284","Reporting Patterns and Results of Initial Antibiotic Treatment in Patients With cUTI, cIAI,NP Including VAP","RECOMMEND","Completed","No Results Available","Urinary Tract Infection (cUTI)|Intra-abdominal Infection (cIAI) and|Nosocomial Pneumonia (NP)",,"To describe antibiotic management and document treatment outcome among hospitalized patients with hospital acquired or healthcare associated cUTI, cIAI and NP|To identify potential risk factors related to outcomes of initial antibiotic treatment of hospitalized patients with hospital acquired or healthcare associated cUTI, cIAI and NP|To describe healthcare utilization and costs associated with hospital acquired or healthcare associated cUTI, cIAI and NP initial antibiotic treatment outcome","Pfizer","All","18 Years and older   (Adult, Older Adult)",,"1322","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","D4280R00005","February 2015","February 2016","February 2016","February 18, 2015",,"September 5, 2017","Research Site, Belo Horizonte, Brazil|Research Site, Campinas, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Argenteuil, France|Research Site, Bordeaux Cedex, France|Research Site, Creteil cedex, France|Research Site, Limoges cedex, France|Research Site, Lyon Cedex 03, France|Research Site, Nantes Cedex 1, France|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Patras, Greece|Research Site, Thessaloniki, Greece|Research Site, Bologna, Italy|Research Site, Brescia, Italy|Research Site, Monza, Italy|Research Site, Roma, Italy|Research Site, Vicenza, Italy|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Sestroretsk, St. Petersburg, Russian Federation|Research Site, Badalona, Spain|Research Site, Barcelona, Spain|Research Site, Oviedo, Spain|Research Site, Sevilla, Spain|Research Site, Terrassa, Spain",,"https://ClinicalTrials.gov/show/NCT02364284"
768,"NCT01874158","DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women",,"Completed","No Results Available","Trichomonas Vaginitis",,"TV negative by PCR, post treatment","Tulane University Health Sciences Center|Louisiana State University Health Sciences Center in New Orleans|Tulane University","Female","18 Years and older   (Adult, Older Adult)",,"99","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","8115","November 2012","April 2014","April 2014","June 10, 2013",,"December 19, 2016","Delgado Personal Health Center, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT01874158"
769,"NCT02741323","Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients",,"Completed","Has Results","HIV Infections|Kidney Diseases","Drug: Maraviroc|Drug: Placebo","Mean Glomerular Filtration Rate by Iohexol Clearance at Week 52|Cumulative Incidence of Graft Loss, Toxicities ≥ Grade 3 Per the DAIDS Toxicity Table and/or Permanent Treatment Discontinuation|Mean CD45 Gene Expression Count (PTPRC)|Mean CD45 Quantitative Immunohistochemistry (IHC)|Tissue Common Rejection Module (tCRM) Score Using the 11-gene tCRM Module on FFPE Biopsy Shaves|Urine Common Rejection Module (uCRM) Score Using the 11-gene uCRM Module on Urine Cell Pellets|Proportion of Participants With Estimated Glomerular Filtration Rate (eGFR) Less Than 60 mL/Min/1.73 m² at Week 52|Proportion of Participants With Defined CKD Stage 4 or 5 at Year 1|Mean eGFR at Week 52 Based on CKD-EPI Creatinine Equation|The Slope of eGFR Over Time in Year 1|HIV DNA in Peripheral Blood CD4+ T Cells at Week 52|HIV RNA in Peripheral Blood CD4+ T Cells at Week 52.|Plasma HIV RNA Levels (Single Copy Assay) at Week 52|Cumulative Incidence/Proportion of Biopsy Proven Acute Rejection Within 1 Year Post Transplant|Cumulative Incidence/Proportion of Acute Cellular Rejection Grade Equal to or Greater Than 1A During the Entire Study Follow-up|Incidence/Proportion of Antibody Mediated Rejection|Proportion of Participants With de Novo Anti-donor Human Leukocyte Antigen (HLA) Antibodies|Incidence/Proportion of Participants With HIV Infection in the Renal Allograft|Incidence of Death at Year 1|Incidence of Graft Loss in Year 1|Incidence of All Adverse Events (AEs) Greater Than or Equal to Grade 3 at Year 1|Incidence of Serious Adverse Events (SAEs) Greater Than or Equal to Grade 3 Within Year 1|Incidence of Opportunistic Infections or Neoplasms Within Year 1|Incidence of Non-opportunistic Infections Requiring Hospitalization Within Year 1|Calcineurin Inhibitor (Tacrolimus) Trough Levels for Participants on Maraviroc Versus Placebo|Calcineurin Inhibitor (Tacrolimus) AUC for Participants on Maraviroc Versus Placebo|AUC of CCR5 Blockade (Maraviroc)|Trough Levels of CCR5 Blockade (Maraviroc)","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 2","97","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HIVTR-CCR5|20730","January 1, 2017","May 10, 2022","May 10, 2022","April 18, 2016","August 21, 2023","August 21, 2023","UAB HIVTR-CCR5 Non-Network CRS, Birmingham, Alabama, United States|UCLA HIVTR-CCR5 Non-Network CRS, Los Angeles, California, United States|UCSF HIVTR-CCR5 Non-network CRS, San Francisco, California, United States|Georgetown HIVTR-CCR5 Non-Network CRS, Washington, District of Columbia, United States|Emory HIVTR-CCR5 Non-Network CRS, Atlanta, Georgia, United States|Northwestern HIVTR-CCR5 Non-Network CRS, Chicago, Illinois, United States|Univ. of Maryland HIVTR-CCR5 Non-Network CRS, Baltimore, Maryland, United States|JHU HIVTR-CCR5 Non-Network CRS, Baltimore, Maryland, United States|Mt. Sinai Med. Ctr. HIVTR-CCR5 Non-Network CRS, New York, New York, United States|Univ. of Penn HIVTR-CCR5 Non-network CRS, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/23/NCT02741323/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/23/NCT02741323/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02741323"
770,"NCT05254808","EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care","EXFOCY","Terminated","No Results Available","Urinary Tract Infections","Drug: Fosfomycin|Drug: Nitrofurantoin","Time to recovery|Clinical failure|Microbiological failure|Development of pyelonephritis or urosepsis|Relapse|Reinfection|All-cause mortality|All-cause hospital admission|Adverse events symptoms|Incidence and nature of severe adverse events|Therapy adherence|Satisfaction with treatment|Absenteeism education or work","MJM Bonten|ZonMw: The Netherlands Organisation for Health Research and Development|Saltro|UMC Utrecht","Female","18 Years and older   (Adult, Older Adult)","Phase 3","13","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL75841.041.20","September 6, 2021","February 14, 2022","February 14, 2022","February 24, 2022",,"March 15, 2022","Medisch Centrum Heuvelrug, Doorn, Utrecht, Netherlands|Huisartsenpraktijk Mariahoek, Utrecht, Netherlands|Huisartsenpraktijk Binnenstad, Utrecht, Netherlands|UMC Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT05254808"
771,"NCT00483158","First Time in Man Study of Finafloxacin Hydrochloride",,"Completed","No Results Available","Helicobacter Infections|Urinary Tract Infection","Drug: Finafloxacin hydrochloride","To evaluate the safety and tolerability of single and multiple oral doses of Finafloxacin HCl by assessing adverse events, physical examinations, clinical chemistry examination, hematology, ECG and urinalysis.|To determine the pharmacokinetic profile of single and multiple oral doses of Finafloxacin HCl in healthy subjects|To determine the bactericidal activity of urine obtained from healthy subjects after administration of Finafloxacin HCl|To explore the activity of multiple oral doses of Finafloxacin HCl against Helicobacter pylori using the effect on the urease breath test in healthy carriers as a model","MerLion Pharmaceuticals GmbH","All","18 Years to 55 Years   (Adult)","Phase 1","95","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FINA-001","August 2007","May 2008","May 2008","June 6, 2007",,"July 29, 2008","Swiss Pharma Contract Ltd, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT00483158"
772,"NCT04763382","The Effect of Nursing Interventions for Clean Intermittent Catheterization Caregivers and Child",,"Unknown status","No Results Available","Intermittent Urethral Catheterization|Spinal Dysraphism|Urinary Tract Infections","Other: experimental group: Training of caregivers|Other: Control gruop","knowledge / skill level of caregivers.|The coping / adaptation scala of the caregivers.|Anxiety Level of caregivers|Urinary infection in the child.|Roy adaptatıon model question form","Karadeniz Technical University","All","27 Days to 17 Years   (Child)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Nurse_clean intermittent cat.","March 23, 2020","June 20, 2020","May 25, 2021","February 21, 2021",,"February 21, 2021","Karadeniz Techical University Health Faculty of Health Sciences, Trabzon, Health Faculty Of Health Sciences, Turkey|Karadeniz Technıcal University, Trabzon, Health Faculty Of Health Sciences, Turkey",,"https://ClinicalTrials.gov/show/NCT04763382"
773,"NCT04719754","Epidemiology of Abnormal Vaginal Discharge During Pregnancy",,"Unknown status","No Results Available","Vaginal Infection","Diagnostic Test: Vaginal swab","The prevalence of microorganism in the vaginal discharge during pregnancy.","Assiut University","Female","19 Years to 40 Years   (Adult)",,"164","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","VD-WHH","June 1, 2021","October 2022","December 2022","January 22, 2021",,"January 22, 2021","Woman's Health Hospital - Assiut university, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT04719754"
774,"NCT00583648","Does Implementing a Urinanylsis Protocol Based on Symptoms Decrease Length of Stay in the Emergency Department?",,"Withdrawn","No Results Available","Urinary Tract Infections","Other: Urinanlysis","Length of Stay in the Emergency Department|Physician decision making on ordering urinalysis based off of chief complaints","University of California, Los Angeles","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","UCLA-urineprotocol|UCLA-12345","February 2008",,"February 2009","December 31, 2007",,"May 13, 2016","University of California, Los Angeles Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00583648"
775,"NCT03379389","Clinical Assessment of Urinary Antiseptics Methenamine and Methylthioninium in Recurrent Cystitis",,"Completed","No Results Available","Urinary Tract Infections","Drug: Methenamine + Methylthioninium|Drug: Methenamine + Methylthioninium + Acriflavine + Atropa belladona|Drug: Antibiotics","Urination regularity|Total UTISA score|UTISA question # 9|Adverse events|Problems with Urination at Visit 2|Problems with Urination at Visit 3|Pain Associated with UTI at Visit 2|Pain Associated with UTI at Visit 3|Blood in Urine at Visit 2|Blood in Urine at Visit 3","Fundação Educacional Serra dos Órgãos","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","284","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AUCR-01-05-17","March 31, 2018","May 1, 2019","June 1, 2021","December 20, 2017",,"December 14, 2021","Centro Universitário Serra dos Órgãos - UNIFESO, Teresópolis, RJ, Brazil",,"https://ClinicalTrials.gov/show/NCT03379389"
776,"NCT01561248","Study of Repetitive Intestinal Lavage in Patients With EHEC Associated Hemorrhagic Colitis","EHEC-PEG","Completed","No Results Available","Hemolytic Uremic Syndrome|Hemorrhagic Colitis|Intestinal Infectious Disease|Intestinal Infection Due to E. Coli","Drug: polyethylene glycol solution for daily bowel lavage.","Thrombocytopenia (Defined as platlet count below 100.000/microliter)|Duration of hospitalisation","Universitätsklinikum Hamburg-Eppendorf","All","Child, Adult, Older Adult","Not Applicable","33","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","EHEC-2011-PEG","May 2011","June 2011","February 2012","March 22, 2012",,"March 22, 2012","1Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT01561248"
777,"NCT00122525","Effect of Male Circumcision on HIV Incidence (ANRS 1265)",,"Terminated","No Results Available","HIV Infections|Herpes Genitalis|Venereal Diseases","Procedure: Male Circumcision","Measure the protective effect of medicalized male circumcision on HIV infection|Measure the protective effect on infections by the genital herpes agent Herpes simplex virus type 2 (HSV-2)|Measure the protective effect on the incidence of genital ulcer disease","French National Agency for Research on AIDS and Viral Hepatitis","Male","18 Years to 24 Years   (Adult)","Phase 3","3274","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ANRS 1265","July 2002",,"July 2005","July 22, 2005",,"April 30, 2009","MC Centre, Orange Farm, Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT00122525"
778,"NCT00365716","Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)",,"Completed","Has Results","Papillomavirus Infections|Genital Diseases, Female","Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20|Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|Biological: Placebo (mcg) (Aluminum Adjuvant)225|Biological: Placebo (mcg) (Aluminum Adjuvant) 450","Number of Subjects With Injection Site Adverse Experiences|Incidence of HPV 6-, 11-, 16- or 18-related Persistent Infection or Disease (Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, Adenocarcinoma in Situ, Cervical Cancer, and Genital Warts)","Merck Sharp & Dohme LLC","Female","16 Years to 23 Years   (Child, Adult)","Phase 2","1158","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","V501-007|2006_516","May 2000","May 2004","September 2009","August 17, 2006","August 3, 2010","October 7, 2015",,,"https://ClinicalTrials.gov/show/NCT00365716"
779,"NCT05860231","Comparative Study Between Foley and T-Control® Catheter in Patients With Long-term Catheterization",,"Recruiting","No Results Available","Catheter-Associated Urinary Tract Infection|Catheter Related Complication|Quality of Life","Device: Foley catheter|Device: T-Control catheter","Patient experience for both types of catheterization|Self-perceived general health status using 5 dimensions of 5 levels each, and a VAS ranging from 0 to 100.|Quantitively assessed self-perceived catheter-related experience|Rate and magnitude of infections (symptomatic and asymptomatic)|Catheter tip-positive culture rate|Number of adverse events related to catheterization|Indication of antibiotic treatments|Total costs of each type of catheterization (cost-effectiveness) per quality-adjusted life year (QALY) of catheterized participants|The workload perceived by health professionals participating in the study.|Opinion of healthcare professionals of the devices used during the study","Rethink Medical SL","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","RM-TCONTROL-2022-02","September 1, 2023","November 1, 2024","December 1, 2024","May 16, 2023",,"April 4, 2024","Hospital Universitario de Canarias, Santa Cruz De Tenerife, Tenerife, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT05860231"
780,"NCT03945110","Intravesical Glycosaminoglycan Instillation and Urinary Tract Infection in Acute Spinal Cord Injury",,"Completed","No Results Available","Spinal Cord Injuries","Device: iAluRil® intravesical instillations","Proportion of eligible traumatic SCI patients who start iAluRil within 10 days post injury|Proportion of eligible traumatic SCI patients administered iAluRil within 10 days of SCI who completed seven iAluRil instillations as per protocol over 12 weeks|Median time to first symptomatic UTI|Incidence of symptomatic UTI/100 patient days|Incidence of other urological complications/100 patient days|Length of hospital stay|Bladder-related quality of life - bladder management difficulties|Bladder-related quality of life - bladder complications|Incidence of Adverse Events","The University of Western Australia|Royal Perth Hospital|Fiona Stanley Hospital|Perth Urology Clinic","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","RA/4/20/5351","September 18, 2019","September 22, 2020","March 18, 2021","May 10, 2019",,"May 3, 2021","Royal Perth Hospital, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT03945110"
781,"NCT03898167","Prospective Evaluation of Self-Testing to Increase Screening","PRESTIS","Enrolling by invitation","No Results Available","Cervical Cancer|Human Papillomavirus Infection","Behavioral: Telephone Recall|Behavioral: Mailed HPV Self-Sampling Kit|Behavioral: Patient Navigation","Primary screening participation|Screening tests results|completion of clinical follow-up among women with an abnormal screening test result","Baylor College of Medicine|National Institute on Minority Health and Health Disparities (NIMHD)","Female","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","2268","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening","H-44944|R01MD013715","February 13, 2020","December 31, 2023","May 2024","April 1, 2019",,"June 8, 2023","Harris Health System, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03898167"
782,"NCT00316706","Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine",,"Completed","Has Results","Cervical Intraepithelial Neoplasia|Papillomavirus Infection","Biological: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)|Biological: Havrix™","Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies|Titers of Anti-3-O-desacyl-4'-Monophosphoryl Lipid A (Anti-MPL) Antibodies During the Initial 2 Years Follow-up|Titers of Anti-3-O-desacyl 4'-Monophosphoryl Lipid A (Anti-MPL) Antibodies During the Last 2 Years Follow-up|Number of Subjects Reporting Pregnancies, Serious Adverse Events (SAEs), New Onset Chronic Diseases (NOCDs), and Conditions Prompting Emergency Room (ER) Visits or Physician Visits That Are Not Related to Common Diseases During the First 2 Years Follow-up|Number of Subjects Reporting Pregnancies, Serious Adverse Events (SAEs), New Onset Chronic Diseases (NOCDs), and Conditions Prompting Emergency Room During the Last 2 Years Follow-up","GlaxoSmithKline","Female","10 Years to 14 Years   (Child)","Phase 3","1245","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","104896 (month 18 FU)|104902|104904|104918","October 2005","January 2009","January 2009","April 21, 2006","March 1, 2010","September 18, 2012","GSK Investigational Site, Bogota, Colombia|GSK Investigational Site, Bogota, Colombia|GSK Investigational Site, Deggingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ettenheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Kehl, Baden-Wuerttemberg, Germany|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tauberbischofsheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Weilheim, Bayern, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Buetzow, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Rostock, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Wolfenbuettel, Niedersachsen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Willich, Nordrhein-Westfalen, Germany|GSK Investigational Site, Trier, Rheinland-Pfalz, Germany|GSK Investigational Site, Brunsbuettel, Schleswig-Holstein, Germany|GSK Investigational Site, Flensburg, Schleswig-Holstein, Germany|GSK Investigational Site, Harrislee, Schleswig-Holstein, Germany|GSK Investigational Site, Husum, Schleswig-Holstein, Germany|GSK Investigational Site, Niebuell, Schleswig-Holstein, Germany|GSK Investigational Site, Weimar, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Comayaguela, Honduras|GSK Investigational Site, La Chorrera, Panamá, Panama|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Tao Yuan County, Taiwan",,"https://ClinicalTrials.gov/show/NCT00316706"
783,"NCT01772875","Bladder Lavage as Decontamination Method for Asymptomatic Bacteriuria With Uropathogens in Catheterized Patients",,"Withdrawn","No Results Available","Catheter Related Infections","Procedure: bladder lavage","urinary culture|pyuria","National Multiple Sclerosis Center|Universitaire Ziekenhuizen KU Leuven","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","BLLAV-1","January 2013","December 2013","January 20, 2014","January 21, 2013",,"August 5, 2020","National MS Center, Steenokkerzeel, Vlaams-Brabant, Belgium",,"https://ClinicalTrials.gov/show/NCT01772875"
784,"NCT00089518","Optimal Treatment for Kidney Disease in HIV Infected Adults",,"Withdrawn","No Results Available","HIV Infections|Kidney Disease","Drug: Valsartan",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","ACTG A5179",,,,"August 6, 2004",,"March 9, 2015","Indiana University Hospital, Indianapolis, Indiana, United States|Methodist Hospital of Indiana, Indianapolis, Indiana, United States|Wishard Hospital, Indianapolis, Indiana, United States|Washington University (St. Louis), St. Louis, Missouri, United States|NYU/Bellevue, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Stanley Street Treatment and Resource, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT00089518"
785,"NCT00005663","A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients",,"Unknown status","No Results Available","Herpes Simplex|HIV Infections|Herpes Genitalis","Drug: Valacyclovir hydrochloride",,"Glaxo Wellcome|NIH AIDS Clinical Trials Information Service","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Masking: Double|Primary Purpose: Treatment","104C|HS230018","June 1999",,,"August 31, 2001",,"June 24, 2005","East Bay AIDS Ctr, Berkeley, California, United States|Pacific Oaks Research, Beverly Hills, California, United States|Kraus Med Partners, Los Angeles, California, United States|ViRx Inc, San Francisco, California, United States|IDC Research Initiative, Altamonte Springs, Florida, United States|Healthnet Institute, Fort Lauderdale, Florida, United States|Univ of Miami School of Medicine, Miami, Florida, United States|Treasure Coast Infectious Disease Consultants, Vero Beach, Florida, United States|Palm Beach Research Ctr, West Palm Beach, Florida, United States|Indiana Univ School of Medicine / Dept of Infect Dis, Indianapolis, Indiana, United States|Univ of Minnesota, Minneapolis, Minnesota, United States|Advanced Biomedical Research Inc, Hackensack, New Jersey, United States|Nalle Clinic / Clinical Research Dept, Charlotte, North Carolina, United States|Wake County Dept of Health, Raleigh, North Carolina, United States|Westover Heights Clinic, Portland, Oregon, United States|Philadelphia FIGHT, Philadelphia, Pennsylvania, United States|Dr Alvan Fisher, Providence, Rhode Island, United States|Baylor College of Medicine / Dept of Medicine, Houston, Texas, United States|Richmond AIDS Consortium, Richmond, Virginia, United States|Univ of Washington Virology Research Clinic, Seattle, Washington, United States|Dr Barbara Romanowski, Edmonton, Alberta, Canada|Sunnybrook Health Science Ctr, Toronto, Ontario, Canada|Clinique Medicale L'Actuele, Montreal, Quebec, Canada|Centre De Recherche En Infectiologie, Ste Foy, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00005663"
786,"NCT01515605","Molecular Biological and Moleculargenetic Monitoring of Therapy After Kidney Transplantation","MoMoTxRes","Recruiting","No Results Available","Transplantation Infection|Kidney Diseases",,"Cellular transcripts|Plasma proteome|Urine proteome|Association of kidney function, glomerular filtration rate, infections, therapy","Odense University Hospital","All","18 Years and older   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MoMoTxRes","January 1, 2011","March 31, 2033","March 31, 2033","January 24, 2012",,"March 28, 2023","Odense University Hospital, Odense, DK, Denmark",,"https://ClinicalTrials.gov/show/NCT01515605"
787,"NCT03818321","Urinary Track Infection Prevention After Urogynecological Surgery",,"Completed","Has Results","Urinary Tract Infections|Urinary Retention Postoperative|Pelvic Organ Prolapse","Drug: Methenamine Hippurate 1 g tablet|Drug: Placebo tablet","Incidence of Urinary Track Infection (UTI)","TriHealth Inc.","Female","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","185","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","18-115","June 17, 2019","July 1, 2021","July 1, 2021","January 28, 2019","November 14, 2022","November 14, 2022","Cincinnati Urogynecology Associates, Cincinnati, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/21/NCT03818321/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03818321"
788,"NCT00976963","Single Dose Monurol for Treatment of Acute Cystitis",,"Completed","Has Results","Urinary Tract Infection","Drug: TMP/SMX|Drug: Fosfomycin","Number of Participants Who Were Cured","University of Washington","Female","18 Years to 45 Years   (Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","34776","September 17, 2009","December 27, 2016","December 27, 2016","September 15, 2009","June 5, 2023","June 5, 2023","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00976963"
789,"NCT03786900","Fecal Microbiota Transplantation (FMT): PRIM-DJ2727",,"Available","No Results Available","Recurrent Clostridium Difficile Infection|Multidrug-resistant Klebsiella Pneumoniae Urinary Tract Infection","Biological: Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727",,"Herbert DuPont, MD|The University of Texas Health Science Center, Houston",,"Child, Adult, Older Adult",,,"Other","Expanded Access:Individual Patients",,"HSC-SPH-15-0991",,,,"December 26, 2018",,"May 24, 2023",,,"https://ClinicalTrials.gov/show/NCT03786900"
790,"NCT00716183","Use of Probiotic Lactobacilli for the Treatment of Lactational Mastitis",,"Completed","No Results Available","Mastitis","Biological: Lactobacillus salivarius HN6|Biological: Lactobacillus reuteri CR20|Biological: Lactobacillus fermentum LC40|Drug: Beta-lactam antibiotic","Staphylococcal and/or streptococcal count in milk|Assessment of local and systemic symptoms associated to mastitis","Universidad Complutense de Madrid","Female","19 Years to 38 Years   (Adult)","Phase 2|Phase 3","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Promast08","July 2008","July 2008","May 2009","July 16, 2008",,"May 25, 2009","Dpt. Nutricion, Bromatologia y Tecnologia de los Alimentos, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00716183"
791,"NCT00598403","Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis",,"Completed","No Results Available","Urinary Tract Infections","Drug: cefditoren pivoxil|Drug: Ciprofloxacin","Microbiological efficacy|Clinical efficacy","Tedec-Meiji Farma, S.A.","Female","18 Years and older   (Adult, Older Adult)","Phase 3","611","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TM-ME1207/311|2007-001486-15","November 2007","December 2009","June 2010","January 21, 2008",,"June 29, 2010","General Hospital of Chest Disease of Athens, Athens, Greece|General Hospital of Thessaloniki, Thessaloniki, Greece|CS Rincón de Loix, Benidorm, Alicante, Spain|CAP Cornella, Cornella de Llobregat, Barcelona, Spain|CAP 17 setembre, El Prat de Llobregat, Barcelona, Spain|CAP Bartomeu Fabres Anglada, Gava, Barcelona, Spain|CAP Amadeu Torner, Hospitalet de Llobregat, Barcelona, Spain|CAP Florida Nord, Hospitalet de Llobregat, Barcelona, Spain|CAP Dr. Vicens Papaceit, La Roca del Valles, Barcelona, Spain|CAP Les Bases-Manresa 3, Manresa, Barcelona, Spain|CAP La Riera, Mataro, Barcelona, Spain|CAP El Maresme, Mataro, Barcelona, Spain|CAP Navas-Balsareny, Navas, Barcelona, Spain|CAP Remei, Vic, Barcelona, Spain|CS San Telmo, Jerez de la frontera, Cadiz, Spain|CS Cabra, Cabra, Cordoba, Spain|CS Lucena, Lucena, Cordoba, Spain|CS Rute, Rute, Cordoba, Spain|CS Billabona, Billabona, Guipuzcoa, Spain|CS Legazpi, Legazpi, Guipuzcoa, Spain|CS Monzón Urbano, Monzon, Huesca, Spain|CS Basurto, Bilbao, Vizcaya, Spain|CS Cabo Huertas, Alicante, Spain|CAP El Clot, Barcelona, Spain|Fundacion Puigvert, Barcelona, Spain|CS Sagasta Ruiseñores, Zaragoza, Spain|CS Torrero La Paz, Zaragoza, Spain|CS Torre Ramona, Zaragoza, Spain|CS Arrabal, Zaragoza, Spain|CS Bombarda, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT00598403"
792,"NCT05826925","Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy",,"Not yet recruiting","No Results Available","Hypertension, Pregnancy Induced|Hypertension Complicating Pregnancy|Preeclampsia|Cardiovascular Diseases|Patient Engagement","Other: Decision aid","Decisional conflict","University of Utah|National Heart, Lung, and Blood Institute (NHLBI)","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","00151518|K23HL159316","March 2025","August 2027","August 2027","April 24, 2023",,"April 24, 2023","University of Utah Hospital, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT05826925"
793,"NCT00000685","A Study of Zidovudine in HIV-Infected Patients With Kidney Problems",,"Withdrawn","No Results Available","HIV Infections|Kidney Disease","Drug: Zidovudine",,"National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","ACTG 088|NSC 602670|11063",,,"February 1990","August 31, 2001",,"November 2, 2021","Univ of North Carolina, Chapel Hill, North Carolina, United States|Univ of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00000685"
794,"NCT00391651","Short Course Nitrofurantoin for Acute Cystitis",,"Completed","No Results Available","Urinary Tract Infection","Drug: Nitrofurantoin 100mg twice daily x 5 days|Drug: TMP/SMX DS twice daily x 3 days","Microbiological Cure","University of Washington|Procter and Gamble","Female","18 Years to 45 Years   (Adult)","Phase 2","338","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20580-A|01-1002-A 07","January 2002","July 2005","July 2005","October 24, 2006",,"June 5, 2014","University of WA, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00391651"
795,"NCT04032574","Efficacy and Tolerability of a Phytotherapy Combination (Aqualibra) in Patients With Uncomplicated Cystitis","AquUTI","Completed","No Results Available","Urinary Tract Infection Lower Acute","Combination Product: Herbal Medicinal Product|Other: Placebo","microbiologic response|Leukocyturia","Medice Arzneimittel Pütter GmbH & Co KG|Dr. Wiedey GmbH - Institut Für Klinische Forschung|Medidata Dr. Möller GmbH","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","200","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","97.019/91","October 8, 1991","March 27, 1992","March 27, 1992","July 25, 2019",,"July 26, 2019",,,"https://ClinicalTrials.gov/show/NCT04032574"
796,"NCT00194532","Cefpodoxime vs Ciprofloxacin for Acute Cystitis",,"Completed","Has Results","Urinary Tract Infection","Drug: Cefpodoxime|Drug: Ciprofloxacin","Clinical Cure|Microbiologic Cure","University of Washington","Female","18 Years to 45 Years   (Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","27085-D","June 2005","February 2009","February 2009","September 19, 2005","April 28, 2011","June 10, 2014","University of Miami Miller School of Medicine, Miami, Florida, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00194532"
797,"NCT05018546","Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery","RIRS","Completed","No Results Available","Urinary Tract Infections|Ureteric Injury|Sepsis","Procedure: Irrigation force","INFECTION|stone clearance","Tribhuvan University Teaching Hospital, Institute Of Medicine.|Nepal Health Research Council","All","18 Years and older   (Adult, Older Adult)","Not Applicable","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","21/(6-11)/E2/077/078","September 24, 2020","September 24, 2021","December 24, 2021","August 24, 2021",,"June 2, 2022","Tribhuvan University Teaching Hospital, Kathmandu, Bagmati, Nepal",,"https://ClinicalTrials.gov/show/NCT05018546"
798,"NCT05022212","Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition",,"Completed","No Results Available","Bacterial Vaginosis|HIV Infections","Drug: LACTIN-V|Drug: Placebo","Determine the effect of repeat dosing of LACTIN-V (2 x 109 cfu/dose) on genital tract inflammation in young South African women at risk of HIV.|Determine the ability of LACTIN-V to promote a Lactobacillus-dominant vaginal microbiota in young South African women at risk of HIV.|Determine the ability of LACTIN-V for vaginal colonization of L. crispatus CTV-05 in young South African women at risk of HIV.|Determine the ability of LACTIN-V for preventing bacterial vaginosis in young South African women at risk of HIV.|Determine the safety of LACTIN-V in a population of young South African women at risk for HIV.|Determine the acceptability of LACTIN-V in a population of young South African women at risk for HIV.","Osel, Inc.|University of California, San Francisco|University of KwaZulu|Harvard University|Aurum Institute|Health Systems Trust","Female","18 Years to 23 Years   (Adult)","Phase 2","45","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","LV-007","May 10, 2021","March 31, 2023","March 31, 2023","August 26, 2021",,"February 26, 2024","FRESH (Females Rising through Education, Support and Health) Clinical Research Site, Durban, KwaZulu-Natal, South Africa",,"https://ClinicalTrials.gov/show/NCT05022212"
799,"NCT02354937","Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment",,"Completed","No Results Available","Infection, Human Immunodeficiency Virus|HIV Infections","Drug: GSK1265744 30 mg","Composite of PK parameters evaluated by measurement of AUC (0-infinity) and Cmax following single oral dose.|Unbound concentration and unbound fraction in plasma of GSK1265744 at 2 and 24 hours post dose|Composite of PK parameters for GSK1265744 evaluated by measurement of Plasma AUC(0-t), %AUCex, C24, t1/2, CL/F, tlag, tmax and Vz/F following a single oral dose|Number of participants with adverse events as measure of safety and tolerability|Safety and tolerability of single oral dose of 744 assessed by clinical laboratory tests|Safety and tolerability of single oral dose of 744 assessed by12-Lead electrocardiogram|Safety and tolerability of single oral dose of 744 assessed by vital signs","ViiV Healthcare","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","201480","July 13, 2015","November 1, 2016","November 1, 2016","February 3, 2015",,"August 28, 2020","GSK Investigational Site, Lakewood, Colorado, United States|GSK Investigational Site, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02354937"
800,"NCT02074852","Comparison of Immediate Versus Delayed Removal of Urinary Catheter Following Elective Cesarean Section",,"Completed","No Results Available","Urinary Catheter|Cesarean Section|Urinary Infection","Other: Foley urethral catheter","Number of cases with significant bacteriuria and urinary symptoms","Akmal El-Mazny|Cairo University","Female","20 Years to 40 Years   (Adult)",,"300","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","urinary catheter following CS","November 2012","December 2013",,"February 28, 2014",,"March 4, 2014","Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02074852"
801,"NCT03379194","Routine Antibiotic Prescription Monitoring in Primary Care Physicians: A Nationwide Trial",,"Completed","No Results Available","Acute Respiratory Tract Infection|Urinary Tract Infections","Behavioral: Antibiotic stewardship program","Overall antibiotic use|Use of broad spectrum antibiotics|Hospitalizations rates|Antibiotic use in four specific age groups","University Hospital, Basel, Switzerland|University of Bern|University Children's Hospital Basel","All","Child, Adult, Older Adult","Not Applicable","3426","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","CEB-NFP72","January 2, 2018","December 31, 2019","December 31, 2019","December 20, 2017",,"November 18, 2022","University Hospital Basel, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT03379194"
802,"NCT03055130","HPV Infection and Cervical Neoplasm in Women With Inflammatory Bowel Disease: a Cross-sectional Study",,"Unknown status","No Results Available","HPV-Related Cervical Carcinoma|Inflammatory Bowel Diseases|Cervical Neoplasm","Other: Thinprep Cytology Test (TCT) and HPV infection types were tested by gynecologist","The different infection rate of HPV between controls and patients by detecting HPV-DNA using reverse dot-blot method.|The different incidence of cervical neoplasm between controls and patients by performing Thinprep Cytology Test|Find drugs relating to HPV infection of IBD patients","Sixth Affiliated Hospital, Sun Yat-sen University","Female","20 Years to 60 Years   (Adult)",,"160","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","HHBY-YJFA-20160813","July 2015","May 2017","July 2017","February 16, 2017",,"February 16, 2017","Department of Gastroenterology, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03055130"
803,"NCT03263845","Evaluation of Pain in Urinary Collections in Pediatric Emergencies in Children Who Have Not Acquired Cleanliness","SONDAPU","Completed","No Results Available","Urinary Tract Infections in Children",,"Evaluation of pain|The experience of the gesture by the parent and the caregiver|Time needed to collect urine","Rennes University Hospital","All","up to 3 Years   (Child)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","35RC16_3036_SONDAPU","July 5, 2016","January 13, 2017","January 13, 2017","August 28, 2017",,"August 28, 2017","Rennes University Hospital, Rennes, France",,"https://ClinicalTrials.gov/show/NCT03263845"
804,"NCT04791579","Antibiotic Prophylaxis for Neurogenic Bladder Botox",,"Not yet recruiting","No Results Available","Neurogenic Bladder|Post-operative Urinary Tract Infections","Drug: Ciprofloxacin|Drug: Placebo","Rate of Postoperative Urinary Tract Infection|Rate of Other Adverse Events","University of Alberta","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Pro00108452","June 1, 2024","March 31, 2025","August 31, 2025","March 10, 2021",,"December 22, 2023",,,"https://ClinicalTrials.gov/show/NCT04791579"
805,"NCT01358916","Intervention Study to Improve Antibiotic Prescription in Outpatient Care","SAPI","Completed","No Results Available","Respiratory Tract Infections|Urinary Tract Infections","Other: Mailing of antibiotic therapy guidelines to the sentinel physicians","Percentage of prescriptions of penicillin for respiratory tract infections|Percentage of prescriptions of TMP/SMX for lower urinary tract infections in adults|Percentage of prescriptions of quinolone for COPD exacerbations in adults|Percentage of antibiotic prescriptions for the indications ""sinusitis"" and ""other upper respiratory tract infections""","University of Bern|Bundesamt für Gesundheit|Sentinella Netzwerk|Schweizerische Gesellschaft für Infektiologie|Pädiatrische Infektiologie Gruppe Schweiz","All","Child, Adult, Older Adult","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","Swiss Federal Office of Health","November 2010","December 2012","December 2012","May 24, 2011",,"March 29, 2013","Institute for Infectious Diseases, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT01358916"
806,"NCT01359046","Silver-impregnated Suprapubic Catheters (SPC) in Urogynecology",,"Completed","Has Results","Infection Associated With Catheter|Urinary Tract Infection","Device: silver SPC|Device: standard SPC","Urinary Tract Infection Rate|Risk of Urinary Tract Infections in Diabetics","Mayo Clinic","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","288","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","10-007421","July 2011","March 2, 2018","March 9, 2018","May 24, 2011","April 26, 2019","May 9, 2019","Mayo Clinic, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/46/NCT01359046/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01359046"
807,"NCT01222585","Metronidazole Pharmacokinetics (PK) in Premature Infants","PTN_METRO","Completed","Has Results","Serious Systemic Infections|Necrotizing Enterocolitis","Drug: Metronidazole","Area Under the Curve at Steady State|Loading Dose Maximum Concentration|Loading Dose Minimum Concentration|Multiple Dose Maximum Concentration|Multiple Dose Minimum Concentration|Clearance|Volume of Distribution","Michael Cohen-Wolkowiez|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The Emmes Company, LLC|Duke University","All","up to 90 Days   (Child)","Phase 1","24","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00024571|HHSN27500003I","January 2011","November 2011","November 2011","October 18, 2010","December 18, 2013","February 6, 2014","CHOC Children's, Orange, California, United States|Wesely Medical Center, Wichita, Kansas, United States|Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01222585"
808,"NCT01934426","Identification of Admission High Risk Elderly",,"Completed","No Results Available","Pneumonia|Urinary Tract Infection|Stroke",,"Determine percentages of high risk in elderly 14 days readmission to geriatric ward","National Taiwan University Hospital","All","65 Years and older   (Older Adult)",,"760","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201303058RINC","April 2013","February 2014","April 2014","September 4, 2013",,"April 23, 2014","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01934426"
809,"NCT01773824","Routine Prescription Feedback and Peer Comparison to Lower Antibiotic Prescriptions in Primary Care",,"Completed","No Results Available","Upper Respiratory Tract Infections|Urinary Tract Infections","Behavioral: Antibiotic prescription feedback|Behavioral: No Feedback","Prescription rate of antibiotics as defined daily doses (DDD) per 100 consultations|Costs-savings from the intervention|Rate of physicians rating that the continuous update on antibiotic prescription data is useful|Percentage of prescriptions fulfilling disease-specific quality indicators for outpatient antibiotic criteria by the European Surveillance of Antimicrobial Consumption (ESAC).|Number of logins into the web-application","University Hospital, Basel, Switzerland|Swiss National Science Foundation","All","Child, Adult, Older Adult","Not Applicable","2900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","USB-2012-074","October 2013","December 2015","December 2015","January 23, 2013",,"May 12, 2016","Switzerland, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT01773824"
810,"NCT05658614","Anti-Schistosomiasis Sm14-vaccine in Senegal",,"Recruiting","No Results Available","Schistosomiasis Mansoni|Schistosomiasis Haematobium|Vaccination; Infection","Biological: Sm14 recombinant vaccine+ GLA-SE adjuvant","assessment of Immunogenicity 1|assessment of Immunogenicity 2|assessment of Immunogenicity 3|assessment of Immunogenicity 4|assessment of Immunogenicity 5|assessment of Immunogenicity 6|assessment of Immunogenicity 7|assessment of Immunogenicity 8|assessment of immunogenicity 9|assessment of immunogenicity 10|assessment of immunogenicity 11|assessment of immunogenicity 12|assessment of immunogenicity 13|assessment of immunogenicity 14|Safety of the vaccine candidate Sm14 -1|Safety of the vaccine candidate Sm14 - 2|Safety of the vaccine candidate Sm14 -3|Safety of the vaccine candidate Sm14 -4|Safety of the vaccine candidate Sm14 -5|Safety of the vaccine candidate Sm14 _6|Safety of the vaccine candidate Sm14 -7|Safety of the vaccine candidate Sm14 -8|Safety of the vaccine candidate Sm14 -9","Oswaldo Cruz Foundation","Male","18 Years to 49 Years   (Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Sm14-2c-Sn","July 1, 2022","September 15, 2023","December 31, 2023","December 21, 2022",,"December 21, 2022","Biomedical Research Center EPLS, Saint Louis, Senegal",,"https://ClinicalTrials.gov/show/NCT05658614"
811,"NCT02346227","Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix","KINVAV","Completed","No Results Available","Uterine Cervical Dysplasia|Papillomavirus Infections","Drug: AV2|Drug: Placebo","Change of lesions|absence of HPV DNA|correlation between change of lesions and change in HPV DNA|Change in HPV viral particle load","Jean-Pierre Van geertruyden|University of Kinshasa|University Hospital, Antwerp|Universiteit Antwerpen","Female","25 Years and older   (Adult, Older Adult)","Phase 3","327","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UA-IHU- 2012-01","January 2015","August 2018","August 2018","January 26, 2015",,"October 12, 2018","Centre de Santé Lisungi, Kinshasa, Mont-Ngafula, Congo, The Democratic Republic of the",,"https://ClinicalTrials.gov/show/NCT02346227"
812,"NCT04291768","Shortened Antibiotic Treatment of 5 Days in Gram-negative Bacteremia","GNB5","Recruiting","No Results Available","Gram-negative Bacteremia|Urinary Tract Infection Bacterial","Other: Shortened antibiotic treatment|Other: Standard antibiotic treatment","90-day survival without clinical or microbiological failure to treatment|Mortality|Total duration of antibiotic treatment|Type of antibiotic treatment|Duration of antibiotic treatment|Total length of hospital stay|Hospital re-admission|Antibiotic adverse events|Use of antimicrobials after discharge|Severe adverse events|Acute kidney injury|Clostridioides difficile infection|Multidrug-resistance organism","Thomas Benfield|Hvidovre University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","380","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","190801|2019-003282-17|H-19085920","March 11, 2020","October 1, 2026","October 1, 2026","March 2, 2020",,"February 8, 2023","University Hospital of Aalborg, Aalborg, Denmark|Rigshospitalet, Copenhagen, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Gentofte Hospital, Hellerup, Denmark|Herlev Hospital, Herlev, Denmark|Herning Hospital, Herning, Denmark|Nordsjaellands Hospital, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Kolding Hospital, Kolding, Denmark|Odense University Hospital, Odense, Denmark|Roskilde Hospital, Roskilde, Denmark|Regionshospitalet Silkeborg, Silkeborg, Denmark|University Hospital of Aarhus, Århus, Denmark","""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/68/NCT04291768/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04291768"
813,"NCT05781581","A Retrospective Cohort Study for Main Postoperative Complications After SARS-CoV-2 Infection",,"Not yet recruiting","No Results Available","Intestines Cancer|Pulmonary Cancer|Liver Cancer|Trauma|Fractures, Bone|Gynecologic Disease","Other: no intervention","All-cause mortality at 30 days after operation|Main pulmonary complications at 30 days after operation|Major Adverse Cardiovascular Events (MACE)","RenJi Hospital|The First Affiliated Hospital of Anhui Medical University|First Affiliated Hospital of Chongqing Medical University|Sichuan Academy of Medical Sciences|Second Hospital of Shanxi Medical University","All","18 Years and older   (Adult, Older Adult)",,"50000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","retro-MPOC","March 19, 2023","August 31, 2023","December 31, 2024","March 23, 2023",,"March 23, 2023",,,"https://ClinicalTrials.gov/show/NCT05781581"
814,"NCT03172039","Antimicrobial Use and Stewardship in an Outpatient Hemodialysis Unit",,"Completed","No Results Available","End Stage Renal Failure on Dialysis|Infection, Bacterial",,"Prevalence of antimicrobial prescriptions in an ambulatory hemodialysis population|Congruence of prescribed antimicrobial regimens","University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)",,"53","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","16-6388","May 12, 2017","September 1, 2017","September 1, 2017","June 1, 2017",,"October 26, 2017","Toronto General Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03172039"
815,"NCT01230814","Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women",,"Completed","Has Results","Bacterial Vaginosis|Candidiasis|Trichomoniasis","Drug: Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)|Drug: Placebo","Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing Vulvovaginal Candidiasis (VVC).|Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing Bacterial Vaginosis (BV).|Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Placebo for Preventing Any Vaginal Infection (a Combined Endpoint Including BV, VVC, and Trichomonas Vaginalis Infection).|Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing BV by Clinical Criteria (Amsel's Criteria).","National Institute of Allergy and Infectious Diseases (NIAID)","Female","18 Years to 45 Years   (Adult)","Phase 2","234","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","09-0070|DMID STI CTG 09-0070 PVI","April 2011","August 2013","August 2013","October 29, 2010","September 26, 2014","October 6, 2014","University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States|Women's Health Project - Ganjoni Municipal Clinic, Mombasa, Coast, Kenya|University of Nairobi - Center for STD/HIV Research & Training, Nairobi, Kenya|University of Nairobi - Kenya AIDS Vaccine Initiative, Nairobi, Kenya",,"https://ClinicalTrials.gov/show/NCT01230814"
816,"NCT05702762","Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting",,"Recruiting","No Results Available","Urinary Tract Infections","Drug: Gentamicin|Drug: Standard of Care","Clinical Resolution","Mercy Health Ohio|Northeast Ohio Medical University","Female","18 Years and older   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","22-010","October 1, 2022","June 30, 2023","June 30, 2024","January 27, 2023",,"January 27, 2023","St. Elizabeth Youngstown Hospital, Youngstown, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05702762"
817,"NCT03764631","Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration",,"Completed","Has Results","Diabetes Mellitus, Type 2","Drug: Empagliflozin|Drug: Dipeptidyl-peptidase 4 (DPP-4) inhibitors","Number of Participants With Ketoacidosis|Number of Participants With Severe Urinary Tract Infections (UTIs)|Number of Participants With Volume Depletion|Number of Participants With Dehydration|Number of Participants With Ketoacidosis During Ramadan Periods|Number of Participants With Severe Urinary Tract Infections (UTIs) During Ramadan Periods|Number of Participants With Volume Depletion During Ramadan Periods|Number of Participants With Dehydration During Ramadan Periods","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)",,"1502","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","1245-0149","September 26, 2018","January 11, 2021","January 11, 2021","December 5, 2018","February 10, 2022","February 10, 2022","Abha International Private Hospital, Abha, Saudi Arabia|DAFA Special Polyclinic, Jeddah, Saudi Arabia|Ghassan Najeeb Pharaon Hospital, Jeddah, Saudi Arabia|International Medical Center, Jeddah, Saudi Arabia|Dr.Bakhsh Hospital, Jeddah, Saudi Arabia|Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia|Saudi German Hospital, Jeddah, Saudi Arabia|Al Abeer Medical Center, Jeddah, Saudi Arabia|Al-Abeer Medical Center, Jeddah, Saudi Arabia|Al Abeer Polyclinic, Jeddah, Saudi Arabia|Al Rahman Polyclinic, Makkah, Saudi Arabia|Shifa Hospital, Makkah, Saudi Arabia|Al-Noor Specialist Hospital, Makkah, Saudi Arabia|Al Zafer Hospital, Najran, Saudi Arabia|Obesity, Endocrine and Metabolism Center, Riyadh, Saudi Arabia|Riyadh Medical Center, Riyadh, Saudi Arabia|Alalam Medical Center, Riyadh, Saudi Arabia|Prince Fahad bin Sultan hospital, Tabuk, Saudi Arabia|Al Hada Armed Forces Hospital, Taif, Saudi Arabia|Al Amal Medical Group, Yanbu, Saudi Arabia|Alansari Specialist Hospital, Yanbu, Saudi Arabia","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/31/NCT03764631/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/31/NCT03764631/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03764631"
818,"NCT02247960","Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy","Abx","Terminated","Has Results","Prostate Cancer|Urinary Tract Infection|Clostridium Difficile","Drug: Ciprofloxacin","Number of Participants With a Positive Urinary Tract Infection|Number of Participants Positive for Clostridium Difficile|Number of Participants With Bacteria in Urine","University of Rochester","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","175","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RSRB#50607","July 2014","May 2016","May 2016","September 25, 2014","March 15, 2017","April 17, 2017","University of Rochester Medical Center, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT02247960"
819,"NCT03931538","Rapid Molecular Organism Identification and Mixed Flora Antibiotic Resistance Profiling (MixAR) Prospective Study","RapIDMixAR","Completed","No Results Available","Urinary Tract Infections|Prostatitis|Interstitial Cystitis","Diagnostic Test: Guidance 4.0 PCR test|Diagnostic Test: Urine Culture","Establish Safety: composite adverse event rate|Number of Patients with Recurrent and Persistent Infections in Each Arm|Time to Symptom Resolution in Each Arm","Pathnostics|Comprehensive Urology-a Division of Michigan Healthcare Professionals","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2511","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Care Provider)|Primary Purpose: Diagnostic","Pathnostics RapID MixAR","July 17, 2018","February 22, 2019","October 1, 2019","April 30, 2019",,"August 28, 2023","Comprehensive Urology, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03931538"
820,"NCT00873626","Treatment's Duration of Acute Uncomplicated Pyelonephritis","DTP","Completed","No Results Available","Urinary Tract Infection|Fever","Drug: levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)","Compare the rates of clinical and microbiological cure at 30 ± 5 days of the end of antibiotherapy in acute uncomplicated pyelonephritis of young women, according to the duration of antibiotherapy: 5 days versus 10 days.|Evaluate the effectiveness bacteriological (ECBU negative direct examination and culture) of treatment to 30 ± 5 days of the end of antibiotherapy|Evaluate the clinical effectiveness of treatment: apyrexia and disappearance of clinical signs initial J2 ± 1; J5 ± 1, ± 1 of J10 beginning of treatment and 30 ± 5 days of the end of antibiotherapy,|Identifying risk factors for failure of antibiotic treatment (co-morbidities, bacteremia)|Assessing the tolerance of the antibiotic, the presence of adverse events related to drug|To assess adherence to treatment, the proportion of patients observant good, average and low observant|Assess the changes in sensitivity to antibiotics (fluoroquinolones) in the nasal flora, pharyngeal and digestive.","Assistance Publique - Hôpitaux de Paris","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","310","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P071208","June 2009","August 2011","August 2011","April 1, 2009",,"November 6, 2014","University hospital of Garches, Garches, France|university hospital of TOURS, Tours, France",,"https://ClinicalTrials.gov/show/NCT00873626"
821,"NCT02755012","Impact of Maternal Stress on Infant Stunting",,"Completed","No Results Available","Maternal; Malnutrition|Infant Malnutrition|Physiological Stress|Emotional Stress|Life Stress|Domestic Violence|Infection|Breast Feeding|Mastitis",,"Infant stunting (Infant height-for-age score)|Change in infant HAZ per month","McGill University|Center for Studies of Sensory Impairment, Aging and Metabolism","Female","Child, Adult, Older Adult",,"271","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","A04-B01-12A","June 2012","November 2013","November 2013","April 28, 2016",,"April 28, 2016",,,"https://ClinicalTrials.gov/show/NCT02755012"
822,"NCT02795845","Oral Probiotics for the Treatment and Prevention of Vulvovaginal Infections in Pregnancy - Double-blind, Randomized, Placebo-controlled Study",,"Completed","No Results Available","Bacterial Vaginosis and Vaginal Candidiasis at Pregnancy","Dietary Supplement: Probiotic Capsule containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus and Bifidobacterium bifidum|Other: Placebo","The degree of vaginal lactobacilli colonization in the probiotic formula group versus placebo|The rate of women in the primary prevention group, who developed any vaginal infection (BV/AVF/VVC) during the study period until delivery in the probiotic formula group versus placebo.|The rate of women in the second prevention group who developed any vaginal infection (BV/AVF/VVC) during the study period until delivery in the probiotic formula group versus placebo.|Duration of time from the beginning of the study until an episode of vaginal infection (either AVF/BV or VVC).|The number of episodes of vaginal infections during pregnancy (either AVF/BV or VVC).|The rate of women, who suffer from obstetrical complications|The rate and type of adverse effects in the probiotic versus placebo groups (e.g gastrointestinal symptoms).|Number of urinary tract infections during the study period|The rate of neonatal complications|The rate of women in the primary prevention group who developed AVF/BV during the study period until delivery in the probiotic formula group versus placebo.|The rate of women in the primary prevention group who developed VVC during the study period until delivery in the probiotic formula group versus placebo.|The rate of women in the second prevention group who developed AVF/BV during the study period until delivery in the probiotic formula group versus placebo.|The rate of women in the second prevention group who developed VVC during the study period until delivery in the probiotic formula group versus placebo.","HaEmek Medical Center, Israel","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","157","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","0079-15","November 2016","July 2021","August 2021","June 10, 2016",,"August 3, 2021","Departement of obstetric and gynecology, HaEmek medical center, Afula, Israel|Women Helth center - Clalit, Afula, Israel|The holy family hospital, Nazareth, Israel",,"https://ClinicalTrials.gov/show/NCT02795845"
823,"NCT05415904","Hantavirus Nephropathy in North-Eastern France : Severity Risk Factors and Prognostic Tools","HANTA-NE","Active, not recruiting","No Results Available","Hantavirus Nephropathy|Hantavirus Infection","Other: HANTA-NE","Creatinin level|Hemorrhagic syndrome|Death|Hospitalisation in intensive care unit|Score performance to predict severity|Hypotension|Proteinuria|Urinary dipstick|ALAT, ASAT|calcium|phosphorus|potassium|sodium|bicarbonate blood level|Heamoglobin|platelets level|Urine output","Central Hospital, Nancy, France","All","18 Years to 125 Years   (Adult, Older Adult)",,"170","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2022PI034","May 20, 2022","October 30, 2023","July 31, 2024","June 13, 2022",,"June 13, 2022","Central Hospital, Nancy, France",,"https://ClinicalTrials.gov/show/NCT05415904"
824,"NCT05828550","Detection of Efflux Pump Genes Mediating Ciprofloxacin Resistance in Staphylococcus Aureus Isolates in Sohag University Hospitals",,"Not yet recruiting","No Results Available","Patients withInfections Caused by S.Aureus Like Skin Infections , Chest Infections , Surgical Site Infections , and Urinary Tract Infections","Diagnostic Test: antibiotic sensitivity","Ciprofloxacin Resistance in Staphylococcal strains isolated|presence of Efflux pump genes ( norA , norB , norC ) mediating Resistance in such strains","Sohag University","All","Child, Adult, Older Adult","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Soh-Med-23-04-01MS","May 2023","November 2023","November 2023","April 25, 2023",,"April 25, 2023","Sohag University Hospital, Sohag, Egypt",,"https://ClinicalTrials.gov/show/NCT05828550"
825,"NCT02487199","Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease",,"Completed","Has Results","Hepatitis C Virus (HCV)","Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir|Drug: ombitasvir/paritaprevir/ritonavir","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Number of Participants With Adverse Events|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-461|2015-002012-33","September 30, 2015","December 5, 2016","December 5, 2016","July 1, 2015","December 4, 2017","December 4, 2017",,,"https://ClinicalTrials.gov/show/NCT02487199"
826,"NCT02674581","A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)",,"Completed","No Results Available","HIV Infections","Drug: Oral BMS-663068 (pro-drug)","Effect of Renal Impairment on The Primary Endpoints of Cmax|Safety and Tolerability as assessed by the Incidence of Serious Adverse Events (SAEs), Adverse Events (AEs), AEs leading to discontinuation, and the results of ECGs, vital signs, physical examination, and clinical laboratory tests.","ViiV Healthcare|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","206217|AI438-070","February 26, 2016","May 24, 2016","May 24, 2016","February 4, 2016",,"May 15, 2018","GSK Investigational Site, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02674581"
827,"NCT01293799","Prevention of Peritonitis in Peritoneal Dialysis","PEPS","Completed","No Results Available","Kidney Failure, Chronic|Peritoneal Dialysis-associated Peritonitis|Dialysis Capd Infection","Behavioral: Follow-up of PD patients´ theoretical and practical skills","The incidence of peritonitis during the whole study and the peritonitis-free survival both during the first 12 months after PD start and during the whole study wil be compared in the two groups.|Risk factors for peritonitis|Days of hospitalization due to peritonitis","Sahlgrenska University Hospital, Sweden|Odense University Hospital|Rigshospitalet, Denmark|Central Hospital HF, Lillehammer, Norway (dr Dag Paulsen)|Tampere University Hospital|Pauls Stradins Clinical University Hospital|Tartu University Hospital, Tartu, Estonia (dr Mai Rosenberg)|Karolinska Institutet|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Sheffield Teaching Hospitals NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Not Applicable","713","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Dnr 590-09","January 2010","December 2012","December 31, 2015","February 11, 2011",,"September 12, 2019","Department of Nephrology, Sahlgrenska University Hospital, Gothenburg, Sweden",,"https://ClinicalTrials.gov/show/NCT01293799"
828,"NCT01812889","Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463",,"Completed","No Results Available","Vaginal Infection","Drug: TOL-463 Vaginal ovule|Drug: TOL-463 Vaginal gel","The local (vulvovaginal) and systemic safety and tolerability of TOL-463 gel and ovules following a single intravaginal administration in healthy female subjects and following daily dosing for 7 days in women with BV or VVC will be assessed.|Adverse events (AEs) will be monitored throughout the course of the study following administration of Investigational Product (IP).|Standard PK parameters (half-life, Cmax, Tmax and AUC), will be assessed following single-dose administration of TOL-463 gel and ovule in healthy subjects and after single- and multiple-dose administration of TOL-463 gel or ovules in women with BV or VVC","National Institute of Allergy and Infectious Diseases (NIAID)","Female","18 Years to 45 Years   (Adult)","Phase 1","26","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-0077|HHSN272200800024C|TOL-463","April 2013","January 2014","May 2014","March 18, 2013",,"May 16, 2014","Quintiles Phase I Services - Overland Park, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01812889"
829,"NCT01337791","Efficacy, Safety and Tolerability of Telbivudine in HBeAg Positive Chronic Hepatitis B Pregnant Women With Elevated Alanine Aminotransferase Levels",,"Completed","No Results Available","Chronic Hepatitis B|Pregnancy Complications|High Viral Load|Elevated Alanine Aminotransferase Levels","Drug: Telbivudine treatment","The efficacy of Telbivudine treatment (DNA reduction, ALT normalization, and infants' immunoprophylaxis failure) and safety|Changes in maternal HBeAg titers and lost/seroconversion of HBeAg or HBsAg","Southeast University, China","Female","20 Years to 40 Years   (Adult)","Phase 4","88","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H200804IRB","August 2008","December 2009","December 2009","April 19, 2011",,"April 19, 2011","Department of Gynecology and Obstetrics, The Second Affiliated Hospital of the Southeast University, Nan Jing, Jiang Su, China",,"https://ClinicalTrials.gov/show/NCT01337791"
830,"NCT04495907","COVID-19 Progression in End-Stage Kidney Disease","COPE","Completed","No Results Available","SARS-CoV-2 Infection (Asymptomatic)|SARS-CoV-2 Infection (Symptomatic)",,"SARS-CoV-2 IgG|Anti-SARS-CoV-2 IgG","Davita Clinical Research","All","18 Years to 80 Years   (Adult, Older Adult)",,"412","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","20-M-0047-00","August 6, 2020","April 9, 2021","August 31, 2021","August 3, 2020",,"March 22, 2022","DCR Victorville, Victorville, California, United States|DCR Connecticut, Bridgeport, Connecticut, United States|DCR Twin Cities, Minneapolis, Minnesota, United States|DCR Las Vegas, Las Vegas, Nevada, United States|DCR Bronx, Bronx, New York, United States|DCR Canton, Canton, Ohio, United States|DCR El Paso, El Paso, Texas, United States|DCR Lewisville, Lewisville, Texas, United States|DCR San Antonio, San Antonio, Texas, United States|DCR Norfolk, Norfolk, Virginia, United States|DCR Milwaukee, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04495907"
831,"NCT04319328","Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?",,"Recruiting","No Results Available","Hemodialysis Complication|Infectious Disease|End Stage Renal Disease","Drug: Cefazolin|Drug: Ceftazidime|Drug: Ciprofloxacin","Volume of distribution (Vd) for cefazolin, ceftazidime, and ciprofloxacin in infected patients on chronic intermittent high-flux hemodialysis.|Drug elimination (ke) for cefazolin, ceftazidime, and ciprofloxacin in infected patients on chronic intermittent high-flux hemodialysis.|Drug clearance (CL) for cefazolin, ceftazidime, and ciprofloxacin in infected patients on chronic intermittent high-flux hemodialysis.","University of Manitoba|The Kidney Foundation of Canada","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Other|Time Perspective: Prospective","H2019:031","October 18, 2019","December 31, 2023","December 31, 2023","March 24, 2020",,"May 11, 2023","Saint Boniface Hospital, Outpatient Hemodialysis Unit, Winnipeg, Manitoba, Canada|College of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT04319328"
832,"NCT03442218","Use of Antiseptic Solution for Vaginal Wash Before Cesarean Section",,"Completed","No Results Available","Operation Wound; Infection|Endometritis","Drug: Clorhexidine|Drug: Saline solution","Number of cases of endometritis after cesarean section|Number of cases of cesarean site infection|Number of cases of fever (38°C or above) in the puerperium","Saint Thomas Hospital, Panama|Sistema Nacional de Investigación (SNI) - Panamá","Female","Child, Adult, Older Adult","Not Applicable","203","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MHST2014-20","June 1, 2017","August 31, 2017","February 28, 2018","February 22, 2018",,"December 9, 2019","Saint Thomas Maternity Hospital, Panama, Panama",,"https://ClinicalTrials.gov/show/NCT03442218"
833,"NCT03447639","Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal",,"Terminated","Has Results","Catheter; Infection (Indwelling Catheter)|Catheter Infection|Catheter-Related Infections|Catheter Bacteraemia|Urinary Tract Infections","Drug: Povidone-iodine irrigation","Diagnosis of Urinary Tract Infection (UTI)|Diagnosis of UTI at 7 Days|Diagnosis of UTI at 28 Days","William Beaumont Hospitals","Male","18 Years and older   (Adult, Older Adult)","Phase 4","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2018-001","March 29, 2018","October 18, 2018","October 22, 2018","February 27, 2018","April 24, 2019","January 18, 2020","Beaumont Hospital, Royal Oak, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/39/NCT03447639/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/39/NCT03447639/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03447639"
834,"NCT00071214","Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis",,"Completed","No Results Available","Staphylococcal Infections|Kidney Failure, Chronic","Biological: S. aureus Type 5 and 8 Capsular Polysaccharide Conjugate Vaccine","Documented S. aureus invasive infection, weeks 3-35|Documented S. aureus invasive infection in other time periods|Immunogenicity at mulitple time points|Safety|Health economics","Nabi Biopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","3600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","Nabi-1371","September 2003",,"September 2005","October 17, 2003",,"July 11, 2006",,,"https://ClinicalTrials.gov/show/NCT00071214"
835,"NCT06304610","Hospital-based Validation of the New ELEVATE Screening Tool in Belgium and Ecuador","ELEVATE-Pilot","Not yet recruiting","No Results Available","Cervical Cancer|HPV Infection","Behavioral: Questionnaire|Procedure: HPV self-sample|Procedure: Endocervical sample","Clinical validation|Concordance|HPV DNA test validation|Protein test validation","University Hospital, Ghent|Horizon 2020 - European Commission|Universidad de Cuenca","Female","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ONZ-2024-0044","May 1, 2024","December 31, 2024","December 31, 2024","March 12, 2024",,"March 28, 2024","Ghent University Hospital, Ghent, East-Flanders, Belgium|SOLCA University Hospital, Cuenca, Ecuador",,"https://ClinicalTrials.gov/show/NCT06304610"
836,"NCT04155294","Re-Evaluation of Annual Cytology Using HPV Testing to Upgrade Prevention in Women Living With HIV","REACH-UP","Completed","No Results Available","Cervical Cancer|HPV Infection|HIV Infections",,"Prevalence of HR HPV in WLWH aged 25-64 years in the UK|Rates of enrolment|Response rate to questionnaires|Feasibility of self-sampling|Participants retention rate|Acceptability of study procedures including self-taken vaginal swabs|Awareness of cervical cancer risk|Compliance to standard screening procedures","University of Oxford|British HIV Association (BHIVA)","Female","25 Years to 64 Years   (Adult)",,"71","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRAS Reference 259611","October 28, 2019","October 31, 2021","October 31, 2021","November 7, 2019",,"May 24, 2022","Oxford University Hospital NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom|Buckinghamshire Healthcare NHS Trust, High Wycombe, United Kingdom|Royal Free Hospital Nhs Foundation Trust, London, United Kingdom|GUY's AND ST THOMAS' NHS FOUNDATION TRUSTS, London, United Kingdom|Milton Keynes University NHS Foundation Trust, Milton Keynes, United Kingdom|ROYAL BERKSHIRE NHS FOUNDATION TRUST, Upton Hospital, Albert Street, Slough, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04155294"
837,"NCT06177236","Clinic or Self-Sampling for Cervical Cancer Screening",,"Completed","No Results Available","Cervical Cancer|HPV Infection","Diagnostic Test: cervical cancer screening","The Effect of in Clinic or Self-Sampling for Cervical Cancer Screening on Status of Participation|The Effect of in Clinic or Self-Sampling for Cervical Cancer Screening on Status of ling for Cervical Cancer Screening on Status of Attitude","Istanbul University - Cerrahpasa (IUC)|Health Institutes of Turkey","Female","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","110","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","stanbulUC","October 1, 2022","October 1, 2023","December 1, 2023","December 20, 2023",,"December 20, 2023","Istanbul Unıversıty-Cerrahpasa, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT06177236"
838,"NCT01295645","Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis",,"Active, not recruiting","No Results Available","Transplantation Infection","Drug: Cidofovir|Other: No Cidofovir","Number of Patients with Microbiologic Response","M.D. Anderson Cancer Center","All","6 Years and older   (Child, Adult, Older Adult)","Phase 2","27","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-0518|NCI-2011-00250","March 17, 2011","March 15, 2026","March 15, 2026","February 14, 2011",,"February 7, 2024","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01295645"
839,"NCT05990270","The Effect of Education Given to Women on Cervical Cancer on Knowledge, Attitude and Belief","EEWCCKAB","Recruiting","No Results Available","Cancer of Cervix|HPV Infection","Behavioral: education","First Measurement: Human Papilloma Virus (HPV) Knowledge Scale|Second Measurement:Cervical Cancer and Pap-Smear Test Health Belief Model Scale","Kahramanmaras Sutcu Imam University","Female","Child, Adult, Older Adult","Not Applicable","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","KahramanmaraşSIUU","August 15, 2023","September 30, 2023","December 30, 2023","August 14, 2023",,"August 14, 2023","Kahramanmaraş ISU, Kahramanmaraş, K.Maraş, Turkey",,"https://ClinicalTrials.gov/show/NCT05990270"
840,"NCT05059015","Human Papilloma Virus (HPV) Self-collection and Women Adherence",,"Unknown status","No Results Available","Cervical Cancer|HPV Infection","Diagnostic Test: CERVICAL HPV|Diagnostic Test: SELF SAMPLING HPV","Participation|Adherence|Quality of HPV samples|CIN2 + rate in the study population|CIN2 + rate in population with positive screening","Instituto Nacional de Cancerologia, Columbia","Female","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","C19010300532","May 1, 2019","September 24, 2020","December 3, 2022","September 28, 2021",,"December 10, 2021","Instituto Nacional de Cancerología, Bogotá, Cundinamarca, Colombia",,"https://ClinicalTrials.gov/show/NCT05059015"
841,"NCT00912834","Study of Prevalence of Proteinuria, Urinary Tract Infection or Hematuria in Athletes",,"Unknown status","No Results Available","Proteinuria",,,"Far Eastern Memorial Hospital","All","18 Years to 25 Years   (Adult)",,"300","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","97088","December 2008","May 2009","November 2009","June 3, 2009",,"September 23, 2009",,,"https://ClinicalTrials.gov/show/NCT00912834"
842,"NCT03816111","Targeted Education ApproaCH to Improve Peritoneal Dialysis Outcomes Trial","TEACH-PD","Recruiting","No Results Available","Kidney Disease, Chronic|Peritoneal Dialysis Catheter-Associated Peritonitis|Peritoneal Dialysis Catheter Exit Site Infection|Peritoneal Dialysis Catheter Tunnel Infection","Behavioral: TEACH-PD Training Curriculum|Behavioral: Current standard PD training","Time to the first occurrence of any PD-related infection|Time to first exit site infection|Time to first tunnel infection|Time to first episode of peritonitis|Time to infection-associated catheter removal|Incidence of technique failure - 30 days|Incidence of technique failure - 180 days|Incidence of all-cause hospitalization|Incidence of all-cause mortality|Participant Quality of Life questionnaire|Health-care cost-effectiveness analysis","The University of Queensland|The HOME Network|Australia and New Zealand Dialysis and Transplant Registry|New Zealand Peritoneal Dialysis Registry","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AKTN 17.03","July 22, 2019","March 30, 2023","April 30, 2025","January 25, 2019",,"August 5, 2022","Canberra Hospital, Canberra, Australian Capital Territory, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Lismore Hospital, Lismore, New South Wales, Australia|Orange Hospital, Orange, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|Nepean/Blacktown Hospital, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Royal Prince Alfred/Concord Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Tamworth Hospital, Tamworth, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Royal Darwin Hospital, Darwin, Northern Territory, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Cairns Hospital, Cairns, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Mackay Base Hospital, Mackay, Queensland, Australia|Logan Hospital, Meadowbrook, Queensland, Australia|Sunshine Coast University Hospital, Nambour, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Monash Health, Dandenong, Victoria, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Barwon Health, Geelong, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Waitakere Hospital, Auckland, New Zealand|North Shore Hospital, Auckland, New Zealand|Auckland Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Wairau Hospital, Blenheim, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Gisborne Hospital, Gisborne, New Zealand|Waikato Hospital, Hamilton, New Zealand|Hawke's Bay Hospital, Hastings, New Zealand|Nelson Hospital, Nelson, New Zealand|Taranaki Hospital, New Plymouth, New Zealand|Palmerston North/Whanganui Hospital, Palmerston North, New Zealand|Wellington Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand",,"https://ClinicalTrials.gov/show/NCT03816111"
843,"NCT03077711","Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs",,"Completed","Has Results","Urinary Tract Infections, Recurrent","Drug: Trimethoprim|Drug: Methenamine hippurate","Time to Subsequent Infection as Defined From Time of Treatment Initiation to Recurrence of UTI|Recurrent UTI|Number of Infections|Adverse Effects|Morisky Medication Adherence Survey|Bacterial Infection Prevalence and Types","NorthShore University HealthSystem","Female","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","EH16-216","June 2016","June 21, 2019","June 21, 2019","March 13, 2017","January 14, 2020","January 14, 2020","NorthShore Univeristy HealthSystem, Skokie, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/11/NCT03077711/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03077711"
844,"NCT01838213","Extended Spectrum Betalactamase Producing Bacteria; Epidemiology and Treatment in Non-hospitalized Patients","ESCAPE","Completed","Has Results","Urinary Tract Infection|Infection Due to ESBL Bacteria|Environmental Contamination of ESBL",,"Treatment Failure|Subjective Outcome","Vestre Viken Hospital Trust|Helse Sor-Ost|University Hospital of North Norway|University of Oslo","All","18 Years and older   (Adult, Older Adult)",,"760","Other","Observational","Time Perspective: Prospective","REK S-08901b","February 2009","December 2014",,"April 23, 2013","November 23, 2015","November 23, 2015",,,"https://ClinicalTrials.gov/show/NCT01838213"
845,"NCT00305071","Effect of Adjuvant Treatment With Compound Cranberry Extract Tablets in Acute Bacterial Cystitis.",,"Unknown status","No Results Available","Pyuria|Urinary Tract Infections","Drug: compound cranberry extract tablet","Time to symptoms relief|Pyuria eradication rate","Min-Sheng General Hospital|Acrobio Healthcare Inc.","Female","20 Years to 65 Years   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","ICMJE IRB NO：950113-1","April 2006",,,"March 21, 2006",,"March 21, 2006","Min-Sheng General Hospital, Taoyuan City, Taiwan",,"https://ClinicalTrials.gov/show/NCT00305071"
846,"NCT00113191","Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants",,"Completed","No Results Available","Nosocomial Infections|Sepsis|Staphylococcal Infections|Candidemia","Drug: Veronate","To assess the efficacy of Veronate® compared to placebo in preventing nosocomial S. aureus sepsis in premature infants|To assess the safety profile of Veronate® compared to placebo in premature infants as measured by frequencies of adverse events, serious adverse events and morbidities associated with prematurity|To compare the proportions of infants with nosocomial coagulase negative staphylococcus (CoNS) sepsis between premature infants treated with Veronate® versus placebo|To compare the proportions of infants with all nosocomial staphylococcal sepsis between premature infants treated with Veronate® versus placebo|To compare the proportions of infants with nosocomial candidemia between premature infants treated with Veronate® versus placebo|To compare mortality between premature infants treated with Veronate® versus placebo","Bristol-Myers Squibb","All","3 Days to 5 Days   (Child)","Not Applicable","2000","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Prevention","IgG-CL-006","May 2004","June 2006","June 2006","June 7, 2005",,"August 2, 2012","Birmingham, Alabama, United States|Mobile, Alabama, United States|Anchorage, Alaska, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Hayward, California, United States|Loma Linda, California, United States|Long Beach, California, United States|Oakland, California, United States|Oakland, California, United States|Orange, California, United States|Sacramento, California, United States|San Francisco, California, United States|San Francisco, California, United States|Santa Clara, California, United States|Walnut Creek, California, United States|Newark, Delaware, United States|Washington, District of Columbia, United States|Gainesville, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Plantation, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Honolulu, Hawaii, United States|Evanston, Illinois, United States|Park Ridge, Illinois, United States|Indianapolis, Indiana, United States|South Bend, Indiana, United States|Wichita, Kansas, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Flint, Michigan, United States|Grand Rapids, Michigan, United States|Lansing, Michigan, United States|Royal Oak, Michigan, United States|Duluth, Minnesota, United States|Jackson, Mississippi, United States|St. Louis, Missouri, United States|Camden, New Jersey, United States|Newark, New Jersey, United States|Voorhees, New Jersey, United States|Albany, New York, United States|Bronx, New York, United States|Manhasset, New York, United States|Mineola, New York, United States|New Hyde Park, New York, United States|Syracuse, New York, United States|Valhalla, New York, United States|Charlotte, North Carolina, United States|Charlotte, North Carolina, United States|Greenville, North Carolina, United States|Raleigh, North Carolina, United States|Akron, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Toledo, Ohio, United States|Youngstown, Ohio, United States|Bryn Mawr, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Wynnewood, Pennsylvania, United States|Providence, Rhode Island, United States|Greenville, South Carolina, United States|Memphis, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Ogden, Utah, United States|Provo, Utah, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Spokane, Washington, United States|Morgantown, West Virginia, United States|New Westminster, British Columbia, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Halifax, Nova Scotia, Canada|Kingston, Ontario, Canada|Windsor, Ontario, Canada|Montreal, Quebec, Canada|Saskatoon, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT00113191"
847,"NCT03638427","Screening for Cervical Intraepithelial Neoplasia Using Self-collected Menstrual Blood",,"Enrolling by invitation","No Results Available","HPV - Anogenital Human Papilloma Virus Infection","Diagnostic Test: Menstrual Blood Analysis (Menstrual Blood Analysis)","Detection of HR-HPV DNA or HPV E6/E7 mRNA","Stanford University","Female","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB-47250|NCI-2020-04139|GYNCVX0005","January 1, 2019","May 31, 2023","January 1, 2024","August 20, 2018",,"December 5, 2022","Stanford Gynecology Clinic, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT03638427"
848,"NCT04323904","Hantavirus Registry Gathers Knowledge on Epidemiology, Clinical Course, Prognostic Factors and Molecular Characteristics for Hantavirus Infections and Their Complications (HantaReg)","HantaReg","Recruiting","No Results Available","Hantavirus Infections|Hemorrhagic Fever With Renal Syndrome|Nephropathia Epidemica|Hantavirus Cardiopulmonary Syndrome","Other: Retrospective data collection","Incidence|Mortality|Complications|Therapeutic approaches|First-line and salvage treatment approaches|Recommendations for diagnosis and treatment","University of Cologne","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","HantaReg","March 4, 2020","March 2030","December 2030","March 27, 2020",,"May 24, 2022","University Hospital of Cologne, Cologne, North-Rhine Westfalia, Germany",,"https://ClinicalTrials.gov/show/NCT04323904"
849,"NCT05674032","Bacterial Metallophores in the Diagnosis of Acute Pyelonephritis",,"Recruiting","No Results Available","Acute Pyelonephritis|Complicated Urinary Tract Infection",,"Detection of metallophores|Classification of microorganisms|Metallophores versus culture|Cases versus Controls 1 versus Controls 2","Thomayer University Hospital|Czech Academy of Sciences","All","18 Years and older   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","TUH00064190","June 24, 2020","December 2024","December 2024","January 6, 2023",,"January 6, 2023","Thomayer University Hospital, Praha, Czechia",,"https://ClinicalTrials.gov/show/NCT05674032"
850,"NCT01818596","Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment",,"Completed","Has Results","HIV|HIV Infections","Drug: E/C/F/TAF","Change From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24|Change From Baseline in eGFR Calculated by the Chronic Kidney Disease Epidemiology Collaboration Method Based on Cystatin C (eGFR_CKD-EPI,cysC) at Week 24|Change From Baseline in eGFR Calculated by the CKD-EPI Method Based on Serum Creatinine (eGFR_CKD-EPI,Creatinine) at Week 24|Change From Baseline in Actual GFR (aGFR) of E/C/F/TAF for Participants Enrolled in the PK/PD Substudy|Percent Change From Baseline in C-type Collagen Sequence (CTX) at Weeks 24 and 48|Percent Change From Baseline in Procollagen Type 1 N-terminal Propeptide (P1NP) at Weeks 24 and 48|Percent Change From Baseline in Retinol Binding Protein (RBP) to Creatinine Ratio (μg/g) at Weeks 24, 48, 96, and 144|Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio (μg/g) at Weeks 24, 48, 96, and 144|Percentage of Participants Experiencing Adverse Events or Graded Laboratory Abnormalities|Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Weeks 24, 48, 96, and 144|Pharmacokinetic (PK) Parameter: Cmax of TAF|PK Parameter: Tmax of TAF|PK Parameter: Clast of TAF|PK Parameter: Tlast of TAF|PK Parameter: λz of TAF|PK Parameter: AUCtau of TAF|PK Parameter: t1/2 of TAF|PK Parameter: AUCtau of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cell (PBMC) for Participants Enrolled in PK/PD Sub-study|Change From Baseline in the eGFR_CG at Weeks 48, 96, and 144|Change From Baseline in eGFR_CKD-EPI,cysC at Weeks 48, 96, and 144|Change From Baseline in eGFR_CKD-EPI,Creatinine at Weeks 48, 96, and 144","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 3","252","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-292-0112|2013-000516-25","March 27, 2013","July 31, 2014","July 18, 2018","March 26, 2013","February 18, 2016","March 2, 2020","Maricopa Integrated Health System - McDowell Clinic, Phoenix, Arizona, United States|Pueblo Family Physicians, Phoenix, Arizona, United States|Health for Life Clinic PLLC, Little Rock, Arkansas, United States|Pacific Oaks Medical Group, Beverly Hills, California, United States|Kaiser Permanente, Hayward, California, United States|Long Beach Education and Research Consultants, Long Beach, California, United States|LA Gay & Lesbian Center - Jeffrey Goodman Special Care Clinic, Los Angeles, California, United States|Peter J Ruane, MD, Inc, Los Angeles, California, United States|Anthony Mills MD, Inc, Los Angeles, California, United States|Desert Medical Group Inc. dba Desert Oasis Healthcare Medical Group, Palm Springs, California, United States|Kaiser Permanente Medical Group, Sacramento, California, United States|Metropolis Medical, San Francisco, California, United States|Kaiser Permanente CTU San Francisco, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|Dupont Circle Physician's Group, Washington, District of Columbia, United States|Gary J. Richmond, MD PA, Fort Lauderdale, Florida, United States|Midway Immunology and Research Center, Fort Pierce, Florida, United States|Idocf/Valuhealthmd, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Triple O Research Institute, P.A., West Palm Beach, Florida, United States|Rowan Tree Medical, P.A., Wilton Manors, Florida, United States|Infectious Disease Specialists of Atlanta, Decatur, Georgia, United States|Mercer University, Macon, Georgia, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Community Research Initiative of New England, Boston, Massachusetts, United States|The Research Institute, Springfield, Massachusetts, United States|Be Well Medical Center, P.C., Berkley, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|The Kansas City Care Clinic (KC Free Health Clinic), Kansas City, Missouri, United States|Southampton Healthcare, Inc., Saint Louis, Missouri, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|Southwest CARE Center, Santa Fe, New Mexico, United States|Albany Medical College, Albany, New York, United States|Upstate Infectious Diseases Associates, Albany, New York, United States|Jacobi Medical Center, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|North Shore University Hospital/Division of Infectious Diseases, Manhasset, New York, United States|Aids Care, Rochester, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|University of PA HIV Clinical Trials Unit, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|St. Hope Foundation, Bellaire, Texas, United States|North Texas Infectious Diseases Consultants, PA, Dallas, Texas, United States|Garcias' Family Health Group, Harlingen, Texas, United States|Therapeutic Concepts, PA, Houston, Texas, United States|Gordon E. Crofoot MD, PA, Houston, Texas, United States|Peter Shalit, MD, Seattle, Washington, United States|Holdsworth House Medical Practice, Darlinghurst, New South Wales, Australia|Clinical Research Infectious Diseases Department- Alfred Hospital, Melbourne, Victoria, Australia|Prahran Market Clinic, Prahran, Victoria, Australia|Instituto Dominicano de Estudios Virologicos (IDEV), Santo Domingo, Dominican Republic|Hopital de la Croix Rousse, Lyon, France|GHPS Service des maladies infectieuses et tropicales pavillon Laveran unité de recherche clinique, Paris, France|Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Jalisco, Mexico|University Medical Center Utrecht, Utrecht, Netherlands|Hospital Universitari de Bellvitge, Barcelona, Spain|Germans Trias i Pujol University Hospital, Barcelona, Spain|Hospital La Paz, Madrid, Spain|HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand|Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand|Department of Preventive and Social Medicine, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand|Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand|Brighton & Sussex University Hospitals NHS Trust, Brighton, United Kingdom|Kings College London, London, United Kingdom|Chelsea and Westminster NHS Foundation Trust Hospital, London, United Kingdom|Central Manchester University Hospitals NHS foundation Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01818596"
851,"NCT04388930","The Microbiota in Kidney Donation and Transplantation",,"Recruiting","No Results Available","Kidney Diseases|Kidney Transplant Failure and Rejection|Urinary Tract Infections","Other: Pre-operative assessment - blood, urine, & faecal sample|Other: Post-operative day 3 assessment - blood, urine, & faecal sample|Other: Post-operative week 4-6 assessment - blood, urine, & faecal sample|Other: Post-operative 3 month assessment - blood, urine, & faecal sample|Other: Pre-operative 6 month assessment - blood, urine, & faecal sample|Other: Post-operative month 12 recipient assessment - blood, urine, & faecal sample","Change in gastrointestinal and urinary microbiota composition and diversity|Correlation of change in gastrointestinal and urinary microbiota diversity with post-transplantation outcomes.|Change in frequency of conventional and regulatory immune phenotypes and correlation with clinical outcome and microbial diversity changes|Change in microbial-associated metabolite profile and correlation with clinical outcomes and/or microbial diversity changes|Incidence of renal graft dysfunction as determined by the MDRD-derived estimated Glomerular Filtration Rate (eGFR).|The proportion of patients reaching a defined CKD stage at up to 5 years after transplantation.|Incidence of biopsy proven acute or chronic cellular or humoral rejection up to 5 years after transplantation as per Banff classification|Incidence of post-donation and post-transplant bacterial or viral infections up to 5 years after surgery|Patient and graft survival rates up to 5 years after transplantation.","Royal Free Hospital NHS Foundation Trust|University College, London","All","18 Years and older   (Adult, Older Adult)",,"130","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","125570","March 1, 2020","June 1, 2025","June 1, 2025","May 14, 2020",,"December 14, 2023","Royal Free London NHS Trust, London, United Kingdom","""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/30/NCT04388930/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04388930"
852,"NCT04815226","The Role of Active Administration of Peristeen Bowel Evacuation for the Management of Urinary Tract Infection",,"Enrolling by invitation","No Results Available","Neurogenic Bladder|Neurogenic Bowel|Spina Bifida|Fecal Incontinence|Fecal Impaction|Urinary Incontinence","Device: Peristeen Transanal Irrigation","Change in nitrite and leukocyte esterase|Seoul Fecal Scoring|Korean Neurogenic Bowel Dysfunction Score|Safety efficacy of Peristeen Transanal Irrigation","Seoul National University Hospital|Coloplast A/S","All","5 Years to 18 Years   (Child, Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2102-095-1198","April 14, 2021","December 31, 2023","December 31, 2023","March 24, 2021",,"May 6, 2023","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04815226"
853,"NCT05319561","Dissemination and Implementation of a Videoconference Antimicrobial Stewardship Team","VAST","Active, not recruiting","No Results Available","Common Infections|Urinary Tract Infections|Pneumonia","Other: Antibiotic Use Report","Days of Antibiotic Therapy / 1000 Bed Days of Care|Rate of broad-spectrum antibiotics|Antibiotic Starts","VA Office of Research and Development","All","Child, Adult, Older Adult","Not Applicable","8","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IIR 20-246|HX003364","March 28, 2022","March 31, 2025","March 31, 2026","April 8, 2022",,"February 15, 2024","Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States|VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05319561"
854,"NCT02533609","Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis","DIADSORBMAB","Unknown status","No Results Available","Acute Kidney Injury|Bacterial Infection",,"Removal of antibiotic drugs during day 1 - 2 - 3 of citrate anticoagulated CVVHD (mg/d)|Filter patency during day 1 - 2 - 3 of citrate anticoagulated CVVHD","Heinrich-Heine University, Duesseldorf|Fresenius Medical Care Deutschland GmbH","All","18 Years and older   (Adult, Older Adult)",,"30","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2015-02-ENDVERSION","September 2015","August 2020","December 2020","August 27, 2015",,"May 11, 2020","Prof. Kindgen-Milles, Duesseldorf, Germany",,"https://ClinicalTrials.gov/show/NCT02533609"
855,"NCT00695422","Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials",,"Completed","No Results Available","Aids-related Malignancies|Lymphoma|Precancerous Condition|Sarcoma","Genetic: polymerase chain reaction|Other: cytology specimen collection procedure|Other: histological technique|Procedure: colposcopic biopsy","Activity of pharmacotherapeutic agents being investigated in AIDS Malignancy Clinical Trials (AMC) against anogenital human papillomavirus (HPV) infection or anogenital squamous intraepithelial lesions (ASIL)|Cervical HPV infection and cervical/vulvovaginal disease in women participating in AMC clinical trials|Changes in cervical HPV infection and cervical/vulvovaginal disease after treatment on AMC studies|Changes in anal HPV types present|Frequency of ASIL","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC","All","18 Years and older   (Adult, Older Adult)",,"47","Other|NIH|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AMC-058|U01CA121947|CDR0000590397","May 14, 2008","April 19, 2017","April 19, 2017","June 11, 2008",,"August 10, 2020","Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Boston University Cancer Research Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Baylor University Medical Center - Houston, Houston, Texas, United States|Benaroya Research Institute at Virginia Mason Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00695422"
856,"NCT03032003","Prophylactic Use of Cranberries in Recurrent Bacterial Cystitis in Women",,"Unknown status","No Results Available","Recurrent Urinary Tract Infections in Women","Other: Cysticlean|Other: Placebo","Effectiveness of the use of Cranberries in the prevention of the recurrent UTIs is women.","University of Thessaly","Female","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Cranberries1","February 15, 2017","March 31, 2018","May 31, 2018","January 26, 2017",,"January 26, 2017",,,"https://ClinicalTrials.gov/show/NCT03032003"
857,"NCT02882360","Kerlix for Pregnant Women With Elevated BMI to Prevent Wound Infection by 6 Weeks Post Partum",,"Unknown status","No Results Available","Obesity|Wound Infection|Pregnancy","Device: Kerlix-AMD|Other: placebo--normal gauze","surgical site infection|patient satisfaction","Lawson Health Research Institute","Female","15 Years to 50 Years   (Child, Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Health Services Research","106708","October 2016","January 2018","December 2018","August 29, 2016",,"August 29, 2016",,,"https://ClinicalTrials.gov/show/NCT02882360"
858,"NCT02116699","Oropharyngeal Administration of Mother's Colostrum for Premature Infants (NS-72393-360)",,"Completed","No Results Available","Infection|Enterocolitis, Necrotizing|Ventilator-associated Pneumonia","Other: oropharyngeal mother's milk|Other: oropharyngeal sterile water","Incidence of of late-onset sepsis|Incidence of necrotizing enterocolitis|Incidence of ventilator-associated pneumonia|Time to reach full enteral feeds|Length of hospital stay|Concentrations of lactoferrin in urine|Changes in stool microbiome|Changes in urinary biomarkers of oxidative stress","NorthShore University HealthSystem|The Gerber Foundation|Fundacion Para La Investigacion Hospital La Fe|University of Chicago","All","1 Day to 4 Days   (Child)","Not Applicable","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","EH11-360","November 20, 2013","October 30, 2021","January 4, 2022","April 17, 2014",,"March 1, 2023","South Miami Hospital, Miami, Florida, United States|NorthShore University health System, Evanston, Illinois, United States|Advocate Children's Hospital-Park Ridge, Park Ridge, Illinois, United States|Morristown Medical Center, Morristown, New Jersey, United States|Betty Cameron Women & Children's Hospital, Wilmington, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02116699"
859,"NCT02113774","The Impact of Antimicrobial Treatment for Asymptomatic Bacteriuria in Renal Transplant Patients",,"Unknown status","No Results Available","Urinary Tract Infection|Bacteriuria|Renal Transplantation","Other: antimicrobial treatment according to in-vitro susceptibility","development of symptomatic urinary tract infection|25% reduction in estimated glomerular filtration rate (eGFR)","Rabin Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4",,"Other","Interventional","Primary Purpose: Treatment","7687","April 2014","April 2019",,"April 15, 2014",,"April 15, 2014",,,"https://ClinicalTrials.gov/show/NCT02113774"
860,"NCT02490046","D-mannose for the Prevention of UTIs in Multiple Sclerosis",,"Unknown status","No Results Available","Multiple Sclerosis|Recurrent Urinary Tract Infections","Dietary Supplement: D Mannose","Compliance (self-usage diary and weight of returned containers of D-mannose)|Antibiotic prescription (Number of prescriptions for antibiotics required)","University College, London|UCLH","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","14/0384","February 2015","October 2015","November 2015","July 3, 2015",,"July 3, 2015","The National Hospital for Neurology and Neurosurgery, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02490046"
861,"NCT04215991","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants",,"Recruiting","No Results Available","Gram-negative Bacterial Infections|Hospital Acquired Bacterial Pneumonia (HABP)|Complicated Urinary Tract Infection (cUTI)|Ventilator Associated Bacterial Pneumonia (VABP)","Drug: Cefiderocol|Drug: Standard of Care","Number of Participants with Adverse Events in the Single Dose Phase|Maximum Observed Plasma Concentration (Cmax) of Cefiderocol in the Single Dose Phase|Area Under the Plasma Concentration Time Curve Extrapolated from Time 0 to Infinity (AUCinf) of Cefiderocol in the Single Dose Phase|Apparent Terminal Elimination Half-life of Cefiderocol in the Single Dose Phase|Number of Participants with Adverse Events in the Multiple Dose Phase|Maximum Observed Plasma Concentration of Cefiderocol in the Multiple Dose Phase|Area Under the Plasma Concentration Time Curve Over the Dosing Interval τ (AUC0-τ) of Cefiderocol in the Multiple Dose Phase|Apparent Terminal Elimination Half-life of Cefiderocol in the Multiple Dose Phase","Shionogi|Shionogi Inc.","All","3 Months to 17 Years   (Child)","Phase 2","85","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1704R2133|2019-002121-30","February 19, 2020","May 15, 2024","June 15, 2024","January 2, 2020",,"January 24, 2024","Cook Children's Medical Center, Fort Worth, Texas, United States|Queensland Children's Health Precinct Level 8, Centre for Children's Health Research 62 Graham Street, South Brisbane, Queensland, Australia|Heraklion University General Hospital, Heraklion, Crete, Greece|University General Hospital of Larissa, Larissa, Thessaly, Greece|University Hospital ""ATTIKON"" 3rd Pediatric Clinic of NKUA, Chaidari, Greece|Hippokration Hospital 3rd Pediatric Clinic of AUTH Konstantinoupoleos 49, Thessaloniki, Greece|General Hospital of Thessaloniki Papageorgiou, Thessaloniki, Greece|Hospital of Lithuanian University of Health Sciences Kauno klinikos, Kaunas, Lithuania|Klaipeda Children's Hospital, Klaipeda, Lithuania|Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania|Hospital Civil de Guadalajara Hospital 278, El retiro, Torre Piso 10, Infectología Ped., Guadalajara, Jalisco, Mexico|Instituto Nacional de Pediatría ""Laboratorio de la Unidad de Apoyo a la Investigación Clínica"", Planta Baja Col. Insurgentes Cuicuilco, Delegacion Coyoacán Av. Insurgentes Sur 3700-C, Ciudad de México, Mexico|Hospital de Especialidades Ped Via España y Calle Zarak, Ciudad de Panama, Panama|Hospital del Niño, Epidemiologia, Panama City, Panama|Chong Hua Hospital, Cebu City, Philippines|Western Visayas and Medical Center, Iloilo City, Philippines|Manila Doctor's Hospital, Manila, Philippines|Hospital Val d'Hebron, Barcelona, Spain|Hospital del Mar, Passeig Marítim 25-29, Barcelona, Spain|Municipal Noncommercial Enterprise of Kharkiv Regional Council "" V.I.Shapoval Regional Clinical Center of Urology and Nephrology"", Department of Children Urology # 7, Kharkiv, Ukraine|Vinnytsia Regional Children's Hospital, Vinnytsia, Ukraine|Zaporizhzhia Regional Children Clinical Hospital, Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT04215991"
862,"NCT03930017","Pregnancy, Arsenic and Immune Response","PAIR","Completed","No Results Available","Arsenic--Toxicology|Immunologic Disorders Complicating Pregnancy|Vaccine Response Impaired|Micronutrient Deficiency|Influenza","Biological: Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated)","Change in influenza hemagglutination-inhibition (HI) antibody titer|Mean percent influenza virus antibody avidity|Seroconversion rate|Change in geometric mean HI antibody titer (GMT)|Geometric mean ratio of infant:mother HI titer|Change in influenza virus neutralizing antibody titer|Change in anti-influenza virus total immunoglobulin G (IgG) enzyme immunoassay|Maternal influenza-like illness (ILI)|Infant influenza-like illness (ILI)|Laboratory-confirmed influenza (LCI)|Acute respiratory illness (ARI)","Johns Hopkins Bloomberg School of Public Health|Sanofi Pasteur, a Sanofi Company|Institute of Epidemiology, Disease Control and Research|Johns Hopkins Bangladesh - The JiVitA Project Site|University of Graz|Columbia University|UNC Gillings School of Global Public Health","Female","13 Years to 45 Years   (Child, Adult)",,"784","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","R01ES026973","October 14, 2018","January 6, 2020","January 6, 2020","April 29, 2019",,"January 5, 2023","JiVitA Maternal and Child Health and Nutrition Research Program, Gaibandha, Bangladesh",,"https://ClinicalTrials.gov/show/NCT03930017"
863,"NCT06296615","Whether Vaginal Microbiota Affects Pregnancy Outcomes After Embryo Transfer",,"Completed","No Results Available","Infertility, Female|Microbial Colonization",,"Rate of clinical pregnancy","ShangHai Ji Ai Genetics & IVF Institute","Female","20 Years to 40 Years   (Adult)",,"161","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2020-022","April 1, 2021","October 30, 2022","October 30, 2022","March 6, 2024",,"March 8, 2024","Shanghai Ji Ai Genetics & IVF Institute, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT06296615"
864,"NCT05963711","The Genital Microbiome of Male Partners of Women With Recurrent BV Undergoing Vaginal Microbiome Transplantation",,"Recruiting","No Results Available","Bacterial Vaginosis|Microbial Colonization","Other: chlorhexidine gluconate 4%","Penile microbiome composition|Penile microbiome composition after disinfection","Hadassah Medical Organization","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","0463-22-HMO","October 17, 2022","December 2025","June 2026","July 27, 2023",,"July 27, 2023","Hadassah Medical Center, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT05963711"
865,"NCT00158509","Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding",,"Completed","No Results Available","Herpes Genitalis|HIV Infection","Drug: Valacyclovir","To assess the impact of HSV-2 suppressive therapy on HIV shedding among co-infected women taking highly active antiretroviral therapy (HAART) or not needing HAART|To assess the impact of HSV-2 suppressive therapy on HSV-2 shedding among co-infected women taking HAART or not needing HAART","French National Agency for Research on AIDS and Viral Hepatitis","Female","16 Years and older   (Child, Adult, Older Adult)","Phase 2","215","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","ANRS 1285","August 2004",,"July 2005","September 12, 2005",,"June 7, 2006","Service d'Hygiene du Centre Muraz, Bobo-Dioulasso, Burkina Faso",,"https://ClinicalTrials.gov/show/NCT00158509"
866,"NCT03345875","Feasibility and Acceptability of HPV Self-Collection Cervical Cancer Screening and Treatment in Botswana",,"Completed","No Results Available","Human Papillomavirus Infection|Cervical Cancer","Diagnostic Test: HPV self collection, followed by visual assessment of the cervix for treatment (VAT) and treatment","Screening-to-treatment completion rates for assessing feasibility of HPV self collection, VAT screening and treatment|Qualitative interviews and surveys to assess acceptability of HPV Self Collection from women|Qualitative interviews and surveys to assess acceptability of HPV Self Collection from health providers and managers","Jhpiego|Botswana Ministry of Health","Female","30 Years to 49 Years   (Adult)","Not Applicable","1022","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","IRB00007974","October 16, 2017","June 30, 2018","June 30, 2018","November 17, 2017",,"August 9, 2018","Kopong Health Clinic, Kopong, Botswana|Lephepe Health Clinic, Lephepe, Botswana|Phuthadikobo, Molepolole, Botswana|Scottish Livingstone Hospital, Molepolole, Botswana|Thamaga Health Clinic, Thamaga, Botswana",,"https://ClinicalTrials.gov/show/NCT03345875"
867,"NCT01843166","Vaginal Estrogen With Pessary Treatment",,"Completed","No Results Available","Vaginal Infection|Urinary Tract Infection|Quality of Life","Drug: Premarin vaginal cream|Drug: Placebo cream","Vaginal infections|Frequency of urinary tract infection|Quality of life","Lawson Health Research Institute|Academic Medical Organization of Southwestern Ontario|University of Western Ontario, Canada","Female","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","102186|18798","July 2012","December 2016","December 2016","April 30, 2013",,"November 6, 2018","London Health Sciences Centre, University of Western Ontario, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01843166"
868,"NCT01558336","Schistosoma Haematobium Infections and Praziquantel",,"Completed","No Results Available","Schistosomiasis","Drug: praziquantel","cure rate|reduction in the intensity of infection by","University of Khartoum|Hikma Pharmaceuticals LLC","All","6 Years to 15 Years   (Child)","Phase 3","520","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Schistosmiasis","August 2008","August 2012","September 2012","March 20, 2012",,"January 17, 2013","Al Salamania, Al Salamania, Nile, Sudan",,"https://ClinicalTrials.gov/show/NCT01558336"
869,"NCT04836910","Microbiome and Polycystic Ovaries",,"Recruiting","No Results Available","Polycystic Ovary Syndrome|Microbial Colonization","Other: Dietary recommendations|Drug: Oral contraceptive pills|Drug: Metformin","Vaginal and gut microbiota composition before and after intervention recommended and in comparison to women without PCOS.|Hirsutism|Acne|Fertility","Sheba Medical Center","Female","18 Years to 42 Years   (Adult)",,"40","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","8032-20-SMC","September 1, 2024","March 30, 2026","March 30, 2026","April 8, 2021",,"December 5, 2023","Sheba Medical Center, Ramat-Gan, Israel",,"https://ClinicalTrials.gov/show/NCT04836910"
870,"NCT00115388","Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease","POPI","Completed","No Results Available","Pelvic Inflammatory Disease|Chlamydia Infections","Procedure: Screening for chlamydia using self-taken vaginal swabs","Primary outcome measure in the complete cohort: Incidence of clinical PID over 12 months in intervention and control groups.|Secondary outcome measures after 12 months in women with chlamydial infection at baseline:|Control group (untreated):|Incidence of PID.|Percentage with spontaneous clearance of genital infection.|Relative risk of PID in women with and without BV|3. Intervention group (treated): Reinfection rate.","St George's, University of London","Female","16 Years to 27 Years   (Child, Adult)","Not Applicable","2531","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","COHSR4PG","September 2004","December 2008","December 2008","June 22, 2005",,"November 24, 2014","St George's Hospital Medical School, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00115388"
871,"NCT00138450","Urinary Schistosomiasis Infection",,"Completed","No Results Available","Diseases of the Urinary System|Schistosomiasis Haematobia",,,"National Institute of Allergy and Infectious Diseases (NIAID)","All","up to 99 Years   (Child, Adult, Older Adult)",,"4400","NIH","Observational","Time Perspective: Prospective","01-588",,,"November 2004","August 30, 2005",,"January 30, 2019","KEMRI Centre for Geographic Medicine Research, Kilifi, Kenya",,"https://ClinicalTrials.gov/show/NCT00138450"
872,"NCT01926353","Polyacrylate Polyalcohol Copolymer for Vesicoureteral Reflux",,"Completed","No Results Available","Vesicoureteral Reflux (VUR)|Urinary Tract Infection",,"Rate of Treatment success|Rate of renal scar development|Length of VUR treatment related hospital stay|Rate of failed treatment response","St. Luke's Medical Center, Philippines","All","1 Year to 5 Years   (Child)",,"25","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","SLMC13-100","July 2013","February 2014","February 2014","August 20, 2013",,"April 7, 2015","St. Luke's Medical Center, Quezon City, NCR, Philippines",,"https://ClinicalTrials.gov/show/NCT01926353"
873,"NCT04987164","Incidence of Cystitis in Women Consuming a Mixture of Cranberry, Cinnamon, Probiotics",,"Completed","No Results Available","Cystitis|Urinary Tract Infections","Dietary Supplement: Feminabiane CBU","Occurence of symptomatic cystitis-like episodes|Change of the quality of life related to urinary discomfort|Severity of urinary discomfort|Time-period without antibiotics|Mean time to onset of symptomatic episodes of the cystitis|Effect of blend consumption in preventing symptomatic episode of cystitis","CEN Biotech|PiLeJe","Female","18 Years to 65 Years   (Adult, Older Adult)",,"80","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","C1671","November 18, 2021","August 4, 2022","August 4, 2022","August 3, 2021",,"March 2, 2023","CEN Nutriment, Dijon, Bourgogne, France|CEN Nutriment, Dijon, Burgundy, France",,"https://ClinicalTrials.gov/show/NCT04987164"
874,"NCT02742636","When is the Best Moment to Remove the Urinary Catheter After Laparoscopic Hysterectomy?","MUCH","Completed","No Results Available","Urinary Tract Infection|Bladder Retention","Device: Foley catheter","Urinary retention (inability to void)|Rate of re-catheterisation|Urinary tract infection (by performing a urine dipstick test and based on clinical symptoms)|Patient satisfaction (self-administrated questionnaire)|Visual analogue scale score (VAS score)","Leiden University Medical Center|Bronovo Hospital|Haga Hospital|Alrijne Hospital|Reinier de Graaf Groep|Groene Hart Ziekenhuis|Medical Center Haaglanden","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","162","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","P15.382","May 31, 2016","June 21, 2017","June 21, 2017","April 19, 2016",,"August 23, 2017","Leiden University Medical Center, Leiden, Noord-Holland, Netherlands|Reinier de Graaf Groep, Delft, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|Alrijne Hospital, Leiden, Netherlands|Bronovo Hospital, The Hague, Netherlands|Haga Hospital, the Hague, Netherlands|Medisch Centrum Haaglanden, the Hague, Netherlands",,"https://ClinicalTrials.gov/show/NCT02742636"
875,"NCT02598362","Pharmacokinetics of Ciprofloxacin in Pediatric Patients",,"Completed","No Results Available","Urinary Tract Infection|Pyelonephritis","Drug: ciprofloxacin","Serum concentrations|Urine concentrations","University Hospital, Ghent|Universitair Ziekenhuis Brussel","All","3 Months to 17 Years   (Child)","Phase 4","22","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-004638-24","April 2015","May 2017","October 2017","November 5, 2015",,"September 5, 2023","Universitair Ziekenhuis Brussel, Brussel, Belgium|Ghent University Hospital, Ghent, Belgium",,"https://ClinicalTrials.gov/show/NCT02598362"
876,"NCT03960970","Two-drug Antibiotic Prophylaxis in Scheduled Cesarean Deliveries",,"Unknown status","No Results Available","Endometritis|Cesarean Section; Infection|Wound Infection","Drug: Azithromycin 500 mg|Drug: Mefoxin 2g","Rates of Endometritis|Rates of Wound Infection|Rates of Maternal Fever|Rates of Maternal Postpartum Readmission or Unscheduled Visit|Rates of Postpartum Antibiotic Use|Rates of Serious Adverse Events","RWJ Barnabas Health at Jersey City Medical Center","Female","18 Years and older   (Adult, Older Adult)","Phase 2","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Prophylaxis Trial","September 15, 2019","September 30, 2019","November 30, 2020","May 23, 2019",,"September 17, 2019","Jersey City Medical Center, Jersey City, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03960970"
877,"NCT02455375","Diagnostic of Puumala Virus Infection in France","HANTADIAG","Completed","No Results Available","Nephropathia Epidemica|Hemorrhagic Fever With Renal Syndrome",,"Proportion of patients positive for the detection of IgG or IgM againt PUUV by commercial assays and by molecular/serological techniques|Proportion of urine samples tested positive for the detection of PUUV","Centre Hospitalier de Charleville-Mézières|Institut Pasteur","All","18 Years to 75 Years   (Adult, Older Adult)",,"179","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","PHRC-14-0063","July 2015","November 30, 2021","November 30, 2021","May 27, 2015",,"August 25, 2023","CH Belfort-Montbéliard, Belfort, France|CHU Besançon, Besançon, France|CH Charleville Mézières, Charleville Mézières, France|CHP Sud de l'Oise, Creil, France|CHU Dijon, Dijon, France|CH de Laon, Laon, France|CHU Reims, Reims, France|CH de Saint Claude, Saint Claude, France|CHU Nancy, Vandoeuvre Les Nancy, France|CH de Verdun, Verdun, France",,"https://ClinicalTrials.gov/show/NCT02455375"
878,"NCT04165122","Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection","MATCH-2","Completed","No Results Available","Herpes Genitalis","Biological: HDIT101|Drug: Valaciclovir|Biological: HDIT101 placebo|Drug: Valaciclovir placebo","Percentage of days with lesion(s) per treatment group|Time to first recurrence of lesion|Recurrence rate of lesions|Duration of recurrent lesions|Disease-specific symptoms|Herpes outbreak impact|QoL","Heidelberg ImmunoTherapeutics GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","122","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HTX101-02G","November 15, 2019","August 25, 2021","November 1, 2021","November 15, 2019",,"January 18, 2022","emovis GmbH, Berlin, Germany|Praxis Jessen2+Kollegen, Berlin, Germany|WIR ""Walk In Ruhr"" im St. Elisabeth Hospital, Bochum, Germany|Infektio Research GmbH & Co. KG, Frankfurt, Germany|Universitätsklinikum Freiburg, Medizin II, Infektiologie, Freiburg, Germany|ICH Grindel, Hamburg, Germany|Dr. Scholten und Schneeweiß GbR, Koeln, Germany|Prinzmed, Muenchen, Germany",,"https://ClinicalTrials.gov/show/NCT04165122"
879,"NCT00330278","Timing of Prophylactic Antibiotics for Cesarean Sections",,"Completed","No Results Available","Endometritis|Wound Infection","Drug: Cefazolin","Combined infectious morbidity - endometritis + wound infection|Neonatal sepsis|Allergic reactions","Medical University of South Carolina","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","HR # 11120","January 2003",,"January 2006","May 26, 2006",,"September 27, 2007","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00330278"
880,"NCT01708889","Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction","PK","Completed","No Results Available","Chronic Hepatitis B Virus Infection|Chronic Hepatitis C Virus Infection","Biological: BMS-914143 (Peginterferon Lambda-1a)","Area under the serum concentration-time curve from time 0 extrapolated to infinity [AUC(INF)] of a single 180-μg subcutaneous (SC) dose of Lambda in subjects with normal renal function and subjects with renal dysfunction|Area under the serum concentration-time curve from time 0 to the time of last quantifiable concentration [AUC(0-T)] of a single 180-μg subcutaneous (SC) dose of Lambda in subjects with normal renal function and subjects with renal dysfunction|Maximum observed serum concentration (Cmax) of a single 180-μg subcutaneous (SC) dose of Lambda in subjects with normal renal function and subjects with renal dysfunction|Apparent volume of distribution (Vz/F) of a single 180-μg subcutaneous (SC) dose of Lambda in subjects with normal renal function and subjects with renal dysfunction|Total body clearance (CLT/F) of a single 180-μg subcutaneous (SC) dose of Lambda in subjects with normal renal function and subjects with renal dysfunction|Time to maximum observed serum concentration (Tmax) using serum levels of Lambda|Half life (T-HALF) using serum levels of Lambda|Immunogenicity assessed by serum levels of anti-Lambda antibodies|Safety assessed by Vital signs measurements, electrocardiograms (ECGs), clinical laboratory tests, marked laboratory abnormalities, physical measurements, and adverse events (AEs)|Serious adverse events (SAEs) Safety assessed by Vital signs measurements, electrocardiograms (ECGs), clinical laboratory tests, marked laboratory abnormalities, physical measurements, and adverse events (AEs)","Bristol-Myers Squibb","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","43","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","AI452-019","September 2012","February 2013","February 2013","October 17, 2012",,"June 5, 2013","Clinical Pharmacology Of Miami Inc., Miami, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States|New Orleans Center For Clinical Research - Knoxville, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01708889"
881,"NCT03677960","Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection",,"Terminated","No Results Available","HSIL, High-Grade Squamous Intraepithelial Lesions|Human Papilloma Virus Infection|HIV Infection|Anal Cancer|Anus Neoplasm","Drug: Topical ABI-1968 cream","Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of aHSIL|Systemic exposure to ABI-1968 Topical Cream following topical application to the anal canal.","Antiva Biosciences","All","27 Years and older   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-1968-202","December 17, 2018","June 30, 2019","June 30, 2019","September 19, 2018",,"July 24, 2019","Research Center, Chicago, Illinois, United States|Research Center, Darlinghurst, Sydney, Australia",,"https://ClinicalTrials.gov/show/NCT03677960"
882,"NCT03282006","Treating Pyelonephritis an Urosepsis With Pivmecillinam","MePUr","Completed","No Results Available","Pyelonephritis|Urinary Tract Infections","Drug: pivmecillinam","Clinical efficacy|C-reactive protein-level (CRP)|Readmission due to urinary tract infection (UTI)|Readmission - any cause|Adverse effects|Microbial efficacy","Sykehuset i Vestfold HF|University of Oslo","All","18 Years to 110 Years   (Adult, Older Adult)","Phase 4","53","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-000984-18","September 29, 2017","April 21, 2020","April 21, 2020","September 13, 2017",,"April 22, 2020","Vestfold Hospital Trust, Tønsberg, Vestfold, Norway",,"https://ClinicalTrials.gov/show/NCT03282006"
883,"NCT04092257","HPV-Based Screen-and-Treat Demonstration Project in Lilongwe",,"Active, not recruiting","No Results Available","HPV Infection|Cervical Cancer|HIV Infections","Procedure: VIA and thermocoagulation","Number (and %) of women with HPV-positive results who receive VIA same-day|Number (and %) of women with VIA positive results and are ablation-eligible by colposcopy who receive thermocoagulation same-day","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)|United States Agency for International Development (USAID)","Female","25 Years to 50 Years   (Adult)","Not Applicable","1250","Other|NIH|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 1905|R21CA236770|AID-OAA-A-11-00012","June 24, 2020","February 28, 2024","February 28, 2025","September 17, 2019",,"March 15, 2024","University of North Carolina (UNC) Project-Malawi, Lilongwe, Malawi",,"https://ClinicalTrials.gov/show/NCT04092257"
884,"NCT05340322","Identification and Treatment of Cervical Abnormalities in Perú Through Integration of Pocket Colposcopy and Telemedicine",,"Completed","No Results Available","Cervical Cancer|HPV Infection|HIV Infections","Device: Colposcopy using pocket colpscope and thermocoagulator","Number of HPV+ women examined|Proportion of HPV positive women who completed the 6 month follow-up after evaluation and treatment.","Duke University|United States Agency for International Development (USAID)|Universidad Peruana Cayetano Heredia","Female","30 Years to 49 Years   (Adult)","Not Applicable","497","Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00106490","May 1, 2022","April 15, 2023","October 15, 2023","April 22, 2022",,"November 30, 2023","Universidad Peruana Cayetano Heredia, Lima, Peru",,"https://ClinicalTrials.gov/show/NCT05340322"
885,"NCT04603664","Role of NGAL and Cystatin C in Prediction of Acute Kidney Injury Covid-19 Infection",,"Completed","No Results Available","Biochemical Markers ,NGAL,Cystatin c, Acute Kidneyinjury, Covid 19","Diagnostic Test: serum NGAL and cystatin c","measure both cystatin c and Neutrophil gelatinase-associated lipocalin on admission and after 48 hours. (NGAL) as recent biomarkers in prediction of AKI in patients with COVID-19.|development of acute kidney injury lipocalin (NGAL) to AKI severity and prognosis of AKI in patients with COVID-19 infection","Ain Shams University","All","18 Years to 85 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","FMASU P82b/2020","October 30, 2020","June 30, 2021","June 30, 2021","October 27, 2020",,"September 13, 2021","Ainshams hospitals, Cairo, Egypt|Sanaa Wasfy, New Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04603664"
886,"NCT03187457","PreFem: ""What Happens to the Vaginal Microbiota When a BV Infection is Treated With Metronidazole?""","PreFem","Completed","No Results Available","Bacterial Vaginosis","Other: Metronidazole|Other: Control: no treatment","Change in vaginal microbiota assessed with sequencing|Vaginal microbiota/lactobacilli levels with Nugent scoring|Diagnosis of BV with ""Canestest""","Danisco|Community Pharmacology Services Ltd","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","NH-03708","September 4, 2017","November 14, 2017","November 14, 2017","June 15, 2017",,"December 13, 2017","CPS Research, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03187457"
887,"NCT02537847","Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli","SETAP","Unknown status","No Results Available","Infection Due to Escherichia Coli|Acute Pyelonephritis","Drug: Sitafloxacin|Drug: Ertapenem","no symptoms of urinary tract infection|no evidence of Extended Spectrum Beta Lactamase Escherichia coli in urine culture","Mahidol University","All","18 Years and older   (Adult, Older Adult)","Phase 2","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Sitafloxacin123","November 2012","September 2015","May 2016","September 2, 2015",,"September 2, 2015","Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT02537847"
888,"NCT03202992","Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection",,"Completed","No Results Available","HSIL, High-Grade Squamous Intraepithelial Lesions|Human Papilloma Virus Infection|HIV Infection|Anal Cancer|Anus Neoplasms","Drug: ABI-1968","Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of aHSIL|Systemic exposure to ABI-1968 Topical Cream following topical application to the anal canal.|Histopathology of areas with biopsy-proven disease following single and multiple doses of ABI-1968 Topical Cream.","Antiva Biosciences","All","27 Years and older   (Adult, Older Adult)","Phase 1","57","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-1968-201","August 11, 2017","February 4, 2019","February 4, 2019","June 29, 2017",,"February 7, 2019","Research Center, San Francisco, California, United States|Research Center, Orlando, Florida, United States|Research Center, Chicago, Illinois, United States|Research Center, New York, New York, United States|Research Center, Winston-Salem, North Carolina, United States|Research Center, Sydney, Darlinghurst, Australia",,"https://ClinicalTrials.gov/show/NCT03202992"
889,"NCT04998318","1:1 Comparison of the Pocket Colposcope in Kenya",,"Recruiting","No Results Available","Cervical Cancer|HPV Infection|HIV Infections","Device: Pocket Colposcope|Procedure: Standard of Care Colposcopy","Percentage of lesions identified by the pocket colposcope|Percentage of lesions identified by the visual inspection|Percentage of Provider who identified possible obstacles as measured by surveys|Percentage of participants who identified possible obstacles as measured by surveys","Duke University|Kenya Medical Research Institute","Female","25 Years to 65 Years   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pro00106169","November 28, 2022","April 2024","April 2024","August 10, 2021",,"January 10, 2024","Kenya Medical Research Institute, Nairobi, Kenya",,"https://ClinicalTrials.gov/show/NCT04998318"
890,"NCT00414362","Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin",,"Completed","No Results Available","Urinary Tract Infection|Fluoroquinolone|Bacteremia",,"dead or alive","University of Pittsburgh|Japan Health Sciences Foundation","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","IRB#0611103|no additional IDs","February 2007","June 2017","June 2017","December 21, 2006",,"June 12, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00414362"
891,"NCT04491227","Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection",,"Unknown status","No Results Available","Covid19|AKI|CKD|ESRD|Transplant;Failure,Kidney",,"AKI incidence|Dialysis requirement|hospital mortality|Renal functional recovery|Functional status|Resource utilization","University of California, San Diego","All","18 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","000295","May 5, 2020","April 30, 2022","March 31, 2023","July 29, 2020",,"July 29, 2020","University of Alabama, Birmingham, Birmingham, Alabama, United States|University of California, San Diego, San Diego, California, United States|University of Colorado, Aurora, Colorado, United States|St. Peter's Hospital, Albany, New York, United States|Jacobi Medical Center, New York, New York, United States|Hospital Obrero #2, Cochabamba, Bolivia|Hopital Sacre Coeur & Universite de Montreal, Montreal, Quebec, Canada|Universidad de Los Andes, Santiago, Chile|Postgraduate Institute of Research, Chandigarh, Chandigarh, India|Royal Free Hospital, London, United Kingdom|Guy's & St Thomas's Hospital, London, United Kingdom|University of Nottingham, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04491227"
892,"NCT05226416","Analysis of Health Status of Сomorbid Adult Patients With COVID-19 Hospitalised in Fourth Wave of SARS-CoV-2 Infection","ACTIV4","Completed","No Results Available","COVID-19|Chronic Heart Failure|Diabetes Mellitus|Chronic Kidney Diseases|Ischemic Heart Disease|Arrythmia|Hypertensive Heart Disease|Overweight and Obesity|Oncology|Ischemic Stroke|Myocardial Infarction|Atrial Fibrillation|DVT|Stroke|Copd|Asthma|Pulmonary Embolism|Anemia|Myocarditis",,"death for any cause|hospitalization for any cause|onset of any disease diagnosed 1 year after discharge|rate of demand for medical care","Eurasian Association of Therapists","All","18 Years and older   (Adult, Older Adult)",,"3554","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ACTIV4","February 21, 2022","March 31, 2022","April 21, 2023","February 7, 2022",,"May 9, 2023","Eurasian Association of Therapists, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05226416"
893,"NCT01588301","Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention","APACHE-2","Completed","No Results Available","Cervical Cancer|Human Papillomavirus Infection","Behavioral: Attending for cervical cytology|Behavioral: Kit for Self-collected vaginal sample","Comparison of women's attitude according to the arm: participation or not to a whole screening action|Analysis in sub-groups|Identification of the psychological determinants and mechanisms (checks and motivational factors)","University Hospital, Tours","Female","30 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","5998","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening","INCA08-KH / APACHE-2","February 2012","December 2012","December 2012","April 30, 2012",,"September 12, 2014",,,"https://ClinicalTrials.gov/show/NCT01588301"
894,"NCT06256471","The Impact of Parasitic Infection on Multiple Sclerosis and Nephrotic Syndrome",,"Not yet recruiting","No Results Available","Parasitic Disease","Other: Follow up of multiple sclerotic and nephrotic syndrome patients after 3 months","The impact of parasitic infection on multiple sclerosis and nephrotic syndrome","Assiut University","All","up to 50 Years   (Child, Adult)",,"200","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","Parasitic infection","June 1, 2024","June 1, 2025","August 1, 2025","February 13, 2024",,"February 13, 2024",,,"https://ClinicalTrials.gov/show/NCT06256471"
895,"NCT01405183","Association Between Hepatitis C Infection and Renal Cell Carcinoma",,"Completed","No Results Available","Hepatitis C|Renal Cell Carcinoma|Colorectal Cancer","Other: Hepatitis C testing","Prevalence of hepatitis C in renal cell carcinoma patients","Henry Ford Health System|Schering-Plough","All","18 Years and older   (Adult, Older Adult)",,"240","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","P08406","January 2011","August 2013","September 2013","July 29, 2011",,"September 17, 2014","Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01405183"
896,"NCT04587050","Screening for HPV and Cervical Cancer in Young Women With Perinatally Acquired HIV","SHiP","Recruiting","No Results Available","HIV Infections|Human Papillomavirus Infection|Cervical Cancer","Diagnostic Test: Human papillomavirus testing|Diagnostic Test: Cervical cytology|Diagnostic Test: HPV serology","Prevalence of abnormal cervical cytology|Prevalence of high risk HPV by subtype|Prevalence of CIN2+|HPV type-specific antibody titres (16/18)","Imperial College London|Public Health England","Female","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","19SM5242","July 19, 2021","July 2023","December 2023","October 14, 2020",,"August 5, 2022","Imperial College Healthcare NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04587050"
897,"NCT05570331","Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women",,"Recruiting","No Results Available","HPV Infection|Cervical Cancer","Diagnostic Test: HPV integration test","Risk of CIN2+ disease|Risk of CIN3+ disease","Ding Ma|Tongji Hospital","Female","20 Years to 70 Years   (Adult, Older Adult)",,"2200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TJ-IRB20220142","January 1, 2022","February 28, 2023","December 31, 2025","October 6, 2022",,"October 6, 2022","Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT05570331"
898,"NCT04264130","Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection","SACT","Completed","No Results Available","Schistosomiasis Haematobia","Drug: Artesunate-Pyronaridine|Drug: Artemether-Lumefantrine|Drug: Artefenomel-Ferroquine","Egg Reduction Rate (ERR)|Cure Rate (CR)","Centre de Recherche Médicale de Lambaréné","All","Child, Adult, Older Adult","Phase 2","54","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CEI-006/2018","July 31, 2018","December 31, 2019","December 31, 2019","February 11, 2020",,"February 11, 2020","Centre de Recherches Medicales de Lambarene, Lambaréné, Gabon",,"https://ClinicalTrials.gov/show/NCT04264130"
899,"NCT04552210","Mannose Binding Lectin Gene Polymorphism Versus Microbial Virulence in the Pathogenesis of Vulvovaginal Candidiasis",,"Unknown status","No Results Available","Infection","Diagnostic Test: blood sample","the number of women who have mutation in MBL2 gene polymorphism","Aljazeera Hospital|Cairo University","Female","18 Years to 42 Years   (Adult)",,"50","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Mannose","September 16, 2020","December 15, 2020","February 20, 2021","September 17, 2020",,"November 10, 2020","Algazeerah, Giza, Egypt",,"https://ClinicalTrials.gov/show/NCT04552210"
900,"NCT05691179","COVID-19 Infection and Idiopathic Membranous Nephropathy",,"Recruiting","No Results Available","Idiopathic Membranous Nephropathy",,"primary outcome|secondary outcome","Beijing Friendship Hospital|Beijing Pinggu District Hospital|Beijing Fangshan District Liangxiang Hospital","All","18 Years and older   (Adult, Older Adult)",,"130","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2022-P2-429-01","December 10, 2022","May 31, 2023","May 31, 2023","January 19, 2023",,"February 14, 2023","Beijing Friedship Hospital, Beijing, Beijing, China|Beijing Pinggu Hospital, Beijing, Beijing, China|Beijing Liangxiang Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05691179"
901,"NCT00308906","Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children",,"Completed","No Results Available","Infection|Renal Dysfunction","Drug: aminoglycoside","Indicators of renal injury","Virginia Commonwealth University|University of Louisville","All","up to 18 Years   (Child, Adult)",,"166","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Aminoglycoside Waste Specimen","June 2006","December 2010","December 2010","March 30, 2006",,"February 2, 2016","University of Lousiville, Louisville, Kentucky, United States|Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00308906"
902,"NCT04664127","Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel",,"Completed","No Results Available","Herpes|Herpes Simplex|Herpes Oral|Herpes Simplex 2|Herpes Genitalis","Drug: Kagocel+Valacyclovir|Drug: Valacyclovir","Change of the patients proportion with different localizations of herpes simplex exacerbations.|Change of the rate of exacerbations of orolabial, genital and other localization herpes simplex|Change of the number of patients with varying degrees of severity illness|Change in the number of local complaints (pain, itching, burning, rash) against the background of a recurrence of herpes simplex|Number of participants with treatment-related adverse events (AE) with regards to type and severity of AE (mild, moderate, severe; according to physician's opinion)|Change of the duration of each herpes simplex relapse and the rate of epithelialization|Change of the occurrence rate of morphological elements of the rash and General symptoms|Change of the rate of herpes simplex rash (relapses)|Change of the intensity of herpes simplex exacerbations in points|Change in the number of herpes viruses in saliva and blood by PCR|Change of antibodies titers to herpes simplex viruses type 1 and 2|Change of immune status parameters (flow cytometry)|Change of lymph nodes sizes (submandibular, axillary, inguinal) according to ultrasound data|The assessment of quality of life according to questionnaire","Nearmedic Plus LLC","All","18 Years to 100 Years   (Adult, Older Adult)",,"45","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","version 1.0 from 20.10.2017","October 30, 2017","October 29, 2018","October 29, 2018","December 11, 2020",,"December 11, 2020","Scientific Information Center for Prevention and Treatment of Viral Infections, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04664127"
903,"NCT04057924","Therapeutic Abstention and Surveillance of Intra-epithelial Histological Lesions of High Grade Cervical CIN2 (Cervical Intraepithelial Neoplasia Grade 2). SUIVICIN","SUIVICIN","Recruiting","No Results Available","HPV Infection|Cervical Cancer","Other: abstention from CIN2 treatment and surveillance for at least 2 years","rate of spontaneous regression of CIN2 at 2 years|rate of regression of CIN2 at 4 years|4-year regression rate of CIN2 that persisted for 2 years|HPV viral expression","University Hospital, Bordeaux","Female","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CHUBX 2019/03","August 23, 2019","September 1, 2029","September 1, 2029","August 15, 2019",,"December 7, 2023","CHU Bordeaux, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT04057924"
904,"NCT04714060","UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals",,"Not yet recruiting","No Results Available","Recurrent Genital Herpes","Biological: UB-621","Proportion of subjects with episodes before and after UB-621 treatment (self-comparison)|Lesion rate|Duration of recurrent lesions|Recurrence rate|Time to first recurrence of lesion","UBP Greater China (Shanghai) Co., Ltd","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","UBP-A228-HSV","October 1, 2023","October 1, 2024","January 31, 2025","January 19, 2021",,"May 18, 2022",,,"https://ClinicalTrials.gov/show/NCT04714060"
905,"NCT01140516","Effectiveness of Antibiotics Versus Placebo to Treat Antenatal Hydronephrosis","ALPHA","Active, not recruiting","No Results Available","Hydronephrosis|Urinary Tract Infection","Drug: Trimethoprim|Other: Simple Syrup","To determine whether antibiotics (ATB) prophylaxis prevents urinary tract infection (UTI) in infants with antenatal hydronephrosis (AHN).","McMaster University|The Physicians' Services Incorporated Foundation|Hamilton Health Sciences Corporation|McMaster Surgical Associates","All","1 Month to 7 Months   (Child)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALPHA","July 2010","September 2024","September 2024","June 9, 2010",,"October 19, 2023","McMaster Children's Hospital, Hamitlon, Ontario, Canada|Sick Kids Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01140516"
906,"NCT03425396","Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis",,"Completed","Has Results","Uncomplicated Urinary Tract Infection|Cystitis","Drug: Omadacycline tablets|Drug: Nitrofurantoin capsules","Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population)|Number of Participants With an Investigator Assessment of Clinical Response at the End of Treatment (EOT) Visit (ITT Population)|Number of Participants With an Investigator Assessment of Clinical Response at the EOT Visit (Microbiological [Micro]-ITT Population)|Number of Participants With an Investigator Assessment of Clinical Response at the EOT Visit (CE-EOT Population)|Number of Participants With an Investigator Assessment of Clinical Response at the PTE Visit (CE-PTE Population)|Number of Participants With an Investigator Assessment of Clinical Response at the PTE Visit (Micro-ITT Population)|Number of Participants With an Investigator Assessment of Clinical Response at the Final Follow-up (FFU) Visit (ITT Population)|Number of Participants With an Investigator Assessment of Clinical Response at the FFU Visit (CE-FFU Population)|Number of Participants With an Investigator Assessment of Clinical Response at the FFU Visit (Micro-ITT Population)|Number of Participants With a Microbiological Response at the EOT Visit (Micro-ITT Population)|Number of Participants With a Microbiological Response at the EOT Visit (ME-EOT Population)|Number of Participants With a Microbiological Response at the PTE Visit (Micro-ITT Population)|Number of Participants With a Microbiological Response at the PTE Visit (ME-PTE Population)","Paratek Pharmaceuticals Inc","Female","18 Years and older   (Adult, Older Adult)","Phase 2","225","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PTK0796-UUTI-17201","January 4, 2018","May 15, 2019","June 5, 2019","February 7, 2018","June 4, 2020","June 9, 2020","Site 106, Chula Vista, California, United States|Site 101, La Mesa, California, United States|Site 109, Los Angeles, California, United States|Site 114, Aventura, Florida, United States|Site 102, DeLand, Florida, United States|Site 103, Hialeah, Florida, United States|Site 125, Jacksonville, Florida, United States|Site 127, Miami Springs, Florida, United States|Site 121, Miami, Florida, United States|Site 130, Miami, Florida, United States|Site 115, Miami, Florida, United States|Site 126, Orlando, Florida, United States|Site 113, Newton, Kansas, United States|Site 110, Wichita, Kansas, United States|Site 112, Omaha, Nebraska, United States|Site 132, Las Vegas, Nevada, United States|Site 108, Las Vegas, Nevada, United States|Site 122, Berlin, New Jersey, United States|Site 118, Raleigh, North Carolina, United States|Site 104, Jackson, Tennessee, United States|Site 105, Smyrna, Tennessee, United States|Site 131, Houston, Texas, United States|Site 120, San Antonio, Texas, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/96/NCT03425396/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/96/NCT03425396/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03425396"
907,"NCT02580474","The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure",,"Completed","No Results Available","Hepatitis C","Drug: Daclatasvir plus Asunaprevir","the proportion of subjects with plasma HCV RNA levels below 15 IU/mL at Week 12 After End of Treatment|To evaluate the percentage of subjects with Sustained Virologic Response at Week 12 After End of Treatment|Percentage of subjects with ALT normalization at each visit from the baseline|Change in HCV RNA at each visit from the baseline|Percentage of subjects who experience viral breakthrough at each visit from the baseline|Percentage of subjects who shows Tolerability of Daclatasvir and Asunaprevir at each visit from","Myeong Jun Song|Bristol-Myers Squibb|Soonchunhyang University Hospital|Dankook University|Chungnam National University Hospital|Konyang University Hospital|Eulji University Hospital|Saint Vincent's Hospital, Korea|Konkuk University Hospital|Cheongju St. Mary's Hospital, Cheongju, Korea|Severance Hospital|Korea University Guro Hospital|Eulji General Hospital|The Catholic University of Korea","All","19 Years and older   (Adult, Older Adult)","Phase 4","21","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AI447-118","February 2016","April 2018","April 2018","October 20, 2015",,"July 18, 2018","Myeong Jun Song, Daejeon, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02580474"
908,"NCT03729336","PEEZY Midstream Urine Device Compared to Catheterized Urine Sample","PEEZY","Completed","No Results Available","Lower Urinary Tract Symptoms|Lower Urinary Tract Infection","Device: Midstream urine collection device|Device: Catheter for urine collection","Contamination of urine specimen with urethral and vaginal flora|Visual Analog Scale (this is the only title for this scale)","Baylor Research Institute|Forte Medical","Female","18 Years to 95 Years   (Adult, Older Adult)","Not Applicable","74","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","018-702","February 6, 2019","April 12, 2019","June 1, 2019","November 2, 2018",,"June 5, 2019","Baylor Scott and White Health, Temple, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03729336"
909,"NCT04333212","HPV Genotyping by DR. HPV Genotyping in Vitro Diagnostic Device (IVD) Kit in Exfoliated Cells of the Uterine Cervix",,"Completed","No Results Available","Cervical Intraepithelial Neoplasia|Human Papillomavirus Infection|HPV Infection","Device: DR. Chip HPV genotyping IVD kit","Agreement","Chang Gung Memorial Hospital|Dr. Chip Biotechnology Incorporation","Female","21 Years to 65 Years   (Adult, Older Adult)","Not Applicable","1103","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MA1103L9","December 12, 2012","December 30, 2013","July 8, 2014","April 3, 2020",,"April 3, 2020","Changhua Christian Hospital, Changhua, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Cathay General Hospital, Taipei, Taiwan|Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT04333212"
910,"NCT05224401","Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs","PACUTI","Recruiting","No Results Available","Urinary Tract Infections|Bacteremia|Antibiotic Resistant Infection","Drug: Pivmecillinam and amoxicillin/clavulanic acid|Drug: Standard treatment, ciprofloxacin, trimethoprim/sulfamethoxazole or ertapenem depending on susceptibility","Clinical cure|To compare the recurrence prevalence of EPE (phenotypically same species) in urine cultures 10 +/- 2 days after antibiotic treatment between groups (i.e., microbiological cure).|To compare the prevalence of EPE or carbapenemase-producing bacteria in faecal cultures 10 +/- 2 days after antibiotic treatment between groups.|To compare participants' perception of treatment tolerability|To compare the incidence of early study drug discontinuation between groups.|To compare the incidence of additional antibiotic subscriptions (for UTI) within 28 days between groups.|To compare re-admission to hospital (due to UTI-related symptoms) within 28 days between groups.|To compare the incidence of drug-related serious adverse events (SAE) within 28 days between groups.|To compare the all-cause mortality within 28 days between groups.","Lund University","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","330","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2021-PACUTI","May 29, 2023","September 1, 2027","September 1, 2027","February 4, 2022",,"August 28, 2023","Helsingborg hospital, Helsingborg, Sweden|Kristianstad hospital, Kristianstad, Sweden|Skåne University Hospital, Lund, Lund, Sweden|Skåne University Hospital, Malmö, Malmö, Sweden|Västmanland hospital Västerås, Västerås, Sweden",,"https://ClinicalTrials.gov/show/NCT05224401"
911,"NCT03093740","Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant",,"Withdrawn","No Results Available","Renal Failure Chronic|Hepatitis C","Drug: Zepatier|Drug: Zepatier plus Sofosbuvir","Undetectable HCV RNA","Massachusetts General Hospital","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2017P000301","October 1, 2018","December 31, 2020","January 31, 2021","March 28, 2017",,"December 20, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03093740"
912,"NCT00682851","A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test",,"Completed","Has Results","Bacterial Vaginosis|Urogenital Infection by Trichomonas Vaginalis","Device: OSOM Trichomonas Rapid Test|Device: OSOM BVBlue Test","Sensitivity of the OSOM Rapid Test and PCR Wet Mount Microscopy in Diagnosing Trichomonas Vaginalis in Symptomatic and Asymptomatic Women|Specificity of the OSOM Rapid Test and PCR Wet Mount Microscopy in Diagnosing Trichomonas Vaginalis in Symptomatic and Asymptomatic Women|Sensitivity of the BVBlue Test and Amsel Criteria in Diagnosing Bacterial Vaginosis in Symptomatic and Asymptomatic Women.|Specificity of the BVBlue Test and Amsel Criteria in Diagnosing BV in Symptomatic and Asymptomatic Women.","University of Pittsburgh","Female","15 Years and older   (Child, Adult, Older Adult)",,"519","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","PRO08020012","July 2008","April 2009","April 2009","May 22, 2008","August 8, 2011","September 22, 2016","Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00682851"
913,"NCT00868621","Urinary Cytokines in Patients With Overactive Bladder (OAB)",,"Unknown status","No Results Available","Overactive Bladder|Urinary Tract Infection",,,"Cleveland Clinic Florida|Astellas Pharma US, Inc.","Female","18 Years and older   (Adult, Older Adult)",,"56","Other|Industry","Observational","Time Perspective: Prospective","IRB 8848","March 2007","September 2008","June 2009","March 25, 2009",,"March 25, 2009","Cleveland Clinic Florida, Weston, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00868621"
914,"NCT04444440","Antibiotic Prophylaxis for Bladder Botox",,"Recruiting","No Results Available","Idiopathic Overactive Bladder|Postoperative Urinary Tract Infection","Drug: Ciprofloxacin|Other: Placebo Pill","Rate of Postoperative Urinary Tract Infection|Rate of Postoperative Urinary Tract Infection Rate|Rate of Other Adverse Events","University of Alberta|Women and Children's Health Research Institute, Canada","Female","18 Years and older   (Adult, Older Adult)","Phase 4","202","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00101838","July 6, 2021","June 30, 2025","June 30, 2025","June 23, 2020",,"February 8, 2024","Urogynecology Clinic - Royal Alexandra Hospital, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04444440"
915,"NCT03036852","Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease","SOF/VEL ESRD","Completed","Has Results","Chronic Hepatitis C","Drug: SOF/VEL","Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)|Percentage of Participants Who Permanently Discontinued the Study Drug Due to an Adverse Event|Percentage of Participants With Sustained Virologic Response 4 Weeks After Discontinuation of Therapy (SVR4)|Percentage of Participants With Sustained Virologic Response 24 Weeks After Discontinuation of Therapy (SVR24)|Change From Baseline in HCV RNA|Percentage of Participants With HCV RNA < LLOQ on Treatment|Percentage of Participants With Virologic Failure|Number of Participants Who Develop Viral Resistance (as Assessed by Presence of HCV NS5A and NS5B Genes) to SOF and VEL During Treatment and After Discontinuation of Treatment|Pharmacokinetic (PK) Parameter: AUCtau of SOF|PK Parameter: AUCtau of GS-331007 (Metabolite of SOF)|PK Parameter: AUCtau of VEL|PK Parameter: Cmax of SOF|PK Parameter: Cmax of GS-331007 (Metabolite of SOF)|PK Parameter: Cmax of VEL|PK Parameter: Ctau of VEL","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","59","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-342-4062|2016-003625-42","March 22, 2017","August 13, 2018","November 7, 2018","January 30, 2017","November 12, 2019","March 6, 2020","Royal Adelaide Hospital, Adelaide, South Australia, Australia|Kaye Edmonton Clinic, Edmonton, Alberta, Canada|Gordon and Leslie Diamond Health Care Center, Vancouver General Hospital, UBC Division of Gastroenterology, Vancouver, British Columbia, Canada|William Osler Health System- Brampton Civic Hospital, Brampton, Ontario, Canada|Hamilton Health Sciences - McMaster University Medical Centre Site, Hamilton, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM), Montréal, Quebec, Canada|Shaare Zedek Medical Center, Jerusalem, Israel|The Chaim Sheba Medical Centre, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Auckland City Hospital, Grafton, Auckland, New Zealand|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Gartnavel General Hospital, Glasgow, United Kingdom|Barts Health NHS Trust, London, United Kingdom|King's College Hospital, London, United Kingdom|Chelsea and Westminster Hospital, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Derriford Hospital, Plymouth, United Kingdom","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/52/NCT03036852/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/52/NCT03036852/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03036852"
916,"NCT03633994","Heparin Intraoperative Instillation for Lower Urinary Tract Symptoms After Benign Hysterectomy","HILUTS","Unknown status","No Results Available","Lower Urinary Tract Symptoms|Postoperative Urinary Tract Infection","Drug: Heparin|Drug: Normal saline","Lower urinary tract symptoms|Postoperative antibiotic use|Postoperative patient satisfaction","The Christ Hospital","Female","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","TCH #18-12","August 20, 2018","December 31, 2019","March 1, 2020","August 16, 2018",,"October 10, 2019","The Christ Hospital, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03633994"
917,"NCT03214822","Human-derived Human Milk Fortifiers (H2MF), Gut Microbiota and Oxidative Stress in Premature Infants",,"Completed","No Results Available","Very Low Birth Weight Baby|Premature Birth|Microbial Colonization|Oxidative Stress","Dietary Supplement: H2MF","Fecal microbiome composition at end of intervention|Fecal microbiome diversity at end of intervention|Fecal microbiome community structure at end of intervention|Fecal microbiome at 1 week after intervention begins|Fecal microbiome at 2 weeks after intervention ends|Oxidative stress (urinary biomarkers) at end of intervention|Oxidative stress (fecal calprotectin) at end of intervention|Oxidative stress at 1 week after intervention begins|Oxidative stress at 2 weeks after intervention ends","University of Manitoba|Manitoba Developmental Origins of Chronic Diseases in Children Network (DEVOTION)|Prolacta Bioscience|Children's Hospital Foundation","All","up to 7 Days   (Child)","Not Applicable","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","H2MF Study","August 1, 2017","July 30, 2019","July 30, 2019","July 12, 2017",,"September 30, 2019","Health Sciences Centre, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT03214822"
918,"NCT01696227","Novel Probiotic Treatment for Prevention of Recurrent UTIs in Children","Nissle 1917","Completed","No Results Available","Recurrent UTIs|Catheter-Related Infections","Drug: Nissle 1917","Ability of Nissle 1917 to adversely affect the growth in vitro of identified uropathogens","Nationwide Children's Hospital|Thrasher Research Fund","All","Child, Adult, Older Adult",,"50","Other","Observational","Time Perspective: Prospective","IRB12-00279","July 2012","June 2014","June 2014","September 28, 2012",,"October 15, 2014","Nationwide Children's Hospital, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01696227"
919,"NCT01094639","Periodontal Infection and Systemic Inflammation in Renal Patients","PeriRen","Completed","No Results Available","Periodontitis|Chronic Kidney Disease","Procedure: Scaling root planing|Procedure: Supragingival Prophylaxis","Serum Interleukin-6 (IL-6) and C-reactive protein (CRP) levels|Changes in periodontal (gum) clinical presentation and status","UConn Health|National Institute of Dental and Craniofacial Research (NIDCR)","All","21 Years to 85 Years   (Adult, Older Adult)","Not Applicable","52","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","10-092-2|K23DE018689","August 2009","July 2015","August 2015","March 29, 2010",,"October 25, 2016","University of Connecticut Health Center, Farmington, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01094639"
920,"NCT03284866","HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV","COVENANT","Active, not recruiting","No Results Available","AIDS-Related Human Papillomavirus Infection|High Grade Cervical Squamous Intraepithelial Neoplasia|HIV Infection","Other: Laboratory Biomarker Analysis|Biological: Recombinant Human Papillomavirus Nonavalent Vaccine|Other: Saline","Occurrence of cervical high-grade squamous intraepithelial lesions (HSIL) or cervical cancer|Occurrence of cervical HSIL from weeks 52-104|Role of baseline types and quantity of HPV as predictors of sustained absence|Role of presence of HSIL at baseline as a predictor of sustained absence|Role of CD4+ cell count as a predictor of sustained absence|Role of plasma HIV-1 RNA as a predictor of sustained absence|Role of ART use as a predictor of sustained absence|Role of age as a predictor of sustained absence|Role of sexual behavior as a predictor of sustained absence|Role of vaccination use as a predictor of sustained absence|Incident cervical vaccine type HPV infections defined as infections at 2 consecutive timepoints and assessed using type specific HPV DNA polymerase chain reaction (PCR)|Abnormal cervical cytology|Prevalent vulvar HSIL or cancer|Incident vulvar HSIL or cancer|Clinical and demographic factors associated with incident vulvar HSIL or cancer","AIDS Malignancy Consortium|National Cancer Institute (NCI)|University of Arkansas|AIDS and Cancer Specimen Resource|Merck Sharp & Dohme LLC|The Emmes Company, LLC|University of California, Los Angeles","Female","25 Years and older   (Adult, Older Adult)","Phase 3","536","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","AMC-099|NCI-2016-00841|UM1CA121947","July 31, 2019","December 2, 2024","March 15, 2027","September 15, 2017",,"January 23, 2024","Moi University School of Medicine, Eldoret, Kenya|UNC Project Malawi, Lilongwe, Malawi|African Cancer Institute at Stellenbosch, Cape Town, South Africa|University of the Witwatersrand, Johannesburg, South Africa|Uganda Cancer Institute, Kampala, Uganda|University of Zimbabwe, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT03284866"
921,"NCT01012089","Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease",,"Completed","Has Results","Chronic Kidney Disease|Bacterial Infection","Drug: Daptomycin","Maximum Plasma Concentration (Cmax)|Area Under the Concentration Time Curve From Time Zero to 24 Hours (AUC0-24)|Area Under the Concentration Time Curve From Time Zero to 48 Hours (AUC0-48)|Area Under the Concentration Time Curve From Time Zero to Infinity (AUC0-∞)|Volume of Distribution at Steady State (Vss)|Elimination Rate Constant (Ke)|Total Drug Clearance (CLtotal)|Drug Clearance Due to Dialysis (CLdialysis)","University of Oklahoma|Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","All","12 Years to 17 Years   (Child)","Not Applicable","6","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2375","November 2009","April 2014","April 2014","November 11, 2009","June 6, 2018","June 6, 2018","The Children's Hospital at the University of Oklahoma Medical Center, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT01012089"
922,"NCT02806362","Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)","GIFT-R","Withdrawn","No Results Available","Chronic Hepatitis C Virus","Drug: Ombitasvir/paritaprevir/ritonavir","Percentage of participants achieving a 12-week sustained virologic response (SVR12).|Percentage of participants with on-treatment virologic failure|Percentage of participants with relapse","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-733","September 2016","June 2018","August 2018","June 20, 2016",,"December 5, 2016",,,"https://ClinicalTrials.gov/show/NCT02806362"
923,"NCT02402452","Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment",,"Completed","Has Results","HCV Infection","Drug: Voxilaprevir","Pharmacokinetic (PK) Parameter of Voxilaprevir: AUClast|PK Parameter of Voxilaprevir: AUCinf|PK Parameter of Voxilaprevir: Cmax|Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAE) and Laboratory Abnormalities","Gilead Sciences","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-338-1125|2015-000341-23","May 5, 2015","September 28, 2015","September 28, 2015","March 30, 2015","March 20, 2020","March 20, 2020","Orlando Clinical Research Center, Orlando, Florida, United States|Texas Liver Institute, San Antonio, Texas, United States|APEX GmbH, München, Germany|Christchurch Clinical Studies Trust Ltd, Christchurch, New Zealand",,"https://ClinicalTrials.gov/show/NCT02402452"
924,"NCT03143920","Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder","HBOTCICrUTI","Terminated","No Results Available","Chronic Interstitial Cystitis|Painful Bladder Syndrome|Recurrent Urinary Tract Infection","Combination Product: Hyperbaric Oxygen Therapy-","HBOT acceptance|HBOT adherence|Pre and post treatment symptom survey for the chronic interstitial cystitis study group.|Post treatment incidence of recurrent urinary tract infection.|Pre and post treatment symptom survey fro the chronic interstitial cystitis study group. The patient's overall rating of improvement of symptoms (PORIS) will be used.|Time of occurrence of recurrent urinary tract infection.","University of California, San Diego","Female","35 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","11","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HBOTurology.2017","November 1, 2017","July 7, 2022","July 7, 2022","May 8, 2017",,"July 11, 2022","UCSD Hillcrest Hosptial, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT03143920"
925,"NCT04605055","The Interplay Between Oxalate, Immunity and Infection",,"Not yet recruiting","No Results Available","Kidney Stone","Dietary Supplement: Low Oxalate Diet|Dietary Supplement: High Oxalate Diet","Urinary Oxalate|Crystalluria|Monocyte Cellular Bioenergetics|Monocyte Mitochondrial Complex Activity|Monocyte Transcriptomics","University of Alabama at Birmingham","All","18 Years to 60 Years   (Adult)","Not Applicable","88","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB-300005965","June 1, 2024","November 30, 2026","December 31, 2026","October 27, 2020",,"December 12, 2023",,,"https://ClinicalTrials.gov/show/NCT04605055"
926,"NCT05927766","Correlation Between Endoscopic Findings And Helicobacter Pylori Infection In Chronic Kidney Disease Patients",,"Recruiting","No Results Available","Chronic Kidney Diseases","Device: esophagogastroduodenoscopy","Description the gastroduodenal lesions found in upper endoscopy in patients with chronic kidney disease or not and correlate them to helicobacter pylori infection","Sohag University","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CKD and H.Pylori infection","July 1, 2023","December 2023","December 2023","July 3, 2023",,"July 3, 2023","Sohag university hospital, Sohag, Egypt",,"https://ClinicalTrials.gov/show/NCT05927766"
927,"NCT00231322","Influence of Transmission Season on Outcome of Treatment of Schistosoma Haematobium Infection in Mozambique",,"Completed","No Results Available","Hematuria|Hydronephrosis","Drug: praziquantel","cure rate|egg reduction rate|re-infection prevalence and intensity of infection *resolution of urinary tract pathology|re-appearance of pathology after re-infection.|reduction in worm burden (CAA);","DBL -Institute for Health Research and Development|Durban University of Technology","All","8 Years to 12 Years   (Child)","Not Applicable","520","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","30/CNSB/03/624-03-0021","March 2004",,"March 2006","October 4, 2005",,"April 20, 2007","Matola, Maputo, Maputo Province, Mozambique",,"https://ClinicalTrials.gov/show/NCT00231322"
928,"NCT02357199","Interventional Study Targeting Oral Infections in Patients With Chronic Kidney Disease",,"Completed","No Results Available","Mouth Diseases|Renal Insufficiency, Chronic","Other: Intensive oral care & didactic training","Gingival inflammation|C-reactive protein, plasma|Dental bacterial plaque|Periodontal disease|Whole saliva flow rate, unstimulated|Whole saliva flow rate, stimulated|Saliva composition: Sodium|Saliva composition: Chloride|Saliva composition: Potassium|Saliva composition: Total calcium|Saliva composition: Inorganic phosphate|Saliva composition: Total protein|Saliva composition: Albumin|Saliva composition: Amylase activity|Saliva composition: Secretory IgA|Oral candidiasis|Hematologic status: Erythrocytes|Hematologic status: Hemoglobin|Hematologic status: Leukocytes|Hematologic status: Thrombocytes|Hematologic status: Transferrin|Hematologic status: Iron|Calcium metabolism|Phosphate metabolism|Renal function: Carbamide|Renal function: Bicarbonate|Renal function: Creatinine|Renal function: Albumin|Renal function: Potassium|Renal function: Sodium|Oral Health Impact Profile|Medical Outcomes Study Short Version","University of Copenhagen|Rigshospitalet, Denmark|Danish Council for Independent Research - Medical Sciences|The Danish Dental Association","All","18 Years and older   (Adult, Older Adult)","Not Applicable","93","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","102-2084/14-3000","January 2015","August 2015","August 2015","February 6, 2015",,"August 31, 2015","Department of Odontology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT02357199"
929,"NCT00211900","Evaluation of Manufacturing Lot of StaphVAX",,"Completed","No Results Available","Staphylococcal Infections|Chronic Kidney Failure","Biological: S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine","Type-specific antibody concentrations|Elicited vaccine reactogenicity.","Nabi Biopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","65","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Nabi-1367","March 2005","August 2005","November 2005","September 21, 2005",,"January 4, 2008","Trialogic Research, Madison, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT00211900"
930,"NCT00130260","Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease","SHIELD-2","Terminated","No Results Available","Staphylococcal Infections|Chronic Kidney Failure","Biological: Staph aureus types 5 and 8 conjugate vaccine|Biological: placebo","serotype-specific antibody concentrations|elicited vaccine reactogenicity","Nabi Biopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Nabi-1372","August 2005","December 2005","April 2006","August 15, 2005",,"January 4, 2008","multiple sites: contact Central Study coordination, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT00130260"
931,"NCT05030727","Intraoperative NGAL Level in Geriatric Patients Undergoing Laparotomy",,"Completed","No Results Available","Geriatric Presentation of Urinary Tract Infection|Acute Kidney Injury","Diagnostic Test: record of pNGAL","the roles of plasma NGAL levels in acute renal failure.","Marmara University","All","64 Years to 90 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","09.2021.392","March 5, 2021","September 2, 2021","September 10, 2021","September 1, 2021",,"October 8, 2021","Marmara University, Istanbul, Maltepe, Turkey",,"https://ClinicalTrials.gov/show/NCT05030727"
932,"NCT03581617","Infections and Unexplained Infertility",,"Completed","No Results Available","Infertility, Female","Diagnostic Test: NK cell analysis|Diagnostic Test: Herpesvirus detection|Diagnostic Test: sHLA-G analysis|Diagnostic Test: HLA-G 14bp INS/DEL typing|Diagnostic Test: sHLA-E analysis","Prognostic value of NK cells in female idiopathic infertility|Herpesvirus detection|Levels of sHLA-G and sHLA-E cellule pNK e eNK|HLA-G and HLA-E genetic polymorphisms|Cytokines levels in endometrial flushing samples","University Hospital of Ferrara","Female","21 Years to 38 Years   (Adult)",,"143","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PRUAlGR-2013-00000084","November 1, 2014","November 1, 2015","November 1, 2016","July 10, 2018",,"July 10, 2018",,,"https://ClinicalTrials.gov/show/NCT03581617"
933,"NCT02260102","Temocillin Pharmacokinetics in Paediatrics","TEMOPEDI","Recruiting","No Results Available","Infection|Liver Dysfunction|Urinary Tract Infection","Drug: Temocillin","Serum levels of temocillin","Université Catholique de Louvain","All","6 Months to 3 Years   (Child)","Phase 4","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","temocillin-pediatrics","February 17, 2016","December 31, 2022","December 31, 2022","October 9, 2014",,"May 31, 2022","Cliniques universitaires St-Luc, Bruxelles, Belgium",,"https://ClinicalTrials.gov/show/NCT02260102"
934,"NCT00079911","A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons",,"Terminated","No Results Available","Herpes Genitalis","Drug: valacyclovir hydrochloride","Adverse Events|Proportion of recurrence of genital HSV|Time to first culture-positive recurrence of genital HSV","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 4","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","100181","March 12, 2004","October 15, 2004","October 15, 2004","March 19, 2004",,"November 24, 2020","GSK Investigational Site, Altamonte Springs, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Darlinghurst, New South Wales, Australia|GSK Investigational Site, Kowloon Bay, Hong Kong",,"https://ClinicalTrials.gov/show/NCT00079911"
935,"NCT02862548","Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant",,"Completed","Has Results","Chronic Hepatitis B","Drug: TAF|Drug: TDF|Drug: Other approved antivirals","Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) at Week 24 Using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation|Percentage of Participants With HBV DNA < 20 IU/mL at Week 24|Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 24|Percent Change From Baseline in Hip BMD at Week 48|Percent Change From Baseline in Spine BMD at Week 24|Percent Change From Baseline in Spine BMD at Week 48|Change From Baseline in Serum Creatinine at Week 24|Change From Baseline in Serum Creatinine at Week 48|Change From Baseline in Serum eGFR_CKD-EPI at Week 48|Percentage of Participants With HBV DNA < 20 IU/mL at Week 48","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-320-3912|ACTRN12616000898459","September 16, 2016","February 8, 2018","May 5, 2021","August 11, 2016","February 26, 2019","June 8, 2022","Auckland City Hospital, Auckland, New Zealand","""Study Protocol: Original"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT02862548/Prot_000.pdf|""Study Protocol: Amendment 1"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT02862548/Prot_001.pdf|""Study Protocol: Amendment 2"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT02862548/Prot_002.pdf|""Study Protocol: Amendment 3"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT02862548/Prot_005.pdf|""Statistical Analysis Plan: Week 24 Analysis"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT02862548/SAP_006.pdf|""Statistical Analysis Plan: Final Analysis"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT02862548/SAP_007.pdf","https://ClinicalTrials.gov/show/NCT02862548"
936,"NCT03220282","The Milk, Growth and Microbiota Study","MGM","Suspended","No Results Available","Preterm Infant|Growth Delay|Microbial Colonization|Breastfeeding|Breast Milk Substitute Intolerance","Other: Donor milk|Other: Preterm infant formula","Weight change|Bifidobacteria|Lactobacillus|Clostridium","University of California, San Francisco|University of California, Davis","All","1 Hour to 96 Hours   (Child)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","17-21587","October 30, 2017","December 31, 2023","January 31, 2024","July 18, 2017",,"February 6, 2023","University of California, San Francisco Medical Center, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03220282"
937,"NCT04846010","Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2","sequelae","Unknown status","No Results Available","Sequelae of; Infection|Post Infection Glomerulonephritis|Post-Infectious Peripheral Neuralgia|Post-Infectious Disorder (Disorder)|Post-Infectious Arthritis|Post-Infectious Polyneuritis|Post-Infectious Parkinsonism|Post-Infectious Hypothyroidism|Post Infectious Osteoarthritis|Anxiety Disorders|Depression|Depression, Anxiety|Depression, Bipolar|Insomnia|GERD|Gastro Esophageal Reflux|Hepatitis|Glomerulonephritis","Combination Product: PurWet|Combination Product: FurFat|Combination Product: PurApo|Combination Product: PurPhl|Combination Product: PurClo|Combination Product: PurInf|Combination Product: Smoliv","Monitoring symptoms|Monitoring emotion changing|Checking heart burn symptom|Monitoring thyroid function|Monitoring liver function|Monitoring kidney function","All Natural Medicine Clinic, LLC","All","Child, Adult, Older Adult","Phase 1|Phase 2","2000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHM2282395-2","March 1, 2021","May 1, 2022","October 1, 2022","April 15, 2021",,"May 26, 2021","All Natural Medicine Clinic, LLC, Rockville, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04846010"
938,"NCT00270530","Intermittent Preventive Treatment of Malaria in HIV-Seropositive Pregnant Women in Zambia",,"Completed","No Results Available","Placental Malaria Infection|HIV Infections|Stillbirth|Prematurity|Neonatal Deaths","Drug: Sulfadoxine-pyrimethamine (Fansidar)","• Prevalence of placental malaria infection|• Prevalence of maternal peripheral parasitemia|• Birth weight, including the proportion of LBW infants|• Incidence of prematurity|• Neonatal and fetal death and third trimester stillbirth|• Incidence of neonatal jaundice|• Third trimester anemia|• Third trimester severe anemia|• Proportion of mothers who develop symptomatic malaria during the course of pregnancy","Center for International Health and Development|Centers for Disease Control and Prevention","Female","18 Years to 50 Years   (Adult)","Phase 4","454","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment","S1954-21/22-2","November 2002",,"October 2004","December 28, 2005",,"January 31, 2006","Tropical Diseases Research Centre, Ndola, Zambia",,"https://ClinicalTrials.gov/show/NCT00270530"
939,"NCT05621005","Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients",,"Completed","No Results Available","Ascites Infection","Drug: Rifaximin 550 milligram Oral Tablet [XIFAXAN]","secondary prophylaxis of SBP and primary prophylaxis for hepatorenal syndrome","Samar Atef Sebaweh Mohammed|Ain Shams University","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","104","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","SBP prophylaxis","March 1, 2019","July 1, 2022","August 1, 2022","November 17, 2022",,"November 21, 2022","faculty of medicine Ain Shams university, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT05621005"
940,"NCT06007352","Use of Antibiotic Based Irrigation for Ureteroscopic Treatment of Urolithiasis",,"Not yet recruiting","No Results Available","Urinary Tract Infections|Sepsis","Drug: Gentamicin|Other: Placebo","Symptomatic urinary tract infection|Urosepsis|Re-admission to hospital|Patient self-reported symptoms","Yale University","All","18 Years and older   (Adult, Older Adult)","Phase 2","412","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2000035721|000","May 2024","June 2025","June 2025","August 23, 2023",,"March 26, 2024","Yale New Haven Health, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT06007352"
941,"NCT00005775","Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants","Glutamine","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Sepsis","Drug: Glutamine|Drug: Placebo","Death or late-onset sepsis|Tolerance of enteral feeding (number of days to reach full enteral feeds) and decrease number of episodes of feeding intolerance|Necrotizing Enterocolitis|Episodes of late-onset sepsis|Growth (days to reach 1500 grams)|Number of days on parenteral nutrition|Length of stay in NICU|Neurodevelopmental outcome|Levels of pro-inflammatory cytokines","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 72 Hours   (Child)","Phase 3","1433","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0020|U10HD027856|U10HD021364|U10HD034216|U10HD034167|U10HD021397|U10HD027853|U10HD027871|U10HD021415|U10HD027904|U10HD027881|U10HD021385|U10HD027851|U10HD027880|U10HD021373|U01HD036790|M01RR008084|M01RR006022|M01RR000750|M01RR000997|M01RR000070|M01RR001032","July 1999","December 2000","August 2001","June 2, 2000",,"June 8, 2015","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|University of California at San Diego, San Diego, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|RTI International, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00005775"
942,"NCT02397395","An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.",,"Withdrawn","No Results Available","Renal Impairment|End-stage Renal Disease","Drug: Simeprevir (SMV) 150 mg|Drug: Daclatasvir (DCV) 60 mg","Percentage of Participants With Sustained Virologic Response at Week 12 After End of Treatment (SVR12)|Percentage of Participants With On-treatment Response|Percentage of Participants With Sustained Virologic Response at Week 4 After End of Treatment (SVR4)|Percentage of Participants With Sustained Virologic Response at Week 24 After End of Treatment (SVR24)|Percentage of Participants With on-treatment Failure|Percentage of Participants With Viral Relapse|Change From Baseline in Hepatitis C Virus (HCV) Nonstructural Protein 3/4A (NS3/4A) and Nonstructural Protein 5A (NS5A) Sequence in Participants not Achieving SVR|Change From Baseline in HCV Symptom and Impact Questionnaire version 4 (HCV-SIQv4) Overall Body Symptom score","Janssen R&D Ireland","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR106396|TMC435HPC2018|2014-004250-34","May 2015","February 2016","May 2016","March 25, 2015",,"July 17, 2015","Paris, France|Toulouse Cedex 9, France|Villejuif, France|Barcelona, Spain|Madrid, Spain|Santander, Spain",,"https://ClinicalTrials.gov/show/NCT02397395"
943,"NCT01322971","Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population",,"Terminated","Has Results","Vaginosis, Bacterial|Infertility|Miscarriage","Drug: Metronidazole|Drug: Placebo","Biochemical Pregnancy Rate (Positive Pregnancy Test)|Pregnancy Rate (Pregnancy Visible on Ultrasound)|Miscarriage Rate (Loss of a Clinically Recognized Pregnancy)|Infectious Morbidity (i.e. Chorioamnionitis, Neonatal Sepsis)","Stanford University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SU-03212011-7604|IRB Protocol Number 20103","February 2011","June 2012","June 2012","March 25, 2011","January 20, 2017","December 20, 2021","Ruth Lathi, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01322971"
944,"NCT04239521","The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata",,"Completed","No Results Available","Alopecia Areata|Depressive Episode|Recurrent Depressive Disorder|Anxiety Disorders|Atopic Dermatitis|Allergic Rhinitis|Asthma|Crohn Disease|Ulcerative Colitis|Pernicious Anemia|Type 1 Diabetes|Hashimoto Thyroiditis|Graves Disease|Rheumatoid Arthritis|Psoriatic Arthritis|Ankylosing Spondylitis|Systemic Lupus Erythematosus|Polymyalgia Rheumatica|Sjogren's Syndrome|Psoriasis|Vitiligo|Multiple Sclerosis|Celiac Disease|Upper Respiratory Tract Infection|Influenza|Lower Resp Tract Infection|Acute Bronchitis|Pneumonia|Gastrointestinal Infection|Skin Infection|Urinary Tract Infections|Genital Infection|Herpes Zoster|Herpes Simplex|Infection|Infection Viral","Other: Exposure of interest (studies 2 & 3).","Study 1: The incidence of Alopecia Areata|Study 1: The incidence of Alopecia Areata stratified by sociodemographic factors|Study 1:The annual rate of primary care visits for people with Alopecia Areata.|Study 1: Secondary care dermatology service utilisation|Study 2: The prevalence of common mental health conditions in adult patients diagnosed with Alopecia Areata at the time of diagnosis|Study 2: Describe the incidence of common mental health conditions in adult patients with Alopecia Areata|Study 2: Describe the mental health medication treatment burden of adult patients diagnosed with Alopecia Areata.|Study 2: Number of patients diagnosed with Alopecia Areata receiving mental health psychological intervention.|Study 3: Describe the prevalence of atopic and autoimmune conditions in adult patients diagnosed with Alopecia Areata at the time of diagnosis|Study 3: Describe the incidence of atopic and autoimmune conditions in adult patients with Alopecia Areata.|Study 4: The incidence of a composite of common infections in adult patients with Alopecia Areata|Study 4: The incidence of a composite of viral infections in adult patients with Alopecia Areata|Study 1: Adjusted incidence rate ratios of Alopecia Areata within England by geographic region.|Study 2: Prevalence (percentage) of common mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder), by socio-demographic factors, in adult patients diagnosed with Alopecia Areata.|Study 2: Describe the burden of 'sick days' in adult patients diagnosed with Alopecia Areata relating to mental health conditions.|Study 2: Describe the prevalence of unemployment in adult patients diagnosed with Alopecia Areata.|Study 4: The incidence of upper respiratory tract infection in adult patients with Alopecia Areata|Study 4: The incidence of lower respiratory tract infection in adult patients with Alopecia Areata|Study 4: The incidence of influenza infection in adult patients with Alopecia Areata|Study 4: The incidence of acute bronchitis in adult patients with Alopecia Areata|Study 4: The incidence of pneumonia in adult patients with Alopecia Areata|Study 4: The incidence of gastrointestinal infection in adult patients with Alopecia Areata|Study 4: The incidence of stool confirmed gastrointestinal infection in adult patients with Alopecia Areata|Study 4: The incidence of skin infection in adult patients with Alopecia Areata|Study 4: The incidence of urinary tract infection in adult patients with Alopecia Areata|Study 4: The incidence of genital infection in adult patients with Alopecia Areata|Study 4: The incidence of herpes zoster infection in adult patients with Alopecia Areata|Study 4: The incidence of herpes simplex infection in adult patients with Alopecia Areata","Momentum Data|Pfizer|University of Surrey|University of Oxford","All","Child, Adult, Older Adult",,"51955","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","P005","October 1, 2020","March 31, 2022","November 28, 2022","January 27, 2020",,"December 15, 2022","Momentum Data Ltd, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04239521"
945,"NCT02002169","Hemodialysis Infection Prevention Using Polysporin Ointment With Shower Technique in Satellite Centres Pilot Study","HIPPO-SAT","Unknown status","No Results Available","End Stage Renal Failure on Dialysis","Other: Shower Technique Protocol|Other: Standard CVC Care","Primary Feasibility Measure of the HIPPO SAT trial: Defined by 5 outcomes|Secondary Feasibility Outcome: The change in Vascular Access Questionnaire (VAQ) score over time using the Shower Technique protocol compared to standard care.|Secondary Feasibility Outcome: The level agreement between the Deep Breath and CVC Seal tests and the blinded photo test","University Health Network, Toronto|Scarborough General Hospital|London Health Sciences Centre|Trillium Health Centre|York Central Hospital, Ontario","All","18 Years and older   (Adult, Older Adult)","Not Applicable","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","REB 12-0404-AE","December 2012","July 2014","November 2014","December 5, 2013",,"December 10, 2013","Toronto General Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02002169"
946,"NCT02032394","Effect of Chlorhexidine on Bacteriuria",,"Unknown status","No Results Available","Urinary Tract Infection|Nosocomial Infection|Bacteriuria","Drug: Povidone-iodine|Drug: Chlorhexidine|Drug: Normal saline","Bacteriuria day 1|Bacteriuria day 3|Bacteriuria day 5|Bacteriuria day 7|Bacteriuria day 9|Microorganism Type day 5|Microorganism type day 10","Mashhad University of Medical Sciences","All","18 Years to 55 Years   (Adult)","Phase 4","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","MUMS910212","July 2013","February 2014","April 2014","January 10, 2014",,"January 10, 2014","Shahid Beheshti Hospital, Babol, Mazandaran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02032394"
947,"NCT06314113","Evaluation of Oral EGCG Treatment for L-SIL Associated With HPV Infection","EGCG-HPV","Recruiting","No Results Available","Low-Grade Intraepithelial Neoplasia of Cervix","Dietary Supplement: Epigallocatechin Gallate","Persistence","University of Palermo","Female","18 Years to 65 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","EGCG-HPV","March 1, 2024","March 1, 2025","September 1, 2025","March 15, 2024",,"March 15, 2024","""Paolo Giaccone"" Hospital, Palermo, Italy",,"https://ClinicalTrials.gov/show/NCT06314113"
948,"NCT05231577","7.5F Versus 9.2F Flexible Ureteroscopy for the Treatment of 1-2cm Renal Calculi on Postoperative Infection",,"Unknown status","No Results Available","Kidney Stones","Procedure: 7.5fr ultra-fine ureteroscopy|Procedure: 9.2fr Ureteroscopy","postoperative fever|Stone free rate (SFR)","The First Affiliated Hospital of Guangzhou Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RCT(2022)","February 1, 2022","August 31, 2022","August 31, 2022","February 9, 2022",,"February 9, 2022","Department of Urology, Minimally invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong,China, China",,"https://ClinicalTrials.gov/show/NCT05231577"
949,"NCT05964088","Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Infection Patients",,"Completed","No Results Available","Acute Kidney Injury",,"Mortality","Arrowhead Regional Medical Center","All","18 Years to 100 Years   (Adult, Older Adult)",,"267","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","22-18","March 1, 2020","February 12, 2022","February 12, 2022","July 27, 2023",,"July 27, 2023","Arrowhead Regional Medical Center, Colton, California, United States",,"https://ClinicalTrials.gov/show/NCT05964088"
950,"NCT03774940","Blood Parameters as a Predictor of Fever After Percutaneous Nephrolithotomy",,"Completed","No Results Available","Urinary Tract Infection Bacterial|Nephrolithiasis","Diagnostic Test: peripheric blood count","White blood cell count|Neutrophil count|N/L|Lymphocyte count","TC Erciyes University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","519","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2013/198","January 1, 2005","December 1, 2013","January 31, 2014","December 13, 2018",,"December 13, 2018","Erciyes University Faculty of Medicine Department of Urology, Kayseri, Turkey",,"https://ClinicalTrials.gov/show/NCT03774940"
951,"NCT00405704","Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)","RIVUR","Completed","Has Results","Vesicoureteral Reflux|Urinary Tract Infections","Drug: Trimethoprim-Sulfamethoxazole|Drug: Placebo","Recurrent Febrile or Symptomatic Urinary Tract Infection During 2-year Follow-up|Outcome Renal Scarring|Severe Renal Scarring on Outcome Scan|New Renal Scarring on Outcome Scan|Treatment Failure Composite|Presence of E.Coli Resistant to Trimethoprim-Sulfamethoxazole (TMP-SMZ) (Based on Rectal Swab)|Recurrent Febrile or Symptomatic UTI With Resistant E. Coli|Recurrent Febrile or Symptomatic UTI With Any Resistant Pathogen","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of North Carolina, Chapel Hill","All","2 Months to 71 Months   (Child)","Phase 3","607","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DK074059 (IND)|U01DK074059","May 2007","June 2013","May 2014","November 30, 2006","April 16, 2015","April 21, 2020","University of Alabama, Birmingham, Alabama, United States|Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Ann & Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|Children's Hospital of Boston, Boston, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Women and Children's Hospital of Buffalo, Buffalo, New York, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Texas Children's Hospital, Houston, Texas, United States|University of Wisconsin Children's Hospital, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00405704"
952,"NCT03087812","Durability of Flexible Ureteroscopes and Causes of Infection During Flexible Ureterorenoscopy",,"Completed","No Results Available","Kidney Stones",,"Microbiological load|Durability|Factors affecting durability","Clinical Research Office of the Endourological Society","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NL201501","December 2015","December 2017","December 2017","March 23, 2017",,"April 10, 2018","AMC University Hospital, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT03087812"
953,"NCT03005353","Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories.",,"Completed","No Results Available","Infection, Fungal","Drug: Cumin seed extract|Drug: clotrimazole","The percentage of patients with complete cure","Assiut University","Female","18 Years to 49 Years   (Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CSE","March 1, 2018","October 31, 2019","January 31, 2020","December 29, 2016",,"June 9, 2020","Assiut University, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT03005353"
954,"NCT05611255","Comparison of Two Bladder Catheterization Strategies in Thoracic Surgery Patients With an Enhanced Recovery After Surgery (ERAS)","URICATHOR","Recruiting","No Results Available","Urinary Retention|Chronic Kidney Infection|Urinary Infection","Procedure: Systematic Intermittent Catheterization|Procedure: Bladder Scan Guided Catheterization","Occurrence of acute urinary retention (AUR) within 24 hours postoperatively|Occurrence of acute urinary retention (AUR) after Day 1 and during the first 5 days after surgery or during the hospital stay|Bladder volume drained|Total duration of the first bladder catheterization|Total number of bladder catheterizations|The rate of complications related to catheterization|The rate of complications related to AUR|Other postoperative complications|Duration before putting in the chair (in hours)|Duration before standing up (in hours)|Length of hospital stay|Estimated cost of stay","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)","Not Applicable","112","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","RECHMPL20_0461","December 8, 2022","June 8, 2024","June 8, 2024","November 10, 2022",,"April 18, 2023","University Hospital of Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT05611255"
955,"NCT06056947","Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL Ovule","One-Shot","Completed","No Results Available","Trichomonal Vaginitis|Bacterial Vaginosis|Candidal Vulvovaginitis|Mixed Vaginal Infections","Drug: EVEGYN A|Drug: EVEGYN B|Drug: Gynomax® XL Vaginal Ovule","Percentage of patients who had complete response to treatment according to clinical findings|Percentage of patients who had partial response to treatment according to clinical findings|Percentage of patients who recovered according to microbiological findings|Frequency and percentage of patients with SAEs/AEs in each arm","Ege University|Monitor CRO|Exeltis Turkey","Female","18 Years to 55 Years   (Adult)","Phase 3","577","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MON580.130.3","July 20, 2020","May 6, 2021","August 26, 2021","September 28, 2023",,"September 28, 2023","Ege University Family Planning and Infertility Application and Research Center, Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT06056947"
956,"NCT04580927","Breastfeeding and Postpartum Cardiovascular Health","sheMATTERS","Active, not recruiting","No Results Available","Hypertensive Disorder of Pregnancy|Pregnancy Complications|Pre-Eclampsia|Hypertension, Pregnancy-Induced|Breastfeeding","Behavioral: Breastfeeding self-efficacy (BSE)","Number of Participants with Lower Systolic and/or diastolic BP, in mmHg.|Number of Participants Using Antihypertensive Therapy|Number of Participants Providing Exclusive Breastfeeding (weeks)|Proportion of Participants who Breastfeed (exclusive or non-exclusive)|Number of Participants that Develop Metabolic Syndrome","McGill University Health Centre/Research Institute of the McGill University Health Centre|Heart and Stroke Foundation of Canada|McGill University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","221","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MP-37-2021-7201: she MATTERS","March 15, 2021","August 2024","November 2025","October 9, 2020",,"March 25, 2024","Kingston General Hospital, Kingston, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|St Mary's Hospital, Montreal, Quebec, Canada|Muhc-Rimuhc, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04580927"
957,"NCT00628680","A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis",,"Unknown status","No Results Available","End Stage Renal Disease","Device: AAT-023 solution (Zuragen)|Drug: Heparin","To show that AAT-023 (Zuragen) solution is superior to Heparin in preventing CRBSI when used as a catheter lock solution in CVCD's between hemodialysis treatments.|To show that AAT-023 (Zuragen) solution is non-inferior to Heparin in terms of patency failure.","Ash Access Technology","All","18 Years and older   (Adult, Older Adult)","Phase 3","415","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AATML2003-A","July 2006","July 2008",,"March 5, 2008",,"March 5, 2008","Bakersfield Dialysis Center, Bakersfield, California, United States|Renal Medical Associates, Lynwood, California, United States|Nephrology & Hypertension Associates, PC, Middlebury, Connecticut, United States|Brandon nephrology, Brandon, Florida, United States|Gulf Breeze Dialysis Center, Dunedin, Florida, United States|Bayonet Point Hudson Kidney Center, Hudson, Florida, United States|Outcomes Research International, Inc., Hudson, Florida, United States|Bay Breeze Dialysis, Largo, Florida, United States|New Port Richey Kidney Center, New Port Richey, Florida, United States|Discovery Medical Research Group, Ocala, Florida, United States|Nephrology consultants, Orlando, Florida, United States|Hernando Kidney Center, Spring Hill, Florida, United States|Nephrology Associates, P.C., Augusta, Georgia, United States|MId Atlantic Nephrology Associates, PA, Baltimore, Maryland, United States|Caritas St. Elizabeth Center, Boston, Massachusetts, United States|Western New England Renal & Transplant Associatea, Springfield, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Hypertension & Renal Research Group, Buffalo, New York, United States|Bayview Nephrology, Inc., Erie, Pennsylvania, United States|Kidney Associates, PLLC, Houston, Texas, United States|Southwest Houston Research, LTD, Houston, Texas, United States|Fox Valley Nephrology Associates, Appelton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00628680"
958,"NCT03891433","Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae","CAPITIS","Unknown status","No Results Available","Urinary Tract Infections|Enterobacteriaceae Infections|Infection Due to ESBL Bacteria|Carbapenem|Escherichia Coli Infection|Klebsiella Pneumoniae Infection|Clinical Trial|Drug Resistance, Bacterial","Drug: Meropenem|Drug: Ertapenem 1000 MG|Drug: Piperacillin, Tazobactam 4-0.5G Solution for Injection","Clinical cure.|Microbiologic cure.|Mortality in patient follow-up.|Length of hospital stay in patient follow-up.|Relapse.|Reinfection.|Resistant clinical isolates in patient follow-up.|Adverse events in patient follow-up.|ICU admission in patient follow-up.|Clinical or microbiological failure of antibiotic therapy in patient follow-up.","Universidad del Norte","All","18 Years and older   (Adult, Older Adult)","Phase 4","198","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HUN-INF-CAPITIS-2018-1","April 1, 2019","April 1, 2020","April 1, 2021","March 27, 2019",,"April 23, 2019","Universidad del Norte´s Hospital, Soledad, Atlantico, Colombia",,"https://ClinicalTrials.gov/show/NCT03891433"
959,"NCT01095198","Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV)",,"Unknown status","No Results Available","Human Papillomavirus Infection|Cervical Intraepithelial Neoplasia","Device: offer of vaginal self collection|Other: 2nd reminder letter for Pap testing","uptake of screening invitation|Cervical Intraepithelial Neoplasia (CIN) 3 identified","McMaster University|Juravinski Cancer Centre Foundation|Merck Frosst Canada Ltd.|Public Health Agency of Canada (PHAC)","Female","35 Years to 69 Years   (Adult, Older Adult)","Phase 2|Phase 3","1440","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","RCTself","April 2010","November 2012","January 2013","March 30, 2010",,"July 21, 2011","McMaster University, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01095198"
960,"NCT03458338","Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa","RenalOne","Completed","No Results Available","Chronic Kidney Diseases|Diabetes Mellitus|Hypertension|Tuberculosis|Schistosomiasis|HIV Infections","Diagnostic Test: estimated glomerular filtration rate and albuminuria","Point prevalence of chronic kidney disease measured by lab values|Risk factors for chronic kidney disease measured by lab values and questionnaire","University Hospital, Basel, Switzerland|Swiss Tropical & Public Health Institute|Ifakara Health Institute","All","18 Years to 100 Years   (Adult, Older Adult)",,"1006","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","RenalOne","December 8, 2010","May 30, 2011","May 30, 2011","March 8, 2018",,"March 8, 2018","Universitätsspital Basel, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT03458338"
961,"NCT02811367","The HPV Self-test as a Test of Cure in Madagascar",,"Completed","No Results Available","Human Papilloma Virus Infection|Cervical Intraepithelial Neoplasia Grade 2/3","Device: HPV test","Cervical intra-epithelial neoplasia grade 2 or worse","University Hospital, Geneva","Female","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","117","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016-00030","June 2016","September 2016","September 2016","June 23, 2016",,"October 17, 2016","Saint Damien Medical Center, Ambanja, Madagascar",,"https://ClinicalTrials.gov/show/NCT02811367"
962,"NCT01812772","The Effect of Ureteric Stent Tethers on Patient Symptoms and Urinary Infection",,"Terminated","No Results Available","Kidney Stone","Device: Double J-stent with a long tether|Device: Double J-stent without a long tether","The difference in stent related lower urinary tract symptoms based on mean scores from the Ureteral Stent Symptoms questionnaires|the rate of stent bacterial colonization","Unity Health Toronto","All","18 Years and older   (Adult, Older Adult)","Not Applicable","11","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-370","March 2013","February 2014","February 2014","March 18, 2013",,"May 21, 2015","St. Michael Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01812772"
963,"NCT03178734","Foley Catheter vs a Self-contained Valved Urinary Catheter",,"Completed","No Results Available","Catheter-Related Infections|Urinary Tract Infections|Urogynecologic Surgery","Device: Foley Catheter vs Self-Contained Valved Catheter","Number of urinary tract infections|Patient satisfaction|Number of days until spontaneous void/Number of calls for device-related issues","charbel salamon|Atlantic Health System","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","908398","July 22, 2016","June 14, 2019","June 30, 2019","June 7, 2017",,"July 28, 2020","Atlantic Urogynecology Associates, Morristown, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03178734"
964,"NCT01414959","Target Site Pharmacokinetics of Doripenem at Steady State in Intubated Intensive Care Patients",,"Completed","No Results Available","Pneumonia|Abdominal Infection|Urinary Tract Infection",,,"Medical University of Vienna","All","18 Years and older   (Adult, Older Adult)",,"16","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Dori_MD_ICU","August 2011","July 2013","July 2013","August 11, 2011",,"August 29, 2017","Med. Univ. of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT01414959"
965,"NCT03838965","The Effects of Labor Stages and Interventions on Hemodynamic Measures During & After Childbirth With Noninvasive Sensors",,"Completed","No Results Available","Rupture of Membranes; Premature|Cesarean Section; Infection|Preeclampsia","Device: biobeat sensor","biobeat sensor is a noninvasive sensor of the the hymodynamic measures during the childbirth|biobeat sensor is a noninvasive sensor of the the hymodynamic measures after 24 hours of the childbirth","Hillel Yaffe Medical Center","Female","18 Years to 45 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","0101-18-HYMC","March 1, 2019","December 16, 2020","December 16, 2020","February 12, 2019",,"June 23, 2022","Hillel Yaffe Medical Center, Hadera, Israel",,"https://ClinicalTrials.gov/show/NCT03838965"
966,"NCT02116660","Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)","RANIA","Terminated","Has Results","HIV Infections","Drug: Raltegravir (MK-0518)|Drug: Nevirapine|Drug: Lamivudine|Drug: Tenofovir|Drug: Emtricitabine|Drug: Lopinavir|Drug: Ritonavir|Drug: Atazanavir|Drug: Darunavir","Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)|Percentage of Participants With Suppressed Viremia (<50 Copies/mL HIV-1 Ribonucleic Acid [RNA]) at Week 48|Percentage of Participants With Suppressed Viremia (<50 Copies/mL HIV-1 RNA) at Week 96|Percentage of Participants With Decline in Renal Function at Week 48|Percentage of Participants With Virologic Failure (HIV-1 RNA > 50 Copies/mL)|Change From Baseline of HIV-RNA Absolute Values|Percentage of Participants With Mutations Associated With Resistance to NRTIs, NNRTIs, INI, at Virological Failure.|Change From Baseline in Absolute CD4+ T-lymphocyte Count|Percentage of Participants With Altered Liver Enzymes and Lipid Profile|Percentage of Participants With Altered Values of Tubular Kidney Injury Markers.|Percentage of Participants Having Changes From Baseline in Metabolic Bone Markers|Area Under the Concentration Time Curve From Time 0 the Last Measurement Time t (AUC0-t) for Raltegravir and Nevirapine|Trough Concentration (Ctrough) for Raltegravir and Nevirapine|Percentage of Participants With Genotypic Resistance at Virologic Failure.|Percentage of Participants With Adherence to Study Therapy|Change From Baseline in Bone Disease Risk Assessment|Change From Baseline in the VACS Index|Percentage of Participants Experiencing a Decline of Renal Function|Change From Baseline in eGFR at Week 96","Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","11","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0518-284|2013-001637-40|MK-0518-284","September 3, 2014","July 10, 2017","July 10, 2017","April 17, 2014","April 8, 2019","April 8, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/60/NCT02116660/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02116660"
967,"NCT02384200","A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])",,"Completed","Has Results","Nephrolithiasis|Urinary Tract Infections","Drug: nitrofurantoin monohydrate/macrocrystalline capsules|Drug: ampicillin|Drug: gentamicin|Drug: vancomycin|Drug: ceftriaxone","Number of Participants That Developed Sepsis After Surgery|Participants With Positive Renal Pelvic Urine Culture|Participants With Positive Kidney Stone Culture|Positive Bladder Urine Culture|Number of Participants With Postoperative Urinary Tract Infection (UTI)|Number of Participants With a Postoperative Fever Greater Than 38.3 Celsius|Number of Participants Admitted to Intensive Care Unit (ICU) After Surgery|Number and Grade of Postoperative Complications Following Surgery as Graded by the Clavien-Dindo Complication Scale|Hospital Length of Stay After Surgery|Number of Partcipants That Were Stone Free After Surgery","University of California, San Diego|Mayo Clinic|University of British Columbia|The Cleveland Clinic|Duke University|Ohio State University|Dartmouth-Hitchcock Medical Center|Vanderbilt University|New York University","All","18 Years and older   (Adult, Older Adult)","Phase 4","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","160405|150013","March 2015","February 1, 2017","June 1, 2019","March 10, 2015","August 22, 2019","August 22, 2019","Mayo Clinic in Arizona, Phoenix, Arizona, United States|UCSD Medical Center, San Diego, California, United States|UCSF, San Francisco, California, United States|Mayo Clinic, Rochester, Minnesota, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Vanderbilt, Nashville, Tennessee, United States|University of British Columbia, Vancouver, British Columbia, Canada","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/00/NCT02384200/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02384200"
968,"NCT05203016","Complications Associated With Intraoperative Hypothermia.",,"Completed","No Results Available","Hypothermia|Hemorrhage, Postpartum|Infection Surgical Wound|Transfusion-dependent Anemia","Other: Hipotermia/Normotermia","Hypothermia","Instituto de Investigación Hospital Universitario La Paz","All","18 Years to 65 Years   (Adult, Older Adult)",,"402","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PI-3697","January 1, 2019","October 30, 2019","January 1, 2020","January 24, 2022",,"January 24, 2022","Hospital Universitario La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT05203016"
969,"NCT03100682","Prevention of Human Papillomavirus (HPV) Infection in Paediatric Kidney and Liver Transplant Recipients and in Paediatric Patients With Advanced Chronic Kidney Disease",,"Unknown status","No Results Available","Paediatric Kidney or Liver Transplantation|Chronic Kidney Disease",,"Immune Response to HPV vaccine","University Hospital Heidelberg","All","9 Years and older   (Child, Adult, Older Adult)",,"140","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HPVaxResponse Study","March 18, 2017","March 2022","December 2022","April 4, 2017",,"June 2, 2021","University Children's Hospital, Heidelberg, Germany",,"https://ClinicalTrials.gov/show/NCT03100682"
970,"NCT03839875","Evaluation of Efficacy and Safety of Gynomax® XL Ovule","Gyno-Türk","Completed","No Results Available","Trichomonal Vaginitis|Bacterial Vaginosis|Candidal Vulvovaginitis|Mixed Vaginal Infections","Drug: Gynomax® XL Vaginal Ovule","Percentage of patients with complete response to treatment|Percentage of patients with partial response to treatment|Percentage of patients with no response to treatment","Exeltis Turkey|Monitor CRO","Female","18 Years to 45 Years   (Adult)","Phase 4","116","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MON564.130.1","April 3, 2019","August 9, 2019","August 9, 2019","February 15, 2019",,"January 31, 2020","Ege University Family Planning and Infertility Application and Research Centeraştırma Merkezi, İzmir, Turkey",,"https://ClinicalTrials.gov/show/NCT03839875"
971,"NCT02547103","Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection","COSMO-PD","Unknown status","No Results Available","End Stage Renal Disease|Peritoneal Dialysis","Other: Chlorhexidine gluconate-soaked cloths|Other: Normal saline|Other: mupirocin ointment","Incidence of PD-related infections|Incidence of infection-related catheter removal|Incidence of hospitalization due to PD-related infection|Incidence of PD technical failure (change of modal of dialysis)|Incidence of death due to PD-related infection|Rate of Staphylococcus aureus colonization|Changes in health-related quality of life|Number of participants with depression|Changes in medication adherence|Total healthcare costs|Incidence of skin reactions","Chiang Mai University|Health Systems Research Institute,Thailand","All","18 Years and older   (Adult, Older Adult)","Phase 4","354","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","THOR-PD Group","June 1, 2016","June 30, 2021","August 2021","September 11, 2015",,"July 29, 2019","Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand",,"https://ClinicalTrials.gov/show/NCT02547103"
972,"NCT01152528","Va-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery",,"Unknown status","No Results Available","Vaginal Infections|Bacterial Vaginosis|Late Miscarriage|Preterm Birth|Preterm Premature Rupture of Membranes","Device: VA-SENSE","Incidence of preterm birth, gestational week at delivery.","Common Sense","Female","18 Years to 50 Years   (Adult)","Phase 3","248","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","F-7-27.3-1","July 2010","June 2011","June 2011","June 29, 2010",,"June 29, 2010","Western Galilee Hospital, Nahariya, Western Galilee, Israel",,"https://ClinicalTrials.gov/show/NCT01152528"
973,"NCT02786810","Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy",,"Completed","Has Results","Urinary Tract Infection|Vesicoureteral Reflux","Drug: Sulfur hexafluoride type-a lipid microspheres","Visualization of Renal Scars Compared to Previous Imaging|Number of Participants With Adverse Events Related to the Study Drug.","University of Tennessee","All","8 Years to 50 Years   (Child, Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1504311FB","March 2016","November 2016","November 2016","June 1, 2016","April 4, 2018","May 11, 2018","University of Tennessee Health Science Center, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02786810"
974,"NCT01214395","Nasal Tea Tree Oil for the Prevention of Infections in PD Patients",,"Completed","Has Results","End Stage Renal Failure on Dialysis","Drug: 5% tea tree oil nasal ointment","Primary Endpoint Will be the Number of Tea Tree Oil Patients That Did Not Have a Catheter-related Infection Within 6 Months After Entry Into the Trial.|The Number of Patients That Did Not Have a Staphylococcus Aureus Infection","PathWest Laboratory Medicine WA","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2006-199","June 2010","November 2011","December 2011","October 5, 2010","August 3, 2012","August 3, 2012","Sir Charles Gairdner Hospital, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT01214395"
975,"NCT04353583","Acute Kidney Injury and Acute Kidney Disease in COVID-19",,"Active, not recruiting","No Results Available","Acute Kidney Injury|Corona Virus Infection",,"Incidence of AKI|Cystatin C as indicator of mortality|Cystatin C as indicator of renal disease|Cystatin C as indicator of respiratory illness|Cystatin C as indicator of disease severity","University of Giessen","All","18 Years and older   (Adult, Older Adult)",,"900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AZ 58/20","April 21, 2020","May 17, 2022","February 28, 2024","April 20, 2020",,"December 7, 2023","University Hospital Giessen and Marburg, Giessen, Giessen, Hessen, Germany",,"https://ClinicalTrials.gov/show/NCT04353583"
976,"NCT00892099","DIVINE: Dialysis Infection and Vitamin D In New England",,"Completed","Has Results","End Stage Renal Disease","Drug: Ergocalciferol|Other: Placebo","Serum 25D Level|Serum Calcium|Serum Phosphate|Serum 25-OH Vitamin D|Serum 1,25(OH)2 Levels|Parathyroid Hormone","Massachusetts General Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","105","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2009P-000398|R01DK084974","November 2009","October 2014","October 2014","May 4, 2009","June 8, 2015","April 20, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00892099"
977,"NCT04473924","Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk","STIFLE-RISK","Withdrawn","No Results Available","Infection|Transplant;Failure,Kidney","Drug: Mycophenolate Mofetil","Enrollment rate in a trial of BSA-based vs. fixed dosing of mycophenolate|Feasibility of a trial of BSA-based vs. fixed dosing of mycophenolate|Collect pilot data of efficacy in a trial of BSA-based vs. fixed dosing of mycophenolate","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","20-31500","July 2022","January 2023","May 2023","July 16, 2020",,"May 6, 2022","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04473924"
978,"NCT03507751","Pharmacokinetics of Meropenem During High-dose CRRT",,"Completed","No Results Available","Infection|Renal Failure","Drug: Meropenem|Device: CRRT","Plasma concentration of meropenem","Medical University of Lublin|University of Warmia and Mazury in Olsztyn","All","18 Years to 80 Years   (Adult, Older Adult)",,"19","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","90/2009/IV","April 2, 2018","December 31, 2018","February 2, 2019","April 25, 2018",,"November 28, 2023","Oddział Kliniczny Anestezjologii i Intensywnej Terapii, Wojewódzki Szpital Specjalistyczny w Olsztynie, Olsztyn, Poland",,"https://ClinicalTrials.gov/show/NCT03507751"
979,"NCT02830321","The Association of Helicobacter Pylori in the Pathogenesis of Hyperemesis Gravidarum in Pregnant Women","AOHPIPOHGIPW","Completed","No Results Available","Hyperemesis Gravidarum","Other: helicopacter pylori stool antigen test (CER TEST BIOTEC)","The Association of Helicobacter Pylori in the Pathogenesis of Hyperemesis Gravidarum in Pregnant Women","rasha fawzy abd el kader|Ain Shams University","Female","18 Years to 40 Years   (Adult)",,"90","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","FDAAA","March 2015","December 2015","December 2015","July 12, 2016",,"July 12, 2016",,,"https://ClinicalTrials.gov/show/NCT02830321"
980,"NCT01985620","The Impact of a Short Intervention During RSV Prophylaxis on Influenza Vaccination Rate.",,"Unknown status","No Results Available","Prematurity|RSV|Influenza|Upper Respiratory Tract Infection|Lower Respiratory Tract Infection","Behavioral: Educational intervention","Influenza vaccination rate|respiratory morbidity","Tel-Aviv Sourasky Medical Center","All","6 Months to 2 Years   (Child)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TASMC-13-YS-0503-13-CTIL|0503-13-TLV","November 2013","April 2015",,"November 15, 2013",,"June 26, 2014","Sourasky Medical Center, Tel-Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT01985620"
981,"NCT02758288","BK Virus Post-Kidney Transplant: New Practice Versus Traditional Approach",,"Withdrawn","No Results Available","BK Virus Infection|BK Virus Nephropathy","Other: New Protocol - BK viremia or BK virus nephropathy|Other: Standard Protocol - BK viremia or BK virus nephropathy","Kidney function to compare effectiveness of a new care protocol for the treatment of BK viremia (BK PCR viral load over 500 copy) and BKVAN (confirmed by kidney biopsy) with a similar cohort treated with traditional methods.|Rate of BK nephropathy in both treatment groups confirmed by kidney biopsy|Rate of acute cellular or humoral rejection in both treatment groups confirmed by kidney biopsy|Rate of graft loss in both group as determined by elevated creatinine level and kidney biopsy|Estimated glomerular filtration rate (eGFR) at start of the study (0) , 3, 6, 12 and 24 months between two groups","Loma Linda University","All","18 Years and older   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Other|Time Perspective: Prospective","5150278","September 2015","July 2021","July 2022","May 2, 2016",,"October 5, 2020","Loma Linda University Medical Center, Loma Linda, California, United States",,"https://ClinicalTrials.gov/show/NCT02758288"
982,"NCT02034279","The INFECIR-2 Albumin Prevention Study","INFECIR2","Terminated","No Results Available","Advanced Chronic Liver Disease|Urinary Infection|Pneumonia|Cholangitis|Other Bacterial Diseases","Drug: Albumin","survival|Renal dysfunction|circulatory dysfunction|Inflammation and endothelial function|subsequent organ failure","EASL - CLIF Consortium","All","18 Years and older   (Adult, Older Adult)","Phase 4","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INFECIR 2|2013-002416-27","May 2014","December 31, 2016","February 10, 2017","January 13, 2014",,"May 18, 2017","Hospital Clinic, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02034279"
983,"NCT05733104","A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea",,"Not yet recruiting","No Results Available","Complicated Intra-abdominal Infection|Complicated Urinary Tract Infection|Hospital-acquired Pneumonia",,"Number of patient reporting an adverse event|Clinical response: Number of patient recorded as cure","Pfizer","All","3 Months and older   (Child, Adult, Older Adult)",,"600","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","C3591027","January 31, 2024","September 28, 2029","September 28, 2029","February 17, 2023",,"February 2, 2024",,,"https://ClinicalTrials.gov/show/NCT05733104"
984,"NCT00614679","A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia",,"Completed","No Results Available","End-Stage Renal Disease|Hemodialysis Catheter-associated Infection","Drug: catheter lock solution consisting of N-acetylcystein, tigecycline and heparin","Treatment success within 90 days|catheter salvage","University of California, San Diego","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-17624","October 2006","December 2008","December 2009","February 13, 2008",,"October 9, 2019","Ben Taub General Hospital, Houston, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00614679"
985,"NCT04761107","Impact of COVID-19 on GU Disease",,"Recruiting","No Results Available","COVID-19 Infection|Genitourinary Cancer|Benign Urologic Conditions",,"Proportion of patients with a new diagnosis of GU|Proportion of GU cancer patients, with active disease or in remission|Proportion of patients with the benign urologic condition","Icahn School of Medicine at Mount Sinai","All","40 Years and older   (Adult, Older Adult)",,"15240","Other","Observational","Observational Model: Other|Time Perspective: Prospective","GCO 20-1053|STUDY-20-01467","February 18, 2021","February 2026","February 2026","February 18, 2021",,"November 14, 2023","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04761107"
986,"NCT02733432","RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections",,"Completed","No Results Available","Candidiasis, Vulvovaginal|Mycoses|Yeast Infection|Moniliasis, Vulvovaginal|Vaginitis, Monilial","Drug: CD101 Vaginal Gel (3%)|Drug: CD101 External gel (1%)|Drug: CD101 Vaginal Ointment (6%)|Drug: CD101 External ointment (1%)|Drug: Fluconazole","Number of Subjects with Incidence of Treatment Emergent Adverse Events [Safety and Tolerability]|Change in Vulvovaginal Scoring System|Mycological Culture","Cidara Therapeutics Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","126","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CD101.TP.2.01","June 8, 2016","November 23, 2016","December 23, 2016","April 11, 2016",,"August 31, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Precision Trials AZ LLC, Phoenix, Arizona, United States|The Women's Clinical, P.A., Little Rock, Arkansas, United States|Women's Health Care Research Corp, San Diego, California, United States|Olympian Clinical Research, Clearwater, Florida, United States|Women's Medical Research, Clearwater, Florida, United States|Altus Research Inc, Lake Worth, Florida, United States|New Age Medical Research Corporation, Miami, Florida, United States|Augusta University, Augusta, Georgia, United States|Clinical Trials Management LLC, Metairie, Louisiana, United States|Tolan Park Clinic, Detroit, Michigan, United States|Saginaw Valley Medical Research Group LLC, Saginaw, Michigan, United States|Alliance Women's Research Group LLC, Delran, New Jersey, United States|Lawrence OB GYN Clinical Research LLC, Lawrenceville, New Jersey, United States|ProHEALTH Care Associates, LLP, Port Jefferson, New York, United States|Eastern Carolina Women's Center, New Bern, North Carolina, United States|Hawthorne Medical Research Inc, Winston-Salem, North Carolina, United States|Unified Women's Clinical Research - Hickory, Winston-Salem, North Carolina, United States|Aventiv Research Inc, Columbus, Ohio, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|TMC Life Research Inc., Houston, Texas, United States|Clinical Trials of Texas Inc, San Antonio, Texas, United States|Tidewater Clinical Research, Inc, Norfolk, Virginia, United States|Seattle Women's Health, Research, Gynecology, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02733432"
987,"NCT06253169","HPV DNA Self-sampling in a General Practitioner's Office.","ASTRA","Not yet recruiting","No Results Available","Cervical Cancer|HPV Infection|Precancerous Lesion","Diagnostic Test: HPV DNA self-test","To assess response rates to being approached about the possibility of self-testing for HPV in both study cohorts and overall.|Evaluation of the frequency of positivity of the HPV tests taken.|Evaluation of follow-up gynaecological care in women who tested positive.","Patient Organization Veronica","Female","30 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","V01","February 2024","March 2025","June 2025","February 12, 2024",,"February 12, 2024","CGOP, s.r.o., Prague, Czechia|Department of Gynecology, Obstetrics and Neonatology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czechia",,"https://ClinicalTrials.gov/show/NCT06253169"
988,"NCT06136702","ELEVATE Acceptability Study","ELEVATE AS","Recruiting","No Results Available","Cervical Cancer|HPV Infection|Acceptability of Health Care","Behavioral: Educational session|Behavioral: Self-sampling|Behavioral: Follow-up assessment","Uptake of cervical cancer screening|Attitudes towards HPV self-sampling|User's experiences of HPV self-sampling","University Ghent|Horizon 2020 - European Commission|Universidade Nova de Lisboa|Universidad de Cuenca|Hospital de Cancer de Barretos - Fundacao Pio XII","Female","25 Years to 65 Years   (Adult, Older Adult)","Not Applicable","1048","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ONZ-2022-0326","December 7, 2022","December 2024","December 2024","November 18, 2023",,"November 18, 2023","International centre for reproductive health, Ghent, East-Flanders, Belgium|Barretos Cancer Hospital - Fundação Pio XII, Barretos, Brazil|Universidad de Cuenca, Cuenca, Ecuador|Escola Nacional de Saúde Pública da Universidade NOVA de Lisboa, Lisboa, Portugal","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/02/NCT06136702/Prot_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/02/NCT06136702/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT06136702"
989,"NCT04488991","Nabothian Cyst Protects or Facilitates Against Cervical Cancer",,"Unknown status","No Results Available","HPV Infection|Nabothian Cyst|Cervical Cancer","Other: Cervical Cancer Rate","Nabothian cyst affects the HPV infection in cervix|Does the other factors(like cigarette, birth number, vaginitis) affect HPV infection and Cervical Cancer","Haseki Training and Research Hospital","Female","25 Years to 65 Years   (Adult, Older Adult)",,"1005","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-74","July 23, 2020","March 1, 2021","March 1, 2021","July 28, 2020",,"July 28, 2020","Cihan Comba, Istanbul, Sultangazi, Turkey",,"https://ClinicalTrials.gov/show/NCT04488991"
990,"NCT00371631","Colonizing Neurogenic Bladders With Benign Flora",,"Completed","Has Results","Spinal Cord Injury|Urinary Tract Infection","Biological: Insertion of urinary catheters coated with E. coli 83972","Bladder Colonization|The Rate of Symptomatic UTI While Colonized","US Department of Veterans Affairs|VA Office of Research and Development","All","Child, Adult, Older Adult","Phase 1","13","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","B4444-P","October 2006","February 2008","April 2008","September 4, 2006","November 24, 2014","November 24, 2014","Michael E DeBakey VA Medical Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00371631"
991,"NCT04196192","Febrile Infants - Diagnostic Assessment and Outcome","FIDO","Completed","No Results Available","Meningitis, Bacterial|Bacterial Infections|Urinary Tract Infections",,"Invasive bacterial infection|Serious bacterial infections","Belfast Health and Social Care Trust|Bristol Royal Hospital for Children|University Hospitals, Leicester|Barts & The London NHS Trust|Children's Health Ireland|Royal Hospital for Children Glasgow|Royal Belfast Hospital for Sick Children","All","up to 90 Days   (Child)",,"555","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","QIP10/12/19HJ","March 1, 2020","March 1, 2021","May 1, 2021","December 12, 2019",,"May 11, 2021","Children's Health Ireland, Dublin, Ireland|Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom|Bristol Royal Children's Hospital, Bristol, United Kingdom|Royal Hospital for Children Glasgow, Glasgow, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Royal London Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04196192"
992,"NCT05760300","A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function",,"Recruiting","No Results Available","Chronic Hepatitis D Infection","Drug: Bulevirtide (BLV)","Pharmacokinetic (PK) Parameter: AUCtau of Bulevirtide (BLV)|PK Parameter: Cmax ss of BLV|PK Parameter: AUC0-24 of BLV|PK Parameter: Cmax of BLV|PK Parameter: Tmax of BLV|PK Parameter: t1/2 of BLV|PK Parameter: CLss/F of BLV|PK Parameter: Vss/F of BLV|PK Parameter: Ctrough of Total Bile Acids (BA)|PK Parameter: Cmax of Total BA|PK Parameter: AUC0-24 of Total BA|PK Parameter: Tmax of Total BA|Percentage of Participants With Treatment-Emergent Adverse Events|Percentage of Participants With Laboratory Abnormalities","Gilead Sciences","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-589-6160|2022-502054-13-00","March 15, 2023","May 2026","May 2026","March 8, 2023",,"March 15, 2024","Velocity Clinical Research, New Smyrna Beach, Edgewater, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Floridian Clinical Research, LLC, Miami Lakes, Florida, United States|Clinical Pharmacology of Miami, LLC, Miami, Florida, United States|Advanced Pharma CR, LLC, Miami, Florida, United States|Global Clinical Professionals Research, Saint Petersburg, Florida, United States|Genesis Clinical Research, LLC, Tampa, Florida, United States|Nucleus Network, Saint Paul, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05760300"
993,"NCT03634904","Serum Ceftazidime Concentrations in Hemodialysis Patients","CEFTAHEMOD","Unknown status","No Results Available","Bacterial Infections|Ceftazidime|Renal Failure Chronic Requiring Hemodialysis","Drug: Drug bood sampling","Trough level at 8 mg/L or 1 x the MIC|Trough level at 32 mg/L or 4 x the MIC|Free trough level at 8 mg/L or 1 x the MIC|Free trough level at 32 mg/L or 4 x the MIC|Impact of trough levels at 8 mg/L ot 1 x the MIC on clinical outcome|Impact of trough levels at 32 mg/L ot 4 x the MIC on clinical outcome|Impact of hemodialysis parameter #1 on ceftazidime total serum levels|Impact of hemodialysis parameter #1 on ceftazidime free serum levels|Impact of hemodialysis parameter #2 on ceftazidime total serum levels|Impact of hemodialysis parameter #2 on ceftazidime free serum levels|Impact of hemodialysis parameter #3 on ceftazidime total serum levels|Impact of hemodialysis parameter #3 on ceftazidime free serum levels|Impact of hemodialysis parameter #4 on ceftazidime total serum levels|Impact of hemodialysis parameter #4 on ceftazidime free serum levels|Impact of patient's residual renal function on ceftazidime total serum levels|Impact of patient's residual renal function on ceftazidime free serum levels|Impact of other drugs on ceftazidime serum total concentrations (mg/L).|Impact of other drugs on ceftazidime serum free concentrations (mg/L).|Impact of MIC on the clinical effectiveness of ceftazidime","Centre Hospitalier Universitaire de Charleroi|Université Catholique de Louvain","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHUCHARLEROIPKPD001","September 15, 2018","September 15, 2020","September 15, 2021","August 17, 2018",,"August 17, 2018",,,"https://ClinicalTrials.gov/show/NCT03634904"
994,"NCT04072913","Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix","MMP-HPV","Completed","No Results Available","Papillomavirus Infections|Dysplasia|Cervix Cancer","Other: Vaginal samples (biopsies + vaginal smear)","Immunohistochemical score of expressions of matrix metalloproteinases|Immunohistochemical score of expressions of matrix metalloproteinases inhibitors","University Hospital, Bordeaux","Female","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","216","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CHUBX 2007/08","October 10, 2007","January 31, 2011","January 31, 2011","August 28, 2019",,"August 28, 2019",,,"https://ClinicalTrials.gov/show/NCT04072913"
995,"NCT01022346","A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection",,"Completed","No Results Available","Cervical Intraepithelial Neoplasia","Drug: Placebo|Drug: RO5217790","Percentage of participants with CIN2/CIN3 associated with HPV16 single infection who achieved Histologic resolution (Defined as no CIN), determined by evaluation of tissue derived from surgical excision|Percentage of participants who achieved Histologic resolution (Defined as no CIN), determined by evaluation of tissue derived from surgical excision|Percentage of participants who achieved Histologic response (Defined as CIN Grade less than [<] 2), determined by evaluation of tissue derived from surgical excision|Percentage of participants with viral clearance based on Roche Linear assay results|Percentage of participants with immunologic response to HPV antigens|Percentage of Participants with at least one Adverse Events (AEs)","Hoffmann-La Roche","Female","18 Years and older   (Adult, Older Adult)","Phase 2","206","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NV25025|2008-006946-24","August 2009","September 2013","September 2013","December 1, 2009",,"August 15, 2016","Mobile, Alabama, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Colton, California, United States|Los Angeles, California, United States|Colorado Springs, Colorado, United States|Stamford, Connecticut, United States|Washington, District of Columbia, United States|Lake Worth, Florida, United States|Miami, Florida, United States|Plantation, Florida, United States|Sarasota, Florida, United States|South Miami, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Decatur, Georgia, United States|Marrero, Louisiana, United States|Framingham, Massachusetts, United States|Kansas City, Missouri, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Lawrenceville, New Jersey, United States|Brightwaters, New York, United States|Bronx, New York, United States|New Bern, North Carolina, United States|Winston-salem, North Carolina, United States|Englewood, Ohio, United States|Gallipolis, Ohio, United States|Oklahoma City, Oklahoma, United States|West Reading, Pennsylvania, United States|Columbia, South Carolina, United States|Greenville, South Carolina, United States|Myrtle Beach, South Carolina, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|Sandy, Utah, United States|Norfolk, Virginia, United States|Antwerpen, Belgium|Brussel, Belgium|Bruxelles, Belgium|Edegem, Belgium|Gent, Belgium|Leuven, Belgium|Tienen, Belgium|Hus, Finland|Kuopio, Finland|Oulu, Finland|Tampere, Finland|Bordeaux, France|Dijon, France|Nantes, France|Paris, France|Reims, France|Strasbourg, France|San Juan, Puerto Rico|San Juan, Puerto Rico|Bilbao, Vizcaya, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01022346"
996,"NCT01055106","Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis",,"Completed","No Results Available","Vaginosis, Bacterial|Vaginal Infection","Drug: GW05|Drug: Metronidazole","proportion of subjects with therapeutic cure","Graceway Pharmaceuticals, LLC","Female","18 Years and older   (Adult, Older Adult)","Phase 2","255","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","GW05-0904","January 2010","April 2010","April 2010","January 25, 2010",,"July 1, 2011","Women's Health Research, Phoenix, Arizona, United States|Precision Trials, Phoenix, Arizona, United States|NEA Women's Clinic, Jonesboro, Arkansas, United States|Women's Health Center Inc, San Diego, California, United States|Downtown Women's Healthcare, Denver, Colorado, United States|Miami Research Associates, Miami, Florida, United States|Segal Institiute for Clinical Research, North Miami, Florida, United States|All Women's Healthcare of West Broward, Plantation, Florida, United States|Atlanta North Gynecology, Roswell, Georgia, United States|Women's Health Practice, Champaign, Illinois, United States|ActivMed Practices & Research, Haverhill, Massachusetts, United States|Grand Rapids Women's Health, Grand Rapids, Michigan, United States|Saginaw Valley Medical Research Group, Saginaw, Michigan, United States|Women's Health Research Center, Plainsboro, New Jersey, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Jackson Clinic, Jackson, Tennessee, United States|Adams Patterson OBGYN, Memphis, Tennessee, United States|Women's Partners in Health, Austin, Texas, United States|TMC Life Research, Houston, Texas, United States|Tidewater Physicians for Women, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01055106"
997,"NCT00511186","A Study in Sepsis Patients With Renal Failure",,"Terminated","No Results Available","Sepsis|Bacterial Infections and Mycoses","Drug: Placebo|Drug: BIAP","Haematology, biochemistry, and microbiological evaluation. Adverse event monitoring.|To investigate the effect of AP on inflammatory parameters in sepsis patients with renal failure.|To investigate the effect of AP on clinical variables in sepsis patients with renal failure.|To investigate the effect of AP on renal function markers in sepsis patients with renal failure.","AM-Pharma","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AP REN 01-01","May 2008","December 2009","December 2009","August 3, 2007",,"April 2, 2012","University Medical Center Antwerp (UZA), Antwerp, Belgium|Cliniques Universitaires Saint Luc-UCL, Brussels, Belgium|ULB Hopital Erasme, Brussels, Belgium|Universitair Ziekenhuis Brussel, Brussels, Belgium|UMC Nijmegen University Medical Center St Radboud, Nijmegen, Gelderland, Netherlands|Isala Clinics, Zwolle, Overijssel, Netherlands|Jeroen Bosch Ziekenhuis lokatie GZG, 's-Hertogenbosch, Netherlands|VU University Medical Center, Amsterdam, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands",,"https://ClinicalTrials.gov/show/NCT00511186"
998,"NCT04583553","Comparative Microbial Analysis of Cystitis in Non-muscle-invasive Bladder Cancer Patients Using Vikor Scientific Urine-ID Testing Menu (IDTM) and Standard Laboratory Culture","VS-UrineID","Unknown status","No Results Available","Urinary Tract Infections|Bladder Cancer","Diagnostic Test: Vikor Scientific Urine-IDTM","To determine if Vikor Scientific Urine-IDTM can identify pathogen (or absence thereof) causing post-TURBT or post-bacillus Calmette Guerin (BCG) cystitis in a timelier manner than standard laboratory culture.|To determine if Vikor Scientific Urine-IDTM provides concordant identification or urinary pathogen and antimicrobial sensitivity compared to standard laboratory culture in post-TURBT or post-BCG cystitis.|To characterize the pathogens involved in post-TURBT and post-BCG Urinary Tract Infection (UTI) and their antibiotic susceptibility/resistance profile|To determine the prevalence of post-TURBT and post-BCG cystitis with no causative pathogenic organism","University of Kansas Medical Center|Vikor Scientific","All","18 Years and older   (Adult, Older Adult)",,"175","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VS-UrineID","December 15, 2021","December 30, 2022","December 30, 2022","October 12, 2020",,"May 5, 2021","University of Kansas Medcial Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT04583553"
999,"NCT00931190","Use of Human Papillomavirus Persistence for Determination of Treatment Efficacy Among Women With Cervical Dysplasia",,"Completed","No Results Available","Human Papillomavirus Infection|Cervical Intraepithelial Neoplasia",,,"Lund University|Swedish Cancer Society","Female","Child, Adult, Older Adult",,"195","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","95-240","February 2001",,"November 2005","July 2, 2009",,"September 15, 2009","Dept. obstetrics and gynecology, University hospital of Northern Sweden, Umeå, Sweden",,"https://ClinicalTrials.gov/show/NCT00931190"
1000,"NCT05557318","Using Micro Electro Mechanical Systems to Detect the Air of Vaginal Discharge",,"Recruiting","No Results Available","Vaginal Infection|Vaginitis","Device: Vaginal swab for RT-PCR|Device: Vaginal swab for culture|Device: Metabolic gas signatures detected by Ainos Flora (operated by participant)|Device: Metabolic gas signatures detected by Ainos Flora (operated by medical staff)","To assess the sensitivity and specificity of Ainos Flora in subjects compared to RT-PCR and culture groups in identifying the types of vaginitis.|Assess the change in sensitivity as the number of subjects is changed.|Assess the change in specificity as the number of subjects is changed.","Taiwan Carbon Nano Technology Corporation|Ainos, Inc. (f/k/a Amarillo Biosciences Inc.","Female","20 Years to 50 Years   (Adult)","Not Applicable","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","A202203003","October 8, 2022","September 2025","October 2025","September 28, 2022",,"April 10, 2024","MacKay Memorial Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT05557318"
1001,"NCT05796921","Lacticaseibacillus Rhamnosus CA15 (DSM 33960) Strain as a New Driver in Restoring the Normal Vaginal Microbiota",,"Recruiting","No Results Available","Bacterial Vaginosis|Candidosis Vaginal|Urinary Tract Infections","Dietary Supplement: Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain|Dietary Supplement: placebo","Microbiota|Symptomatology|Sign|Well-being","Agnese Maria Chiara Rapisarda|ProBioEtna|Universita degli Studi di Catania","Female","18 Years to 48 Years   (Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","113/2022/PO","January 2, 2023","December 29, 2023","March 30, 2024","April 4, 2023",,"April 10, 2023","University of Catania, Catania, Italy",,"https://ClinicalTrials.gov/show/NCT05796921"
1002,"NCT04472377","Agreement of hrHPV Type Between Self-collected Sample From Vaginal Fornix and Physician Collected Sample From the Cervical Surface",,"Completed","No Results Available","Human Papillomavirus Infection|Self Sampling|Vaginal Discharge","Device: Self sampling kit for collecting discharge from vaginal fornix","Agreement in the detection of high-risk HPV type in physician collected specimen and patient sampled specimen.|Agreement in HPV detection between physician collected sample and self-collected sample|Percentage of a valid specimen, according to the presence of the beta-globin gene in the self-collected specimen, and compares to the physician-collected specimen|Any adverse event resulted from collecting the specimen","Hygeia Touch Inc.","Female","21 Years to 65 Years   (Adult, Older Adult)","Not Applicable","1210","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HT19-HPV-01","May 29, 2020","December 21, 2021","April 18, 2022","July 15, 2020",,"April 22, 2022","Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT04472377"
1003,"NCT02124252","Community-Driven Cervical Cancer Prevention in Western Kenya",,"Completed","No Results Available","Human Papilloma Virus Infection|Carcinoma in Situ of Uterine Cervix","Behavioral: Community-based testing with standard linkage to care|Behavioral: Community-based HPV testing with enhanced linkage to care","Reach of cervical cancer screening using self-collected HPV specimens in community health campaigns compared to clinics|Determine the Efficacy of the cervical cancer prevention program","Duke University","Female","25 Years to 65 Years   (Adult, Older Adult)","Not Applicable","7200","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Pro00077442","January 2016","October 2016","March 2019","April 28, 2014",,"April 10, 2019","Kenya Medical Research Institute, Nairobi, Kenya",,"https://ClinicalTrials.gov/show/NCT02124252"
1004,"NCT00986102","PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region",,"Completed","Has Results","Pneumonia|Pneumonia, Ventilator-Associated|Urinary Tract Infections","Drug: doripenem","Number of Participants With the Usage of Doripenem as Per the Approved Indication|Number of Participants With Different Mode of Usage of Doripenem|Duration of Antibiotic Therapy|Number of Participants With Acute Physiology and Chronic Health Evaluation II (APACHE II) Score|Number of Participants Who Achieved Clinical Cure, Clinical Failure and Intermediate Outcome at End-of-treatment Visit (EOT)|Number of Participants Who Achieved Clinical Cure, or Experienced Clinical Failure, Relapse or Intermediate Outcome at Test-of-cure (TOC) Visit|Number of Participants Who Experienced Eradication, Presumed Eradication, Persistence, Presumed Persistence and Indeterminate Response at End-of-treatment Visit (EOT) Visit|Medical Resource Utilization|Number of Participants Readmitted to the Intensive Care Unit (ICU) Within 28 Days After End-of-treatment (EOT)|Number of Participants Readmitted to the Hospital Within 28 Days After End-of-treatment (EOT)","Johnson & Johnson Pte Ltd|Johnson & Johnson (Hong Kong) Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 4","216","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR016321|DORIBAC4007","July 2009","September 2011","September 2011","September 29, 2009","February 7, 2013","February 7, 2013","Hk, Hong Kong|Bandung, Indonesia|Jakarta, Indonesia|Surabaya, Indonesia|Ipoh, Malaysia|Johor Bahru, Malaysia|Kota Bharu, Malaysia|Kuala Lumpur K Lumpur, Malaysia|Kuala Lumpur N/A, Malaysia|Pulau Pinang, Malaysia|Selangor, Malaysia|Seremban, Malaysia|Terengganu, Malaysia|Singapore, Singapore|Hanoi, Vietnam|Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT00986102"
1005,"NCT06243666","Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls",,"Not yet recruiting","No Results Available","Cervical Intraepithelial Neoplasia|Cervical Cancer|Persistent Infection","Biological: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|Other: No intervention","Incidence of persistent infection, transient infection, and cervical precancerous CIN1+ lesions associated with HPV types 16 and 18|Anti-HPV 16 and 18 IgG antibody seropositive rates and geometric mean concentrations|Incidence of persistent infection, transient infection, and cervical precancerous CIN1+ lesions associated with HPV types 31/33/45","Xiamen University|Xiamen Innovax Biotech Co., Ltd|Center for Disease Control and Prevention, Sheyang County, Yancheng City, Jiangsu Province, China","Female","18 Years and older   (Adult, Older Adult)",,"2188","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HPV-PRO-006-4","February 20, 2024","December 31, 2026","December 31, 2026","February 6, 2024",,"February 13, 2024","Sheyang County Center for Disease Control and Prevention, Yancheng, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT06243666"
1006,"NCT05643950","Effectiveness and Cost-effectiveness of the T-Control® Catheter in Patients With Acute Urine Retention",,"Withdrawn","No Results Available","Urinary Retention|Catheter-Associated Urinary Tract Infection|Catheter Complications","Device: Foley catheter|Device: T-Control catheter","Magnitude of infections|Rate of symptomatic and asymptomatic infections|Self-perceived health-related quality of life (HRQoL)|Indication of antibiotic treatments|Determination of the biofilm formed in the catheters|Number of adverse events related to catheterization|Total costs of each type of catheterization (cost-effectiveness) per quality-adjusted life year (QALY) of catheterized participants|Level of satisfaction and workload of health professionals.|Acceptability of the T-Control® device","Rethink Medical SL","Male","50 Years to 100 Years   (Adult, Older Adult)","Not Applicable","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","RM-TCONTROL-2022-01|2022-002862-34","August 1, 2023","December 2023","April 2024","December 9, 2022",,"December 27, 2023","Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Las Palmas De Gran Canaria, Las Palmas, Spain|Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz De Tenerife, Spain",,"https://ClinicalTrials.gov/show/NCT05643950"
1007,"NCT02575495","A Randomized Control Trial of Antibiotic Treatment Duration For Asymptomatic Bacteriuria After Kidney Transplantation",,"Completed","No Results Available","Kidney Transplantation|Bacteriuria|Asymptomatic Infections","Drug: 7 days course of antibiotic treatment|Drug: 14 days course of antibiotic treatment","Composite end point of Symptomatic urinary tract infection, Sepsis, Graft function and Mortality rate|Composite end point of Symptomatic urinary tract infection, Sepsis, Graft function and|duration of hospital stay","Mahidol University","All","15 Years and older   (Child, Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC_580278","February 2015","January 2016","February 2016","October 14, 2015",,"March 16, 2016","Pattraporn Ponglorpisit, Ratchathewi, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT02575495"
1008,"NCT04385680","Chlorhexidine Vaginal Preparation for Reduction of Post-cesarean Endometritis and Sepsis",,"Completed","No Results Available","Postpartum Endometritis|Wound Infection|Chlorhexidine Adverse Reaction|Postoperative Fever","Drug: Chlorhexidine Gluconate vaginal solution 0.05%","post-cesarean endometritis|Postoperative wound infection|Significant leukocytosis|Chlorhexidine adverse drug reaction|incidence of hospital readmission|length of hospital stay","Zagazig University","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","840","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","chlorhex. post cs endometritis","May 15, 2020","March 10, 2022","August 30, 2022","May 13, 2020",,"September 23, 2022","Armed Forces Hospitals Southern Region, Khamis Mushait, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT04385680"
1009,"NCT02591901","Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods)","PReSuTINeB","Completed","No Results Available","UTI|Neurogenic Bladder|Antibiotic Resistance","Drug: Uro vaxom|Other: Placebo comparator","Checklist or consensus guideline which can be used to measure a symptomatic urinary tract infection and Practicality of carrying out a definitive randomised controlled clinical study|Number of participants willing to participate|Number of successfully collected urine samples via courier|Drug compliance","Buckinghamshire Healthcare NHS Trust|National Institute for Health Research, United Kingdom|Oxford Clinical Trials Research Unit","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","RXQ/648","April 6, 2018","August 2, 2019","September 21, 2019","October 30, 2015",,"March 18, 2020","Stoke Mandeville Hospital, Aylesbury, Buckinghamshire, United Kingdom|Oxford Centre for Enablement, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02591901"
1010,"NCT04825314","Noble Meta Alloy Coated Catheters in Patients With Long Term Catheterization",,"Unknown status","No Results Available","Urinary Tract Infections|Catheter Infection|Catheter-Related Infections|Infection","Device: Urethral catheter","Urinary tract infection|Catheter tolerance","Alexandria University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Prevention","0106462","May 21, 2020","May 21, 2021","June 21, 2021","April 1, 2021",,"April 8, 2021","Alexandria University Hospitals, Alexandria, Egypt",,"https://ClinicalTrials.gov/show/NCT04825314"
1011,"NCT00365430","SAFE or SORRY? Patient Safety Study of the Prevention of Adverse Patient Outcomes",,"Completed","No Results Available","Pressure Ulcer|Urinary Tract Infection|Accidental Falls","Behavioral: safety program","Incidence of adverse events (count incidence of Pressure Ulcers, Urinary Tract Infections, and Falls|Utilization of preventive interventions and knowledge of nurses and caregivers","Radboud University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development","All","18 Years and older   (Adult, Older Adult)","Not Applicable","3000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","SoS245119|54010002","September 2006","December 2008","December 2008","August 17, 2006",,"January 23, 2009","Alysis Zorggroep lokatie Rijnstate, Arnhem, Gelderland, Netherlands|Zorggroep Maas en Waal, Beneden-Leeuwen, Gelderland, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands|Radboud University Nijmegen Medical Center, Nijmegen, Gelderland, Netherlands|Stichting De Waalboog, Nijmegen, Gelderland, Netherlands|Zorggroep Zuid-Gelderland, Nijmegen, Gelderland, Netherlands|Universitair Longcentrum Dekkerswald, Nijmegen, Gelderland, Netherlands|Stichting SVVE De Archipel, Eindhoven, Noord-Brabant, Netherlands|Stichting De Riethorst Stromenland, Geertruidenberg, Noord-Brabant, Netherlands|Zorggroep Noord-Limburg Venlo, Venlo, Noord-Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT00365430"
1012,"NCT05026021","Prediction of BKvirus Nephropathy Risk by the NEPHROVIR Method in Kidney Transplant Patients With BKvirus Viremia","BK-VIR","Active, not recruiting","No Results Available","BK Virus Infection|Nephropathy|Kidney Transplantation","Biological: Blood sample","Evaluate by the NEPHROVIR method the risk of developing histologically proven BKvAN with renal impairment in kidney transplant recipients|Assessment of the time to reconstitution of an effective anti-BK-v immune response from baseline (inclusion) at 12 months|Assessment of the prognostic character of NEPHROVIR on BKv infection from baseline (inclusion) at 12 months|Assessment of the prognostic character of NEPHROVIR on kidney graft function from baseline (inclusion) at 24 months|Assessment of the prognostic character of NEPHROVIR on kidney graft allorejection risk from baseline (inclusion) at 12 months","Assistance Publique - Hôpitaux de Paris|SATT Paris Saclay","All","18 Years and older   (Adult, Older Adult)",,"41","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-A01443-36","September 2, 2021","September 2, 2023","September 2, 2025","August 30, 2021",,"April 3, 2024","Henri Mondor Hospital (001), Créteil, France|Saint Louis Hospital (003), Paris Cedex 10, France|La Pitié Salpêtrière Hospital (004), Paris Cedex 13, France|Necker Hospital (005), Paris Cedex 15, France|Foch Hospital (002), Suresnes, France",,"https://ClinicalTrials.gov/show/NCT05026021"
1013,"NCT04335539","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants",,"Completed","No Results Available","Gram-negative Bacterial Infections|Bloodstream Infections (BSI)|Complicated Intra-abdominal Infection (cIAI)|Hospital Acquired Pneumonia (HAP)|Ventilator-acquired Pneumonia|Complicated Urinary Tract Infection (cUTI)|Sepsis","Drug: Cefiderocol|Drug: Standard of Care","Number of Participants with Adverse Events in the Single Dose Phase|Maximum Observed Plasma Concentration (Cmax) of Cefiderocol in the Single Dose Phase|Area Under the Plasma Concentration Time Curve Extrapolated From Time 0 to Infinity (AUCinf) of Cefiderocol in the Single Dose Phase|Apparent Terminal Elimination Half-life of Cefiderocol in the Single Dose Phase|Number of Participants with Adverse Events in the Multiple Dose Phase|Maximum Observed Plasma Concentration (Cmax) of Cefiderocol in the Multiple Dose Phase|Area Under the Plasma Concentration Time Curve Extrapolated From Time 0 to Infinity (AUCinf) of Cefiderocol in the Multiple Dose Phase|Apparent Terminal Elimination Half-life of Cefiderocol in the Multiple Dose Phase|Percentage of Participants with a Clinical Response in the Multiple Dose Phase|Percentage of Participants with a Microbiological Response Per Pathogen in the Multiple Dose Phase","Shionogi|Shionogi Inc.","All","3 Months to 17 Years   (Child)","Phase 2","54","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1802R2135|2019-002120-32","August 21, 2020","February 6, 2023","February 6, 2023","April 6, 2020",,"January 24, 2024","Universitair Ziekenhuis Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Tallinn Childrens Hospital, Tallin, Estonia|Tartu Ulikooli Kliinikum - Anestesioloogia ja Intensiivravi Kliinik, Tartu, Estonia|JSC ""Medical Corporation Evex"" "" M. Iashvili Batumi Maternal and Child Central Hospital"", Batumi, Georgia|JSC ""EVEX Medical Corporation""- M Lashvili Childrens Central Hospital, Tbilisi, Georgia|Ltd Unimedi Kakheti Childrens New Clinic, Tbilisi, Georgia|Heim Pl Orszgos Gyermekgygyszati Intzet, Pilisborosjenő, Hungary|Szegedi Tudomnyegyetem, Szegedi Tudomnyegyetem, Hungary|Daugavpils regional Hospital, Daugavpils, Latvia|Bernu Kliniska Universitates Slimnica Childrens Hospital - Tornakalna, Riga, Latvia|Smolensk State Medical University, Smolensk, Russian Federation|St. Petersburg State Pediatric Medical University, St. Petersburg, Russian Federation|Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital Universitario y Politecnico La Fe, Valencia, Spain|Siriraj Hospital, Bangkok-noi, Thailand|King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand|PHPT-Chiangrai PrachanuKroh Hospital, Chiang Mai, Thailand|Khon Kaen University (KKU) - Faculty of Medicine-Srinagarind Hospital, Khon Kaen, Thailand|Dnipropetrovsk Regional Children Clinical Hospital, Kharkiv, Ukraine|Regional Children Clinical Hospital, Kharkiv, Ukraine|National Childrens Specialized Hospital OHMATDYT of the Ministry of Health of Ukraine, Kiev, Ukraine|Higher State Educational Institute of Ukraine Ukrainian Medical Stamatological Academy, Poltava, Ukraine",,"https://ClinicalTrials.gov/show/NCT04335539"
1014,"NCT03438214","Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients","ETERNITY","Unknown status","No Results Available","Gram-Positive Bacterial Infections|Nephrotoxicity|Sepsis","Drug: Vancomycin Continuous infusion|Drug: Vancomycin Intermittent infusion","Acute renal failure|Hypersensibility reactions with vancomycin|Length of ICU stay|Time of treatment with the antimicrobial|Length of hospitalization|Mortality rate","University of Sao Paulo","All","18 Years and older   (Adult, Older Adult)","Phase 4","222","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","81226617.8.1001.0065","April 28, 2018","February 28, 2020","December 1, 2022","February 19, 2018",,"April 5, 2018","Faculty of Medicine University os São Paulo, São Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT03438214"
1015,"NCT02693483","Preoperative Vaginal Cleansing With Povidone Iodine and the Risk of Post Cesarean Endometritis",,"Unknown status","No Results Available","Infection; Cesarean Section","Drug: 10% povidone iodine","Number of Subjects with post cesarean endometritis|Number of Subjects with allergic reaction to povidone iodine","Ain Shams Maternity Hospital","Female","18 Years to 40 Years   (Adult)","Phase 4","306","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","povidone iodine","April 2015","June 2016","October 2016","February 26, 2016",,"February 26, 2016","Ain Shams maternity hospital, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02693483"
1016,"NCT02785445","Healthy.io Method Comparison & User Performance Study",,"Completed","No Results Available","Urinary Tract Infection|Kidney Failure|Diabetes","Device: Dip.io Home Based Dipstick Analyzer|Device: ACON U500 Mission® U500 Urine Analyzer","Exact and ±1 agreement to compared device|User performance","Healthy.io Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","425","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CTP-Healthy.io-01/03","October 2015","June 2017","September 2017","May 27, 2016",,"September 11, 2017","Atlanta Center for Medical Research, Atlanta, Georgia, United States|AccuMed Research Associates, Garden City, New York, United States",,"https://ClinicalTrials.gov/show/NCT02785445"
1017,"NCT00929526","Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study",,"Completed","Has Results","Infections, Papillomavirus","Procedure: Liquid-based cytology (LBC) sampling|Procedure: Blood sampling","Number of Subjects Reporting Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Cases Associated With HPV16 and/or HPV18 Detected Within the Lesional Component of the Cervical Tissue Specimen.|Number of Subjects Reporting Cytological Abnormalities and Lesions Associated With HPV-16 and/or HPV-18.|Number of Subjects Reporting Cytologically Confirmed Abnormalities and Lesions Concurrently Associated With Any Oncogenic HPV Types.|Number of Subjects Reporting CIN1+ Associated With Any Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen.|Number of Subjects Reporting Incident Cervical Infection Associated With HPV-16 and/or 18.|Number of Subjects Reporting Incident Cervical Infection With Any Oncogenic HPV Types.|Number of Subjects Reporting Persistent Long-term Cervical Infection (12-month Definition) With HPV-16 and/or 18.|Number of Subjects Reporting Persistent Long-term Cervical Infection (12-month Definition) With Any Oncogenic HPV-types.|Number of Subjects With HPV-16 and HPV-18 Antibodies Titers Equal to or Above the Assay Cut-off Values.|HPV-16 and HPV-18 Antibody Titers|Number of Subjects Reporting Serious Adverse Events (SAEs).|Number of Subjects With New Onset of Chronic Diseases (NOCDs) Regardless of Causal Relationship to Vaccination and Intensity.|Number of Subjects With New Onset of Autoimmune Diseases (NOADs) Regardless of Causal Relationship to Vaccination and Intensity.|Number of Subjects With Medically Significant Conditions (MSCs).|Number of Subjects With Pregnancies and Pregnancy Outcomes.","GlaxoSmithKline","Female","20 Years to 25 Years   (Adult)","Phase 3","752","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","112949","June 2009","February 2011","February 2011","June 29, 2009","October 15, 2012","October 20, 2016","GSK Investigational Site, Aomori, Japan|GSK Investigational Site, Fukui, Japan|GSK Investigational Site, Hiroshima, Japan|GSK Investigational Site, Hiroshima, Japan|GSK Investigational Site, Kagoshima, Japan|GSK Investigational Site, Kagoshima, Japan|GSK Investigational Site, Miyazaki, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00929526"
1018,"NCT00546195","Infant Immune Response to Bacterial Infection",,"Completed","No Results Available","Prematurity|Histologic Chorioamnionitis",,,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"45","NIH","Observational","Time Perspective: Prospective","999908011|08-CH-N011","October 15, 2007",,"March 29, 2011","October 18, 2007",,"July 2, 2017","National Institute of Child Health and Human Development (NICHD), 9000 Rockville, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00546195"
1019,"NCT02740777","Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females",,"Completed","No Results Available","Human Papillomavirus|Cervical Intraepithelial Neoplasia|Persistent Infection","Biological: HPV-16/18 vaccine","HPV-16 and HPV-18 antibody titers (GMT)|HPV-16 and HPV-18 antibody titers (GMT) and the seroconversion rate|Local and systemic adverse events (AEs)","Shanghai Zerun Biotechnology Co.,Ltd|Guangxi Center for Disease Control and Prevention","Female","9 Years to 24 Years   (Child, Adult)","Phase 2","900","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","311-HPV-1004","February 2016","November 2016","July 2019","April 15, 2016",,"April 13, 2023","Hezhou Center for Disease Prevention and Control, Hezhou, Guangxi, China|Zhongshan Center for Disease Prevention and Control, Zhongshan, Guangxi, China",,"https://ClinicalTrials.gov/show/NCT02740777"
1020,"NCT02812914","NACER II: Reducing Prenatal Exposures to Household Air Pollution in Rural Guatemala Through a Gas Stove/Behavior Intervention to Improve Neonatal Health",,"Completed","No Results Available","Premature Birth|Fetal Growth Retardation|Infections, Respiratory|Exposure to Environmental Pollution, Non-occupational|Infant, Small for Gestational Age","Other: Low-cost gas stove|Behavioral: Peer education classes|Behavioral: Resource-intensive behavioral intervention approach","Change in urinary polycyclic aromatic hydrocarbon (PAH) and volatile organic compound (VOC) metabolite concentrations|Change in 48-hour mean personal carbon monoxide exposure|Change in 48-hour mean kitchen particulate matter concentration|Change in 48-hour mean personal particulate matter exposure|Change in weekly use of gas stoves (cooking events and total cooking time) using temperature loggers|Preterm birth|Low birth weight|Respiratory illness","University of California, San Francisco|Universidad del Valle, Guatemala","Female","18 Years to 45 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","15-17003","April 2016","June 19, 2017","June 19, 2017","June 24, 2016",,"October 27, 2017","San Lorenzo Health Center, San Lorenzo, Guatemala",,"https://ClinicalTrials.gov/show/NCT02812914"
1021,"NCT03341819","Comparative Study Between Retained and Non-retained Urinary Catheter in Total Knee Arthorplasty With Epidural Anesthesia",,"Completed","No Results Available","Postoperative Urinary Retention|Urinary Tract Infections|Epidural Anesthesia","Procedure: Total knee arthroplasty|Procedure: Urinary Catheterization","postoperative urinary retention|urinary tract infection","Navamindradhiraj University","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","242","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","COA 126/2560","November 6, 2017","April 5, 2019","October 25, 2019","November 14, 2017",,"November 25, 2019","Navamindradhiraj University, Dusit, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT03341819"
1022,"NCT03813576","Acceptability and Efficacy of Self-sampling for Cervical Cancer Screening: A Pilot Study",,"Unknown status","No Results Available","Cervical Cancer|Cervical Dysplasia|Human Papillomavirus Infection","Diagnostic Test: Self-collected HPV vaginal swab","Sensitivity and specificity of self-collected HPV swabs|Participant acceptability of self-collected HPV swabs","National University Hospital, Singapore","Female","30 Years to 69 Years   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2018/00846","March 2019","August 2019","December 2019","January 23, 2019",,"January 23, 2019",,,"https://ClinicalTrials.gov/show/NCT03813576"
1023,"NCT04390113","Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)",,"Terminated","No Results Available","BK Virus Infection|Hemorrhagic Cystitis","Biological: Posoleucel (ALVR105)|Biological: Placebo","Time until urine is visually clear of hematuria|Time until bladder pain is resolved|Days in the hospital for any reason|Time to resolution for target all viruses|Average daily bladder/lower abdominal pain|Incidence and severity of acute graft versus host disease and cytokine release syndrome","AlloVir","All","1 Day and older   (Child, Adult, Older Adult)","Phase 3","97","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AVM-003-HC","March 18, 2021","January 31, 2024","January 31, 2024","May 15, 2020",,"February 2, 2024","City of Hope National Medical Center, Duarte, California, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|Yale University School of Medicine - Yale Cancer Center, New Haven, Connecticut, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Moffitt, Tampa, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Johns Hopkins Medicine, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Children's Mercy Hospital - Kansas City, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Ohio State University Medical Center (OSUMC), Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|CHU de Lille - Hopital Claude Huriez, Lille, France|CHU de Nantes - Hôtel-Dieu, Nantes, France|AP-HP Hopital Saint-Louis, Paris, France|HCL Centre Hospitalier Lyon Sud, Pierre-Bénite, France|IUCT-Oncopole, Toulouse, France|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Ospedale Pediatrico Bambino Gesù, Roma, Italy|Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Rome, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento, Verona, Italy|Chonnam National University Hwasun Hospital, Jeongnam, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Pusan National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Hospital Clinic Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Malaga, Málaga, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Karolinska University Hospital, Stockholm, Sweden|University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom|Queen Elizabeth University Hospital - Glasgow, Glasgow, United Kingdom|Great Ormond Street Hospital for Children, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|University College London Hospital, London, United Kingdom|Nottingham University Hospitals, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04390113"
1024,"NCT03790826","Chronic Indwelling Foley and Catheter Associated Trauma (CIF-CAT) Study",,"Unknown status","No Results Available","Bladder Infections and Inflammations","Device: cystoscopy","Bladder mucosa damage assessment via computerized image analysis|Bladder mucosa damage urologist visual assessment|Patient discomfort via Numeric Pain Rating Scale","Nellie Medical, LLC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CIFCAT-001","April 2019","December 2019","March 2021","January 2, 2019",,"March 26, 2019",,,"https://ClinicalTrials.gov/show/NCT03790826"
1025,"NCT01919099","Study of the Complications Associated With Certain Stem Cell Transplants",,"Completed","No Results Available","Post-Transplant Infections|Post-Transplant Renal Insufficiency|Post-Transplant Pulmonary Complications",,"Characterize the infectious and noninfectious complications associated with allo-HSCT, including incidence, clinical course, cost to the Clinical Center and distribution within each NIH intramural transplant protocol","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","2 Years and older   (Child, Adult, Older Adult)",,"100","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","130177|13-I-0177","July 31, 2013","August 24, 2017","August 24, 2017","August 8, 2013",,"March 22, 2024","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01919099"
1026,"NCT06344884","Early Patient Removal of Urinary Catheters After Urogynecologic Surgery","CARES2","Not yet recruiting","No Results Available","Urinary Retention Postoperative|Postoperative Urinary Tract Infection|Catheter Site Pain","Procedure: Early catheter removal","Number of patients with ongoing urinary retention (noninferiority)|Number of patient contacts for voiding dysfunction by Type|Total patient contacts for voiding dysfunction Combined|Number of patients treated for postoperative UTI.|Number of patients with ongoing urinary retention|Patient Satisfaction Survey Score-Pain|Patient Satisfaction Survey Score-Ease of Use|Patient Satisfaction Survey Score-Satisfaction|Patient Satisfaction Survey Score-Likelihood to Use Again","University of North Carolina, Chapel Hill","Female","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","23-2619","May 2024","July 2025","July 2025","April 3, 2024",,"April 3, 2024","UNC Health Rex, Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT06344884"
1027,"NCT06259266","Catheter Dysfunction Rate in Patients Undergoing Kidney Replacement Therapy. Evaluation of the Safety and Efficacy of Anti-reflux Valves Without Heparin Lock Solution","DUKE","Withdrawn","No Results Available","Chronic Renal Failure|Haemodialysis, Haemodiafiltration, Haemofiltration|Kidney Replacement Therapy|Catheter Infection, Catheter Dysfunction, Catheter Related Bloodstream Infections","Other: Anti-reflux valve for dialysis catheter","Rate of dialysis session with dysfunctions|evaluation of the infectious complications associated with CDLD (catheters for long-term dialysis)","University Hospital, Clermont-Ferrand|Laboratoire HEMOTECH","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHU-0171|2012-A00530-43","December 2013","January 2016","January 2016","February 14, 2024",,"February 14, 2024","CHU de CERMONT-Ferrand, Clermont-Ferrand, France",,"https://ClinicalTrials.gov/show/NCT06259266"
1028,"NCT05669911","Development of a Self-collection Device for Cervical Cancer Screening",,"Active, not recruiting","No Results Available","Human Papilloma Virus Infection Type 16|Human Papilloma Virus Infection Type 18|Human Papilloma Virus","Device: Teal Health Self-Collection Device Group","Primary Safety: SAEs|Primary Effectiveness: Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA)|Primary Effectiveness: Sample Inadequacy Rate|Usability Survey|Satisfaction and Needs Survey|Rate of sample adequacy for liquid-based cytology analysis","Teal Health, Inc.","Female","25 Years to 65 Years   (Adult, Older Adult)","Not Applicable","235","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","TLH-ED-004","August 28, 2022","November 6, 2023","December 31, 2023","January 3, 2023",,"November 2, 2023","Crescendo MD, Portola Valley, California, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Woman's Hospital, Baton Rouge, Louisiana, United States|Boston Metro, Westwood, Massachusetts, United States|Planned Parenthood Gulf Coast, Houston, Texas, United States|University of Wisconsin - Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT05669911"
1029,"NCT02789501","Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction",,"Completed","No Results Available","Catheter Infections|End-stage Renal Disease","Device: 4% citrate lock solution regimen|Device: TauroLock lock solution regimen","Number of Catheter Related Blood Stream Infections (CRBSI)|Number of Catheter Dysfunctions (inadequate blood flow during dialysis, necessity of catheter rescue with alteplase)","Medical University of Vienna","All","18 Years and older   (Adult, Older Adult)","Phase 4","106","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Vienna CathLock-Study","January 2012","August 2016",,"June 3, 2016",,"December 5, 2016","Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT02789501"
1030,"NCT06002126","Optimization of Cervical Cancer Screening Among Women Living With HIV in Latin American Countries",,"Recruiting","No Results Available","Cervix Cancer|HPV Infection|Cervical High Grade Squamous Intraepithelial Lesion|HIV Infections","Diagnostic Test: Xpert HPV|Diagnostic Test: S5 DNA methylation classifier","Number of participants with cervical HSIL or invasive cancer on histology at baseline|Number of participants with hrHPV at baseline who are found to have cervical HSIL or invasive cancer on histology at months 6 or 12","Weill Medical College of Cornell University|National Cancer Institute (NCI)|H. Lee Moffitt Cancer Center and Research Institute|University of Sao Paulo|Mexican National Institute of Public Health|Rutgers University","Female","25 Years to 65 Years   (Adult, Older Adult)","Not Applicable","1000","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","23-02025683|U54CA242639","August 2, 2023","December 1, 2024","November 1, 2025","August 21, 2023",,"August 21, 2023","University of São Paulo, São Paulo, Brazil|National Institute of Public Health, Mexico, Cuernavaca, Morelos, Mexico",,"https://ClinicalTrials.gov/show/NCT06002126"
1031,"NCT01021904","Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China",,"Unknown status","No Results Available","HPV Infections|Precancerous Disease of the Cervix|Cervical Cancer|HPV Related Diseases","Biological: Gardasil (VLP, HPV Quadrivalent prophylactic vaccine)","The quadrivalent HPV vaccine can prevent HPV naive girls at baseline from being infected at least on a five year follow-up and longer.|Knowledge of HPV and the link between HPV and cervical cancer|Attitudes towards HPV vaccine|Attitudes towards sex and the proper age of sexual debut;","Chinese Academy of Medical Sciences|ChineseAMS","Female","13 Years to 15 Years   (Child)","Phase 4","6200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","37207","June 2010","June 2014","December 2014","November 30, 2009",,"November 30, 2009",,,"https://ClinicalTrials.gov/show/NCT01021904"
1032,"NCT04624568","Papilocare®: Effects on Regression of Histologically Confirmed Cervical Intraepithelial Lesions 1 and Tolerance","PAPILOCARE","Completed","No Results Available","Squamous Intraepithelial Lesions of the Cervix|Human Papilloma Virus Infection|Cervix Lesion","Device: PAPILOCARE","Cervical cytology normalization after 12 months.|Cervical cytology normalization after 6 months.|HPV clearance after 6 months|HPV clearance after 12 months|Evaluation of tolerance of Papilocare vaginal gel","Centre Hospitalier Régional d'Orléans","Female","25 Years and older   (Adult, Older Adult)","Not Applicable","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CHRO-2020-13","November 17, 2020","May 17, 2023","May 17, 2023","November 12, 2020",,"June 15, 2023","Centre Hospitalier Régional d'Orléans, France, Orléans, France",,"https://ClinicalTrials.gov/show/NCT04624568"
1033,"NCT01406288","Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4","SHU O104 CUB","Completed","No Results Available","Hemolytic-uremic Syndrome|Escherichia Coli Infections","Other: HUS standard coverage care (including in ICU)","Improve scientific knowledge on epidemic HUS in the context of an outbreak of E. coli O104:H4 HUS in the town of Bègles, urban area of Bordeaux, France|evaluate efficiency of therapeutic and diagnostic strategies","University Hospital, Bordeaux","All","2 Years and older   (Child, Adult, Older Adult)",,"9","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHUBX2011/26","July 2011","March 2012","March 2012","August 1, 2011",,"November 20, 2012","Service de Néphrologie, transplantation dialyse - Hôpital Pellegrin, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT01406288"
1034,"NCT06120205","SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening",,"Enrolling by invitation","No Results Available","Hpv|HPV 16 Infection|HPV Infection|High Risk HPV","Device: Teal Wand Self-Collection Device Group","Efficacy: Detection of hrHPV in self-collect and clinician collect samples|Safety: SAE rate","Teal Health, Inc.","Female","25 Years to 65 Years   (Adult, Older Adult)","Not Applicable","870","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CLN-TP-020","November 15, 2023","May 1, 2024","June 1, 2024","November 7, 2023",,"March 19, 2024","Birmingham OBGYN / Alabama Clinical Therapeutics, Birmingham, Alabama, United States|Planned Parenthood Arizona, Tucson, Arizona, United States|Planned Parenthood Northern California, San Francisco, California, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Planned Parenthood Southern New England, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Woman's Hospital, Baton Rouge, Louisiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Planned Parenthood League of Massachusetts, Boston, Massachusetts, United States|Planned Parenthood St. Louis Region, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States|New York University Langone Hospital, Mineola, New York, United States|Unified Women's Clinical Research Raleigh, Raleigh, North Carolina, United States|Unified Women's Clinical Research - Lyndhurst, Winston-Salem, North Carolina, United States|Planned Parenthood Gulf Coast, Houston, Texas, United States|University of Wisconsin - Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT06120205"
1035,"NCT01931644","At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions",,"Recruiting","No Results Available","All Diagnosed Health Conditions|ADD/ADHD|Alopecia Areata|Ankylosing Spondylitis|Asthma|Atopic Dermatitis Eczema|Beta Thalassemia|Bipolar Disorder|Breast Cancer|Celiac Disease|Cervical Cancer|Chronic Inflammatory Demyelinating Polyneuropathy|Chronic Kidney Diseases|Chronic Obstructive Pulmonary Disease|Colon Cancer|Colorectal Cancer|Crohn's Disease|Cystic Fibrosis|Depression|Diabetes Mellitus|Duchenne Muscular Dystrophy|Endometriosis|Epilepsy|Facioscapulohumeral Muscular Dystrophy|G6PD Deficiency|General Anxiety Disorder|Hepatitis B|Hereditary Hemorrhagic Telangiectasia|HIV/AIDS|Human Papilloma Virus|Huntington's Disease|Idiopathic Thrombocytopenic Purpura|Insomnia|Kidney Cancer|Leukemia|Lung Cancer|Lupus Nephritis|Lymphoma|Melanoma|Multiple Myeloma|Multiple Sclerosis|Myositis|Myotonic Dystrophy|Ovarian Cancer|Pancreatic Cancer|Parkinson's Disease|Polycystic Kidney Diseases|Prostate Cancer|Psoriasis|Psoriatic Arthritis|Rosacea|Scleroderma|Sickle Cell Anemia|Sickle Cell Trait|Sjogren's Syndrome|Skin Cancer|Spinal Muscular Atrophy|Systemic Lupus Erythematosus|Thrombotic Thrombocytopenic Purpura|Trisomy 21|Ulcerative Colitis",,"Biospecimen & Clinical Data Collection","Sanguine Biosciences","All","18 Years to 100 Years   (Adult, Older Adult)",,"20000","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","SAN-BB-01","July 2013","August 2025","December 2040","August 29, 2013",,"October 8, 2019","Sanguine Biosciences, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01931644"
1036,"NCT05234112","Prevention and Screening Towards Elimination of Cervical Cancer","PRESCRIP-TEC","Completed","No Results Available","HPV Infection|Cervix Cancer|Cervical Dysplasia","Behavioral: Community mobilisation for hrHPV self-testing|Diagnostic Test: hrHPV self-testing|Behavioral: Follow-up after testing|Diagnostic Test: VIA|Procedure: Thermo-ablation or cryotherapy for dysplasia|Diagnostic Test: Pap smear cytology","Uptake of hrHPV self-test in community|Coverage of hrHPV self-test in community|Uptake of VIA or Pap-smear of eligible women|Implementation fidelity of screening protocol|Sustainability of screening protocol","University Medical Center Groningen|Trnavska Universita v Trnavě|Uganda Cancer Institute|International Centre for Diarrhoeal Disease Research, Bangladesh|Manipal Academy for Higher Education|Female Cancer Foundation","Female","30 Years to 60 Years   (Adult)","Not Applicable","30000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","202100943","September 15, 2022","December 30, 2023","January 31, 2024","February 10, 2022",,"February 22, 2024","Mpasana, Kakumiro, Uganda",,"https://ClinicalTrials.gov/show/NCT05234112"
1037,"NCT00194519","Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission",,"Completed","No Results Available","HIV Infection|Herpes Simplex, Genital|Sexually Transmitted Diseases","Drug: Generic acyclovir|Drug: Placebo","Sequence-verified HIV-transmission from index to partner participant|Measure effect of viral load, gender and other factors on HIV transmission|Assess adherence to acyclovir suppressive therapy|Assess effect of twice daily acyclovir on the frequency of genital ulcers|Assess effect of twice daily acyclovir on plasma HIV viral load|Assess effects of twice daily acyclovir on the sexual behaviors|Assess host immunologic and virologic determinants of HIV transmission","University of Washington|Bill and Melinda Gates Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 3","3408","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","STUDY00000867|Gates Foundation Grant #26469","November 2004","November 2009","March 2010","September 19, 2005",,"October 12, 2018","Botswana-Harvard Partnership, Gabarone, Botswana|Moi University - Indiana University, Eldoret, Kenya|Kemri - Ucsf, Kisumu, Kenya|University of Nairobi, Nairobi, Kenya|Partners Study Thika Site, Thika, Kenya|Projet San Francisco-Emory University, Kigali, Rwanda|University of Cape Town, Cape Town, South Africa|Perinatal HIV Research Unit, University of Witswatersrand, Johannesburg, South Africa|Reproductive Health and HIV Research Unit, Johannesburg, South Africa|Kilimanjaro Christian Medical College-Harvard University, Moshi, Tanzania|Mulago Hospital - IDI, Kampala, Uganda|Zambia-Emory HIV Research Project, Lusaka, Zambia|Zambia-Emory HIV Research Project, Ndola/Kitwe, Zambia",,"https://ClinicalTrials.gov/show/NCT00194519"
1038,"NCT02882256","Video Discharge Instructions (VDI) as Adjuncts to Written Discharge Instructions in the Emergency Department",,"Completed","No Results Available","Urinary Tract Infection|Head Injury|Laceration","Other: Video discharge instructions","Understanding of discharge diagnosis using questionnaire|Patient satisfaction of overall care in ED using questionnaire|Self-reported compliance with post-discharge care using questionnaire|Comprehension of return precautions using questionnaire|Retention of understanding of discharge diagnosis using questionnaire","George Washington University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","193","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","061612","June 2016","September 2018","September 2018","August 29, 2016",,"December 7, 2018","George Washington University Hospital, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT02882256"
1039,"NCT02733068","A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.",,"Completed","No Results Available","Human Papilloma Virus Infection Type 16|Human Papilloma Virus Infection Type 18|Cervical Intraepithelial Neoplasia","Biological: HPV-16/18 vaccine|Biological: HPV-16/18 placebo","Cervical intraepithelial neoplasia grade 2 or more (CIN 2+) caused by HPV type 16 and/or 18.|Persistent infection of HPV type 16 and/or 18.","Shanghai Zerun Biotechnology Co.,Ltd|Guangxi Center for Disease Control and Prevention","Female","18 Years to 30 Years   (Adult)","Phase 3","12000","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","311-HPV-1003","November 2, 2014","July 30, 2019","January 16, 2020","April 11, 2016",,"December 19, 2022",,,"https://ClinicalTrials.gov/show/NCT02733068"
1040,"NCT02189291","Study to Assess Duration of Indwelling Catheter After Sacrocolpopexy","CARESS","Completed","No Results Available","Pelvic Organ Prolapse|Urinary Tract Infections|Urinary Retention","Procedure: Immediate catheter removal|Procedure: Post op day 1 catheter removal","Hospital stay|Re-catheterization|Urinary tract infection","Oregon Health and Science University","Female","21 Years to 85 Years   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","00010603","July 2014","July 1, 2018","December 31, 2018","July 14, 2014",,"March 15, 2019","St John Hospital & Medical Center, Detroit, Michigan, United States|Oregon Health & Science University, Portland, Oregon, United States|Legacy Good Samaritan Medical Center, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02189291"
1041,"NCT03243864","Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis",,"Unknown status","No Results Available","Renal Failure|Bacterial Infections|Critical Illness","Drug: Ceftazidime-avibactam","Ceftazidime plasma concentrations|Avibactam plasma concentrations|Ceftazidime effluent concentrations|Avibactam effluent concentrations|Maximum plasma concentration (Cmax)|Number of participants with adverse effects as a measure of safety|Minimum plasma concentration (Cmin)|Half-life (t1/2)|Clearance (Cl)|AUC 0 to 8 hours|Sieving Coefficient","Temple University|Allergan","All","18 Years and older   (Adult, Older Adult)",,"10","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","866","March 13, 2017","March 21, 2020","October 21, 2020","August 9, 2017",,"April 10, 2019","Temple University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03243864"
1042,"NCT04361552","Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)",,"Withdrawn","No Results Available","Cerebrovascular Accident|Chronic Obstructive Pulmonary Disease|Chronic Renal Failure|Coronary Artery Disease|Diabetes Mellitus|Malignant Neoplasm|SARS Coronavirus 2 Infection","Other: Best Practice|Biological: Tocilizumab","7-day length of invasive mechanical ventilation (MV)|30-day mortality rate|Rate of intensive care (ICU) transfer|Rate of invasive mechanical ventilation|Rate of tracheostomy|Length of ICU stay|Length of hospital stay","Emory University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000419|NCI-2020-02314|WINSHIP4998-20|P30CA138292","April 7, 2020","June 2, 2020","June 2, 2020","April 24, 2020",,"June 18, 2020","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04361552"
1043,"NCT01640379","Technology Enhanced Community Health Nursing (TECH-N) Study","TECH-N","Completed","Has Results","Pelvic Inflammatory Disease (PID)","Behavioral: Technology Enhanced Community Health Nursing","Number of Participants With Positive Sexually Transmitted Infection Test (STI)|Number of Participants That Adhered to Self-treatment","Johns Hopkins University|National Institute of Nursing Research (NINR)","Female","13 Years to 25 Years   (Child, Adult)","Not Applicable","286","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","NA_00068846|1R01NR013507-01","July 2012","March 2017","April 2017","July 13, 2012","May 7, 2018","June 1, 2020","Johns Hopkins School of Medicine, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/79/NCT01640379/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01640379"
1044,"NCT01375439","Maternal and Perinatal Outcome in Women With History of Premature Labor in Previous Pregnancy",,"Completed","No Results Available","Pregnancy|Vulvovaginitis|Uterine Cervicitis|Pregnancy Outcome","Other: Active search of lower genital tract infections","Track pregnant women priority for the exams that allow the etiologic diagnosis of lower genital tract infections.","UPECLIN HC FM Botucatu Unesp","Female","Child, Adult, Older Adult","Not Applicable","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ddt1333","August 2011","December 2012","May 2013","June 17, 2011",,"June 23, 2015",,,"https://ClinicalTrials.gov/show/NCT01375439"
1045,"NCT02112630","Boceprevir in End Stage Renal Disease (ESRD)",,"Withdrawn","No Results Available","Hepatitis C Infection|End Stage Renal Disease","Drug: P-IFN alfa 2a|Drug: P-IFN alfa 2b|Drug: Ribavirin|Drug: Boceprevir","Proportion of patients who achieve sustained virologic response","Columbia University|Merck Sharp & Dohme LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAL5200","May 2013","February 2015","February 2015","April 14, 2014",,"September 23, 2015",,,"https://ClinicalTrials.gov/show/NCT02112630"
1046,"NCT04514484","Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV",,"Active, not recruiting","No Results Available","Advanced Differentiated Thyroid Gland Carcinoma|Advanced Head and Neck Carcinoma|Advanced Hepatocellular Carcinoma|Advanced Kaposi Sarcoma|Advanced Lung Non-Small Cell Carcinoma|Advanced Lung Small Cell Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Ovarian Carcinoma|Advanced Prostate Carcinoma|Advanced Renal Cell Carcinoma|Advanced Thyroid Gland Medullary Carcinoma|Advanced Triple-Negative Breast Carcinoma|Advanced Urothelial Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Castration-Resistant Prostate Carcinoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|HIV Infection|Metastatic Differentiated Thyroid Gland Carcinoma|Metastatic Head and Neck Carcinoma|Metastatic Hepatocellular Carcinoma|Metastatic Kaposi Sarcoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Lung Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Ovarian Carcinoma|Metastatic Prostate Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Thyroid Gland Medullary Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Kaposi Sarcoma|Recurrent Lung Non-Small Cell Carcinoma|Recurrent Lung Small Cell Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Medullary Carcinoma|Recurrent Triple-Negative Breast Carcinoma|Recurrent Urothelial Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v8|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8","Procedure: Biospecimen Collection|Drug: Cabozantinib S-malate|Procedure: Computed Tomography|Procedure: Magnetic Resonance Imaging|Biological: Nivolumab","Incidence of dose limiting toxicities (DLTs)|Immune status|Human immunodeficiency virus (HIV) viral loads","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2020-05956|2020-12258|10387","November 22, 2021","November 2, 2025","November 2, 2025","August 17, 2020",,"March 6, 2024","Northwestern University, Chicago, Illinois, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04514484"
1047,"NCT05408624","Pilot Study Evaluating Outpatient Management of Tubo-ovarian Abscesses","AmbATO","Recruiting","No Results Available","Abscess|Pelvic Inflammatory Disease|Pelvic Infection","Procedure: ultrasound transvaginal drainage|Procedure: laparoscopy","Cure rate|eligibility|Discharge|Rehospitalization|Measure of Pain|residual mass|complications|antibiotic therapy|Quality of life with EQ-5D-5L|Quality of life with Medical Outcome Study Short Form 12 (SF12)|Quality of life with Patient Global Impression of Improvement (PGI-I) questionnaires|Evaluation of the direct costs","Nantes University Hospital","Female","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Other|Time Perspective: Prospective","RC21_0011","July 15, 2022","June 30, 2024","December 1, 2024","June 7, 2022",,"March 21, 2024","CHU Nantes, Nantes, France",,"https://ClinicalTrials.gov/show/NCT05408624"
1048,"NCT00264368","Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy",,"Terminated","No Results Available","Acute Renal Failure|Cytomegalovirus Infections|Multi Organ Failure","Drug: intravenous (IV) ganciclovir","comparing the total clearance with the RRT derived clearance of GCV|comparing the volume of distribution with historic controls of non Intensive Care Unit (ICU) patients|comparing GCV plasma concentration and population model derived estimates of these concentrations when including different relevant clinical co-factors such as: weight, S-creatinine, CL-creatinine, hydration, albumin, rest function of native kidneys etc.|determine RRT derived GCV clearance during the different filtration/dialysis settings of the RRT machine","University of Oslo School of Pharmacy","All","18 Years and older   (Adult, Older Adult)","Phase 4","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCV-PRISMA","December 2005",,"June 2007","December 12, 2005",,"June 28, 2007","Rikshospitalet, Section of Nephrology, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT00264368"
1049,"NCT06106204","Reducing Overuse of Antibiotics at Discharge Home","ROAD Home","Enrolling by invitation","No Results Available","Pneumonia|Urinary Tract Infection|Antibiotic Stewardship|Care Transition","Other: ROAD Home Intervention","Days of antibiotic overuse at hospital discharge|Number of cases with antibiotic-associated adverse events","University of Utah|University of Michigan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","R01HS029482","November 1, 2023","August 31, 2027","August 31, 2028","October 30, 2023",,"December 6, 2023","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT06106204"
1050,"NCT04226313","Self-sampling for Non-attenders to Cervical Cancer Screening","KOPRETINA","Recruiting","No Results Available","Cervical Cancer|Cervical Dysplasia|Human Papillomavirus Infection","Diagnostic Test: Self-sampling by Evalyn Brush|Diagnostic Test: Self sampling by Evalyn Brush home or in GP´s clinic","Screening participation|Prevalence of high-risk HPV|Sociodemographic characteristics","The Institute of Molecular and Translational Medicine, Czech Republic|Cancer Research Czech Republic","Female","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","15000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","5850","September 23, 2019","December 1, 2024","December 1, 2024","January 13, 2020",,"January 3, 2024","University Hospital Olomouc, Olomouc, Czechia",,"https://ClinicalTrials.gov/show/NCT04226313"
1051,"NCT04133610","HPVPro Study: Comparison of HPV Detection in Clinician-collected Cervical Swabs and Self-sampled Cervicovaginal Swabs","HPVPro","Completed","No Results Available","Cervical Cancer|Cervical Dysplasia|Human Papillomavirus Infection","Diagnostic Test: Self-sampling using digene HC2 DNA Collection Device|Diagnostic Test: Self-sampling using Evalyn Brush","HPV prevalence|Concordance of HPV positivity in self-collected cervicovaginal swabs and clinician-collected cervical swabs|Comparison of different human papillomavirus DNA detection methods in cervical and cervicovaginal swabs.","The Institute of Molecular and Translational Medicine, Czech Republic|Cancer Research Czech Republic","Female","30 Years to 64 Years   (Adult)","Not Applicable","1044","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","343","September 1, 2018","October 30, 2019","November 25, 2019","October 21, 2019",,"November 26, 2019","GYN-PREN, Ltd., Frýdek-Místek, Czechia|GYNPRENATAL, Ltd., Havířov, Czechia|MEDIOL, Ltd., Olomouc, Czechia",,"https://ClinicalTrials.gov/show/NCT04133610"
1052,"NCT00892866","CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells",,"Active, not recruiting","No Results Available","Atypical Endometrial Hyperplasia|Human Papillomavirus Infection|Stage 0 Cervical Cancer AJCC v7","Other: Cytology Specimen Collection Procedure|Other: Laboratory Biomarker Analysis","Biomarker expression in patients from North America|Biomarker expression in patients from Japan|Biomarker expression in patients from Korea|Effect of patient age on the accuracy of diagnosis based on CA-IX, HPV, p16, Ki-67, and/or MCM2 expression in the North American population|Effect of patient age on the accuracy of diagnosis based on CA-IX, HPV, p16, Ki-67, and/or MCM2 expression in the Korean and Japanese populations","GOG Foundation|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","877","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","GOG-0237|NCI-2009-01103|CDR0000632236|N01CM62201|U10CA101165|UG1CA189867","February 9, 2009","May 31, 2025","May 31, 2025","May 5, 2009",,"February 22, 2024","Banner University Medical Center - Tucson, Tucson, Arizona, United States|University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Olive View-University of California Los Angeles Medical Center, Sylmar, California, United States|Hartford Hospital, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Elkhart Clinic, Elkhart, Indiana, United States|Michiana Hematology Oncology PC-Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Community Howard Regional Health, Kokomo, Indiana, United States|IU Health La Porte Hospital, La Porte, Indiana, United States|Michiana Hematology Oncology PC-Mishawaka, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center-Mishawaka, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Plymouth, Plymouth, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC-South Bend, South Bend, Indiana, United States|South Bend Clinic, South Bend, Indiana, United States|Michiana Hematology Oncology PC-Westville, Westville, Indiana, United States|Providence Medical Center, Kansas City, Kansas, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Advent Health - Shawnee Mission Medical Center, Shawnee Mission, Kansas, United States|Woman's Hospital, Baton Rouge, Louisiana, United States|Maine Medical Center-Bramhall Campus, Portland, Maine, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Lakeland Hospital Niles, Niles, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Truman Medical Centers, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Saint Joseph Health Center, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Joseph Oncology Inc, Saint Joseph, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Women's Cancer Center of Nevada, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Norris Cotton Cancer Center-Nashua, Nashua, New Hampshire, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Dublin Methodist Hospital, Dublin, Ohio, United States|Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Community Medical Center, Scranton, Pennsylvania, United States|Geisinger Medical Oncology-Selinsgrove, Selinsgrove, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Women and Infants Hospital, Providence, Rhode Island, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|University of Texas Medical Branch, Galveston, Texas, United States|Memorial Hermann Texas Medical Center, Houston, Texas, United States|UTMB Cancer Center at Victory Lakes, League City, Texas, United States|Big Horn Basin Cancer Center, Cody, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States|Tohoku University School of Medicine, Sendai, Aoba-ku, Japan|Kure National Hospital, Kure, Hiroshima, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Hyogo Cancer Center, Akashi-city, Hyogo, Japan|Iwate Medical University Hospital, Shiwa-gun, Iwate, Japan|Kagoshima City Hospital, Kagoshima City, Kagoshima, Japan|Niigata University Medical and Dental Hospital, Niigata City, Niigata, Japan|University of the Ryukyus Hospital-Col Health Scnc, Nakagami-gun, Okinawa, Japan|Keio University, Shinjuku-ku, Tokyo, Japan|Hiroshima University Hospital, Hiroshima City, Japan|Shikoku Cancer Center, Matsuyama, Japan|National Kyushu Cancer Center, Minami-ku, Japan|Jikei University School of Medicine, Minato-ku, Tokyo, Japan|Kindai University, Osaka, Japan|Saitama Medical University International Medical Center, Saitama, Japan|National Cancer Center Hospital, Tokyo, Japan|Tottori University, Tottori, Japan|Keimyung University-Dongsan Medical Center, Dalseo-gu, Daegu, Korea, Republic of|National Cancer Center-Korea, Goyang-si, Gyeonggi-do, Korea, Republic of|Inha University, Jung-gu, Incheon, Korea, Republic of|Catholic University of Korea-Seoul Saint Mary's Hospital, Seoul, Korea, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam City, Kyeonggi-do, Korea, Republic of|Gachon University Gil Hospital, Incheon, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Yonsei University Health System-Severance Hospital, Seoul, Korea, Republic of|Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00892866"
1053,"NCT03535558","Fluoroquinolone Associated Disability",,"Completed","No Results Available","Bronchitis|Sinusitis|Urinary Tract Infections","Drug: Fluoroquinolone (FQ)|Drug: Azithromycin (AZ)|Drug: Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination","Number of Participants with Disability in Temporal Proximity","Janssen Research & Development, LLC","All","18 Years to 65 Years   (Adult, Older Adult)",,"239306","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CR108484|RRA-20379","May 17, 2018","December 31, 2018","December 31, 2018","May 24, 2018",,"January 29, 2019","Janssen Investigative Site, Titusville, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03535558"
1054,"NCT05260554","Effect of Cranberry Extract on the Urinary System",,"Completed","No Results Available","Urinary Tract Disease|Cystitis|Antibiotic Reaction","Drug: Fosfomycin|Dietary Supplement: Cranberry","Treatment time","Kırklareli University","All","18 Years and older   (Adult, Older Adult)",,"2","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Kırklareli University","January 26, 2022","February 18, 2022","February 18, 2022","March 2, 2022",,"March 2, 2022","Oya Guven, MD, Kirklareli, Center, Turkey",,"https://ClinicalTrials.gov/show/NCT05260554"
1055,"NCT05414305","The Female Microbiome in Patients Undergoing Bladder Instillation Therapy",,"Active, not recruiting","No Results Available","Interstitial Cystitis|Bladder Pain Syndrome|Microbial Colonization","Drug: Heparin & Alkalinized Lidocaine Bladder Instillation","Change of the female microbiome as measured by bacterial ribosomal RNA sequencing in patients with BPS/IC at baseline and during bladder instillation therapy|Correlation of female microbiome as measured by bacterial ribosomal RNA sequencing and O'Leary-Sant questionnaire scores|Correlation of female microbiome as measured by bacterial ribosomal RNA sequencing and Female Sexual Function Index (pain) questionnaire scores|Correlation of female microbiome as measured by bacterial ribosomal RNA sequencing and Female Sexual Distress-Revised Inventory questionnaire scores|Correlation of female microbiome as measured by bacterial ribosomal RNA sequencing and Short Form 12 questionnaire scores|Correlation of female microbiome as measured by bacterial ribosomal RNA sequencing and Visual Analog Scale questionnaire scores|Characterization of bacterial species present as measured by bacterial ribosomal RNA sequencing in the vaginal and urinary microbiome|Characterization of bacterial species diversity as measured by bacterial ribosomal RNA sequencing in the vaginal and urinary microbiome","Walter Reed National Military Medical Center|US Army Medical Research Institute of Infectious Diseases","Female","18 Years and older   (Adult, Older Adult)","Phase 2","29","U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","WRNMMC-EDO-2021-0728","October 1, 2020","December 2023","December 2023","June 10, 2022",,"October 13, 2023","Walter Reed National Military Medical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT05414305"
1056,"NCT05044156","Investigation of the Relationship Between Salivary Histatine-5 Level and Vaginal Candidiasis in Women",,"Completed","No Results Available","Vaginal Infection|Candidiasis","Other: salivary sample","SALIVARY HISTATINE-5 LEVEL IN THE WOMEN WITH VAGINAL CANDIDIASIS","Usak State Hospital","Female","18 Years to 50 Years   (Adult)",,"90","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Usak State Hospital","October 21, 2021","March 6, 2022","March 6, 2022","September 14, 2021",,"March 8, 2022","İrem Şenyuva, Usak, Turkey",,"https://ClinicalTrials.gov/show/NCT05044156"
1057,"NCT03168178","Intrapartum Fever: Antibiotics Versus no Treatment",,"Withdrawn","No Results Available","Chorioamnionitis|Intrapartum Fever|Intra-amniotic Infection","Drug: Standard Antibiotic Treatment|Other: No Antibiotic Treatment","Neonatal antibiotic treatment as recommended by the EONS (Early Onset Neonatal Sepsis) calculator.|Positive blood culture|Need for NICU admission|Newborn length of stay|Maternal endometritis|Maternal length of stay|Patient satisfaction|Cost","University of Utah","Female","18 Years to 50 Years   (Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91955","June 8, 2017","July 26, 2018","July 26, 2018","May 30, 2017",,"October 23, 2018","University of Utah, Department of Obstetrics & Gynecology, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03168178"
1058,"NCT01101087","Taurolock for Preventing Bacterial Peritonitis During Renal Insufficiency",,"Completed","No Results Available","Peritonitis|Catheter-related Infections|Renal Insufficiency","Device: Taurolock|Other: Placebo","Occurence of bacterial peritonitis","Centre Hospitalier Universitaire de Nīmes","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PHRC-N/2009/BB|2009-A00599-48","July 2010","December 2015","December 2015","April 9, 2010",,"December 18, 2015","CHU de Nîmes - Hôpital Universitaire Carémeau, Nimes, Gard, France|CH d'Avignon - Centre Hospitalier Henri Duffaut, Avignon, France|CHU de Caen - Hôpital Clemenceau, Caen, France|CH de Chambéry, Chambery, France|CH de Colmar - Hôpitaux Civils de Colmar, Colmar, France|Association CALYDIAL Vienne, Irigny, France|Centre Hospitalier Départemental Vendée - Site de la Roche sur Yon, La Roche sur Yon, France|AIDER - Clinque Jacques Mirouze, Montpellier, France|APHP - Groupe Hospitalier Pitié-Salpetrière, Paris, France|CH Pontoise - Centre Hospitalier René Dubos, Pontoise, France|Association AUB Santé Quimper, Quimper, France|Centre Hospitalier Regional - Site Groupe Hospitalier Sud Réunion (GHSR), Saint Pierre, France|CH de Valenciennes - Hôpital Jean Bernard et Hôtel Dieu, Valenciennes, France|ALTIR - Hôpital Brabois, Vandoeuvre les Nancy Cedex, France|Association APURAD, Paéa, French Polynesia",,"https://ClinicalTrials.gov/show/NCT01101087"
1059,"NCT00907946","Comparing Previously Placed Nephrostomy Tract (NT) Versus Single Stage Percutaneous Nephrolithotomy (PCNL)",,"Terminated","No Results Available","Urolithiasis","Procedure: NT 1 day before PCNL","Reduction of complications related to bleeding and infection","Washington University School of Medicine","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Alana Desai PCNL Study-09-0709","December 2009","October 2010","October 2010","May 25, 2009",,"January 11, 2019","Washington University, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00907946"
1060,"NCT01052545","Asymptomatic Bacteriuria Guideline Implementation Study","ABU","Completed","Has Results","Infection Due to Indwelling Urinary Catheter|Asymptomatic Bacteriuria","Behavioral: Audit-Feedback","Number of Cases of ABU That Are Treated Inappropriately With Antibiotics|Urine Cultures Ordered|Number of Cases of CAUTI Inappropriately Under-treated (no Antibiotics Given)|Number of Days Antibiotics Are Given to Treat ABU|Clinicians' Awareness of and Familiarity With the ABU Guidelines.|Clinicians Acceptance of and Outcome Expectancy From Following the ABU Guidelines|Number of Catheter-days of Use Per 1000 Patient Bed Days on Each Unit|Patient Level Analysis of Inappropriate Antibiotic Use","VA Office of Research and Development","All","Child, Adult, Older Adult","Not Applicable","1598","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","IIR 09-104|H-24180","July 2011","June 2013","June 2013","January 20, 2010","November 6, 2014","February 25, 2019","Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01052545"
1061,"NCT03131609","Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department",,"Completed","No Results Available","Urinary Tract Infections|Bacteriuria|Urinalysis","Other: Container|Other: Silver Impregnated Wipe|Other: Funnel|Other: Castile-soap wipe","Decrease in the number of contaminated urine cultures","Stanford University|EBLEN Charities|Forte Medical Ltd.|Avadim Technologies, Inc.","All","18 Years and older   (Adult, Older Adult)",,"1471","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","33879","September 2015","September 2016","September 2016","April 27, 2017",,"April 20, 2020","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03131609"
1062,"NCT05282095","Effect of HPV Integration on Prognosis of Young Women With CIN2 in China",,"Recruiting","No Results Available","Cervical Intraepithelial Neoplasia|HPV Infection|Virus Integration|HSIL, High Grade Squamous Intraepithelial Lesions","Other: Follow up","Cervical histopathology testing at baseline|Cervical histopathology testing at 6-month follow-up|Cervical histopathology testing at 12-month follow-up|Human Papillomavirus (HPV) viral integration test at baseline|Human Papillomavirus (HPV) viral integration test at 6-month follow-up|Human Papillomavirus (HPV) viral integration test at 12-month follow-up|Cervical cytology testing at baseline|Cervical cytology testing at 3-month follow-up|Cervical cytology testing at 6-month follow-up|Cervical cytology testing at 9-month follow-up|Cervical cytology testing at 12-month follow-up|16SrRNA sequencing of the vaginal secretions at baseline|16SrRNA sequencing of the vaginal secretions at 3-month follow-up|16SrRNA sequencing of the vaginal secretions at 6-month follow-up|16SrRNA sequencing of the vaginal secretions at 9-month follow-up|16SrRNA sequencing of the vaginal secretions at 12-month follow-up|Human Papillomavirus (HPV) genotyping tests at baseline|Human Papillomavirus (HPV) genotyping tests at 3-month follow-up|Human Papillomavirus (HPV) genotyping tests at 9-month follow-up","Fujian Maternity and Child Health Hospital","Female","up to 45 Years   (Child, Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HPVZHCIN22021","June 1, 2022","May 31, 2025","May 31, 2025","March 16, 2022",,"July 3, 2023","Fujian Maternity and Child Health Hospital, Fuzhou, Fujian, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, China|The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China|Longyan First Hospital, Longyan, Fujian, China|Longyan People Hospital of Fujian, Longyan, Fujian, China|The Second Hospital of Longyan, Longyan, Fujian, China|Nanping Second Hospital, Nanping, Fujian, China|Mindong Hospital of Ningde City, Ningde, Fujian, China|Ningde Municipal Hospital of Ningde Normal University, Ningde, Fujian, China|The First Hospital of Putian City, Putian, Fujian, China|The Affiliated Hospital of Putian University, Putian, Fujian, China|Quanzhou First Hospital Afflicated to Fujian Medical University, Quanzhou, Fujian, China|Sanming Second Hospital, Sanming, Fujian, China|Zhongshan Hospital Xiamen University, Xiamen, Fujian, China|Zhangzhou affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian, China|Gansu Provincial Maternal and Child Health Care Hospital, Lanzhou, Gansu, China|Shenzhen Maternity and Child HealthCare Hospital, Shenzhen, Guangdong, China|Guiyang maternal and child health care hospital, Guiyang, Guizhou, China|Hubei Maternal and Child Health Care Hospital, Wuhan, Hubei, China|Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Jiangxi maternal and Child Health Hospital, Nanchang, Jiangxi, China|Shanghai First Maternity and Infant Hospital, Shanghai, Shanghai, China|Northwest Women's and Children's Hospital, Xi'an, Shanxi, China|The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT05282095"
1063,"NCT03108079","Bladder Morphology Using 2 Different Catheter Designs",,"Unknown status","No Results Available","Urologic Injuries|Urologic Diseases|Bladder Infection|Urinary Tract Infections|Mucosal Inflammation|Mucosal Infection|Bladder Injury|Catheter-Related Infections|Catheter Complications|Catheter; Infection (Indwelling Catheter)|Pelvic Floor Disorders|Urinary Incontinence","Device: Cystosure Urinary Access System|Device: Foley Catheter","Bladder shape after emptying","The Pelvic Floor Institute|Cystosure|Innovative Research Inc.","Female","21 Years to 70 Years   (Adult, Older Adult)","Not Applicable","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","03082017","April 2017","May 2017","June 2017","April 11, 2017",,"April 12, 2017","The Pelvic Floor Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03108079"
1064,"NCT04903847","Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil","AVERTAS-2","Unknown status","No Results Available","Hiv|HIV Infections|HIV Lipodystrophy|Osteoporosis|Renal Insufficiency|Weight Gain|Obesity","Drug: Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]|Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]","Body weight|Virological control|Self-rated health|Insulin resistance|Diabetic profile|Cholesterol profile|Fat distribution|Hepatic elasticity|Hepatic fat infiltration|Body composition/perfiferal and central fat distribution|Estimated Glomerular Filtration Rate (eGFR) (creatinine)|eGFR (cystatin)|Urea|Urine RBP/creatinine ratio|Urine Beta-2-Microglobulin(B2M)/creatinine ratio|Urine albumin/creatinine ratio|Urine protein/creatinine ratio|Urine phosphate|Bone mass density (BMD)|Bone-specific alkaline phosphate|Procollagen type 1 N-pro-peptide|Type 1 collagen cross-linked C-telopeptide|Osteocalcin|Fasting ionized calcium|25(OH)vitamin D vitamin D 25(OH)vitamin D|Parathyroid hormone (PTH) vitamin D 25(OH)vitamin D|Inflammation","Thomas Benfield|Hvidovre University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-20012194","February 2, 2021","February 2, 2023","February 2, 2023","May 27, 2021",,"May 27, 2021","Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark|Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark|Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark|Department of Infectious Diseases, Hvidovre University Hospital, Hvidovre, Denmark|Department of Infectious Diseases, Odense University Hospital, Odense, Denmark",,"https://ClinicalTrials.gov/show/NCT04903847"
1065,"NCT02527941","Effect of Bacterial Vaginosis on HIV Susceptibility and Female Genital Immunology",,"Completed","No Results Available","Bacterial Vaginosis|HIV Infections","Drug: Metronidazole","Percent HIV pseudovirus entry into cervical CD4+ T cells.|Total number of cervical CD4+ T cells infected ex vivo with HIV.|A genital inflammation score based on genital levels of pro-inflammatory cytokines and chemokines.|The cervico-vaginal microbiome.|Genital proteome analysis.|CD4+ expression of pre-defined HIV susceptibility markers","University of Toronto","Female","18 Years to 49 Years   (Adult)","Phase 1","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","UTorontoBV","August 2015","November 2015","November 2015","August 19, 2015",,"February 10, 2016","Kenya AIDS Vaccine Initiative Clinic, Nairobi, Kenya",,"https://ClinicalTrials.gov/show/NCT02527941"
1066,"NCT00740584","Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.",,"Completed","Has Results","HIV Infections|HSV-2 Genital Herpes","Drug: 3% SPL7013 Gel (VivaGel)","HIV Antiviral Activity of Each of the Cervico-vaginal Samples (Samples Taken From the Vagina Using the Softcup)|Number of Participants With Adverse Experiences","Starpharma Pty Ltd|National Institute of Allergy and Infectious Diseases (NIAID)","Female","18 Years to 45 Years   (Adult)","Phase 1|Phase 2","12","Industry|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SPL7013-003|NIH contract HHSN266200500042C|DAIDS ES number 10730","August 2008","March 2009","March 2009","August 25, 2008","August 14, 2012","October 30, 2018","Nucleus Network, Melbourne, Australia",,"https://ClinicalTrials.gov/show/NCT00740584"
1067,"NCT00527618","Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV",,"Completed","Has Results","Genital Herpes|HIV Infection","Drug: valacyclovir|Drug: acyclovir","The Quantity of HIV-1 RNA in Plasma While on 400 mg Twice Daily of Acyclovir Versus 1000 mg Twice Daily of Valacyclovir.|The Genital HSV Shedding Rate While on 400 mg Twice Daily of Acyclovir Versus 1000 mg Twice Daily of Valacyclovir.|The Effect of Valacyclovir 1 Gram Twice Daily Compared to Acyclovir 400 mg Twice Daily on the Percentage of Days With Genital Herpes Lesions.|The Effect of Valacyclovir 1 g Twice Daily Compared With Acyclovir 400 mg Twice Daily on the Quantity of Genital HSV Detected During Shedding Episodes.|Sub-Study: To Evaluate the Kinetics of Plasma HIV-1 Decline Over the First Three Days of High-dose Valacyclovir Administration.","University of Washington|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 4","28","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","31203|GSK VAL111009 - VAL140","December 2007","March 2011","March 2011","September 11, 2007","July 31, 2012","June 7, 2018","University of Washington Virology Research Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00527618"
1068,"NCT06261736","The Effectiveness of Prophylactic Antibiotics for Urethral Bulking",,"Recruiting","No Results Available","Stress Urinary Incontinence|Postoperative Urinary Tract Infection|Urethral Bulking","Other: Prophylactic antibiotics|Other: No antibiotics","Rate of urinary tract infection (UTI)|Rate of postoperative urinary retention|Rates of other postoperative complications","Atlantic Health System","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2107044-1","October 24, 2023","May 2025","May 2025","February 15, 2024",,"February 15, 2024","Atlantic Health, Morristown, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT06261736"
1069,"NCT00405821","Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda",,"Completed","Has Results","HIV Infections|Herpes Genitalis","Drug: Acyclovir|Drug: Placebo","Progression to AIDS (CD4+ Less Than 250 Cells/Microliter or World Health Org Stage IV dx, Excluding Esophageal Candidiasis)|Difference in Number of Episodes of Genital Ulcer Disease Between Arms|HIV-1 Viral Load Difference Between Arms|Toxicity of Acyclovir|Adherence to Acyclovir|Virologic and Immunologic Responses to ART in Those Who Progress to CD+4 Less Than 250cells/mL","National Institute of Allergy and Infectious Diseases (NIAID)|University of Washington|Johns Hopkins University|Translational Genomics Research Institute|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","440","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","999907032|07-I-N032","November 2006","October 2010","November 2010","November 30, 2006","September 28, 2012","September 28, 2012","Rakai Health Sciences Program, Uganda Virus Research Institute, Kalisizo, Rakai District, Uganda",,"https://ClinicalTrials.gov/show/NCT00405821"
1070,"NCT04189744","The ASPIRE Trial - Aiming for Safe Pregnancies by Reducing Malaria and Infections of the Reproductive Tract",,"Completed","No Results Available","Pregnancy Malaria|Bacterial Vaginoses|Trichomonas Vaginitis","Drug: IPTp-sulphadoxine-pyrimethamine plus metronidazole|Drug: IPTp-dihydroartemisinin-piperaquine plus metronidazole|Drug: IPTp-sulphadoxine-pyrimethamine","Adverse pregnancy outcome|Individual components of the primary outcome- adverse pregnancy outcomes|Foetal loss|Neonatal mortality|Low birthweight|Preterm birth|Birth weight (continuous)|Gestational age at delivery (continuous)|Z-score for birthweight (continuous)|Small for gestational age (binary)|Clinical malaria during pregnancy (binary)|Maternal malaria infection (binary)|Any malaria at delivery (binary)|Placental malaria infection (binary)|Congenital malaria infection (binary)|Placental malaria by histology (binary)|Placental Inflammation or chorioamnionitis (binary)|Maternal anaemia (binary) and haemoglobin concentration (continuous (g/dL) at enrolment and delivery|Congenital anaemia in umbilical cord blood at delivery|Congenital malformations (binary)|Maternal mortality (binary)|SAEs and AEs defined by MedDRA (listings)|History of vomiting study drug - Prevalence at each cycle of treatment (binary)|Dizziness - Prevalence at each cycle of treatment|Gastrointestinal complaints - Prevalence at each cycle of treatment (binary)|Presence of any one or more STIs/RTIs - Prevalence at enrolment (binary)","London School of Hygiene and Tropical Medicine","Female","Child, Adult, Older Adult","Phase 3","5436","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ITDCZO83","December 15, 2019","October 21, 2022","March 31, 2023","December 6, 2019",,"May 22, 2023","Nchelenge District Health Facilites, Nchelenge, Luapula Province, Zambia",,"https://ClinicalTrials.gov/show/NCT04189744"
1071,"NCT03080961","The VIBLOK SAfety and perFormancE Trial","SAFE","Completed","Has Results","HSV-2 Infection|Genital Herpes","Device: VIBLOK barrier cream","Serious Adverse Device Effects|HSV-2 Detection Rate in AT Population|HSV-2 Copy Number in AT Population|ADE Description","CLJI Worldwide|Applied Clinical Services BV|UMC Utrecht|University of Rotterdam, The Netherlands|University of Washington|EB FlevoResearch BV|PreCare Trial & Recruitment B.V.","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","82","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2015-01","March 27, 2017","November 13, 2017","November 13, 2017","March 15, 2017","February 13, 2020","February 13, 2020","EB FlevoResearch, Almere, Flevoland, Netherlands|PT&R, Beek, Limburg, Netherlands|EB UtrechtResearch, Utrecht, Netherlands","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/61/NCT03080961/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/61/NCT03080961/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03080961"
1072,"NCT00002397","A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease",,"Completed","No Results Available","HIV Infections|AIDS-Associated Nephropathy","Drug: Nelfinavir mesylate|Drug: Saquinavir|Drug: Lamivudine|Drug: Stavudine",,"Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service","All","18 Years and older   (Adult, Older Adult)","Phase 3","24","Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","229P|NR15690/M61021",,,,"August 31, 2001",,"June 24, 2005","Mount Sinai Med Ctr, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00002397"
1073,"NCT00000819","A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)",,"Completed","No Results Available","HIV Infections|AIDS-Associated Nephropathy","Drug: Prednisone",,"National Institute of Allergy and Infectious Diseases (NIAID)|Upjohn","All","18 Years and older   (Adult, Older Adult)","Phase 2","54","NIH|Industry","Interventional","Primary Purpose: Treatment","ACTG 271|11247",,,"September 1996","August 31, 2001",,"October 29, 2021","UCLA CARE Center CRS, Los Angeles, California, United States|Ucsf Aids Crs, San Francisco, California, United States|Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States|Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States|Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States|Beth Israel Med. Ctr. (Mt. Sinai), New York, New York, United States|Case CRS, Cleveland, Ohio, United States|MetroHealth CRS, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00000819"
1074,"NCT06273098","School-Based Bladder Health Intervention",,"Not yet recruiting","No Results Available","Urinary Dysfunction|Lower Urinary Tract Symptoms|Urinary Tract Infections|Urinary Tract Infections in Children","Behavioral: Bladder Health Education","Bathroom use|Symptom score|Urine volume","Stanford University","All","5 Years to 10 Years   (Child)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","73162","January 1, 2025","December 31, 2029","December 31, 2029","February 22, 2024",,"February 22, 2024","Stanford Hospital and Clinics, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT06273098"
1075,"NCT01727609","Speed of Increasing Milk Feeds Trial","SIFT","Completed","No Results Available","Premature Birth|Late-onset Invasive Infection|Necrotizing Enterocolitis","Dietary Supplement: Milk feed (breast milk or formula milk)","Survival without moderate or severe disability|Survival to discharge home|Incidence of microbiologically-confirmed or clinically suspected late-onset invasive infection|Incidence of necrotizing enterocolitis (Bell stage 2 or 3)|Time taken to reach full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)|Growth (weight and head circumference) at hospital discharge|Duration of parenteral feeding before hospital discharge|Length of time in intensive care|Length of hospital stay","University of Oxford|National Institute for Health Research, United Kingdom","All","up to 32 Weeks   (Child)","Not Applicable","2804","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SIFT01","June 2013","May 10, 2018","May 10, 2018","November 16, 2012",,"March 11, 2019","National Maternity Hospital, Dublin, Dublin, Ireland|William Harvey Hospital, Ashford, United Kingdom|Royal Maternity Hospital, Belfast, Belfast, United Kingdom|Birmingham Women's Hospital, Birmingham, United Kingdom|Birmingham City Hospital, Birmingham, United Kingdom|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Bradford Royal Infirmary, Bradford, United Kingdom|Southmead Hospital, Bristol, United Kingdom|St Michael's Hospital, Bristol, United Kingdom|St Peters Hospital, Chertsey, United Kingdom|Countess of Chester Hospital, Chester, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Leighton Hospital, Crewe, United Kingdom|Derbyshire Children's Hospital, Derby, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Royal Devon and Exeter Hospital, Exeter, United Kingdom|Princess Royal Maternity Hospital, Glasgow, Glasgow, United Kingdom|Southern General Hospital, Glasgow, United Kingdom|Gloucestershire Royal Hosptial, Gloucester, United Kingdom|Calderdale Royal Hospital, Halifax, United Kingdom|Hull Royal Infirmary, Hull, United Kingdom|Kettering General Hospital, Kettering, United Kingdom|Leeds General Infirmary, Leeds, United Kingdom|St James's University Hospital, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Lincoln County Hospital, Lincoln, United Kingdom|Altnagelvin Area Hospital, Londonderry, United Kingdom|St George's Hospital, London, United Kingdom|James Cook University Hospital, Middlesbrough, United Kingdom|Royal Victoria Infirmary, Newcastle, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Queen's Medical Centre, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Craigavon Area Hospital, Portadown, United Kingdom|Queen Alexandra Hospital, Portsmouth, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|Queen's Hospital, Romford, Romford, United Kingdom|Jessop Wing, Sheffield, Sheffield, United Kingdom|Royal Shrewsbury Hospital, Shrewsbury, United Kingdom|Princess Anne Hospital, Southampton, Southampton, United Kingdom|University Hospital of North Tees, Stockton on Tees, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom|Sunderland Royal Hospital, Sunderland, United Kingdom|King's Mill Hospital, Sutton-in-Ashfield, United Kingdom|Singleton Hospital, Swansea, United Kingdom|Great Western Hospital, Swindon, Swindon, United Kingdom|Croydon University Hospital, Thornton Heath, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Arrowe Park Hospital, Wirral, Upton, United Kingdom|Pinderfields General Hospital, Wakefield, United Kingdom|Warrington Hospital, Warrington, United Kingdom|Wishaw General Hospital, Wishaw, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom|Worcestershire Royal Hospital, Worcester, United Kingdom|York Hospital, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01727609"
1076,"NCT02869165","Vaginal and Urinary Microbiome Trial",,"Completed","No Results Available","Atrophic Vaginitis|Menopause|Recurrent Urinary Tract Infections","Drug: Conjugated equine estrogen topical cream|Drug: Apricot kernel oil","Vaginal and urinary predominance of anaerobic/fastidious taxonomy of micro-organisms on genomic, microbial DNA analysis of vaginal and urinary specimens.|Change in vaginal symptom questionnaire (VSQ)","University of Louisville","Female","18 Years and older   (Adult, Older Adult)","Phase 4","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16.0428","January 2017","June 30, 2018","December 31, 2019","August 16, 2016",,"May 18, 2021","Health Care Outpatient Center and Springs Medical Center, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT02869165"
1077,"NCT05590195","Effect of PreforPro® on Urinary and Vaginal Health",,"Not yet recruiting","No Results Available","Bacterial Vaginosis|Bacterial Infections|Bacterial Vaginosis &#X7C; Vaginal &#X7C; Microbiology|Vaginal Infection","Drug: Preforpro|Other: Placebo","To change Nugent score in women with intermediate grade or BV|Determine whether the bacteriophage can translocate from the gastrointestinal system to genitourinary system.|Determine if the microbiota in the gut and urinary system change|Determine change in vaginal cell exfoliation.|Determine whether probiotics can translocate from the gastrointestinal system to genitourinary system.|Determine change in urogenital ATP levels.","Jeremy Burton|Deerland Enzymes|Lawson Health Research Institute|St. Joseph's Health Care London","Female","18 Years to 45 Years   (Adult)","Phase 3","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BVPFB2021","May 1, 2024","March 1, 2025","June 1, 2025","October 21, 2022",,"January 9, 2024",,,"https://ClinicalTrials.gov/show/NCT05590195"
1078,"NCT05259683","Febrile Infant Diagnostic Assessment and Outcome Study","FIDO","Completed","No Results Available","Urinary Tract Infections|Meningitis|Sepsis|Bacterial Infections",,"Urinary Tract Infection|Bacterial Meningitis|Bacteriaemia","Queen's University, Belfast","All","up to 90 Days   (Child)",,"2076","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","278080","August 1, 2022","August 31, 2023","December 31, 2023","February 28, 2022",,"February 16, 2024","Queen's University Belfast, Belfast, Antrim, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05259683"
1079,"NCT04818216","Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection","NIRVANA","Completed","Has Results","SARS-CoV-2 Infection|Acute Kidney Injury","Drug: Placebo|Drug: Nicotinamide riboside","Change in Whole Blood NAD+ Level|Number of Participants With Adverse Events of Grade 3 or Higher|Occurrence of Thrombocytopenia|Change in Area Under the Curve (AUC)|Effect of NR on Major Adverse Kidney Events (MAKE)|Change in Estimated Glomerular Filtration Rate (eGFR)|Change in Proteinuria","The University of Texas Health Science Center at San Antonio|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HSC20200914H|3UH3DK114920-04S2","June 11, 2021","December 9, 2021","January 3, 2022","March 26, 2021","December 26, 2023","December 26, 2023","Icahn School of Medicine at Mount Sinai, New York, New York, United States|The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University Health Systems, San Antonio, Texas, United States|Harborview Medical Center, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/16/NCT04818216/Prot_SAP_002.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/16/NCT04818216/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04818216"
1080,"NCT03941509","Nurse-led Antimicrobial Stewardship Intervention to Increase Antibiotic Appropriateness in Residential Aged Care Facilities",,"Unknown status","No Results Available","Antimicrobial Stewardship|Urinary Tract Infections|Respiratory Tract Infections|Skin and Soft Tissue Infections","Behavioral: Antimicrobial stewardship","Cumulative proportion of residents prescribed a systemic antimicrobial|Rate of total days of systemic antimicrobial therapy per 1,000 occupied bed days (OBD)|Number of courses of systemic antimicrobial therapy per 1,000 OBD.|Proportion of appropriate antimicrobial use.|Frequency of carriage of antimicrobial-resistant organisms|Rate of Clostridium Difficile infection|Change in facility-level antimicrobial susceptibility profile|Incidence of resident transfer to hospital for infectious indications|All-cause mortality|Perceptions from stakeholders on quality and uptake of the intervention","Bayside Health|Bupa Aged Care Australia|Monash University","All","Child, Adult, Older Adult","Not Applicable","700","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","591/18","January 1, 2021","April 2022","June 2022","May 8, 2019",,"January 13, 2022","Bupa residential aged care facilities, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03941509"
1081,"NCT05354921","Indwelling vs Intermittent Catheterization Pilot Study","PEE","Unknown status","No Results Available","Urogenital|Urinary Tract Infections|Hip Fractures|Catheter Complications","Device: Indwelling Catheter|Device: Intermittent Catheterization","Study Feasibility - Enrollment|Study Feasibility - Screening|Study Feasibility - Retention|Study Feasibility - Follow-up|Safety-Related Outcomes - Rates of UTI|Safety-Related Outcomes - Rates of POUR|patient experience questionnaire","Ottawa Hospital Research Institute|The Ottawa Hospital","All","50 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","20220067-01H","June 2022","May 2023","July 2023","May 2, 2022",,"May 2, 2022","The Ottawa Hospital, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT05354921"
1082,"NCT06206564","Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants","ART-AIN IIB-2","Recruiting","No Results Available","Anal High-grade Squamous Intraepithelial Lesion|Anal HSIL|Anal HPV Infection","Drug: Artesunate ointment|Drug: Placebo","Complete and partial response by week 18|HPV clearance|Complete and partial response after week 18|Complete and partial peri-anal response after intra-anal ointment application|Persistence of response","Frantz Viral Therapeutics, LLC|Laser Surgery Care, LLC|Anal Dysplasia Clinic MidWest","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ART-AIN IIB-2","January 12, 2024","December 31, 2025","December 31, 2025","January 16, 2024",,"February 22, 2024","Anal Dysplasia Clinic MidWest, Chicago, Illinois, United States|Laser Surgery Care, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT06206564"
1083,"NCT04558996","Spanish Registry of Pregnant Women With COVID-19","OBS COVID","Unknown status","No Results Available","Covid19|Pregnancy Complications|Premature Rupture of Membrane|Abruptio Placentae|Prelabor Rupture of Membranes|Stillbirth",,"MATERNAL COMPLICATIONS|NEONATAL INFECTION","Puerta de Hierro University Hospital|Hospital Universitario La Paz|Hospital Universitario 12 de Octubre|Hospital General Universitario Gregorio Marañon|Hospital Universitario La Fe","Female","18 Years and older   (Adult, Older Adult)",,"3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","55/20|COV20/0021","March 1, 2020","December 31, 2020","March 31, 2021","September 22, 2020",,"September 22, 2020","Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04558996"
1084,"NCT04404855","Antibiotic Selection Using Next Generation Sequencing vs Urine Culture","ACCESS","Completed","Has Results","Kidney Stone|Renal Stone|Infection, Bacterial","Other: NGS + Antibiotic Recommendation|Procedure: Standard of Care treatment","Incidence of Infection Post Surgery|Number of Participants for Whom Additional Antibiotics Were Selected","The University of Texas Health Science Center at San Antonio|MicroGen DX","All","18 Years and older   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HSC20190678H","December 18, 2019","January 31, 2022","August 31, 2022","May 28, 2020","March 12, 2024","March 12, 2024","Audie Murphy VA Hospital, San Antonio, Texas, United States|The University of Texas Health Science Center at San Antonio, Medical Arts and Research Center, San Antonio, Texas, United States|University Health System, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/55/NCT04404855/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04404855"
1085,"NCT05895162","Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis.",,"Recruiting","No Results Available","Vulvovaginal Candidiasis|Vaginal Yeast Infections","Drug: JUVIA zinc containing vaginal gel treatment|Drug: Fluconazole 150Mg Tab","Clinical cure|Time to initial symptom resolution.|Vaginal fungal culture for Candida species.|Clinical cure at days 28, 56, 84|Candida severity score|PRA-1 level|CVL zinc level|Vaginal pH|Vaginal neutrophil count|Concentration of calprotectin, IL-1beta, IL-8 in the vaginal sample by ELISA|Vaginal measurement of CEF1, ACT1, PRA1, ECE1, HWP1, SAP6 expression by qRT-PCR|Vulvovaginal symptoms questionnaire|Vaginal Health Index|Reported Adverse Events (AEs) and Serious Adverse Events (SAEs)","FEMPHARMA Kft.","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2023VVC","June 10, 2023","December 31, 2024","January 7, 2025","June 8, 2023",,"June 13, 2023","Dr. Secret Private Clinic, Debrecen, HB, Hungary",,"https://ClinicalTrials.gov/show/NCT05895162"
1086,"NCT04333602","Asymptomatic Bacteriuria in Early Kidney Transplantation Follow up",,"Completed","No Results Available","Asymptomatic Bacteriuria|Kidney Transplant Infection","Diagnostic Test: Urinary culture and treatment if asymptomatic bacteriuria is detected","Incidence of symptomatic urinary tract infection|Time to the first symptomatic urinary tract infection|Incidence of pyelonephritis or hospitalization related to urinary tract infection|Bacterial virulence genes related to urinary tract infection","Centenario Hospital Miguel Hidalgo","All","Child, Adult, Older Adult","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","2019-R-03","January 1, 2020","February 16, 2022","February 16, 2022","April 3, 2020",,"February 17, 2022","Jose Manuel Arreola, Aguascalientes, Mexico",,"https://ClinicalTrials.gov/show/NCT04333602"
1087,"NCT00551655","Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients",,"Completed","No Results Available","Human Immunodeficiency Viruses|Kidney Failure|HIV Infections",,,"AIDS Arms Inc.|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)",,"684","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","COL109413","May 2007",,"September 2007","October 31, 2007",,"November 6, 2007","Peabody Health Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00551655"
1088,"NCT02631863","Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)",,"Completed","No Results Available","Cervical Intraepithelial Neoplasia|Low-Grade Squamous Intraepithelial Lesions|Papillomavirus Infections","Drug: Aminolaevulinic acid|Drug: Placebo","Response rate|Complete response rate|Clearance of high risk HPV","Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","Female","25 Years to 50 Years   (Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FDZJALA-201510","March 22, 2016","November 24, 2018","November 24, 2018","December 16, 2015",,"July 8, 2019","Peking University People's Hospital, Beijing, Beijing, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|The Obstetrics & Gynecology Hospital of Fudan University, Shanghai, Shanghai, China|Women's Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT02631863"
1089,"NCT01529710","Safety and Efficacy of Mirazid for Schistosomiasis Treatment","PHAR0211","Completed","No Results Available","Schistosoma Hematobium Infection|Schistosomiasis Mansoni","Drug: Myrrh","Compare Mirazid and Praziquantel cure rates for both Schistosoma species, and effect in lowering the intensity of infection for both Schistosoma species.|Identify and compare the types and severity of side and adverse effects between the Mirazid and Praziquantel.","Pharco Pharmaceuticals","All","15 Years to 30 Years   (Child, Adult)","Phase 3","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Mirazid2012","December 2011","September 2012","September 2012","February 9, 2012",,"February 20, 2015","Tanta Health Unit, Gharbiya, Egypt|Health Unit of Atfeeh, Giza, Egypt",,"https://ClinicalTrials.gov/show/NCT01529710"
1090,"NCT00596167","Intradialytic Drug Removal by Short-daily Hemodialysis",,"Completed","Has Results","End Stage Renal Disease|Infection","Drug: Intravenous antibiotics","Intradialytic Clearance of Levofloxacin, Gentamicin and Vancomycin in Patients Receiving Short-daily Hemodialysis","Indiana University School of Medicine|Indiana University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","0609-18","September 2007","April 2009","September 2009","January 16, 2008","March 25, 2016","March 25, 2016","Indiana University School of Medicine, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00596167"
1091,"NCT02694679","Randomized Controlled Trial of Social Network Targeting in Honduras",,"Completed","No Results Available","Preterm Delivery|Hypothermia|Diarrhea|Upper Respiratory Infection|Omphalitis","Behavioral: CBNH","Speed of adoption of intervention and fraction of adoption of CBNH intervention (participant survey).|Percent of participants reporting paternal involvement during pregnancy and postpartum care (participant survey).|Percent of newborns with appropriate umbilical cord care (participant survey)|Percent of children under 5 with diarrheal illness in the last 4 weeks (participant survey)|Percent of children under age 5 with symptoms of acute respiratory illness in the last 4 weeks (participant survey).|Percent of women experiencing a pregnancy danger sign who sought professional medical care (participant survey).|Percent of children experiencing a newborn danger sign who were taken to professional medical care (participant survey)|Percent of children who were breastfed exclusively during first 6 months (participant survey)|Percentage of deliveries taking place in medical facilities (participant survey, medical records).|Receipt of post-natal care medical check-up within 7 days of delivery - Mother (participant survey, medical records).|Receipt of post-natal care medical check-up within 7 days of delivery - Newborn (participant survey, medical records).|Percent of newborns receiving appropriate thermal care during first 7 days after birth (participant survey).|Knowledge/attitudes about thermal care in newborns (Participant survey)|Knowledge/attitudes about paternal involvement (Participant survey)|Knowledge/attitudes about proper cord care (Participant survey)|Knowledge/attitudes about prevention and/or treatment of diarrhea (Participant survey)|Knowledge/attitudes about prevention and/or treatment of respiratory illness (Participant survey)|Knowledge about danger signs during pregnancy (Participant survey).|Knowledge about danger signs for newborns (Participant survey).|Knowledge/attitudes about facility-based births (Participant survey).|Knowledge/attitudes about post-natal care for women (Participant survey).|Knowledge/attitudes about post-natal care for newborns (Participant survey).","Yale University|Inter-American Development Bank|University of California, San Diego","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","31195","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Other","1506016012","June 2015","January 2020","January 2020","February 29, 2016",,"August 8, 2023","Yale Institute for Network Science, New Haven, Connecticut, United States|Community intervention, Copan Ruinas, Copan, Honduras",,"https://ClinicalTrials.gov/show/NCT02694679"
1092,"NCT00892359","Anidulafungin During Continuous Venovenous Hemofiltration (CVVHF)",,"Unknown status","No Results Available","Acute Renal Failure|Infection","Drug: Anidulafungin","Anidulafungin area under the curve (AUC), half-live (t1/2), maximum plasma concentration (Cmax) and elimination fraction.","Medical University of Vienna","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1.1 - Leitner","April 2009","April 2010",,"May 4, 2009",,"May 4, 2009","Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT00892359"
1093,"NCT05467527","PACT Programme for Parents of Children With SHCN",,"Recruiting","No Results Available","Urologic Diseases|Gastrointestinal Diseases|Vascular Diseases|Cleft Lip and Palate|Neurodevelopmental Disorders|Attention Deficit Hyperactivity Disorder|Autism Spectrum Disorder|Developmental Delay","Behavioral: Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice|Behavioral: Positive parenting advice","Parental mental well-being|Child mental well-being|Parental psychological flexibility|Parental prosociality|Parenting competence|Family functioning","Chinese University of Hong Kong|Hong Kong Children's Hospital|Hong Kong Young Women's Christian Association","All","21 Years and older   (Adult, Older Adult)","Not Applicable","196","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2191269","June 27, 2022","June 30, 2024","December 31, 2024","July 20, 2022",,"February 7, 2024","Department of Surgery, Hong Kong Children's Hospital, Ngau Tau Kok, Kowloon, Hong Kong|Hong Kong Young Women's Christian Association, Kowloon, Hong Kong",,"https://ClinicalTrials.gov/show/NCT05467527"
1094,"NCT00417365","Efficacy of (WaterWorks®)Douching Device for Elimination of Perceived Vaginal Odor Not Caused by BV or Vaginitis",,"Unknown status","No Results Available","Vaginal Odor","Device: WaterWorks Douching Device","The primary endpoint of the study is the reduction or abatement of the|subject's perceived vaginal odor as determined at Visit 3.|This improvement will be measured using a visual analog scale that|asks subjects to rate their perception of vaginal odor on a scale that|is anchored at two extremes, ""no odor"", and, ""strong offensive odor"".|Effects on the vaginal Eco-System will be assessed using the|Lactobacilli score and the Nugent score. The safety profile of the douching|device (Water Works® versus control) will be assessed through the collection|of any reported adverse events. Any adverse event, will be reported in terms|of severity, relationship to treatment, duration, and resolution.","Abbott Research Group","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","ARG105B|Pre-IDE I060071","August 2006",,"September 2007","January 1, 2007",,"August 15, 2007","Segal Institute of Clinical Research, Aventura, Florida, United States|Discovery Research, Inc., Plantation, Florida, United States|Atlanta Women's Research Institute, Atlanta, Georgia, United States|Wayne State University, Harper Hospital, Detroit, Michigan, United States|Salem Research, Winston Salem, North Carolina, United States|University of Oklahoma, Tulsa, Oklahoma, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00417365"
1095,"NCT00142064","A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures",,"Completed","No Results Available","Urinary Tract Infection|Kidney Diseases|Ureteral Diseases|Ureteral Obstruction","Behavioral: observed levels of pain","Cumulative pain score utilizing the FLACC pain scale(0-10), for pediatric patients age 2 months through 7 years of age.|Other data collected:|patient age in years/months|gender|race/ethnicity|patient heart rate pre-catheterization and at time of|catheterization|type of procedure requiring catheterization|time of procedure|type of age-appropriate child life techniques used during|the procedure|parental survey","Children's Mercy Hospital Kansas City","All","2 Months to 7 Years   (Child)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","05 06-080","August 2005",,"April 2007","September 2, 2005",,"April 18, 2007","Children's Mercy Hospital, Kansas City, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00142064"
1096,"NCT05453006","HPV Self-Sampling in Somali Women","Isbaar","Recruiting","No Results Available","Cervical Cancer|Papillomavirus Infection|Uterine Diseases|Uterine Cervical Disease","Device: COPAN 552c.80 FLOQSwab","Cervical cancer screening uptake rate","University of Minnesota","Female","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","5680","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","FMCH-2019-27849","February 20, 2023","May 19, 2024","May 31, 2025","July 12, 2022",,"February 1, 2024","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05453006"
1097,"NCT05362955","5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa",,"Active, not recruiting","No Results Available","CIN 2/3|HIV Infections","Drug: Intravaginal 5-Fluorouracil (5-FU)","Safety of intravaginal 5-FU|Tolerability of intravaginal 5-FU|Adherence of intravaginal 5-FU|Acceptability of intravaginal 5-FU|Uptake of intravaginal 5-FU","UNC Lineberger Comprehensive Cancer Center","Female","18 Years to 49 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UNCPM22120","April 26, 2023","August 1, 2024","August 1, 2024","May 5, 2022",,"February 13, 2024","Lumumba Sub-County Hospital KEMRI- Research Care Training Program (RCTP) Building, Kisumu, Kenya",,"https://ClinicalTrials.gov/show/NCT05362955"
1098,"NCT02702297","Multimodal Monitoring of Fetal Risk of Inflammation in Preterm Premature Rupture of Membranes","MuMFI-PPROM","Completed","No Results Available","Preterm Premature Rupture of Membranes|Fetal Inflammatory Response Syndrome|Early Onset Neonatal Sepsis|Infection of Amniotic Cavity","Other: single arm","Odds ratio for severe fetal/early onset neonatal Infection|combined neonatal adverse outcome|late onset neonatal sepsis|Severe neonatal cerebral hemorrhage|necrotizing enterocolitis|umbilical cord blood IL 6 concentration|neonatal early onset sepsis|histological funisitis","Martin-Luther-Universität Halle-Wittenberg|Jena University Hospital|University of Leipzig|St. Elisabeth Hospital Halle","Female","18 Years and older   (Adult, Older Adult)",,"57","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MuMFI-PPROM","January 7, 2016","February 28, 2018","November 10, 2018","March 8, 2016",,"November 14, 2018","Maternity Clinic/Perinatal Treatment Center, university hospital, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Sachsen-Anhalt, Germany|St. Elisabeth Hospital Halle, Halle, Sachsen-Anhalt, Germany|Maternity clinic, University of Leipzig, Leipzig, Saxony, Germany|Maternity Clinic, Jena University Hospital, Jena, Thüringen, Germany",,"https://ClinicalTrials.gov/show/NCT02702297"
1099,"NCT04651244","Diagnostic Imaging of Acute Pyelonephritis",,"Completed","No Results Available","Pyelonephritis Acute","Diagnostic Test: MRI|Diagnostic Test: Ultrasound performed by a radiologist|Diagnostic Test: Point of care ultrasound","Comparison of inflammatory changes in the kidneys on CEUS compared to MRI|Comparison of inflammatory changes in the kidneys on gray scale US and spectral doppler compared to the reference standard MRI|Sensitivity and specificity of point-of-care ultrasound on identifying hydronephrosis compared to MRI|Proportion of patients with APN and hydronephrosis","University of Southern Denmark","All","18 Years and older   (Adult, Older Adult)",,"19","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SHS-ED-11a-2020","March 1, 2021","February 28, 2022","June 1, 2022","December 3, 2020",,"September 16, 2022","Hospital of Southern Jutland, Aabenraa, Denmark",,"https://ClinicalTrials.gov/show/NCT04651244"
1100,"NCT00821847","Renal Function Assessment in HIV Patient","HIVERS","Completed","No Results Available","Chronic Kidney Disease|HIV Infections","Other: DEXA scan","GFR estimated with Cockcroft and Gault and MDRD formulae and cystatin C dosage compared to isotopic evaluation of GFR|Variability of creatinine plasma dosage within two different methods|Role of bone density on validity of renal function markers in HIV patients","Assistance Publique - Hôpitaux de Paris|Sidaction","Male","18 Years and older   (Adult, Older Adult)",,"45","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","P080202","June 2009","March 2012","March 2012","January 14, 2009",,"July 31, 2012","Pitié Salpetriere Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT00821847"
1101,"NCT01044771","Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria","RALPIR","Completed","Has Results","HIV Infections|Proteinuria","Drug: change from tenofovir to raltegravir","Patients With Reduced or Resolved Proteinuria|Patients Without HIV Re-bound","Metropolis Medical|Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RALPIR","January 2010","December 2010","June 2011","January 8, 2010","May 12, 2015","May 12, 2015",,,"https://ClinicalTrials.gov/show/NCT01044771"
1102,"NCT05783167","Self-collected Vaginal and Urine Samples in HIV-positive Women",,"Recruiting","No Results Available","HIV Infections|HPV-Related Cervical Carcinoma|Cervical Cancer|Coinfection, HIV","Diagnostic Test: Self-sampling for HPV infection","Feasibility of implementing HPV self sampling for cervical cancer screening|HPV-prevalence among HIV-infected women in Guinea-Bissau|Experiences with self-collected vaginal and urine samples|HPV-genotype agreement between vaginal- and urine samples","University of Aarhus|Aarhus University Hospital|Universiteit Antwerpen|Randers Regional Hospital|Bandim Health Project","Female","18 Years to 65 Years   (Adult, Older Adult)",,"502","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","R351-A20092","May 29, 2023","November 23, 2023","February 28, 2024","March 24, 2023",,"December 13, 2023","Centro Tratamento Ambúlatorios na Guinea-Bissau, Bissau, Guinea-Bissau",,"https://ClinicalTrials.gov/show/NCT05783167"
1103,"NCT01347632","Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue","CONRADBV","Completed","Has Results","Bacterial Vaginosis|Vaginal Discharge","Drug: Metronidazole","p24 Antigen Production in Tissue|p24 Antigen Production at Baseline Versus After Treatment With Metronidazole","CONRAD|Dartmouth-Hitchcock Medical Center","Female","18 Years to 50 Years   (Adult)","Not Applicable","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","D11115","April 2011","December 2011","December 2011","May 4, 2011","August 26, 2014","December 19, 2017","Eastern Virginia Medical School CONRAD Clinical Research Center, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01347632"
1104,"NCT05591742","Bacterial Composition and Recurrent Cystitis in Postmenopausal Women After Treatment With Lactobacilli.",,"Recruiting","No Results Available","Cystitis Recurrent|Lactobacillus Infection","Dietary Supplement: FEMIDUR®|Other: Placebo Z Cap V-3 Pla","The change in the urine microbiome among postmenopausal women when treated with lactobacillis|episodes of UTI|changes in vaginal micobiome|Changes in fecal microbiome","Aalborg University Hospital|Aalborg University","Female","50 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","N-20200092","October 1, 2021","October 1, 2024","October 1, 2025","October 24, 2022",,"February 5, 2024","AalborgH, Aalborg, Region Nord, Denmark","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/42/NCT05591742/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05591742"
1105,"NCT05471908","Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial","FAAN-C","Recruiting","No Results Available","Pneumonia|Urinary Tract Infections|Soft Tissue Infections|Gastroenteritis","Behavioral: As-needed follow up|Behavioral: Automatic follow-up","Hospital readmission|Medical interventions|Child health-related quality of life","University of Utah|Patient-Centered Outcomes Research Institute","All","up to 18 Years   (Child, Adult)","Not Applicable","2674","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","IHS-2021C1-22388","August 22, 2022","February 2027","February 28, 2028","July 25, 2022",,"April 8, 2024","Phoenix Children's Hospital, Phoenix, Arizona, United States|Packard at El Camino Hospital, Mountain View, California, United States|Lucile Packard Children's Hospital, Palo Alto, California, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|Penn Medicine Princeton Medical Center, Plainsboro, New Jersey, United States|Cincinnati Children's Hospital Medical Center - Main Campus, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center - Liberty Campus, Liberty Township, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Texas Children's Main, Houston, Texas, United States|Texas Children's West, Houston, Texas, United States|Intermountain Primary Children's Hospital Larry H. and Gail Miller Family Campus, Lehi, Utah, United States|Riverton Hospital, Riverton, Utah, United States|Primary Children's Hospital, Salt Lake City, Utah, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/08/NCT05471908/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT05471908"
1106,"NCT04985110","Administration of Antibiotic Prophylaxis for Transperineal Prostate Biopsy in Cipto Mangunkusumo Hospital",,"Unknown status","No Results Available","Prostate Cancer|Prostate Biopsy|Perioperative Complication|Bacteriuria|Urinary Tract Infections|Sepsis","Drug: Cotrimoxazole|Drug: Placebo","Incidence of infection complications|Rate of readmission","Indonesia University","Male","45 Years and older   (Adult, Older Adult)","Phase 2","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","21-02-0154","July 6, 2021","July 6, 2023","July 6, 2023","August 2, 2021",,"August 5, 2021","Dr. Cipto Mangunkusumo Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04985110"
1107,"NCT00978848","Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing",,"Completed","No Results Available","Trichomonas Vaginitis|Chlamydia Trachomatis|Neisseria Gonorrhoeae Infection",,,"University of Pittsburgh|Gen-Probe, Incorporated","Female","15 Years and older   (Child, Adult, Older Adult)",,"305","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","PRO8120077","November 2009","April 2010","April 2010","September 17, 2009",,"May 18, 2016","Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00978848"
1108,"NCT05008640","Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using TrueLoo™",,"Completed","No Results Available","Urinary Tract Infections|Infectious Diarrhea|Clostridium Difficile Infection|Gastrointestinal Disease|GastroIntestinal Bleeding","Device: TrueLoo™","Bowel movement and urinary event dataset creation|Comparison with current methodologies","Toi Labs, Inc.","All","55 Years and older   (Adult, Older Adult)",,"143","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20191822|TLSD-001","November 14, 2019","June 1, 2021","June 18, 2021","August 17, 2021",,"August 17, 2021","Carlton Senior Living (Concord), Concord, California, United States|Carlton Senior Living (Davis), Davis, California, United States|Carlton Senior Living (Elk Grove), Elk Grove, California, United States|Eskaton Village Carmichael, Sacramento, California, United States|Eskaton Lodge Cameron Park, Sacramento, California, United States|Masonic Homes, Union City, California, United States","""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/40/NCT05008640/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT05008640"
1109,"NCT05908682","Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes",,"Recruiting","No Results Available","Vulvovaginal Candidiasis|Candida Infection|Vaginal Candidiasis","Other: Non-interventional study","Major Structural Defects|To collect and describe pregnancy outcomes","Scynexis, Inc.|AWINSA","Female","0 Years and older   (Child, Adult, Older Adult)",,"100","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Other","SCY-078-401","July 28, 2022","October 31, 2029","October 31, 2029","June 18, 2023",,"June 18, 2023","AWINSA, New Delhi, Vasant Vihar, India",,"https://ClinicalTrials.gov/show/NCT05908682"
1110,"NCT00002047","Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure",,"Completed","No Results Available","HIV Infections|Kidney Failure, Chronic","Drug: Zidovudine",,"Glaxo Wellcome|NIH AIDS Clinical Trials Information Service","All","18 Years and older   (Adult, Older Adult)","Not Applicable",,"Industry","Interventional","Primary Purpose: Treatment","014H|27433-19",,,,"August 31, 2001",,"June 24, 2005","Univ of Maryland at Baltimore, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00002047"
1111,"NCT01453192","Renal Transplantation and Raltegravir in HIV-Infected Patients","ANRS153TREVE","Completed","No Results Available","HIV-1 Infection|Chronic Renal Insufficiency","Drug: Raltegravir","Incidence of acute clinical renal graft rejection|Incidence of acute clinical and subclinical renal graft rejection|One year graft survival|Patients' survival|Phenotyping of lymphocytic infiltrates in case of acute rejection|Incidence of AIDS defined diseases and severe morbidity diseases after renal transplantation|Immunological and virologic status after renal transplantation|Evaluation of the switch by raltegravir at the time of renal transplantation|Viral load control after switch by antiretroviral treatment including raltegravir after renal transplantation|Survival and waiting period of HIV patients registered on French biomedicine agency for renal transplantation|Measurement of Area under plasma concentration (AUC) variability of immunosuppressive drugs after introduction of antiretroviral regimen containing Raltegravir","ANRS, Emerging Infectious Diseases|Merck Sharp & Dohme LLC","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","27","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-001004-35|ANRS 153 TREVE","December 2011","November 2015","November 2015","October 17, 2011",,"July 12, 2016","Hôpital Pellegrin, Service de Nephrologie, Transplantation Rénale, Dialyse, Bordeaux, France|CHU De Caen, Service de Néphrologie Hémodialyse, Caen, France|Hôpital Henri Mondor, Service de Néphrologie Transplantation, Créteil, France|Hôpital Kremlin Bicêtre, Service de Néphrologie, Kremlin Bicêtre, France|CHRU Lille, Service de néphrologie, Lille, France|CHU de Nantes, Service de Néphrologie et Immunologie Clinique, Nantes, France|Hôpital Pasteur, Service de Néphrologie - Transplantation, Nice, France|Hopital Saint Louis, Service de Néphrologie, Paris, France|Hôpital Necker, Service de Néphrologie adulte, Paris, France|Hôpital TENON, Urgences Néphrologiques et Transplantation Rénale, Paris, France|Hôpital civil, Service de Néphrologie et Transplantation, Strasbourg, France|Hôpital Foch, Service de Néphrologie Transplantation, Suresnes, France|Hôpital Rangueil, Service de Néphrologie, HTA, Dialyse, Transplantation, Toulouse, France|Hôpital Bretonneau, Service de Néphrologie, Tours, France",,"https://ClinicalTrials.gov/show/NCT01453192"
1112,"NCT03275792","Shiga Toxin Producing Escherichia Coli (STEC) Volume Expansion",,"Withdrawn","No Results Available","Hemolytic-Uremic Syndrome","Drug: D5-0.9%NS|Drug: Routine home oral rehydration","Number of children enrolled in the study protocol|The proportion of children enrolled in each study arm who develop adverse events|Retention|Time requirements|Child/family perspectives|compliance/adherence|data collection tool performance|Impact on clinical services|Cost","University of Calgary","All","6 Months to 18 Years   (Child, Adult)","Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CHREB-12345","May 2020","April 2021","April 2021","September 8, 2017",,"November 9, 2020","Alberta Children's Hospital, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT03275792"
1113,"NCT01593124","Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation","Biomarkers","Completed","No Results Available","Vaginal Inflammation|Vaginal Infections","Drug: Imiquimod|Other: Placebo|Drug: Nonoxynol-9","Differential Microarray gene expression (particularly looking at pathways involved in inflammation and immune response) in vaginal tissues after exposure to N9, HEC or imiquimod","CONRAD","Female","21 Years to 45 Years   (Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D11-119","May 2012","April 2013","April 2013","May 7, 2012",,"March 31, 2015","Eastern Virginia Medical School CONRAD Clinical Research Center, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01593124"
1114,"NCT00000758","A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women",,"Completed","No Results Available","HIV Infections|Cervix, Dysplasia","Drug: Fluorouracil",,"National Institute of Allergy and Infectious Diseases (NIAID)|Hoffmann-La Roche","Female","13 Years and older   (Child, Adult, Older Adult)","Phase 3","158","NIH|Industry","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Prevention","ACTG 200|11176",,,"April 1998","August 31, 2001",,"November 4, 2021","Usc La Nichd Crs, Los Angeles, California, United States|Univ. of Miami AIDS CRS, Miami, Florida, United States|Northwestern University CRS, Chicago, Illinois, United States|Cook County Hosp. CORE Ctr., Chicago, Illinois, United States|Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease, Chicago, Illinois, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States|Bmc Actg Crs, Boston, Massachusetts, United States|Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|NJ Med. School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|SUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States|Memorial Sloan-Kettering Cancer Ctr., New York, New York, United States|Univ. of Rochester ACTG CRS, Rochester, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|Unc Aids Crs, Chapel Hill, North Carolina, United States|Univ. of Cincinnati CRS, Cincinnati, Ohio, United States|UW School of Medicine - CHRMC, Seattle, Washington, United States|Puerto Rico-AIDS CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00000758"
1115,"NCT05313230","Safety and Efficacy of Intermittent Renal Replacement Therapy Using CITRASATE in Critically-ill Patients","CITRA-SAFE","Unknown status","No Results Available","Acute Kidney Injury|Chronic Kidney Infection","Other: CITRASATE SLED","change of blood ionized calcium level disorders|Description of therapeutic consequences required|Description of Clotting event|Description of Dialysis dose","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)",,"61","Other","Observational","Observational Model: Other|Time Perspective: Prospective","RECHMPL21_0739","February 1, 2022","June 1, 2022","June 30, 2022","April 6, 2022",,"April 6, 2022","Uhmontpellier, Montpellier, Montepllier, France",,"https://ClinicalTrials.gov/show/NCT05313230"
1116,"NCT02971007","Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)",,"Completed","Has Results","Vulvovaginitis|Yeast Infection|Yeast Infection Vaginal|Candidiasis, Vulvovaginal","Drug: Oral Encochleated Amphotericin B (CAMB)|Drug: Fluconazole","Clinical Outcome Assessed at Test of Cure Visit|Mycological Outcome Assessed at Test of Cure|Overall Response|Change in Composite Clinical Cure Score","Matinas BioPharma Nanotechnologies, Inc.","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","137","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MB-70005","November 2016","May 2017","May 2017","November 22, 2016","October 5, 2018","November 2, 2018","Alabama Clinical Therapeutics, Birmingham, Alabama, United States|Precision Trials, LLC, Phoenix, Arizona, United States|National Research Institute - Wilshire, Los Angeles, California, United States|South Florida Medical Research, Aventura, Florida, United States|Neostart Corporation dba AGA Clinical Trials, Hialeah, Florida, United States|Altus Research, Lake Worth, Florida, United States|Advanced Research Institute Inc, New Port Richey, Florida, United States|Healthcare Clinical Data, Inc., North Miami, Florida, United States|Clinical Research of West Florida - Tampa, Tampa, Florida, United States|Visions Clinical Research, Wellington, Florida, United States|Mt. Vernon Clinical Research - Wake Research, Atlanta, Georgia, United States|Brighton Clinical Research Associates, Norcross, Georgia, United States|Medpharmics, Metairie, Louisiana, United States|New England Center for Clinical Research, Inc., Fall River, Massachusetts, United States|Lawrence OB/GYN, Lawrenceville, New Jersey, United States|ProHEALTH Care Associates, LLC - Suffolk OB-GYN, Port Jefferson, New York, United States|PMG Research of Salisbury, LLC., Salisbury, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Complete Health Care for Women, Columbus, Ohio, United States|Study Center, Columbus, Ohio, United States|Jackson Clinic, Jackson, Tennessee, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Tidewater Clinical Research, Inc., Norfolk, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/07/NCT02971007/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02971007"
1117,"NCT05813184","Prenatal Antibiotics and Breast Milk / Neonatal IgA","PAIGAN 1","Not yet recruiting","No Results Available","Prenatal Exposure Delayed Effects|Antibiotic Prophylaxis|Dysbiosis|Neonatal Infection|Breast Milk; Noxious Influence, Affecting Fetus","Drug: Antibiotics","breast milk IgA|fecal IgA|breast milk microbiota|fecal microbiota|maternal CCL28","Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Humanitas Hospital, Italy","Female","18 Years to 40 Years   (Adult)",,"82","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","6530","April 30, 2023","April 30, 2025","October 30, 2025","April 14, 2023",,"April 14, 2023",,,"https://ClinicalTrials.gov/show/NCT05813184"
1118,"NCT01213459","Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi Arabia",,"Completed","No Results Available","Infections, Papillomavirus|Cervical Cancer","Procedure: Cervical samples|Other: Data collection","Prevalence of any human papillomavirus deoxyribo nucleic acid and of different types of human papillomavirus (including multiple infections) among women undergoing cervical screening.|Prevalence of any human papillomavirus deoxyribo nucleic acid and of different types of human papillomavirus (high risk and low risk) among women of different age strata undergoing cervical screening.|Behavioural risk factors such as age at first marriage and age at first pregnancy (assessed through administration of a behavioural questionnaire).|Level of awareness of human papillomavirus and its relation to transmission and to causation of cervical cancer.","GlaxoSmithKline","Female","15 Years and older   (Child, Adult, Older Adult)",,"420","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","111336","April 2010","December 2011","December 2011","October 4, 2010",,"November 22, 2012","GSK Investigational Site, Riyadh, Saudi Arabia|GSK Investigational Site, Riyadh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT01213459"
1119,"NCT01207999","Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer",,"Completed","No Results Available","Infections, Papillomavirus|Cervical Cancer","Procedure: Collection of cervical cancer tissue samples|Other: Data collection","Occurrence of any of the human papillomavirus types (HPV-16, 18, 31, 33, 35, 45, 52 and 58) among the women diagnosed with invasive cervical cancer|Occurrence of any of the human papillomavirus types (human papillomavirus-16, 18, 31, 33, 35, 45, 52 and 58) among the women diagnosed with squamous cell carcinoma|Proportion of squamous cell carcinoma cases versus adenocarcinoma and other histologic tumour types of invasive cancer among the women diagnosed with invasive cervical cancer","GlaxoSmithKline|University of Cape Town|African Organization for Research and Training in Cancer (AORTIC)","Female","21 Years and older   (Adult, Older Adult)",,"591","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","109117","October 2007","March 2010","March 2010","September 23, 2010",,"November 22, 2012","GSK Investigational Site, Accra, Ghana|GSK Investigational Site, Kumasi, Ghana|GSK Investigational Site, Ibadan, Nigeria|GSK Investigational Site, Lagos, Nigeria|GSK Investigational Site, Observatory, Western Province, South Africa",,"https://ClinicalTrials.gov/show/NCT01207999"
1120,"NCT05597540","Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Multicentre Randomized Non-inferiority Trial.","SHORTCUT","Recruiting","No Results Available","Pyelonephritis Acute|Kidney Transplant Infection","Drug: Short antibiotic treatment|Drug: Usual antibiotic treatment","Clinical cure day 30|Clinical cure day 90|Clinical cure day 180|Microbiological cure day 30|Microbiological cure day 90|Microbiological cure day 180|Incidence of relapse/recurrence day 30|Incidence of relapse/recurrence day 90|Incidence of adverse event|MDRD|CKD|Hospital length of stay|Antibiotic consumption|Rectal carriage","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 3","470","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","APHP200020","February 22, 2024","March 22, 2027","August 22, 2027","October 28, 2022",,"March 13, 2024","CHU Bordeaux, Bordeaux, France|Hôpital Foch, Boulogne-Billancourt, France|CHU Mondor, Créteil, France|CHRU Lille, Lille, France|CHU Lyon, Lyon, France|CHU Nantes, Nantes, France|CHU Kremlin-Bicêtre, Paris, France|CHU Necker, Paris, France|CHU Saint Louis, Paris, France|CHU Toulouse, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT05597540"
1121,"NCT05788991","Comparison of Dequalinium Chloride (Fluomizin) vs Oral Metronidazole for the Treatment of Bacterial Vaginosis",,"Terminated","No Results Available","Bacterial Vaginosis|Vaginal Infection|Vaginal Diseases","Drug: Dequalinium Chloride|Drug: Metronidazole Oral","Clinical cure rate|Bacteriological cure rate|Therapeutic cure|Individual Amsel Criteria over time|Nugent score over time|Subjective assessment of efficacy|Subjective assessment of tolerability|Adverse events","Medinova AG","Female","18 Years and older   (Adult, Older Adult)","Phase 4","151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MNFM380119|2020-002489-15","July 26, 2021","August 25, 2022","August 25, 2022","March 29, 2023",,"March 29, 2023","Centrum ambulantní gynekologie a primární péče, s.r.o., Brno, Czechia|G-CENTRUM Olomouc s.r.o., Olomouc, Czechia|GYNEKO spol. s r.o, Vsetín, Czechia|Gynekologicko-porodnická ambulance, Ústí nad Labem, Czechia|1 Wojskowy Szpital Kliniczny z Polikliniką SPZOZ, Lublin, Poland|KO-MED CENTRA KLINICZNE Sp. z o.o. Ośrodek, Lublin, Poland|Salve Medica Sp. z o. o. S. K., Łódź, Poland|NZOZ All-Med Centrum Medyczne, Łódź, Poland|Prywatny Gabinet Ginekologiczno-Położniczy, Żurawica, Poland|GPN, s.r.o., Bratislava, Slovakia|RADMA GYN s.r.o., Bratislava, Slovakia|GYNEDUR s.r.o, Dubnica nad Vahom, Slovakia|MCM GYNPED s.r.o., Dubnica Nad Váhom, Slovakia|GYNECARE s.r.o., Puchov, Slovakia",,"https://ClinicalTrials.gov/show/NCT05788991"
1122,"NCT02135419","Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions","ANCHOR","Active, not recruiting","Has Results","Anal Cancer|High-grade Squamous Intraepithelial Lesion|HIV Infection|Human Papilloma Virus Infection","Drug: imiquimod|Drug: fluorouracil|Device: infrared photocoagulation therapy|Device: thermal ablation therapy|Device: laser therapy|Other: clinical observation|Other: laboratory biomarker analysis","Anal Cancer Incidence|Incidence of Adverse Events for Each Treatment|Change in Physical Symptom Score From Baseline (2-7 Days Post Randomization) Until 4 Weeks Post Randomization","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC|University of Arkansas|University of California, San Francisco|University of Arizona","All","35 Years and older   (Adult, Older Adult)","Phase 3","4446","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AMC-A01|NCI-2014-00636|U01CA121947|UM1CA121947|ANCHOR","September 24, 2014","August 6, 2021","March 31, 2024","May 12, 2014","December 2, 2022","January 19, 2024","UCLA CARE Clinic, Los Angeles, California, United States|UCLA School of Nursing, Los Angeles, California, United States|DAP Health, Palm Springs, California, United States|University of California at San Francisco Anal Dysplasia Clinic, San Francisco, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Public Health, Denver, Colorado, United States|Capital Digestive Care, Washington, District of Columbia, United States|Dupont Circle Physicians Group, Washington, District of Columbia, United States|ACC Clinic, Jackson Hospital, Miami, Florida, United States|University of Miami Miller School of Medicine - Sylvester Cancer Center, Miami, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Anal Dysplasia Clinic MidWest, Chicago, Illinois, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|CrescentCare Health, New Orleans, Louisiana, United States|Boston Medical Center, Boston, Massachusetts, United States|Fenway Health, Boston, Massachusetts, United States|Rutgers University New Jersey Medical School, Newark, New Jersey, United States|Montefiore - Albert Einstein College of Medicine, Bronx, New York, United States|Cornell Clinical Trials Unit, Chelsea Center, New York, New York, United States|Laser Surgery Care, New York, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|The Polyclinic, Seattle, Washington, United States|University of Puerto Rico, San Juan, Puerto Rico","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/19/NCT02135419/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/19/NCT02135419/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02135419"
1123,"NCT03771651","Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube",,"Active, not recruiting","No Results Available","Fallopian Tube Cancer|Fallopian Tube Infection","Drug: Aspirin 81 mg","Number of subjects who exhibited alterations in the fallopian tube immune microenvironment|Number of subjects who exhibited less carcinogenic potential than control specimens|Number of subjects who exhibited changes in transcriptome profile compared to control specimens","University of Oklahoma","Female","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9955","March 1, 2019","May 6, 2022","June 2025","December 11, 2018",,"November 22, 2023","Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT03771651"
1124,"NCT05618769","Towards Life-Long Healthy Lungs: A Multidisciplinary Follow-up Framework for Preterm Infants","LONG LOVE","Recruiting","No Results Available","Premature Birth|Respiratory Disease|Respiratory Tract Infections|Preterm Birth|Bronchopulmonary Dysplasia|Pollution Related Respiratory Disorder|Pollution; Exposure|Smoking Cessation|Health-Related Behavior|RSV Infection|RSV Pneumonia|Bronchial Hyperreactivity|Telemedicine|eHealth","Combination Product: LONG LOVE Framework","Number of lower Respiratory Tract Infections (RTI)|Number of wheezing episodes|time to first lower RTI or wheezing episode|total number of RTI|total number of wheezing episodes|distribution of viruses (in case of hospital admission)|medication use|lung function as measured by expiratory variability index (EVI)|comparison of expiratory variability index in moderate/late prematurity compared to term cohort (reference cohort from other center)|correlation between expiratory variability index and Lung Capacity Index and Hypoxic Challenge Test|association between expiratory variability index and number of RTI/wheezing|Analysis of outdoor air quality|indoor air quality|Preschool Children Quality of Life|Total costs of framework|Care-related Quality of Life|Cost-effectiveness of framework","Franciscus Gasthuis|Stichting BeterKeten|Revenio Research|Chiesi Farmaceutici S.p.A.","All","Child, Adult, Older Adult","Not Applicable","330","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2021-117","July 18, 2022","June 30, 2025","July 31, 2025","November 16, 2022",,"November 16, 2022","Franciscus Gasthuis & Vlietland, Rotterdam, Zuid-Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT05618769"
1125,"NCT04098744","Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)","ART-CIN_IIB","Recruiting","No Results Available","CIN 2/3|HPV Infection|Pre-Cancerous Dysplasia|Cervical Dysplasia|HPV Related Disease","Drug: Artesunate vaginal insert|Drug: Placebo vaginal insert","Proportion of participants with histologic regression by week 17|Number of participants who have achieved clearance of detectable human papilloma virus (HPV) by week 17|Number of participants who have achieved clearance of detectable human papilloma virus (HPV) after three 5-day cycles of artesunate and the LEEP procedure.","Frantz Viral Therapeutics, LLC|Amarex Clinical Research|M.D. Anderson Cancer Center|Harris Health System (L.B.J. Hospital)|The Cleveland Clinic|University of Michigan|Morehouse School of Medicine","Female","25 Years to 100 Years   (Adult, Older Adult)","Phase 2","78","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ART-CIN IIB|2020 0237|20 1148","September 9, 2020","July 31, 2025","December 31, 2025","September 23, 2019",,"February 21, 2024","Florida Gynecologic Oncology, Fort Myers, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|Cleveland Clinic Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Hillcrest Hospital, Mayfield Heights, Ohio, United States|The Harris Health System (L.B.J Hospital), Houston, Texas, United States|University of Texas, M.D. Anderson, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04098744"
1126,"NCT06049693","Iron Prehabilitation in Endometrial Cancer","IROGYN","Completed","No Results Available","Endometrial Cancer|Perioperative Complication|Prehabilitation","Drug: Ferrous Gluconate 300 MG","Number of participants with surgical site infection|Required blood transfusions per participant and aggregated mean differences|Number of participants with other postoperative infections|Duration of hospitalization per participant|Onset of adjuvant treatment per participant|Survival rates of included participants","National and Kapodistrian University of Athens","Female","18 Years to 79 Years   (Adult, Older Adult)","Phase 4","156","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","129/20","January 1, 2023","January 1, 2024","January 1, 2024","September 22, 2023",,"March 29, 2024","First department of Obstetrics and Gynecology, Athens, Greece",,"https://ClinicalTrials.gov/show/NCT06049693"
1127,"NCT05907187","Research in Ethno-Medicine and Education (REMED)","REMED","Completed","No Results Available","Cervical Cancer|Human Papilloma Virus|HPV|Human Papillomavirus Infection","Behavioral: Cervical Cancer Prevention Education","Plant products used for intravaginal twalet deba.|Methods of using plant products for intravaginal twalet deba.|Cultural beliefs surrounding the practice of intravaginal twalet deba.|Health access for cervical cancer screening as measured by REMED tool","University of Miami|Cigna Foundation","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20170445|NCI-2023-00177","November 7, 2017","November 21, 2018","June 9, 2020","June 18, 2023",,"June 18, 2023","Martine Poitevien, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT05907187"
1128,"NCT04340037","Prediction of Sepsis After Percutaneous Nephrolithotomy",,"Completed","No Results Available","Percutaneous Nephrolithotomy|Infection|Urolithiasis|Albumin Globulin Ratio","Procedure: percutaneous nephrolithotomy","sepsis","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)",,"745","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","2019S1035v2","March 1, 2019","January 1, 2020","February 20, 2020","April 9, 2020",,"April 9, 2020","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04340037"
1129,"NCT02556190","Colistin Pharmacokinetics in Critically Ill Patients During Extended Dialysis",,"Completed","No Results Available","Infection Due to Resistant Bacteria|Acute Kidney Injury",,"Colistin elimination during extended dialysis|Colistin peak concentration during extended daily dialysis C(max)|Colistin trough Level during extended daily dialysis C(max)|Colistin dialyzer clearance during extended dialysis","Hannover Medical School","All","18 Years and older   (Adult, Older Adult)",,"8","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COL-6446-2013","June 2013","May 2016","May 2016","September 22, 2015",,"August 24, 2016","Hannover Medical School, Hannover, Lower Saxony, Germany",,"https://ClinicalTrials.gov/show/NCT02556190"
1130,"NCT05426148","Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female",,"Completed","No Results Available","Cervical Intraepithelial Neoplasia|Cervical Cancer|Vaginal Intraepithelial Neoplasia|Vulvar Intraepithelial Neoplasia|Persistent Infection","Biological: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®","The Geometric Mean concentration (GMC) of anti-HPV16/18 IgG at at one month after the 2nd dose.|Seroconversion rate of anti-HPV16/18 IgG at one month after the 2nd dose.|Measure solicited local adverse reactions within 7 days after each vaccination.|Measure solicited systematic adverse reactions within 7 days after each vaccination.|Measure unsolicited adverse reactions within 30 days after vaccination.|Measure serious adverse events occurred throughout the study.|Measure Potential Immune Mediated Diseases occurred throughout the study.","Xiamen Innovax Biotech Co., Ltd|Jiangsu Province Centers for Disease Control and Prevention|Dongtai City Centers for Disease Control and Prevention","Female","9 Years to 14 Years   (Child)","Phase 4","540","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","HPV-PRO-010","May 1, 2020","August 1, 2020","April 30, 2021","June 21, 2022",,"June 29, 2022","Dongtai City Center for Disease Control and Prevention Dongtai, Jiangsu, Dongtai, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT05426148"
1131,"NCT05655936","Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial","HHD","Recruiting","No Results Available","Preeclampsia|Hypertensive Disorder of Pregnancy|Toxemia|Pregnancy Complications|Hypertension, Pregnancy-Induced|Hypertension|Obesity|Overweight|Nutrition Disorders|Vascular Diseases|Cardiovascular Diseases|Pre-Eclampsia|Eclampsia|Gestational Hypertension","Behavioral: Heart Health Doula Intervention Program|Behavioral: Usual Care","Assess MAP at 12 months postpartum|Change from baseline in racial disparities and blood pressure & MAP at 12 months|Assess Racial Disparities in Healthcare Delivery","University of Pittsburgh|National Institute on Minority Health and Health Disparities (NIMHD)","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","454","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STUDY22060056|1R01MD017083-01A1","June 29, 2023","July 1, 2027","July 1, 2027","December 19, 2022",,"July 6, 2023","Magee Women's Hospital of UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05655936"
1132,"NCT04000503","Integrated Cervical Cancer Screening in Mayuge District Uganda (ASPIRE Mayuge)","ASPIRE","Completed","No Results Available","Human Papillomavirus 16|Human Papillomavirus 18|Papillomavirus Infections|Cervical Cancer|Pre-Cancerous Dysplasia","Behavioral: Self-collected HPV testing for cervical cancer screening","VIA follow-up and treatment when indicated (screen and treat)|HPV prevalence|STI-HPV co-infection rate (Gonorrhea, Syphilis, etc.)|HPV and co-morbid conditions|Barriers and facilitators of engagement in care|Identify mediators of engagement of care","University of British Columbia|Uganda Cancer Institute","Female","25 Years to 49 Years   (Adult)","Not Applicable","2019","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","H17-03332","August 1, 2019","July 31, 2021","October 31, 2022","June 27, 2019",,"November 3, 2022","Uganda Cancer Institute, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT04000503"
1133,"NCT00948779","Antibiotic Education for Children in an Emergency Care Unit","ACHEEN","Completed","No Results Available","Otorhinolaryngologic Diseases|Respiratory Tract Infections|Pyelonephritis|Urinary Tract Infections","Other: antibiotic education for children in an emergency care unit","satisfaction (likert scale)|Parent's knowledge","Assistance Publique - Hôpitaux de Paris","All","1 Month to 6 Years   (Child)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","ID RCB 2008-A00892-53","February 2009","March 2012","March 2012","July 29, 2009",,"February 3, 2023","Hôpital Robert Debré, Paris, France",,"https://ClinicalTrials.gov/show/NCT00948779"
1134,"NCT00536848","The Effect of Probiotics on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients",,"Unknown status","No Results Available","HIV Infections|Diarrhea|Bacterial Vaginosis","Dietary Supplement: Lactobacillus rhamnosus GR-1 + Lactobacillus reuteri RC-14|Dietary Supplement: Placebo|Drug: Metronidazole","CD4 count|Bacterial vaginosis cure rate|Total serum IgE levels|Serum cytokine levels|Diarrhea incidence and length of episodes","National Institute for Medical Research, Tanzania|University of Western Ontario, Canada|Erasmus Medical Center|Sekou-Toure Regional Hosipital, Mwanza, Tanzania|Lawson Health Research Institute|Danone Institute International","Female","18 Years to 45 Years   (Adult)","Phase 2|Phase 3","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MRRC HIV-Probiotics15","October 2007","August 2008","August 2008","September 28, 2007",,"January 30, 2009","Sekou-Toure Regional Hospital, Mwanza, Tanzania",,"https://ClinicalTrials.gov/show/NCT00536848"
1135,"NCT02114060","Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine",,"Completed","No Results Available","Genital Herpes Simplex Type 2","Biological: GEN-003 Vaccine (30μg of each antigen)|Biological: GEN-003 Vaccine (60μg of each antigen)|Biological: Matrix-M2 Adjuvant (25μg)|Biological: Matrix-M2 Adjuvant (50μg)|Biological: Matrix-M2 Adjuvant (75μg)|Biological: Placebo","Change in proportion of days with detectable viral shedding|Immunogenicity measured by humoral (antibody) and T-cell responses to vaccine antigens|Impact on clinical HSV-2 disease based on time to recurrence and lesion rate|Number of patients with adverse events as a measure of safety and tolerability","Genocea Biosciences, Inc.","All","18 Years to 50 Years   (Adult)","Phase 2","310","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GEN-003-002","July 2014","February 2016","February 2016","April 15, 2014",,"October 16, 2017","University of Alabama Vaccine Research Unit, Birmingham, Alabama, United States|Medical Center for Clinical Research, San Diego, California, United States|Quest Clinical Research, San Francisco, California, United States|University of Illinois Department of Medicine, Chicago, Illinois, United States|Indiana University Infectious Disease Research, Indianapolis, Indiana, United States|The Fenway Institute, Boston, Massachusetts, United States|UNC Global HIV Prevention and Treatment Clinical Trials Unit, Chapel Hill, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Westover Heights Clinic, Portland, Oregon, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|Tekton Research, Austin, Texas, United States|Center for Clinical Studies - Houston, Houston, Texas, United States|Center for Clinical Studies, Houston, Texas, United States|Center for Clinical Studies - Clear Lake/Webster, Webster, Texas, United States|University of Utah, Salt Lake City, Utah, United States|UW Virology Research Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02114060"
1136,"NCT06023056","Hepatitis B Vaccination After Neonatal Surgery",,"Recruiting","No Results Available","Vaccination Reaction|Hepatitis B Virus Infection|Digestive System Disorders of Fetus and Newborn|Blood Transfusion Complication|Hepatitis B Vaccine Adverse Reaction",,"Prenatal hepatitis B surface markers|Newborn condition|Vaccination time|Adverse reactions|Immune effect of vaccine","Children's Hospital of Chongqing Medical University","All","Child, Adult, Older Adult",,"180","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","chcmuzhb20221114","November 1, 2022","November 1, 2030","November 1, 2030","September 5, 2023",,"September 11, 2023","Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT06023056"
1137,"NCT03125616","Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B","BEAR Men B","Completed","No Results Available","Prematurity|Vaccination|Meningococcal Disease","Biological: 4CMenB Vaccine","hSBA GMT|hSBA proportions|Reactions within 7 days|Cardiorespiratory status for 72 hours following vaccination|Suspicion of sepsis in 7 days following vaccination|Fever and/or suspicion of sepsis in the 28 days following vaccination|Serious adverse events|Persistence of hSBA GMTs|Persistence of hSBA proportions ≥1:4|Booster response: hSBA GMTs|Booster response: hSBA proportions ≥1:4","St George's, University of London|GlaxoSmithKline|MeningitisNow|Public Health England","All","7 Weeks to 11 Weeks   (Child)","Phase 4","136","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16.0247|2017-001487-38","August 1, 2017","September 2, 2019","August 28, 2020","April 24, 2017",,"December 1, 2020","St Georges University Hospital NHS Foundation Trust, Tooting, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03125616"
1138,"NCT03403751","Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury",,"Terminated","Has Results","Acute Kidney Injury|Peritonitis|Necrotizing Soft Tissue Infection","Drug: Reltecimod 0.5 mg/kg|Drug: Placebo","Freedom From Durable Loss of Renal Function at Day 28|Serious Adverse Events (SAEs)|Adverse Events (AEs)|Freedom From Durable Loss of Renal Function at Day 14|Intensive Care Unit (ICU)-Free Days|Ventilator-free Days|Vasopressor-free Days|Hospital Days|Cumulative Number of Deaths|Secondary Infections|ICU-free Days by Day 14 Modified Sequential Organ Failure Assessment (mSOFA) Category|Ventilator-free Days by Day 14 mSOFA Category|Vasopressor-free Days by Day 14 mSOFA Category|Hospital Days by Day 14 mSOFA Category|Hospital Discharge Location by Day 14 mSOFA Category","Atox Bio Ltd","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ATB-203","May 24, 2018","December 14, 2019","December 14, 2019","January 19, 2018","September 16, 2021","October 12, 2021","Maricopa Medical Center, Phoenix, Arizona, United States|Banner University Medical Center, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Loma Linda University Medical Center, Loma Linda, California, United States|University of California, Davis Medical Center, Sacramento, California, United States|UCSD Medical Center, San Diego, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|UCH-Memorial Health System, Colorado Springs, Colorado, United States|University of Colorado Hospital, Denver, Colorado, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Washington Hospital Center, Washington, District of Columbia, United States|UF Health Shands Hospital, Gainesville, Florida, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|LSU Health Science Center, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|University of Missouri, Columbia, Missouri, United States|Capital Health System, Inc., Trenton, New Jersey, United States|Erie County Medical Center-Affliate of SUNYat Buffalo, Buffalo, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|University of Cincinnati Medical Center (UCMC), Cincinnati, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|The Pennsylvania State University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|The Trauma Center at PENN, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|MUSC, Charleston, South Carolina, United States|John Peter Smith Health Network, Fort Worth, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Harborview Medical Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Hopital Victor Dupouy, Argenteuil, France|CHRU la Cavale Blanche, Brest, France|CHU Clermont-Ferrand, Clermont-Ferrand, France|CHU Dijon, Dijon, France|CHD Vendee, La Roche-sur-Yon, France|CH Le Mans, Le Mans, France|Robert Salengro Hopital-CHRU Lille, Lille, France|CHU de Limoges, Limoges, France|CHU Lyon Sud, Lyon, France|Hopital Edouard Herriot, Lyon, France|Hopital Saint Eloi, Montpellier, France|CHU de Nante Hotel-Dieu, Nantes, France|CHU Nimes, Nîmes, France|Hopital Cochin, Paris, France|CHU Rennes, Rennes, France|Nouvel Hopital Civil, Strasbourg, France","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/51/NCT03403751/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/51/NCT03403751/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03403751"
1139,"NCT01539668","Hybrid Capture Test on Mobile Unit Program to Improve Cervical Cancer Screening in Brazilian Rural and Remote Areas","careHPV","Completed","No Results Available","Cervical Cancer Squamous Cell|Human Papilloma Virus Infection|Human Papilloma Virus-Related Carcinoma|Prevention",,"HR-HPV presence in the studied population.|The meaning of HPV presence relating with the conventional screening test (Papanicolaou smear), and the pattern of setting cervical lesion (biopsy).","Barretos Cancer Hospital|QIAGEN Gaithersburg, Inc","Female","Child, Adult, Older Adult",,"5079","Other|Industry","Observational","Time Perspective: Prospective","careHPV_2012","March 2012","December 2012","February 2014","February 27, 2012",,"February 26, 2014","Barretos Cancer Hospital, Barretos, São Paulo, Brazil|Barretos Cancer Hospital, Barretos, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT01539668"
1140,"NCT04048356","Chlorhexidine vs. Iodine for Vaginal Preparation in Urogynecologic Procedures","CLNUP","Completed","Has Results","Pelvic Organ Prolapse|Urinary Incontinence|Pelvic Floor Disorders|Gynecologic Disease|Post-Op Infection|Surgical Site Infection|Urinary Tract Infections","Drug: Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.","Rate of Urinary Tract Infection|Rate of Surgical Site Infection|Vaginal Irritation","University of New Mexico","Female","18 Years and older   (Adult, Older Adult)","Phase 3","137","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","19-039","July 15, 2019","February 28, 2021","March 14, 2021","August 7, 2019","July 10, 2023","July 10, 2023","University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/56/NCT04048356/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/56/NCT04048356/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04048356"
1141,"NCT01667341","Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine",,"Completed","No Results Available","Genital Herpes Simplex Type 2","Biological: GEN-003 with Matrix M-2|Biological: GEN-003|Biological: Placebo","Number of patients with adverse events as a measure of safety and tolerability|Immunogenicity measured by humoral (antibody) and T-cell responses to vaccine antigens|Change in proportion of days with detectable viral shedding","Genocea Biosciences, Inc.","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","143","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GEN-003-001","July 2012","May 9, 2014","May 9, 2014","August 17, 2012",,"June 1, 2018","University of Alabama Vaccine Research Unit, Birmingham, Alabama, United States|Indiana University Infectious Disease Research, Indianapolis, Indiana, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Westover Heights Clinic, Portland, Oregon, United States|Center for Clinical Studies - Houston, Houston, Texas, United States|Center for Clinical Studies - Clear Lake/Webster, Webster, Texas, United States|UW Virology Research Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01667341"
1142,"NCT02864420","Hospitalization at Home: The Acute Care Home Hospital Program for Adults",,"Completed","No Results Available","Pneumonia|Heart Failure|Cellulitis|Urinary Tract Infections","Other: Home hospitalization|Other: Inpatient Hospitalization","Total cost of hospitalization, $|Direct margin, $|Direct margin, modeled with backfill, $|Length of stay, days|Imaging, #|Lab Orders, #|Discharge Disposition|Readmission(s) after index hospitalization, y/n|Time to readmission after index hospitalization, days|Emergency Department (ED) observation stay(s) after index hospitalization, y/n|Time to ED observation stay(s) after index hospitalization, days|ED visit(s) after index hospitalization, y/n|Time to ED visit(s) after index hospitalization, days|Delirium, y/n|Transfer back to hospital, y/n|Hours of sleep, #|Daily steps, #|EuroQol -5D-5L, composite score|Short Form 1|Activities of daily living, score|Instrumental activities of daily living, score|3-item Care Transition Measure, score|Picker Experience Questionnaire, score|Global satisfaction with care, score|Qualitative interview","Brigham and Women's Hospital|Partners HealthCare|Smiths Medical, ASD, Inc.|Vital Connect, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","21","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016P001337","September 2016","December 2016","December 2016","August 12, 2016",,"July 11, 2017","Brigham and Women's Hospital, Boston, Massachusetts, United States|Brigham and Women's Faulkner Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02864420"
1143,"NCT04705766","KIDney Injury in Times of COVID-19 (KIDCOV)","KIDCOV","Recruiting","No Results Available","SARS-CoV Infection|Covid19|Corona Virus Infection|Acute Kidney Injury|Kidney Injury","Other: Urine Collection","Continuous, Quantitative KIT Score|Number of participants with a level of Kidney Injury Molecule-1 (KIM1) above 1 ng/ml|Number of participants with a level of Neutrophil Gelatinase-Associated Lipocalin (NGAL) above 1 ng/ml|Number of participants with a level of soluble urokinase-type plasminogen activator receptor (suPAR) above 1 ng/ml","University of California, San Francisco|Rush University Medical Center|University of Michigan|University of California","All","18 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KIDCOV2020","March 1, 2021","March 2026","March 2026","January 12, 2021",,"March 18, 2024","UCSF, San Francisco, California, United States|Rush University, Chicago, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04705766"
1144,"NCT02203942","Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis","VAST","Completed","No Results Available","Bacterial Vaginosis|Vulvovaginal Candidiasis|Trichomoniasis","Other: NAAT testing","Diagnosis of Vaginal Infections","University of Pittsburgh","Female","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Only","PRO14010349","July 2014","June 2015","June 2015","July 30, 2014",,"January 27, 2016","Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02203942"
1145,"NCT04578015","A Randomized Controlled Trial of Treatment of Bacterial Vaginosis",,"Terminated","Has Results","Bacterial Vaginoses","Drug: Metronidazole|Drug: Placebo","Evaluating Composite of Chorioamnionitis, Postpartum Endometritis, SSI, Wound Infection, or Other Post-cesarean Infections (Occurring Within 6 Weeks After Delivery)|Evaluating Incidence of Individual Infections.|Evaluating Incidence of Maternal Death|Evaluating Incidence of Puerperal Fever.|Evaluating Incidence of Use of Resources.|Evaluating Incidence of Adverse Events|Evaluating Incidence of Suspected Sepsis for Newborns|Evaluating Incidence of Confirmed Sepsis for Newborns|Evaluating Incidence of Newborn Intensive Care Unit (NICU) Admission and Duration|Evaluating Incidence of Neonatal Morbidities","Ohio State University","Female","18 Years to 50 Years   (Adult)","Phase 4","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2020H0476","April 26, 2021","February 9, 2022","February 9, 2022","October 8, 2020","June 15, 2023","June 15, 2023","The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/15/NCT04578015/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04578015"
1146,"NCT01067131","Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection",,"Completed","No Results Available","Recurrent Vulvovaginal Candidiasis","Biological: PEV7C1|Biological: PEV7C9|Biological: PEV7B2|Biological: PEV7B1","Systemic and local AE rates / SAE rates|Titers of vaccine antigen specific antibodies|Neutralisation capacity of vaccine antigen specific antibodies","Pevion Biotech Ltd","Female","18 Years to 45 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PCAN001","March 2010","December 2012","December 2012","February 11, 2010",,"December 24, 2012","Covance Clinical Research Unit AG, Allschwil, Basel, Switzerland|CHUV, Vaccine and Immunotherapy Center, Lausanne, Switzerland",,"https://ClinicalTrials.gov/show/NCT01067131"
1147,"NCT02979951","Fosfomycin i.v. for Treatment of Severely Infected Patients","FORTRESS","Recruiting","No Results Available","Bacterial Infections|Bone Diseases, Infectious|Osteomyelitis|Central Nervous System Bacterial Infections|Meningitis, Bacterial|Encephalitis|Brain Abscess|Urinary Tract Infections|Respiratory Tract Infections|Pneumonia, Bacterial|Skin Diseases, Bacterial|Soft Tissue Infections|Intraabdominal Infections|Sepsis|Bacteremia|Endocarditis, Bacterial",,"Percentage of patients with clinical success as defined as clinical cure or clinical improvement|Microbiological cure|Clinical success as defined as clinical cure or clinical improvement|Clinical cure|Clinical improvement|Sodium serum levels|Potassium serum levels|Adverse events|Non-serious adverse events|Serious adverse events|Cases of death|Adverse drug reactions (ADRs)|Serious adverse drug reactions (SADRs)|Dropouts due to treatment failure or due to adverse events","Infectopharm Arzneimittel GmbH|INPADS GmbH|Dr. Oestreich + Partner GmbH","All","18 Years and older   (Adult, Older Adult)",,"1000","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FORTRESS","December 2016","December 2030","December 2030","December 2, 2016",,"November 13, 2023","Landeskrankenhaus Hall - Tirol Kliniken, Hall In Tirol, Austria|A.ö. Bezirkskrankenhaus, Reutte, Austria|Klinikum Wels-Grieskirchen, Institut für Hygiene und Mikrobiologie, Wels, Austria|AKH Wien, Universitätsklinik für Innere Medizin 1, Wien, Austria|Universitätsmedizin Charité, Berlin, Germany|Vivantes Kliniken Neukölln, Berlin, Germany|Städtisches Klinikum Braunschweig, Braunschweig, Germany|Universitäts Düsseldorf; Klinik für Anästhesiologie, Dusseldorf, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Universität Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Jena; Zentrum für Infektionsmedizin, Jena, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Germany|Universitätsklinik Schleswig-Holstein, Lübeck, Germany|LMU München, München, Germany|Universitätsklinikum Münster, Münster, Germany|Klinikum Oldenburg, Oldenburg in Holstein, Germany|Universitätsklinik Regensburg; Klinik für Anästhesiologie, Regensburg, Germany|Kliniken Nordoberpfalz, Weiden, Germany|RIO Univ. Hospital, Dept of Pathology, Division of Infectious Diseases, Patras, Greece|Clinical Malattie Infettive, Bari, Italy|Azienda Ospedaliera S.Croce e Carle, Cuneo, Italy|Ospedal Policlinico San Martino, Genova, Italy|Ospedale L. Sacco, Mailand, Italy|Istituto Mediterraneo per i Trapianti Ismett IRCCS, Palermo, Italy|Policlinico Paolo Giaccone, Palermo, Italy|Policlinico Umberto I, Malattie Infettive, Rom, Italy|Lazzaro Spallanzani, Rom, Italy|Polocinico Tor Vergata, Rom, Italy|AOU Città della Salute e Scienza-Presidio Molinette, Torino, Italy|Ospedale S.M.della Misericordia, Udine, Italy|ASST-Sette Lagh Viale Borre, Varese, Italy|Royal Bolton Hospital, Bolton, United Kingdom|Hull & East Yorkshire Hospitals NHS Trust, Cottingham, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Queen Elisabeth University Hospital, Glasgow, United Kingdom|University of Glasgow/Royal Infirmary, Glasgow, United Kingdom|University Hospital Crosshouse, Kilmarnock, United Kingdom|Chelsea & Westminster Hospial, London, United Kingdom|Queen Elisabeth Hospital, London, United Kingdom|Univresity College Londen (UCL) Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02979951"
1148,"NCT06273553","A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3",,"Not yet recruiting","No Results Available","Human Papillomavirus Associated Intraepithelial Neoplasia|Cervical Intraepithelial Neoplasia Grade 2/3|Human Papillomavirus Type 16 Infection|Human Papillomavirus Type 18 Infection","Biological: RG002 injection","Part A: Safety and Tolerability of RG002 Injection, measured by the incidence of adverse events|Part A: Maximum tolerated dose (MTD) and/or RP2D of RG002 Injection|Part B: Primary efficacy of RG002 Injection, measured by the proportion of subjects with histopathological regression|Part A: Preliminary efficacy of RG002 Injection,measured by proportion of subjects with histopathological regression|Part A: Preliminary efficacy of RG002 Injection,measured by proportion of subjects with clearance of HPV16/18|Part A: Preliminary efficacy of RG002 Injection,measured by proportion of subjects with histopathological regression and clearance of HPV16/18|Part A and B: Immunogenicity of RG002 Injection,measured by the level of cellular immune response|Part A and B: Immunogenicity of RG002 Injection,measured by the proportion of T lymphocytes|Part A and B: Immunogenicity of RG002 Injection,measured by the expression of cytokines in serum|Part A and B: Immunogenicity of RG002 Injection,measured by the serum levels of anti-HPV16 and anti-HPV18 IgG antibodies.|Part A and B: Exposure level of RG002 Injection, measured by mRNA|Part A and B: Exposure level of RG002 Injection, measured by cationic lipids|Part A and B: Anti-drug antibody (ADA) to polyethylene glycol (PEG) of RG002 injection, measured by the serum titer of anti-PEG IgG and anti-PEG IgM|Part B: Secondary efficacy, measured by proportion of subjects with histopathological regression|Part B: Secondary efficacy, measured by proportion of subjects with clearance of HPV16/18|Part B: Secondary efficacy, measured by proportion of subjects with histopathological regression and clearance of HPV16/18|Part B: Safety and tolerability of RG002 Injection, measured by the incidence of adverse events|Part B: Optionally assess the biomarker of RG002 Injection, measured by the level of potential biomarkers and the level of infiltrating T cells and myeloid cells in the lesions.","RinuaGene Biotechnology Co., Ltd.","Female","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","39","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RG002-A1201","March 2024","October 2026","December 2027","February 22, 2024",,"February 22, 2024",,,"https://ClinicalTrials.gov/show/NCT06273553"
1149,"NCT00457873","Isotonic Versus Hypotonic Fluid for Maintenance IV Therapy",,"Completed","No Results Available","Gastroenteritis|Bronchiolitis|Sepsis|Urinary Tract Infection","Drug: 0.9% saline in 5% dextrose (intravenous)|Drug: 0.45% saline in 5% dextrose (intravenous)","rate of change in serum sodium|hypertension|congestive heart failure","McGill University Health Centre/Research Institute of the McGill University Health Centre","All","1 Month to 18 Years   (Child, Adult)","Phase 3","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PED-06-016","January 2007","April 2008","April 2008","April 9, 2007",,"April 12, 2022","Montreal Children's Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00457873"
1150,"NCT05639504","Sepsis Prognosis and Diagnosis in the Emergency Department (SPEED)",,"Withdrawn","No Results Available","Respiratory Tract Infections|Urinary Tract Infections|Intra-Abdominal Infections|Skin and Soft Tissue Infection|Suspected Meningitis/Encephalitis or Any Other Infection|Sepsis","Diagnostic Test: IMX-BVN-4 and IMX-SEV-4","Primary Outcome 1|Primary Outcome 2|Secondary Outcome 1|Secondary Outcome 2|Secondary Outcome 3","Inflammatix","All","16 Years and older   (Child, Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","INF-25","December 2022","April 2023","May 2023","December 6, 2022",,"December 27, 2023",,,"https://ClinicalTrials.gov/show/NCT05639504"
1151,"NCT04815954","Early vs Late Urinary Catheter Removal After Renal Transplantation","ELUCATR","Recruiting","No Results Available","Kidney Transplant; Complications|Kidney Transplant Infection|Urinary Fistula|Urinary Tract Infections|Urinary Catheter","Procedure: Urinary catheter removal","Urinary fistula|Urinary stenosis|30 day graft function measured as serum creatinine|1 year graft survival in days and function measured as serum creatinine|Urinary tract infections|BK virus infection|Length of hospital stay","Medical University of Warsaw","All","18 Years and older   (Adult, Older Adult)","Not Applicable","450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment","Not assigned","March 26, 2019","March 26, 2025","April 26, 2026","March 25, 2021",,"April 26, 2023","Department of General and Transplantation Surgery, Warszawa, Poland",,"https://ClinicalTrials.gov/show/NCT04815954"
1152,"NCT01911143","A Retrospective, Blinded Validation of a Host-response Based Diagnostics","PATHFINDER","Completed","No Results Available","Fever|Respiratory Tract Infections|Urinary Tract Infections|Gastroenteritis|Arthritis, Infectious",,"The sensitivity and specificity of the assay in differentiating between bacterial and viral etiology of patients with an acute febrile disease|The sensitivity and specificity of the assay in differentiating between infectious and non-infectious disease etiology.","MeMed Diagnostics Ltd.|Bnai Zion Medical Center|University Hospital, Geneva","All","1 Month to 18 Years   (Child, Adult)",,"600","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","MM-1002-BV","September 2013","August 2015","August 2015","July 30, 2013",,"March 8, 2016","Hillel Yaffe Medical Center, Hadera, Israel|Bnai Zion Medical Center, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT01911143"
1153,"NCT00074386","Kidney and Liver Transplantation in People With HIV",,"Completed","No Results Available","HIV Infections|Kidney Disease|Liver Disease",,"Subject survival|graft survival|Opportunistic complications|CD4+ T cell counts and HIV-1 RNA levels|viral markers and host-response (CFC and ELISPOT) to viral co-pathogens, including HBV, HCV,CMV, EBV, HHV-6, HHV-8, and HPV|rejection rates and markers of alloresponse|pharmacokinetic interactions between immunosuppressive agents and antiretrovirals","University of California, San Francisco|National Institute of Allergy and Infectious Diseases (NIAID)","All","1 Year and older   (Child, Adult, Older Adult)",,"275","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","1U01AI052748","October 2003","August 2013","August 2013","December 15, 2003",,"January 17, 2014","Cedar-Sinai Hospital, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Georgetown University, Washington, District of Columbia, United States|Washington Hospital Center, Washington, District of Columbia, United States|University of Miami, Jackson Memorial Medical Center, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Beth Israel Deaconess, Boston, Massachusetts, United States|Mt. Sinai Medical Center, New York, New York, United States|Columbia Presbyterian Hospital, New York, New York, United States|The University Hospital, Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Thomas E. Starzl Institute, Pittsburgh, Pennsylvania, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00074386"
1154,"NCT01525498","Foley Catheterization Following Sacrocolpopexy",,"Withdrawn","No Results Available","Pelvic Organ Prolapse|Catheter Infection|Urinary Retention",,"Urinary retention following catheter removal|need for repeat catheterization|Presence of bacteriuria at catheter removal","University of Oklahoma","Female","21 Years and older   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Foley","August 2011","April 2013","April 2013","February 3, 2012",,"October 16, 2013","University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT01525498"
1155,"NCT04278326","Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments","ORGANOIDES","Recruiting","No Results Available","HPV Infection|Vaginal Cancer|Cervical Dysplasia|Cervical Cancer","Procedure: Vaginal Biopsy","To develop a 3D vaginal organoid culture model.|Inhibition of HPV molecular therapeutics using oligonucleotide, and siRNA (small interfering RNA)","Centre Hospitalier Régional d'Orléans|CNRS - Pr Chantal PICHON","Female","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CHRO-2019-08","March 6, 2020","April 2024","April 2024","February 20, 2020",,"May 6, 2023","CHR Orléans, Orléans, France",,"https://ClinicalTrials.gov/show/NCT04278326"
1156,"NCT03820752","Vaccination Coverage and Level of Protection in Patients at Risk",,"Completed","No Results Available","Diabetes|Chronic Kidney Disease|Allergy|Cystic Fibrosis|Heart Disease",,"Proportion of pediatric chronically ill patients correctly vaccinated with the hexavalent (DTaP-IPV-Hib-HBV), pneumococcal, rotavirus, MMR and MenC vaccine according to the Belgian recommended vaccination schedule.|Proportion of adult chronically ill patients correctly vaccinated diphtheria, tetanus, pneumococci, hepatitis B and influenza according to Belgian recommended vaccination schedule|Proportion of pediatric patients with antibodies against measles, mumps, rubella, diphtheria, tetanus and pertussis in children included in the study and who provided a blood sample|Proportion of adult patients with antibodies against diphtheria, tetanus and pertussis.","Universitaire Ziekenhuizen KU Leuven","All","2 Years to 85 Years   (Child, Adult, Older Adult)",,"2179","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","UZVACC","October 2014","June 2017","August 30, 2020","January 29, 2019",,"October 23, 2020","UZ Leuven, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT03820752"
1157,"NCT00303823","Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia",,"Completed","Has Results","Cervical Cancer|Cervical Intraepithelial Neoplasia Grade 1|Human Papilloma Virus Infection","Drug: placebo|Dietary Supplement: defined green tea catechin extract|Other: laboratory biomarker analysis","Complete Response - Clearance of Oncogenic Human Papillomavirus (HPV) and Complete Colposcopic, Histologic and Cytologic Clearance of Disease|Partial Response - Clearance of Oncogenic HPV With Evidence of Low Grade Cervical Intraepithelial Neoplasia|No Response - Persistent Oncogenic HPV Positivity, With or Without Evidence of Low Grade Cervical Intraepithelial Neoplasia|Progression - Persistent Oncogenic HPV Positivity, With Evidence of Progression to Worsening Cervical Intraepithelial Neoplasia or Invasive Cancer","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Phase 2","98","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","NCI-2009-00893|CDR0000458081|HSC 05-40|05-0144-01|UAZ03-1-02|P30CA023074|N01CN35158","September 2005","November 2010","February 2011","March 17, 2006","August 17, 2012","May 5, 2015","Arizona Cancer Center - Tucson, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00303823"
1158,"NCT03834571","Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women",,"Withdrawn","No Results Available","Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|FIGO Stage IIB Cervix Carcinoma|FIGO Stage III Cervix Carcinoma|FIGO Stage IVA Cervix Carcinoma|HIV Infection","Drug: Carboplatin|Drug: Cisplatin|Drug: Paclitaxel|Procedure: Patient Monitoring|Radiation: Radiation Therapy","Progression-free survival (PFS) evaluated using Response Evaluation Criteria in Solid Tumors 1.1|Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0|Progression free survival by stage|Treatment effect on participants HIV disease status by assessing CD4 counts|Treatment effect on HIV disease status by assessing HIV viral load|Cervical cancer recurrence patterns|Overall survival (OS)|Progression free survival (PFS) in women not meeting criteria for randomization by stage","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC|University of Stellenbosch|University of Arkansas","Female","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMC-102|NCI-2018-01903|UM1CA121947","May 31, 2022","January 2025","January 2025","February 8, 2019",,"June 21, 2022","Stellenbosch University, Cape Town, South Africa|University of Witwatersrand, Johannesburg, South Africa|Parirenyatwa Hospital, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT03834571"
1159,"NCT00054041","Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia",,"Completed","No Results Available","Cervical Cancer|Cervical Intraepithelial Neoplasia Grade 3|Human Papilloma Virus Infection","Biological: HspE7|Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis","Complete histologic regression of all CIN 3 lesions|Frequency and severity of adverse events assessed by Common Toxicity Criteria (CTC) version 2.0","National Cancer Institute (NCI)","Female","17 Years and older   (Child, Adult, Older Adult)","Phase 2","84","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02513|GOG-0197|U10CA027469|CDR0000269709","June 2004","January 2007",,"February 6, 2003",,"January 24, 2013","Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00054041"
1160,"NCT00337818","Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women",,"Completed","Has Results","Papillomavirus Type 16/18 Infection|Cervical Intraepithelial Neoplasia","Biological: Cervarix™","Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies|Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies in Cervical Samples|Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies in Blood Samples|Number of Subjects Reporting Pregnancies, New Onset Chronic Diseases (NOCDs) and Other Medically Significant Conditions (MSCs)|Number of Subjects Reporting SAEs","GlaxoSmithKline","Female","10 Years to 25 Years   (Child, Adult)","Phase 3","770","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","107476 (M18)|107477|107479|107481","June 2006","June 2006","January 2009","June 16, 2006","March 2, 2010","May 30, 2017","GSK Investigational Site, Tallinn, Estonia",,"https://ClinicalTrials.gov/show/NCT00337818"
1161,"NCT02142075","Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure","DAPTOREA","Completed","No Results Available","Renal Failure|Critical Care|Gram Positive Bacteria","Drug: Daptomycin","area under the curve / minimum inhibitory concentration ratio of distribution and elimination of daptomycin in plasma and urine|Cmin and Cmax of distribution and elimination of daptomycin in plasma and urine|volume of distribution of daptomycin in plasma and urine|clearance of distribution and elimination of daptomycin in plasma and urine|the clinical and microbiological efficacy during Daptomycine treatment and two weeks after the end of it|renal and muscular tolerance during Daptomycin treatment and two weeks after the end of it","Poitiers University Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3",,"Other","Interventional",,"DAPTOREA","March 2014","September 2015",,"May 20, 2014",,"October 11, 2016","Lasocki S, University Hospital of Angers, Angers, France|Asehnoune K, University Hospital of Nantes, Nantes, France|Seguin P, University Hospital of Rennes, Rennes, France|Ferrandiere M, University Hospital of Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT02142075"
1162,"NCT04307069","Management of Prelabor Rupture of the Membranes at Term",,"Recruiting","No Results Available","Fetal Infection|Chorioamnionitis|Endometritis|Cesarean Section Complications","Drug: Oxytocin","Maternal infectious morbidity|Length of latent and active phases of labor.|Adverse maternal outcome|Adverse neonatal outcome","Rambam Health Care Campus","Female","18 Years to 45 Years   (Adult)","Not Applicable","524","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Rambam Health-Care Center","May 1, 2020","May 1, 2024","May 1, 2024","March 13, 2020",,"April 12, 2024","Rambam, Ramat Yishai, Israel",,"https://ClinicalTrials.gov/show/NCT04307069"
1163,"NCT00192738","Does Telephone Follow-up Improve Patients Satisfaction",,"Completed","No Results Available","Congestive Heart Failure|Angina Pectoris|Pneumonia|Urinary Tract Infection",,,"Rambam Health Care Campus","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Defined Population|Time Perspective: Prospective","ZSA1677CTIL","April 2003",,"January 2006","September 19, 2005",,"April 11, 2007","Rambam Medical Center, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT00192738"
1164,"NCT00214045","Rigid Versus Flexible Cystoscopy in Women",,"Completed","Has Results","Hematuria|Urination Disorders|Voiding Dysfunction|Recurrent Urinary Tract Infection","Device: Flexible Cystoscopy|Device: Rigid Cystoscopy","Visual Analog Scale for Pain","University of Wisconsin, Madison","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","H-2004-0254","July 2004","June 2009","June 2009","September 21, 2005","April 30, 2019","May 15, 2019","University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00214045"
1165,"NCT02787486","Expanded Noninvasive Genomic Medical Assessment: The Enigma Study",,"Completed","No Results Available","Down Syndrome|Edwards Syndrome|Patau Syndrome|Klinefelter Syndrome|Turner Syndrome|DiGeorge Syndrome|Chromosome Deletion|Aneuploidy","Other: Blood sampling for Laboratory Developed Test (LDT) analysis","Point estimates and 95% CIs for sensitivity, specificity, PPV, and NPV versus birth outcome (trisomy or Unaffected/non-trisomy) for the LDT in the population of pregnancies at mixed-risk for chromosomal abnormalities|To estimate the false positive rate of the LDT versus birth outcome (trisomy or Unaffected/ non-trisomy) in a low-risk sub-population of pregnant women undergoing serum biochemical screening for fetal aneuploidy.","Progenity, Inc.","Female","18 Years to 54 Years   (Adult)",,"760","Industry","Observational","Observational Model: Family-Based|Time Perspective: Prospective","PRO-102-ENIGMA","October 2015","September 2018","September 2018","June 1, 2016",,"August 21, 2019","Valley Perinatal, Scottsdale, Arizona, United States|Heinen Obstectrics & Gynecology, Eunice, Louisiana, United States|Newlife Wellness OBGYN, Brooklyn, New York, United States|Lakeshore Women's Specialists, Mooresville, North Carolina, United States|Cincinnati Obgyn, Cincinnati, Ohio, United States|James D. Kasten, M.D., Inc., Norwalk, Ohio, United States|Regional Obstetrical Consultants, Chattanooga, Tennessee, United States|Texas Maternal-Fetal Medicine, Webster, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02787486"
1166,"NCT02329808","Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics","PROTECT","Completed","No Results Available","Hematologic Diseases|Oncology Problem|Kidney Diseases|Transplantation Infection","Procedure: blood drawing","drug concentration|Questionnaire|costs|Area under the curve","Radboud University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development","All","2 Years to 18 Years   (Child, Adult)",,"93","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UMCN-AKF 14.02","June 2015","December 3, 2021","December 3, 2021","January 1, 2015",,"May 10, 2022","Radboud University Medical Center, Nijmegen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT02329808"
1167,"NCT05085353","Fetal Outcomes Among Pregnant Emergency General Surgery Patients",,"Enrolling by invitation","No Results Available","Pregnancy Complications|Acute Appendicitis|Acute Cholecystitis|Biliary Pancreatitis|Bowel Obstruction|Acute Diverticulitis","Procedure: non-obstetric acute general surgical disease","past medical history/comorbidities|prenatal care prior to surgery|medical care within one year of conception|disease process","Methodist Health System","Female","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","076.TRA.2019.D","February 25, 2020","February 25, 2025","February 25, 2025","October 20, 2021",,"March 27, 2024","Trauma Center at Methodist Dallas Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05085353"
1168,"NCT00695734","Detection of Latent Tuberculosis in Hemodialysis Patients",,"Completed","No Results Available","Chronic Renal Failure",,"Relative performance of tuberculin skin test and interferon gamma release assays for detecting latent tuberculosis infection|Agreement between tuberculin skin test and interferon gamma release assays as well as agreement between interferon gamma release assays","University Hospital, Geneva|Ligue Pulmonaire Genevoise","All","18 Years and older   (Adult, Older Adult)",,"62","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","JJanssens 4","January 2007","January 2008","January 2008","June 12, 2008",,"June 12, 2008","Geneva University Hospital, Geneva, Geneva 14, Switzerland",,"https://ClinicalTrials.gov/show/NCT00695734"
1169,"NCT05774561","Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring",,"Recruiting","No Results Available","Cervical Cancer|Cervical Dysplasia|Oropharyngeal Cancer|Human Papillomavirus Infection","Diagnostic Test: Arm A - Diagnostic test: HPV detection in liquid biopsies|Diagnostic Test: Arm B - Diagnostic test: HPV detection in liquid biopsies","Dynamics of HPV infection in cervical cancer patients during 4-year follow-up.|Dynamics of HPV infection in oropharyngeal cancer patients during 4-year follow-up.|Dynamics of circulating tumor (ct) HPV DNA in oropharyngeal cancer patients.|Dynamics of circulating tumor (ct) HPV DNA in cervical cancer patients|Analysis of the mutational landscape of oropharyngeal cancer cases.|Analysis of the mutational landscape of cervical cancer cases.","The Institute of Molecular and Translational Medicine, Czech Republic|Cancer Research Czech Republic|University Hospital Olomouc","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","480","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NU-23-03-00255","June 1, 2022","May 31, 2026","December 1, 2026","March 17, 2023",,"March 17, 2023","University Hospital Olomouc, Olomouc, Czechia",,"https://ClinicalTrials.gov/show/NCT05774561"
1170,"NCT03786497","Protecting Brains and Saving Futures - the PBSF Protocol","PBSF","Unknown status","No Results Available","Brain Injuries|Congenital Heart Disease|Newborn Morbidity|Intraventricular Hemorrhage|CNS Infection|Neonatal Seizure|Nosocomial Infection|Hypoxic-Ischemic Encephalopathy|Extreme Prematurity|Brain Malformation|Congenital Infection|Neonatal Stroke|Hemodynamic Instability|Extracorporeal Membrane Oxygenation Complication|Inborn Errors of Metabolism|Respiratory Complication|Neonatal Death",,"Applicability of telemedicine model for monitored infants|Applicability of telemedicine model for recorded remote monitoring|Use of aEEG/EEG monitoring|Duration of aEEG/EEG monitoring|Number primary neurologic or medical patients with aEEG or EEG monitoring and the duration of the monitoring (hours)|Number of primary neurologic or medical patients with NIRS monitoring and the duration of the NIRS monitoring (hours)|Number of primary neurologic or medical patients with brain MRI, neurology consult, and neurosurgery consult.|Number of clinical case discussions and videoconference meetings|Length of hospital stay|Number of electroencephalographic seizures during hospitalization|Use and types of anticonvulsants administered|Number and types of anticonvulsants prescribed at discharge|Use and types of inotropes administered during NICU stay|Use and types of fluid resuscitation administered during NICU stay|Death before hospital discharge|Number of patients referred to neurology or neurosurgery|Number of patients referred to high-risk infant follow-up|Number of remote communications between CSI and local team|Number of reports issued for aEEG / EEG exams with or without the use of NIRS|Number of patients who performed Therapeutic Hypothermia|Association of pathological brain monitoring findings (aEEG/EEG and NIRS) and alterations in imaging exams including brain magnetic resonance imaging (brain MRI) and cranial ultrasonography (cranial US) performed during hospitalization|Association of pathological brain monitoring findings with morbi-mortality and length of hospital stay|Adverse effects of therapeutic hypothermia measured by cardiac arrhythmia, thrombocytopenia and coagulation disorders in general, skin lesion and pulmonary hypertension|Adverse effects of brain monitoring expressed by skin lesion due to electrode / sensor positioning|Association of pathological brain monitoring findings with evaluation of neurodevelopment by application of the Bayley test between 18 and 24 months of life","Protecting Brains Saving Futures","All","up to 3 Months   (Child)",,"2268","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PBSF_2020","January 1, 2021","December 31, 2023","December 31, 2023","December 26, 2018",,"November 16, 2020","Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil|Protecting Brains and Saving Futures - PBSF, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03786497"
1171,"NCT05666778","Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs","POWWERHealth","Recruiting","No Results Available","Bacterial Vaginosis|Vaginal Microbiome|Chlamydia Trachomatis Infection|Neisseria Gonorrheae Infection|Trichomonas Vaginitis","Device: Menstrual Cup","Evaluate the impact of menstrual cups on BV|Evaluate the impact of menstrual cups on STI|Evaluate the impact of menstrual cups on vaginal microbiome (VMB)","Rush University Medical Center|Nyanza Reproductive Health Society|Liverpool School of Tropical Medicine|University of Illinois at Chicago|National Institute of Allergy and Infectious Diseases (NIAID)","Female","15 Years to 35 Years   (Child, Adult)","Phase 2","402","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","22040505|R01AI170564","February 13, 2023","December 1, 2025","July 31, 2027","December 28, 2022",,"May 1, 2023","Rush University Medical Center, Chicago, Illinois, United States|Nyanza Reproductive Health Society, Kisumu, Nyanza, Kenya",,"https://ClinicalTrials.gov/show/NCT05666778"
1172,"NCT02860845","Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections","DOBO","Completed","Has Results","Candidiasis|Vaginosis, Bacterial","Device: Boric acid and probiotics|Drug: Antibiotic (Clindamycin)|Drug: Antifungal (Clotrimazole)","Change in the Presence of Vaginitis Clinical Symptoms Determined by Sobel Score.|Change in the Level of Lactobacillus in Vaginal Flora Determined by Vaginal Cultures.|Number of Participants With Recurrent Infections","Laboratorios Ordesa|Clever Instruments S.L.","Female","18 Years and older   (Adult, Older Adult)","Phase 4","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DOBO-01-16","July 12, 2016","October 16, 2017","November 30, 2017","August 9, 2016","November 4, 2019","November 19, 2019","Ginemed Sevilla, Sevilla, Andalucía, Spain","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/45/NCT02860845/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02860845"
1173,"NCT06101563","Duration Between Drainage and Ureteroscopic Lithotripsy",,"Recruiting","No Results Available","Ureter Stone|Renal Stone|Ureteric Obstruction","Procedure: Early ureteroscopy|Procedure: Delayed Ureteroscopy","Post-ureteroscopy Urosepsis.","Mansoura University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2371","May 1, 2023","June 1, 2024","October 1, 2024","October 26, 2023",,"October 26, 2023","Urology and Nephrology Center, Mansoura, Egypt",,"https://ClinicalTrials.gov/show/NCT06101563"
1174,"NCT00173485","The Study of Infection and Cell Inflammation in Peritoneal Dialysate",,"Unknown status","No Results Available","Peritonitis|Kidney Failure",,,"National Taiwan University Hospital","All","18 Years to 80 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Defined Population|Time Perspective: Other","9461700636","June 2005",,"June 2009","September 15, 2005",,"November 24, 2005","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00173485"
1175,"NCT00616330","Vaginal Infection Study",,"Completed","No Results Available","Vulvovaginitis|Vaginitis","Drug: clindamycin phosphate/butoconazole nitrate|Drug: clindamycin phosphate|Drug: butoconazole nitrate","Clinical symptom resolution.|Yeast Culture for Candida|Gram stain Nugent score|Saline wet mount for clue cells","Lumara Health, Inc.","Female","16 Years and older   (Child, Adult, Older Adult)","Phase 3","1443","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CBC-302-602-622467","January 2008","December 2009","December 2009","February 15, 2008",,"March 5, 2012","Clinical Research Consultants, Inc, Birmingham, Alabama, United States|Jefferson Clinic, PC, Birmingham, Alabama, United States|Choice Research, LLC, Enterprise, Alabama, United States|Star W. Research, Chandler, Arizona, United States|Precision Trials, LLC/Desert West OB/GYN, Glendale, Arizona, United States|Women's Health Research, Phoenix, Arizona, United States|Precision Trials LLC, Phoenix, Arizona, United States|Visions Clinical Research - Tucson, Tucson, Arizona, United States|NEA Women's Clinic, Jonesboro, Arkansas, United States|Arkansas Primary Care Clinic, PA, Little Rock, Arkansas, United States|The Woman's Clinic, P.A., Little Rock, Arkansas, United States|Precision Clinical Research, Searcy, Arkansas, United States|Med Center, Carmichael, California, United States|Universal Biopharma Research Institute, Inc./Alta Family Health Clinic, Inc., Dinuba, California, United States|Sierra Medical Research, Fresno, California, United States|Grossmont Center for Clinical Research, La Mesa, California, United States|San Diego Clinical Research Center, San Diego, California, United States|Lynn Institute of the Rockies, Colorado Springs, Colorado, United States|Red Rocks OB/GYN, Lakewood, Colorado, United States|Lynn Institute of Pueblo, Pueblo, Colorado, United States|Women's Health Care Associates, PC, Hartford, Connecticut, United States|Greater Hartford Womens Association/Women's Health, West Hartford, Connecticut, United States|Women's Medical Research Group, LLC, Clearwater, Florida, United States|Segal Institute for Clinical Research, North Miami, Florida, United States|Physician Care Clinical Research, Sarasota, Florida, United States|Insignia Clinical Research, Tampa, Florida, United States|Comprehensive Clinical Trials, LLC, West Palm Beach, Florida, United States|Atlanta Medical Research Institute, Alpharetta, Georgia, United States|AMR Research Associates, Bogart, Georgia, United States|Medical Network for Educators and Research, Decatur, Georgia, United States|Soapstone Center for Clinical Research, Decatur, Georgia, United States|Atlanta West Women's Center, Douglasville, Georgia, United States|The Woman's Clinic, Boise, Idaho, United States|Rosemark Women Care Specialists, Idaho Falls, Idaho, United States|Womans Health Practice, LLC, Champaign, Illinois, United States|Northern Indiana Womens Health Research, South Bend, Indiana, United States|Clinical Trials Management, Mandeville, Louisiana, United States|Regional Research Specialists, LLC, Shreveport, Louisiana, United States|New England Center for Clinical Research, Inc., Fall River, Massachusetts, United States|Activmed Practices & Research, Inc., Haverhill, Massachusetts, United States|Healthcare for Women, New Bedford, Massachusetts, United States|Female Pelvic Medicine and Urogynecology Institute of Michigan, Grand Rapids, Michigan, United States|Women's Health Care Specialists, PC, Paw Paw, Michigan, United States|Women's Health Partner, St. Louis, Missouri, United States|Consultants in Women's Healthcare, St. Louis, Missouri, United States|New Ballas OB-GYN, Inc., St. Louis, Missouri, United States|The Medical Group of Northern Nevada, Reno, Nevada, United States|Suffolk Ob/Gyn, Port Jefferson, New York, United States|Preferred OB/GYN/ Women's Health, Woodbury, New York, United States|Eastowne OB-GYN and Infertility, Chapel Hill, North Carolina, United States|Eastern Carolina Women's Center, New Bern, North Carolina, United States|Hawthorne Medical Research, Inc., Winston-Salem, North Carolina, United States|Valaores & Lewis Obstetrics & Gynocology, Winston-Salem, North Carolina, United States|Mid Dakota Clinic Center for Women, Bismark, North Dakota, United States|Complete Healthcare for Women, Columbus, Ohio, United States|HWC Women's Research Center, Englewood, Ohio, United States|Holzer Clinic, Gallipolis, Ohio, United States|Pacific Women's Center, LLC, Eugene, Oregon, United States|Medford Women's Clinic, LLP, Medford, Oregon, United States|Laurel Highlands Ob/Gyn, PC, Hopwood, Pennsylvania, United States|Clinical Trials Research Services, LLC, Natrona Heights, Pennsylvania, United States|Associates Ob/Gyn, Germantown, Tennessee, United States|Women's Care Center, PLC, Memphis, Tennessee, United States|Women Partners in Health, Austin, Texas, United States|Advanced Research Associates, Corpus Christi, Texas, United States|Research Across America, El Paso, Texas, United States|Planned Parenthood of Houston, Houston, Texas, United States|The Woman's Hospital of Texas Clinical Research Center, Houston, Texas, United States|TMC Life Research, Inc, Houston, Texas, United States|Bexar Clinical Trials, LLC, Irving, Texas, United States|Willowbend Health and Wellness, Plano, Texas, United States|InVisions Consultants, LLC c/o Northeast Ob/Gyn, San Antonio, Texas, United States|King's Daughter Clinic, Temple, Texas, United States|Tanner Clinic, Layton, Utah, United States|Mt. Timpangos Women's Healthcare, Pleasant Grove, Utah, United States|Salt Lake Research, Salt Lake City, Utah, United States|Salt Lake Women's Center, Sandy, Utah, United States|Tidewater Clinical Research, Inc, Virginia Beach, Virginia, United States|Walla Walla Clinic, Walla Walla, Washington, United States|Hyperion Clinical Research, LLC, Charleston, West Virginia, United States|Aurora Advanced Healthcare, Inc, Milwaukee, Wisconsin, United States|Institute of Kidney Disease and Research Centre, Ahmedabad, Gujarat, India|Krishna Hospital Surgical & Maternity 201/2/3 Suryadeep Complex, Vadodara, Gujarat, India|Father Muller Medical College Hospital, Mangalore, Kamataka, India|Neha Prakash Hospital, Bangalore, Karnataka, India|KMC Hospital, Mangalore, Karnataka, India|Yenepoya Medical College and Hospital, Mangalore, Karnataka, India|Om Women's Hospital, Nagpur, Maharashtra, India|Avanti Institute of Cardiology, Nagpur, Maharashtra, India|Nagpur Test Tube Baby Centre, Nagpur, Maharashtra, India|VSG Healthcare, Dr. Ganorkar Hospital, Nashik, Maharashtra, India|Nivedita Hospital, Nashik, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India|KEM Hospital Research Centre, Pune, Maharashtra, India|Dr. D. Y. Patil Medical College & Hospital, Pune, Maharashtra, India|Sri Ramachandra Medical College, Chennai, Tamil Nadu, India|Chopra Nursing and Maternity Home, Agra, India|Yashoda Super Speciality Hospital, Ghaziabad, India|Government Maternity Hospital, Hyderabad, India|Government Maternity Hospital, Hyderabad, India|Makker Medical Center, Lucknow, India|M.K.W. Hospital and Research Centre, New Delhi, India|Sri Ramachandra Medical College, Tamil Nadu, India|Ponce School of Medicine, Ponce, Puerto Rico|Dermatovenerologic Dispensary, Korolev, Moscow Region, Russian Federation|D.O. Ott Research Institute of Ob/Gyn--Family Planning and Female Health Center, Mendeleevskaya line, Saint Petersburg, Russian Federation|D.O. Ott Research Institute of Ob/Gyn--Gynecologic Endocrinology, Mendeleyevskaya, Saint Petersburg, Russian Federation|Orkli, LLC, V.o., Saint Petersburg, Russian Federation|Smolensk State Medical Academy of Roszdrav, Smolensk, Smolensk Region, Russian Federation|Kaluga Regional Dermatovenerologic Dispensary, Kaluga, Russian Federation|Moscow Regional Research Insitute of Obstetrics and Gynecology, Moscow, Russian Federation|Dermatovenerologic Dispensary #15, Moscow, Russian Federation|Family Planning and Reproductive Centre, Moscow, Russian Federation|The Peoples' Friendship University of Russia, Moscow, Russian Federation|City Clinical Hospital #52, Moscow, Russian Federation|City Clinical Hospital #31, Moscow, Russian Federation|Clinic of Skin and Sexual Transmitted Diseases, Moscow, Russian Federation|City Clinical Hospital #51, Moscow, Russian Federation|Nizhegorodskiy Dermatovenerologic Scientific Research Institute of Federal Agency for Public Health and Human Services, Nizhny Novgorod, Russian Federation|Regional Dermatovenerologic Dispensary, Rostov-on-Don, Russian Federation|Ryazan Regional Clinical Dermatovenerologic Dispensary, Ryazan, Russian Federation|Juventa--Reproductive Health, Saint Petersburg, Russian Federation|442 District Military Clinical Hospital of Leningradsky Military District, Saint Petersburg, Russian Federation|City Dermatovenerologic Dispensary, Saint Petersburg, Russian Federation|S.M. Kirov Military Medical Academy, MoD of the Russian Federation, Saint Petersburg, Russian Federation|L.G. Sokolov Clinical Hospital #122 of the Federal Medical-Biologic Agency--#321, Saint Petersburg, Russian Federation|L.G. Sokolov Clinical Hospital #122 of the Federal Medical-Biologic Agency--#322, Saint Petersburg, Russian Federation|Leningradskiy Regional Clinical Hospital, Saint Petersburg, Russian Federation|Family Planning and Reproductive Centre, Saint Petersburg, Russian Federation|St. Petersburg State I.I. Mechnikov Medical Academy of Roszdrav, Saint Petersburg, Russian Federation|Andros Clinic, LLC, Saint Petersburg, Russian Federation|Smolensk Dermatovenerologic Dispensary, Smolensk, Russian Federation|Medical Mycology Scientific Research Institute at St. Petersburg Medical Academy of Postgraduate Studies of Roszdrav, St. Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00616330"
1176,"NCT01661985","Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced",,"Unknown status","No Results Available","Urethritis|Cervicitis|Genital Mycoplasma Infection|Chlamydia Trachomatis","Drug: Azithromycin|Drug: Doxycycline|Drug: lymecycline","Time from treatment starts to date of first negative test result is achieved up to 30 days.|Number of patients with emerging or existing macrolide resistance against Mycoplasma genitalium during or after treatment with azithromycin","Ostergotland County Council, Sweden|Statens Serum Institut","All","18 Years and older   (Adult, Older Adult)","Phase 4","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ostergotland CC","February 2010","August 2015","September 2016","August 10, 2012",,"December 15, 2014","R&D dept of Local Health Care, Östergötland county council, Linköping, Sweden",,"https://ClinicalTrials.gov/show/NCT01661985"
1177,"NCT02682355","Optimizing Clinical Use of Polymyxin B",,"Completed","No Results Available","Pneumonia|Blood Stream Infection|Urinary Tract Infections|Respiratory Tract Infection (Including Tracheobronchitis)|Sepsis",,"Polymyxin B plasma concentrations|Changes in serum creatinine|Clinical response based on resolution of signs and symptoms of infection|Microbiologic response based on eradication of pathogens from blood and respiratory cultures","Rutgers, The State University of New Jersey","All","18 Years and older   (Adult, Older Adult)",,"155","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","R01AI119446-01","February 2016","May 31, 2022","August 3, 2022","February 15, 2016",,"November 21, 2023","Northwestern University, Chicago, Illinois, United States|Columbia University Medical Center, New York, New York, United States|New York Presbyterian-Weill Cornell Medical Center, New York, New York, United States|Hospital Sao Lucas da - PUC / RS, Porto Alegre, Brazil|Hospital Moinhos de Vento, Porto Alegre, Brazil|Singapore General Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02682355"
1178,"NCT01915251","Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women",,"Terminated","No Results Available","Microbiome|Antibiotic-Induced VVC|Vaginal Candidiasis",,"Microbiomic profile|Immunologic profile","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","Female","18 Years to 40 Years   (Adult)",,"13","NIH","Observational","Time Perspective: Prospective","130181|13-I-0181","July 30, 2013","August 15, 2019","September 10, 2019","August 2, 2013",,"September 12, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01915251"
1179,"NCT05826873","Discharge Stewardship in Children's Hospitals","DISCO","Enrolling by invitation","No Results Available","Pneumonia, Bacterial|Pneumonia Childhood|Urinary Tract Infections|Soft Tissue Infections|Skin Infections|Community-acquired Pneumonia","Behavioral: Discharge antibiotic stewardship intervention","Rate of suboptimal prescribing|Impact of the discharge stewardship intervention on post-discharge treatment failure|Impact of the discharge stewardship intervention on adverse drug events","Children's Hospital of Philadelphia|Seattle Children's Hospital|Primary Children's Hospital|St. Louis Children's Hospital|University of Pennsylvania|Agency for Healthcare Research and Quality (AHRQ)","All","28 Days to 18 Years   (Child, Adult)","Not Applicable","5720","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","20-017269|R01HS027428-01","June 10, 2020","January 2025","July 2025","April 24, 2023",,"May 11, 2023","St. Louis Children's Hospital, Saint Louis, Missouri, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States","""Informed Consent Form: Patient Consent"", https://classic.clinicaltrials.gov/ProvidedDocs/73/NCT05826873/ICF_000.pdf|""Informed Consent Form: Clinician Verbal Consent"", https://classic.clinicaltrials.gov/ProvidedDocs/73/NCT05826873/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT05826873"
1180,"NCT05580341","Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9",,"Active, not recruiting","No Results Available","Cervical Cancer|Genital Wart|CIN|VIN|Papillomavirus Infections","Biological: Zerun HPV-9|Biological: GARDASIL ®9","Geometric Mean Titers (GMT) of HPV neutralizing antibodies|Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58|Percentage of subjects reporting solicited local symptoms|Percentage of subjects reporting solicited general symptoms|Percentage of subjects reporting unsolicited adverse events (AEs)|Percentage of subjects reporting serious adverse events (SAEs)","Shanghai Zerun Biotechnology Co.,Ltd|Walvax Biotechnology Co., Ltd.","Female","16 Years to 26 Years   (Child, Adult)","Phase 3","1200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","312-HPV-2002","September 1, 2022","June 2023","December 2023","October 14, 2022",,"October 28, 2022","GuangXi Center for Diseases Control and Prevention, Nanning, Guangxi, China",,"https://ClinicalTrials.gov/show/NCT05580341"
1181,"NCT03083366","Sacral Nerve Stimulation in Improving Bladder Function After Acute Traumatic Spinal Cord Injury",,"Terminated","No Results Available","Spinal Cord Injury, Acute|Neurogenic Bladder|Incontinence|Urinary Tract Infections","Device: PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)","Urodynamic determined maximum cystometric capacity|Quality of Life differences measured by mean SCI-QoL|Number of urinary tract infections per year|Urodynamics determined maximum cystometric capacity|Urodynamics determined bladder compliance|Presence of detrusor overactivity during urodynamics|Urodynamics determined volume at first detrusor contraction|Urodynamics determined detrusor pressure at first detrusor contraction|Number of daily catheterizations|Average catheterization volume|Urinary incontinence episodes per day|24 hour pad weight test|Development of hydronephrosis|Need for anticholinergic medication|Need for onabotulinum toxin A injection|Need for device revision|Need for device explanation|Hospitalizations|Urologic related surgeries|Death","University of Utah|Rancho Research Institute, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","96153","August 7, 2019","April 20, 2023","April 20, 2023","March 20, 2017",,"July 17, 2023","Rancho Los Amigos National Rehabilitation Center, Downey, California, United States|University of Utah, Salt Lake City, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/66/NCT03083366/Prot_SAP_001.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/66/NCT03083366/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03083366"
1182,"NCT01691430","A Trial of Cranberry Capsules for Urinary Tract Infection Prevention in Nursing Home Residents",,"Completed","Has Results","Bacteriuria","Dietary Supplement: 2 cranberry capsules|Dietary Supplement: Placebo","Participants With Urine Cultures With Bacteriuria (>100,000 Cfu/ml or >=100,000 Cfu/ml) Plus Pyuria (Any WBC)|Number of Episodes of Symptomatic UTI|Number of Hospitalizations|Number of Deaths|Number of Antibiotic Prescriptions|Bacteriuria With Multidrug-resistant Gram-negative Bacilli|Number of Antibiotic Prescriptions for Suspected UTI|Subjects With 1, 2, or 3 Episodes of UTIs","Yale University|National Institute on Aging (NIA)","Female","65 Years and older   (Older Adult)","Phase 3","185","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1112009472|2P30AG021342-11|1R01AG041153-01A1","August 2012","October 2015","October 2015","September 24, 2012","January 29, 2018","March 6, 2020","Branford Hills Health Care, Branford, Connecticut, United States|Northbridge Health Care Center, Bridgeport, Connecticut, United States|Bridgeport Health Care Center, Bridgeport, Connecticut, United States|Bridgeport Manor, Bridgeport, Connecticut, United States|Riverside Health & Rehabilitation Center, East Hartford, Connecticut, United States|Ludlowe Health Care Center, Fairfield, Connecticut, United States|Glastonbury Health Care Center, Glastonbury, Connecticut, United States|The Nathaniel Witherell, Greenwich, Connecticut, United States|Arden House Care and Rehabilitation Center, Hamden, Connecticut, United States|Hamden Health Care Center, Hamden, Connecticut, United States|Avery Heights, Hartford, Connecticut, United States|Wadsworth Glen Health Care and Rehabilitation Center, Middletown, Connecticut, United States|Water's Edge Center for Health & Rehabilitation, Middletown, Connecticut, United States|Grimes Center, New Haven, Connecticut, United States|Mary Wade Home, New Haven, Connecticut, United States|Advanced Nursing & Rehab Center of New Haven, New Haven, Connecticut, United States|Shady Knoll Health Center, Seymour, Connecticut, United States|Lord Chamberlain Nursing & Rehabilitation Center, Stratford, Connecticut, United States|Village Green of Wallingford, Wallingford, Connecticut, United States|Abbott Terrace Health Center, Waterbury, Connecticut, United States|Hughes Health & Rehab Center, West Hartford, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01691430"
1183,"NCT00153621","Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric HIV-Infected Patients",,"Completed","No Results Available","Chronic Kidney Failure|AIDS-Associated Nephropathy|HIV Infections",,,"Children's National Research Institute","All","1 Year to 21 Years   (Child, Adult)",,"320","Other","Observational","Time Perspective: Prospective","3406|NCRR 1K12RR017613-01","September 2004",,"September 2007","September 12, 2005",,"May 5, 2008","Children's National Medical Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT00153621"
1184,"NCT03840616","Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections","ultraVIOLET","Completed","Has Results","Recurrent Vulvovaginal Candidiasis","Drug: Oteseconazole (VT-1161) 150mg capsule|Drug: Fluconazole 150mg capsule|Drug: Placebo","Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-treat (ITT) Population","Mycovia Pharmaceuticals Inc.","Female","12 Years and older   (Child, Adult, Older Adult)","Phase 3","219","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","VMT-VT-1161-CL-017","March 13, 2019","December 2, 2020","December 2, 2020","February 15, 2019","February 4, 2022","February 4, 2022","34, Tucson, Arizona, United States|39, Encino, California, United States|25, Los Angeles, California, United States|22, Englewood, Colorado, United States|49, Boca Raton, Florida, United States|14, Gainesville, Florida, United States|13, Leesburg, Florida, United States|33, Loxahatchee Groves, Florida, United States|36, Miami, Florida, United States|17, Savannah, Georgia, United States|27, Idaho Falls, Idaho, United States|10, Nampa, Idaho, United States|62, Chicago, Illinois, United States|41, Fort Wayne, Indiana, United States|30, Marrero, Louisiana, United States|50, Dearborn Heights, Michigan, United States|29, Saginaw, Michigan, United States|55, Traverse City, Michigan, United States|32, Troy, Michigan, United States|26, Kansas City, Missouri, United States|42, New Brunswick, New Jersey, United States|47, Ocean City, New Jersey, United States|37, Charlotte, North Carolina, United States|38, Fayetteville, North Carolina, United States|15, Columbus, Ohio, United States|18, Bluffton, South Carolina, United States|48, Myrtle Beach, South Carolina, United States|20, Bristol, Tennessee, United States|21, Murfreesboro, Tennessee, United States|24, Austin, Texas, United States|23, Fort Worth, Texas, United States|63, Katy, Texas, United States|58, League City, Texas, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/16/NCT03840616/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/16/NCT03840616/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03840616"
1185,"NCT04984902","Reduction of BK Viremia in Kidney Transplant Patients","CP026","Unknown status","No Results Available","Kidney Diseases|Kidney Transplant Infection|Kidney Transplant; Complications","Device: Extracorporal therapy","Change in log 10 viral load|Number of participants with leukopenia|Number of participants with increase in serum creatinine|Number of participants with inoperative hypotension|Number of participants with decreasing haemoglobin measurements","ExThera Medical Europe BV|University Hospital, Essen","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CP026","February 1, 2022","February 1, 2023","April 1, 2023","August 2, 2021",,"December 17, 2021","University Hospital Essen, Essen, Germany",,"https://ClinicalTrials.gov/show/NCT04984902"
1186,"NCT03562156","A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)","VIOLET","Completed","Has Results","Recurrent Vulvovaginal Candidiasis","Drug: Oteseconazole (VT-1161)|Drug: Placebo","Percentage of Subjects With 1 or More Culture-Verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-Treat Population","Mycovia Pharmaceuticals Inc.","Female","12 Years and older   (Child, Adult, Older Adult)","Phase 3","438","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","VMT-VT-1161-CL-011","August 16, 2018","October 19, 2020","August 6, 2021","June 19, 2018","January 13, 2022","April 6, 2022","31123, Birmingham, Alabama, United States|31108, San Diego, California, United States|31139, Lauderdale Lakes, Florida, United States|31143, Sarasota, Florida, United States|31106, Wellington, Florida, United States|31111, Norcross, Georgia, United States|31146, Covington, Louisiana, United States|31107, Metairie, Louisiana, United States|31105, Metairie, Louisiana, United States|31147, Fall River, Massachusetts, United States|31118, Las Vegas, Nevada, United States|31103, Las Vegas, Nevada, United States|31114, Lawrenceville, New Jersey, United States|31142, Port Jefferson, New York, United States|31127, West Seneca, New York, United States|31132, Greensboro, North Carolina, United States|31116, Morehead City, North Carolina, United States|31144, Raleigh, North Carolina, United States|31145, Winston-Salem, North Carolina, United States|31125, Franklin, Ohio, United States|31134, Philadelphia, Pennsylvania, United States|31120, Bristol, Tennessee, United States|31102, Houston, Texas, United States|31117, Draper, Utah, United States|31113, Richmond, Virginia, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/56/NCT03562156/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/56/NCT03562156/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03562156"
1187,"NCT03456544","Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China",,"Unknown status","No Results Available","Vancomycin|Staphylococcal Infections|Adverse Effect|Acute Kidney Injury|Cross-sectional Study","Drug: Vancomycin","Vancomycin-associated acute kidney injury(VAN-AKI) occuration rate|VAN-AKI detection rate|TDM detction rate|0h Serum creatinine detction rate|48h Serum creatinine detction rate","Peking University First Hospital","All","18 Years and older   (Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Retrospective","20180122","October 31, 2018","October 31, 2019","December 31, 2019","March 7, 2018",,"August 28, 2019","Peking University First Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03456544"
1188,"NCT04530448","Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization",,"Terminated","Has Results","COVID|Coronavirus|Coronavirus Infection|AKI|Acute Kidney Injury","Drug: Sodium bicarbonate|Other: Standard of Care","pH|Number of Days Alive Free of Stage 2-3 AKI|Stage 2-3 AKI|Vent-Free|Hospital-Free","West Virginia University","All","18 Years and older   (Adult, Older Adult)","Phase 4","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005006707","October 5, 2020","July 15, 2021","July 15, 2021","August 28, 2020","December 22, 2023","December 22, 2023","WVU Medicine Heart & Vascular Institute, Morgantown, West Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT04530448/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/48/NCT04530448/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04530448"
1189,"NCT03561701","A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)","VIOLET","Completed","Has Results","Recurrent Vulvovaginal Candidiasis","Drug: Oteseconazole (VT-1161)|Drug: Placebo","Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-treat (ITT) Population.","Mycovia Pharmaceuticals Inc.","Female","12 Years and older   (Child, Adult, Older Adult)","Phase 3","425","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","VMT-VT-1161-CL-012","August 23, 2018","October 13, 2020","August 3, 2021","June 19, 2018","December 20, 2021","December 20, 2021","31215, Phoenix, Arizona, United States|31227, Little Rock, Arkansas, United States|31217, Los Angeles, California, United States|31240, Hartford, Connecticut, United States|31204, Homestead, Florida, United States|31233, North Bay Village, Florida, United States|31255, Wichita, Kansas, United States|31245, Hagerstown, Maryland, United States|31223, Winston-Salem, North Carolina, United States|31244, Columbus, Ohio, United States|31229, Columbus, Ohio, United States|31222, Englewood, Ohio, United States|31218, Jackson, Tennessee, United States|31232, Frisco, Texas, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/01/NCT03561701/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/01/NCT03561701/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03561701"
1190,"NCT04841785","RECOVAC - Long Term Efficacy and Safety of COVID-19 (SARS-CoV-2) Vaccination in Kidney Disease Patients","LESS CoV-2","Completed","No Results Available","Covid19|SARS-CoV Infection|Chronic Kidney Diseases","Diagnostic Test: mailer-based finger-prick","The incidence of COVID-19|Incidence of mortality|Incidence of adverse events|Incidence of acute rejection or graft failure in kidney transplant recipients|Incidence of HLA antibodies measured in blood|The antibody level against the SARS-CoV-2 Receptor Binding Domain measured in blood|The antibody level against SARS-CoV-2 Receptor Binding Domain measured in blood","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)",,"4868","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NL76839.042.21","April 22, 2021","November 30, 2021","December 18, 2023","April 12, 2021",,"March 18, 2024","University Medical Center Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT04841785"
1191,"NCT02267382","A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)",,"Completed","Has Results","Recurrent Vulvovaginal Candidiasis","Drug: VT-1161|Drug: Placebo","The Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes Through Week 48 of the Study in the Intent-to-treat Population.","Viamet","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","254","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VMT-VT-1161-CL-006","February 10, 2015","November 9, 2016","November 9, 2016","October 17, 2014","October 4, 2019","October 15, 2019","University of Alabama Birmingham, Birmingham, Alabama, United States|Precision Trials, Phoenix, Arizona, United States|NEA Baptist Clinic, Jonesboro, Arkansas, United States|Axis Clinical Trials, Los Angeles, California, United States|Axis Clinical Trials, Los Angeles, California, United States|Genesis Center for Clinical Research, San Diego, California, United States|Altus Research, Lake Worth, Florida, United States|Healthcare Clinical Data, Miami, Florida, United States|Community Medical Research, North Miami, Florida, United States|Vision Clinical Research, Palm Beach, Florida, United States|Physician Care Clinical Research LLC, Sarasota, Florida, United States|Clinical Research of West Florida, Tampa, Florida, United States|Cypress Medical Research Center, Wichita, Kansas, United States|Clinical Trials Management LLC, Covington, Louisiana, United States|Clinical Trials Management LLC, Metairie, Louisiana, United States|New England Center for Clinical Research, Fall River, Massachusetts, United States|Clinical Research of Nevada, Las Vegas, Nevada, United States|R. Garn Mabey, Jr. M.D. Chartered, Las Vegas, Nevada, United States|OB/GYN Clinical Research, Lawrenceville, New Jersey, United States|Women's Health Research Center, Plainsboro, New Jersey, United States|Suffolk OB-GYN, Port Jefferson, New York, United States|United Women's Clinical Research-Raleigh, Raleigh, North Carolina, United States|Lyndhurst Clinical Research, Winston-Salem, North Carolina, United States|Radiant Research, Akron, Ohio, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Magee Women's Hospital, Pittsburgh, Pennsylvania, United States|Brownstone Clinical Trials, Fort Worth, Texas, United States|TMC Life Research, Houston, Texas, United States|Brownstone Clinical Trials, Irving, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Physician's Research Options LLC, Sandy, Utah, United States|Seattle Women's Health Research Gynecology, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02267382"
1192,"NCT01891331","A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)",,"Completed","Has Results","Candidiasis, Vulvovaginal","Drug: VT-1161|Drug: Fluconazole","Percentage of Subjects With Therapeutic Cure at 28 Days for All-Analysis Population","Viamet","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","VMT-VT-1161-CL-004","August 2013","December 2014","December 2014","July 3, 2013","July 6, 2018","August 1, 2018","Altus Research, Lake Worth, Florida, United States|Healthcare Clinical Data, Inc, North Miami, Florida, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Lyndhurst Clinical Research, Raleigh, North Carolina, United States|Lyndhurst Clinical Research, Winston-Salem, North Carolina, United States|Drexel Vaginitis Center, Philadelphia, Pennsylvania, United States|Brownstone Clinical Trials, LLC, Irving, Texas, United States|Harborview ID Research Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01891331"
1193,"NCT06075264","Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)","ART-VIN IIB","Recruiting","No Results Available","Vulvar Diseases|HPV Infection|Vulvar HSIL|Pre-Cancerous Dysplasia|HPV Disease|VIN, Usual Type|VIN 2 of Usual Type|VIN 3 of Usual Type|Vin II|Vin III|VIN Grade 2|VIN Grade 3|High Grade Intraepithelial Neoplasia","Drug: Artesunate ointment|Drug: Placebo ointment","Number of participants with complete histologic response|Number of participants who have achieved viral clearance|Number of participants who show partial response|Number of participants who have durable response|Incidence of Treatment-Emergent Adverse Events (TEAE)","Frantz Viral Therapeutics, LLC|The Cleveland Clinic","Female","18 Years and older   (Adult, Older Adult)","Phase 2","27","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ART-VIN IIB|23-889","December 6, 2023","December 2024","December 2025","October 10, 2023",,"February 21, 2024","Florida Gynecologic Oncology, Fort Myers, Florida, United States|Cleveland Clinic Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Hillcrest Hospital, Mayfield Heights, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT06075264"
1194,"NCT04976010","Single Cell Leukocyte Landscapes and Cardiovascular Risk in Children With Chronic Kidney Disease",,"Completed","No Results Available","Chronic Kidney Diseases|Cardiovascular Diseases|Microbial Colonization|Aging","Other: No intervention","Immunephenotyping of human PBMC|Microbiome sequencing of fecal samples|Targeted metabolomics of plasma samples|Pulse wave velocity|Carotid intima media thickness|Echocardiography","Charite University, Berlin, Germany","All","5 Years to 18 Years   (Child, Adult)",,"38","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EA2/162/17","July 17, 2021","November 19, 2021","November 19, 2021","July 26, 2021",,"February 8, 2022","Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT04976010"
1195,"NCT05309122","Cervical Cancer Screening Strategies",,"Recruiting","No Results Available","Cervical Cancer|Cervical Intraepithelial Neoplasia|Human Papillomavirus Infection|Cervical Cytology|Cancer Screening",,"CIN2+|Invasive procedures|Vaginal intraepithelial neoplasia (VaIN)|Vulval intraepithelial neoplasia (VIN)","Lei Li|Peking Union Medical College Hospital","Female","18 Years and older   (Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","EVUCC","March 19, 2022","March 19, 2024","March 19, 2025","April 4, 2022",,"April 4, 2022","Lei Li, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05309122"
1196,"NCT04248322","Qualitative Assessment of the Impact of TTNS on QOL and Participation",,"Recruiting","No Results Available","Neurogenic Bladder|Urinary Retention|Urinary Tract Infections|Spinal Cord Injuries","Behavioral: Semi-structured interview","Consumer user-defined themes from qualitative interviews|Follow-up calls regarding user-defined themes","Medstar Health Research Institute","All","18 Years to 75 Years   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STUDY00004862","May 31, 2022","October 2024","October 2024","January 30, 2020",,"September 6, 2023","MedStar National Rehabilitation Hospital, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT04248322"
1197,"NCT01431326","Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care","PTN_POPS","Completed","No Results Available","Adenovirus|Anesthesia|Anxiety|Anxiolysis|Autism|Autistic Disorder|Bacterial Meningitis|Bacterial Septicemia|Benzodiazepine|Bipolar Disorder|Bone and Joint Infections|Central Nervous System Infections|Convulsions|Cytomegalovirus Retinitis|Early-onset Schizophrenia Spectrum Disorders|Epilepsy|General Anesthesia|Gynecologic Infections|Herpes Simplex Virus|Infantile Hemangioma|Infection|Inflammation|Inflammatory Conditions|Intra-abdominal Infections|Lower Respiratory Tract Infections|Migraines|Pain|Pneumonia|Schizophrenia|Sedation|Seizures|Skeletal Muscle Spasms|Skin and Skin-structure Infections|Treatment-resistant Schizophrenia|Urinary Tract Infections|Withdrawal|Sepsis|Gram-negative Infection|Bradycardia|Cardiac Arrest|Cardiac Arrhythmia|Staphylococcal Infections|Nosocomial Pneumonia|Neuromuscular Blockade|Methicillin Resistant Staphylococcus Aureus|Endocarditis|Neutropenia|Headache|Fibrinolytic Bleeding|Pulmonary Arterial Hypertension|CMV Retinitis|Hypertension|Chronic Kidney Diseases|Hyperaldosteronism|Hypokalemia|Heart Failure|Hemophilia|Heavy Menstrual Bleeding|Insomnia","Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:","Composite of pharmacokinetic outcomes for understudied drugs in children|Composite pharmacodynamic outcomes of understudied drugs in children|Biomarkers associated with understudied drugs in children","Daniel Benjamin|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The Emmes Company, LLC|Duke University","All","up to 21 Years   (Child, Adult)",,"3520","Other|NIH|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00029638|IND 113645|IND 114369|IND 114531|IND 118358|HHSN20100006|HHSN27500020|HHSN27500027|HHSN27500043|HHSN27500049","November 2011","November 2019","November 2019","September 9, 2011",,"September 6, 2023","Alaska Native Medical Center, Anchorage, Alaska, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|University of California at San Diego Medical Center, La Jolla, California, United States|Axis Clinical Trials, Los Angeles, California, United States|University of California, Los Angeles Medical Center, Los Angeles, California, United States|The Children's Hospital Colorado, Aurora, Colorado, United States|Yale New Haven Children's Hospital, New Haven, Connecticut, United States|Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States|Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States|Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Children's Mercy Hospital and Clinics, Kansas City, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Tulane University Health Science Center, New Orleans, Louisiana, United States|Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|University of Montana, Missoula, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico, Health Sciences Center, Albuquerque, New Mexico, United States|UNC Hospital Neonatal-Perinatal Medicine, Chapel Hill, North Carolina, United States|Duke University Medical Center (PICU / NICU), Durham, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Akron Children's Hospital, Cleveland, Ohio, United States|Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Virginia Children's Hospital, Charlottesville, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Manitoba Institute of Child Health, Winnipeg, Manitoba, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|Hospital Sainte-Justine, Montreal, Quebec, Canada|Assaf Harofeh Medical Center, Zerifin, Tel Aviv, Israel|Schneider Children's Medical Center of Israel, Petah Tikva, Israel|KK Women's and Children's Hospital Pte Ltd, Singapore, Singapore|Southampton General Hospital, Southampton, Hampshire, United Kingdom|Alder Hey Children's Hospital, Liverpool, Merseyside, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01431326"
1198,"NCT05564299","Rapid Diagnostic Assay for Gonorrhea and Chlamydia",,"Recruiting","No Results Available","Urethritis|Cervicitis|Sexually Transmitted Infections","Diagnostic Test: Rapid 30-minute Desktop Assay","Mean number of antibiotic doses administered per patient with symptomatic urethritis or cervicitis|Participant Visit Duration|Sample Processing Time|Time to result","Massachusetts General Hospital|American Sexually Transmitted Diseases Association","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2022P002099","March 22, 2023","June 30, 2024","June 30, 2024","October 3, 2022",,"March 12, 2024","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05564299"
1199,"NCT03961178","A Cohort Study for the Following up of Conization",,"Unknown status","No Results Available","Precancerous Lesions|Conization|High Grade Intraepithelial Neoplasia|Uterine Cervical Cancer|Fertility|Pregnancy|Human Papillomavirus Infection","Diagnostic Test: High-risk HPV|Diagnostic Test: TCT","The cumulative incidences of precancerous lesions or cancers|The cumulative pregnancy rates|The cytological results after conization|The virus outcomes after conization|The cumulative pregnancy loss rates|The cumulative live birth rates","Lei Li|Peking Union Medical College Hospital","Female","18 Years and older   (Adult, Older Adult)",,"10000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CONE","June 3, 2019","May 22, 2021","May 22, 2021","May 23, 2019",,"June 20, 2019","Lei Li, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03961178"
1200,"NCT05654909","Prehospital Assessment Units - a Matched Cohort Study",,"Completed","No Results Available","Pneumonia|Urinary Tract Infections|Fall|Infections|GI Disorders|Orthopedic Disorder","Procedure: Prehospital assessment unit","Admission within 48 hours|Admission within 7 days|Admission within 6 hours|30-day survival","Prehospital Center, Region Zealand","All","18 Years and older   (Adult, Older Adult)",,"10849","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PHV_2022","November 1, 2021","October 31, 2022","January 1, 2023","December 16, 2022",,"February 16, 2023","Prehospital Center, Næstved, Denmark",,"https://ClinicalTrials.gov/show/NCT05654909"
1201,"NCT00457600","ParentLink: Better and Safer Emergency Care for Children",,"Completed","No Results Available","Otitis Media|Urinary Tract Infection|Asthma|Head Injury","Procedure: patient-driven health IT product",,"Boston Children's Hospital|South Shore Hospital","All","up to 12 Years   (Child)",,"3000","Other","Observational","Observational Model: Defined Population|Time Perspective: Prospective","CHB-R01HS014947","June 2005",,"July 2006","April 6, 2007",,"April 6, 2007","Children's Hospital Boston, Boston, Massachusetts, United States|South Shore Hospital, Weymouth, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00457600"
1202,"NCT05587283","Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women",,"Recruiting","No Results Available","Bacterial Vaginosis|Vaginal Disease|Bacterial Infections|Vaginitis|Infection, Bacterial","Drug: Experimental: Low dose LABTHERA-001 capsule|Drug: Experimental: Medium dose LABTHERA-001 capsule|Drug: Experimental: High dose LABTHERA-001 capsule|Other: Placebo Comparator: Low dose Placebo capsule|Other: Placebo Comparator: Medium dose Placebo capsule|Other: Placebo Comparator: High dose Placebo capsule","Number of AEs in participants throughout the study and their severity and relationship to the study product.|Changes in Clinical Laboratory Tests, Vital signs (body temperature, respiratory rate, heart rate, blood pressure), Gynaecological Examination, and Physical Examination.|Acceptability evaluation","AtoGen Co. Ltd|ATOGEN AUSTRALIA PTY LTD","Female","18 Years to 45 Years   (Adult)","Phase 1","24","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","LT-001","November 2, 2022","April 2023","May 2023","October 20, 2022",,"March 9, 2023","Scientia Clinical Research, Randwick, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT05587283"
1203,"NCT00890747","Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy",,"Completed","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Grade III Lymphomatoid Granulomatosis|Adult Langerhans Cell Histiocytosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Aggressive NK-cell Leukemia|AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Malignancies|AIDS-related Small Noncleaved Cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Clear Cell Renal Cell Carcinoma|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extramedullary Plasmacytoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|HIV Infection|HIV-associated Hodgkin Lymphoma|Intraocular Lymphoma|Isolated Plasmacytoma of Bone|Light Chain Deposition Disease|Mast Cell Leukemia|Myelodysplastic Syndrome With Isolated Del(5q)|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myeloid/NK-cell Acute Leukemia|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Osteolytic Lesions of Multiple Myeloma|Peripheral T-cell Lymphoma|Plasma Cell Neoplasm|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Primary Systemic Amyloidosis|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Renal Cell Cancer|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Stage IV Renal Cell Cancer|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia","Drug: sunitinib malate|Other: pharmacological study|Other: laboratory biomarker analysis","Grades 3, 4, and 5, treatment-related adverse events, graded according to the National Cancer Institute (NCI) CTCAE version 3.0|Dose-limiting toxicity (DLT) defined as an adverse event that is possibly related to the study medication, graded according to the NCI CTCAE version 3.0|Evaluation of response|Antiretroviral drug pharmacokinetics due to sunitinib malate|Alterations in immune parameters, including total leukocyte count, CD4, and viral load","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","42","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02208|AMC-061|U01CA121947","August 2009","May 2011",,"April 30, 2009",,"March 17, 2014","Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|Northwestern University, Chicago, Illinois, United States|AIDS - Associated Malignancies Clinical Trials Consortium, Rockville, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Washington University - Jewish, Saint Loius, Missouri, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States|Virginia Mason Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00890747"
1204,"NCT03779347","Schistosomiasis Diagnosis Using a CAA Antigen Test","FreebiLyGAB","Unknown status","No Results Available","Schistosomiasis Hematobium|Diagnostic|Drug Reaction|Pregnancy","Drug: Praziquantel|Diagnostic Test: UCP-LF CAA|Diagnostic Test: composite diagnostic","UPC-LF CAA performance|Egg reduction rate|CAA reduction rate|Prevalence of S. hematobium in children using UCP-LF CAA|Prevalence of S. hematobium in children using microscopy|Clinical safety assessment upon PZQ intake|Efficacy rate using microscopy|Efficacy rate using UCP-LF CAA test","Centre de Recherche Médicale de Lambaréné|Universität Tübingen","Female","Child, Adult, Older Adult","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","FreebiLyGAB","May 1, 2019","April 1, 2022","May 1, 2022","December 19, 2018",,"July 27, 2021","Centre de Recherches Médicales de Lambaréné, Lambaréné, Moyen Ogooué, Gabon|Centre de Recherches Medicales de Lambaréné, Lambaréné, Gabon",,"https://ClinicalTrials.gov/show/NCT03779347"
1205,"NCT03045809","Women's Improvement of Sexual Health (WISH) Demonstration Project","WISH","Completed","Has Results","Sexually Transmitted Disease|Bacterial Vaginosis|Vaginal Candidiasis|Urinary Tract Infections","Diagnostic Test: Urogenital infection point-of-care tests","Feasibility of Integrating Point-of-care Testing (Monitoring & Evaluation Indicators)|Feasibility of Integrating Point-of-care Testing (Client Satisfaction Surveys)|Performance of Syndromic Management With or Without Integration of Point-of-care Tests","Janneke van de Wijgert|Rinda Ubuzima, Rwanda|Institute of Tropical Medicine, Belgium|University of Liverpool","Female","18 Years and older   (Adult, Older Adult)",,"705","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","UoL001208","July 5, 2016","March 14, 2017","August 6, 2018","February 8, 2017","September 11, 2019","September 11, 2019","Rinda Ubuzima, Kigali, Rwanda","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/09/NCT03045809/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/09/NCT03045809/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03045809"
1206,"NCT00878098","Study of DDT and Loss of Clinically-Recognized Pregnancies in South Africa",,"Completed","No Results Available","Spontaneous Abortion|Malaria|Pregnancy Outcome|Stillbirth|HIV Infections",,,"National Institute of Environmental Health Sciences (NIEHS)|National Institutes of Health Clinical Center (CC)","Female","20 Years to 34 Years   (Adult)",,"513","NIH","Observational","Time Perspective: Prospective","999909115|09-E-N115","June 1, 2009",,"July 12, 2019","April 8, 2009",,"July 18, 2019","Pretoria Academic Hospital, Thulamela Municipality, South Africa",,"https://ClinicalTrials.gov/show/NCT00878098"
1207,"NCT02375295","Struvite Stones Antibiotic Study",,"Recruiting","No Results Available","Kidney Stones","Drug: ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin","any recurrent kidney stones|UTI|treated site stone recurrence rates|Clostridiuum difficile colitis|ER visit|Readmission for sepsis.|Readmission for renal colic|Morbidity or mortality related to sepsis or renal failure|Repeat surgical procedures for stone recurrence|Ancillary procedures for stones such as ureteric stenting and nephrostomy tubes","University of British Columbia","All","19 Years and older   (Adult, Older Adult)","Phase 4","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","H13-02514","March 2015","December 2023","December 2023","March 2, 2015",,"May 17, 2022","Mayo Clinic - Scottsdale/Phoenix, AZ, Scottsdale, Arizona, United States|University California San Diego, San Diego, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|Harvard University - Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic - Rochester, MN, Rochester, Minnesota, United States|Dartmouth University, Lebanon, New Hampshire, United States|New York University, New York, New York, United States|Duke University, Durham, North Carolina, United States|Ohio State University, Athens, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Vanderbilt University, Nashville, Tennessee, United States|The Stone Centre, VGH/UBC, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT02375295"
1208,"NCT03816384","Effect of Active Drain Line Clearance on Catheter-Associated Bacteriuria","CAB","Withdrawn","No Results Available","Critical Illness|Burns|Surgery|Urinary Tract Infections|Bacteriuria","Device: Standard of Care|Device: DLC Group|Device: DLCS Group","Difference in percentage of catheter-associated bacteriuria|Percentage of asymptomatic (ASB) and symptomatic (CAUTI) bacteriuria|Time to Bacteriuria (ASB and CAUTI)|Urine Culture Comparisons","Potrero Medical","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CRD-06-100548","January 31, 2020","January 31, 2020","January 31, 2020","January 25, 2019",,"January 29, 2020",,,"https://ClinicalTrials.gov/show/NCT03816384"
1209,"NCT03167957","Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis",,"Withdrawn","No Results Available","Vulvovaginal Candidiases|Yeast Infection|Vulvovaginitis|Yeast Infection Vaginal|Candidiasis, Vulvovaginal","Drug: Oral Encochleated Amphotericin B (CAMB)","The proportion of subjects with clinical cure at the Test of Cure visit|The proportion of subjects with mycological eradication at the Test of Cure visit|Incidence of treatment emergent adverse events","Matinas BioPharma Nanotechnologies, Inc.","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MB-70008","December 2019","December 2020","December 2020","May 30, 2017",,"March 8, 2019","Tolan Park Clinic, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03167957"
1210,"NCT05483725","Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.",,"Active, not recruiting","No Results Available","Kidney Diseases|Kidney Transplant; Complications|COVID-19|Vaccine Adverse Reaction|Rejection Acute Renal|Rejection Chronic Renal","Biological: Booster dose of mRNA vaccine","Immunological safety - anti-HLA antibodies|Immunological safety - donor-derived cell-free DNA|Immunological effectiveness - anti-SARS-CoV-2 antibodies","Institute for Clinical and Experimental Medicine","All","18 Years and older   (Adult, Older Adult)",,"108","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","G-21-71","October 4, 2021","December 4, 2024","December 31, 2024","August 2, 2022",,"March 6, 2024","Institute for Clinical and Experimental Medicine, Praha, Czechia",,"https://ClinicalTrials.gov/show/NCT05483725"
1211,"NCT05630326","Association Between COVID-19 and UTIs Caused by ESBL Organism in Infants","ABCUCEOI","Completed","No Results Available","Renal Insufficiency","Other: comparing, prevalence|Other: assessment|Other: association|Other: evaluation","Assessment risk factors , prevalence, and the relation between ESBL UTI and COVID-19 infection of all infants with ESBL- UTIs","Hamad Medical Corporation","All","up to 1 Year   (Child)",,"5600","Industry","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","MRC-01-22-158","March 1, 2023","July 1, 2023","July 20, 2023","November 29, 2022",,"July 27, 2023","Hamad Medical Corporation, Doha, Qatar",,"https://ClinicalTrials.gov/show/NCT05630326"
1212,"NCT02515175","Evaluating New Formulation of Therapeutic HSV-2 Vaccine",,"Completed","No Results Available","Genital Herpes Simplex Type 2","Biological: Matrix-M2|Biological: GEN-003|Drug: Placebo","Change in HSV-2 viral shedding rate|Immunogenicity measured by humoral (antibody) responses to vaccine antigens|Impact on clinical HSV-2 disease based on time to first recurrence|Number of patients with adverse events as a measure of safety and tolerability|Reduction in HSV-2 viral shedding rate|Impact on clinical HSV-2 disease based on lesion rate|Impact on clinical HSV-2 disease based on percent recurrence-free","Genocea Biosciences, Inc.","All","18 Years to 50 Years   (Adult)","Phase 2","131","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GEN-003-003","November 2015","July 2016","May 25, 2017","August 4, 2015",,"May 22, 2018","University of Alabama-Birmingham, Birmingham, Alabama, United States|Medical Center for Clinical Research, San Diego, California, United States|Quest Clinical Research, San Francisco, California, United States|The Fenway Institute, Boston, Massachusetts, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Cincinnati Childrens Hospital, Cincinnati, Ohio, United States|Tekton Research, Austin, Texas, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02515175"
1213,"NCT04686318","Accuracy of Infection Biomarkers in the Investigation of Patients With Suspected Acute Pyelonephritis",,"Completed","No Results Available","Acute Pyelonephritis","Diagnostic Test: Biomarkers for acute pyelonephritis","Verified and non verified acute pyelonephritis (APN)|Intensive care unit treatment|Length of stay|The number of participants who died within 30 days|The number of participants who died within 90 days|Readmission|In-hospital mortality","University of Southern Denmark","All","18 Years and older   (Adult, Older Adult)",,"229","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SHS-ED-12c-2020","March 1, 2021","February 28, 2022","June 1, 2022","December 28, 2020",,"September 14, 2022","Hospital of Southern Jutland, Aabenraa, Denmark",,"https://ClinicalTrials.gov/show/NCT04686318"
1214,"NCT02910284","Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity",,"Completed","No Results Available","Genital Herpes Simplex Type 2","Biological: Observational","Long-term effect of GEN-003 on anogenital Herpes simplex virus type 2 (HSV-2) shedding (percent of anogenital swabs positive for HSV-2 DNA by PCR)|Long-term effect of GEN-003 on anogenital Herpes simplex virus type 2 (HSV-2) shedding (magnitude of HSV-2 viral shedding by PCR)|Long-term effect of GEN-003 on HSV-lesion rate (percent of days with genital lesions present) during the swab collection periods|Long-term immune responses to GEN-003 (Serum IgG levels assessed by ELISA)|Long-term immune responses to GEN-003 (Serum HSV-2 neutralizing antibody levels assessed by a colorimetric neutralization assay)|Long-term immune responses to GEN-003 (Spot-forming units (SFUs), fold rise, responder rate assessed by GrB ELISPOT)","Genocea Biosciences, Inc.","All","18 Years to 50 Years   (Adult)",,"140","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GEN-003-002b","September 16, 2016","July 14, 2017","July 14, 2017","September 22, 2016",,"October 20, 2017","University of Alabama - Birmingham, Birmingham, Alabama, United States|Medical Center for Clinical Research, San Diego, California, United States|Quest Clinical Research, San Francisco, California, United States|University of Illinois - Chicago, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|The Fenway Institute, Boston, Massachusetts, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|NW Dermatology and Research, Portland, Oregon, United States|Magee - Women's Hospital of UPMC, Pittsburgh, Pennsylvania, United States|Tekton Research, Austin, Texas, United States|Center for Clinical Studies, Houston, Texas, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02910284"
1215,"NCT03883698","Safety of Sofosbuvir in People With Advanced Kidney Failure",,"Completed","No Results Available","Kidney Failure, Chronic|Hepatitis C","Drug: Sofosbuvir|Drug: Daclatasvir 60 mg","Pharmacokinetics study|Clinical response","Sanjay Gandhi Postgraduate Institute of Medical Sciences","All","19 Years to 60 Years   (Adult)","Phase 3","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2018-167-IMP-107|CTRI/2019/03/018011","March 15, 2019","August 1, 2020","August 1, 2020","March 21, 2019",,"April 6, 2021","Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT03883698"
1216,"NCT04578132","Description of the Population With Genitourinary Tumors and COVID-19","SOGUGCOVID","Unknown status","No Results Available","Covid19|Genito Urinary Cancer",,"Baseline characteristics|Frequency of complications of COVID-19 intercurrent infection|Frequency of complications of COVID-19 infection in patients stratified by oncological treatment|Frequency of adverse events related to immunotherapy targeted to cancer (classified by type and severity)|Frequency of complications of COVID-19 infection in patients with prostate cancer stratified by anti-androgenic oncological treatment|COVID-19 mortality rate in patients with genitourinary cancer|COVID-19 complication rate in patients with genitourinary cancer|Asymptomatic rate|Frequency of delays/modifications on cancer treatment schedule|Progression free survival in patients with genitourinary tumors that suffered COVID-19|Overall survival in patients with genitourinary tumors that suffered COVID-19","Spanish Oncology Genito-Urinary Group","All","18 Years and older   (Adult, Older Adult)",,"408","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Other","SOG-INM-2020-04","November 24, 2020","June 2022","October 2022","October 8, 2020",,"September 22, 2021","Institut Català d'Oncologia L'Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Althaia, Manresa, Barcelona, Spain|Hospital Universitari Parc Taulí, Sabadell, Barcelona, Spain|Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario de Badajoz, Badajoz, Spain|Hospital del Mar, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Vall d Hebron, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital de Ciudad Real, Ciudad Real, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Instituto Catalán de Oncología- Girona, Girona, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico San Carlos de Madrid, Madrid, Spain|Hospital Infanta Leonor,, Madrid, Spain|Hospital Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Quironsalud, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Complejo Hospitalario Universitario Ourense, Orense, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Nuestra Señora del Prado, Talavera De La Reina, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Txagorritxu, Vitoria, Spain|Hospital Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT04578132"
1217,"NCT05038488","Phase 2a MIB-626 vs. Placebo COVID-19",,"Completed","No Results Available","Covid19|Stage 1 Acute Kidney Injury","Drug: MIB-626|Drug: Placebo|Other: Home Treatment","Change from baseline in serum cystatin C levels|Change from baseline to peak concentrations of inflammatory biomarkers (IL6, TNF-alpha, hsCRP, Angiotensin 2 to Angiotensin1, 7 ratio, ACE 2)|The trajectory of change from baseline in concentrations of inflammatory biomarkers (IL6, TNF-alpha, hsCRP, Angiotensin 2 to Angiotensin1, 7 ratio, ACE 2)|Change from baseline in markers of endothelial damage (vWF, VCAM, PAI-1)|Change from baseline in markers of microvascular thrombosis (D-dimer, fibrinogen)|The trajectory of change in plasma (NGAL, KIM-1) and urinary (KIM-1, NGAL, albumin) biomarkers of acute kidney injury|Change in urinary albumin concentration (normalized to urine creatinine) from enrollment to peak during hospitalization|Change from baseline in oxygen saturation|Change in high sensitivity troponin-1 concentration from enrollment to peak during hospitalization (measured daily in stored biospecimens)|Change from baseline in intracellular NAD+ concentrations in blood during the 14-day treatment period in a subset of study participants|Circulating concentrations of MIB-626 and its key metabolites P2Y, NAAD, NAM, 1-methylnicotinamide during the 14-day treatment period","Metro International Biotech, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MIB-626-202","October 26, 2021","August 17, 2023","August 17, 2023","September 9, 2021",,"March 15, 2024","The Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05038488"
1218,"NCT02640326","McMaster Catheterization for Thoracoscopic Surgery Study","UCATh","Withdrawn","No Results Available","Non-Small Cell Lung Cancer|Lung Neoplasms|Metastatic Lung Cancer|Urinary Retention|Urinary Tract Infections","Other: No Foley Urinary Catheter|Other: Standard of care Foley urinary catheter insertion","Postoperative urinary complications|Length of Hospital Stay|Rate of Post-operative Hypotension|Total IV fluid administration|Validity of the bladder scanner tool relative to actual urine output|Rate of peri-operative pulmonary complications|Rate of peri-operative cardiac complications","McMaster University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SJHH_UCATh","December 1, 2018","December 1, 2018","December 1, 2018","December 28, 2015",,"December 21, 2018","St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02640326"
1219,"NCT05225493","HIV Indicator Diseases in Hospital and Primary Care","#AwareHIV","Recruiting","No Results Available","HIV Infections|Primary Health Care|Acquired Immunodeficiency Syndrome|Sexually Transmitted Diseases, Viral|Herpes Zoster|Dermatitis, Seborrheic|Pneumonia|Infectious Mononucleosis|Psoriasis|Candida Infection|Lymphadenopathy|Uterine Cervical Dysplasia|Weight Loss|Diarrhea Chronic|Leukopenia|Thrombocytopenia|AIDS Defining Illness|HIV Indicator Condition","Behavioral: Peer to peer feedback|Diagnostic Test: HIV rapid test","The number of adequately performed HIV tests of identified HIV indicator conditions in relation to the total number of identified HIV indicator conditions by physicians in hospital settings during the project.|The number of adequately performed HIV tests of identified HIV indicator conditions in relation to the total number of identified HIV indicator conditions by general practitioners in primary care during the project.|The number of positive HIV tests in relation to the total number of HIV tests for identified HIV indicator conditions.|The percentage of adequately HIV tested patients per HIV indicator condition and per medical specialism.|The prevalence of HIV indicator conditions in primary care and hospitals.|The incidence of HIV indicator conditions in primary care and hospitals.|A sensitive and specific supervised artificial Intelligence tool that recognizes risk factors for HIV and HIV indicator conditions through natural language processing (NLP) and supports the hospital and primary care in proactive HIV testing policies.|Acceptance of HIV testing in by patients, medical specialist and in primary care.|The costs of pro-active HIV indicator case finding and relation to the savings and QALY's gained","Erasmus Medical Center|Huisartspraktijk Gezondheidscentrum Mathenesserlaan|TU Delft department of Artificial Intelligence and MyTomorrows|Huisartsen Groep Rotterdam|AwareHIV Project Group|Huisartspraktijk Handellaan|Huisartspraktijk Leerdam|Huisartspraktijk Capelle ad IJssel|Leiden University Medical Center|Maasstadziekenhuis|Rijnstate Hospital|Medical Center Haaglanden","All","18 Years and older   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MEC-2021-0277","January 1, 2020","May 2024","May 2024","February 4, 2022",,"February 4, 2022","Carlijn CCE Jordans, Rotterdam, South-Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT05225493"
1220,"NCT02905890","The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis","HCBV","Completed","No Results Available","Bacterial Vaginosis|HIV","Drug: Norethisterone enantate|Device: Condoms","Time to diagnosis of recurrent BV|Proportional of participants with Lactobacillus-dominant cluster|Concentration of markers for inflammation|Acceptability of norethisterone enanthate as measured by qualitative interviews","London School of Hygiene and Tropical Medicine|Imperial College London|University of Liverpool|MRC/UVRI and LSHTM Uganda Research Unit","Female","18 Years to 35 Years   (Adult)","Phase 4","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","QA906","October 2, 2017","December 20, 2019","December 20, 2019","September 19, 2016",,"March 12, 2020","MRC/UVRI Mengo Clinic and Research Station, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT02905890"
1221,"NCT04751149","Incidence of Acute Urine Retention: Randomized Clinical Trial Comparing Early, Mid or Late Urinary Catheter Removal in Patients With Rectal Resection","RAOREC","Unknown status","No Results Available","Rectal Cancer|Retention, Urinary|Urinary Tract Infections|Surgical Site Infection|Anastomotic Leak","Procedure: Removal of Urinary Catheter","to compare the incidence of acute urine retention after removal of the urinary catheter in the postoperative period of rectal resection.|Incidence of urinary tract infection after urinary catheter removal.|Incidence of surgical wound infection|Incidence of respiratory infection|Incidence of anastomotic dehiscence|Incidence of ileus|Incidence of postoperative complications","Hospital Donostia","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","143","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ELO-RAO-2019-01","May 1, 2019","May 1, 2022","December 1, 2022","February 11, 2021",,"February 11, 2021","Hospital Donostia, Donostia, Guipuzcos, Spain",,"https://ClinicalTrials.gov/show/NCT04751149"
1222,"NCT02837575","Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine","HSV-2","Completed","No Results Available","Herpes Genitalis","Biological: VCL-HB01|Other: Phosphate-buffered saline","Lesion recurrences|Number of participants with adverse events|Time to first recurrence|Proportion of subjects recurrence-free","Vical","All","18 Years to 50 Years   (Adult)","Phase 2","261","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HSV2-201","September 2016","April 2018","December 2018","July 19, 2016",,"February 27, 2019","Alabama Vaccine Research Clinic at University of Alabama at Birmingham, Birmingham, Alabama, United States|Medical Center for Clinical Research, San Diego, California, United States|QPS Broward Research, Hollywood, Florida, United States|QPS Miami Research Associates, South Miami, Florida, United States|Comprehensive Clinical Trials, LLC, West Palm Beach, Florida, United States|University of Illinois, Chicago, Illinois, United States|Indiana University Infectious Disease Research, Indianapolis, Indiana, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Central Kentucky Research Associates, Inc., Lexington, Kentucky, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|University of North Carolina (UNC) Institute of Global Health and Infectious Diseases, Chapel Hill, North Carolina, United States|Clinical Research Associates, Inc., Nashville, Tennessee, United States|University of Utah School of Medicine - Division of Infectious Diseases, Salt Lake City, Utah, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02837575"
1223,"NCT04979975","Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes",,"Not yet recruiting","No Results Available","Recurrent Genital Herpes","Other: Placebo|Biological: UB-621 low-dose|Biological: UB-621 high-dose","Time to first recurrence|Proportion of subjects with episodes|Lesion rate|Duration of recurrent lesions|Recurrence rate","UBP Greater China (Shanghai) Co., Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","UBP-A229-HSV","December 2023","December 2025","December 2026","July 28, 2021",,"October 3, 2022",,,"https://ClinicalTrials.gov/show/NCT04979975"
1224,"NCT06141395","NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification","BIOARTE","Completed","No Results Available","Pneumonia|Acute Pyelonephritis|Bacteremia|Biliary Tract Infection","Diagnostic Test: NGS-based assay for bacterial identification","The rate of matching between the results of Next Generation Sequencing and the Standard-of-Care culture for patients with sepsis.|Difference in time to identification of the bacterial pathogen between Next Generation Sequencing and the Standard-of-Care culture|Difference in time to Antibiotic Susceptibility Testing between Next Generation Sequencing and the Standard-of-Care culture","Hellenic Institute for the Study of Sepsis|The BioArte","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BIOARTE","November 16, 2023","March 14, 2024","March 14, 2024","November 21, 2023",,"March 29, 2024","4th Department of Internal Medicine,""Attikon"" University Hospital, National and Kapodistrian University of Athens, Medical School, Chaïdári, Attiki, Greece|1st Department of Internal Medicine, General Hospital of Eleusis THRIASIO, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens SOTIRIA, Athens, Greece|3rd Department of Internal Medicine, General Hospital of Nikaia AGIOS PANTELEIMON, Nikaia, Greece",,"https://ClinicalTrials.gov/show/NCT06141395"
1225,"NCT00392132","Impact of Screening Patients With HIV for Kidney Disease",,"Withdrawn","No Results Available","HIV Infections|Renal Insufficiency, Chronic|Proteinuria",,,"University of Mississippi Medical Center","All","18 Years and older   (Adult, Older Adult)",,"0","Other","Observational","Time Perspective: Other","UMMC - HIV and CKD","October 2005","October 2006","October 2006","October 25, 2006",,"May 30, 2018","University of Mississippi Medical Center, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT00392132"
1226,"NCT03426787","Helping Empower Liver and Kidney Patients","Project HELP","Completed","Has Results","Hepatitis C|Chronic Kidney Diseases|Patient Education","Behavioral: Decision Aid","Change in Knowledge|Change in Decisional Conflict Scale|Change in Decision Self-Efficacy Scale|System Usability Scale","Washington University School of Medicine|Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","201707154","September 26, 2017","October 15, 2018","July 30, 2019","February 8, 2018","July 5, 2019","September 11, 2019","Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States","""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/87/NCT03426787/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/87/NCT03426787/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03426787"
1227,"NCT03490045","Intervention to Reduce Diaper Need and Increase Use of Pediatric Preventive Care",,"Completed","No Results Available","Diaper Dermatitis|Urinary Tract Infections|Infection|Depressive Symptoms|Stress","Other: Diaper Incentive|Other: Conditional Cash Transfer Condition","Well-Child Visits|Diaper Need|Incidence of Diaper Dermatitis/Rash|Incidence of Urinary Tract Infections|Depressive Symptoms Among Mothers|Diaper-related Absences Among Mothers|Stress|Basic Need","Yale University|National Diaper Bank Network|Yale New Haven Health Primary Care Consortium","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","77","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2000023616","April 1, 2019","August 17, 2020","August 17, 2020","April 6, 2018",,"April 24, 2023","Center for Wellbeing of Women and Mothers, 40 Temple Street, Ste 6B, Yale University, New Haven, Connecticut, United States|Yale School of Medicine, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03490045"
1228,"NCT03009968","Reducing Postoperative Catheterization",,"Completed","No Results Available","Urinary Retention|Urinary Incontinence|Pelvic Organ Prolapse|Urinary Tract Infections","Other: Post-void residual free voiding trial","Rate of postoperative catheterization|Duration of catheterization|Treatment of clinical-suspected or culture proven urinary tract infection|Time spent in the Post Anesthesia Care Unit (PACU).|Short term catheter burden|Number of post-operative patient calls and subsequent clinic visits.","University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute","Female","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16-2888","March 17, 2017","January 1, 2018","February 1, 2018","January 4, 2017",,"March 19, 2018","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03009968"
1229,"NCT03764358","AUSTrian Randomized Interventional Study on Dialysis Accesses","AUSTRIA","Unknown status","No Results Available","End Stage Renal Disease|Catheter Infection|Shunt Malfunction","Device: Arteriovenous Fistula|Device: Tunneled Cuffed Catheter","Composite primary end-point of any access related complication","Medical University of Vienna","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","AUSTRIA","March 6, 2019","April 4, 2022","October 4, 2022","December 5, 2018",,"December 5, 2018","Department of Medicine III, Devision of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT03764358"
1230,"NCT02049736","Effect of Telbivudine on Renal Function and Proteinuria in Patients With CHB & Chronic Renal Diseases",,"Withdrawn","No Results Available","Chronic Hepatitis B","Drug: Telbivudine","change in estimated glomerular filtration rate|proteinuria|HBV DNA level","Chinese University of Hong Kong","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Telbivudine for CKD","December 2013","June 2015","June 2015","January 30, 2014",,"July 28, 2016","Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT02049736"
1231,"NCT03595995","A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621",,"Not yet recruiting","No Results Available","Genital Herpes","Biological: UB-621|Other: Placebo","change of HSV-2 shedding rate.|change of HSV-2 viral load|change of genital lesion rates|Clinical and Subclinical HSV-2 Shedding Rates|Rate of HSV-2 Shedding Episodes","United BioPharma","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UBP-A206-HSV","June 1, 2023","June 30, 2024","June 30, 2024","July 23, 2018",,"October 3, 2022",,,"https://ClinicalTrials.gov/show/NCT03595995"
1232,"NCT03697226","Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.",,"Completed","No Results Available","HSIL of Cervix|HSIL, High Grade Squamous Intraepithelial Lesions|High-Grade Cervical Intraepithelial Neoplasia|Human Papilloma Virus|HIV Negative|Cervical Cancer|CIN - Cervical Intraepithelial Neoplasia|Cervical Neoplasm|Cervical Dysplasia","Drug: Topical ABI-1968","Safety & Tolerability of ABI-1968 for the treatment of cHSIL|Systemic exposure to ABI-1968 Topical Cream following topical application to the cervix.","Antiva Biosciences","Female","25 Years to 50 Years   (Adult)","Phase 1","8","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-1968-103","December 21, 2018","May 26, 2020","June 12, 2020","October 5, 2018",,"January 13, 2021","Research Center, Bloemfontein, Free State Province, South Africa",,"https://ClinicalTrials.gov/show/NCT03697226"
1233,"NCT03239223","Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection",,"Completed","No Results Available","HSIL|HSIL of Cervix|High-Grade Squamous Intraepithelial Lesions|High-grade Cervical Intraepithelial Neoplasia|Human Papilloma Virus|Cervical Cancer|Cervical Intraepithelial Neoplasia|Cervical Neoplasm|Cervical Dysplasia|CIN","Drug: ABI-1968","Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of cHSIL|Systemic exposure to Topical ABI-1968 Cream following topical application to the cervix.|Histopathology of areas with biopsy-proven disease following multiple doses of Topical ABI-1968 Cream.","Antiva Biosciences","Female","25 Years to 50 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ABI-1968-102","January 1, 2018","October 30, 2018","October 30, 2018","August 3, 2017",,"July 10, 2019","Research Center, Los Angeles, California, United States|Research Center, Lake Worth, Florida, United States|Research Center, Idaho Falls, Idaho, United States|Research Center, Chapel Hill, North Carolina, United States|Research Center, Winston-Salem, North Carolina, United States|Research Center, Norfolk, Virginia, United States|Research Center, Camperdown, New South Wales, Australia|Research Center, Darlinghurst, New South Wales, Australia|Research Center, South Brisbane, Queensland, Australia",,"https://ClinicalTrials.gov/show/NCT03239223"
1234,"NCT02092350","Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)","C-SURFER","Completed","Has Results","Hepatitis C Virus","Drug: Grazoprevir|Drug: Elbasvir|Drug: Placebo to Grazoprevir|Drug: Placebo to Elbasvir","Percentage of Participants With Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12)|Number of Participants Experiencing an Adverse Event (AE) During the Initial Treatment and 14-day Follow-up Periods|Number of Participants Discontinuing Study Drug Due to AEs During the Initial Treatment Period|Percentage of Participants With Sustained Virologic Response 24 Weeks After Completing Study Therapy (SVR24)|Percentage of Participants With Sustained Virologic Response 4 Weeks After Completing Study Therapy (SVR4)","Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","237","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","5172-052|2013-003858-25","March 17, 2014","March 11, 2015","September 2, 2015","March 20, 2014","April 12, 2016","September 24, 2018",,,"https://ClinicalTrials.gov/show/NCT02092350"
1235,"NCT04022148","The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years",,"Unknown status","No Results Available","Cancer of Cervix|Vaccinia","Biological: Gardasil","The rate of the persistent infection","University of Fukui|Merck Sharp & Dohme LLC","Female","27 Years to 45 Years   (Adult)",,"2800","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","C2018001F","August 1, 2019","December 31, 2020","December 31, 2020","July 16, 2019",,"July 19, 2019",,,"https://ClinicalTrials.gov/show/NCT04022148"
1236,"NCT04045652","Factors Predicting Persistence of Oncogenic HPV and Cervical Dysplasia in HIV Infected Kenyan Women",,"Recruiting","No Results Available","HIV/AIDS|Cervical Dysplasia|HIV Infections",,"Frequency of oncogenic Human Papillomavirus (HPV) in Human Immunodeficiency Virus(HIV)-infected women with a normal Visual Inspection with Acetic Acid (VIA) at baseline|Frequency oncogenic HPV in non HIV-infected women with a normal VIA at baseline|Incidence of abnormal VIA|Incidence of cervical dysplasia in Kenyan women with normal VIA at baseline, and who are HIV-infected during 4 years of observation|Incidence of cervical dysplasia in Kenyan women with normal VIA at baseline, and who are HIV-uninfected during 4 years of observation|Identify potentially modifiable sex behavioral risk factors associated with oncogenic HPV|Identify potentially modifiable sex behavioral risk factors associated with cervical dysplasia|Identify potentially modifiable health behavioral risk factors associated with oncogenic HPV|Identify potentially modifiable health behavioral risk factors associated with cervical dysplasia|Incidence of potentially modifiable biological risk factors associated with oncogenic HPV through HPV testing will occur through cervical and/or vaginal swabs|Incidence of potentially modifiable biological behavioral risk factors associated with cervical dysplasia through cervical and/or vaginal swabs for HPV and CT/GC testing|Time to HPV|Time to Cervical Dysplasia","Indiana University","Female","18 Years to 45 Years   (Adult)",,"220","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IUCRO-0492","November 18, 2021","October 1, 2025","October 1, 2026","August 5, 2019",,"May 19, 2023","Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States|Moi University School of Medicine, Eldoret, Kenya|Infectious Disease Institute, Makerere University, Kampala, Uganda",,"https://ClinicalTrials.gov/show/NCT04045652"
1237,"NCT02859493","Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis",,"Terminated","No Results Available","Candidiasis, Vulvovaginal","Device: Saccharomyces cerevisiae|Device: Placebo","Diminution of the vaginal load in Candida spp (Candida albicans, Candida glabrata) in subjects presenting a vulvo-vaginal candidosis","Lesaffre International","Female","18 Years to 50 Years   (Adult)","Not Applicable","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","15E2899","August 2016","March 2017",,"August 9, 2016",,"June 13, 2018","Dermscan, Villeurbanne, France",,"https://ClinicalTrials.gov/show/NCT02859493"
1238,"NCT02207088","Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease",,"Completed","Has Results","Chronic Hepatitis C|Hepatitis C Virus|Compensated Cirrhosis|Severe Renal Impairment|End-stage Renal Disease","Drug: ombitasvir/paritaprevir/ritonavir|Drug: dasabuvir|Drug: Ribavirin","Percentage of Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-Treatment Relapse","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","68","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-226|2014-001527-77","September 23, 2014","December 6, 2016","December 6, 2016","August 1, 2014","November 9, 2017","November 9, 2017",,,"https://ClinicalTrials.gov/show/NCT02207088"
1239,"NCT00239161","Safety and Efficacy Study of the Treatment of Kidney Infections With Short Course Levofloxacin",,"Terminated","No Results Available","Acute Uncomplicated Pyelonephritis","Drug: Levofloxacin","Microbiological cure at the 10-14 day and 33-35 day followup|Clinical outcome at each visit. Microbiologic outcomes at 24,48,and72 hrs, adverse antimicrobial effects, adverse events or antimicrobial resistance. Correlation between pharmacodynamic parameters, bacteriologic and clinical resolution will be analyzed.","University of Manitoba|Ortho-McNeil Pharmaceutical|Janssen-Ortho Inc., Canada|PriCara, Unit of Ortho-McNeil, Inc.","Female","18 Years to 50 Years   (Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAPSS-353|LOF-UTI-2","September 2004",,"July 2005","October 14, 2005",,"October 14, 2005","St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada|Misericordia Urgent Care, Winnipeg, Manitoba, Canada|University of Manitoba, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT00239161"
1240,"NCT00353561","Diabetes Mellitus and Vulvovaginal Candidiasis",,"Completed","No Results Available","Diabetes Mellitus|Vulvovaginal Candidiasis","Drug: Boric|Drug: Fluconazole","Mycological cure on the 15th day of therapy and defined as the absence of Candida growth on fungal culture of high vaginal swab|Relief in clinical symptoms and signs of vulvovaginal candidiasis including vaginal discharge, pruritus, burning sensation and vaginal congestion","Indian Council of Medical Research","Female","18 Years to 66 Years   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RHN/Adhoc/23/2003-2004","June 2004","April 2006","April 2006","July 18, 2006",,"May 22, 2008","Dr Ravinder Goswami, Delhi, India",,"https://ClinicalTrials.gov/show/NCT00353561"
1241,"NCT00683865","Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.","MAIDEN","Completed","No Results Available","Pelvic Inflammatory Disease","Drug: Ofloxacin|Drug: Avelox (Moxifloxacin, BAY12-8039)","Clinical response 5 to 24 days after the last dose of study medication|Bacterial response at the test of cure visit and at the FU visit 28 to 42 days after last dose of study medication|Clinical response at during-treatment visit (Day 4-7) and at follow-up 28 to 42 days after last dose|Reduction from baseline in pain report at the different assessment visits|Necessity for modifying antibiotic therapy at the during-treatment visit and TOC visit and necessity for institution of an antibiotic therapy at follow-up","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","749","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10995","April 2003","October 2004","October 2004","May 26, 2008",,"October 15, 2014","Hvidovre, Denmark|Odense C, Denmark|Roskilde, Denmark|Helsinki, Finland|Hämeenlinna, Finland|Joensuu, Finland|Kotka, Finland|Antony Cedex, France|Beaumont, France|Bordeaux, France|Brive-la-gaillarde, France|Cenon, France|Colombes Cedex, France|Creteil Cedex, France|Domont, France|Lille, France|Montauban, France|Montpellier, France|Muret, France|Nancy Cedex, France|Paris, France|Paris, France|Toulouse, France|München, Bayern, Germany|Rostock, Mecklenburg-Vorpommern, Germany|Essen, Nordrhein-Westfalen, Germany|Grevenbroich, Nordrhein-Westfalen, Germany|Leverkusen, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Berlin, Germany|Berlin, Germany|Athens, Attica, Greece|Athens, Attica, Greece|Dourouti-Ioannina, Ioannina, Greece|Budapest, Hungary|Budapest, Hungary|Eger, Hungary|Györ, Hungary|Kecskemet, Hungary|Pavia, Italy|Perugia, Italy|Trieste, Italy|Klaipeda, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|Bialystok, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Owock, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Bloemfontein, Free State, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Durban, KwaZulu Natal, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Göteborg, Sweden|Linköping, Sweden|Lund, Sweden|Trollhättan, Sweden|Varberg, Sweden|Bristol, Avon, United Kingdom|London, Greater London, United Kingdom|London, Greater London, United Kingdom|London, Greater London, United Kingdom|Southampton, Hampshire, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00683865"
1242,"NCT02059499","Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions",,"Active, not recruiting","No Results Available","Anal Intraepithelial Neoplasia|High-grade Squamous Intraepithelial Lesion|HIV Infection","Drug: imiquimod|Drug: fluorouracil|Other: questionnaire administration|Other: laboratory biomarker analysis","Proportion of participants achieving complete response (Arm A and B)|Proportion of participants with spontaneous regression (Arm C)|Presence of intra-anal HSIL on cytology or histology|Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Proportion of participants achieving complete response or spontaneous regression|Number of quadrants with HSIL found on biopsies|Proportion of patients achieving complete or partial responses|Persistence of HPV type specific infections","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC|University of Arkansas","All","21 Years and older   (Adult, Older Adult)","Phase 3","91","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","AMC-088|NCI-2013-02288|U01CA121947","December 28, 2015","December 5, 2023","May 21, 2024","February 11, 2014",,"January 22, 2024","UCLA CARE Center, Los Angeles, California, United States|UCSF-Mount Zion, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|Emory University, Atlanta, Georgia, United States|Louisiana State University Health Sciences Center - New Orleans, New Orleans, Louisiana, United States|Boston Medical Center, Boston, Massachusetts, United States|Montefiore Medical Center, Bronx, New York, United States|Laser Surgery Care, New York, New York, United States|Cornell Clinical Trials Unit, New York Presbyterian Hospital, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Benaroya Research Institute at Virginia Mason Medical Center, Seattle, Washington, United States|University of Puerto Rico, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02059499"
1243,"NCT03158220","Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)",,"Completed","Has Results","Cervical Cancer|Vulvar Cancer|Vaginal Cancer|Genital Warts|Human Papillomavirus Infection","Biological: V503","Anti-HPV Geometric Mean Titers (GMTs) for Each Anti-HPV Type|Percentage of Participants That Experienced at Least 1 Adverse Event (AE)|Percentage of Participants Who Had Study Vaccine Discontinued Due to Adverse Event.|Percentage of Participants With at Least 1 Solicited Injection-site Adverse Event|Percentage of Participants That Reported at Least 1 Systemic Adverse Event|Percentage of Participants With Elevated Temperature (Fever)|Percentage of Participants Who Seroconverted to Each of the Anti-HPV Types","Merck Sharp & Dohme LLC","Female","16 Years to 45 Years   (Child, Adult)","Phase 3","1212","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","V503-004","September 20, 2017","November 19, 2018","November 19, 2018","May 18, 2017","November 21, 2019","November 21, 2019","Universitatsklinik fuer Frauenheilkunde und Geburtshilfe ( Site 0002), Graz, Austria|Klin. Abtlg. fuer Gynaekologie und Geburtshilfe ( Site 0001), Wien, Austria|Universitair Ziekenhuis Antwerpen ( Site 0007), Edegem, Belgium|Universitair Ziekenhuis Gent ( Site 0006), Gent, Belgium|Universitair Ziekenhuis Gasthuisberg ( Site 0005), Leuven, Belgium|University of Antwerp ( Site 0004), Wilrijk, Belgium|HUS Katiloopiston sairaala ( Site 0009), Helsinki, Finland|Ita-Helsingin Rokotetutkimuskeskus ( Site 0011), Helsinki, Finland|Porin Rokotetutkimusklinikka ( Site 0012), Pori, Finland|Tampereen yliopisto - Tampereen rokotetutkimusklinikka ( Site 0010), Tampere, Finland|Turun rokotetutkimusklinikka ( Site 0037), Turku, Finland|Universitaetsmedizin Berlin Charite ( Site 0016), Berlin, Germany|Universitaetsklinikum Duesseldorf ( Site 0014), Dusseldorf, Germany|Praxis Dr. Peters ( Site 0015), Hamburg, Germany|Universitaetsklinikum Hamburg-Eppendorf ( Site 0017), Hamburg, Germany|Universitaetsklinikum Tuebingen ( Site 0013), Tuebingen, Germany|Istituto Nazionale dei tumori ( Site 0020), Milano, Milan, Italy|Ospedale San Raffaele ( Site 0022), Milano, Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello ( Site 0023), Palermo, Italy|CAP Centelles ( Site 0027), Centelles, Barcelona, Spain|Complejo Hospitalario de Torrecardenas ( Site 0030), Almeria, Spain|Institut Catala Oncologia de Bellvitge - ICO ( Site 0026), Hospitalet de Llobregat, Spain|Hospital Sanitas La Moraleja ( Site 0031), Madrid, Spain|Hospital Universitario Infanta Leonor ( Site 0028), Madrid, Spain","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/20/NCT03158220/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03158220"
1244,"NCT05249192","Immediate Versus Early (24-hours) Urinary Catheter Removal After Elective Minimally Invasive Colonic Resection",,"Recruiting","No Results Available","Surgical Complication|Colonic Disease|Postoperative Complications|Urinary Retention Postoperative|Urinary Tract Infections","Device: Immediate urinary catheter removal|Device: Early urinary catheter removal","Acute urinary retention rate|Urinary tract infections|UC reinsertion|Pain scores|Bowel function|Mobilization|Morbility|Length of hospital stay","Azienda Ospedaliera Universitaria Integrata Verona|Faenza Hospital|Ravenna Hospital|IRCCS Humanitas Research Hospital|Humanitas University|Universita di Verona","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","216","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","EURiCaRe","February 15, 2022","October 31, 2023","December 31, 2023","February 21, 2022",,"July 21, 2023","Division of General and Hepatobiliary Surgery, Verona, Italy",,"https://ClinicalTrials.gov/show/NCT05249192"
1245,"NCT01663181","Pain-perception During Outpatient cystoscopy-a Prospective Controlled Study",,"Completed","No Results Available","Urinary Incontinence|Overactive Bladder|Pelvic Organ Prolapse|Recurrent Urinary Tract Infections",,"subjective pain perception immediately after examination as measured by a standard visual analog scale|difference between anticipated pain and actual pain perception","Medical University of Vienna","Female","18 Years and older   (Adult, Older Adult)",,"109","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","413/2009","May 2009","February 2010","April 2010","August 13, 2012",,"April 12, 2022","Medical University Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT01663181"
1246,"NCT00870649","Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium","Bilhvax3","Completed","No Results Available","Urinary Schistosomiasis|Schistosoma Haematobium","Biological: Bilhvax vaccine (Sh28GST)|Biological: placebo","A significant delay of recurrence of the schistosomiasis pathology in vaccine group compared to control group.|Evaluation of safety Percentage of children presenting at least one adverse event of degree ≥ 2. Percentage of children presenting at least one adverse event implying modification of the vaccine strategy.","Institut National de la Santé Et de la Recherche Médicale, France","All","6 Years to 9 Years   (Child)","Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","BT05-01|2008-006757-40","February 2009","June 2012","December 2012","March 27, 2009",,"November 8, 2016","ESPOIR Pour La Santé, Saint Louis, Senegal",,"https://ClinicalTrials.gov/show/NCT00870649"
1247,"NCT02246361","Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication","EDIFIP","Completed","No Results Available","Ankle Sprain|Infectious Colitis|Diverticulitis|Pyelonephritis|Prostatitis|Pneumonitis","Procedure: Patient Information Leaflet (PIL)","Doctor Patient Communication score|Adherence score|Satisfaction score","Floralis|Groupe Hospitalier Mutualiste de Grenoble","All","15 Years and older   (Child, Adult, Older Adult)","Phase 4","211","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","N°IRB 5891","September 2014","May 2015","May 2015","September 22, 2014",,"August 27, 2015","Groupe Hospitalier Mutualiste, service des urgences, Grenoble, Isere, France|Centre Hospitalier, Chambery, Savoie, France",,"https://ClinicalTrials.gov/show/NCT02246361"
1248,"NCT00943722","A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)",,"Completed","Has Results","Cervical Cancers|Vulvar Cancer|Vaginal Cancer|Genital Lesions|PAP Test Abnormalities|HPV Infections","Biological: V503","Base Study: Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])|Base Study: GMTs for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] and 16- to 26-Year-Old Females [Lot 1])|Base Study: GMTs for Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)|Base Study: Percentage of Participants With Injection Site Adverse Experiences (AEs)|Base Study: Percentage of Participants With Systemic AEs|Base Study: Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC)|Extension Study: GMTs For Each of the HPV Types Contained in the Vaccine|Extension Study: Percentage of Participants Who Are Seropositive to Each of the HPV Types Contained in the Vaccine|Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])|Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Males [Lot 1] Versus 16- to 26-Year-Old Females [Lot 1])|Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)|Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Females|Extension Study: Combined Incidence of HPV 6/11/16/18/31/33/45/52/58-Related Persistent Infection in Males|Extension Study: Combined Incidence of Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Vaginal Intraepithelial Neoplasia, Genital Warts, and Cervical/Vulvar/Vaginal Cancers Related to HPV 6/11/16/18/31/33/45/52/58 in Females|Extension Study: Combined Incidence of Penile Intraepithelial Neoplasia, Penile/Perineal/Perianal Cancers and Genital Warts Related to HPV 6/11/16/18/31/33/45/52/58 in Males|Extension Study: Percentage of Participants With Vaccine-Related or Procedure-Related Serious Adverse Events","Merck Sharp & Dohme LLC","All","9 Years to 26 Years   (Child, Adult)","Phase 3","3074","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","V503-002|2009_611|2009-011617-25","August 27, 2009","April 30, 2011","April 22, 2021","July 22, 2009","January 13, 2015","October 3, 2022",,"""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/22/NCT00943722/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00943722"
1249,"NCT00368446","Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease",,"Completed","No Results Available","Cystic Fibrosis|Pseudohypoaldosteronism|Nontuberculous Mycobacterial Infection|Chronic Granulomatous Disease|Primary Ciliary Dyskinesia",,"PCD compatible clinical phenotype or sibling with PCD, plus defect in ciliary ultrastructure","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","2 Years to 65 Years   (Child, Adult, Older Adult)",,"87","NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","060217|06-H-0217","October 17, 2006",,,"August 24, 2006",,"March 13, 2024","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00368446"
1250,"NCT00551187","A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)",,"Completed","No Results Available","Cervical Cancer|Vulvar Cancer|Vaginal Cancer|Genital Warts|Human Papillomavirus Infection","Biological: V504|Biological: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Biological: Comparator: Placebo (unspecified)","Geometric mean titers (GMTs) to HPV types contained in the administered vaccines|Seroconversion percentages to HPV types contained in the administered vaccines","Merck Sharp & Dohme LLC","Female","16 Years to 26 Years   (Child, Adult)","Phase 2","620","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","V504-001|2007_566","October 2007","May 2009","May 2009","October 30, 2007",,"June 8, 2015",,,"https://ClinicalTrials.gov/show/NCT00551187"
1251,"NCT00543543","Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)",,"Completed","Has Results","Cervical Cancer|Vulvar Cancer|Vaginal Cancer|Genital Warts|Human Papillomavirus Infection","Biological: Comparator: GARDASIL|Biological: Experimental: V503","Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis)|Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (End-of-study Update)|Base Study: Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18/31/33/45/52/58|Base Study: Percentage of Participants With One or More Adverse Event|Base Study: Percentage of Participants With One or More Injection-site Adverse Event|Base Study: Percentage of Participants With One or More Non-injection-site (Systemic) Adverse Event|Base Study: Percentage of Participants With One or More Vaccine-related Adverse Event|Base Study: Percentage of Participants With Study Medication Withdrawn Due to an Adverse Event|Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Persistent Infection|Base Study: Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18/31/33/45/52/58","Merck Sharp & Dohme LLC","Female","16 Years to 26 Years   (Child, Adult)","Phase 3","14840","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","V503-001|2007_538","September 24, 2007","April 10, 2013","July 7, 2016","October 15, 2007","December 19, 2014","November 27, 2018",,,"https://ClinicalTrials.gov/show/NCT00543543"
1252,"NCT00520598","Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)",,"Completed","No Results Available","Cervical Cancer|Vulvar Cancer|Vaginal Cancer|Genital Warts|Human Papillomavirus Infection","Biological: Comparator: V505 formulation 1|Drug: Comparator: V505 formulation 2|Biological: Comparator: V505 formulation 3|Biological: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant|Biological: Comparator: Placebo (unspecified)","Geometric mean titers (GMTs) to HPV types contained in the vaccines administered in a 3-dose regimen|Geometric mean titers (GMTs) to HPV types contained in the vaccines administered in a 2-dose regimen","Merck Sharp & Dohme LLC","Female","16 Years to 26 Years   (Child, Adult)","Phase 2","511","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","V505-001|2007_567","October 2007","May 2011","May 2011","August 24, 2007",,"November 26, 2015",,,"https://ClinicalTrials.gov/show/NCT00520598"
1253,"NCT05999851","Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy","EDIPE","Not yet recruiting","No Results Available","Preeclampsia|Hypertensive Disorder of Pregnancy","Device: Arterial applanation tonometry|Device: In vivo endothelial glycocalyx measurement|Diagnostic Test: Serum markers of angiogenesis and endothelial dysfunction|Diagnostic Test: Blood chemistry test|Diagnostic Test: Serum xanthine oxidase activity","Perfused Boundary Region (PBR)|Carotid-femoral pulse wave velocity (cf-PWV)|Number of participants with hypertensive disorders of pregnancy|Number of participants with preeclampsia|Serum Angiopoietin 1 (ANG-1)|Serum Angiopoietin 2 (ANG-2)|Serum Endothelin-1 (ET-1)|Serum Intercellular adhesion molecule-1 (ICAM-1)|Serum Vascular Cell Adhesion Molecule-1 (VCAM-1)|Number of participants with long-term cardiovascular outcomes","IRCCS Azienda Ospedaliero-Universitaria di Bologna|University of Bologna","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","346/2023/Oss/AOUBo","September 2023","May 2026","September 2031","August 21, 2023",,"August 21, 2023","Cardiovascular Internal Medicine Unit, IRCCS University Hospital of Bologna, Bologna, Italy, Bologna, Italy",,"https://ClinicalTrials.gov/show/NCT05999851"
1254,"NCT05275257","Can the Use of Uricap Female Device Lead to Better Care for Women > 75+Years?","U-PROTECT","Withdrawn","No Results Available","Urinary Incontinence|Urinary Tract Infections|Incontinence-associated Dermatitis|Cognition Disorders in Old Age|Behavioral and Psychiatric Symptoms of Dementia","Device: Use of Uricap Female, a New Urine Collecting Device","UTIs|Inflammation|Genital skin status|Cognitive status|QoL|Health economics|Behavioural and psychological symptoms|Neuropsychiatric symptoms in dementia","Region Örebro County|Örebro kommun|Kumla kommun","Female","75 Years and older   (Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","274847","April 2022","April 2026","April 2028","March 11, 2022",,"September 13, 2023","Department of Geriatrics, University Hospital Örebro, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT05275257"
1255,"NCT05045755","The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female",,"Recruiting","No Results Available","Cervical Intraepithelial Neoplasia|Cervical Cancer|Vaginal Intraepithelial Neoplasia|Vulvar Intraepithelial Neoplasia|Persistent Infection","Biological: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)","Number of Subjects With CIN2+ and/or VIN2+ and/or VaIN2+ Associated With HPV-16 and/or -18 Cervical Infection on 90m and 114m after dose 1|Number of Subjects With HPV-16 and/or -18 persistent cervical infection(6-month+ definition) on 90m and 114m after dose 1|Anti-HPV16 and anti-HPV18 type-specific IgG antibody level on 90m and 114m after dose 1","Jun Zhang|Xiamen Innovax Biotech Co., Ltd|Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.|Xiamen University","Female","26 Years to 54 Years   (Adult)",,"1339","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HPV-PRO-003-2","April 13, 2021","August 10, 2023","January 2024","September 16, 2021",,"January 26, 2023","Henan Cancer Hospital, Zhengzhou, Henan, China",,"https://ClinicalTrials.gov/show/NCT05045755"
1256,"NCT04969445","The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female",,"Recruiting","No Results Available","Cervical Intraepithelial Neoplasia|Cervical Cancer|Vaginal Intraepithelial Neoplasia|Vulvar Intraepithelial Neoplasia|Persistent Infection","Biological: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)","Number of Subjects With CIN2+ and/or VIN2+ and/or VaIN2+ Associated With HPV-16 and/or -18 Cervical Infection on 90m and 114m after dose 1|Number of Subjects With HPV-16 and/or -18 persistent cervical infection(6-month+ definition) on 90m and 114m after dose 1","Jun Zhang|Xiamen Innovax Biotech Co., Ltd|Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.|Xiamen University","Female","26 Years to 54 Years   (Adult)",,"647","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HPV-PRO-003-3","March 30, 2021","July 27, 2023","January 2024","July 20, 2021",,"January 26, 2023","Peking University People's Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04969445"
1257,"NCT04704908","Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)",,"Active, not recruiting","No Results Available","Cervical Intraepithelial Neoplasia|Cervical Cancer|Vaginal Intraepithelial Neoplasia|Vulvar Intraepithelial Neoplasia|Persistent Infection","Drug: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)","Anti-HPV16 and anti-HPV18 seroprevalence and geometric mean concentrations at Month 54 (type-specific IgG antibody)|Anti-HPV16 and anti-HPV18 seroprevalence and geometric mean concentrations at Month 54 (type specific neutralizing antibody)","Jun Zhang|Xiamen Innovax Biotech Co., Ltd|Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.|Xiamen University","Female","14 Years to 32 Years   (Child, Adult)",,"979","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HPV-PRO-006-3","February 6, 2021","April 1, 2021","December 2023","January 12, 2021",,"January 26, 2023","Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04704908"
1258,"NCT02973178","Scanadu Urine Device Validation Study Protocol",,"Unknown status","No Results Available","Urinary Tract Infections|Proteinuria|Ketone Urine|Hematuria|Glucose Intolerance","Device: Scanadu Urine Device","Usability: % successful scans in three tests conducted by lay users in following the app on the iPhone and obtain user experience on questionnaire|Method Comparison: Conduct two tests by following iPhone app (self and patient samples), results in concordance with professional testers; achieve accuracy in different concentrations of six urine analytes each using approximately 20 samples per level.|Reproducibility: Lay user's ability to repeat a urine test nine times by following iPhone app and obtain nine results that are in concordance.","Scanadu, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","FO-004","August 2016","December 2016","December 2016","November 25, 2016",,"November 25, 2016","West Coast Research, LLC, Mountain View, California, United States|West Coast Research, LLC, San Leandro, California, United States",,"https://ClinicalTrials.gov/show/NCT02973178"
1259,"NCT05284877","The Organ Transplant Recipient HPV and Skin Cancer Study",,"Recruiting","No Results Available","Solid Organ Transplant Recipient|Skin Cancer|Skin Dysplasia|HPV Infection|Cervical Intraepithelial Neoplasia|Cervical Cancer|HPV-Related Malignancy","Other: No intervention","Difference in prevalence, incidence and persistence of cervical HPV infection in female OTRs compared to immunocompetent controls.|Difference in prevalence of oral HPV infection in female OTRs compared to immunocompetent controls.|Correlations between lifestyle factors, clinical factors and occurrence of cervical HPV infection in female OTRs.|Correlations between lifestyle factors, clinical factors and occurrence of oral HPV infection in female OTRs.|Difference in prevalence and incidence of HPV-related dysplasia and cancer in female OTRs compared to immunocompetent controls.|Correlations between lifestyle factors, clinical factors and prevalence of skin dysplasia and cancer in OTRs.|Correlation between Vitamin D and prevalence of skin dysplasia and cancer in OTRs.|Correlations between skin pigmentation, facial solar lentigines and prevalence of skin dysplasia and cancer in OTRs.|Correlation between prevalence of cervical HPV infection and prevalence of skin dysplasia and cancer in OTRs.|Correlations between history of herpes zoster, prevalence of cervical HPV infection and prevalence of skin dysplasia and cancer in OTRs.|Difference in prevalence and incidence of skin cancer in female OTRs compared to immunocompetent controls.","Merete Haedersdal|Danish Cancer Society|Zealand University Hospital|Vejle Hospital|Herlev and Gentofte Hospital|Rigshospitalet, Denmark|Bispebjerg Hospital","All","18 Years and older   (Adult, Older Adult)",,"1800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HPV Skin Cancer OTR|Journal-nr.: H-21038387","March 10, 2022","April 2027","April 2027","March 17, 2022",,"March 24, 2023","Department of Dermatology, Bispebjerg Hospital, Copenhagen NV, Region Hovedstaden, Denmark|Department of Dermatology and Allergy, Herlev og Gentofte Hospital, Hellerup, Region Hovedstaden, Denmark|Department of Dermatology, Zealand University Hospital, Roskilde, Region Sjælland, Denmark",,"https://ClinicalTrials.gov/show/NCT05284877"
1260,"NCT03206255","Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls",,"Completed","No Results Available","Cervical Intraepithelial Neoplasia|Cervical Cancer|Vaginal Intraepithelial Neoplasia|Vulvar Intraepithelial Neoplasia|Persistent Infection","Procedure: 3 doses of HPV 16/18 bivalent vaccine|Procedure: 2 doses of HPV 16/18 bivalent vaccine","Anti-HPV16 and anti-HPV18 seroprevalence and geometric mean concentrations at Months 18 and 30 (type specific IgG antibody)|Anti-HPV16 and anti-HPV18 seroprevalence and geometric mean concentrations at Months 18 and 30 (type specific neutralizing antibody)|All the Serious Adverse Events(SAE) occurred during clinical trial time frame would be recorded","Jun Zhang|Xiamen Innovax Biotech Co., Ltd|Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.|Xiamen University","Female","10 Years to 28 Years   (Child, Adult)",,"940","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HPV-PRO-006-2","July 1, 2017","August 15, 2018","August 15, 2018","July 2, 2017",,"January 4, 2019","Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT03206255"
1261,"NCT05931887","Evaluation of the Novel Silq ClearTract Catheter in Patients With Chronic Urinary Retention",,"Recruiting","No Results Available","Catheter Infection|Catheter Blockage|Catheter Related Complication|Catheter Calcification","Device: SILQ ClearTract 100% Silicone 2-Way Foley Catheter","Number of Catheter Related Complications|Catheter Related Complication Treatment Costs|Catheter Encrustation|Patient Preference|Patient Satisfaction","Silq Technologies Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","STC002","July 26, 2023","October 26, 2024","December 26, 2024","July 5, 2023",,"August 1, 2023","Rancho Los Amigos National Rehabilitation Center, Downey, California, United States",,"https://ClinicalTrials.gov/show/NCT05931887"
1262,"NCT02562508","A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls",,"Completed","No Results Available","Cervical Intraepithelial Neoplasia|Cervical Cancer|Vaginal Intraepithelial Neoplasia|Vulvar Intraepithelial Neoplasia|Persistent Infection","Procedure: 3 doses of HPV 16/18 bivalent vaccine|Procedure: 2 doses of HPV 16/18 bivalent vaccine","Anti-HPV16 and anti-HPV18 seroconversion rates and geometric mean concentrations at Months 7 (type specific IgG antibody)|Number of Participants with Adverse Events","Jun Zhang|Xiamen Innovax Biotech Co., Ltd|Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.|Xiamen University","Female","9 Years to 26 Years   (Child, Adult)","Phase 3","979","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","HPV-PRO-006","December 5, 2015","August 12, 2016","August 12, 2016","September 29, 2015",,"August 16, 2018","Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02562508"
1263,"NCT05670535","Sjögren and Gynecologic Considerations",,"Completed","No Results Available","Primary Sjögren Syndrome|Vaginitis Candida|Vaginitis|Sexual Dysfunction","Other: Visual analogue scale (VAS) for dyspareunia|Other: Visual analogue scale (VAS) for vaginal dryness|Other: The European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)|Other: The European League Against Rheumatism Sjögren's Syndrome Patient Reported Index (ESSPRI)","Vaginal candidiasis|Acute vaginitis|Visual analogue scale for dyspareunia|Visual analogue scale for vaginal dryness|The European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)|The European League Against Rheumatism Sjögren's Syndrome Patient Reported Index (ESSPRI)","Ankara City Hospital Bilkent","Female","20 Years to 50 Years   (Adult)",,"118","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","E1-20-1290","March 1, 2021","October 15, 2022","November 10, 2022","January 4, 2023",,"January 4, 2023","Ankara City Hospital, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT05670535"
1264,"NCT04140669","Automated Myocardial Performance Index Using Samsung HERA W10",,"Terminated","No Results Available","Twin to Twin Transfusion Syndrome|Congenital Diaphragmatic Hernia|Neural Tube Defects|Lower Urinary Tract Infection","Device: Automated Myocardial Performance Index (MPI)","Automated MPI can used to diagnosis and predict fetal cardiac dysfunction in fetal surgeries.","Mayo Clinic","Female","18 Years and older   (Adult, Older Adult)",,"7","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","18-005189","September 16, 2019","July 7, 2020","July 7, 2020","October 28, 2019",,"July 13, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04140669"
1265,"NCT02746588","Description of the Uterine Cavity in Patients With Recurrent Miscarriages",,"Completed","No Results Available","Recurrent Miscarriages|Habitual Abortions","Other: Office hysteroscopy","Description of the Uterine Cavity in Patients With Recurrent Miscarriages","Hvidovre University Hospital","Female","18 Years to 45 Years   (Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-15011157","February 1, 2016","January 1, 2019","January 1, 2019","April 21, 2016",,"March 29, 2022","Hvidovre Hospital, Department of Gynecology and Obstetrics, Copenhagen, Hvidovre, Denmark",,"https://ClinicalTrials.gov/show/NCT02746588"
1266,"NCT04407156","Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom",,"Completed","No Results Available","COVID|AKI","Other: acute kidney injury","Incidence of Acute kidney injury in COVID-19|All-cause mortality in AKI patients","University Hospitals of Derby and Burton NHS Foundation Trust","All","18 Years to 110 Years   (Adult, Older Adult)",,"724","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","UHDB/2020/050","June 1, 2020","June 7, 2020","July 20, 2020","May 29, 2020",,"September 9, 2020","Derby Hospital NHS Foundation Trust, Derby, Derbyshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04407156"
1267,"NCT00109525","Early Diagnosis of Candidiasis in Premature Infants","Candida","Completed","No Results Available","Infection|Candida|Candidiasis|Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature",,"Probability of invasive candidiasis based on new assay results|Determine test performance of clinical predictive model|Determine test performance (sensitivity and specificity) of polymerase chain reaction (PCR) testing|Determine test performance of Beta-glucan assay|Determine test performance of Gas Chromatography Mass Spectrometry for D-arabinitol of blood samples|Determine test performance of Gas Chromatography Mass Spectrometry for D-arabinitol of urine samples|Determine test performance of the blood culture|Determine test performance of the lumbar puncture (cell count, protein, glucose, and culture)|Determine test performance of tracheal aspirates|Determine test performance of urine cultures|Compare clinical predictive model performance to neonatologist clinical judgment|Determine incidence of end-organ damage in neonates with candidemia|Determine resistance patterns of organisms isolated|Determine molecular epidemiology of candidemia|Determine genetic expression of organism virulence factors|Neurodevelopmental outcome","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Days to 120 Days   (Child)",,"1500","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0030|UL1RR024139|UL1RR024160|M01RR016587|M01RR000030|M01RR000032|M01RR000039|M01RR000044|M01RR000054|M01RR000059|M01RR006022|M01RR000633|M01RR000070|M01RR007122|M01RR000750|M01RR000080|M01RR008084|M01RR000997|U10HD036790|U10HD021364|U10HD021373|U10HD021385|U10HD021397|U10HD027851|U10HD027853|U10HD027856|U10HD027871|U10HD027880|U10HD027904|U10HD034216|U10HD040461|U10HD040492|U10HD040498|U10HD040521|U10HD040689|U10HD053089|U10HD053109|U10HD053119","March 2004","July 2007","December 2009","April 29, 2005",,"March 22, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|University of California at San Diego, San Diego, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Tufts Medical Center, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|Wake Forest University, Charlotte, North Carolina, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00109525"
1268,"NCT05124327","Remote Monitoring and Follow-up for Postpartum Hypertensive Disorders of Pregnancy",,"Completed","No Results Available","Hypertensive Disorder of Pregnancy|Preeclampsia|Gestational Hypertension","Other: QI project- usage of RPM","Patient satisfaction with RPM compared with standard of care|Adherence with the program|Readmission rate|Out of range blood pressures|titration of blood pressure medication","Cedars-Sinai Medical Center|University of California, Los Angeles","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STUDY00001570","March 7, 2022","June 30, 2022","June 30, 2022","November 17, 2021",,"February 8, 2023","Cedars Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT05124327"
1269,"NCT05392244","Characteristics of Peripheral Blood Lymphocyte Subsets in Children With PNS",,"Not yet recruiting","No Results Available","Lymphocyte Disorder|Nephrotic Syndrome",,"peripheral blood lymphocyte subsets|biochemical indicators","Nanfang Hospital, Southern Medical University","All","up to 18 Years   (Child, Adult)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","NFEC-2022-076","May 30, 2022","June 30, 2022","August 31, 2022","May 26, 2022",,"May 26, 2022",,,"https://ClinicalTrials.gov/show/NCT05392244"
1270,"NCT02453646","Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter",,"Completed","No Results Available","End Stage Renal Disease","Device: NexSite HD Patients","Number of participants with Catheter-Related Blood Stream Infection (CRBSI)(bacteremia/fungemia) as an adverse event.|Number of participants with adverse events associated with device placement and use.|Number of participants with unhealed catheter exit sites|Number of participants with tunnel infection as an adverse event|Number of participants with exit site infection as an adverse event|Number of participants with Pneumothorax, haemothorax, arrhythmia, air embolism or arterial perforation as an adverse event.|Number of participants with Catheter dislodgement, Catheter tip dislodgement and catheter thrombosis as an adverse event.","Marvao Medical","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","120","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TR 0147","April 2015","September 2017","July 2018","May 25, 2015",,"October 1, 2018","Eastern Nephrology Associates, Greenville, North Carolina, United States|Eastern Nephology Associates, New Bern, North Carolina, United States|Capital Nephrology Associates, Raleigh, North Carolina, United States|South Carolina Nephrology and Hypertension Center Inc, Orangeburg, South Carolina, United States|Lubbock Vascular Access Centre, Lubbock, Texas, United States|Renal Associates, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02453646"
1271,"NCT02653118","Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)",,"Active, not recruiting","No Results Available","Cervical Cancer|Vulvar Cancer|Vaginal Cancer|Genital Warts|Human Papillomavirus Infection","Biological: V503|Biological: GARDASIL","Combined Incidence of HPV Type 16, 18, 31, 33, 45, 52, or 58-related Cervical Intraepithelial Neoplasia (CIN) Grades 2 or 3, Adenocarcinoma In Situ (AIS), and Cervical Cancer in Cohort 1","Merck Sharp & Dohme LLC","Female","16 Years to 26 Years   (Child, Adult)",,"4453","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","V503-021|2013-003549-40","January 22, 2016","January 1, 2040","January 1, 2040","January 12, 2016",,"December 7, 2023",,,"https://ClinicalTrials.gov/show/NCT02653118"
1272,"NCT04754737","Antibiotic Usage Prior to OnabotulinumtoxinA Injection",,"Recruiting","No Results Available","Antibiotic Stewardship|Overactive Bladder|Onabotulinumtoxin A|UTI","Other: No antibiotic|Other: Prophylactic antibiotic|Procedure: cystoscopic injection of onabotulinumtoxinA","symptomatic UTI|Percentage of subjective improvement in overactive bladder symptoms|Rate of adverse events including dysuria, gross hematuria, and urinary retention","Benaroya Research Institute|Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU)|Stony Brook University|Northwell Health|Virginia Mason Hospital/Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB20-101","March 23, 2021","July 2023","December 2023","February 15, 2021",,"July 25, 2022","Vriginia Mason Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04754737"
1273,"NCT02831556","Point of Care 3D Ultrasound for Various Applications: A Pilot Study",,"Recruiting","No Results Available","Appendicitis|Evidence of Cholecystectomy|Gallstones|Pregnancy, Ectopic|Aortic Aneurysm|Kidney Stones|Intrauterine Pregnancy|Diverticulitis|Abdominal Injuries|Tumors|Pancreatitis|Digestive System Diseases|Gastrointestinal Diseases|Intraabdominal Infections|Intestinal Diseases|Pregnancy|Vascular Disease|Uterine Fibroids|Ovarian Cysts|Uterine Abnominalies|Bladder Abnominalies|Testicular Abnominalies|Polyps",,"Experimental ultrasound diagnosis agreement with final reference standard diagnosis|Duration of experimental ultrasound exam|Experimental ultrasound image quality.","Duke University|Wallace H. Coulter Foundation","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00071789","July 2016","January 2025","February 2025","July 13, 2016",,"November 2, 2023","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02831556"
1274,"NCT03692715","Antibiotic Prophylaxis Before Shock Wave Lithotripsy","APPEAL","Recruiting","No Results Available","Ureteral Stones|Ureteral Calculi|Nephrolithiasis","Drug: Ciprofloxacin|Drug: Placebo","Composite outcome including positive urine culture, symptoms of cystitis, pyelonephritis or urosepsis|Bacteriuria defined as ≥ 100000 Colony Forming Unit/ml|Symptoms of cystitis defined as new onset burning sensation or pain with voiding, frequency, urgency|Pyelonephritis or urosepsis defined as Hospital admission with fever ≥38.5 Celsius|Change in International Prostate Symptom Score (IPSS) total score (0-35, higher score indicates worse outcome)|Individual components of International Prostate Symptom Score (0-7 per domain, with higher score indicating worse outcome)|Pain scale determined on a range of 0-5 with higher score indicating worse outcome","Clinical Urology and Epidemiology Working Group|University of Helsinki|Helsinki University Central Hospital|University of Western Ontario, Canada|Centre de recherche du Centre hospitalier universitaire de Sherbrooke|King Abdulaziz University|Hospital Sao Luiz|St. Petersburg State Pavlov Medical University|University Hospital, Basel, Switzerland|Tallaght University Hospital|Tabriz University of Medical Sciences|Dr Cipto Mangunkusumo General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CLUE","September 27, 2018","December 31, 2024","December 31, 2024","October 2, 2018",,"October 18, 2021","Hospital Sao Luiz, São Paulo, Brazil|Western University Hospital, London, Ontario, Canada|University of Sherbrooke, Sherbrooke, Quebec, Canada|Helsinki University Hospital, Helsinki, Finland|Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia|Tabriz University of Medical Science, Tabriz, Iran, Islamic Republic of|Tallaght University Hospital, Dublin, Ireland|St Petersburg State Pavlov Medical University, Saint Petersburg, Russian Federation|King Abdulaziz University, Jeddah, Saudi Arabia|Department of Urology, University Hospital Basel, Basel, Switzerland","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/15/NCT03692715/Prot_SAP_000.pdf|""Informed Consent Form: Informed consent form Generic"", https://classic.clinicaltrials.gov/ProvidedDocs/15/NCT03692715/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03692715"
1275,"NCT05569746","A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS",,"Completed","No Results Available","Diarrhea-Associated Hemolytic Uremic Syndrome|Pediatric Kidney Disease|Hemolytic-Uremic Syndrome","Drug: INM004|Other: SoC","Days of dialysis|Adverse events (AEs)|Pharmacokinetics (PK) Evaluation of INM004|Mortality|Change in thrombotic microangiopathy involvement (Creatinine %)|Change in thrombotic microangiopathy involvement (Creatinine)|Change in thrombotic microangiopathy involvement (Hematuria %)|Change in thrombotic microangiopathy involvement (Hematuria)|Change in thrombotic microangiopathy involvement (Proteinuria %)|Change in thrombotic microangiopathy involvement (Proteinuria)|Change in thrombotic microangiopathy involvement (GFR)|Change in thrombotic microangiopathy involvement (GFR %)|Change in thrombotic microangiopathy involvement (LDH %)|Change in thrombotic microangiopathy involvement (LDH)|Change in thrombotic microangiopathy involvement (Platelet)|Change in thrombotic microangiopathy involvement (Platelet %)|Change in thrombotic microangiopathy involvement (Hemoglobin %)|Change in thrombotic microangiopathy involvement (Hemoglobin)|Change in renal involvement (dialysis)|Change in renal involvement (dialysis subgroups)|Change in renal involvement (anuria)|Change in renal involvement (hypertension)|Change in extrarenal involvement (hematological Interventions)|Change in extrarenal involvement (hematological Clinical)|Change in extrarenal involvement (neurological)|Change in extrarenal involvement (cardiovascular)|Change in extrarenal involvement (gastrointestinal)|Change in extrarenal involvement (endocrine)|Change in secondary complications (pulmonary)|Change in secondary complications (infectious involvement)|Change in the length of hospital stay|Change in laboratory parameters associated with worse prognosis","Inmunova S.A.|KLIXAR|Linical Co., Ltd.|PHV LATAM","All","1 Year to 12 Years   (Child)","Phase 2","57","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT-INM004-03","October 6, 2022","May 15, 2023","July 14, 2023","October 6, 2022",,"August 21, 2023","Hospital Interzonal Dr. José Penna, Bahía Blanca, Buenos Aires, Argentina|Hospital El Cruce - Néstor Kirchner, Florencio Varela, Buenos Aires, Argentina|Hospital De Niños Sor María Ludovica, La Plata, Buenos Aires, Argentina|Hospital Interzonal Especializado Materno Infantil Don Victorio Tetamanti, Mar Del Plata, Buenos Aires, Argentina|Hospital Dr. Lucio Molas, Santa Rosa, La Pampa, Argentina|Sanatorio de Niños, Rosario, Santa Fe, Argentina|Hospital General de Niños Pedro de Elizalde, Ciudad Autonoma de Buenos aires, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aire, Argentina|Hospital de Niños Dr. Ricardo Gutierrez, Ciudad Autonoma de Buenos Aire, Argentina|Sanatorio Güemes, Ciudad Autonoma de Buenos Aire, Argentina|Clínica Zabala Swiss Medical, Ciudad Autónoma de Buenos Aires, Argentina|Hospital de Pediatría Garrahan, Ciudad Autónoma de Buenos Aires, Argentina|Hospital de Niños de la Santísima Trinidad, Córdoba, Argentina|Sanatorio Allende, Córdoba, Argentina|Hospital Pediátrico Dr. Humberto Notti, Mendoza, Argentina|Hospital Provincial Neuquén Dr. Eduardo Castro Rendón, Neuquén, Argentina",,"https://ClinicalTrials.gov/show/NCT05569746"
1276,"NCT03093194","Vaginal Antimicrobacterial Preparation Before Cesarean Secation for Endometritis Prevention",,"Unknown status","No Results Available","A Known Allergy to Antiseptic Soap|Women Who Had Any Infection in the Perioperative Period|A Known Allergy to Chlorohexidine Alcohol or Shellfis","Other: vaginal preparation before CS with Septal soap and septol.|Other: No vaginal preparation before CS with Septal soap and septol.","rates of endometritis|rates of Urinary Tract Infections","Rambam Health Care Campus","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","1040","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","RAMBAMMV","April 10, 2017","April 30, 2019","April 30, 2020","March 28, 2017",,"April 5, 2017",,,"https://ClinicalTrials.gov/show/NCT03093194"
1277,"NCT04378686","Serological Testing for COVID-19 (SARS-CoV-2) in ESKD",,"Unknown status","No Results Available","SARS-CoV 2|End Stage Renal Failure on Dialysis","Other: dialysis","Antibodies against SARS-CoV-2","Universitaire Ziekenhuizen KU Leuven","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","S64000","April 23, 2020","May 1, 2021","May 1, 2022","May 7, 2020",,"May 12, 2020","Jessa Ziekenhuis, Hasselt, Limburg, Belgium|University Hospitals Leuven, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT04378686"
1278,"NCT00023582","HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru",,"Completed","No Results Available","HIV Infections|Herpes Genitalis|HIV Seronegativity|Syphilis",,,"National Institute of Allergy and Infectious Diseases (NIAID)","Male","18 Years and older   (Adult, Older Adult)",,"250","NIH","Observational",,"HPTN 036",,,,"September 11, 2001",,"August 8, 2008","Rachael McClennen, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00023582"
1279,"NCT02200120","Evaluation of Catheter Placement for Renal Replacement Therapy in Patients With Acute Kidney Injury",,"Completed","No Results Available","Acute Kidney Injury",,"Dialysis adequacy|blood stream infection rates","Brigham and Women's Hospital","All","Child, Adult, Older Adult",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","99904021982","January 2013","June 2015","June 2015","July 25, 2014",,"July 21, 2015","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02200120"
1280,"NCT05228132","The Pristine Post-Market Study",,"Terminated","Has Results","Kidney Failure, Chronic|Hemodialysis Complication|Hemodialysis Catheter Infection|Hemodialysis Access Failure|Central Venous Catheter Related Bloodstream Infection|End Stage Renal Disease","Device: Pristine™ Long-Term Hemodialysis Catheter","Overall Complication Rate of the Pristine™ Catheter|Rate of Freedom From Catheter-related Bloodstream Infection (CRBSI)|Rate of Freedom From Device and/or Procedure-related Adverse Events|Rate of Technical Success|Overall Participant Survival Rate|Overall Catheter Survival Rate|Overall Patency Rate","C. R. Bard","All","18 Years and older   (Adult, Older Adult)","Not Applicable","142","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BDPI-21-001","May 16, 2022","September 21, 2022","September 21, 2022","February 8, 2022","April 11, 2024","April 11, 2024","Trinity Research Group LLC, Dothan, Alabama, United States|Yale University, New Haven, Connecticut, United States|Louisiana State University Health Shreveport Medical Center, Shreveport, Louisiana, United States|Henry Ford Health System, Detroit, Michigan, United States|North Carolina Nephrology, PA, Raleigh, North Carolina, United States|JML Research Associates, Providence, Rhode Island, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/32/NCT05228132/Prot_002.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/32/NCT05228132/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT05228132"
1281,"NCT03959410","Impact of HPV on a Cohort of Southern Italian Women: Epidemiological, Clinical, Morphological and Microbiological Features",,"Completed","No Results Available","Cervix Cancer","Diagnostic Test: Cervical biopsy","Evaluation of Cervical microbiome","University of Campania ""Luigi Vanvitelli""","Female","18 Years to 50 Years   (Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","N.594","January 4, 2019","December 10, 2021","January 1, 2022","May 22, 2019",,"April 13, 2023","Department of Woman, Child and General and Specialized Surgery, University of Campania ""Luigi Vanvitelli"", Napoli, Italy",,"https://ClinicalTrials.gov/show/NCT03959410"
1282,"NCT00124878","Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community",,"Unknown status","No Results Available","HIV Infections|Sexually Transmitted Diseases|Papillomavirus Infections|Genital Herpes|Gonorrhea|Chlamydia Infections|Syphilis|Bacterial Vaginosis","Procedure: Male circumcision","Rates of HIV acquisition in HIV-negative (neg) males and HIV-neg female partners|Rates of STD acquisition in HIV-neg and HIV positive (+) males and HIV-neg and HIV+ female partners|Circumcision safety in HIV+ and HIV-neg males|Behaviors among males and females in couples where the male is randomized to immediate versus delayed circumcision|Behaviors among men and women in the general community","Wawer, Maria J., M.D.|MRC/UVRI and LSHTM Uganda Research Unit|Rakai Health Sciences Program|Johns Hopkins Bloomberg School of Public Health","All","15 Years to 49 Years   (Child, Adult)","Phase 3","5200","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","22006","August 2003",,"September 2009","July 28, 2005",,"August 10, 2007","Rakai Health Sciences Program, Kalisizo, Rakai District, Uganda",,"https://ClinicalTrials.gov/show/NCT00124878"
1283,"NCT05473325","Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)","BRANCH-P","Not yet recruiting","No Results Available","Diabetes|Chronic Kidney Diseases|Cancer|Bowel Disease|Cardiovascular Diseases|Mononucleosis|Flu|Heart Diseases|HIV Infections|AIDS and Infections|Bulimia|Chest Infections|Arthritis|Leukaemia|Alcoholic Liver Disease|Allergies|Alzheimer Disease|Appendicitis|Eczema|Bronchitis|Cellulitis|Cirrhosis|Depression|Gout|High Cholesterol|Indigestion|Obesity|Osteoporosis",,"Signal to Noise","Willows Health|Nottingham Trent University","All","18 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","CRT00442|315046","January 1, 2023","January 1, 2024","June 22, 2025","July 25, 2022",,"August 15, 2022","Willows Medical Centre, Leicester, Leicestershire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05473325"
1284,"NCT04278404","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","POPS or POP02","Recruiting","No Results Available","Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Fibrinolysis; Hemorrhage|Attention Deficit Hyperactivity Disorder|Multisystem Inflammatory Syndrome in Children (MIS-C)|Kawasaki Disease|Coagulation Disorder|Down Syndrome","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:","Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling|Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling|Elimination rate constant (ke) as measured by PK sampling|Half-life (t1/2) as measured by PK sampling|Absorption rate constant (ka) as measured by PK sampling|AUC (area under the curve) as measured by PK sampling|Maximum concentration (Cmax) as measured by PK sampling|Time to achieve maximum concentration (Tmax) as measured by PK sampling","Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","0 Years to 20 Years   (Child, Adult)",,"5000","Other|Industry|NIH","Observational","Observational Model: Other|Time Perspective: Prospective","Pro00103838","March 5, 2020","May 2024","July 2024","February 20, 2020",,"April 1, 2024","Phoenix Children's Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|University of California, Los Angeles Medical Center, Los Angeles, California, United States|Lucile Packard Children's Hospital, Palo Alto, California, United States|Colorado University Denver, Aurora, Colorado, United States|The Children's Hospital Colorado, Aurora, Colorado, United States|Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States|Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States|Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States|University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States|University of Kansas Medical Center-JG Kidney Institute, Kansas City, Kansas, United States|University of Louisville Norton Childrens Hospital, Louisville, Kentucky, United States|Tulane University Health Science Center, New Orleans, Louisiana, United States|Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Lexington, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Mississippi Center for Advanced Medicine, Madison, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico Health Science Center, Albuquerque, New Mexico, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Pennsylvania State University--Hershey Children's Hospital, Hershey, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Children's Hospital, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States|Avera McKennan Hospital & University Medical Center, Sioux Falls, South Dakota, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|University of Texas-Southwestern Medical Center Dallas, Dallas, Texas, United States|University of Texas--Memorial Hermann Texas Medical Center, Houston, Texas, United States|The Womens Hospital of Texas, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|University Wisconsin Madison, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04278404"
1285,"NCT03044223","Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis","MIPSA","Recruiting","No Results Available","Pseudomonas Infections|Pseudomonas Septicemia|Pseudomonas; Pneumonia|Pseudomonal Bacteraemia|Pseudomonas Urinary Tract Infection|Pseudomonas Gastrointestinal Tract Infection|Sepsis|Sepsis, Severe|Critically Ill",,"Monocyte surface marker expression in critically ill patients with Pseudomonas aeruginosa sepsis|Cytokine concentrations in serum and production after ex-vivo stimulation of isolated monocytes of critically ill patients with Pseudomonas aeruginosa sepsis with LPS","University of Ulm","All","18 Years to 90 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PSA_Sepsis_M_1_2","August 2014","November 2025","December 2026","February 6, 2017",,"January 17, 2024","Clinic of Anesthesiology, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT03044223"
1286,"NCT00727519","The Effect of Pomegranate Juice on Oxidative Stress in Hemodialysis Patients",,"Completed","No Results Available","End Stage Renal Disease|Hemodialysis","Dietary Supplement: Pomegranate juice|Dietary Supplement: Placebo",,"Western Galilee Hospital-Nahariya","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Other","Interventional","Primary Purpose: Prevention","PJHD-23-7-08CTIL","July 2008",,"January 2010","August 4, 2008",,"March 23, 2010","Western Galilee hospital, Nahariya, Israel",,"https://ClinicalTrials.gov/show/NCT00727519"
1287,"NCT00382343","A Randomized Controlled Trial on Antibiotic Prophylaxis in Children With Vesico-Ureteral Reflux",,"Completed","No Results Available","Pyelonephritis|Renal Scars","Drug: Sulfamethoxazole/trimethoprim","Recurrence of pyelonephritis|Renal scars|Persistence of vesico-ureteral reflux","IRCCS Burlo Garofolo","All","1 Day to 30 Months   (Child)","Phase 4","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","RC 35/00","November 1999","March 2003","March 2007","September 29, 2006",,"April 28, 2015","San Polo Hospital, Monfalcone, Gorizia, Italy|San Daniele Hospital, San Daniele, Udine, Italy|Sant'Antonio Abate Hospital, Tolmezzo, Udine, Italy|Sant'Orsola Hospital, Bologna, Italy|Bufalini Hospital, Cesena, Italy|Santa Maria degli Angeli Hospital, Pordenone, Italy|Institute of Child Health IRCCS Burlo Garofolo, Trieste, Italy",,"https://ClinicalTrials.gov/show/NCT00382343"
1288,"NCT02993185","Making Healthy Decisions: A Trial Evaluating the ""Your Move"" Teen Pregnancy-prevention Intervention",,"Completed","No Results Available","Pregnancy, Abdominal|Sexual Behavior|Sexually Transmitted Infection|Sexually Transmitted Diseases|Dietary Modification|Eating Behaviors","Behavioral: Your Move|Behavioral: Eat Smart","Number of sexual partners for vaginal intercourse|Number of incidents of vaginal sex without using hormonal contraception, copper IUD, or condoms|Number of incidents of vaginal sex without condoms|Number of incidents of vaginal intercourse|Condom errors or failure|Number of incidents of vaginal, oral, or anal sex without using condoms|Number of sexual partners for vaginal, oral, or anal intercourse|Perceived self efficacy to communicate about sexual boundaries and condom use","Carnegie Mellon University|ETR Associates","Female","14 Years to 19 Years   (Child, Adult)","Not Applicable","808","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TP2AH000027","October 1, 2016","December 31, 2020","December 31, 2020","December 15, 2016",,"May 24, 2021","Carnegie Mellon University, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02993185"
1289,"NCT05372016","Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females",,"Completed","No Results Available","HPV Infections|Cervical Cancer|Vulvar Cancer|Vaginal Cancer|CIN1|CIN2|CIN3|VaIN1|VaIN2|VaIN3|Genital Wart|VIN 1|VIN 2|VIN 3|AIS","Biological: Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|Biological: Active Comparator: GARDASIL ®9","The seroconversion rate of neutralizing antibodies|Number of subjects with postive antibodies after the whole schedule vaccination from the former negative subjects|The level of neutralizing antibody elicited by the vaccine among the subjects with pre-immune positive after the whole schedule vaccination|Number of subjects with seroconversion rate (4-fold increase) after the whole schedule vaccination|Number of AE within 30 minutes after each dose|Number of SAE within 7days after each dose|Number of unsolicited adverse events within 30days after each dose|Number of all SAE during the study period|Number and rate of pregnancy events","Shanghai Bovax Biotechnology Co., Ltd.|Chongqing Bovax Biopharmaceutical Co., Ltd.","Female","16 Years to 26 Years   (Child, Adult)","Phase 3","1200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","9-HPV-3002","September 19, 2020","June 17, 2022","June 17, 2022","May 12, 2022",,"November 24, 2023","Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Guangxi, China",,"https://ClinicalTrials.gov/show/NCT05372016"
1290,"NCT05371353","Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine",,"Not yet recruiting","No Results Available","HPV Infections|Cervical Cancer Stage IIa|Vaginal Cancer|Genital Wart|CIN1|CIN2|CIN3",,"Seroconversion rate (SCR) for Each of the HPV Types Contained in the Vaccine|SCR for Each of the HPV Types Contained in the Vaccine|Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine|GMTs for Each of the HPV Types Contained in the Vaccine","Shanghai Bovax Biotechnology Co., Ltd.","Female","9 Years to 45 Years   (Child, Adult)",,"600","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","4-HPV-3003","May 2022","May 2027","May 2027","May 12, 2022",,"May 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05371353"
1291,"NCT05027776","Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years",,"Recruiting","No Results Available","HPV Infections|Cervical Cancer Stage IIa|Vaginal Cancer|Genital Wart|CIN1|CIN2|CIN3","Biological: 2-doses Group among 9-14 years|Biological: 3-doses Group among 9-19 years|Biological: 3-doses Group among 20-26 years","Primary immunogenicity outcome|Secondary immunogenicity outcome|Number of subjecs with AEs|Numbers of subjects with solication of AEs|Numbers of subjects with unsolicited AEs|Number of subjects receiving the whole schedule vaccination with SAEs|Number of subjects with pregnancy events","Shanghai Bovax Biotechnology Co., Ltd.|Chongqing Bovax Biopharmaceutical Co., Ltd.","Female","9 Years to 26 Years   (Child, Adult)","Phase 3","1348","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","4-HPV-3002","September 15, 2021","May 29, 2022","September 29, 2026","August 30, 2021",,"February 25, 2022","Center for Disease Control and Prevention, Mianyang, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT05027776"
1292,"NCT04895020","Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years",,"Recruiting","No Results Available","HPV Infections|Cervical Cancer|Vulvar Cancer|Vaginal Cancer|CIN1|CIN2|CIN 3|VaIN1|VaIN2|VaIN3|Genital Wart|VIN 1|VIN 2|VIN 3|AIS","Biological: 9-valent HPV vaccine","The primary immunogenicity objective|Number of patients with postive antibodies after the whole schedule vaccination from the former negative subjects|Rate of seroconversion among the patient aged 9-26 after the whole schedule vaccination|GMT and seropositive rate of HPV in the 9-19 age group after 60-month follow-up","Shanghai Bovax Biotechnology Co., Ltd.|Chongqing Bovax Biopharmaceutical Co., Ltd.","Female","9 Years to 45 Years   (Child, Adult)","Phase 3","1200","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","9-HPV-3003","May 28, 2021","May 2026","May 2026","May 20, 2021",,"February 25, 2022","Huakun Lv, Hangzhou, China",,"https://ClinicalTrials.gov/show/NCT04895020"
1293,"NCT00091130","SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells",,"Completed","No Results Available","Atypical Squamous Cells of Undetermined Significance|Cervical Cancer|High-grade Squamous Intraepithelial Lesion|Low-grade Squamous Intraepithelial Lesion","Biological: HspE7|Other: placebo|Other: laboratory biomarker analysis","HPV-16 viral load|Natural history of HPV 16 viral load|Regression or non-regression of the cellular atypia|Time to infection resolution|Time to disease resolution","National Cancer Institute (NCI)","Female","18 Years to 50 Years   (Adult)","Phase 2","139","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","NCI-2012-02623|UCI#02-55|N01CN25139|CDR0000383786","September 2004","June 2007",,"September 8, 2004",,"June 3, 2013","University of California Medical Center At Irvine-Orange Campus, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT00091130"
1294,"NCT04706533","Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19","M2C2","Completed","No Results Available","Covid19|Kidney Diseases|Inflammation|SARS-CoV Infection","Diagnostic Test: Biomarkers of inflammation","Death, need for mechanical ventilation or need for dialysis|All-cause death|Need for mechanical ventilation|Need for dialysis","University of Michigan","All","18 Years and older   (Adult, Older Adult)",,"3402","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HUM00178971","March 23, 2020","December 1, 2022","December 1, 2022","January 13, 2021",,"October 31, 2023","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04706533"
1295,"NCT05266898","Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV","AGO-Gard","Recruiting","No Results Available","Papillomavirus Vaccines|Human Immunodeficiency Virus|Papillomavirus Infection|Serology|Cervical Intraepithelial Neoplasia|Anal Intraepithelial Neoplasia|Oral Cavity Infection","Biological: Human papillomavirus 9-valent vaccine, recombinant","change in serological response to Gardasil-9|change in HPV infection status: resolution of prevalent HPV infection|change in HPV infection status: protection against incident HPV infection","Louisiana State University Health Sciences Center in New Orleans|Merck Sharp & Dohme LLC","All","18 Years to 45 Years   (Adult)","Phase 4","150","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2070|MISP61476","November 30, 2022","June 2024","March 2025","March 4, 2022",,"March 15, 2023","University Medical Center New Orleans, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT05266898"
1296,"NCT01735006","Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine",,"Completed","No Results Available","Cervical Intraepithelial Neoplasia|Cervical Cancer|Vaginal Intraepithelial Neoplasia|Vulvar Intraepithelial Neoplasia|Persistent Infection","Biological: HPV Vaccine|Biological: HEV vaccine","Number of Subjects With Histopathologically-confirmed CIN2+ and/or VIN2+ and/or VaIN2+ Associated With HPV-16 and/or -18 Cervical Infection|Number of Subjects With HPV-16 and/or -18 persistent cervical infection(6-month+ definition)|Number of Subjects Reporting Solicited Local and General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events|Number of Subjects Reporting Serious Adverse Events (SAEs)|number of subjects with persistent cervical infection (12-month+ definition)associated with HPV-16 and/or HPV-18|number of subjects Histopathologically-confirmed CIN1+ and/or VIN1+ and/or VaIN1+ associated with HPV-16 and/or -18 cervical infection|number of subjects with incidence infection associated with HPV-16 and/or HPV-18|Anti-HPV16 and anti-HPV18 seroconversion rates and geometric mean concentrations at Months 7","Xiamen University|Xiamen Innovax Biotech Co., Ltd|Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.|Ministry of Science and Technology of the People´s Republic of China","Female","18 Years to 45 Years   (Adult)","Phase 3","7372","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HPV-PRO-003","November 22, 2012","August 1, 2019","October 18, 2019","November 28, 2012",,"February 24, 2020","Cancer Institute ＆ Hospital Chinese Academy of Medical Sciences, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01735006"
1297,"NCT03305627","Optimized Perioperative Antibiotic Prophylaxis in Radical Cystectomy","PAPRAC","Active, not recruiting","No Results Available","Radical Cystectomy|Surgical Site Infection|Urologic Cancer|Perioperative/Postoperative Complications|Antibiotic Resistant Infection|Antibiotic Side Effect|Antibiotic-associated Diarrhea","Other: Short PAP|Other: Extended PAP","Rate of Surgical Site infections (SSI)|Time to event of SSI|Rate of Urinary tract infections (UTI)|Time to event of UTI|Rate and type of Antibiotic associated adverse events (AEs)|Frequency of multi-drug-resistant bacteria in urinary samples|Changes in fecal flora|Antibiotic associated costs","Insel Gruppe AG, University Hospital Bern","All","18 Years and older   (Adult, Older Adult)","Not Applicable","196","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-01480","April 9, 2018","October 30, 2022","February 28, 2024","October 10, 2017",,"November 30, 2023","Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland|Department of Urology, University Hopspital Bern, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT03305627"
1298,"NCT05030974","RECOVAC Repeated Vaccination Study",,"Completed","No Results Available","Covid19|Kidney Diseases|Vaccine Response Impaired|SARS-CoV2 Infection","Biological: mRNA-1273|Biological: Ad26.COV2.S vaccine","Positive SARS-CoV-2 seroresponse|SARS-CoV-2 antibody concentration|Virus-neutralizing capacity of SARS-CoV-2 antibodies|Mucosal SARS-CoV-2 antibodies|SARS-CoV-2 specific T cell response|Solicited local and systemic adverse events|Serious adverse events","University Medical Center Groningen|Radboud University Medical Center|Erasmus Medical Center|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|ZonMw: The Netherlands Organisation for Health Research and Development","All","18 Years and older   (Adult, Older Adult)","Phase 4","336","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NL78963.042.21","October 21, 2021","March 12, 2022","March 12, 2022","September 1, 2021",,"March 29, 2022","Radboud umc, Nijmegen, Gelderland, Netherlands|Amsterdam UMC, Amsterdam, Noord-Holland, Netherlands|Erasmus mc, Rotterdam, Zuid-Holland, Netherlands|University Medical Center Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT05030974"
1299,"NCT00128661","Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants",,"Completed","Has Results","Cervical Cancer|Precancerous Condition","Biological: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine|Biological: hepatitis A inactivated virus vaccine","Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical Cytology Specimen.|Number of Cervical Infection With HPV16 or HPV18.|Number of Histopathologically Confirmed CIN2+ Cases Associated With Infection by Any Oncogenic HPV Type|Number of Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 Cases|Geometric Mean Titers (GMTs) for HPV-16 Antibody in the Immunogenicity Subcohort.|Geometric Mean Titers (GMTs) for HPV-18 Antibody in the Immunogenicity Subcohort|HPV-16 Geometric Mean Titers (GMTs) (V5 Monoclonal Antibody Inhibition Test)|HPV-18 Geometric Mean Titers (GMTs) (J4 Monoclonal Antibody Inhibition Test)|Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.|Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms.|Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms on a 10% Random Subset of Participants.|Number of Subjects Reporting Any and Grade 3 Solicited General Symptoms on a 10% Random Subset of Participants.|Number of Subjects Reporting Serious Adverse Events (SAEs).|Number of Subjects Reporting Unsolicited Adverse Events (AEs).|Number of Subjects With All Possible Pregnancy Outcomes","GlaxoSmithKline","Female","18 Years to 25 Years   (Adult)","Phase 3","7466","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CDR0000441189|NCI-04-C-N191|NCI-590299/009|GSK-590299/009","June 30, 2004","December 31, 2010","December 31, 2010","August 10, 2005","May 2, 2012","March 8, 2019","Proyecto Epidemiologico Guanacaste, Liberia, Costa Rica",,"https://ClinicalTrials.gov/show/NCT00128661"
1300,"NCT02858310","E7 TCR T Cells for Human Papillomavirus-Associated Cancers",,"Recruiting","No Results Available","Papillomavirus Infections|Cervical Intraepithelial Neoplasia|Carcinoma In Situ|Vulvar Neoplasms|Vulvar Diseases","Biological: E7 TCR cells|Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide","Phase II: Determine safety and effficacy of E7 TCR cells plus aldesleukin|Phase I: Determine a safe dose for E7 TCR cells plus aldesleukin|To assess progression-free survival","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 1|Phase 2","180","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","160154|16-C-0154","January 27, 2017","December 31, 2025","January 1, 2026","August 8, 2016",,"April 11, 2024","National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02858310"
1301,"NCT05837962","Nursing Intervention for Knowledge and Self-care Behaviors in the Face of Hypertensive Disorders of Pregnancy","EducaTHE","Recruiting","No Results Available","Hypertensive Disorders of Pregnancy","Behavioral: Nursing intervention to improve knowledge and self-care behaviors in the face of HDP","Feasibility: recruitment, attrition, follow-up|Acceptability","Universidad de Antioquia","Female","18 Years to 45 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Acta No 234 CEI-FE","April 10, 2023","August 16, 2023","December 28, 2023","May 1, 2023",,"May 1, 2023","Local Hospital of Piedecuesta, Santander, Piedecuesta, Colombia",,"https://ClinicalTrials.gov/show/NCT05837962"
1302,"NCT05592626","A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","START-001","Recruiting","No Results Available","Advanced Solid Tumors|Genital Neoplasm, Female|Urogenital Neoplasms|Lung Neoplasm|Neoplasms by Site|Papillomavirus Infection|Epstein-Barr Virus Infections|Carcinoma|Neoplasms|Vulvar Neoplasms|Vulvar Diseases|Abdominal Neoplasm","Drug: STAR0602","Phase 1 (Dose Escalation):Number of Participants with Dose-limiting Toxicities (DLTs) in Cycle 1|Phase 1 and 2 (Dose Escalation and Expansion): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Phase 2 (Dose Expansion): Percentage of Participants with Overall Objective Tumor Responses (ORR)|Phase 1 and 2 (Dose Escalation and Expansion): Percentage of Participants with ORR|Phase 1 and 2 (Dose Escalation and Expansion): Duration of Responses (DOR)|Phase 1 and 2 (Dose Escalation and Expansion): Percentage of Participants with Disease Control (CR, PR, and Stable Disease)|Phase 2 (Dose Expansion): Progression Free Survival (PFS)|Phase 2 (Dose Expansion): Overall Survival (OS)|Phase 1 and 2 (Dose Escalation and Expansion): Maximum Observed Plasma Concentration (Cmax) for STAR0602|Phase 1 and 2 (Dose Escalation and Expansion): Time (Tmax) to Reach the Maximum Plasma Concentration (Cmax) for STAR0602|Phase 1 and 2 (Dose Escalation and Expansion): Area Under the Plasma Concentration (AUC) Versus Time Curve for STAR0602|Phase 1 and 2 (Dose Escalation and Expansion): Terminal Elimination Half-life (t1/2) for STAR0602|Phase 1 and 2 (Dose Escalation and Expansion): Apparent Total Body Clearance (CL) for STAR0602|Phase 1 and 2 (Dose Escalation and Expansion): Apparent Volume of Distribution (Vd) for STAR0602|Phase 1 and 2 (Dose Escalation and Expansion): Anti-drug Antibody (ADA) formation","Marengo Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","365","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CP-START-001","January 4, 2023","October 2026","October 2026","October 24, 2022",,"September 22, 2023","National Institutes of Health, Bethesda, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT05592626"
1303,"NCT02024282","Optimising Diagnosis and Antibiotic Prescribing for Acutely Ill Children in Primary Care","ERNIE2","Completed","No Results Available","Sepsis|Bacteraemia|Meningitis|Abscess|Pneumonia|Osteomyelitis|Cellulitis|Gastro-enteritis With Dehydration|Complicated Urinary Tract Infection|Viral Respiratory Infection Complicated With Hypoxia","Device: Use of C-reactive protein (CRP) point of care test|Other: Brief intervention and parent leaflet|Device: Finger Pulse Oximeter","Serious infection|Immediate antibiotic prescribing rates|Parental satisfaction|Parental concern|Use of other diagnostic tests and medical services (including re-consultation)|Cost-effectiveness|Impact of the communicator style on the effect of the intervention (interaction)","KU Leuven|National Institute for Health and Disability Insurance (RIZIV), Belgium|Research Foundation Flanders","All","1 Month to 16 Years   (Child)","Not Applicable","8962","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","S54664|CGV 2012/135","January 2013","December 2014","December 2014","December 31, 2013",,"February 18, 2015","Universitaire Ziekenhuizen Gent, Gent, Oost-Vlaanderen, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Vlaams-Brabant, Belgium",,"https://ClinicalTrials.gov/show/NCT02024282"
1304,"NCT06019715","Remote Postpartum Intervention Targeting Movement Behaviors After Hypertensive Disorders of Pregnancy",,"Active, not recruiting","No Results Available","Hypertensive Disorder of Pregnancy","Behavioral: Postpartum Remote Physical Activity Intervention","Change in physical activity|Intervention feasibility|Intervention acceptability|Change in postpartum blood pressure","Jackie Dziewior|University of Iowa","Female","18 Years to 45 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","202302470","June 1, 2023","March 1, 2024","July 1, 2024","August 31, 2023",,"August 31, 2023","University of Iowa, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT06019715"
1305,"NCT04486625","Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment",,"Completed","Has Results","Renal Insufficiency","Drug: Aztreonam-Avibactam","Total Daily Area Under the Plasma Concentration-time Profile From Time 0 to 24 Hours at Steady-state (AUC0-24,ss) of Aztreonam (ATM)|Maximum Plasma Concentration (Cmax) of ATM|AUC0-24,ss of Avibactam (AVI)|Cmax of AVI|Area Under the Plasma Concentration-time Profile From Time 0 to Time Tau (The Dosing Interval)(AUC0-tau) of ATM|Time for Cmax (Tmax) of ATM|Observed Plasma Concentration at the End of the Dosing Interval (Tau) (Ctau) of ATM|Terminal Elimination Half-life (t1/2) of ATM|Clearance (CL) of ATM|Renal Clearance (CLr) of ATM|Apparent Volume of Distribution (Vz) of ATM|Apparent Volume of Distribution at Steady-state (Vss) of ATM|Cumulative Amount of Drug Recovered Unchanged in Urine up to Time Tau (Ae0-tau) of ATM|Percent of Dose Recovered Unchanged in Urine up to Time Tau (Ae0-tau%) of ATM|AUC0-tau of AVI|Tmax of AVI|Ctau of AVI|t1/2 of AVI|CL of AVI|CLr of AVI|Vz of AVI|Vss of AVI|Ae0-tau of AVI|Ae0-tau% of AVI|Number of Participants With Treatment Emergent Adverse Events (TEAEs) (All-causality)|Number of Participants With TEAEs (Treatment-related)|Number of Participants With Categorical Post-Baseline Vital Signs Data|Number of Participants With Abnormal Electrocardiogram (ECG)|Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)","Pfizer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","11","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","C3601006","August 10, 2020","September 20, 2021","October 18, 2021","July 24, 2020","July 28, 2023","July 28, 2023","Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/25/NCT04486625/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/25/NCT04486625/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04486625"
1306,"NCT01187004","Extracardiac Complications After Cardiac Surgery",,"Completed","Has Results","Acute Lung Injury|Sepsis|Infections|Acute Kidney Injury",,"Acute Lung Injury After Cardiac Surgery|Intensive Care Unit (ICU) Length of Stay","University of Turin, Italy","All","18 Years to 85 Years   (Adult, Older Adult)",,"164","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","82755","April 2007","December 2008","December 2009","August 23, 2010","January 6, 2012","February 12, 2013","Cardiac Intensive Care Unit, San Giovanni Battista Hospital, Turin, Italy",,"https://ClinicalTrials.gov/show/NCT01187004"
1307,"NCT05995106","mHealth for Hypertensive Disorder of Pregnancy",,"Recruiting","No Results Available","Hypertensive Disorder of Pregnancy|Preeclampsia","Other: Heart4U","delta SBP|Blood pressure (systolic, diastolic, mean) trajectory|obstetric outcomes|Body mass index (kg/m2) trajectory|trajectory of the recorded step counts|Depression evaluation questionnaire","Seoul National University Hospital","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","580","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B-2308-844-302","October 2, 2023","August 2026","June 2027","August 16, 2023",,"December 21, 2023","Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05995106"
1308,"NCT04079218","Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial",,"Completed","No Results Available","HIV Infection|Vaginal Atrophy|Menopause|Menopause Related Conditions|Aging|Premature Aging|Atrophic Vaginitis|Dysbiosis|Vaginitis","Drug: Estradiol Vaginal Insert","Vaginal Atrophy Symptoms|Vaginal Microbiome|Vaginal cytokines and chemokines|Immunoglobulin (Ig)A and IgG coated bacteria|HIV-1 RNA levels in the genital tract","Albert Einstein College of Medicine|National Institute on Aging (NIA)|Novo Nordisk A/S","Female","45 Years to 70 Years   (Adult, Older Adult)","Phase 4","51","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-10529|1K23AG062400-01A1","September 1, 2020","August 9, 2023","August 9, 2023","September 6, 2019",,"February 2, 2024","Albert Einstein College of Medicine, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT04079218"
1309,"NCT03728790","Remote BP Monitoring in the PP Period",,"Completed","Has Results","Hypertensive Disorder of Pregnancy","Device: Remote Patient Monitoring","Blood Pressure (BP) Surveillance Adherence|Elevated Blood Pressure Percentage|Number of Participants With Outpatient BP Assessment Within 14 Days|Incidence of BP Elevations|Number of Participants With Outpatient PP Assessment|Time to Medication Initiation|Number of Participants Initiated on Antihypertensive Therapy After Hospital Discharge|Number of Participants Readmitted|Number of Participants With ED Visit|Number of Participants Who Developed Preeclampsia-associated Complications|Number of Participants Referred to Primary Care for Continued Blood Pressure Management|Score on the Modified Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ)|Change in Score on the Philips Program Survey|Communications","Columbia University|Philips Healthcare|New York Presbyterian Hospital","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","213","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAS0065","November 9, 2018","July 28, 2019","May 11, 2020","November 2, 2018","September 28, 2020","September 28, 2020","Columbia University Medical Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/90/NCT03728790/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03728790"
1310,"NCT04977739","Research on the Application and Mechanism of New Biological Probes in Biomedicine",,"Completed","No Results Available","Tumors|Cardiovascular Diseases|Respiratory System Diseases|Digestive System Diseases|Endocrine System Diseases|Metabolic Diseases|Immune System Diseases|Urinary System Diseases|Nervous System Diseases|Blood Diseases|Infectious Diseases","Diagnostic Test: No intervention","signal intensity of the probes","Nanfang Hospital, Southern Medical University","All","18 Years to 70 Years   (Adult, Older Adult)",,"737","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NFEC-2021-007","August 3, 2021","July 15, 2022","July 25, 2022","July 27, 2021",,"August 22, 2022","Nanfang Hospital, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04977739"
1311,"NCT02092558","Evaluation of Immunological Disorders of T Lymphocytes and Endocrinological Disorders as Pathogen Factors in Patients With Metaplasia of Urinary Bladder",,"Completed","No Results Available","The Follow-up Duration Was 1-8 Years.|The Main Reasons Behind Visiting the Hospital Were Recurrent Urinary Tract Infection,|Urinary Urgencies, Pollakiuria, Difficulty in Initiating Micturition, Pain in Hypogastrium,|Night Wetting and Day Wetting, Menstruation's Disorders, Urolithiasis, Defects of Urinary|System and Hematuria.","Drug: Second-generation cephalosporin, nitrofurantoin, 1% aminoglycoside solution|Drug: cephalosporin with chemotherapeutics","Symptoms of stratified squamous metaplasia of urinary bladder and treatment's ways","Children's Hospital, Dziekanów Leśny, Poland","All","5 Years to 17 Years   (Child)",,"2","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","KB/677/09|Bioethics Commitee of Regional","January 2005","January 2009","December 2013","March 20, 2014",,"March 20, 2014","Children's Hospital, Marii Konopnickiej Street 65, Dziekanów Lesny, Poland",,"https://ClinicalTrials.gov/show/NCT02092558"
1312,"NCT05555862","Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL","anal HSIL HIV-","Active, not recruiting","No Results Available","Anal High Grade Squamous Intraepithelial Lesion|Anal Precancerous Condition|AIN 2/3|HPV Infection|Anal Dysplasia|HPV Disease","Drug: Artesunate|Drug: Placebo","Number of subjects with complete and partial response by week 18|Number of participants who have achieved clearance of detectable human papilloma virus (HPV) over the study window|Number of participants with complete and partial response after week 18 but over the study window|Number of participants who achieve complete and partial response of peri-anal HSIL, following 4 cycles of intra-anal artesunate suppositories, as determined by HRA-directed biopsy|Number of participants who undergo complete response who maintain their response over the study window","Frantz Viral Therapeutics, LLC|Amarex CRO|University of California, San Francisco|Anal Dysplasia Clinic MidWest|Laser Surgery Care","All","18 Years and older   (Adult, Older Adult)","Phase 2","17","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ART-AIN IIB","February 10, 2023","February 28, 2024","August 31, 2024","September 27, 2022",,"February 21, 2024","Anal Neoplasia and Cancer Research and Education Center, San Francisco, California, United States|Anal Dysplasia Clinic MidWest, Chicago, Illinois, United States|Laser Surgery Care, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT05555862"
1313,"NCT00213057","Safety and Acceptability of Carraguard™ Among HIV-negative Couples in Thailand",,"Completed","No Results Available","HIV Infections|Chlamydia Trachomatis|Nesseria Gonorrhea|Trichomonas Vaginitis|Syphilis","Drug: Carraguard (PC-515)","Safety (toxicity/local irritation): Genital exam and interview for signs and symptoms, 14-days after enrollment and monthly thereafter for 6 months; testing for bacterial vaginosis and candida (women) and balanitis (men) monthly.|Acceptability: Interview about gel use to assess compliance (monthly) and acceptability (quarterly).|Preliminary effectiveness: Swabs taken from women an urine specimens collected from men to test for sexually transmitted infections - gonorrhea, chlamydia, trichomoniasis (monthly) and for genital ulcer disease, if ulceration was detected; blood drawn","Population Council|Centers for Disease Control and Prevention|Ministry of Health, Thailand|Chiang Rai Public Health Office|Chiang Rai District Health Office|Chiang Rai Municipal Health Office|Chiang Rai Hospital|Bill and Melinda Gates Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 1","110","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","Population Council #270|CDC Protocol #2968","June 2001",,"June 2002","September 21, 2005",,"August 14, 2017","Chiang Rai Health Club, Chiang Rai, Thailand",,"https://ClinicalTrials.gov/show/NCT00213057"
1314,"NCT00213018","Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission",,"Completed","No Results Available","HIV Infections|Chlamydia Trachomatis|Neisseria Gonorrhoeae|Trichomonas Vaginitis|Syphilis","Drug: Carraguard (PC-515)","Safety (toxicity): Symptoms 14 days after enrollment and monthly thereafter (6-12 months); tests (monthly) to detect change in vaginal flora;|Compliance: collection of applicators and interview(monthly)|Acceptability: interview (quarterly)|Preliminary effectiveness: Swabs taken to test for sexually transmitted infections - gonorrhea, chlamydia, trichomoniasis (monthly) and blood drawn for syphilis and HIV testing (Month 1 and quarterly thereafter).","Population Council|Bill and Melinda Gates Foundation|FHI 360|National Institute of Allergy and Infectious Diseases (NIAID)|Medical Research Council, South Africa|University of Cape Town|University of Limpopo|United States Agency for International Development (USAID)","Female","18 Years and older   (Adult, Older Adult)","Phase 2","400","Other|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","Population Council #210|R01AI045468-02","October 1999",,"January 2002","September 21, 2005",,"August 14, 2017","University of Cape Town, Department of Community Health, Cape Town, South Africa|Medical University of Southern Africa, Soshanguve, South Africa",,"https://ClinicalTrials.gov/show/NCT00213018"
1315,"NCT04612413","A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients",,"Active, not recruiting","No Results Available","Sepsis|Community-acquired Pneumonia|Urinary Tract Infections|Cholecystitis, Acute|Cholangitis Acute|Intraabdominal Infections","Drug: Allocetra-OTS|Other: Placebo","Efficacy: Change from baseline in SOFA score|Safety: Number and severity of AEs and SAEs|Ventilator-free days|Vasopressor-free days|Days without renal replacement therapy (dialysis).|Time in ICU and time in hospital|Number of days with creatinine ≤ Baseline levels +20%|All-cause mortality|Changes from baseline in CRP levels|Number and severity of AEs and Serious Adverse Events (SAEs)|Detection of autoimmune and human leukocyte antigen (HLA) antibodies","Enlivex Therapeutics Ltd.","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ENX-CL-02-002","November 30, 2020","December 31, 2024","March 31, 2025","November 3, 2020",,"March 13, 2024","Clinique Saint-Pierre, Brussel, Belgium|Saint-Luc Hospital University, Brussel, Belgium|CHU de Charleroi, Charleroi, Belgium|Ziekenhuis Oost-Limburg, Genk, Belgium|CHU d'Angers, Angers, France|Vendee Departmental Hospital Center, La Roche-sur-Yon, France|University Hospital of Limoges, Limoges, France|CHU de Montpellier, Montpellier, France|CHU de Nantes, Nantes, France|Bretonneau Hospital, Paris, France|Centre Hospitalier Victor Dupouy, Paris, France|Reims University Hospital Robert Debre, Reims, France|CHU de Rennes, Rennes, France|Strasbourg University Hospital, Strasbourg, France|Soroka Medical Center, Be'er Sheva, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Bnai Zion Medical Center, Haifa, Israel|Hadassah Ein Kerem Medical Center, Jerusalem, Israel|Beilinson Medical Center, Petah tikva, Israel|Poriya Medical Center, Tverya, Israel|Ziv Medical Center, Zefat, Israel|Canisius Wilhelmina Hospital, Nijmegen, Netherlands|Radboud UMC, Nijmegen, Netherlands|Clinic Barcelona University Hospital, Barcelona, Spain|University Hospital Sagrat Cor, Barcelona, Spain|Vall d'Hebron, Barcelona, Spain|Getafe University Hospital, Getafe, Spain|Dr. Josep Trueta University Hospital, Girona, Spain|University Hospital Arnau de Vilanova of Lleida, Lleida, Spain|General University Hospital Gregorio Maranon, Madrid, Spain|University Hospital Joan XXIII of Tarragona, Tarragona, Spain",,"https://ClinicalTrials.gov/show/NCT04612413"
1316,"NCT01820793","Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli","FOXICOLI","Terminated","No Results Available","Acute Pyelonephritis Without Severity Symptoms Due to ESBL-producing E.Coli","Drug: Cefoxitin","To assess Clinical and microbiological response|To detect of cefoxitin resistant strains|To assess the bacteriological Relapse|To evaluate Clinical and microbiological response|to measure the Pharmacokinetic parameters|Measure of efficacy of cefoxitin|To measure the Pharmacodynamic parameters","Assistance Publique - Hôpitaux de Paris","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P120202|2012-002730-36","May 2013","July 2015","November 2015","March 29, 2013",,"January 12, 2018","Agnès LEFORT, Clichy, France",,"https://ClinicalTrials.gov/show/NCT01820793"
1317,"NCT05648747","Pelvic Inflammatory Disease in COVID-19 Era",,"Recruiting","No Results Available","Pelvic Inflammatory Disease","Other: impact of COVID-19 on Health-Seeking Behaviors","Incidence of pelvic inflammatory disease (PID)","Università degli Studi di Ferrara","Female","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","826/2022/Oss/AOUFe","January 1, 2023","January 1, 2024","January 30, 2024","December 13, 2022",,"December 13, 2022","Section of Obstetrics and Gynecology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy, Ferrara, Italy",,"https://ClinicalTrials.gov/show/NCT05648747"
1318,"NCT00207467","Study to Improve Partner Services for STD Prevention",,"Completed","No Results Available","Trichomonas Vaginalis|Urethritis","Behavioral: Patient-delivered partner treatment|Behavioral: Booklet-enhanced partner referral","Index patient report of partner taking medicine at 6-8 weeks|Index patient re-infection at 6-8 weeks|Cost effectiveness outcomes","Centers for Disease Control and Prevention|Tulane University","All","16 Years to 44 Years   (Child, Adult)","Phase 2","1500","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CDC-NCHSTP-3196|CA# R30/CCR619143-01","December 2001",,"December 2004","September 21, 2005",,"September 21, 2005","Delgado STD Clinic, New Orleans, Louisiana, United States|Orleans Women's Health Clinic, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT00207467"
1319,"NCT04723069","Efficacy and Safety of Fuke Qianjin Capsule in Patients With Pelvic Inflammatory Diseases",,"Completed","No Results Available","Pelvic Inflammatory Disease","Drug: Control Group|Drug: Test Group","Improvement in Visual Analog Scale (VAS) for pain assessment|Assessment of changes in main clinical Symptom|gynaecological B-ultrasound","University of Karachi|Zhuzhou Qianjin Pharmaceutical Co., Ltd., 801, Zhuzhou, China|Center for bioequivalence studies and Clinical Research (CBSCR), ICCBS, University of Karachi","Female","18 Years to 55 Years   (Adult)","Phase 2","198","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CRO-007-TCM-FKQJ -2020","September 21, 2021","March 11, 2022","March 11, 2022","January 25, 2021",,"April 4, 2023","Center for Bioequivalence Studies and Clinical Research (CBSCR), ICCBS, university of Karachi, Karachi, Pakistan",,"https://ClinicalTrials.gov/show/NCT04723069"
1320,"NCT04035785","A Clinical Study on Kangfu Anti-inflammatory Suppository of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Evidence of Dampness and Heat Accumulation)",,"Unknown status","No Results Available","Pelvic Inflammatory Diseases","Drug: Kangfu Anti-inflammatory Suppository","The MCCormack scale scores of 240 subjects will be assessed|The neutrophils of 240 participants will be assessed|The whole blood reduced viscosity from hemorheological tests of 240 participants will be assessed|The plasma viscosity from hemorheological tests of 240 participants will be assessed|The CRP of 240 participants will be assessed|The volume of liquid on B-mode of 240 subjects will be assessed|The white blood cells of 240 participants will be assessed|The TCM syndrome scores of 240 subjects will be assessed|The VAS score of 240 subjects will be assessed","China Academy of Chinese Medical Sciences|Xiyuan Hospital of China Academy of Chinese Medical Sciences|Peking University First Hospital|Beijing Obstetrics and Gynecology Hospital|Longhua Hospital|Third Hospital of Peking University|Peking Union Medical College Hospital|First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine|Shenzhen Maternal and Child Health Hospital|First Affiliated Hospital of Heilongjiang University of Traditional Chinese|Chengdu University of Traditional Chinese Medicine","Female","20 Years to 50 Years   (Adult)","Phase 4","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Kangfu","July 28, 2019","July 28, 2019","December 31, 2020","July 29, 2019",,"July 29, 2019",,,"https://ClinicalTrials.gov/show/NCT04035785"
1321,"NCT04031664","A Clinical Study on Qianjin Capsule of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Damp-heat Stasis and Qi Deficiency Syndrome)",,"Unknown status","No Results Available","Pelvic Inflammatory Diseases","Drug: Qianjin Capsule of Gynaecology","The MCCormack scale scores of 184 subjects will be assessed|The neutrophils of 184 participants will be assessed|The whole blood reduced viscosity from hemorheological tests of 184 participants will be assessed|The plasma viscosity from hemorheological tests of 184 participants will be assessed|The fibrinogen determination from hemorheological tests of 184 participants will be assessed|The CRP of 184 participants will be assessed|The volume of liquid on B-mode of 184 subjects will be assessed|The white blood cells of 184 participants will be assessed|The TCM syndrome scores of 184 subjects will be assessed|The VAS score of 184 subjects will be assessed","China Academy of Chinese Medical Sciences|Xiyuan Hospital of China Academy of Chinese Medical Sciences|Peking University First Hospital|Beijing Obstetrics and Gynecology Hospital|Longhua Hospital|Third Hospital of Peking University|Peking Union Medical College Hospital|First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine|Shenzhen Maternal and Child Health Hospital|First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine|Chengdu University of Traditional Chinese Medicine","Female","20 Years to 50 Years   (Adult)","Phase 4","184","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Qianjin Capsule","August 2, 2019","August 2, 2019","December 31, 2020","July 24, 2019",,"July 31, 2019",,,"https://ClinicalTrials.gov/show/NCT04031664"
1322,"NCT03828994","Technology Based Community Health Nursing(TECH-N) to Prevent Recurrent STIs After PID II",,"Active, not recruiting","No Results Available","Pelvic Inflammatory Disease","Behavioral: Tech-PN","Rate of STI Trichomonas vaginalis|Rate of STI Mycoplasma genitalium|Vaginal health as assessed by proportion of high Lactobacilli community state-type 1 properties (CST)","Johns Hopkins University|National Institute of Nursing Research (NINR)","Female","13 Years to 25 Years   (Child, Adult)","Not Applicable","150","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","NA_00068846-2|R01NR013507-03","February 10, 2019","December 31, 2024","March 31, 2025","February 4, 2019",,"February 26, 2024","Johns Hopkins School of Medicine, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03828994"
1323,"NCT05960006","A Study to Determine Pharmacokinetic Changes of Ceftriaxone in Patients With Liver Cirrhosis","TACTILE","Recruiting","No Results Available","Antibiotic Toxicity|Liver Cirrhosis|Renal Insufficiency|Ceftriaxone Overdose|Ascites Hepatic|Infection, Bacterial","Other: No intervention","Clearance (CL) of unbound ceftriaxone|Volume of distribution (VD) of unbound ceftriaxone|Penetration rate of unbound ceftriaxone from blood to ascites|Elimination rate of unbound ceftriaxone from ascites by paracentesis|Target attainment of ceftriaxone in blood, defined as the unbound plasma concentration of ceftriaxone above at least one time the minimal inhibitory concentration (MIC) for 50% of the dosing interval (50%fT > 1MIC)|Target attainment of ceftriaxone in ascites, defined as the unbound ascites concentration of ceftriaxone above at least one time the minimal inhibitory concentration (MIC) for 50% of the dosing interval (50%fT > 1MIC)|Explorative analysis on the effect of Child Pugh-score on individual pharmacokinetic parameters|Explorative analysis on the effect of MELD-score on individual pharmacokinetic parameters|Explorative analysis on the effect of CKD-stage on individual pharmacokinetic parameters","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Erasmus Medical Center","All","18 Years to 100 Years   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","W23_012 # 23.033","July 10, 2023","July 10, 2024","September 10, 2024","July 25, 2023",,"July 25, 2023","Amsterdam university medical centers location AMC, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT05960006"
1324,"NCT05334706","A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)","RIFT-HPV","Recruiting","No Results Available","Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III)|Human Papillomavirus (HPV) Infections|High-risk HPV|HPV-16/ 18","Biological: Nonavalent HPV vaccine (9vHPV/Gardasil-9™).","To demonstrate that vaccination with a 3-dose regimen of 9vHPV will change viral infectivity in cervical, anal and oral samples from HPV 16/18/16+18-positive women.|Detection of HPV 6/11/16/18/31/33/45/52/58 L1 antibodies in cervical, anal and oral samples collected before and after 9vHPV vaccination, using ELISA and cLIA.|HPV16/18 virion detection in cervical, anal and oral samples collected before and after 9vHPV vaccination.|HPV DNA detection in cervical, anal and oral samples collected before and after 9vHPV vaccination.|HPV DNA genotyping in cervical, anal and oral samples collected before and after 9vHPV vaccination.|To determine HPV antibody titration before and after vaccination for each of the 9vHPV-covered HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58).|To demonstrate viral infectivity change in cervical, oral and anal samples from HPV 16/18/16+18-positive women after vaccination with 1-dose or 2-dose regimen of 9vHPV.","Miquel Angel Pavon Ribas|Hospital del Mar|Catalan Institute of Health|Institut d'Investigació Biomèdica de Bellvitge","Female","27 Years and older   (Adult, Older Adult)","Phase 2","69","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","RIFT-HPV|2021-005229-26","September 13, 2022","May 2024","May 2024","April 19, 2022",,"May 9, 2023","Gynaecology Unit, Bellvitge University Hospital (HUB), L'Hospitalet De Llobregat, Catalunya, Spain",,"https://ClinicalTrials.gov/show/NCT05334706"
1325,"NCT03391440","A Trial to Assess the Efficacy and Safety of Morinidazole in Women With Pelvic Inflammatory Disease",,"Unknown status","No Results Available","Pelvic Inflammatory Disease","Drug: morinidazole","Clinical cure Rate|The incidence of AE|Incidence of ADR|Incidence of serious ADR|Bacteriological response（Bacterial elimination rate）|PPK parameters","Jiangsu Hansoh Pharmaceutical Co., Ltd.","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","469","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS-10090-401","September 2016","December 2018","December 2018","January 5, 2018",,"January 5, 2018","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT03391440"
1326,"NCT01693783","Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer",,"Completed","Has Results","Cervical Adenocarcinoma|Cervical Squamous Cell Carcinoma|Human Papillomavirus Infection|Recurrent Cervical Carcinoma|Stage IVA Cervical Cancer AJCC v6 and v7|Stage IVB Cervical Cancer AJCC v6 and v7","Biological: Ipilimumab|Other: Laboratory Biomarker Analysis","Number of Adverse Events, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0|Objective Response Rate Using Response Evaluation Criteria in Solid Tumors|Antitumor Activity (Partial Response, Complete Response, and Stable Disease) Using Immune-related Response Criteria (irRC)|Biologic Responses of Exposure to Ipilimumab by Analysis of Lymphocyte Subsets and Assessment of Cervical Cancer-antigen Specific T Cells Anti-tumor Response|Disease Stabilization|Markers of Immune Population, Evaluated in Archival Tissue|Predictive Value of Baseline C-reactive Protein|Progression Free Survival","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Phase 2","42","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02877|PHL-085|9209|N01CM00032|N01CM00038|N01CM00071|U10CA180821|UM1CA186705","December 3, 2012","March 18, 2021","November 24, 2021","September 26, 2012","November 8, 2022","November 8, 2022","City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|City of Hope South Pasadena, South Pasadena, California, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Research Centre, Vancouver, British Columbia, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Ottawa Hospital and Cancer Center-General Campus, Ottawa, Ontario, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/83/NCT01693783/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01693783"
1327,"NCT03054402","First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845",,"Completed","No Results Available","Pelvic Inflammatory Disease","Drug: BAY1834845|Drug: Placebo","Frequency of treatment-emergent adverse events (TEAEs)|Severity of treatment-emergent adverse events|Area under the plasma concentration vs. time curve (AUC)|Maximum drug concentration in plasma after single dose administration (Cmax)","Bayer","Male","18 Years to 50 Years   (Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","18384|2016-002668-15","February 13, 2017","November 30, 2017","March 29, 2018","February 15, 2017",,"March 27, 2019","CRS Clinical Research Services Berlin GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03054402"
1328,"NCT02972151","Clinical Research of TCM on Pelvic Inflammatory Disease Sequelae",,"Unknown status","No Results Available","Pelvic Inflammatory Disease","Drug: Comprehensive treatment of TCM|Other: Expectant treatment","changes of The Symptom score|changes of The Hamilton Depression Scale (HAMD) (17 items)|changes of The Sign score sheet","Shanghai University of Traditional Chinese Medicine","Female","18 Years to 60 Years   (Adult)","Phase 2","175","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","42501190","November 2016","December 2018","December 2018","November 23, 2016",,"November 23, 2016","Shanghai Longhua Hosptial, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02972151"
1329,"NCT02567812","Database of Pelvic Inflammatory Disease",,"Recruiting","No Results Available","Inflammatory Pelvic Disease",,"PID database","Kangbuk Samsung Hospital","Female","19 Years to 80 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2015-04-009","October 2015","September 2024","September 2024","October 5, 2015",,"April 3, 2019","Kangbuk Samsung Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02567812"
1330,"NCT03185169","GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors","GSM","Terminated","No Results Available","Genitourinary Abnormality|Breast Cancer Female|Vaginal Abnormality|Urinary Tract Infections|Dyspareunia|Dysuria","Combination Product: Replens and coconut oil","Improvement of GSM signs and/or symptoms|Sexual health of breast cancer survivors who are sexually active who are enrolled in this study","Alta Bates Summit Medical Center","Female","Child, Adult, Older Adult","Early Phase 1","14","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GSM","November 18, 2016","July 23, 2018","July 23, 2018","June 14, 2017",,"July 26, 2018","Alta Bates Summit Medical Center, Berkeley, California, United States",,"https://ClinicalTrials.gov/show/NCT03185169"
1331,"NCT01799356","Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials",,"Completed","No Results Available","Pelvic Inflammatory Disease","Drug: Moxifloxacin|Drug: Ofloxacin|Drug: Metronidazole","Clinically cure|Microbiological cure","Istanbul Bakirkoy Maternity and Children Diseases Hospital","Female","14 Years to 45 Years   (Child, Adult)","Phase 4","1303","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","Asicioglu03|treatment|treatment uPID","June 2010","March 2013","March 2013","February 26, 2013",,"August 28, 2013","T.C.S.B. İstanbul Training Research Hospital, Samatya, Fatih, Turkey|T.C.S.B. Kanuni Sultan Suleyman Training Hospital, İstanbul, Kucukcekmece, Turkey|T.C.S.B Mardin Women and Children Hospital, Mardin, Turkey|T.C.S.B. Şişli Etfal Training Research Hospital, Şişli, Turkey",,"https://ClinicalTrials.gov/show/NCT01799356"
1332,"NCT01050465","MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use",,"Completed","No Results Available","Acne Vulgaris|Allergic Rhinitis|Anxiety|Asthma|Back Pain|Prostatic Hyperplasia|Bursitis|Chronic Obstructive Pulmonary Disease|Cough|Coronary Artery Disease|Depression|Diabetes Mellitus|Diarrhea|Gastroesophageal Reflux|Fibromyalgia|Headache|HIV Infections|Hypothyroidism|Hyperlipidemia|Hypertension|Influenza|Sleep Initiation and Maintenance Disorders|Irritable Bowel Syndrome|Migraine Disorders|Obesity|Obstructive Sleep Apnea|Osteoarthritis|Senile Osteoporosis|Shoulder Pain|Sinusitis|Smoking Cessation|Tobacco Use Cessation|Menopause|Urinary Incontinence|Urinary Tract Infection|Vaginitis|Vertigo","Other: health information prescription","seeking information using MedlinePlus","University of Missouri-Columbia|National Library of Medicine (NLM)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","907","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","HHSN276200800445P","May 2009","October 2010","December 2010","January 15, 2010",,"September 30, 2016",,,"https://ClinicalTrials.gov/show/NCT01050465"
1333,"NCT01299259","Improving Primary Care Follow-up for Patients With Pelvic Inflammatory Disease",,"Completed","No Results Available","Pelvic Inflammatory Disease","Behavioral: Text Message Reminders","PCP follow-up rates will be used to evaluate the efficacy of text message reminders.|Number of adolescents who accept text message reminders as an measure of feasibility and acceptability.|Number of adolescents satisfied with ED care between the control group and intervention group as a measure of patient satisfaction.|Type of participant characteristics associated with PCP follow-up as a measure of behavior change, compliance and rate of follow-up care|Barriers to PCP follow-up from an ED visit to measure use of text message technology and rate of change in follow-up care between groups","Children's Hospital of Philadelphia","Female","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","95","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","10-007744","February 2011","October 2014","October 2014","February 18, 2011",,"October 28, 2014","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01299259"
1334,"NCT01241110","To Compare Ofloxacin With Azitromycin for Pelvic Inflammatory Disease (PID) Treatment","CTO","Completed","No Results Available","Pelvic Inflammatory Disease","Drug: Ofloxacin group A, Azitromycin group B|Drug: azitromycin","to compare two oral antibiotic protocols in terms of side effects and efficacy.|single oral dose of Azitromicine could be the drug of choice in the outpatient treatment of Pelvic Inflammatory Disease","Guilan University of Medical Sciences","Female","Child, Adult, Older Adult","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ClinicalTrials.gov|R01DA013131","January 2010","August 2010","September 2010","November 16, 2010",,"November 16, 2010","Alzahra Maternity Hospital, Rasht, Guilan, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01241110"
1335,"NCT00634608","Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow",,"Completed","No Results Available","Allergic Rhinitis|Asthma|Back Pain|Benign Prostatic Hypertrophy|Bursitis|Depression|Anxiety|Diabetes Mellitus|Esophageal Reflux|HIV Infections|Hyperlipidemia|Hypertension|Insomnia|Irritable Bowel Syndrome|Obesity|Osteoporosis (Senile)|Shoulder Pain|Sinusitis|Symptomatic Menopause|Urinary Incontinence|Urinary Tract Infection|Vaginitis","Other: Health Information Prescription","health information experiences of the patient|clinician feedback on the health information prescription process","University of Missouri-Columbia|National Library of Medicine (NLM)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","224","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","HHSN276200700263P","February 2008","March 2009","September 2009","March 13, 2008",,"September 30, 2016","University of Missouri, Department of Internal Medicine, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00634608"
1336,"NCT01160640","The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)",,"Completed","Has Results","Pelvic Inflammatory Disease","Drug: Ceftriaxone|Drug: Doxycycline|Drug: Metronidazole|Drug: Placebo Oral Capsule","Clearance of Anaerobic Organisms From the Endometrium|The Prevalence of M. Genitalium in the Cervix and Endometrium From Women With Acute PID.|The Eradication of M. Genitalium From the Lower and Upper Genital Tract Following Antibiotic Therapy for Acute PID.|Resolution of Clinical Signs and Symptoms of Acute PID - Intention to Treat Analysis|Identification of Endometrial Microorganisms Present Obtained From Women With or Without Evidence of Endometritis.","Harold Wiesenfeld|National Institute of Allergy and Infectious Diseases (NIAID)|University of Pittsburgh","Female","15 Years to 40 Years   (Child, Adult)","Phase 2","233","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO10010112|1U19AI084024-01","November 2010","August 2015","August 2015","July 12, 2010","December 21, 2016","July 10, 2018","Allegheny County Health Department Sexually Transmitted Diseases Clinic, Pittsburgh, Pennsylvania, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|UPMC Mercy Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01160640"
1337,"NCT02856633","Preliminary Testing of the Vitaliti CVSM Wearable, Vitaliti Spirotoscope, and Vitaliti IVD Station",,"Completed","No Results Available","Urinary Tract Infection|Diabetes Mellitus|Atrial Fibrillation|OSA|COPD|Pneumonia|Acute Otitis Media|Leukocytosis|Iron Deficient Anemia|Hypertension|Healthy Volunteers","Device: Vitaliti","Successful diagnosis of patient's condition by Vitaliti software as compared to patient's Medical Record","Cloud DX Inc.","All","18 Years to 65 Years   (Adult, Older Adult)",,"40","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","STP-VIT-001","July 2016","February 19, 2017","May 2017","August 5, 2016",,"May 9, 2017","Oakville Trafalgar Memorial Hospital, Oakville, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02856633"
1338,"NCT00871494","Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan",,"Completed","Has Results","Pelvic Inflammatory Disease","Drug: Azithromycin","Response Rate (Clinical Response, Data Review Committee Assessment) in Participants Who Enrolled After Protocol Amendment (the Inclusion Criterion Regarding Fever of 37℃ or Higher Was Option)|Response Rate (Clinical Response, Investigator Assessment) in Participants Who Enrolled After Protocol Amendment (the Inclusion Criterion Regarding Fever of 37℃ or Higher Was Option)|Eradication Rate (Bacteriological Response, Data Review Committee Assessment) in Participants Who Enrolled After Protocol Amendment (the Inclusion Criterion Regarding Fever of 37℃ or Higher Was Option)|Eradication Rate (Bacteriological Response, Investigator Assessment) in Participants Who Enrolled After Protocol Amendment (the Inclusion Criterion Regarding Fever of 37℃ or Higher Was Option)","Pfizer","Female","16 Years to 80 Years   (Child, Adult, Older Adult)","Phase 3","76","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A0661192","May 2009","November 2010","November 2010","March 30, 2009","November 3, 2011","November 3, 2011","Pfizer Investigational Site, Nagoya-city Naka-ku, Aichi-prefecture, Japan|Pfizer Investigational Site, Tanba-gun Fusou-chou, Aichi-prefecture, Japan|Pfizer Investigational Site, Aichi-gun, Aichi, Japan|Pfizer Investigational Site, Ichinomiya, Aichi, Japan|Pfizer Investigational Site, Hirosaki-city, Aomori-prefecture, Japan|Pfizer Investigational Site, Niihama-city, Ehime, Japan|Pfizer Investigational Site, Niihama, Ehime, Japan|Pfizer Investigational Site, Chuou-ku, Fukuoka-city, Japan|Pfizer Investigational Site, Kitakyushu-shi, Yahatanishi-ku, Fukuoka-ken, Japan|Pfizer Investigational Site, Kasuga-city, Fukuoka-prefecture, Japan|Pfizer Investigational Site, Kitakyusyu, Fukuoka, Japan|Pfizer Investigational Site, Takasaki-shi, Gunma-ken, Japan|Pfizer Investigational Site, Takasaki-city, Gunma-prefecture, Japan|Pfizer Investigational Site, Hakodate-shi Goryoukaku-cho, Hokkaido, Japan|Pfizer Investigational Site, Hakodate-shi Hon-cho, Hokkaido, Japan|Pfizer Investigational Site, Sapporo-shi, Hokkaido, Japan|Pfizer Investigational Site, Chuo-ku, Hyogo, Japan|Pfizer Investigational Site, Kobe, Hyogo, Japan|Pfizer Investigational Site, Kounoike shinmachi, Kagoshima-city, Japan|Pfizer Investigational Site, Kamigyou-ku, Kyoto-city, Japan|Pfizer Investigational Site, Suzaka-shi, Nagano-ken, Japan|Pfizer Investigational Site, Okayama-shi, Okayama-ken, Japan|Pfizer Investigational Site, Koshigaya, Saitama, Japan|Pfizer Investigational Site, Aoba-ku, Sendai-city, Japan|Pfizer Investigational Site, Meguro-ku, Tokyo, Japan|Pfizer Investigational Site, Minato-ku, Tokyo, Japan|Pfizer Investigational Site, Naka-ku, Yokohama-city Kanagawa, Japan|Pfizer Investigational Site, Fukushima, Japan|Pfizer Investigational Site, Kagoshima, Japan|Pfizer Investigational Site, Nagano, Japan|Pfizer Investigational Site, Okayama-city, Japan",,"https://ClinicalTrials.gov/show/NCT00871494"
1339,"NCT00783419","Rate of Pelvic Inflammatory Disease at St. Michael's Hospital",,"Completed","No Results Available","Pelvic Inflammatory Disease",,,"Unity Health Toronto","Female","Child, Adult, Older Adult",,"55","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","07-042","March 2007","January 2010","January 2011","October 31, 2008",,"December 12, 2023","St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00783419"
1340,"NCT06332781","Intravesical Gentamicin to Prevent Recurrent UTI",,"Not yet recruiting","No Results Available","Recurrent Uti","Drug: Gentamicin|Drug: Nitrofurantoin","UTIs|Patient reported outcome measures","Women and Infants Hospital of Rhode Island","Female","40 Years and older   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2126175","August 1, 2024","June 1, 2025","July 31, 2025","March 27, 2024",,"March 28, 2024",,,"https://ClinicalTrials.gov/show/NCT06332781"
1341,"NCT00453349","A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease",,"Completed","Has Results","Pelvic Inflammatory Disease","Drug: Moxifloxacin (Avelox, BAY12-8039)|Drug: Levofloxacin & Metronidazole","Clinical Response 7 to 14 Days After Completion of Study Drug Therapy in Per Protocol (PP) Population|Clinical Response 7 to 14 Days After Completion of Study Drug Therapy on Intent To Treat (ITT) Population|Clinical Response on Treatment for Per Protocol Population|Clinical Response on Treatment for Intent To Treat Population|Bacteriological Response at Test Of Cure (TOC) Visit Microbiologically Valid|Bacteriological Response at Test Of Cure (TOC) Visit in Intent To Treat Population With Causative Organism|Clinical Response at Follow-up Visit on Per Protocol Population|Clinical Response at Follow-up Visit on Intent To Treat Population|Bacteriological Response at Follow-up Visit Microbiologically Valid|Bacteriological Response at Follow-up Visit in Intent To Treat Population With Causative Organism|Number of Subjects Who Received Alternative Medicine","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","460","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11981|2006-000874-56","January 2007","May 2008","May 2008","March 28, 2007","November 30, 2009","September 8, 2014","Shenyang, Liaoning, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Jakarta, Indonesia|Seoul, Korea, Republic of|Karachi, Pakistan|Manila, Philippines|Taipei, Taiwan|Taizung, Taiwan|Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00453349"
1342,"NCT00499187","Fanconi Syndrome Due to ARVs in HIV-Infected Persons",,"Completed","No Results Available","HIV Infections|Fanconi Syndrome|Kidney Disease|Renal Impairment","Procedure: Blood Draws","Time to TDF discontinuation after diagnosis of Fanconi syndrome|Time to confirmed resolution of Fanconi syndrome","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)",,"56","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","GS-US-104-0353","September 2007","March 2011","March 2011","July 11, 2007",,"March 17, 2014","Los Angeles, California, United States|Denver, Colorado, United States|Miami, Florida, United States|Atlanta, Georgia, United States|University of Indiana, Indianapolis, Indiana, United States|Baltimore, Maryland, United States|Detroit, Michigan, United States|New York, New York, United States|Cleveland, Ohio, United States|Houston, Texas, United States|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00499187"
1343,"NCT03546842","Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)",,"Completed","Has Results","Papillomavirus Infections|Uterine Cervical Neoplasms|Vulvar Neoplasms|Vaginal Neoplasms|Adenocarcinoma in Situ|Condylomata Acuminata","Biological: 9vHPV vaccine","Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7|Percentage of Participants With a Solicited Injection-site Adverse Event|Percentage of Participants With a Solicited Systemic Adverse Event|Percentage of Participants With a Vaccine-related Serious Adverse Event|Geometric Mean Titers of Serotype-specific Antibodies: Predose Day 1|Geometric Mean Titers of Antibodies to HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7","Merck Sharp & Dohme LLC","All","9 Years to 26 Years   (Child, Adult)","Phase 3","201","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","V503-017|2017-001205-33","June 29, 2018","January 29, 2019","January 29, 2019","June 6, 2018","February 5, 2020","February 25, 2020","National Institute of Hygiene and Epidemiology ( Site 0001), Hanoi, Vietnam","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/42/NCT03546842/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03546842"
1344,"NCT04788394","Renal Involvement in Hospitalized Children With COVID-19","RIHCC","Completed","No Results Available","Acute Kidney Injury|Covid19|Renal Dysfunction|Coronavirus Infection|AKI|Pediatric Kidney Disease|Renal Insufficiency","Other: data review|Other: data comparing","determine the prevalence of renal dysfunction in hospitalized children with COVID19 in Qatar.","Hamad Medical Corporation","All","1 Day to 14 Years   (Child)",,"400","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","MRC01-21-089","March 1, 2021","December 31, 2021","December 31, 2021","March 9, 2021",,"July 25, 2023","Hamad General corporation, Doha, Qatar",,"https://ClinicalTrials.gov/show/NCT04788394"
1345,"NCT05415865","The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder",,"Recruiting","No Results Available","Urge Incontinence|Overactive Bladder|Anesthesia, Local|Pain, Procedural|Urinary Tract Infections|Hematuria","Combination Product: Alkalinized Lidocaine|Drug: Placebo Sodium Chloride 0.9% Inj","100 mm Visual Analogue Scale (VAS) score|Post-void residual requiring Clean Intermittent Catheterization (CIC)|Urinary tract infection (UTI)|Hematuria|5-point rating scale","Herlev and Gentofte Hospital|Region Hovedstadens Apotek","Female","18 Years and older   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","BTXA2021","September 12, 2022","April 1, 2024","May 1, 2024","June 13, 2022",,"September 22, 2022","Kvinde- og Bækkenbundssygdomme, klinik 1, Herlev, Region Hovedstaden, Denmark",,"https://ClinicalTrials.gov/show/NCT05415865"
1346,"NCT03749746","Heart Health 4 New Moms: A Randomized Trial in the First Year After Preeclampsia","HH4NM","Completed","No Results Available","Preeclampsia|Gestational Hypertension|Hypertension|Obesity|Overweight and Obesity|Pregnancy Complications|Pregnancy Toxemia|Postpartum Preeclampsia","Behavioral: Home Blood Pressure Monitoring|Behavioral: Heart Health 4 New Moms|Other: Usual care","Weight loss|Systolic blood pressure|Diastolic blood pressure|Hypertension","University of Pittsburgh","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","148","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","18080007","January 26, 2019","December 1, 2021","December 1, 2021","November 21, 2018",,"December 3, 2021","University of Pittsburgh Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03749746"
1347,"NCT00803127","VS-Sense Result Reading Clarity",,"Completed","No Results Available","Vaginitis","Device: vs-sense","The clinician reports of the VS-SENSE test results, the pH measurement by Nitrazine Paper test records, and the results reading clarity grade from the clinician.","Carmel Medical Center|Lin Medical Center, Haifa|Common Sense","Female","18 Years to 70 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","F-7-25.2-1","January 2009","April 2009","May 2009","December 5, 2008",,"August 11, 2009","Lin Medical center, Haifa, West Galil, Israel",,"https://ClinicalTrials.gov/show/NCT00803127"
1348,"NCT06015854","Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II","Vvax","Recruiting","No Results Available","CIN3|Cervical Intraepithelial Neoplasia|Cervical Intraepithelial Neoplasia Grade 3|HPV 16 Infection","Biological: Vvax001 therapeutic cancer vaccine","Clinical efficacy of Vvax001|Immunogenicity of Vvax001|HPV 16 clearance|Side effects/ adverse events","University Medical Center Groningen|Dutch Cancer Society|ViciniVax B.V","Female","18 Years and older   (Adult, Older Adult)","Phase 2","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Vvax001-UMCG-02","March 23, 2021","February 6, 2024","April 1, 2024","August 29, 2023",,"August 29, 2023","University Medical Center Groningen (UMCG), Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT06015854"
1349,"NCT05456906","Avoidable Hospitalizations/ Emergency Department Visits- Systematic Review and Meta-synthesis of Qualitative Research",,"Recruiting","No Results Available","Diabetes|Heart Failure|Chronic Obstructive Pulmonary Disease|Asthma|Hypertension|Urinary Tract Infections|Pneumonia, Bacterial","Other: No intervention","preventable hospitalizations and/or preventable emergency department visits","Kaohsiung Medical University|The Ministry of Science and Technology|National Taipei University of Nursing and Health Sciences","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","11|MOST110-2410-H-037-018-MY3","June 1, 2022","July 20, 2022","August 31, 2022","July 13, 2022",,"July 13, 2022","Kaohsiung Medical University, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT05456906"
1350,"NCT03975569","Study of the Vaginal Microbiota and the Potential of a Vaginal Probiotic Cream in Vaginal Candidosis",,"Completed","No Results Available","Candidiasis, Vulvovaginal","Other: Probiotic vaginal gel","Vaginal persistence of Candida species|Clinical scores of patients|Microbiome analysis","University Hospital, Antwerp","Female","18 Years to 50 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16/7/66|B300201628296","April 4, 2016","March 31, 2017","March 31, 2017","June 5, 2019",,"June 5, 2019",,,"https://ClinicalTrials.gov/show/NCT03975569"
1351,"NCT04615065","Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine","Acutelines","Recruiting","No Results Available","Acute Disease|Sepsis|Pneumonia|Frailty|Complication of Treatment|Pulmonary Embolism|Thrombosis|Acute Kidney Injury|Electrolyte Disturbance|Hemorrhage|Shock|Polypharmacy|Intoxication by Drug|Emergencies|Urinary Tract Infections|Skin Infection|Syncope|Anaphylaxis|Dyspnea",,"Mortality (time and cause)|Katz ADL-6 (functioning)|World Health Organization (WHO) performance status (functioning)|Karnofsky performance score (functioning)|Utrecht Activity List (daily activities)|Short QUestionnaire to ASsess Health-enhancing physical activity (daily activities)|Quality of Life and experienced symptoms|Experienced somatic symptoms|Fatigue|Patient Health Questionnaire-2 (mental health)|Patient Health Questionnaire-9 (mental health)|Geriatric Depression scale-15 (mental health)|Patient satisfaction|Decision making|Co-morbidity|Length-of-stay in hospital/intensive care unit (ICU)|Biomarkers|Medication use|Treatment (non-pharmacological, including organ support)|Sequential organ failure assessment (SOFA)|Vital parameters","Hjalmar Bouma|University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)",,"35000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201900635","September 1, 2020","September 1, 2030","September 1, 2030","November 4, 2020",,"May 20, 2022","University Medical Center Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT04615065"
1352,"NCT05881447","Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa","RenalTWO","Recruiting","No Results Available","Chronic Kidney Diseases|Type 2 Diabetes Mellitus|Arterial Hypertension|Obesity|Cardiovascular Diseases|HIV Infections|Anemia|Underweight|Infections|Albuminuria|Dyslipidemias",,"Chronic kidney disease (CKD) prevalence rates|Prevalence of cardiovascular and non-classic risk factors of CKD|Incidence of chronic kidney disease (CKD) and cardiovascular- and non-classic risk factors of CKD:|Incidence of cardiovascular- and non-classic risk factors of CKD:|Longitudinal assessed concordance and usefulness of glycated hemoglobin A1c (HbA1c) in patients with anaemia|Validation of semi-quantitative colorimetric urine dipstick test in diagnosis of albuminuria in a setting with repeated measurement|Assessment of lipid profile for incidence|Assessment of Hypertension incidence","Swiss Tropical & Public Health Institute|University Hospital, Basel, Switzerland|Ifakara Health Institute","All","18 Years to 99 Years   (Adult, Older Adult)",,"1200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HSR-2022-27","June 21, 2023","December 31, 2024","December 31, 2025","May 31, 2023",,"October 26, 2023","Bagamoyo District Hospital, Bagamoyo, Pwani, Tanzania",,"https://ClinicalTrials.gov/show/NCT05881447"
1353,"NCT03627884","Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation",,"Completed","No Results Available","End Stage Renal Disease|Acute Renal Failure|Hemodialysis Catheter Infection|Hemodialysis Complication|Hemodialysis Access Failure|Hemodialysis Catheter-Associated Bacteremia","Drug: Sodium Bicarbonate Catheter Lock Solution|Drug: Normal Saline Catheter Lock Solution","Lumen Clot Formation|Catheter Related Infection|Malfunction|Overall Cause|Death|Arrhythmia|Hemodynamic Instability","Coney Island Hospital, Brooklyn, NY","All","18 Years and older   (Adult, Older Adult)","Phase 4","451","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2015-06-25","October 1, 2016","March 30, 2018","March 30, 2018","August 14, 2018",,"August 14, 2018",,"""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/84/NCT03627884/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03627884"
1354,"NCT00003267","Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer",,"Completed","No Results Available","Cervical Cancer|Endometrial Cancer|Infection|Perioperative/Postoperative Complications|Vaginal Cancer","Procedure: infection prophylaxis and management|Procedure: management of therapy complications|Procedure: surgical procedure",,"European Organisation for Research and Treatment of Cancer - EORTC","All","Child, Adult, Older Adult","Phase 3","214","Other","Interventional","Allocation: Randomized|Primary Purpose: Supportive Care","EORTC-55962","February 1998","July 2000",,"July 22, 2004",,"July 11, 2012","Kaiser Franz Josef Hospital, Vienna (Wien), Austria|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|U.Z. Gasthuisberg, Leuven, Belgium|Institut Gustave Roussy, Villejuif, France|University Medical Center, Freiburg, Germany|Universita di Brescia, Brescia, Italy|Instituto Scientifico H.S. Raffaele, Milano (Milan), Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano (Milan), Italy|Azienda Ospedaliera Di Parma, Parma, Italy|University and I.R.C.C.S. Policlinico San Matteo, Pavia, Italy|Ospedale di Circolo e Fondazione Macchi, Varese, Italy|Ospedale Civile, Voghera (PV), Italy|Antoni van Leeuwenhoekhuis, Amsterdam, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Academisch Ziekenhuis Utrecht, Utrecht, Netherlands|Hospitais da Universidade de Coimbra (HUC), Coimbra, Portugal|Instituto Valenciano De Oncologia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT00003267"
1355,"NCT05275595","COVID-19 Among Children With Chronic Renal Diseases in Qatar","CCCRDQ","Completed","No Results Available","Chronic Kidney Diseases|COVID-19 Infection|Acute Kidney Injury|Chronic Renal Failure in Children|COVID-19 Pandemic","Other: Medical records review","The relationship between chronic kidney disease and COVID-19 infection in children","Hamad Medical Corporation","All","up to 18 Years   (Child, Adult)",,"1300","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","MRC-01-22-052","March 1, 2022","December 31, 2022","December 31, 2022","March 11, 2022",,"July 25, 2023","Hamad Medical Corporation, Doha, Qatar",,"https://ClinicalTrials.gov/show/NCT05275595"
1356,"NCT00213031","Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide",,"Completed","No Results Available","HIV Infections|Chlamydia Trachomatis|Neisseria Gonorrhoeae|Trichomonas Vaginitis|Syphilis|Herpes Simplex","Drug: Carraguard (PC-515)","Safety: Genital exam & interview for symptoms after 14 days & monthly thereafter; colposcopy done throughout trial at clinicians' discretion; monthly testing to detect changes in vagina flora.|Compliance: collection of applicators and interview(monthly)|Acceptability: interview (quarterly)|Preliminary effectiveness: Swabs taken to test for sexually transmitted infections - gonorrhea, chlamydia, trichomoniasis and for genital ulcer disease, if ulceration was detected; blood drawn for syphilis and HIV testing and for HSV-2 Pap smear to det","Population Council|Bill and Melinda Gates Foundation|Centers for Disease Control and Prevention|Nat'l Cntr. for HIV, STD, & TB Prevention Atlanta: Division of STD Prevention,Div. of HIV/AIDS Prevention-Surveillance & Epidemiology|National Center for Infectious Diseases|Ministry of Health, Thailand|Collaboration (TUC)|Chiang Rai Public Health Office|Chiang Rai District Health Office|Chiang Rai Municipal Health Office|Chiang Rai Hospital","Female","18 Years and older   (Adult, Older Adult)","Phase 2","165","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Other","Population Council #271|CDC & Prevention #2485","February 2000",,"December 2001","September 21, 2005",,"August 14, 2017","Chiang Rai Health Club, Chiang Rai, Thailand",,"https://ClinicalTrials.gov/show/NCT00213031"
1357,"NCT03470584","Vegetarian Diet and Chronic Degenerative Diseases",,"Completed","No Results Available","Dementia|Depression|Cardiovascular Diseases|Stroke|Gout|Cataract|Gallstone|Urinary Tract Infections","Other: Diet Exposure","Gout|Stroke|Cataract|Gallstone disease|Dementia and mild cognitive impairment|Depression|Urinary tract infections (UTI)|Medical expenditures","Dalin Tzu Chi General Hospital",,"18 Years and older   (Adult, Older Adult)",,"18064","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TCHS-02","March 1, 2005","December 30, 2005","December 31, 2014","March 20, 2018",,"March 20, 2018","Dalin Tzu Chi Hospital, Chiayi City, Taiwan",,"https://ClinicalTrials.gov/show/NCT03470584"
1358,"NCT02888197","Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization",,"Completed","No Results Available","Candidiasis, Vulvovaginal|Yeast Infection|Mycoses|Moniliasis, Vulvovaginal|Vaginitis, Monilial",,"Time to recurrence of clinical signs/symptoms of VVC|Rate of candida colonization|Rate of recurrence of clinical signs/symptoms of VVC|Time to recurrence of culture confirmed VVC|Rates of recurrence of culture confirmed VVC","Cidara Therapeutics Inc.","Female","18 Years and older   (Adult, Older Adult)",,"32","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CD101.TP.2.02","August 16, 2016","March 15, 2017","March 15, 2017","September 2, 2016",,"March 2, 2018","Precision Trials AZ, Phoenix, Arizona, United States|The Women's Clinical, P.A., Little Rock, Arkansas, United States|Women's Health Care Research Corp, San Diego, California, United States|Olympian Clinical Research, Clearwater, Florida, United States|Women's Medical Research, Clearwater, Florida, United States|Altus Research Inc, Lake Worth, Florida, United States|New Age Medical Research Corporation, Miami, Florida, United States|Augusta University, Augusta, Georgia, United States|Clinical Trials Management LLC, Metairie, Louisiana, United States|Wayne State University, Detroit, Michigan, United States|Saginaw Valley Medical Research Group LLC, Saginaw, Michigan, United States|Alliance Women's Research Group LLC, Delran, New Jersey, United States|Lawrence OB GYN Clinical Research LLC, Lawrenceville, New Jersey, United States|Soffolk OB/GYN, Port Jefferson, New York, United States|Eastern Carolina Women's Center, New Bern, North Carolina, United States|Hawthorne Medical Research Inc, Winston-Salem, North Carolina, United States|Unified Women's Clinical Research - Hickory, Winston-Salem, North Carolina, United States|Women's Health Research, Columbus, Ohio, United States|Drexel University, Philadelphia, Pennsylvania, United States|TMC Life Research Inc., Houston, Texas, United States|Clinical Trials of Texas Inc, San Antonio, Texas, United States|Tidwewater Physicians for Women, Norfolk, Virginia, United States|Seattle Women's Health, Research, Gynecology, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02888197"
1359,"NCT03965975","Clinical Validation Through Analytical Study With Urine Samples to Compare the Effectiveness and Security of an Intelligent Device","STSD-2019-001","Unknown status","No Results Available","Renal Insufficiency, Chronic|Heart Failure|Diabete Mellitus|Diabetes; Nephropathy (Manifestation)|Hematuria|Urinary Tract Infections","Device: Lab Gold Standard|Device: S-There","Accuracy to compared device","S-There Technologies SL|Biocruces Bizkaia Health Research Institute|Hospital de Cruces","All","18 Years and older   (Adult, Older Adult)","Not Applicable","700","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","S-There Smart Device-2019-001","June 10, 2019","March 2020","March 2020","May 29, 2019",,"December 5, 2019","Hospital de Cruces, Barakaldo, Bizkaia, Spain",,"https://ClinicalTrials.gov/show/NCT03965975"
1360,"NCT04654507","Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children",,"Recruiting","No Results Available","Urinary Tract Infections in Children|Dexamethasone|Kidney Scarring|Acute Pyelonephritis|Hypertension in Children|Chronic Renal Failure|UTI","Drug: Dexamethasone Oral|Drug: Placebo","Renal scarring comparatively with patients those don't take the medicine","Hamad Medical Corporation","All","2 Months to 14 Years   (Child)","Phase 3","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MRC-01-20-085","March 3, 2021","December 2023","December 2024","December 4, 2020",,"July 25, 2023","Hamad Medical Corporation, Doha, Qatar",,"https://ClinicalTrials.gov/show/NCT04654507"
1361,"NCT05343403","Parental Participation on the Neonatal Ward - the neoPARTNER Study","neoPARTNER","Active, not recruiting","No Results Available","Premature|Premature Birth|Prematurity|Perinatal Problems|Neonatal Sepsis|Neonatal Infection|Neonatal Hyperbilirubinemia|Infant Development|Infant, Newborn, Disease|Infant, Premature, Diseases|Infant, Small for Gestational Age|Small for Gestational Age Infant|Maternal Distress|Parent-Child Relations|Parents","Other: Family Integrated Care","Level of parental stress|Experiences of Shared Decision Making|Parent-infant attachment|Level of parental participation in neonatal care|Symptoms of parental depression|Symptoms of parental anxiety|Symptoms of parental posttraumatic stress|Cost-effectiveness on parent and infant level|Infant development|Length of hospital stay (infant)|Amount of breastfeeding|Infant growth|Change in experience of Shared decision making (healthcare professionals)|Change in experienced work engagement (healthcare professionals)|Change in experienced work autonomy (healthcare professionals)|Cost-effectiveness (healthcare professionals)|Family Centred Rounds","Onze Lieve Vrouwe Gasthuis|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","All","1 Day and older   (Child, Adult, Older Adult)",,"613","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NL78176.100.21","March 7, 2022","February 2, 2024","March 1, 2025","April 25, 2022",,"February 6, 2024","Amphia Ziekenhuis, Breda, Brabant, Netherlands|Flevoziekenhuis, Almere, Flevoland, Netherlands|Noordwest Ziekenhuisgroep, Alkmaar, Noord Holland, Netherlands|Ziekenhuis Amstelland, Amstelveen, Noord Holland, Netherlands|BovenIJ Ziekenhuis, Amsterdam, Noord Holland, Netherlands|Tergooi Medisch Centrum, Blaricum, Noord Holland, Netherlands|Zaans Medisch Centrum, Zaandam, Noord Holland, Netherlands|Medisch Spectrum Twente, Enschede, Overijssel, Netherlands|Juliana Kinderziekenhuis, Den Haag, Zuid Holland, Netherlands|Franciscus Gasthuis & Vlietland, Rotterdam, Zuid Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT05343403"
1362,"NCT05413811","Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV","ACT2","Recruiting","No Results Available","Cervical Cancer|CIN2|CIN3|Human Immunodeficiency Virus|Human Papillomavirus","Drug: 5 Fluorouracil (5 FU) Cream|Drug: Placebo","The number of subjects adhered to and retained in the study|The number of participants who found the intervention acceptable|The proportion of participants with CIN2 or CIN 3 that regressed to CIN1|The percentage of participants who demonstrate clearance of high-risk HPV","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","180","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IGHID12046|1R01CA250850-01","March 22, 2023","May 31, 2025","May 31, 2025","June 10, 2022",,"February 2, 2024","Clinical HIV Research Unit Temba Lethu Wing Helen Joseph Hospital, Westdene, Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT05413811"
1363,"NCT05975151","Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer",,"Recruiting","No Results Available","Bladder Cancer","Drug: Pseudomonas aeruginosa","recurrence rate|Disease-free survival","Qilu Hospital of Shandong University","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","63","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","bks02","October 1, 2023","August 1, 2025","December 1, 2025","August 3, 2023",,"September 21, 2023","Qilu hospital, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT05975151"
1364,"NCT04237883","Primary Care Clinical Excellence Incentive Study","PCCE","Completed","No Results Available","Behavioral Economics|Primary Health Care|Health Maintenance|Diabetes|Colorectal Cancer Screening|Cervical Cancer Screening|Chlamydia Screening|HPV Screening","Behavioral: Standard communication email|Behavioral: Social comparison Intervention|Behavioral: Leadership Training","Aggregate Focus Quality Measure order rates at the first visit|Aggregate Focus Quality Measure completion rates measured at the patient level|Individual Focus Quality Measure order status at the first visit|Individual Focus Quality Measure completion status at the patient level|Complementary Health Maintenance order rate at the first visit|Complementary Health Maintenance completion rate at the patient level|Physician Burnout|Physician Satisfaction|Physician Experience|Physician Incentive Payouts|Patient Satisfaction|Profesional Participation|Aggregate Focus Quality Measure order rates measured at the patient level|Aggregate Health Maintenance (HM) order rates measured at the patient level|Aggregate Health Maintenance (HM) completion rates measured at the patient level|Individual Focus Quality Measure order status at the patient level|The proportion of patients in the panel who visited a given physician|New Patients|Number of Visits|Number of Open Tests","University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)","Not Applicable","225","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","12345","November 1, 2019","November 1, 2020","January 1, 2021","January 23, 2020",,"January 26, 2021","UCLA Health Department of Medicine, Quality Office, Brentwood, California, United States",,"https://ClinicalTrials.gov/show/NCT04237883"
1365,"NCT00352300","Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer",,"Completed","No Results Available","Fallopian Tube Carcinoma|Infectious Disorder|Neutropenia|Ovarian Carcinosarcoma|Primary Peritoneal Carcinoma|Stage III Ovarian Cancer|Stage IV Ovarian Cancer","Procedure: Adjuvant Therapy|Drug: Carboplatin|Drug: Paclitaxel|Biological: Pegfilgrastim","Number of patients who have greater than or equal to 1 dose-limiting toxicity, assessed by Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)|Number of patients with > grade 1 peripheral neuropathy based on the GOG neurotoxicity scale|Frequency and duration of objective response (complete and partial response) assessed by Response Evaluation Criteria for Solid Tumors (RECIST)|Grade of toxicity as assessed by CTCAE v3.0","Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation","Female","18 Years and older   (Adult, Older Adult)","Phase 1","43","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GOG-9919|NCI-2009-00622|CDR0000486412|U10CA027469","June 2006","July 2010",,"July 14, 2006",,"December 31, 2014","University of California Medical Center At Irvine-Orange Campus, Orange, California, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|New York University Langone Medical Center, New York, New York, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Lake University Ireland Cancer Center, Mentor, Ohio, United States|Cancer Care Associates-Midtown, Tulsa, Oklahoma, United States|Women and Infants Hospital, Providence, Rhode Island, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00352300"
1366,"NCT04679675","Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial","STEP","Completed","Has Results","Uterine Cervical Neoplasm|Uterine Neoplasms|Genital Neoplasms, Female|Urogenital Neoplasms|Neoplasms by Site|Neoplasms|Uterine Cervical Diseases|Uterine Diseases|Cervical Cancer|Cervical Dysplasia|Human Papilloma Virus|HPV-Related Cervical Carcinoma|HPV Infection|HPV-Related Malignancy","Other: Usual Care|Behavioral: Education|Behavioral: Direct Mail|Behavioral: Opt-in","Screening Completion by Outreach Approach and Prior Screening Behavior|Incremental Cost-effectiveness Ratio by Outreach Approach and Prior Screening Behavior|Screening Initiation by Outreach Approach and Prior Screening Behavior|Time From Randomization to Screening Completion by Outreach Approach and Prior Screening Behavior|Completion of Recommended Follow-up After a Positive Kit Result|Screening Method Choice|Qualitative Information From Focus Groups on Patient Preferences by Prior Screening Behavior|Health System Costs to Implementing Home Testing by Outreach Approach and Prior Screening Behavior","Kaiser Permanente|National Cancer Institute (NCI)|University of Washington|University of Texas Southwestern Medical Center","Female","30 Years to 64 Years   (Adult)","Not Applicable","32771","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research","00002344|R01CA240375","November 20, 2020","July 29, 2022","July 29, 2023","December 22, 2020","August 24, 2023","September 18, 2023","Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/75/NCT04679675/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04679675"
1367,"NCT02808052","Evaluate Safety and Pharmacokinetics of Minocin (Minocycline) for Injection in Subjects With Renal Insufficiency",,"Terminated","Has Results","Renal Insufficiency, Acute|Renal Insufficiency, Chronic|Healthy Subjects","Drug: Minocin (minocycline) for Injection","Safety and Tolerability of Intravenous Dose(s) of Minocin (Minocycline) for Injection Assessed by Number of Subjects With Adverse Events","Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)|Universitätsklinikum Köln|Innovative Medicines Initiative|Melinta Therapeutics, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","9","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MDCO-MIN-16-03|702","May 29, 2017","June 4, 2018","June 4, 2018","June 21, 2016","July 24, 2019","September 4, 2019","University Hospital Cologne-Clinical Trial Center, Koeln, Germany","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/52/NCT02808052/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/52/NCT02808052/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02808052"
1368,"NCT05383521","Safety and Efficacy of Two Oral Tinidazole Regimens for Refractory Trichomonas Vaginitis",,"Not yet recruiting","No Results Available","Trichomonas Vaginitis","Drug: Tinidazole 56|Drug: Tinidazole 42","Cure rate of refractory trichomoniasis|Safety of tinidazole tablets","Shangrong Fan|Peking University Shenzhen Hospital","Female","18 Years to 55 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020PUSZH001","December 1, 2023","December 30, 2023","December 30, 2023","May 20, 2022",,"May 6, 2023","Peking University Shenzhen Hospital, Shenzhen, Guangdong, China|Beijing Obstetrics and Gynecology Hospital,Capital Medical University, Peking, China|Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Peking, China|Peking University First Hospital, Peking, China",,"https://ClinicalTrials.gov/show/NCT05383521"
1369,"NCT05576311","Codesign of an Optical Device to Measure Urine Flow and Volume",,"Not yet recruiting","No Results Available","Urinary Incontinence|Urinary Retention|Urinary Tract Infections|Overactive Bladder|Benign Prostatic Hyperplasia|Underactive Bladder","Other: Focus Group","Understanding the needs of patients and healthcare practitioners for an innovation in the way that changes in bladder function are assessed.","Teesside University|South Tees Hospitals NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)",,"45","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","10852","November 1, 2022","December 31, 2022","February 28, 2023","October 12, 2022",,"October 12, 2022",,,"https://ClinicalTrials.gov/show/NCT05576311"
1370,"NCT03987620","Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis","Vanish 306","Completed","Has Results","Candida Vulvovaginitis","Drug: Ibrexafungerp|Drug: Placebo","Clinical Cure (Complete Resolution of Signs and Symptoms)|Mycological Eradication (Negative Culture for Growth of Yeast)|Clinical Cure and Mycological Eradication (Responder Outcome)|Complete Clinical Response at Follow-up|Safety and Tolerability of Ibrexafungerp","Scynexis, Inc.","Female","12 Years and older   (Child, Adult, Older Adult)","Phase 3","455","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SCY-078-306","June 7, 2019","March 29, 2020","April 29, 2020","June 17, 2019","September 8, 2021","September 8, 2021","Mesa OB-GYN, Mesa, Arizona, United States|Red Rocks OBGYN, Lakewood, Colorado, United States|Planned Parenthood Southern New England, New Haven, Connecticut, United States|New Generation Medical Research, Hialeah, Florida, United States|Healthcare Clinical Data Inc, North Miami, Florida, United States|Physician Care Clinical Research LLC, Sarasota, Florida, United States|CCT LLC - A VitaLink Company- PPDS, West Palm Beach, Florida, United States|Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia, United States|Fellows Research Alliance Inc, Savannah, Georgia, United States|Rosemark Women Care Specialists, Idaho Falls, Idaho, United States|Praetorian Pharmaceutical Research, LLC, Marrero, Louisiana, United States|North County Health Center, Planned Parenthood of the St. Louis Region and Southwest Missouri, Florissant, Missouri, United States|Clinical Research Center Of Nevada, Las Vegas, Nevada, United States|Planned Parenthood North Central Southern New Jersey (PPNCSNJ), Hackensack, New Jersey, United States|Carolina Institute for Clinical Research - M3 Wake Research, Fayetteville, North Carolina, United States|Obstetrics and Gynecology Associates of Erie, PC, Erie, Pennsylvania, United States|Planned Parenthood Southeastern Pennsylvania The Elizabeth Blackwell Health Center, Philadelphia, Pennsylvania, United States|Fellows Research Alliance Inc, Bluffton, South Carolina, United States|Chattanooga Medical Research Inc, Chattanooga, Tennessee, United States|Signature GYN Services, PLLC, Fort Worth, Texas, United States|Brownstone Clinical Trials, LLC, Irving, Texas, United States|Multiprofile Hospital for Active Treatment -Asenovgrad EOOD, Asenovgrad, Bulgaria|MHAT Puls AD - PPDS, Blagoevgrad, Bulgaria|Multiprofile Hospital for Active Treatment - Chirpan EOOD, Chirpan, Bulgaria|Medical Center Asklepii OOD, Dupnitsa, Bulgaria|Diagnostic-Consultative Center I-Gabrovo EOOD, Gabrovo, Bulgaria|Multiprofile Hospital For Active Treatment Dr Tota Venkova, Gabrovo, Bulgaria|Multiprofile Hospital for Active Treatment Sv. Ivan Rilski - Gorna Oryahovitsa EOOD, Gorna Oryahovitsa, Bulgaria|Multiprofile Hospital for Active Treatment- Sveti Nikolay Chudotvoretz - LOM EOOD, Lom, Bulgaria|Multiprofile Hospital for Active Treatment - Prof. Dr. Paraskev Stoyanov AD, Lovech, Bulgaria|MHAT Stamen Iliev AD, Montana, Bulgaria|Multiprofile Hospital For Active Treatment - Pazardzhik AD, Pazardzhik, Bulgaria|Multiprofile Hospital for Active Treatment Trimontsium OOD, Plovdiv, Bulgaria|Multiprofile Hospital for Active Treatment - Samokov EOOD, Samokov, Bulgaria|Medical Center-1-Sevlievo EOOD, Sevlievo, Bulgaria|Multiprofile Hospital for Active Treatment Shumen, Shumen, Bulgaria|Multiprofile Hospital For Active Treatment - Dr. Bratan Shukerov AD, Smolyan, Bulgaria|Medical Center Excelsior OOD - PPDS, Sofia, Bulgaria|Diagnostic Consultative CTR - XX - Sofia - EOOD, Sofia, Bulgaria|Medical center Vip Clinic OOD, Sofia, Bulgaria|Medical Center Medica Plus OOD, Veliko Tarnovo, Bulgaria","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/20/NCT03987620/Prot_001.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/20/NCT03987620/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT03987620"
1371,"NCT04230746","Effect of Antibiotics on Urinary Microbiome",,"Withdrawn","No Results Available","Microtia|UTI|Bacteriuria|Antibiotic Resistant Infection|Antibiotics Causing Adverse Effects in Therapeutic Use","Drug: Bactrim DS 800Mg-160Mg Tablet|Drug: Placebo oral tablet","Change in Microbiome flora number of organisms|Change in Microbiome flora percentage distribution of organisms","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","IRB00224835","October 2023","February 2025","February 2026","January 18, 2020",,"November 3, 2021",,,"https://ClinicalTrials.gov/show/NCT04230746"
1372,"NCT03614286","Trichomonas Vaginalis Genotyping in Upper Egypt",,"Unknown status","No Results Available","Trichomonas Vaginalis Genotyping in Upper Egypt|Vaginitis Trichomonal","Diagnostic Test: culture and pcr","study genetic variability of Trichomonas vaginalis using PCR","Assiut University","Female","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Other|Time Perspective: Other","T V Genotyping","October 2018","October 2019","March 2020","August 3, 2018",,"August 7, 2018",,,"https://ClinicalTrials.gov/show/NCT03614286"
1373,"NCT05613283","Primary Cervical Cancer Screening by Self-sampling HPV Test","PREVENT","Active, not recruiting","No Results Available","Human Papillomavirus Infection|Cervical Cancer|Negative For Intraepithelial Lesion Or Malignancy|Atypical Squamous Cells of Undetermined Significance|Atypical Squamous Cells, Cannot Rule Out High-grade Squamous Intraepithelial Lesion|Cervical Squamous Intraepithelial Lesion|Low-Grade Squamous Intraepithelial Lesions|High-Grade Squamous Intraepithelial Lesions|Cervical Intraepithelial Neoplasia Grade I|Cervical Intraepithelial Neoplasia Grade II|Cervical Intraepithelial Neoplasia, Grade III|Atypical Glandular Cells|Atypical Glandular Cells Not Otherwise Specified|Atypical Glandular Cells, Favor Neoplastic|Cervical Squamous Cell Carcinoma|Adenocarcinoma in Situ|Cervical Adenocarcinoma",,"Accuracy verification|Clinical validity verification","Peking University People's Hospital|BeijingNewBiorayTechnologyCo.,Ltd.|Hangzhou Newhorizon Health Technology Co., Ltd.","Female","21 Years to 65 Years   (Adult, Older Adult)",,"17875","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NH-3004","November 19, 2022","July 2026","August 31, 2027","November 14, 2022",,"December 21, 2023","Peking University People's Hospital, Beijing, Beijing, China|Henan Cancer Hospital, Zhengzhou, Henan, China|The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Hunan Provincial Maternal and Child Health Care Hospital, Changsha, Hunan, China|Chengdu Women's and Children's Central Hospital, Chengdu, Sichuan, China|Women's Hospital School Of Medicine Zhejiang University, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT05613283"
1374,"NCT03064789","Epidemiological Study in Subjects With Vulvovaginal Candidiases",,"Completed","No Results Available","Vulvovaginal Candidiases",,"Estimate cure rate in women with severe vuvovaginal candidiases infection|Estimate recurrences|Evaluate the link between symptomatology and negative culture|Evaluate the effectiveness of probiotic treatment by physician|Evaluate the effectiveness of probiotic treatment by patient. A satisfaction questionnaire will be performed","Dr. Santiago Palacios|Instituto Palacios","Female","18 Years to 50 Years   (Adult)",,"43","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IP-01-2016","December 29, 2016","March 30, 2019","June 30, 2019","February 27, 2017",,"February 11, 2021","Instituto Palacios, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03064789"
1375,"NCT05210348","Clinical Evaluation of Detection of High Risk HPV in Urine","Urine-hrHPV","Unknown status","No Results Available","Human Papillomavirus Infection|Cervical Cancer|Human Papilloma Virus|Negative for Intraepithelial Lesion or Malignancy|Atypical Squamous Cells of Undetermined Significance|Cervical Squamous Intraepithelial Lesion|Atypical Squamous Cells, Cannot Rule Out High-grade Squamous Intraepithelial Lesion|Low-grade Squamous Intraepithelial Lesion|High-Grade Squamous Intraepithelial Lesions|Cervical Intraepithelial Neoplasia Grade I|Cervical Intraepithelial Neoplasia Grade II|Cervical Intraepithelial Neoplasia, Grade III|Atypical Glandular Cells|Atypical Glandular Cells Not Otherwise Specified|Atypical Glandular Cells, Favor Neoplastic|Cervical Squamous Cell Carcinoma|Adenocarcinoma in Situ|Cervical Adenocarcinoma",,"Verification of accuracy|Clinical validity verification","Peking University People's Hospital|Hangzhou Mingze Medical Research Co., Ltd.|Beijing Tsingke Biological Technology Co., Ltd. Hangzhou Branch|Hangzhou Newhorizon Health Technology Co., Ltd.","Female","20 Years to 65 Years   (Adult, Older Adult)",,"1000","Other","Observational",,"Urine-hrHPV 2021","September 15, 2021","February 1, 2022","May 1, 2022","January 27, 2022",,"January 27, 2022","Peking University People's Hospital, Beijing, Beijing, China|The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Nanjing First Hospital, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT05210348"
1376,"NCT05564897","Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer",,"Recruiting","No Results Available","Bladder Cancer","Drug: H101, Camrelizumab","complete response (CR)","Zhejiang Cancer Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHUCAS-030","August 26, 2022","September 30, 2024","December 31, 2024","October 4, 2022",,"October 4, 2022","Hua Wang, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT05564897"
1377,"NCT02536872","A Study of the Effect of Antibiotics on the Microbiology of the Bladder in Patients With Overactive Bladder",,"Completed","No Results Available","Urogynaecology","Other: None - this is a prospective observational study. Patients will be prescribed their usual treatment (antibiotics) and the effect on urine studied","Change in bladder microbiology in patients treated with antibiotics.|Change in the overactive bladder questionnaire (OAB-q) before and after treatment|Change in Patient Perception of Bladder Condition (PPBC)|To identify adherence to the treatment regime|To identify adverse effects of the treatment|Changes in symptoms using (change from baseline to assessment)","Medway NHS Foundation Trust","Female","18 Years to 100 Years   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","19/06/2015","October 2015","September 2016","October 2016","September 1, 2015",,"October 17, 2016","Medway Hospital, Gillingham, Kent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02536872"
1378,"NCT01361048","Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis",,"Completed","Has Results","Trichomonas Vaginitis","Drug: oral metronidazole|Drug: neo penotran forte|Drug: neo penotran forte once a day","Percentage of Participants Cured of Vaginal Trichmonas|Tolerability of the Study Product as Measured by Participant Self-report","University of Alabama at Birmingham|Embil Pharmaceutical Co. Ltd","Female","19 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TV-01","December 2011","August 2012","January 2013","May 26, 2011","February 20, 2014","January 19, 2018","Personal Health Clinic UAB, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT01361048"
1379,"NCT02366676","Efficacy of IARULIL® in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract",,"Completed","No Results Available","Recurrent Cystitis","Drug: hyaluronic acid and chondroitin sulphate","The number of recurrence for recurrent cystitis|Time interval of cystitis|The score change of UTI symptom Assessment questionnaire(UTISA)|Global Respone assessment(GRA) score assessment|safety evaluation Safety evaluation","Samsung Medical Center","Female","20 Years to 80 Years   (Adult, Older Adult)","Phase 4","105","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2013-07-170","January 2014","January 2018","October 30, 2019","February 19, 2015",,"December 2, 2019","Samsung Medical Center, Seoul,, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02366676"
1380,"NCT01590017","Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer",,"Completed","Has Results","Cervical Cancer|Acquired Immunodeficiency Syndrome","Drug: cisplatin|Radiation: external beam radiation therapy","Treatment Completion Rate|Patients With Adverse Events","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC|University of Arkansas|Montefiore Medical Center","Female","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","41","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMC-081|CDR0000732629|UM1CA121947","April 1, 2014","April 20, 2017","April 20, 2017","May 2, 2012","August 7, 2019","July 27, 2022","Clinical HIV Research Unit, a Division of the Wits Health Consortium (Pty) Ltd, Johannesburg, South Africa|University of Zimbabwe Clinical Research Centre / Parirenyatwa Hospital, Harare, Zimbabwe","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/17/NCT01590017/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01590017"
1381,"NCT01410916","Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)","STEC-HUS","Completed","No Results Available","Shiga-like Toxin-producing Escherichia Coli","Drug: Eculizumab (Soliris®)","Improvement in Systemic TMA & Vital Organ Involvement at 8 weeks of treatment defined as either complete or partial responder based on hematologic normalization/improvement & clinically important improvement in Vital Organs: Brain, Kidney, and Thrombosis","Alexion Pharmaceuticals, Inc.","All","2 Months and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","198","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C11-001|2011-002691-17","July 2011","January 2012","June 2012","August 5, 2011",,"April 5, 2013","Bielefeld, Germany|Bielefeld, Germany|Bonn, Germany|Bremen, Germany|Bremerhaven, Germany|Essen, Germany|Flensburg, Germany|Göttingen, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hannover, Germany|Karlsruhe, Germany|Köln, Germany|Lubeck, Germany|Magdeburg, Germany|Munchen, Germany|Munich, Germany|Munster, Germany|Oldenburg, Germany|Ulm, Germany|Wildeshausen, Germany",,"https://ClinicalTrials.gov/show/NCT01410916"
1382,"NCT03346915","Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention",,"Completed","No Results Available","Human Papilloma Virus|Cervical Cancer|Human Papillomavirus Infection|Oropharyngeal Cancer|Vaginal Cancer|Vulvar Cancer|Anal Cancer|Penile Cancer","Behavioral: WoW and BNI","HPV vaccine series start and completion|HPV and Cervical Cancer awareness and knowledge|Provider-patient communication about HPV vaccine and cervical cancer|Wheel of Wellness (WoW) feasibility","Boston Medical Center","All","9 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","H-36669","August 14, 2018","April 19, 2019","April 19, 2019","November 20, 2017",,"October 9, 2019","Boston Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03346915"
1383,"NCT01671280","Drug Use Investigation Of Azithromycin IV For Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)","RESCUE","Completed","Has Results","Pneumonia|Pelvic Inflammatory Disease","Drug: Azithromycin IV","Number of Participants With Treatment-Related Adverse Events|Clinical Effectiveness Rate in Participants With Pneumonia|Clinical Effectiveness Rate in Participants With Pelvic Inflammatory Disease","Pfizer","All","Child, Adult, Older Adult",,"403","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","A0661207","September 20, 2012","April 22, 2016","April 22, 2016","August 23, 2012","April 26, 2017","April 26, 2017",,,"https://ClinicalTrials.gov/show/NCT01671280"
1384,"NCT01550783","Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening",,"Completed","No Results Available","Atypical Squamous Cell of Undetermined Significance|Cervical Carcinoma|Cervical Intraepithelial Neoplasia Grade 2/3|Health Status Unknown|Human Papillomavirus Infection|Low Grade Cervical Squamous Intraepithelial Neoplasia|Stage 0 Cervical Cancer","Other: Cervical Papanicolaou Test|Other: Cytology Specimen Collection Procedure|Other: Questionnaire Administration|Procedure: Screening Method","Cost-effectiveness in the novel approach in vaccinated and unvaccinated women less than 30 years old|Cost-effectiveness in the standard approach in vaccinated and unvaccinated women less than 30 years old|Overall cost-effectiveness and acceptability|Sensitivity and specificity for CIN 1+ of currently recommended in-clinic cytology screening|Sensitivity and specificity for CIN 1+ of novel home-based testing|Sensitivity and specificity of the novel approach in vaccinated women less than 30 years old|Sensitivity and specificity of the standard approach in vaccinated women less than 30 years old","University of Washington|National Cancer Institute (NCI)","Female","21 Years and older   (Adult, Older Adult)","Not Applicable","1335","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","7489|NCI-2013-00745|R01CA157469","March 2012","November 16, 2017","November 16, 2017","March 12, 2012",,"July 31, 2020","University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01550783"
1385,"NCT06360965","Clinical Trial of Acupoint Application in Improving the Sequelae of Pelvic Inflammatory Disease and Chronic Pelvic Pain",,"Recruiting","No Results Available","Pelvic Inflammatory Disease|Chronic Pelvic Pain Syndrome","Drug: Improved warm meridians and relieve pain plaster|Drug: Traditional warm meridians and relieve pain plaster|Drug: Placebo plaster","Main symptoms (lower abdominal pain) improvement level (visual analogue scale)|TCM syndrome score scale|Local physical sign rating scale|Pelvic masses and fluid accumulation|EuroQol Five Dimensions Questionnaire|Recurrence of abdominal pain during 1-month menstrual cycle was followed up.","Beijing Hospital of Integrated Traditional Chinese and Western Medicine","Female","18 Years to 50 Years   (Adult)","Not Applicable","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Shoufa2024-3-7045","January 1, 2024","March 31, 2026","December 31, 2026","April 11, 2024",,"April 11, 2024","Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Beijing, China",,"https://ClinicalTrials.gov/show/NCT06360965"
1386,"NCT05970783","A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease",,"Recruiting","No Results Available","Chronic Pelvic Pain","Drug: Jincaopian Tablets|Other: Placebo","Pain disappearance rate after 12 weeks of treatment|Pain disappearance rate after 4 and 8 weeks of treatment|Change of weekly average Visual Analogue Scale (VAS) score from baseline after 12 weeks of treatment|The area under the VAS score-time curve|McCormick Scale|General quality of life (Short Form-12) scale|Disease efficacy evaluation|Adverse events (AEs)","Beijing Konruns Pharmaceutical Co., Ltd.","Female","18 Years to 50 Years   (Adult)","Phase 3","414","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Z-JCP-T-Ⅲ-2021-BJKC-01","November 8, 2022","February 2024","November 2024","August 1, 2023",,"August 1, 2023","Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05970783"
1387,"NCT05460546","The Effect of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease",,"Completed","No Results Available","Chronic Pelvic Pain","Drug: Jincaopian Tablets high dose|Drug: Jincaopian Tablets low dose|Other: Placebo","Pain Visual Analog Scale (VAS)|Modified McCormick Scale|SF-12 Score","Beijing Konruns Pharmaceutical Co., Ltd.","Female","18 Years to 55 Years   (Adult)","Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Z-JCP-T-II-2020-HMZC-01","January 19, 2021","November 30, 2021","November 30, 2021","July 15, 2022",,"July 15, 2022","Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05460546"
1388,"NCT05723185","Primary Care-Hospital Embedding: a Prospective, Multicentric, Observational Study","PRIME","Recruiting","No Results Available","Heart Failure|Chronic Obstructive Pulmonary Disease|Diabetes Mellitus|Pneumonia|Urinary Tract Infections|Fever of Unknown Origin|Deep Vein Thrombosis|Hypertension","Other: Outpatient visit","Analyse and compare the function of the two outpatient clinic models","Rovere Querini Patrizia|ASST Fatebenefratelli Sacco|ASST Grande Ospedale Metropolitano Niguarda|IRCCS San Raffaele","All","18 Years and older   (Adult, Older Adult)",,"246","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PRIME","February 13, 2023","January 31, 2024","January 31, 2024","February 10, 2023",,"February 23, 2023","San Raffaele Hospital, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT05723185"
1389,"NCT04051073","Can Continuous Non-invasive Monitoring Improve Stability of Intraoperative Blood Pressure - A Feasibility Study.","iSTABILISE","Completed","No Results Available","Hip Fractures|Hypotension on Induction|Intraoperative Hypotension|Acute Kidney Injury|Myocardial Ischemia|Wound Infection|Perioperative/Postoperative Complications","Device: Continuous non-invasive blood pressure monitoring","Feasibility Outcome - Proportion of recruited patients in whom CNAP was successfully applied and full data collected.|Feasibility Outcome - Proportion of eligible patients successfully recruited|Feasibility Outcome - Proportion of enrolled patients in whom there is a full data set recorded.|Feasibility Outcome - Proportion of enrolled patients in which we are able to record full follow up data.|Intraoperative Outcomes - Nadir Blood Pressure|Intraoperative Outcomes - Total time spent with a mean arterial pressure <80mmHg|Intraoperative Outcomes - Total time spent with a mean arterial pressure <65mmHg|Intraoperative Outcomes - Total time spent with a mean arterial pressure <55mmHg|Intraoperative Outcomes - Total volume of intravenous fluids given|Intraoperative Outcomes - Total dose of vasopressors given|Post-operative Outcomes - Incidence of acute kidney injury in the 7 days post-operatively|Post-operative Outcomes - Incidence of myocardial injury in the first 3 days after surgery|Post-operative Outcomes - Incidence of stroke post-operatively|Post-operative Outcomes - Incidence of post-operative surgical site infection|Post-operative Outcomes - Mortality|Health Economic Outcome - Hospital Length of Stay","University Hospital Birmingham NHS Foundation Trust|University of Warwick","All","18 Years and older   (Adult, Older Adult)","Phase 3","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","2019003AN","June 13, 2019","August 5, 2019","August 5, 2019","August 9, 2019",,"May 18, 2022","MIDRU, Birmingham Heartlands Hospital, Birmingham, West Midlands, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/73/NCT04051073/Prot_SAP_000.pdf|""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/73/NCT04051073/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04051073"
1390,"NCT03994055","Effect of an Anti-inflammatory Diet on Patients With Cervical Cancer",,"Active, not recruiting","No Results Available","Cervical Cancer|Uterine Cervical Neoplasm|Pelvic Inflammatory Disease|Radiation Toxicity|Diet Modification","Other: Omega-3 fatty acids|Other: Antioxidants|Other: Soluble fiber|Other: Probiotics|Other: Lactose restriction|Other: Fiber restriction|Other: Fat restriction","Change in body mass index|Change in levels of IFN-g [pg/ml]|Change in levels of calprotectin [pg/ml]|Change in Gastrointestinal toxicity symptoms grading (severity) scale using the Common Toxicity Criteria for Adverse Events (CTCAE v4)|Change in quality of life summary score using the the quality of life questionnaire specifically developed for cancer patients (EORTC QLQ-C30 v3)","National Institute of Cancerología","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CEI/1247/17","November 16, 2018","April 28, 2023","January 2024","June 21, 2019",,"September 21, 2023","Instituto Nacional de Cancerologia, Mexico City, Distrito Federal, Mexico","""Informed Consent Form"", https://classic.clinicaltrials.gov/ProvidedDocs/55/NCT03994055/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03994055"
1391,"NCT01236131","The Role of Novel Organisms in Acute Endometritis",,"Completed","No Results Available","Pelvic Inflammatory Disease","Other: no intervention","Identification of Novel Organsims from PRO10010159|Identification of Novel Organisms from PRO10010112","Sharon Hillier|National Institute of Allergy and Infectious Diseases (NIAID)|University of Pittsburgh","Female","15 Years to 40 Years   (Child, Adult)",,"480","Other|NIH","Observational","Time Perspective: Cross-Sectional","PRO10080491|1U19AI084024-01","November 2010","August 2015","August 2015","November 7, 2010",,"August 17, 2016","Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01236131"
1392,"NCT00958295","Epidemiology of Acute Bacterial Uncomplicated Cystitis in General Practice","BaCyst","Completed","No Results Available","Acute Uncomplicated Bacterial Cystitis",,"Bacterial epidemiology of acute uncomplicated cystitis|Comparison of urine dipstick tests and urine culture results","University Hospital, Rouen","Female","18 Years and older   (Adult, Older Adult)",,"362","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2008/119/HP","March 2009","May 2010","June 2010","August 13, 2009",,"October 22, 2015","JULIENNE Pascal, Louviers, France",,"https://ClinicalTrials.gov/show/NCT00958295"
1393,"NCT03386695","Acceptability and Validity of Self Sampling for High Risk HPV Detection Among Women in Maharashtra","HPV","Unknown status","No Results Available","Cervical Cancer","Other: Education by Pamphlets|Other: Health education programme","Agreement rate between health care personnel collected samples and self collected samples in these two groups.|Test characteristics of HPV self sample and health care worker collected sample by HPV HC 2.|Acceptability and barriers for self-collection of specimens for HPV DNA testing in an urban population.","Tata Memorial Hospital","Female","30 Years to 55 Years   (Adult)","Not Applicable","1600","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","TMHPO 1686","September 2018","January 2019","January 2020","December 29, 2017",,"August 6, 2018","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03386695"
1394,"NCT00067249","Women's Use of Alternative Medicine: A Multiethnic Study",,"Completed","No Results Available","Uterine Fibroids|Osteoporosis|Urinary Tract Infection|High Blood Pressure|Heart Disease|Arthritis|Depression|Headaches",,,"National Center for Complementary and Integrative Health (NCCIH)","Female","18 Years and older   (Adult, Older Adult)",,"3200","NIH","Observational","Observational Model: Natural History|Time Perspective: Other","F31AT001401-01","April 2001",,"September 2001","August 15, 2003",,"February 27, 2007",,,"https://ClinicalTrials.gov/show/NCT00067249"
1395,"NCT04414527","Effects of Video-based Health Education on Maternal and Child Health in Ethiopia","MCH","Completed","No Results Available","Anemia|Antenatal Care|Birth Outcomes|Worm Infection|Bacterial Vaginoses|Exclusive Breastfeeding","Behavioral: Standard counselling|Behavioral: Health-Video","Adherence to iron and folic acid supplementation during pregnancy|Adherence to iron and folic acid supplementation post-partum|Maternal anemia during pregnancy|Maternal anemia post-partum|Early initiation|Exclusive breastfeeding|Dietary intake during six months pregnancy|Dietary intake at six months post-partum|Gestational weight gain|Maternal genital infections|Birth weight|Infant weight|Infant length|Infant anemia|Maternal parasitic infections|Infant parasitic infections|Maternal plasma ferritin|Infant plasma ferritin|Maternal soluble transferrin receptor|Infant soluble transferrin receptor|Maternal serum concentrations in Vitamin A (retinol)|Infant serum concentrations in Vitamin A (retinol)|Maternal serum concentrations in vitamin B12|Infant serum concentrations in vitamin B12","University Ghent|Flemish Interuniversity Council (VLIR)|Arba Minch University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","675","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","BC-06756","March 13, 2020","July 31, 2021","July 31, 2021","June 4, 2020",,"December 6, 2021","Arba Minch University, Arba Minch, Dirashe District, Ethiopia",,"https://ClinicalTrials.gov/show/NCT04414527"
1396,"NCT02635490","Is Prophylactic Antibiotics Necessary In Otherwise Healthy Adult Patients Undergoing Ureteroscopic Procedures for Ureteral Stones?",,"Completed","No Results Available","Ureteral Stones",,"Evidence of clinically definite urinary tract infection confirmed by urinary analysis or urinary culture.","Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","All","20 Years to 65 Years   (Adult, Older Adult)",,"52","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","01-X20-068","April 2013","March 2015","March 2015","December 18, 2015",,"December 18, 2015","Cheng-Hsing Hsieh, Taipei, Xindian, Taiwan",,"https://ClinicalTrials.gov/show/NCT02635490"
1397,"NCT03681678","Laser Therapy for Treatment of Urogenital Symptoms in Women",,"Active, not recruiting","No Results Available","Genitourinary System; Disorder, Female|Burning Vagina|Dyspareunia|Irritation; Vagina|Menopause Related Conditions|Urinary Incontinence|Urinary Bladder, Overactive|Urinary Tract Infections|Stress Urinary Incontinence","Device: fCO2 Laser Therapy Group","Change in Patient Global Impression of Improvement (PGI-I) score at 16 weeks (4 weeks post-initial treatment).|Change in Patient Global Impression of Improvement (PGI-I) score|Change in vaginal pH and overall vaginal health on physical exam as measured by the Vaginal Health Inventory Score (VHIS).|Change in urinary symptoms as measured by the Questionnaire for Urinary Incontinence Diagnosis (QUID).|Change in overactive bladder (OAB) symptoms as measured by the Overactive Bladder Questionnaire-Short Form (OAB-q SF).|Change in voiding diaries.|Change in sexual function, including dyspareunia symptoms, as measured by the Female Sexual Function Inventory (FSFI).|Change in frequency of UTI occurrences, as measured by a positive urine culture test.|Change in mental health status as measured by the Generalized Anxiety Disorder Questionnaire (GAD-7).|Change in mental health status as measured by the Patient Health Questionnaire (PHQ-8).|Change in life and sexual impact of vulvovaginal skin symptoms.|Change in the presence of lactobacillus, assessed by vaginal swab.","William Beaumont Hospitals","Female","18 Years to 90 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018-142","October 8, 2018","December 15, 2022","October 2025","September 24, 2018",,"May 16, 2023","Beaumont Hospital, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03681678"
1398,"NCT00563342","Catheters Dysfunction Rate After Instillation of Ethanol 60% Lock Solution in Tunneled Silicone Catheter of Chronic Hemodialysis Patients","Ethanol","Terminated","No Results Available","End Stage Renal Failure, Hemodialysis","Drug: Ethanol","The catheters dysfunction rate|The dialysis quality is also examined (urea reduction rate, total ultrafiltration)","University Hospital, Clermont-Ferrand","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Treatment","CHU-0027","June 2007","March 2008","March 2008","November 26, 2007",,"October 8, 2008","Lacarin, Clermont-Ferrand, France",,"https://ClinicalTrials.gov/show/NCT00563342"
1399,"NCT01878968","Does Detailed Informed Consent for Cardiopulmonary Resuscitation and Mechanical Ventilation Impact Patients' Decisions and Outcomes?",,"Completed","No Results Available","Congestive Heart Failure|Infections|Sepsis|Acute Renal Failure|Stroke","Other: Script and CPR/Mechanical ventilation video.","Number of patients opting out of routine care - no intubation|Number of patients opting out of routine care - no CPR|Hospital Mortality|30-day mortality|90 day mortality|Number of patients undergoing CPR|Number of patients undergoing intubation","Jewish Hospital, Cincinnati, Ohio","All","65 Years and older   (Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","13-06","April 2013","November 2014","November 2014","June 17, 2013",,"January 6, 2016","The Jewish Hospital, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01878968"
1400,"NCT01478685","A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors",,"Completed","No Results Available","Urinary Bladder Neoplasms|Carcinoma, Transitional Cell|Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms|Carcinoma, Non-Small-Cell Lung|Carcinoma, Pancreatic Ductal|Tumor Virus Infections","Drug: CC-486|Drug: Carboplatin|Drug: ABI-007","Number of participants with adverse events|Cmax|AUC|Tmax|T1/2|CL/F|Vz/F|DNA Methylation|DNMT1 protein levels|Tumor Response Rate|Progression Free Survival|Duration of Response","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1","169","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZA-ST-001","November 29, 2011","November 17, 2015","November 17, 2015","November 23, 2011",,"November 12, 2019","Scottsdale Healthcare Research Institute, Scottsdale, Arizona, United States|University of California, San Francisco, San Francisco, California, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Greenville Hospital, Greenville, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Centre Georges Francois Leclerc, Dijon, France|Institut Curie, Paris, France|The Netherlands Cancer Instiute Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01478685"
1401,"NCT03091777","Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis",,"Completed","Has Results","Bacterial Vaginosis","Drug: GDC-229|Drug: Metronidazole Vaginal Gel 0.75%|Drug: Placebo","Clinical Cure","Balmoral Medical company|Health Decisions","Female","18 Years and older   (Adult, Older Adult)","Phase 3","871","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GDC-229-002","March 10, 2017","November 15, 2017","March 27, 2018","March 27, 2017","October 14, 2019","January 7, 2020","Site 103, Raleigh, North Carolina, United States","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/77/NCT03091777/Prot_000.pdf|""Statistical Analysis Plan"", https://classic.clinicaltrials.gov/ProvidedDocs/77/NCT03091777/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03091777"
1402,"NCT05044169","Efficacy and Safety of Broncho-Vaxom in the First Episode of Pediatric Idiopathic Nephrotic Syndrome",,"Unknown status","No Results Available","Nephrotic Syndrome in Children","Drug: Broncho-Vaxom","1-year relapse-free survival rate|Time to relapse (days)|Proportion of patients with a relapse|The effect of Broncho-Vaxom on peripheral blood B cell subsets and T cell subsets to highlight biomarkers useful for monitoring response to Broncho-Vaxom treatment.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","Fang Deng|Anhui Provincial Children's Hospital","All","1 Year to 18 Years   (Child, Adult)","Not Applicable","83","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AnhuiPCH","September 2021","September 2023","December 2023","September 14, 2021",,"September 14, 2021",,,"https://ClinicalTrials.gov/show/NCT05044169"
1403,"NCT04854382","Tailored Information About the Coronavirus for Patients With Chronic Kidney Disease","TICCKD","Unknown status","No Results Available","Renal Insufficiency, Chronic","Behavioral: Tailored information","Digital health literacy|Health literacy|Self-perceived Health|Anxiety / concern","Ivar Anders Eide|University Hospital, Akershus","All","18 Years and older   (Adult, Older Adult)","Not Applicable","215","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care","REK 144084/2020","April 14, 2021","March 10, 2022","December 31, 2023","April 22, 2021",,"March 29, 2022","Akershus University Hospital, Lørenskog, Akershus, Norway","""Study Protocol"", https://classic.clinicaltrials.gov/ProvidedDocs/82/NCT04854382/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04854382"
